drksId;firstDrksPublishDate;firstPartnerPublishDate;investorInitiated;ethicCommitteeVote;ethic-commission.id;ethic-commission.name;secId.type0;secId.id0;secId.name0;secId.type1;secId.id1;secId.name1;secId.type2;secId.id2;secId.name2;secId.type3;secId.id3;secId.name3;secId.type4;secId.id4;secId.name4;indication.type0;indication.key0;indication.value0;indication.type1;indication.key1;indication.value1;indication.type2;indication.key2;indication.value2;indication.type3;indication.key3;indication.value3;indication.type4;indication.key4;indication.value4;intervention.category0;intervention.value0;intervention.category1;intervention.value1;intervention.category2;intervention.value2;intervention.category3;intervention.value3;intervention.category4;intervention.value4;intervention.category5;intervention.value5;intervention.category6;intervention.value6;intervention.category7;intervention.value7;intervention.category8;intervention.value8;intervention.category9;intervention.value9;type;typeNotInterventional;allocation;masking;control;purpose;assignment;phase;offLabelDrugUse;primaryEndpoint;secondaryEndpoints;recruitmentCountries.key0;recruitmentCountries.value0;recruitmentCountries.key1;recruitmentCountries.value1;recruitmentCountries.key2;recruitmentCountries.value2;recruitmentCountries.key3;recruitmentCountries.value3;recruitmentCountries.key4;recruitmentCountries.value4;recruitmentCountries.key5;recruitmentCountries.value5;recruitmentCountries.key6;recruitmentCountries.value6;recruitmentCountries.key7;recruitmentCountries.value7;recruitmentCountries.key8;recruitmentCountries.value8;recruitmentCountries.key9;recruitmentCountries.value9;recruitmentCountries.key10;recruitmentCountries.value10;recruitmentCountries.key11;recruitmentCountries.value11;recruitmentCountries.key12;recruitmentCountries.value12;recruitmentCountries.key13;recruitmentCountries.value13;recruitmentCountries.key14;recruitmentCountries.value14;recruitmentCountries.key15;recruitmentCountries.value15;recruitmentCountries.key16;recruitmentCountries.value16;recruitmentCountries.key17;recruitmentCountries.value17;recruitmentCountries.key18;recruitmentCountries.value18;recruitmentCountries.key19;recruitmentCountries.value19;recruitmentLocation.type0;recruitmentLocation.value0;recruitmentLocation.city0;recruitmentLocation.type1;recruitmentLocation.value1;recruitmentLocation.city1;recruitmentLocation.type2;recruitmentLocation.value2;recruitmentLocation.city2;recruitmentLocation.type3;recruitmentLocation.value3;recruitmentLocation.city3;recruitmentLocation.type4;recruitmentLocation.value4;recruitmentLocation.city4;recruitmentLocation.type5;recruitmentLocation.value5;recruitmentLocation.city5;recruitmentLocation.type6;recruitmentLocation.value6;recruitmentLocation.city6;recruitmentLocation.type7;recruitmentLocation.value7;recruitmentLocation.city7;recruitmentLocation.type8;recruitmentLocation.value8;recruitmentLocation.city8;recruitmentLocation.type9;recruitmentLocation.value9;recruitmentLocation.city9;recruitmentLocation.type10;recruitmentLocation.value10;recruitmentLocation.city10;recruitmentLocation.type11;recruitmentLocation.value11;recruitmentLocation.city11;recruitmentLocation.type12;recruitmentLocation.value12;recruitmentLocation.city12;recruitmentLocation.type13;recruitmentLocation.value13;recruitmentLocation.city13;recruitmentLocation.type14;recruitmentLocation.value14;recruitmentLocation.city14;recruitmentLocation.type15;recruitmentLocation.value15;recruitmentLocation.city15;recruitmentLocation.type16;recruitmentLocation.value16;recruitmentLocation.city16;recruitmentLocation.type17;recruitmentLocation.value17;recruitmentLocation.city17;recruitmentLocation.type18;recruitmentLocation.value18;recruitmentLocation.city18;recruitmentLocation.type19;recruitmentLocation.value19;recruitmentLocation.city19;startDate;plannedActual;targetSize;studyEnd;monoMultiCentric;national;gender;minAge.amount;minAge.unit;maxAge.amount;maxAge.unit;inclusion;exclusion;address.type0;address.affiliation0;address.form0;address.title0;address.firstname0;address.lastname0;address.streetAndNo0;address.zip0;address.city0;address.land0;address.telephone0;address.fax0;address.email0;address.url0;address.type1;address.affiliation1;address.form1;address.title1;address.firstname1;address.lastname1;address.streetAndNo1;address.zip1;address.city1;address.land1;address.telephone1;address.fax1;address.email1;address.url1;address.type2;address.affiliation2;address.form2;address.title2;address.firstname2;address.lastname2;address.streetAndNo2;address.zip2;address.city2;address.land2;address.telephone2;address.fax2;address.email2;address.url2;address.type3;address.affiliation3;address.form3;address.title3;address.firstname3;address.lastname3;address.streetAndNo3;address.zip3;address.city3;address.land3;address.telephone3;address.fax3;address.email3;address.url3;address.type4;address.affiliation4;address.form4;address.title4;address.firstname4;address.lastname4;address.streetAndNo4;address.zip4;address.city4;address.land4;address.telephone4;address.fax4;address.email4;address.url4;materialSupport.type0;materialSupport.affiliation0;materialSupport.form0;materialSupport.title0;materialSupport.firstname0;materialSupport.lastname0;materialSupport.streetAndNo0;materialSupport.zip0;materialSupport.city0;materialSupport.land0;materialSupport.telephone0;materialSupport.fax0;materialSupport.email0;materialSupport.url0;materialSupport.type1;materialSupport.affiliation1;materialSupport.form1;materialSupport.title1;materialSupport.firstname1;materialSupport.lastname1;materialSupport.streetAndNo1;materialSupport.zip1;materialSupport.city1;materialSupport.land1;materialSupport.telephone1;materialSupport.fax1;materialSupport.email1;materialSupport.url1;materialSupport.type2;materialSupport.affiliation2;materialSupport.form2;materialSupport.title2;materialSupport.firstname2;materialSupport.lastname2;materialSupport.streetAndNo2;materialSupport.zip2;materialSupport.city2;materialSupport.land2;materialSupport.telephone2;materialSupport.fax2;materialSupport.email2;materialSupport.url2;title;acronym;url;publicSummary;scientificSynopsis;recruitmentStatus;publication.category0;publication.key0;publication.type0;publication.value0;publication.category1;publication.key1;publication.type1;publication.value1;publication.category2;publication.key2;publication.type2;publication.value2;publication.category3;publication.key3;publication.type3;publication.value3;publication.category4;publication.key4;publication.type4;publication.value4;url;last-update;
"DRKS00000041";2008/11/26;2008/07/31;yes;"Approved";"63/08";"Ethik-Kommission der Universität Ulm";"Primary Registry-ID";"ISRCTN76120052";"ISRCTN";;;;;;;;;;;;;"Free text";"[---]*";"Intraarticular Fracture of the Distal Radius";"ICD10";"S52.59";"[generalization S52.5: Fracture of lower end of radius]";;;;;;;;;;"Arm 1";"Experimental intervention: Open reduction and internal fixation (ORIF) with angle-stable plates (any manufacturer) via a volar surgical approach";"Arm 2";"Control intervention: Closed reduction and plaster cast stabilization";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Other";"Parallel";"[---]*";"[---]*";"Primary efficacy endpoint: Physical Component Score (PCS) of the Short Form 36 (SF36) 12 ± 1 months after randomizationKey";"secondary endpoint(s):<br/>-	Mental Component Score (MCS) and all other SF36 dimensions after 3 and 12 months of follow-up<br/>-	EuroQOL-5D (EQ5D) after 12 months of follow-up<br/>-	Disability of the Arm, Shoulder, and Hand questionnaire (DASH) after 3 and 12 months of follow-up<br/>-	Surgical Intervention or Revision Composite Measure (SIRCOM)<br/>-	Mortality<br/>-	Need for institutional care/ nursing home admission";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/09/14;"Actual";"560";2012/02/15;"Multicenter trial";"National";"Both, male and female";"65";"Years";"[---]*";"no maximum age";"Men and women >65 years with radiologically confirmed, isolated, closed, comminuted intraarticular distal radial fractures (AO/ASIF 23 C1, C2, C3) (according to surgeon?s judgment)";"Patients with an obvious need for surgical treatment, i.e., open fractures, severe soft tissue damage (>G1 according to Oestern and Tscherne), and a pathological fracture because of malignant disease will be excluded from this trial. <br/>Written informed consent by patients is mandatory, and any lack of consent will exclude subjects from trial participation. Subjects suffering from progressive dementia or other psychiatric diseases, or those who are unwilling to cooperate and thus jeopardize the success of follow-up will be excluded as well. If providers foresee a patient is inability to attend the 12-months follow-up evaluation because of severe frailty or other reasons, the subject will not be offered trial participation. <br/>Both in- and exclusion criteria define a typical target population with i. a high incidence of wrist fractures, ii. therapeutic uncertainty (equipoise) about the benefit-risk-ratio of operative and non-operative fracture management, and iii. a considerable likelihood of sustaining long-term sequelae from inappropriate treatment.";"Primary Sponsor";"Universitätsklinikum Ulm";"[---]*";"[---]*";"[---]*";"[---]*";"Albert-Einstein-Allee 29";"89075";"Ulm";"Germany";"+49-(0)731-500-0";"+49-(0)731-500-43002";"klinikumsvorstand@uniklinik-ulm.de";"www.uniklinik-ulm.de";"Contact for Scientific Queries";"Klinik für Unfall-, Hand-, Plastische und<br/>Wiederherstellungschirurgie<br/>Universitätsklinikum Ulm";"Mr.";"Dr.";"Christoph";"Bartl";"Steinhövelstraße 9";"89075";"Ulm";"Germany";"0731 - 500 54519";"0731 - 500 54502";"christoph.bartl@uniklinik-ulm.de";"http://www.uniklinik-ulm.de/";"Contact for Public Queries";"SDGC - Studienzentrum der Deutschen Gesellschaft für Chirurgie <br/>Chirurgische Universitätsklinik Heidelberg";"Ms.";"[---]*";"Inga";"Wegener";"Im Neuenheimer Feld 110";"69120";"Heidelberg";"Germany";"06221-56-6984";"06221-56-6988";"inga.wegener@med.uni-heidelberg.de";"www.sdgc.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgesellschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"+49 228/885-1";"+49 228/885-2777";"postmaster@dfg.de";"http://www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Open Reduction and Internal Fixation versus Casting for Highly comminuted and Intraarticular Fractures of the Distal Radius";"ORCHID";"www.orchid-studie.de";"There is insufficient evidence to decide whether elderly patients with complex, intra-articular wrist fractures benefit from surgical fixation or may achieve similar outcomes with closed reduction and casting. This randomized multi-centre trial aims at comparing health-related quality of life, function, and the ability of independent living one year after operative and non-operative treatment of intra-articular wrist fractures in patients of 65 years and older.";"Participants will be recruited from fifteen German hospitals and associated surgical practices and randomly assigned to closed reduction and cast stabilization or open reduction and internal fixation with volar angle-stable plates. The study will target a sample size of 504 subjects to detect a difference in Short-Form 36 (SF36) Physical Component Scores of 2.5 ± standard deviation 10 points after one year of follow-up, accepting type I and II errors of 5% and 20%, respectively. Secondary endpoints include SF36 ratings and Disability of the Arm, Shoulder and Hand (DASH) scores after 3 and 12 months, and other patient-centred and health-economically relevant endpoints. After Institutional Review Board approval and registration, the trial is projected to commence in March 2008, with lock-file planned in December 2010.";"Recruiting stopped after recruiting started ";"Further trial documents";"[---]*";"http://www.trialsjournal.com/content/12/1/84";"Studienprotokoll/ Study protocol";"Paper";"[---]*";"http://www.aerzteblatt.de/pdf.asp?id=163519";"Publikation Studienergebnisse/Publication Study results";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000041";"2015-01-12T16:14:16.542+01:00";
"DRKS00000071";2009/02/06;"[---]*";yes;"Approved";"2008035";"Ethikkommission der Ärztekammer Nordrhein";"EudraCT-Number";"2007-003358-27";"[---]*";"PEI-No.";"544/01";"[---]*";;;;;;;;;;"Free text";"[---]*";"juvenile ankylosing spondylitis";"ICD10";"M08.1";"Juvenile ankylosing spondylitis";;;;;;;;;;"Arm 1";"Adalimumab 40mg s.c. every other week";"Arm 2";"Placebo s.c. every other week";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Other";"Parallel";"III";"[---]*";"-	to demonstrate the superiority of adalimumab with respect to the ASAS Working Group response criterion ASAS40 as compared to placebo<br/>-	to contrast the safety profile of adalimumab with placebo in subjects with juvenile ankylosing spondylitis.";"- to show improvement of each of the 4 categories contributing to the ASAS40 criterion (spinal inflammation, back pain, patient's global assessment, physical function)<br/>- to show superiority of adalimumab with respect to the ACR Ped 30 response criterion as compared to placebo<br/>- to show improvement of each of the 6 categories contributing to the ACR Ped Score (physician's global assessment, parents' global assessment of subject's overall well-being, number of active joints, number of joints with limitation of motion, physical function, CRP).";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/07/02;"Actual";"50";2011/03/24;"Multicenter trial";"National";"Both, male and female";"12";"Years";"18";"Years";"-	IN1	Parents / legal guardian are willing to participate in the study and signed voluntarily the Informed Consent form.<br/><br/>-	IN2	Parents / legal guardian are willing to actively supervise storage and administration of study drug and to ensure that the time of each dose is accurately recorded in the subject's diary.<br/><br/>-	IN3	Patient and parents / legal guardian agree to comply with study requirements and are able to be at the clinic for all required study visits.<br/><br/>-	IN4	Patient is at least 12 years old and has not reached his 18th birthday.<br/><br/>-	IN5	The weight of the patient is > 30 kg.<br/><br/>-	IN6	IN FEMALE PATIENT IN WHOM MENARCHE HAS OCCURRED<br/>>	Negative serum pregnancy test prior to administration of study medication.<br/>>	Willingness to use an adequate method of contraception<br/>Adequate contraception can include abstinence if the investigator deems appropriate.<br/>-	IN7	Patient has a diagnosis of juvenile ankylosing spondylitis, i.e.<br/>A	bilateral active sacroiliitis confirmed by magnetic resonance imaging is present<br/>OR<br/>B	unilateral active sacroiliitis confirmed by magnetic resonance imaging is present, and patient has active peripheral joint disease restricted to the lower extremities (hip, knee, ankle)<br/>AND at least 1 clinical criterion is fulfilled:<br/>1.	limitation of lumbar spine motion in all three planes<br/>2.	pain or history of pain at the dorsolumbar junction of the lumbar spine<br/>3.	limitation of chest expansion to 2.5 cm or less at the level of the fourth intercostal space.<br/> <br/>-	IN8	Patient has active disease, i.e.<br/>1.	spinal inflammation score of at least 3<br/>AND at least 2 of the following domains:<br/>2.	back pain score of at least 3<br/>3.	patient global assessment of disease activity of at least 3<br/>4.	physical function score of at least 3.<br/>-	IN9	The disease has been refractory to at least two different non-steroidal antiphlogistic drugs given at appropriate dosage and for appropriate period of time.<br/><br/>-	IN10	Patient has not been treated with either etanercept or infliximab or adalimumab or anakinra at any time for any period.<br/><br/>-	IN11	Patient is able and willing to self-administer sc injections or has a suitable person at his disposal to administer sc injections.<br/><br/>-	IN12	Patient must be evaluated for active or latent TB infection according to the instructions of the protocol. If applicable: Guidelines regarding the treatment of latent TB must be followed prior to the administration of study medication.";"-	EX1	Patient has been diagnosed to have systemic onset of JRA / JIA or has active systemic features including fever or rash.<br/><br/>-	EX2	Patient has active uveitis within a period of 4 weeks prior to the first administration of study medication.<br/><br/>-	EX3	Pregnant or breast feeding female.<br/><br/>-	EX4	Female not willing to use appropriate contraception or sexual abstinence.<br/><br/>-	EX5	Chronic or active infectious disease, especially patient is positive for the hepatitis B surface antigen.<br/><br/>-	EX6	Preceding severe infectious disease during a period of 3 months prior to the first administration of study medication.<br/><br/>-	EX7	Preceding diagnosis of tuberculosis or any opportunistic infection including herpes zoster at any time.<br/><br/>-	EX8	Any preceding diagnosis of malignancy.<br/> <br/>-	EX9	Patient has a history of any chronic disease other than JAS, JRA / JIA, especially chronic renal disease, liver disease, hematological, gastrointestinal, pulmonary, cardiological or neurological disease, which in the opinion of the investigator may influence the efficacy or safety of the study medication or which in the opinion of the investigator leads to an unacceptable risk for the patient if he participates in the study.<br/><br/>-	EX10	Patient had a significant illness during a period of 4 weeks prior to the first administration of study medication other than JAS-related.<br/><br/>-	EX11	Patient is abusing alcohol or drugs.<br/><br/>-	EX12	Patient has been treated with antimalarials, gold salts, sulphasalazine, azathioprine, penicillamine, leflunomide, cyclosporine A, intravenous immunoglobulin, or methotrexate within 4 weeks prior to the first administration of study medication, or plans to begin the intake of these drugs.<br/><br/>-	EX13	Patient has been exposed to etanercept or infliximab or adalimumab or anakinra before receiving the first dose of study medication.<br/><br/>-	EX14	Patient has begun the intake or changed the dose regimen of oral corticosteroids within 4 weeks before Screening, doses of up to 0.2 mg/kg or 10 mg prednisone or equivalent per day, whichever is less, are allowed.<br/><br/>-	EX15	Patient plans to change dosing of oral corticosteroids within the study period.<br/><br/>-	EX16	Patient has received i.v., i.m., i.a. or soft tissue injections of corticosteroids within 4 weeks before first administration of study medication.<br/><br/>-	EX17	Patient has previously been admitted to this study.<br/><br/>-	EX18	Patient has been treated with any other investigational agent within 30 days or 5 half-lifes of the agent, whichever is longer, prior to the screening evaluation.<br/><br/>-	EX19	Patient has been treated with any investigational biologic agent within 6 months prior to the screening evaluation.<br/><br/>-	EX20	Demonstration of clinically significant deviations in any of the following laboratory parameters:<br/>>	platelet count < 100.000/mm3<br/>>	total white cell count < 4000 cells/mm3<br/>>	neutrophils < 1000 cells/mm3<br/>>	hematocrit < or = 24%<br/>>	AST or ALT or serum bilirubin > 2x the upper limit of normal<br/>>	glomerular filtration rate GFR < 90 mL/min / 1.73 m2 BSA<br/>[GFR (mL/min / 1.73 m2 BSA) = 0.55 x height (cm) / plasma creatinine (mg/dL)]<br/> <br/>-	EX21	Patient has a history of an expanding CNS neoplasm, active CNS infection, demyelinating disease, degenerative neurological disease or any progressive CNS disease.<br/><br/>-	EX22	Patient has a poorly controlled diabetes.<br/><br/>-	EX23	Any concurrent medical condition which would, in the investigator's opinion, compromise the patient's ability to tolerate the study drug or would make the patient unable to comply with the protocol.<br/><br/>-	EX24	Patient has a history of or current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent.<br/><br/>-	EX25	Patient has a recent history of alcohol or drug abuse within the past 6 months that would interfere with ability to comply with protocol requirements.<br/><br/>-	EX26	Any other inability to comply with the study requirements.<br/><br/>-	EX27	Any contraindication listed in the German 'Fachinformation' of the drug Humira®.";"Primary Sponsor";"Asklepios Klinik Sankt Augustin";"Mr.";"Prof. Dr. med.";"Gerd";"Horneff";"Arnold-Janssen-Straße 29";"53757";"Sankt Augustin";"Germany";"02241 249201";"02241 249203";"g.horneff@asklepios.com";"www.asklepios-kinderklinik.de";"Contact for Scientific Queries";"Asklepios Klinik Sankt Augustin";"Ms.";"[---]*";"Sigrid";"Fitter";"Arnold-Janssenstr. 29";"53757";"Sankt Augustin";"Germany";"02241 249218";"02241 249203";"s.fitter@asklepios.com";"www.asklepios-kinderklinik.de";"Contact for Public Queries";"Asklepios Klinik Sankt Augustin";"Ms.";"Dr. med.";"Ariane";"Klein";"Arnold-Janssen-Straße 29";"53757";"Sankt Augustin";"Germany";"02241 249240";"02241 249203";"ar.klein@asklepios.com";"www.asklepios-kinderklinik.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Abott GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Max-Planck-Ring 2";"65205";"Wiesbaden";"Germany";"06112 580";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Phase III, multi-center, randomized, double-blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab";"[---]*";"[---]*";"This study aims at patients with juvenile ankylosing spondylitis (M. Bechterew), who did not respond to therapy with nonsteroidal anti-inflammatory drugs.<br/>The TNF inhibitor Adalimumab is approved in the therapy of ankylosing spondylitis in adult patients, the treatment requires a subcutaneous injection of Adalimumab every other week.<br/>This study designed to evaluate the efficacy and safety of treatment of juvenile ankylosing spondylitis with adalimumab.<br/>In the first 12 week period patients will receive either Adalimumab or placebo, in the following 12 week period all patients will receive Adalimumab and can possibly profit from treatment.<br/>During the study monthly visits at the study centre are required.";"This randomized, double-blind, placebocontrolled study is designed to assess efficacy and safety of treatment of juvenile ankylosing spondylitis with Adalimumab, a TNF inhibitor. In the therapy of ankylosing spondylitis in adult patients Adalimumab has been shown to be effective and is already approved. <br/>Study design: In the first placebo-controlled 12 week period subjects who meet all entry criteria will be randomized to either 40 mg Adalimumab or placebo injected subcutaneously every other week. In the following 12 week period all patients will receive 40mg of Adalimumab subcutaneously every other week. <br/>Physical examinations, measures of disease activity and laboratory tests are to be performed at screening, baseline and every 4 weeks.";"Recruiting stopped after recruiting started ";"Abstract";"872c6c49-0ed1-40ad-8a01-1a4adb4fd0f9";"Humira-Study_abstract.pdf";"Abstract";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000071";"2012-09-05T11:43:54.561+02:00";
"DRKS00000213";2009/09/28;2009/07/30;no;"Approved";"FK-2007-0007";"Ethik-Kommission an der Medizinischen Fakultät der Universität Rostock";"Universal Trial Number (UTN)";"U1111-1111-0107";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2006-006404-11";"[---]*";"Primary Registry-ID";"NCT00950274";"ClinicalTrials.gov";"PEI-No.";"501/01";"[---]*";;;;"Free text";"[---]*";"Patients with coronary artery disease scheduled for CABG surgery";"ICD10";"[---]*";"[---]*";;;;;;;;;;"Arm 1";"CD133+ autologous bone marrow stem cells:<br/>5 mL CD133+ cells (0.5-5x10E6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery.";"Arm 2";"5 mL physiological saline + 10% autologous serum solution intramyocardially during CABG surgery.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Other";"Parallel";"III";"[---]*";"Left ventricular ejection fraction (LVEF) at 6 months postoperatively, measured by MRI at rest";"Change in LVEF at 6 months post-OP compared with preoperatively (screening) and early postoperatively (discharge) as assessed by MRI and echocardiography || Change in LV dimensions (left ventricular end systolic dimension [LVESD], left ventricular end diastolic dimension [LVEDD]) at 6 month post-OP compared with preoperatively (screening) and early postoperatively (discharge) as assessed by echocardiography. || Change in physical exercise capacity determined by 6 minute walk test at 6 months post-OP compared with preoperatively (screening) and early postoperatively (discharge). || Change in NYHA and CCS class at 6 months post-OP compared with preoperatively (screening) and early postoperatively (discharge). || MACE (cardiac death, myocardial infarction, secondary intervention/reoperation, ventricular arrhythmia). || QoL-score at 6 months post-OP compared with preoperatively (screening) and 3 months (telephone).";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/10/14;"Actual";"142";2016/03/10;"Multicenter trial";"National";"Both, male and female";"18";"Years";"79";"Years";"Coronary artery disease after myocardial infarction with indication for CABG surgery. <br/>Currently reduced global left ventricular ejection fraction (LVEF) assessed at site by cardiac magnetic resonance imaging (MRI) at rest (25% <= LVEF <= 50%). <br/>Presence of a localized akinetic/hypokinetic/hypoperfused area of LV myocardium for defining the target area. <br/>Informed consent of the patient. <br/>18 years <= Age < 80 years. <br/>Are not pregnant and do not plan to become pregnant during the study.  Females with childbearing potential must provide a negative pregnancy test within 1-7 days before OP and must be using oral or injectable contraception (non childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before study start).";"Emergency operation. <br/>Presence of any moderate-severe valvular heart disease requiring concomitant valve replacement or reconstruction. <br/>Medical History of recent resuscitation in combination with ventricular arrhythmia classified by LOWN >= class II.  <br/>Acute myocardial infarction within last 2 weeks. <br/>Debilitating other disease: Degenerative neurologic disorders, psychiatric disease, terminal renal failure requiring dialysis, previous organ transplantation, active malignant neoplasia, or any other serious medical condition that, in the opinion of the Investigator is likely to alter the patient's course of recovery or the evaluation of the study medication's safety. <br/>Impaired ability to comprehend the study information. <br/>Absence of written informed consent. <br/>Treatment with any investigational drug within the previous 30 days. <br/>Apparent infection (c-reactive protein [CRP] >= 20 mg/L, fever >= 38.5°C). <br/>Contraindication for MRI scan. <br/>Immune compromise including active infection with Hepatitis B, C, HIV virus or seropositivity for Treponema pallidum.  <br/>Pregnant or breast feeding. <br/>Childbearing potential with unreliable birth control methods<br/>Have previously been enrolled in this study, respectively phase I and phase II. <br/>Known hypersensitivity or sensitization against murine products and human-anti-mouse-antibody-titer >= 1:1000. <br/>Contraindication to bone marrow aspiration. <br/>Known hypersensitivity against iron dextran.";"Primary Sponsor";"Miltenyi Biotec GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Friedrich-Ebert-Straße 68";"51429";"Bergisch Gladbach";"Germany";"+49 2204 8306-6625";"+49 2204 8306-6699";"[---]*";"www.miltenyibiotec.com";"Contact for Scientific Queries";"Universität Rostock<br/>Klinik und Poliklinik für Herzchirurgie";"Mr.";"Prof. Dr. med.";"Gustav";"Steinhoff";"Schillingallee 35";"18057";"Rostock";"Germany";"+49 381 494 6100";"[---]*";"gustav.steinhoff@med.uni-rostock.de";"[---]*";"Contact for Public Queries";"Universität Rostock,<br/>Klinik und Poliklinik für Herzchirurgie";"Mr.";"Prof. Dr. med.";"Gustav";"Steinhoff";"Schillingallee 35";"18057";"Rostock";"Germany";"+49 381 494 6100";"[---]*";"gustav.steinhoff@med.uni-rostock.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung (BMBF) <br/>Referat Biotechnologie";"[---]*";"[---]*";"[---]*";"[---]*";"Friedrichstraße 130 B";"10117";"Berlin";"Germany";"030 1857-0";"030 1857-83601";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Intramyocardial TransPlantation Of BonE MaRrow Stem Cells For ImprovEment Of Post-Infarct MyoCardial RegeneraTion In Addition To CABG Surgery: a controlled prospective, randomized, double blinded multicenter trial. (PERFECT)";"PERFECT";"[---]*";"Clinical study using patient's own stem cells from bone marrow in addition to bypass surgery after myocardial infarction.  The blood supply and pump function might be increased by the growth of blood vessels.";"This will be a placebo controlled, prospective, randomized, double-blind multicenter, phase III, clinical trial investigating the effects of intramyocardial injection of 5 ml CD133+ bone marrow cells or placebo in 142 patients with coronary artery disease scheduled for CABG surgery. Patients will be randomized to one of the two treatment groups (CD133+ or placebo) in a 1:1 ratio.";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000213";"2017-03-17T09:45:48.836+01:00";
"DRKS00000268";2010/01/19;"[---]*";no;"Approved";"2009-105-ff";"Ethik-Kommission bei der Landesärztekammer Baden-Württemberg";"EudraCT-Number";"2009-011418-68";"[---]*";"BfArM-No.";"4035599";"[---]*";;;;;;;;;;"ICD10";"N32.8";"Other specified disorders of bladder";;;;;;;;;;;;;"Arm 1";"Capsules with 227,3 mg pumpkin seed oil, 56,0 mg dry extract from fragrant sumach bark and 18,0 mg dry extract from hop strobile, three times daily over eight weeks.";"Arm 2";"Placebo capsules, three times daily over eight weeks.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Treatment";"Parallel";"IV";"[---]*";"Change of micturition frequency after eight weeks of treatment compared to baseline.";"Change of micturition frequency in the course of eight weeks of treatment compared to baseline. || Change of urge frequency in the course of eight weeks of treatment compared to baseline. || Change in Quality of Life mesaured by use of questionnaires at baseline and after 1, 4 and 8 weeks of treatment.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/02/23;"Actual";"100";2010/08/19;"Multicenter trial";"National";"Female";"18";"Years";"60";"Years";"Overactive bladder symptoms persist since at least three months; overactive bladder symptoms have not been treated within two weeks before screening visit; maximum Body Mass Index of 30; eight micturitions minimum within 24 hours; one episode of urge or urge incontinence minimum within 24 hours.";"Known hypersensitivity to pumpkin seed and related plants such as watermelon, courgette etc, to soy, peanut or any other of the ingredients of the study medication; hereditary fructose intolerance or glucose-galactose malabsorption; urinary retention; diseases causing  micturition disorders; bladder cancer; urinary tract infection (acute or within four weeks before the first study visit); isolated nocturia; unexplained hematuria; neurological diseases; preceding surgeries in lower urinary tract and all other medical interventions (e.g. hysterectomy), that may cause urinary incontinence;  preceding irradiation; diabetes mellitus (HbA 1c >6), endocrinologic disorders; preceding venereal disease; depression; diseases causing severe cough or sneezing and chronic pressure on pelvic floor; pregnant or breast-feeding women, women of childbearing potential and who do not maintain effective contraception during the study; severe renal or hepatic diseases; concomitant medication or treatment that may influence bladder function.";"Primary Sponsor";"GlaxoSmithKline Consumer Healthcare GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Bußmatten 1";"77815";"Bühl";"Germany";"+49 (0) 7223 76-2178";"[---]*";"heike.kirstein@gsk.com";"www.gsk-consumer.de";"Contact for Scientific Queries";"GlaxoSmithKline Consumer Healthcare GmbH & Co. KG";"Mr.";"Dr.";"Michael";"Harkenthal";"Bußmatten 1";"77815";"Bühl";"Germany";"+ 49 (0) 7223 76 - 0";"+ 49 (0) 7223 76 - 40 00";"michael.harkenthal@gsk.com";"www.gsk-consumer.de";"Contact for Public Queries";"GlaxoSmithKline Consumer Healthcare GmbH & Co. KG";"Ms.";"Dr.";"Sigrid";"Stiller";"Bußmatten 1";"77815";"Bühl";"Germany";"+49 (0) 7223 76 - 0";"+49 (0) 7223 76 - 40 00";"sigrid.stiller@gsk.com";"www.gsk-consumer.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"GlaxoSmithKline Consumer Healthcare GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Bußmatten 1";"77815";"Bühl";"Germany";"+ 49 (0) 7223 76-0";"+ 49 (0) 7223 76-40 00";"[---]*";"www.gsk-consumer.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Pilot study to investigate the effects of a herbal combination in women suffering from overactive bladder syndrome";"femina study";"[---]*";"The study preparation is a  herbal combination that is common in the traditional use for strengthening and fortification of the bladder function. The active ingredients are pumpkin seed oil, dry extract from fragrant sumach bark and dry extract from hop strobile. This study investigates whether this herbal medicine improves symptoms and health-related quality of life in women suffering from irritable bladder in comparison to placebo treatment.";"This pilot study investigates the effects of a herbal combination in women suffering from overactive bladder. The active ingredients are pumpkin seed oil, dry extract from fragrant sumach bark and dry extract from hop strobile. This combination has been marketed for decades in the treatment of irritable bladder disorders and nowadays is recommended traditionally for strengthening and fortification of bladder function. The ""overactive bladder syndrome"" has been defined by the International Continence Society as urgency, with or without urge incontinence, usually with frequency and nocturia. The synonym ""irritable bladder"" is well-known by the public for this condition.<br/>Already a moderate increase in micturition frequency and incidental episodes of urge can be distressfull for the patients and disturb the patients' quality of life. The purpose of this pilot study is to examine the effects of this herbal medicine on micturition disorders, such as frequency and urge in women suffering from overactive bladder, as well as the influence of the medication on quality of life over a treatment period of  eight weeks, in comparison to placebo treatment. Interim visits are scheduled after one and four weeks of treatment.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000268";"2011-04-26T12:45:48.522+02:00";
"DRKS00000296";2010/01/05;"[---]*";yes;"Approved";"S-333/2009";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";"Universal Trial Number (UTN)";"U1111-1113-0684";"[---]*";;;;;;;;;;;;;"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;;;;"Arm 1";"Interventional arm: Additional psychosocial support by a former patient.";"Arm 2";"Control: Routine counselling without additional intervention.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Control group receives no treatment";"Health care system";"Parallel";"N/A";"[---]*";"Subjective satisfaction with decision-making process and with the finally made decison - self-designed questionnaire";"Feasibility of the additional support program - documented interventions || Depression and self efficiency - PHQ-4 (Löwe, Wahl et al. in press); SWE (Schwarzer and Jerusalem 1995) || Objective and subjective coping parameters: degree of informedness, self-assessment of health, subjective quality of life, satisfaction with provided counselling, emotional distress, subjective judgement on objective symptoms - PCI (Schwarzer und Taubert 2002), Emotion thermometer (Mitchell, Baker-Glenn et al. 2009), SF 12 (Ware, Kosinski et al. 1996), ICS male (Bates, Wright et al. 1998) || Personality traits in intervention and control arm: preferences for decision making, self efficiency, need of social support, communication characteristics, social integration - SWE (Schwarzer and Jerusalem 1995), PCI (Schwarzer and Taubert 2002) || Quality of dyadic peer-to-peer support - self-designed questionnaire";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Urologie";"Heidelberg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/01/12;"Actual";"100";2011/12/31;"Monocenter trial";"National";"Male";"18";"Years";"85";"Years";"Initial diagnosis of localized prostate cancer<br/>Counselling at the Department of Urology, University of Heidelberg<br/>Informed consent";"Missing informed consent<br/>Prostatectomy is not a valid treatment option<br/>Extension of surgery (e.g. cystectomy)<br/>Locally advanced disease (N+, R2-situation) or systemic disease (M1)";"Primary Sponsor";"Urologische Universitätsklinik Heidelberg";"Mr.";"Dr. med.";"Dr. phil. Johannes";"Huber";"Im Neuenheimer Feld 110";"69120";"Heidelberg";"Germany";"+49(0)6221-56 6110";"[---]*";"johannes.huber@med.uni-heidelberg.de";"www.prostatazentrum-heidelberg.de";"Contact for Scientific Queries";"Urologische Universitätsklinik Heidelberg";"Mr.";"Dr. med.";"Dr. phil. Johannes";"Huber";"Im Neuenheimer Feld 110";"69120";"Heidelberg";"Germany";"+49(0)6221-56 6110";"[---]*";"johannes.huber@med.uni-heidelberg.de";"www.prostatazentrum-heidelberg.de";"Contact for Public Queries";"Urologische Universitätsklinik Heidelberg";"Mr.";"Dr. med.";"Dr. phil. Johannes";"Huber";"Im Neuenheimer Feld 110";"69120";"Heidelberg";"Germany";"+49(0)6221-56 6110";"[---]*";"johannes.huber@med.uni-heidelberg.de";"www.prostatazentrum-heidelberg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Urologische Universitätsklinik Heidelberg";"Mr.";"Prof. Dr. med.";"Markus";"Hohenfellner";"Im Neuenheimer Feld 110";"69120";"Heidelberg";"Germany";"[---]*";"[---]*";"[---]*";"www.prostatazentrum-heidelberg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Experienced involvement in counselling for prostate cancer";"[---]*";"http://www.klinikum.uni-heidelberg.de/Urologie-Heidelberg-e-V.113928.0.html";"Besides evaluating counselling for localized prostate cancer from our patients' point of view, we would like to study feasibility, acceptance and efficiency of a dyadic peer-to-peer support program.";"Experienced involvement is a well established idea in psychiatric disease. We would like to transfer this approach to oncology and study the feasibility, acceptance and efficiency of a dyadic peer-to-peer support program for localized prostate cancer. Moreover, we evaluate counselling from our patients' point of view.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000296";"2018-01-12T14:15:03.153+01:00";
"DRKS00000360";2010/03/11;"[---]*";yes;"Approved";"148/06";"Ethik-Kommission des Fachbereichs Medizin der Philipps-Universität Marburg";"EudraCT-Number";"2006-004374-27";"[---]*";"PEI-No.";"293/04";"[---]*";;;;;;;;;;"ICD10";"G70.0";"Myasthenia gravis";;;;;;;;;;;;;"Arm 1";"Mutagrip (vaccine)<br/>intramuscular injection in standard manner (deltoid muscle)";"Arm 2";"NaCl 0,9% (placebo)<br/>intramuscular injection in standard manner (deltoid muscle)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Other";"Parallel";"II-III";"[---]*";"relative changes in % of the AChR-ab titer within three months after anti-Influenza vaccination";"vaccination success, changes in pyridostigmine and/or immunosuppresants dosage, modified Besinger-/MGFA score to quantify weakness";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2006/11/16;"Actual";"160";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"written informed consent<br/>age at least 18 years<br/>age of 80 years maximum<br/>diagnosis of myasthenia gravis according the guideline of the German Neurological Society<br/>positve anti-AChR abs<br/>clinically stable for at least 4 months";"any vaccination within 9 months prior to study entry<br/>history of severe heart disease<br/>cardiac arrythmia<br/>History of cancer<br/>acute infection at screening or Visit 1<br/>allergy against chicken protein<br/>History of severe vaccination reaction";"Primary Sponsor";"Philipps-Universität Marburg<br/>Koordinierungszentrum für Klinische Studien (KKS)";"Ms.";"[---]*";"Carmen";"Schade-Brittinger";"Karl-von-Frisch Str. 4";"35043";"Marburg";"Germany";"06421-2866509";"06421-2866517";"carmen.brittinger@kks.uni-marburg.de";"http://www.kks.uni-marburg.de/";"Contact for Scientific Queries";"Philipps-Universität Marburg<br/>Klinik für Neurologie";"Mr.";"Dr.";"Björn";"Tackenberg";"Rudolf-Bultmann-Str. 8";"35039";"Marburg";"Germany";"06421-5865200";"06421-5865164";"tackenbb@staff.uni-marburg.de";"www.uni-marburg.de";"Contact for Public Queries";"Philipps-Universität Marburg<br/>Klinik für Neurologie";"Ms.";"[---]*";"Babette";"von Hagen";"Rudolf-Bultmann-Str. 8";"35039";"Marburg";"Germany";"06421-5863521";"06421-5865164";"hagen@med.uni-marburg.de";"www.uni-marburg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"Förderverein Neurologi für Forschung, Ausbildung und Therapie, e. V.";"Mr.";"Prof. Dr.";"Felix";"Rosenow";"Rudolf-Bultmann- Str. 8";"35039";"Marburg";"Germany";"06421-5865200";"06421-5865164";"loewerh@med.uni-marburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prospective, randomised, doubleblind, placebo controlled trial on changes in acetylcholine receptor antibody titers in autoimmune myasthenia gravis after influenza vaccination <br/>EudraCT-Nr. 2006-004374-27";"ProPATIent";"n. a.";"It is unknown, wether vaccination in gerneral and especially anti-Influenza vaccination is relevant for the course of myasthenia gravis. In this stud we adress the question, whether myasthenia gravis is a balk for anti-Influenza vaccination. From german legal authorities all healthy humans with age > 60 years (and in special cases alsoger people) were recommended to be vaccinated. The scientific literature does not yet provide evidence for a clear benefit of vaccination in autoimmunity. However, there are hints for a possible causal relationship between vaccination and the onset of immune mediated diseases, like muscle pareses (Guillain-Barre syndrome), inflammation of the brain and spinal cord or inflammation of the vessels. In the ProPATIent-trial the changes in the titer of the Acetylcholinereceptor antibody after vaccination will be systematically analysed.";"Myasthenia gravis (MG) is an autoimmune disease with T-helper cell dependent acetylcholine receptor antibodies, leading to muscle weakness with recovery at rest. Anti-influenza vaccination leads to a T-cell mediated anti-Influenza antibody response against seasonal influenza viruses. It is unclear whether boostering by vaccination may lead to a clinical worsening or changes in the AChR-antibody titer. <br/>Here we present a prospective, randomized, double-blind, placebo-controlled trial to detect changes in the AChR-antibody titers in a 5 months follow-up after vaccination. Secondary endpoints to detect clincially relevant changes are Besinger-score and changes in medication dosage (pyridostigmine).";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000360";"2012-01-12T09:57:48.724+01:00";
"DRKS00000583";2010/11/03;"[---]*";yes;"Approved";"269-08";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2009-015749-22";"[---]*";"PEI-No.";"1183/01";"[---]*";;;;;;;;;;"ICD10";"L97";"Ulcer of lower limb, not elsewhere classified";"ICD10";"[---]*";"[---]*";;;;;;;;;;"Arm 1";"topic application of adalimumab weekly over maximal 8 weeks";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"percental reduction of wound area under serial treatment with Adalimumab, measurement by fotographical documentation and measurement of the wound";"- occurrence of new or aggravation of existent infection<br/>- pain associated with chronic wound<br/>- occurrence of possible contraindications";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/08/12;"Actual";"18";2012/06/29;"Monocenter trial";"National";"Both, male and female";"50";"Years";"[---]*";"no maximum age";"- at least one chronic wound without signs of infection. At the time point of study inclusion the wound must measure between 2,25 cm2 and 64 cm2.<br/>- age ≥50 years<br/>- at least 6 months existence without significant recovery although optimal wound care <br/>- written informed consent<br/>";"- pregnancy and nursing women,<br/>- presence of severe hepatic insufficiency or renal insufficiency <br/>- presence of hepatitis <br/>- chronic severe focus of infection <br/>- severe wound infection <br/>- known hypersensitivity to Adalimumab or other components of IMP <br/>- signs of latent or active tuberculosis <br/>- clinically decompensated heart failure (NYHA III/IV), <br/>- inusfficient compliance <br/>- active demyelinating or other neurological disorder <br/>- malignant or lymphoproliferative disorder <br/>- known autoimmune disorder <br/>- intake of other immunodepressive drugs<br/>- women of child bearing potential (< 2 years after last menstruation)<br/>- concurrent participation in other clinical trials<br/>- persons dependent on investigator";"Primary Sponsor";"Universität Leipzig<br/><br/>";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstraße 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum Leipzig<br/>Klinik für Dermatologie, Venerologie und Allergologie";"Mr.";"Prof. Dr. med.";"Jan Christoph";"Simon";"Ph.-Rosenthal-Str. 23";"04103";"Leipzig";"Germany";"+49-341-9718600";"+49-341-9718759 ";"Jan.Simon@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Universitätsklinikum Leipzig<br/>Klinik für Dermatologie, Venerologie und Allergologie";"Mr.";"Prof. Dr. med.";"Jan Christoph";"Simon";"Ph.-Rosenthal-Str. 23";"04103";"Leipzig";"Germany";"+49-341-9718600";"+49-341-9718759 ";"Jan.Simon@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Abbott Germany<br/><br/>";"[---]*";"[---]*";"[---]*";"[---]*";"Max-Planck-Ring 2a";"65205";"Wiesbaden-Delkenheim";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds";"ADATOP";"[---]*";"Various therapeutic options were used in the former treatment of subjects without healing up. In ADATOP Adalimumab apply in area of the wound external only (so-called topic application). We hope that the clinical trial can improve wound healing, so wound closure could be possible.<br/>";"In this trial we will research the possible influence of wound healing by topic application of adalimumab weekly over maximal 8 weeks in chronic wounds without any other option of treatment.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000583";"2013-09-27T15:23:29.936+02:00";
"DRKS00000600";2010/11/11;2005/12/01;yes;"Approved";"269/03";"Ethik-Kommission der Albert-Ludwig-Universität Freiburg";"Partner Registry-ID";"UKF000577";"Register klinischer Studien des Universitätsklinikums Freiburg";"BfArM-No.";"4021536";"[---]*";;;;;;;;;;"ICD10";"C25.9";"Malignant neoplasm: Pancreas, unspecified";"MedDRA";"[---]*";"10033576";;;;;;;;;;"Arm 1";"Trastuzumab 4 mg/kg as initial infusion, followed by 2 mg/kg weekly and Capecitabin 2 x 1250 mg/m2 daily for days 1-14 followed by 7 days pause; repeated every three weeks until tumour progression.";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"progression free survival rate after 12 weeks";"progression free survival<br/>-           overall survival -<br/>-           time to remission (complete/partial)<br/>-           duration of remission <br/>-           Rate of ""Clinical Benefit Response"" after 12 weeks<br/>-           quality of life before therapy and after every second chemotherapy cycle<br/>-           Toxicity and occurrence of adverse events<br/>-           impact of CA19-9 serum concentration on progression free survival<br/>-           correlation between tumour HER2-expression grade and progression free survival<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2004/09/14;"Actual";"37";2008/05/01;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Written informed consent<br/>- Age over 18 <br/>- Histological confirmed diagnoss of a pancreas carcinoma in Stage IVB (T1-4, N0-1, M1)<br/>- Staging and CA 19-9 Determiantion not older than 4 weeks<br/>- Histologically confirmed overexpression of HER2/neu (immunhistochemical Score 2+ (confirmed by  FISH ) or 3+)<br/>- At least one measurable or assessable lesion  over 2 cm in conventional CT<br/>- No previous chemotherapy <br/>- No previous radiation therapy<br/>- Performance-Status 0 - 2  WHO/ECOG or better 60 Karnofsky<br/>- life expectancy at least 3 month<br/>- Sufficient renal, hepatic and bonemarrow function,<br/>(blood values not older than 1 weel) defined as<br/>absolute Neutrophil count  greater 1,5 x 10 exp9/l,<br/>Hemoglobin greater 80 g/l, platelets greater 100 x 10exp 9 /l, total bilirubin smaller 3-fold upper normal value, creatinine clearance greater 30ml/min (according to Cockroft and Gault), Transaminases smaller 2,5-fold upper normal value, smaller 5-fold upper normal value in case of liver metastases.<br/>- LVEF       > 50%    <br/>- infrastructure for regular and longterm followup <br/>- Negative pregnancy test for women in reproductive age (done during Screening)";"Option of surgical treatment or radiation therapy with curative intention<br/>-  Known Dihydropyrimidin dehydrogenase (DPD) deficiency<br/>- History of known secondary carcinoma with exception of basalioma of skin treated in curative intention or cervical carcinoma in situ <br/>- Known hypersensitivity to one of the study medications or their ingredients<br/>- Clinical relevant disease of the cardiovascular system or other major organ systems or significant systemic disease, which is incompatible with the procol or complicates the interpretation of the protocol. <br/>- Clinically  signioficant pulmonary disease<br/>- Preexisting polyneuropathy<br/>- Simultaneous therapy with the virostatic agent  Sorivudin or chemically related substances, for instance Brivudin<br/>- Pragnancy, lactation or lack of reliable contraception for women in their reproductive age<br/>- Psychiatric disease, addiction or other disease, which keep the patient from understanding character and consequences of the study<br/>- Simultaneous participation in a different clinical study within the last 4 weeks<br/>- Any disease or therapy, which presens a  risk to the patient in the mind of the investigator or is not compatible with the goals of the study";"Primary Sponsor";"Universitätsklinikum Freiburg<br/>Abteilung Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie<br/><br/>";"Mr.";"Prof. Dr. med.";"Michael";"Geißler";"Hugstetterstr. 49";"79110";"Freiburg";"Germany";"0711/31032541";"[---]*";"m.geissler@klinikum-esslingen.de";"[---]*";"Contact for Scientific Queries";"Abteilung für Allgemeine Innere Medizin, Onkologie/Hämatologie, Gastroenterologie und Infektiologie<br/>Klinikum Esslingen GmbH";"Mr.";"Prof. Dr. med.";"Michael";"Geißler";"Hirschlandstr. 97";"73730";"Esslingen";"Germany";"0711/31032541";"[---]*";"m.geissler@klinikum-esslingen.de";"[---]*";"Contact for Public Queries";"Abteilung für Allgemeine Innere Medizin, Onkologie/Hämatologie, Gastroenterologie und Infektiologie";"Mr.";"Prof. Dr. med.";"Michael";"Geißler";"Hirschlandstr. 97";"73730";"Esslingen";"Germany";"0711/31032541";"[---]*";"m.geissler@klinikum-esslingen.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Hoffmann-La Roche AG";"[---]*";"[---]*";"[---]*";"[---]*";"Emil-Barell-Straße 1";"79630";"Grenzach-Wyhlen";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinoma";"ML17-743";"[---]*";"A therapy  for advanced pancreas carcinoma by surgical removal which is the cure for early stages is not possible. Chemotherapy and radiation therapy had only small success rates. <br/>During the last few years a few drugs have been whic had an effect in different malignant tumors. <br/>The new substance capecitabine is converted into the effective drug in tumor tissue. The conversion into the effective drug at the location of the tumor helps to minimize toxicities and side effects concerning other organs. Capecitabine can be applied orally in tablet form. Therefore  venous port systems and intravenou infusions are not necessary. A therapeutic response for Capecitabine  has been observed for patients with pancreas carcinoma.<br/>A second new medication Trastuzumab  has a specific effect on tumor cells, which have a specific protein (HER2/neu) in large quantities on their surface. Trastuzumab is an antibody, which is directed against the  target structure (HER2) and slows down tumor growth. Up to 30% of all pancreas carcinomas carry a sufficient amount of this target proptein. The presence of the target will be assessed by tissue biopsy festgestellt. The medication will be applied once a week by infusion.Preliminary studies for pancrea carcinoma with a combination of Trastuzumab and other Chemotherapies a response.<br/>This study was designed to find outif the  combination of capecitabin and Trastuzumab in comparison with established chemotherapies shows a better response i. e. improves survival time and quality of life.";"A generall accepted standard-chemotherapy for advanced pancreas carcinoma does not exist.  Therapy of advanced, inoperable pancreas carzinoma is still of palliative character. Therefore it is the goal of any therapy to achieve an improvement of survival time with optimal quality of life. <br/>The  specific mechanism of capecitabine (Xeloda®) by accumulation and activation in tumor tissue and the Inhibition of HER2 receptor mediated  tumor cell proliferation by Trastuzumab (Herceptin®) can improve the prognosis of HER2 positive pancreas carcinoma. Because of differentv mechanisms there are no overlapping toxicities. The side effects are all known, managable  and reversible. The  therapy can be applied on an outpatient basis and fullfills the needs of a patient for a minimum of stays in the hospital. Because of the pharmacocinetic similarities and the advantages of  oral capecitabine versus continuous infusion of  5-FU it appears to be in the  interest of improvement of palliative therapies for pancreas carcinoma patients to design combination protocols of Capecitabine with Trastuzumab. Clinical data for this combination are not yet available for the pancreas carcinoma. <br/>In this multicenter phase-II-study the combinationen of Capecitabin/Trastuzumab should be assessed for efficacy and toxicity for the therapy of advanced , inoperable pancreas carcinoma.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000600";"2014-11-14T14:24:09.586+01:00";
"DRKS00000858";2012/04/25;2004/07/22;yes;"Approved";"054/04";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"Partner Registry-ID";"UKF000105";"Register klinischer Studien des Universitätsklinikums Freiburg";;;;;;;;;;;;;"ICD10";"N18.8";"Other chronic renal failure";"ICD10";"Z94.0";"Kidney transplant status";;;;;;;;;;"Arm 1";"15 well-selected immunologically low-risk patients receive a minimized immunsuppressive regime after kidney transplantation. The immunsupression starts with antithymocyte globin<br/>induction following de novo sirollmus monotherapy. This steroid- and CNI-free protocol should reduce the risk of cardiovascular events, chronic allograft nephropathy and the risk of opportunistic infection.";"Arm 2";"Historic patient population treated with standard protocol: cyclosporine, mycophenolatmofetil, steroids";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Historical";"Treatment";"Other";"III";"No";"Transplant function (serum creatinine mg/dl and ceatinin-clearance) after 1, 3, 5 years";"•	patient- and transplant survival<br/>•	rate and degree of acute bioptic confirmed graft shedding(after Banff) and number of steroid-resistant sheddings<br/>•	intake of calcineurin-inhibitors <br/>•	steroid long-term medication<br/>•	incidence of Chronic Allograft Nephropathy (CAN)<br/>•	level of blodd pressure and antihypertensive medication<br/>•		 lipid level and lipid reducing medication<br/>•	liver function<br/>•	rate and degree of oppertunistic infections<br/>•	incidence of  an 	haematological adverse effect<br/>•	incidence of malignant disease<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Chirurgie";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2005/01/26;"Actual";"15";2005/11/29;"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"- first kidney transplantation<br/>- ager 18 - 65 years<br/>- Written informed consent<br/>- Highly effective contraception";"- slave- or multi-transplantation <br/>- combined transplantation<br/>- age < 18 years<br/>- incompatibility (allergy, intolerance, oversensitive) against study medication<br/>- current malignant disease or last malignant disease< 5 years<br/>- Serious intercurrent infections (uncontrolled or requiring treatment (incl. HIV)<br/>- severe diarrhoea, vomiting or active gastric- or duodenal ulcer<br/>- participation in another investigational sudy<br/>- autoimmune disease as primary disease (collagen vascular diseases, colitis, HUS, SLE)<br/>- primary disease focal-sclerotising glomerulonephritis<br/>- disease, which need temporary or permanent treatment with cortisone (also inhalatory medicines)<br/>-severe fat metabolic disturbance  (cholesterine > 300 mg/dl, triglycerides > 400 mg/dl)<br/>- Epstein-Barr-virus  IgG negative<br/>- chronic hepatitis B and hepatitis C infection<br/>- thrombocytopenia < 50.000 tsd/µl<br/>-coagulopathies ( lack of or a defect in v. Willebrand factor, hemophilia, lack of protein S lack of protein C )";"Primary Sponsor";"Universitätsklinikum Freiburg<br/>Klinik für Allgemein und Vizeralchirurgie";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Str. 55";"D-79106";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Abt. Allgemein- und<br/>Viszeralchirurgie";"Mr.";"Prof.";"Oliver";"Thomusch";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"0761-270-28580";"0761-270-27820";"oliver.thomusch@uniklinik-freiburg.de";"[---]*";"Contact for Public Queries";"Abt. Allgemein- und<br/>Viszeralchirurgie";"Mr.";"Prof.";"Oliver";"Thomusch";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"0761-270-28580";"0761-270-27820";"oliver.thomusch@uniklinik-freiburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinik Freiburg";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prospective Institutional review trial to test de novo sirolimus monotherapy following antithmocyte globin induction in kidney transplant recipients";"[---]*";"[---]*";"Kidney transplant recipients with  immunological low-risk to a acute transplantat rejection receive a minimize immunsuppression. The patients undergo a immunsuppression with a polyclonal antibody (Thymoglobulin®, antibody against many defence cells in blood) following de novo sirolimus (Rapamune®) monotherapy.This immunosuppressive therapy should reduce the risk of chronic allograft nephropathy. In all, it can be expected, that the steroid- and CNI-free protocol  will be the risk of cardiovascular events and the related mortality as well as the risk of opportunistic infection beneficially influenced.<br/>The control group is a historic patient population. These patients received standard medication treatments for kidney transplant recipients: cyclosporin, mycophenolatmofetil and steroids.<br/> Planned  recruitment: 1.1. 2005 till 31.12.2006. Planned closure of follow-up: 2010.<br/><br/><br/><br/><br/><br/><br/><br/><br/>";"<br/>Nonsensitized recipients of human leukocyte antigen-nonidentical postmortal kidney grafst will enrol in a prospective trial to test de novo sirolimus monotherapy following antithymocyte globin induction. This steroid- and CNI-free protocol should reduce the risk of cardiovascular events, chronic allograft nephropathy and the risk of opportunistic infection.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000858";"2012-04-25T08:59:29.800+02:00";
"DRKS00003133";2011/06/14;"[---]*";yes;"Approved";"10-4463";"Ethik-Kommission der Medizinischen Fakultät der Universität Duisburg-Essen";"Universal Trial Number (UTN)";"U1111-1122-0680";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-008555-41";"[---]*";"BfArM-No.";"4037292";"[---]*";;;;;;;"ICD10";"E11";"Non-insulin-dependent diabetes mellitus";"ICD10";"F00";"Dementia in Alzheimer's disease";;;;;;;;;;"Arm 1";"Patients with diabetes and MCI: 8 weeks Insulin-Aspart intranasal 4 x 40IU/day";"Arm 2";"Patients with diabetes and MCI: 8 weeks Placebo intranasal 4 x 400µl/day";"Arm 3";"Patients with eAD: 8 weeks Insulin-Aspart intranasal 4 x 40IU/day";"Arm 4";"Patients with eAD: 8 weeks Placebo intranasal 4 x 400µl/day";"Arm 5";"Controls: 8 weeks Insulin-Aspart intranasal 4 x 40IU/day";"Arm 6";"Controls: 8 weeks Placebo intranasal 4 x 400µl/day";;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"IIa";"[---]*";"Primary endpoint is the declarative memory after 8 weeks of treatment with intranasal insulin-aspart compared to memory at baseline before treatment. <br/>The declarative memory is defined as sum of words reproduced from a word list with 30 words, learned one week before, corrected by the sum of words from a word list with 30 words reproduced after one week at baseline.";"•	The declarative memory 8 weeks post-treatment (Follow-up) compared to memory before treatment by means of reproduced words of a word list with 30 words.<br/>•	Changes in extended cognitive performance during and after 8 weeks of treatment by means of BVMT-R, CANTAB, TMT A und B.<br/>•	Changes in parameters measured with 1H MR-spectroscopy before and after treatment of 8-weeks.<br/>•	Changes in blood-based biochemical and other physical parameters before and after treatment of 8-weeks by means of blood analysis.<br/>•	Changes in blood-based biochemical parameters relevant to drug safety before, during and after treatment of 8-weeks by means of blood analysis.<br/>•	Quantitative neuroproteomic analysis in CSF compared to baseline posttreatment, proteomics of liquor.<br/>•	Quantitative expression analysis of neurometabolomic profile in liquor compared to baseline posttreatment.<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Psychiatrie und Psychotherapie";"Essen, Lübeck, Göttingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/11/16;"Actual";"90";2015/03/02;"Multicenter trial";"National";"Both, male and female";"65";"Years";"85";"Years";"Group (1):<br/>Patients with early Alzheimer’s disease (eAD); Mini-Mental-State-Test (MMSE) 18 to 25 points;<br/>Clinical Dementia Rating (CDR) Score = 1.0; pretreatment with cholinesterase inhibitors for at least 3 months;<br/>Group (2):<br/>Patients with type 2 diabetes and amnestic mild cognitive impairment (T2D-aMCI);<br/>HbA1c 6.5-8.0% with stable antidiabetic treatment for at least 4 weeks with duration of the disease > 5 years;<br/>Amnestic MCI in according to the criteria of the Dementia Competence Network: impaired declarative memory in the delayed reproduction of word lists of CERADplus <-1 and in the delayed recall in WMS-R subtest “logical memory” <-1, in the parts not regarding cognitive function of CERADplus no performance <-2, CDR=0.5;<br/>No impairment of activities of daily living (ADL)<br/>Group (3): <br/>Control persons without MCI, dementia and diabetes;<br/>CDR=0;<br/>No impairment of activities of daily living (ADL);<br/>Declarative memory in the delayed reproduction of word lists of CERDAplus <-1 and in the delayed recall in WMS-R subtest  “logical memory” <-1;<br/>In the parts not regarding cognitive function performance of CERADplus <-1 on average and no item <-2.<br/>";"Group (1):<br/>Moderate or severe form of Alzheimer’s disease (MMSE<18; CDR>1.0);<br/>Antidementive pharmacotherapy other than cholinesterase inhibitors. Other neurodegenerative diseases (e.g.  M. Parkinson, Lewy Body Dementia, frontotemporal dementia), diabetes mellitus, other possible reasons for an early Alzheimer’s disease; abuse or addiction to psychoactive substances (other than nicotine) e.g. alcohol or benzodiazepines; stroke or other heart diseases within 3 months before trial participation; insufficiently treated arterial hypertension; acute or chronic neuroinflammation; malignant tumor; moderate or severe form of major depression; suicidality; reasons for exclusion for MRT diagnostics.<br/>Group (2):<br/>T2D with metabolic disturbances (severe hypoglycemia or diabetic coma during the last 3 months, HbA1c > 8.0%); neurodegenerative comorbidities; other possible reasons for an amnestic MCI than T2D (e.g. early Alzheimer’s disease, neuroendocrine or other metabolic disorders); familiar form of Alzheimer’s disease; or any other exclusion criteria apply to group 1.<br/>Group (3): <br/>MCI, dementia, diabetes mellitus, neurodegenerative disorders; any exclusion criteria apply to group 1 and 2.<br/>";"Primary Sponsor";"Universitätsklinikum Essen<br/>45147 Essen<br/>";"[---]*";"[---]*";"[---]*";"[---]*";"Hufelandstrasse 55";"45147 ";"Essen";"Germany";"+49 201 723 2600";"+49 201 723 2600";"reinhold.keil@uk-essen.de";"[---]*";"Contact for Scientific Queries";"Klinik für Psychiatrie und Psychotherapie LVR-Klinikum Essen";"Mr.";"Prof. Dr. med.";"Norbert";"Scherbaum";"Altendorfer Str. 99-101";"45143";"Essen";"Germany";"+49 201 7227 180";"+49 201 7227 254";"norbert.scherbaum@uni-due.de";"[---]*";"Contact for Public Queries";"Klinik für Psychiatrie und Psychotherapie LVR-Klinikum Essen";"Mr.";"Prof. Dr. med.";"Norbert";"Scherbaum";"Altendorfer Str. 99-101";"45143";"Essen";"Germany";"+49 201 7227 180";"+49 201 7227 254";"norbert.scherbaum@uni-due.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Berlin";"[---]*";"[---]*";"[---]*";"[---]*";"Hannoversche Straße 28-30";"10115";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Comparative study on the effect of intranasal insulin on cognitive function in patients with type 2 diabetes and patients with early Alzheimer's Disease";"INSULA";"[---]*";"Effect of intranasal insulin on cognition in patients with mild cognitive impairment and type 2 diabetes and patients with Alzheimer's disease. The hypothesis is that intranasal insulin increases memory capacity.";"The primary endpoint of the study is to show the efficacy of intranasal insulin to improve the declarative memory of elderly  control patients compared to patients with mild cognitive impairment and type 2 diabetes and patients with early Alzheimer’s disease. Treatment with intranasal insulin/placebo will be performed for 8 weeks with a dose of 3 x 40IU/day.<br/>For examination of declarative memory before, during and after treatment with intranasal insulin/placebo standardized lists with 30 words with a rate of 1 word/second will be used.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003133";"2016-03-11T11:11:54.561+01:00";
"DRKS00003217";2011/08/22;"[---]*";yes;"Approved";"837.299.10 (7308)";"Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2010-021782-70";"[---]*";"BfArM-No.";"4036867";"[---]*";;;;;;;;;;"ICD10";"J44.9";"Chronic obstructive pulmonary disease, unspecified";"ICD10";"J45";"Asthma";;;;;;;;;;"Arm 1";"On the first study day three types of MRI scans should be performed on the COPD patients. First the patients receive 1-2 doses of helium of up to 50 ml of helium-3 isotope gas for prepreparation and positioning. Then three MRI measurements should follow (H-MRI and 2 He-MRIs before and after bronchodilation using salbutamol with up to 350 ml of helium-3 isotope gas per measurement) as well as the measurements of the lung function (spirometry and body plethysmography). On study day 2, which takes place one year after study day 1, the same examinations are carried out as in Study 1.";"Arm 2";"On the first study day three types of MRI scans should be performed on the asthma patients. First the patients receive 1-2 doses of helium of up to 50 ml of helium-3 isotope gas for prepreparation and positioning. Then three MRI measurements should follow (H-MRI and 2 He-MRIs before and after bronchodilation using salbutamol with up to 350 ml of helium-3 isotope gas per measurement) as well as the measurements of the lung function (spirometry and body plethysmography). On study day 2, which takes place one year after study day 1, the same examinations are carried out as in Study 1.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Other";"Open (masking not used)";"Uncontrolled/Single arm";"Diagnostic";"Other";"II";"[---]*";"Disease specific findings: He-MRI prior to and after bronchodilation at the study start and after 1 year.";"Safety and tolerability of helium-3";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie der Universitätsmedizin Mainz";"Mainz";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/11/07;"Actual";"24";2014/11/07;"Monocenter trial";"National";"Both, male and female";"18";"Years";"70";"Years";"Group 1: COPD: adults > 40years and < 70 years, verified diagnosis of asthma, 40 ≤ FEV1 ≤ 70%, smokers or former smokers, no exacerbations during the last 2 months<br/><br/><br/>Group2: Asthma: adults >18 years and < 70years, FEV1 ≥ 40%, verfified diagnosis of asthma (DGP) for at<br/>least 6 months";"pregnacy<br/>instable clinical status<br/>MRI contraindications. metallic implants, claustrophobia<br/>myocardial infarctus or cerebrovascular insult during the last 6 weeks<br/>other acute lung diease within the last 6 weeks prior to the first visit<br/>exacerbations during the last 2 months<br/>renal dysfunction (gfr<60mL/min)";"Primary Sponsor";"Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie der Universitätsmedizin Mainz";"Mr.";"Prof. Dr.";"Christoph";"Düber";"Langenbeckstr.1";"55131";"Mainz";"Germany";"06131-177371";"06131-177359";"dueber@radiologie.klinik.uni-mainz.de";"[---]*";"Contact for Scientific Queries";"Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie der Universitätsmedizin Mainz";"Mr.";"Prof. Dr.";"Christoph";"Düber";"Langenbeckstr.1";"55131";"Mainz";"Germany";"06131-177371";"06131-177359";"dueber@radiologie.klinik.uni-mainz.de";"[---]*";"Contact for Public Queries";"Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie der Universitätsmedizin Mainz";"Mr.";"Prof. Dr.";"Christoph";"Düber";"Langenbeckstr.1";"55131";"Mainz";"Germany";"06131-177371";"06131-177359";"dueber@radiologie.klinik.uni-mainz.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Berlin";"[---]*";"[---]*";"[---]*";"[---]*";"Friedrichstraße 130 B";"10117";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well<br/>as dynamic ventilation, intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of<br/>hyperpolarised helium-3 gas; a comparison with pulmonary function tests und H-MRI (long-term<br/>observation).";"COALA-He";"[---]*";"The planned study is based on the experience of the Helium-MRI (Magnetic resonance imaging, a medical imaging technique used to visualize detailed internal structures) of the lung and should provide the data for the phenotyping (investigation of observable characteristics) of asthma and COPD. The study should also establish a basis for the use of the approach in clinical routine.<br/><br/>The study consists of two visits, where a group of asthma patients and a group of COPD patients (both moderately to severely ill) should be investigated with the same study protocol.<br/><br/>This is the first time that the Helium-MRI-parameters are investigated all at once and additionally before and after bronchodilation (widening of the bronchi). Furthermore, structural and functional parameters of conventional MRI, as well as all the relevant parameters of lung function testing, used as a gold standard for assessment of the severity of COPD and the bronchial asthma should be recorded.<br/><br/>The collected data should enable us to make comparative statements for both diseases and for different investigation methods.<br/>";"The objective of the trial is to investigate the He-MRI parameters in comparison with proton-MRI und pulmonary funcion tests in two patient groups and the change of these parameters after 1 year (including the<br/>effect of a bronchodilator)";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003217";"2015-04-27T13:44:23.595+02:00";
"DRKS00004733";2013/03/14;"[---]*";yes;"Approved";"177/11";"Ethik-Kommission der Universität Ulm";"Other Secondary-ID";"ARO 2010-2";"AG Radiologische Onkologie der DKG";;;;;;;;;;;;;"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;;;;"Arm 1";"Wait-and-See (W+S) after radical prostatectomy.<br/>Scheduled follow-up including PSA determination for early diagnosis of a potential (biochemical) relaps.<br/>In case of recurrence, antihormonal treatment with bicalutamid 150mg/day or salvage radiotherapy with individualized dose (at least 66 Gy to the prostate fossa)  are offered.";"Arm 2";"Intensity modulated radiotherapy to the pelvic lymph nodes and the prostate bed with 2 Gy per fraction to a total dose of 50 Gy.<br/>With negative surgical margins boost to 60 Gy to the prostate bed (pT2) and the seminal vesicles (≥pT3); with positive surgical margins boost to 64 Gy. (RapidArc, VMAT optional)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Control group receives no treatment";"Treatment";"Parallel";"N/A";"N/A";"Progression-free survival, maximum follow-up 9 years";"Overall survival (scheduled follow-up max. 9 years) ;  <br/>Distant metastases ;<br/>Rate of acut side effects of radiotherapy ;<br/>Rate of late side effects: Bladder/Urethra and intestine according to RTOG ;<br/>Quality of life  (EORTC query QLQ-C30 after 3-6-12-24-60 months) ; <br/>Erectile dysfunction (International Index of Erectile Function, query form IIEF after 3-6-12-24-60 months)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Urologie; Klinik für Strahlentherapie und Radioonkologie";"Ulm";"Medical Center";"Urologische Klinik; Klinik für Strahlentherapie";"Augsburg";"University Medical Center";"Urologische Klinik, Kliniken für Strahlentherapie und  Radioonkologie ";"Berlin";"Medical Center";"Klinik für Strahlentherapie und Radioonkologie";"Bochum";"Medical Center";"Klinik für Urologie; Klinik für Strahlentherapie";"Tübingen";"University Medical Center";"Klinik für Urologie; Klinik für Strahlentherapie und Radioonkologie";"Homburg/Saar";"Medical Center";"Evang. Huyssens-Stiftung/Knappschaft, Urologie ";"Essen";"University Medical Center";"Klinik für Strahlentherapie";"Essen";"University Medical Center";"Martini-Klinik am UKE, Prostatakrebszentrum ";"Hamburg-Eppendorf";"University Medical Center";"Urologische Klinik; Klinik für Radioonkologie und Strahlentherapie";"Heidelberg";"University Medical Center";"Urologische Klinik, Marienhospital";"Bochum / Herne";"University Medical Center";"Klinik für Urologie und Kinderurologie; Klinik für Strahlentherapie und Radioonkologie";"Homburg / Saar";"University Medical Center";"Klinik für Urologie; Klinik für Strahlentherapie";"Münster";"University Medical Center";"Kliniken für Urologie; Kliniken für Radioonkologie; TU ";"München";"University Medical Center";"Universitätsklinik für Urologie";"Oldenburg";"University Medical Center";"Klinik für Strahlentherapie und Radioonkologie";"Dresden";"University Medical Center";"Klinik für Strahlentherapie, Klinik für Urologie; LMU";"München";;;;;;;;;;2014/04/03;"Actual";"298";"[---]*";"Multicenter trial";"National";"Male";"40";"Years";"[---]*";"no maximum age";"Status post radical prostatectomy (incl. nerve-sparing) with histologically confirmed stage pTx R0/R1 pN+ (micrometastases, 1-2 macrometastases with or without additional micrometastases);<br/>extended lymphadenectomy (≥12 lymph nodes) ;<br/>pre-OP PSA <50 ng/mL ;<br/>negative pre-OP bone scintigram (obligatory for PSA >20 ng/mL or bioptic Gleason Score 8-10) ;<br/>pre-OP abdominal and pelvic CT without pathological findings (obligatory for PSA >20 ng/mL or bioptic Gleason Score 8-10);<br/>Consensus between local and central pathology on pT stage, surgical margin status, Gleason Score and lymph node status ;<br/>Response to prostatectomy confirmed by achieving within 90 days post-OP a PSA nadir <0.1 ng/mL (undetectable) ;<br/>Age ≥40 years ;<br/>Karnofsky Index > 80% ;<br/>Capability and will to adhere to study conditions ;<br/>Written informed consent to participate in the study<br/>";"Persisting complete incontinence (grade III) ; <br/>Tumour stage pN0 ; <br/>>2 lymph nodes involved macroscopically ; <br/>distant metastases ; <br/>Previous or actual inflammation of the large intestine ; <br/>Previous radiotherapy to the true pelvis ; <br/>Previous chemotherapy ; <br/>Status post bilateral orchiectomy ; <br/>Status after pre-OP neoadjuvant hormone therapy ;<br/>Previous or actual post-OP medical hormone therapy ;<br/>Presence of a second tumour except curatively treated basalioma ; <br/>Previous or actual psychiatric disorder or addiction ; <br/>Participation in another clinical study, concurrent or within the last three months before the start of ART-2 ; <br/>Inability to understand  the study purpose or to adhere to study conditions ; <br/>Missing written informed consent<br/><br/><br/><br/>";"Primary Sponsor";"Klinik für Strahlentherapie und Radioonkologie<br/>Universitätsklinikum Ulm";"Mr.";"Prof. Dr.";"Thomas";"Wiegel";"Albert-Einstein-Allee 23";"89081";"Ulm";"Germany";"#49 731 500 56101";"#49 731 500 56110";"thomas.wiegel@uniklinik-ulm.de";"http://www.uniklinik-ulm.de/struktur/kliniken/strahlentherapie-und-radioonkologie.html";"Contact for Scientific Queries";"Klinik für Strahlentherapie und Radioonkologie<br/>Universitätsklinikum Ulm";"Mr.";"Dr.";"Detlef";"Bartkowiak";"Albert-Einstein-Allee 23";"89081";"Ulm";"Germany";"#49 731 500 56240";"#49 731 500 56110";"detlef.bartkowiak@uniklinik-ulm.de";"http://www.uniklinik-ulm.de/struktur/kliniken/strahlentherapie-und-radioonkologie.html";"Contact for Public Queries";"Klinik für Strahlentherapie und Radioonkologie<br/>Universitätsklinikum Ulm";"Mr.";"Prof. Dr.";"Thomas";"Wiegel";"Albert-Einstein-Allee 23";"89081";"Ulm";"Germany";"#49 731 500 56101";"#49 731 500 56110";"thomas.wiegel@uniklinik-ulm.de";"http://www.uniklinik-ulm.de/struktur/kliniken/strahlentherapie-und-radioonkologie.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"Deutsche Krebshilfe e.V.";"[---]*";"[---]*";"[---]*";"[---]*";"Buschstr. 32";"53113";"Bonn";"Germany";"0228/72 99 00";"0228/72 99 011";"[---]*";"http://www.krebshilfe.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Multicenter randomized phase-III trial into adjuvant radiotherapy for prostate cancer patients with or without positive surgical margins post-prostatectomy and with low level lymph node involvement (mircrometastases, ≤2 lymph node macrometastases)";"ART-2 Trial";"[---]*";"Prostate cancer patients who underwent surgical removal of the organ have a risk of recurrence of the disease that depends on the tumour's spatial extent. If the examination of the surgically resected tissue shows the cancer not to be restricted to the prostate gland, but also to involve single pelvic lymph nodes, then the risk of relapse rises. <br/>One option to counter that risk is to irradiate the pelvis precautionary (adjuvant) soon after the relief of post-operative complaints. However, irradiation can cause side effects, which must be justified by significantly improved healing rates.<br/>An alternative to adjuvant radiotherapy is the wait-and-see strategy: During scheduled follow-up, laboratory data (PSA measurements) can signal a relapse (biochemical recurrence). In that case, so-called salvage therapy still offers a good chance for cure, however, usually connected with stronger side effects than from adjuvant radiation.<br/>The ART-2 trial is designed to test whether in patients with low-level lymph node involvement adjuvant radiotherapy can improve by 15% the post-operative 4-years rate of freedom from recurrence to 55%.<br/>";"ART-2 is a prospectively randomized multicenter phase-III trial to compare the effect of adjuvant radiotherapy with a wait-and-see strategy in post prostatectomy patients with pathologically confirmed low-level lymph node involvement (micrometastases, 1-2 macrometastases). For pT3 N0 tumours with positive surgical margins, three randomized trials could show a benefit from adjuvant radiotherapy. For lymph node positive prostate cancer, such a benefit remains to be confirmed.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004733";"2017-11-28T14:38:12.425+01:00";
"DRKS00004744";2013/03/21;"[---]*";yes;"Approved";"2012-051F-MA";"Medizinische Ethik-Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-006211-64";"[---]*";"BfArM-No.";"4038429";"[---]*";;;;;;;;;;"ICD10";"C25";"Malignant neoplasm of pancreas";;;;;;;;;;;;;"Arm 1";"TKI258 (Tablets, oral), Dose 200 - 500mg, daily (5 days on, 2 days off)<br/>Capecitabine (Tablets, oral), Dose 1000mg/m², daily (14 days, 7 days pause)";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"I";"Yes";"To evaluate the maximum tolerable dose (MTD) and assess the safety and tolerability of TKI258 in combination with capecitabine (after each cycle).";"To assess the preliminary antitumor activity of TKI258 in combination with capecitabine.<br/>To assess the response with regard to the expression and/or mutation of the tyrosine kinase receptors.<br/>Progression-free survival and overall survival.<br/>Overall tumor response.<br/>All assessments will be done after each cycle.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinikum Mannheim";"Mannheim";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/08/29;"Actual";"42";2013/11/21;"Monocenter trial";"National";"Both, male and female";"18";"Years";"90";"Years";"Male or female patients age 18-90, with histologically proven chemo-refractory pancreatic cancer patients must have recovered from side effects of previous chemotherapy.  Life expectancy must be more than 12 weeks, organ functions must be adequate.";"The patients must not suffer from any other severe chronic or acute medical or psychiatric disorder. They must be at least 2 weeks from last chemotherapy and must not receive any other conventional medicinal anti-cancer therapy during the treatment phase.";"Primary Sponsor";"Ruprecht-Karls Universität Heidelberg";"[---]*";"[---]*";"[---]*";"[---]*";"Seminarstraße 2";"69117";"Heidelberg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsmedizin Mannheim <br/>Medizinische Fakultät Mannheim der Universität Heidelberg <br/>II. Medizinische  Klinik";"Mr.";"Dr. rer. nat.";"Ralf";"Jesenofsky";"Theodor-Kutzer-Ufer 1-3";"68167";"Mannheim";"Germany";"+49 621 383-5982";"+49 621 383-4139";"ralf.jesenofsky@medma.uni-heidelberg.de";"[---]*";"Contact for Public Queries";"Universitätsmedizin Mannheim <br/>Medizinische Fakultät Mannheim der Universität Heidelberg <br/>II. Medizinische  Klinik";"Mr.";"Dr. rer. nat.";"Ralf";"Jesenofsky";"Theodor-Kutzer-Ufer 1-3";"68167";"Mannheim";"Germany";"+49 621 383-5982";"+49 621 383-4139";"ralf.jesenofsky@medma.uni-heidelberg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Novartis Pharma GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Roonstraße 25";"90327";"Nürnberg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A phase I study of TKI258 and capecitabine in patients with advanced pancreatic cancer and treatment failure after first-line chemotherapy";"CAPDOV";"nicht zutreffend";"To determine the maximum tolerable dose (MTD) and assess the safety and tolerability of TKI258 in combination with capecitabine in patients with non-resectable pancreatic cancer and treatment failure of first-line chemotherapy.";"Single arm open label phase I trial in patients with advanced pancreatic cancer refractory to first-line chemotherapy. We will employ the standard “3+3” phase I dose escalation design to determine the recommended phase II dose of TKI258 in combination with standard doses of capecitabine.";"Recruiting stopped after recruiting started ";"Trial results";"9aa8d0bd-85ba-4b1e-b6f4-71bdc8e5bb61";"CAPDOV_CSR-Synopse_V01_20151211_Final.pdf";"CAPDOV_Synopse_Abschlussbericht";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004744";"2016-01-14T11:53:06.842+01:00";
"DRKS00000521";2010/08/20;"[---]*";yes;"Approved";"10/4325";"Ethik-Kommission der Medizinischen Fakultät der Universität Duisburg-Essen";;;;;;;;;;;;;;;;"ICD10";"I25";"Chronic ischaemic heart disease";"ICD10";"I65.2";"Occlusion and stenosis of carotid artery";;;;;;;;;;"Arm 1";"coronary artery bypass graft surgery without carotid endarterectomy";"Arm 2";"combined carotid artery bypass graft (CABG) surgery and carotid endarterectomy (CEA)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Factorial";"IV";"[---]*";"The primary efficacy endpoint is the event rate of nonfatal strokes or deaths from any cause (whatever occurs first) within 30 days after the intervention (either isolated CABG or synchronous CABG + CEA). ";"Secondary efficacy endpoints are single components of the primary endpoint, myocardial infarction, technical failures, duration of ventilatory support, change of cognitive performance on the Demtec scale and observations at different time points. ";"DE";"Germany";"CZ";"Czech Republic";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Thorax- und Kardiovaskuläre Chirurgie ";"Essen";"University Medical Center";"Klinik und Poliklinik für Herzchirurgie";"Rostock";"University Medical Center";"Klinik für Herz- und Gefäßchirurgie";"Kiel";"Medical Center";"Klinik für Herz-, Thorax- und Gefäßchirurgie";"Dortmund";"University Medical Center";"Klinik für Thorax-, Herz- und thorakale Gefäßchirurg";"Frankfurt a.M.";"University Medical Center";"Herz-Kreislauf Zentrum, Herz- und Gefäßchirurgie";"Freiburg im Breisgau";"Medical Center";"Herz- und Gefäßchirurgie im Herz-Zentrum Bad Krozingen";"Bad Krozingen";"University Medical Center";"Klinik und Poliklinik für Herz- und Gefäßchirurgie";"Hamburg";"University Medical Center";"Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie";"Hannover";"Medical Center";"Klinik für Herz-Thorax-Chirurgie";"Bad Bevensen";"University Medical Center";"Herz-, Kinderherz- und Gefäßchirurgie";"Gießen";"University Medical Center";"Klinik für Herz- und Thoraxchirurgie";"Jena";"Medical Center";"Klinik f. Herz- u. Gefäßchirurgie ";"Rotenburg an der Fulda";"Medical Center";"Klinik für Thorax-, Herz- und Gefäßchirurgie";"Kaiserslautern";"University Medical Center";"Klinik für Thorax und Herz- Gefäßchirurgie ";"Homburg";"Medical Center";"Klinik für Herzchirurgie";"Mühchen Bogenhausen";"University Medical Center";"Klinik für Herzchirurgie";"Leipzig";"University Medical Center";"Klinik und Poliklinik für Herzchirurgie";"Bonn";"University Medical Center";"Klinik für Thorax-, Herz- und Gefäßchirurgie";"Aachen";"University Medical Center";"Klinik für Herz- und Thoraxchirurgie";"Bochum";2010/12/01;"Actual";"316";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Key inclusion criteria: <br/>1. Identification of a ≥80% stenosis (ECST criteria) of the extracranial carotid artery in a patient scheduled for coronary artery bypass graft (CABG) surgery with the stenosis being asymptomatic for the past 180 days <br/>2. Carotid stenosis treatable with CEA<br/>3. Written informed consent<br/>4. Male or female patients of age ≥18 years<br/>";"Key exclusion criteria: <br/>1. Stenosis related neurological symptoms within the previous 180 days <br/>2. Non-atherosclerotic origin of stenosis <br/>3. NSTEMI within the past 48 hours, STEMI within the past 7 days or hemodynamically unstable patients<br/>4. Modified Rankin Scale score >3 or severe aphasia";"Primary Sponsor";"Universitätsklinikum Essen";"[---]*";"[---]*";"[---]*";"[---]*";"Hufelandstraße 55";"45147";"Essen";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinikum-essen.de";"Contact for Scientific Queries";"Neurologische Klinik <br/>Universitätsklinikum Essen";"Mr.";"Prof. Dr. med.";"Christian";"Weimar";"Hufelandstr. 55";"45122";"Essen";"Germany";"0201 723 2495";"0201 723 5919";"christian.weimar@uk-essen.de";"www.uk-essen.de";"Contact for Public Queries";"Klinik für Thorax und kardiovaskuläre Chirurgie<br/>Universitätsklinikum Essen";"Mr.";"Dr. med.";"Stephan";"Knipp";"Hufelandstr. 55";"45122";"Essen";"Germany";"0201 723 84915";"0201 723 5451";"stephan.knipp@uk-essen.de";"www.uk-essen.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Coronary artery bypass graft surgery in patients with asymptomatic carotid stenosis<br/>";"CABACS";"www.cabacs.de";"Of patients undergoing coronary artery bypass graft (CABG) surgery, 6-8% present with a concomitant high grade carotid stenosis.<br/>To date, it remains unknown whether the common practice of a combined carotid endarterectomy is superior to isolated CABG or staged procedures. The objective of this study therefore is to investigate the safety and efficacy of isolated CABG versus combined CEA and CABG in patients with high-grade (≥80%) asymptomatic carotid stenosis. <br/>CABACS is a randomised, controlled clinical study in about 35 German cardio-thoracic surgery centers scheduled to start in September 2010. Over a projected period of 3 years, 1160 patients will be ranomized.";"Of patients undergoing coronary artery bypass graft (CABG) surgery, 6-8% present with a concomitant high grade carotid stenosis.<br/>To date, no clinical study has determined whether the common practice of a combined carotid endarterectomy (CEA), is superior to isolated CABG or staged procedures. The objective of this study therefore is to investigate the safety and efficacy of isolated CABG versus combined CEA and CABG in patients with high-grade (≥80%) asymptomatic carotid stenosis. <br/>CABACS is a randomised, controlled clinical study in about 35 German cardio-thoracic surgery centers scheduled to start in September 2010. Over a projected period of 3 years, 1160 patients will be ranomized.";"Recruiting stopped after recruiting started ";"Background literature";"[---]*";"http://www.ncbi.nlm.nih.gov/pubmed/22103798";"Link 1 via PubMed";"[---]*";"[---]*";"https://www.ncbi.nlm.nih.gov/pubmed/28916664";"Link 2 via Pubmed";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000521";"2018-06-04T16:17:56.879+02:00";
"DRKS00000579";2010/10/15;2007/02/01;yes;"Approved";"124/01";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"Primary Registry-ID";"NCT00567801";"ClinicalTrials.gov";"Partner Registry-ID";"UKF001013";"Register klinischer Studien des Universitätsklinikums Freiburg";;;;;;;;;;"ICD10";"I74.3";"Embolism and thrombosis of arteries of lower extremities";;;;;;;;;;;;;"Arm 1";"Conventional embolectomy/thrombectomy with uncontrolled reperfusion";"Arm 2";"Embolectomy/thrombectomy with controlled reperfusion";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"survival free of amputation (after 4 weeks)";"1. neurological status (motor function, sensation) of the affected limb after 4 weeks<br/>2. frequency of systemic complications in both groups <br/>3. tolerance of the reperfusion solution<br/>4. mortality after 6 and 12 months";"DE";"Germany";"AT";"Austria";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2002/09/30;"Actual";"250";2009/01/13;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- patients > 18 years of age	<br/>- arterial occlusion in one or both of the lower extremities concurrent with acute ischemia causing decompensation ( Rutherford Stage IIA-III)";"- patients who have undergone a recent, or current attempt to revascularize (for example: lysis therapy)<br/>- patients with a known A. poplitea aneurysma in the limb concerned<br/>- patients with severe heart failure (NYHA IV) <br/>- patients with terminal kidney failure (creatinine > 10mg/dl) or undergoing dialysis, kidney transplant <br/>- allopurinol intolerance<br/>- allergy to any of the components in the reperfusion solution<br/>- current participation in a clinical trial (or within the last 30 days)<br/>- pregnant patients, or those currently breastfeeding<br/>- other conditions or circumstances likely to lead to poor treatment adherence (i.e., drug dependency, no fixed abode)";"Primary Sponsor";"Universitätsklinikum Freiburg";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Strasse 49";"79095";"Freiburg";"Germany";"+49 (0) 761 270 0";"[---]*";"[---]*";"www.uniklinik-freiburg.de";"Contact for Scientific Queries";"Universitäts-Herzzentrum Freiburg-Bad Krozingen Klinik für Herz- und Gefäßchirurgie";"Mr.";"Professor";"Friedhelm";"Beyersdorf";"Hugstetter Strasse 55";"79106";"Freiburg";"Germany";"+49 (0) 761 270 2818";"[---]*";"friedhelm.beyersdorf@universitaets-herzzentrum.de";"[---]*";"Contact for Public Queries";"Universitaets-Herzzentrum Freiburg - Bad Krozingen Klinik für Herz- und Gefaesschirurgie";"Mr.";"Professor";"Friedhelm";"Beyersdorf";"Hugstetter Strasse 55";"79106";"Freiburg";"Germany";"+49 (0) 761 270 28180";"[---]*";"friedhelm.beyersdorf@universitaets-herzzentrum.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Firma Dr. F. Köhler Chemie GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Neue Bergstraße 3 - 7";"64665";"Alsbach-Hähnlein";"Germany";"+49 (0) 6257 509 0";"+49 (0) 6257 509 46";"[---]*";"[---]*";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"HP-Medica";"[---]*";"[---]*";"[---]*";"[---]*";"Bahnhofstr. 30";"86150";"Augsburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"CRAIL-study: Prospektive randomized multicenter study for optimization of therapy of the acute ischemic limb by controlled reperfusion.";"[---]*";"[---]*";"Patients with an acute ischemia of a leg undergo surgical opening of the occluded blood vessel. The study compares the subsequent controlled reperfusion to conventional reperfusion. ";"The multicenter prospective randomized CRAIL-study (Controlled Reperfusion of the Acuely Ischemic Limb) compares conventional embolectomy/thrombectomy with embolectomy/thrombectomy accompanied by controlled reperfusion for acute arterial occlusion of the lower extremities. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000579";"2020-03-02T14:10:40.960+01:00";
"DRKS00000102";2009/05/15;"[---]*";yes;"Approved";"251/99";"Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München";"Other Secondary-ID";"DFG GA 245/2";"	DFG, Geldgeber";;;;;;;;;;;;;"ICD10";"P21";"Birth asphyxia";;;;;;;;;;;;;"Arm 1";"Hypothermia :<br/>nursed naked on a cooling matress which is perfused by circulating water at a variable temperature and covered by normal linen. The infant will have diaper aroound the lower half of the abdomen. The rectal temperature is targeted at 33.5°C (range of 33 to 34°C). The duration of hypothermia is 72 hours.";"Arm 2";"Normothertmia <br/>Infants randomized to the control group are treated according to present standards of postnatal care with the aim of achieving a normal body temperature of rectal rtemperature of 37°C (range of 36.5 to 37.5°C). The handling and treatments otherwise should be identical to the hypothermia group.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Treatment";"Parallel";"N/A";"[---]*";"Survival at 18-21 months of postnatal age free of severe neurological handicap";"general developmental quotient (Griffiths test or alternatives) in the subgroups of infants with moderate or severe HIE || Neurological deficit by Thompson score one week postnatal || head circumference at age of 6 months || Adverse events (primarily those monitored during intervention period)";"DE";"Germany";"AT";"Austria";"DK";"Denmark";"BE";"Belgium";"ZA";"South Africa";"FR";"France";"SG";"Singapore";"IT";"Italy";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2001/08/04;"Actual";"150";2008/12/10;"Multicenter trial";"International";"Both, male and female";"0";"Days";"0";"Days";"A: Evidence of severe birth asphyxia in infants >= 36 weeks gestation admitted to NICI: one of the following:<br/>- Apgar score of <= 5 at 10 minutes after birth<br/>- continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth<br/>- Acidosis defined as either umbilical cord pH or any arterial pH within 60 minutes of birth < 7.0<br/><br/>B: Evidence of encephalopathy (assessed by certified study personnel): moderate to severe encephalopathy <br/><br/>C: Evidence of moderate to severe neurophysiological dysfunction by EEG or aEEG<br/><br/>D: Consent of at least one parent.";"- Infants expected to be >5.5 hours of age at the time of randomization<br/>- prophylactic administration of high dose anticonvulsants<br/>- major congenital abnormalities<br/>- imperforate anus<br/>- evidence of head trauma or skull fracture causing major intracranial hemorrhage<br/>- Infants < 1800g birth weight<br/>- Head circumference < (mean - 2sd) for gestation <br/>- Infants ""in extremis""<br/>- overt bleeding";"Primary Sponsor";"Medizinische Universität Innsbruck<br/>Universitätsklinik für Pädiatrie IV";"Mr.";"Prof. Dr. med.";"Georg";"Simbruner";"Anichstrasse 35";"A-6020";"Innsbruck";"Austria";"+43 (512) 504-27307";"+43 (512) 504-27308";"georg.simbruner@i-med.ac.at";"www.i-med.ac.at";"Contact for Scientific Queries";"Medizinische Universität Innsbruck<br/>Universitätsklinik für Pädiatrie IV";"Mr.";"Prof. Dr. med.";"Georg";"Simbruner";"Anichstrasse 35";"A-6020";"Innsbruck";"Austria";"+43 (512) 504-27307";"+43 (512) 504-27308";"georg.simbruner@i-med.ac.at";"www.i-med.ac.at";"Contact for Public Queries";"Medizinische Universität Innsbruck<br/>Universitätsklinik für Pädiatrie IV";"Mr.";"Prof. Dr. med.";"Georg";"Simbruner";"Anichstrasse 35";"A-6020";"Innsbruck";"Austria";"+43 (512) 504-27307";"+43 (512) 504-27308";"georg.simbruner@i-med.ac.at";"www.i-med.ac.at";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft (DFG)<br/>-  Lebenswissenschaften 1 -<br/>- Medizin -";"Mr.";"[---]*";"Frank";"Wissing";"Kennedyallee 40";"53175";"Bonn";"Germany";"+49 (228) 885-2735";"+49 (228) 885-2777";"Frank.Wissing@dfg.de";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Induced systemic hypothermia in asphyxiated new-born infants: a randomised, controlled, multicentre study";"[---]*";"[---]*";"The brain is an organ most essential to man. It allows us to experience the world, to think, to laugh and to dream. For that reason a healthy and functioning brain, capable to develop appropriately, is of outermost importance to your newborn, with all his/her life ahead. However, being born, the time during and after delivery, is one of the time periods with high risk also to our brain. Lack of oxygen occuring during the delivery, also called asphyxia, may severely damage the brain. <br/><br/>Consequently, many research groups are nowadays making enourmous efforts to develop methods, which would allow to reduce the extent of brain injury due to asphyxia and to achieve a more favourable outcome. Over the last years, a large number of animal experiments demonstrated that the occurrence and extent of a brain nerve cell damage due to lack of oxygen largely depends on the temperature of the brain during or after the apshyxia. The brain jury is less, if the brain is kept at a lower temperature. Evidence has been gathered that cooling the body, and with it the brain, has a protective effect. If the brain temperature was decreased by 3 to 6°C below normal during or immediately after asphyxia, cooled animals demonstrated less damage of nerve cells and also developed a less abnormal behaviour than those not being cooled.<br/><br/>Studies in adult humans with brain injury demonstrated a slight benefit of cooling compared to non-cooling. For the human newborn, older and recent studies indicate that cooling the brain could reduce the amount of brain damage caused by low oxygen . Both, studies in adult patients as well as four studies in human newborns with asphyxia, were performed to evaluate the safety of applying cooling to these patients and revealed no specific side effects of cooling. <br/><br/>At present however, there is no scientific proof yet available, that cooling the brain (and body) would result in a distinct and lasting improvement compared to conventional treatment. Furthermore it cannot yet be excluded that cooling is less beneficial than conventional handling in the long run. <br/><br/>To clarify these vital questions, several investigations are under way. In our study, cooling the body and brain to 3 to 4 °C below normal body temperature aims to find out, whether the extent of developmental delay and of neurological or cognitive disabilities can be reduced. <br/><br/>The cooling is achieved by not adding any heat by a heating device and by withdrawing heat by means of a mattress, the newborn is lying upon. Body temperature is decreased to 33-34 °C for the duration of three days. All newborns enrolled in the study will be subjected to a very close and specific control, amongst them the electric activity of the brain will be monitored.<br/>In case of complications, which might result from cooling, the cooling will be promptly terminated. In  the unfortunate case that your baby has suffered from such a severe asphyxia  that a most disenabling damage is very probably and continuing  treatment appears to be unethically, parents, doctors and ethical committee have the option to decide on withdrawal of the vital life support. Such a procedure is justified in cases of total hopelessness of being healed or of having a life in human dignity.<br/><br/>This study is subjected to safety controls and is only continued if there are no indications of disadvantages for the cooled newborns. This study is stopped at the very moment, when an advantage for the cooled newborns becomes obvious.";"Asphyxia often leads to severe damages of the central nervous system with lifelong handicap in motor skills, cognitive and mental capability. No effective therapy is known. A hypothermia of the body and brain of asphyxic animals by 3-6°C over hours till days achieve a strong neuroprotective effect even when the hypothermia was induced after asphyxia. This neuroprotective effect has been verified in animal exerpiments particularly for wholebody hypothermia with which the deep brain regions are cooled (New Engl J Med ?). The study verifies the hypothesis that the induced hypothermia in asphyxiated newborn infants within 6 hours after birth with a temperature of 33-34°C for 3 days leads to a larger number of suvivors without neurological handicap at the age between 18-21 months than the control group without hypothermia.<br/>Main objective of the study is to determine scientifically whether inducing systemic hypothermia in aspyxiated newborn infants at term increases the chance of survival without severe neurodevelopmental handicap in comparison to standard intensive care after birth with normothermia. Secondary objectives are comparison of treatment benefit in infants with mild or severe encephalopathia and evaluation of safety.<br/>Systematic hypothermia with a target temperature of 33-34°C is induced by a cooling mattress, perfused with cold water. Hypothermia must be maintained for 72 hours. Infants in the control group are treated with aim of achieving normal body temperature of 37°C. Infants in both treatment groups receive morphine at a sedative and analgetic dosage.<br/>The study has a multicentre randomised controlled design. It is planned to enroll 2 x 75 infants who will be treated in hospitals mainly in Germany, France, Austria and Belgium. Included infants show evidence of encephalopathy and an abnormal EEG or aEEG (amplitude integrated EEG) within 6 hours of postnatal age. A minimum gestational age of 36 weeks is required.<br/>Study visits including a neurological and a neurodevelopmental examination are performed at baseline, after 7 days, 6 months and 18 months. After 12 months the parents are interviewd on basis of a developmental questionnaire. Safety evaluation is performed on physical, laboratory and clinical information gathered at the end of the intervention period. After 7 days, at discharge from hospital and after 6, 12 and 18 months occurance of serious adverse events are asked.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000102";"2010-05-18T16:56:55.155+02:00";
"DRKS00000086";2009/02/19;"[---]*";yes;"Approved";"837.475.08 (6472)";"Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz";"Universal Trial Number (UTN)";"U111111111728";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-005828-84";"[---]*";"BfArM-No.";"4034966";"[---]*";"Sponsor-ID";"ECP";"[---]*";;;;"MedDRA";"[---]*";"10009137: Chronic sinusitis";"ICD10";"J32";"Chronic sinusitis";;;;;;;;;;"Arm 1";"Low dose p. o. erythromycin, 250 mg/day for 12 weeks";"Arm 2";"Placebo p. o. 1 capsule/day over 12 weeks";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"III";"[---]*";"Concentration changes of inflammation mediatiors MPO and ECP in nasal discharge under a low-dose erythromycin or placebo post-operative treatment.";"Concentration changes of IL-5 and IL-8 in nasal discharge || Changes of saccharine transport time || Changes of SNOT-20 GAV || Changes of subjective nasal health (VAS) || Changes of the Sniffin´ Sticks test score || Changes of the nasal endoscopy score || Alterations in the nasal swab";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinik für Hals-Nasen-Ohrenheilkunde";"Mainz";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/07/05;"Actual";"70";2012/08/03;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- There is a preoperative allergy testing.<br/>- There is a histology finding.<br/>- There is a CT scan of the sinuses, which confirmed the diagnosis of chronic rhinosinusitis.<br/>- Candidates in the location, type, extent and consequences of individual clinical trial is to be understood. - A lies in front of the candidates personally signed and dated consent form before any test-specific measure is implemented.<br/>- Women who are postmenopausal for more than two years, to attend the trial. Women of childbearing age can only participate in the trial if they are surgically sterile, or if they are willing to use reliable contraception during the trial and up to two months after the end of the trial.";"- Pregnancy and lactation.<br/>- Hypersensitivity to the investigational product or a chemically related substance or a component of the investigational product or placebo.<br/>- The existence of a unilateral rhinosinusitis, a tumor of the paranasal sinuses, a fungal sinusitis, sinusitis in cystic fibrosis or a part of a syndrome of immotile cilia.<br/>- Well-known liver or kidney disease, electrolyte disturbances or heart rhythm disturbances, especially QT interval prolongations.<br/>- Regular use of drugs, of which a known interaction is known with simultaneous administration of macrolides.<br/>- Participation in other clinical trials during or within 6 months prior to this trial.<br/>- Medical or psychological circumstances that may endanger the proper conduct of the trial.";"Primary Sponsor";"Johannes Gutenberg Universität Mainz";"[---]*";"[---]*";"[---]*";"[---]*";"Obere Zahlbacherstr. 63";"55131";"Mainz";"Germany";"06131-3930122";"06131-39333487";"dekan@dekanat-med.klinik.uni-mainz.de";"www.uni-mainz.de";"Contact for Scientific Queries";"Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Universitätsmedizin Mainz, Johannes Gutenberg Universität Mainz";"Mr.";"Dr. med.";"Boris";"Haxel";"Langenbeckstr. 1";"55131";"Mainz";"Germany";"06131-177361";"06131-176637";"haxel@hno.klinik.uni-mainz.de";"http://www-klinik.uni-mainz.de/index.php?id=850";"Contact for Public Queries";"Universitätsklinik für Hals-Nasen-Ohrenheilkunde,<br/>Universitätsmedizin Mainz,<br/>Johannes Gutenberg Universität Mainz";"Mr.";"Dr. med.";"Boris";"Haxel";"Langenbeckstr. 1";"55131";"Mainz";"Germany";"06131-177361";"06131-176637";"haxel@hno.klinik.uni-mainz.de";"http://www-klinik.uni-mainz.de/index.php?id=850";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsmedizin Mainz, Johannes Gutenberg Universität Mainz";"[---]*";"[---]*";"[---]*";"[---]*";"Obere Zahlbacherstr. 63";"55131";"Mainz";"Germany";"06131-3930122";"06131-39333487";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.";"ECP";"[---]*";"The aim of the clinical trial is to investigate whether a positive effect of three months low-dose antibiotic therapy on the inflammation status of the nasal mucosa can be achieved in patients underwent a sinus surgery. Additionally, further parameters of the nasal discharge should be used to measure the nasal inflammation activity.";"The aim of the trial is to examine the changes of the inflammation parameters in the nasal discharge under a low-dose macrolide therapy after a sinus surgery. Within 2 to 4 weeks after elective surgical remediation of the sinus the trial subjects become randomized into one therapy and one control group. All patients will apply a topical nasal steroid as over the entire trial duration. The low dose antibiotic therapy will be continued over 12 weeks. The effects of an erythromycin post-operative therapy after a sinus surgery should be evaluated by means of different parameters of the nasal discharge, particularly the concentrations of inflammation mediators ECP and MPO. Potential prognostic factors for the relapse occurrence should be identified in order to improve the treatment of chronic rhinosinusitis.";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"[---]*";"Haxel, B. R., Clemens, M., Karaiskaki, N., Dippold, U., Kettern, L. and Mann, W. J. (2015), Controlled trial for long-term low-dose erythromycin after sinus surgery for chronic rhinosinusitis. The Laryngoscope, 125: 1048–1055. doi: 10.1002/lary.25052";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000086";"2015-05-05T12:31:24.562+02:00";
"DRKS00000157";2009/08/19;"[---]*";yes;"Approved";"7/2006";"Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen";"Universal Trial Number (UTN)";"U1111-1111-5698";"[---]*";;;;;;;;;;;;;"ICD10";"P07.3";"Other preterm infants";;;;;;;;;;;;;"Arm 1";"Cross-over design: intervention A (24-hour manual oxygen control by nurses) will be followed by intervention B (24-hour PC-based automatic oxygen control).";"Arm 2";"Cross-over design: intervention B (24-hour PC-based automatic oxygen control) will be followed by intervention A (24-hour manual oxygen control by nurses).";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Supportive care";"Crossover";"N/A";"[---]*";"The primary outcome variable is the percentage of time within a predefined target range of the puls oximetry-derived haemoglobin oxygen saturation. The target range depends on the study center.";"Secondary outcome variables are the frequency and duration of hypoxic and hyperoxic episodes.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/04/21;"Actual";"54";2012/03/31;"Multicenter trial";"National";"Both, male and female";"0";"Days";"4";"Months";"preterm birth (gestational age <37+0/7 weeks)<br/>invasive ventilation or CPAP<br/>at least 0.25 FiO2<br/>informed parental consent";"cyanotic heart defect validated by echocardiography<br/>diaphragmatic hernia or other diaphragmatic defect";"Primary Sponsor";"Abteilung für Neonatologie<br/>Klinik für Kinder- und Jugendmedizin<br/>Universitätsklinikum Tübingen";"Mr.";"Prof. Dr. med.";"Christian F.";"Poets";"Calwerstr. 7";"72076";"Tübingen";"Germany";"+4970712984742";"+497071293969";"christian-f.poets@med.uni-tuebingen.de";"http://www.medizin.uni-tuebingen.de/kinder/index.php";"Contact for Scientific Queries";"Institut für Medizinische Biometrie, Epidemiologie und Informatik<br/>Universitätsmedizin der Johannes Gutenberg Universität Mainz";"Mr.";"Univ.-Prof. Dr. med.";"Michael";"Urschitz";"Obere Zahlbacher Str. 69";"55131";"Mainz";"Germany";"+49.6131.17.3122";"+49.6131.17.2968";"urschitz@uni-mainz.de";"www.imbei.uni-mainz.de";"Contact for Public Queries";"Klinik für Kinder- und Jugendmedizin<br/>Universitätsklinikum Tübingen";"Ms.";"Dr. med.";"Antonietta";"Hallenberger";"Calwerstr. 7";"72076";"Tübingen";"Germany";"07071.29.84742";"07071.29.3969";"antonietta.hallenberger@med.uni-tuebingen.de";"http://www.med.uni-tuebingen.de/kinder/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Heinen + Löwenstein GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Arzbacher Straße 80";"56130";"Bad Ems";"Germany";"+49260396000";"+492603960050";"info@hul.de";"http://www.hul.de/index.htm";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"CLINICAL LONG-TERM EVALUATION OF AN AUTOMATIC CONTROL OF THE INSPIRED OXYGEN FRACTION IN VENTILATED PRETERM INFANTS";"CLAC";"www.medizin.uni-tuebingen.de";"Preterm infants often need additional oxygen due to their immature lungs. However, additional oxygen could be harmful to lungs, eyes, and brain and should be adjusted appropriately. In preterm infants manual control of additional oxygen is often time-consuming and sometimes difficult. We, thus, developed a computer system for automatic oxygen control and tested this system in non-ventilated preterm infants with good results. Now, we would like to test the system in ventilated preterm infants in three different hospitals.";"Background: In preterm infants receiving supplemental oxygen, manual control of the inspired oxygen fraction is often time-consuming and inappropriate. We developed a system for automatic oxygen control and evaluated this system in non-invasive ventilated preterm infants.<br/>Aims: To assess long-term performance and acceptance by personnel of the system in a multicenter setting. <br/>Methods: Multicenter randomized controlled cross-over clinical trial. Following a run-in-phase, 24-hour-periods with automatic and routine manual oxygen control will be compared regarding the percentage of time with arterial oxygen saturation levels within target range.<br/>Patients: 54 preterm infants receiving supplemental oxygen (FiO2 > 0.25) and invasive or non-invasive ventilation. <br/>Statistical analysis: Analysis of variance and pair-wise post-hoc comparisons.";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"[---]*";"Closed-Loop Automatic Oxygen Control (CLAC) in Preterm Infants: A Randomized Controlled Trial. Hallenberger A, Poets CF, Horn W, Seyfang A, Urschitz MS; CLAC Study Group. Pediatrics. 2014 Feb;133(2):e379-85. doi: 10.1542/peds.2013-1834. Epub 2014 Jan 27.";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000157";"2015-03-02T12:21:15.526+01:00";
"DRKS00000552";2010/10/01;"[---]*";yes;"Approved";"PV3349";"Ethik-Kommission der Ärztekammer Hamburg";;;;;;;;;;;;;;;;"ICD10";"M17.9";"Gonarthrosis, unspecified";;;;;;;;;;;;;"Arm 1";"Implantation of a knee endoprosthesis with a minimal mini-Mid-Vastus approach";"Arm 2";"Implantation of a knee endoprosthesis with a conventional parapatellar medial approach with classical-exposure";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Prognosis";"Parallel";"[---]*";"N/A";"Reaction Time,<br/>Movement Time,<br/>Brake Resonse Time<br/><br/>Repeated Measures Design:<br/>1 day before surgery;<br/>8 days after;<br/>4 weeks after;<br/>8 weeks after;<br/><br/>All variablen will be assessed in an car simulator.";"Muscle Activation Times from:<br/>M .rectus femoris;<br/>M. tibialis anterior;<br/>M. vastus medialis;<br/>M. gastrognemius pars medialis.<br/><br/>Repeated Measures Design:<br/>1 day before surgery;<br/>8 days after;<br/>4 weeks after;<br/>8 weeks after;<br/><br/>All variablen will be assessed in an car simulator. with surface EMG.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/01/10;"Actual";"50";2011/07/12;"Monocenter trial";"National";"Both, male and female";"40";"Years";"[---]*";"no maximum age";". Indication for TKA of the right knee joint.<br/>. The patient is an active driver (at least once a week)<br/>. Consent to participate in the study";". Body Mass Index (BMI)> 40Kg/m2<br/>. Deformity> 20 ° (varus, Valgusachse, extension lag)<br/>. Range of Motion (ROM) <75 ° extension / flexion<br/>. Diagnoses such as rheumatoid arthritis; neurological disorders such as Parkinson's disease; steroid medication or medication; which are known to prolong the RT; diabetes; osteoporosis and pre-surgery on the right knee joint.<br/>. Infection of the prosthetic joint during the follow up and a Thrombosis during this period lead to a exclusion.";"Primary Sponsor";"Faculdade de Motricidade Humana<br/>Universidade Técnica de Lisboa";"Mr.";"Prof. Dr.";"Jan";"Cabri";"Estrada da Costa";"P-1499-002";"Lisboa";"Portugal";"[---]*";"[---]*";"jan.cabri@nih.no";"www.fmh.utl.pt";"Contact for Scientific Queries";"Abteilung für Physikalische und Rehabilitative Medizin<br/>Schön Klinik Hamburg-Eilbek";"Mr.";"MSc";"Carlos J.";"Marques";"Dehnhaide 120";"D-22081";"Hamburg";"Germany";"04020921520";"[---]*";"cmarques@schoen-kliniken.de";"www.schoen-kliniken.de";"Contact for Public Queries";"Abteilung für Physikalische und Rehabilitative Medizin<br/>Schön Klinik Hamburg-Eilbek";"Mr.";"MSc";"Carlos J.";"Marques";"Dehnhaide 120";"D-22081";"Hamburg";"Germany";"04020921557";"04020921557";"cmarques@schoen-kliniken.de";"www.schoen-kliniken.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Faculdade de Motricidade Humana<br/>Universidade Técnica de Lisboa";"[---]*";"[---]*";"[---]*";"[---]*";"Estrada da Costa";"P-1499-002";"Cruz-Quebrada Dafundo, Lisboa";"Portugal";"[---]*";"[---]*";"[---]*";"www.fmh.utl.pt";"Institutional budget, no external funding (budget of sponsor/PI)";"Schön Klinik Hamburg-Eilbek";"[---]*";"[---]*";"[---]*";"[---]*";"Dehnhaide 120";"D-22081";"Hamburg";"Germany";"[---]*";"[---]*";"[---]*";"http://www.schoen-kliniken.de/ptp/kkh/eil/";"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Fundacao para a Ciencia e Tecnologia<br/>Ministério da Ciencia, Técnologia e Ensino Superior";"[---]*";"[---]*";"[---]*";"[---]*";"Av. D. Carlos I, 125";"P-1249-074";"Lisboa";"Portugal";"[---]*";"[---]*";"[---]*";"http://alfa.fct.mctes.pt/";"Lower limb muscle activation pattern in a car braking task before and after TKA: a randomized comparison of minimally invasive vs. standard approach";"[---]*";"[---]*";"There are different approaches used for surgical implantation of knee prostheses. Since some years, minimally invasive (MIS) approaches have bin used. However there is little available evidence on the benefits of MIS when compaired with the standard approaches in respect to shorter rehabilitation times and better functional outcomes. After such an operation, patients often ask when they resume car driving.<br/>In this study, the effects of two surgical approaches on motor performance parameters will be compaired during the execution of a fast perceptual task in a car simulator.";"Minimal invasive procedures for TKA have been used for several years as an alternative to standard procedures. Diferent approaches have been described in the literature: mini-arthrotomy, mini-midvastus, medial and squad-sparing mini-subvastus. Supporters of minimally invasive techniques (Minimally Invasive Surgery, MIS) go from the assumption that a smaller soft tissue injury with a reduction of the M. quadriceps femoris injury lead to a faster rehabilitation with better early functional outcomes, less pain and short length of stay. Critics fear a reduction the intraoperative overview with consecutive failure especially in relation to the alignment of the prosthesis.<br/>In the existing literature MIS vs. Standard approach were compared and the following primary outcomes were used: radiological findings, function of the quadriceps muscle in terms of force parameters, subjective sensation of pain of patients, mobility of the operated knee. Furthermore, in almost all studies scores were used, such as the Knee Society Score.<br/>There is little available evidence available on the effects of the surgical technique used on specific motor parameters operated leg while running fast perceptual motor tasks. Four studies have investigated the effects of TKA on a very important safety parameter while driving, the Brake Response Time (BRT). All studies used car simulators to assess the BRT of the patient while performing an emergency brake before and at different times after the operation. In the studies, in which the BRT component, Reaction Time (RT) and Movement Time (MT), were assessed, it was found that after TKA, the BRT is significantly prolonged by a significant extension of the MT. The RT remained unchanged in both studies after the operation. This fact indicates that such an operation has a temporary negative effect on motor performance aspects that have to do with the execution of the movement, and has no effects on key aspects associated with the perception, decision making and planning of the fast movements.<br/>In another study by Kelly et al., where two other standard approaches for TKA were compared (median parapatellar vs. Vastus-splitting approach), the authors reported that 9 (43%) of 21 patients in the vastus-splitting group had abnormal EMG results six months after the operation, while all patients in the median parapatellar group had normal EMG findings. The authors found no significant correlations between the deviations of the EMG and the knee function. The EMG has not been recorded while performing a functional task.<br/>The aim of this study is to compare the motor performance of two patient groups (conventional vs. minimally invasive) when executing an emergency stop in a car simulator. In one group a conventional parapatellar medial approach with a classic exposition of the knee prosthesis will be used; in the treatment group a minimally invasive mini-mid vastus approach will be performed. For both groups the same inclusion criteria for minimally invasive approaches will be adopted, these are more stringent than that for the conventional approach.<br/>";"Recruiting stopped after recruiting started ";"Paper";"92bd136b-87f0-44a8-9466-f97e35319b94";"Tracking Possible Effects of the Surgery Technique on Motor Performance.pdf";"Marques, C. J. et al. (2011) - BRAKE RESPONSE TIME BEFORE AND AFTER TOTAL KNEE ARTHROPLASTY - Tracking Possible Effects of the Surgery Technique on Motor Performance: Report of Two Cases. In Proceedings of the International Conference on Bio-inspired Systems and Signal Processing, pages 419-422";"Paper";"8ea8026d-851f-49b7-8c32-96f575b963c4";"Protocol of a randomized comparison of minimally invasive vs  standard approach.pdf";"Marques, C. J. et al. (2010) - MUSCLE ACTIVATION THRESHOLDS BEFORE AND AFTER TOTAL KNEE ARTHROPLASTY - Protocol of a Randomized Comparison of Minimally Invasive vs. Standard Approach. In Proceedings of the International Conference on Bio-inspired Systems and Signal Processing, pages 544-547";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000552";"2013-11-14T09:11:11.411+01:00";
"DRKS00000787";2011/05/16;"[---]*";yes;"Approved";"PV3419";"Ethik-Kommission der Ärztekammer Hamburg";;;;;;;;;;;;;;;;"ICD10";"N40";"Hyperplasia of prostate";;;;;;;;;;;;;"Arm 1";"Thulium VapoEnucleation of the Prostate";"Arm 2";"Holmium Laserenucleation of the prostate";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Treatment";"Parallel";"[---]*";"[---]*";"primary outcome: <br/>improvement of Qmax and IPSS score<br/>minimal improvement: <br/>- Qmax 3 ± 5 ml/s <br/>- minimum decrease of IPSS-Score: 2 points.  <br/><br/>Follow-up visit:<br/>- 3, 6 months, 1, 2 und 5 years after surgery";"intra and postoperative complications<br/>during follow up. <br/><br/>Follow-up visit:<br/>- 3, 6 months, 1, 2 und 5 years after surgery";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/10/01;"Actual";"120";"[---]*";"Monocenter trial";"National";"Male";"18";"Years";"[---]*";"no maximum age";"IPSS-Score ≥ 8<br/>Uroflow: Qmax ≤ 15ml/s<br/>Urodynamic: Schäfer-Scale ≥ II°<br/>Prostate volume measured by transrectal ultrasoundl (TRUS) ≥ 60 ml<br/>";"Known urethral or prostate surgery <br/>Voiding symptoms not referred to BPO (Striktur)<br/>Known Prostate Cancer<br/>Neurogenic Bladder";"Primary Sponsor";"Asklepios Klinik Barmbek<br/>Abteilung für Urologie";"Mr.";"dr. med.";"christopher ";"netsch";"Rübenkamp 220";"22291";"Hamburg";"Germany";"49 40 1818 82 8042";"49 40 1818 82 9829";"c.netsch@asklepios.com";"[---]*";"Contact for Scientific Queries";"Asklepios Klinik Barmbek<br/>Abteilung für Urologie";"Mr.";"dr. med.";"christopher ";"netsch";"Rübenkamp 220";"22291";"Hamburg";"Germany";"49 40 1818 82 8042";"49 40 1818 82 9829";"c.netsch@asklepios.com";"[---]*";"Contact for Public Queries";"Asklepios Klinik Barmbek<br/>Abteilung für Urologie";"Mr.";"dr. med.";"christopher ";"netsch";"Rübenkamp 220";"22291";"Hamburg";"Germany";"49 40 1818 82 8042";"49 40 1818 82 9829";"c.netsch@asklepios.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Asklepios Klinik Barmbek<br/>Abteilung für Urologie";"Mr.";"dr. med.";"christopher ";"netsch";"Rübenkamp 220";"22291";"Hamburg";"Germany";"49 40 1818 82 8042";"49 40 1818 82 9829";"c.netsch@asklepios.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Laserenucleation of Prostate Glands > 60g";"ThuVEP vs. HoLEP";"[---]*";"In the treatment of benign prostatic obstruction (BPO) larger than 60gm, different methods have been clinically established: classical transurethral resection of the prostate (TURP), transurethral holium laser enucleation of the prostate (HoLEP), and transurethral thulium vapoenucleation of the prostate (ThuVEP). In addition, BPO can be treated by classical open prostatectomy. In the current guidelines of the European Association of Urology (EAU) HoLEP and TURP were considered to be equally effective for the treatment of BPO. Guidelines are mainly based on prospective randomised trials (PRT). In PRT, the patient gives the consent for several treatment options. The definitive method will however be selected randomly by the surgeon.      <br/><br/>The thulium laser has been established in the recent years for the treatment of BPO. Thulium laserresection of the prostate has been compared in only one prospective randomised trial with classical TURP so far. In this series, thulium laserresection and TURP led to good clinical results with regard to perioperative complications and improvement of voiding parameters. However, blood loss was significantly higher with TURP than with the thulium laser. This advantage has been already shown in PRT for HoLEP, when comparing HoLEP with TURP.     <br/><br/>A complete dissection of prostate tissue to the pseudocapsule of the prostate can be performed with both the thulium and the holmium laser. Therefore, thulium and holmium laser should be equally effective with comparable outcome and morbidity.<br/><br/><br/>Aim of this study is to document differences between the holmium and thulium laser in a PRT with regard to perioperative morbidity and voiding outcome.";"It has been shown, that Holmium Laser Enucleation of the prostate is a size-independent treatment modality for benign prostatic hyperplasia. It has been poven equally effective, compared to open prostatectomy and transurethral resection of the prostate.<br/>Currently, Thulium VapoEnucleation of the prostate has been introduced as a size independent method for the treatment of benign prostatic hyperplasia.<br/>Prospective randomised studies comparing Thulium VapoEnucleation with standard treatment have not been published so far.  We therefore perform a prospective randomised trial comparing Thulium Vapoenucleation of the Prostate with Holmium Laserenucleation of the Prostate for benign prostatic hyperplasia in prostata glands larger than 60ml.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000787";"2014-06-13T09:30:54.064+02:00";
"DRKS00003140";2011/06/22;"[---]*";yes;"Approved";"2563-06/09";"Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät";;;;;;;;;;;;;;;;"ICD10";"E10";"Insulin-dependent diabetes mellitus";"ICD10";"E11";"Non-insulin-dependent diabetes mellitus";;;;;;;;;;"Arm 1";"Intervention group: medical care with telemedicine. Patients have one visit per quarter, all necessary measurements will have on this visit (HbA1c, blood glucose, blood glucose self control, creatinine, microalbuminuria, blood count, weight, blood pressure, pulse). The patients will have a talk about therapy and goal of care with telemedicine with their doctor. Further medical care in this quarter will be by telemedicine. Telemedicine visits are at baseline, after 1, 2, 8 and 12 weeks. If patients have therapy problems, more telemedicine visits are possible. Patient´s measurements of blood glucose will directly import from patients blood glucose analyzer to the electronic health record. Patient´s measurements of blood glucose will be read out from SmartPix and carry it over the computer.";"Arm 2";"control group: usual care<br/>Patients will have at least one visit per quarter (baseline, after 4, 8, 12 weeks). Patient´s document their self control measurements of blood glucose in a diary, which will  be controlled from the doctor at each visit. The doctor decide on the number of visits like usual care. The biomedical measurements are the same like intervention group. Their will be no medical care with telemedicine.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Health economics";"Parallel";"N/A";"[---]*";"HbA1c measured at baseline, 3 and 6 months after Randomisation";"incidence of hypoglycemia will be enquired at baseline, 3 and 6 months after Randomisation, treatment satisfaction will be detect with the DTSQ questionaire at baseline and after 6 months, diabetes dependent quality of life will be detect with the ADDQoL questionaire at baseline and after 6 months, medical costs will be calculated after 6 months";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/02/14;"Actual";"142";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. diabetes type 1 or type 2, access to the internet and telephone, 2. positive informed consent, 3. support in the study center at controls after study 4. duration of diabetes at least one year, 5. participation of a treatment and teaching programme,6. not achieve the treatment goal above two quarters: patients with diabetes type 1: HbA1c >=8% and /or >3 not severe hypoglycemia per week and/or 1 or more nocturnal hypoglycemia; patients with diabetes type 2: HbA1c >=8% and / or >1 not severe hypoglycemia per week";"1. not give their informed consent, 2. patients with indication for hospital treatment, 3. patients who are not able to fulfill the technical requirements, 4. patients with depression, 5. patients with severe concomitant diseases, 6. pregnancy";"Primary Sponsor";"Universitätsklinikum Jena";"[---]*";"[---]*";"[---]*";"[---]*";"Bachstraße 18";"07740";"Jena";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinikum-jena.de";"Contact for Scientific Queries";"Universitätsklinikum Jena";"Ms.";"Dr.";"Nicolle";"Müller";"Am Klinikum 1";"07740";"Jena";"Germany";"[---]*";"[---]*";"nicolle.mueller@med.uni-jena.de";"www.uniklinikum-jena.de";"Contact for Public Queries";"Universitätsklinikum Jena";"Ms.";"Dr.";"Gudrun";"Eidner";"Am Klinikum 1";"07740";"Jena";"Germany";"[---]*";"[---]*";"gudrun.eidner@med.uni-jena.de";"www.uniklinikum-jena.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Roche Diagnostics GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Sandhofer Str. 116";"68305";"Mannheim";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Care with telemedicine of ambulant patients with diabetes mellitus type 1 and 2";"[---]*";"[---]*";"The study want to examine the results of medical care of patients with diabetes mellitus with telemedicine in comparison to usual care. We have two groups, one group receives usual care (control group) and the other group receives medical care with telemedicine above 6 months. Patients with diabetes type 1 and 2 are able to participate in this study.<br/>The hypothesis is, that medical care of patients with diabetes with telemedicine results in the same outcome like usual care, but with lower costs.";"It´s a prospective, randomised controlled trial above 6 months. We recruit ambulant patients with diabetes type 1 and 2 and with the need for medical care because of unsatisfactory HbA1c or hypoglycaemia. Objective of this trial is to indicate that medical care with telemedicine results in the same outcome like usual care, but with lower costs.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003140";"2017-08-18T12:40:40.121+02:00";
"DRKS00003397";2012/01/13;2010/10/01;yes;"Approved";"06-2998";"Ethik-Kommission der Medizinischen Fakultät der Universität Duisburg-Essen";"EudraCT-Number";"2005-006098-29";"[---]*";"Primary Registry-ID";"NCT01215266";"clinical-trials.gov";"BfArM-No.";"4031573";"[---]*";;;;;;;"ICD10";"C67";"Malignant neoplasm of bladder";"Free text";"[---]*";"bladder cancer";;;;;;;;;;"Arm 1";"- Gemcitabin 1250 mg/m2, day 1 + 8, intravenous<br/>- Cisplatin 70 mg/m2, day 2, intravenous<br/>- Sorafenib 2 x 400 mg, day 3 - 21, orally";"Arm 2";"- Gemcitabin 1250 mg/m2, day 1 + 8, intravenous<br/>- Cisplatin 70 mg/m2, day 2, intravenous<br/>- Placebo 2 x 2 tablets, day 3 - 21, orally";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Treatment";"Parallel";"II";"Yes";"Progression free survival [ Time Frame: 5 years ]";"- Response rates, time of response [ Time Frame: 5 years ] <br/>- Time to progression [ Time Frame: 5 years ] <br/>- Overall survival [ Time Frame: 5 years ]<br/>- Evaluation and comparison in both treatment arms [ Time Frame: 5 years ]<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin";"Berlin";"University Medical Center";"Johanniter-Krankenhaus";"Stendal";"University Medical Center";"Universitätsklinikum Kassel";"Kassel";"University Medical Center";"Universitätsklinikum Weiden";"Weiden";"University Medical Center";"Krankenhaus St. Georg";"Hamburg";"University Medical Center";"Technische Universität";"München";"University Medical Center";"Urologie";"Köln";"University Medical Center";"Uniklinikum Dresden C.G.C. Urologie";"Dresden";"University Medical Center";"Urologie";"Münster";"University Medical Center";"Urologie";"Düsseldorf";"Medical Center";"Klinik für Allgemeine Chirurgie, Viszeral-, Gefäß- und Kinderchirurgie";"Saarland";"University Medical Center";"Universitätsklinikum Essen";"Essen";"University Medical Center";"Eppendorf Urologie";"Hamburg";"University Medical Center";"Urologische Klinik und Poliklinik";"Saarland";"University Medical Center";"Urologie";"Tübingen";"University Medical Center";"Urologische Klinik";"Ulm";;;;;;;;;;;;;2006/10/09;"Actual";"132";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"99";"Years";"- Condition ECOG(Eastern Cooperative Oncology Group) 0-1<br/>- Life expectancy at least 12 weeks<br/>- Women in conceptional age: negative pregnancy test and adequate contraception (oral contraceptive, spiral); at men adequate contraception of the man (condom use) to 3 months after discontinuation of therapy with sorafenib<br/>- Histologically or cytologically proven urothelial carcinoma of the bladder or upper urinary tract<br/>- Locally advanced or metastatic urothelial carcinoma of the bladder or upper urinary tract (T3b,T4/ N+/M+)<br/>- At least one unidimensional measurable lesion on CT(Computed Tomography) or MRI(Magnetic resonance imaging) according to RECIST(Response Evaluation Criteria in Solid Tumors) criteria<br/>- Adequate hematologic, renal, hepatic and coagulation-physiological functions<br/>";"- Absence of the above inclusion criteria<br/>- Dialysis after nephrectomy<br/>- Patients with brain tumors and / or brain metastases<br/>- Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction within 6 months prior to enrollment, or patients with serious cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers and digoxin are permitted)<br/>- Patients with uncontrolled high blood pressure, systolic blood pressure> 150 mm Hg or diastolic pressure> 90 mmHg despite optimal medical treatment<br/>- Patients with thrombotic or embolic events such as stroke or pulmonary embolism<br/>- Patients with recently or known bleeding diathesis<br/>- Known significant neurological or psychiatric diseases including dementia and epileptic seizures<br/>- Serious inflammatory eye disease, hearing impairment<br/>- Pulmonary (pO2(Blood oxygen) <60 mm Hg(Millimeters of mercury)), hematopoietic (eg(exempli gratia) severe bone marrow aplasia), hepatic or renal disease<br/>- Patients with poorly controlled diabetes mellitus<br/>- Serious bacterial or fungal infections(>Grade 2 NCI-CTC(National Cancer Institute-Common Terminology Criteria) Version 3)<br/>- chronic hepatitis B or C, HIV(human immunodeficiency virus) infection<br/>- Autoimmune disease<br/>";"Primary Sponsor";"Universitätsklinikum Essen";"[---]*";"[---]*";"[---]*";"[---]*";"Hufelandstraße 55";"45147";"Essen";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinikum-essen.de";"Contact for Scientific Queries";"Ltd. Oberärztin der Klinik u. Poliklinik für<br/>Urologie, Kinderurologie und urologische Onkologie<br/>Universitätsklinikum Essen";"Ms.";"Prof. Dr.";"Susanne";"Krege";"Hufelandstr. 55";"45122";"Essen";"Germany";"0201/723-32 60";"0201/723-31 51";"susanne.krege@uni-essen.de";"[---]*";"Contact for Public Queries";"Ltd. Oberärztin der Klinik u. Poliklinik für<br/>Urologie, Kinderurologie und urologische Onkologie<br/>Universitätsklinikum Essen";"Ms.";"Prof. Dr.";"Susanne";"Krege";"Hufelandstr. 55";"45122";"Essen";"Germany";"0201/723-32 60";"0201/723-31 51";"susanne.krege@uni-essen.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Bayer Vital GmbH";"Mr.";"[---]*";"[---]*";"[---]*";"Gebäude K56";"51368";"Leverkusen";"Germany";"0214 / 30-1";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prospectively randomized, double-blind, multicenter phase II trial comparing the efficacy of chemotherapy with gemcitabine plus cisplatin and sorafenib versus gemcitabine plus cisplatin and placebo in the treatment of advanced or metastatic urothelial carcinoma SUSE - AB 31/05";"SUSE - AB 31/05";"[---]*";"Trial comparing the efficacy of chemotherapy with gemcitabine plus cisplatin and sorafenib versus gemcitabine plus cisplatin and placebo in the treatment of advanced or metastatic urothelial carcinoma.<br/>This study is based on the hypothesis that sorafenib can improve the efficacy of combination chemotherapy in patients with advanced urothelial cancer.<br/>The main target is the 5 year survival free of recurrent disease.<br/>Potential study participants are patients with advanced bladder cancer.<br/>";"Trial comparing the efficacy of chemotherapy with gemcitabine plus cisplatin and sorafenib versus gemcitabine plus cisplatin and placebo in the treatment of advanced or metastatic urothelial carcinoma.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003397";"2012-04-05T14:12:47.858+02:00";
"DRKS00003407";2011/12/22;"[---]*";yes;"Approved";"215/11";"Ethik-Kommission des Fachbereichs Medizin der Justus-Liebig-Universität Gießen";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-000624-16";"[---]*";"BfArM-No.";"4037644";"[---]*";;;;;;;;;;"ICD10";"E88.9";"Metabolic disorder, unspecified";"ICD10";"N46";"Male infertility";"ICD10";"E66";"Obesity";"Free text";"[---]*";"Metabolic Syndrom";;;;"Arm 1";"consultation for metabolic syndrom 4 times/year; individual medical treatment according to guidelines with standard medication<br/>";"Arm 2";"consultation for metabolic syndrom 1 time/year; individual medical treatment according to guidelines with standard medication";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"No";"Increase of the spermatozoa concentration in the ejaculate between baseline and 12 months follow-up visit <br/>to get the required information ejaculate testing will be performed at baseline and at the 12 months follow-up visit ";"pregnancy rate primary/secondary; spermatozoa motility (%); normal formed spermatozoa (%); inflammation parameters in the ejaculate (cellular and humoral parameters); serum level alteration of FSH, LH and testosterone; results of the ""2-Gläser-Probe""; impact on sonographic investigations of prostate and testicle; Impact of the manifestation age of the metabolic syndrom  on fertility; discomfort scores as NIH-CPSI; <br/>""Prostatitis""-questionnaire; Alteration of: bloodpressure, blood suger level, blood lipid level; weight; sCRP; <br/>To get the required information blood testing, urine tests, ejaculate tests, sonographic tests and patient questioning will be performed at the planned study visits<br/><br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Medizinische Klinik und Urologie";"Gießen ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/12/22;"Actual";"30";2014/06/03;"Monocenter trial";"National";"Male";"18";"Years";"[---]*";"no maximum age";"•	age > 18 years, male<br/>•	metabolic syndrome according to International Diabetes Federation (IDF): <br/>- adiposity: waist circumference > 94 cm   (European), and 2 of the following criteria:<br/>- triglyceride > 150 mg/dl (fasting)<br/>- HDL-cholesterol < 40 mg/dl or treated by antilipemics (fasting)<br/>- bloodpresssure > 130/> 85 mmHg or treated  hypertonia<br/>- fasting blood sugar > 100 mg/dl or<br/>   known diabetes<br/>";"•	noncompliance to criteria of metabolic syndrome (e.g. diabetes type 1)<br/>•	Diseases, which might jeopardize patients safety<br/>•	Condition after sterilisation or refertilization<br/>•	Diseases or medicaments, which might obstruct the coduct of the trial (e.g. addiction, psychotic and tumourous diseases, systemic intake of glucocorticoids)<br/>•	Participation in another trial according to AMG";"Primary Sponsor";"Justus Liebig Universität Gießen";"[---]*";"[---]*";"[---]*";"[---]*";"Ludwigstraße 23";"35390";"Gießen";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie";"Mr.";"Prof. Dr. med.";"Florian";"Wagenlehner";"Rudolf-Buchheim-Str. 7";"35385";"Gießen";"Germany";"+49 641 985 44516";"+49 641 985 44509";"Florian.Wagenlehner@chiru.med.uni-giessen.de";"[---]*";"Contact for Public Queries";"Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie";"Mr.";"Prof. Dr. med.";"Florian";"Wagenlehner";"Rudolf-Buchheim-Str. 7";"35385";"Gießen";"Germany";"+49 641 985 44516";"+49 641 985 44509";"Florian.Wagenlehner@chiru.med.uni-giessen.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"LOEWE - Landes-Offensive zur Entwicklung wissenschaftlich ökonomischer Exzellenz<br/>Sprecher: Wolfganf Weidner<br/><br/><br/><br/><br/><br/>        <br/><br/>";"Mr.";"Prof. Dr.";"Wolfgang";"Weidner";"Rudolf-Buchheim-Str. 7";"35392 ";"Gießen";"Germany";"Tel.: 0641 985-44500, 0641 985-44501 (Sekretariat)";"Fax: 0641 985-44509";"E-Mail: Wolfgang.Weidner@chiru.med.uni-giessen.de ";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Project B4: Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome -  male infertility due to infection and inflammation<br/>";"MIBIE";"[---]*";"<br/><br/>study to investigate whether a treatment of overweight and concomitatant diseases as diabetes, hypertension and increased uric acid, may affect gonadal funcion respectively may improve undesired childlessness.";"The potenital correlation between nutritiv caused inflammatory processes in the urogenitale system and metabolic syndrom with respect to a better understanding of route cause and treatment of  infertility shall be investigated in this study<br/><br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003407";"2018-04-06T09:04:23.568+02:00";
"DRKS00003514";2012/03/20;"[---]*";yes;"Approved";"2980-11/10";"Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2010-022660-12";"[---]*";"BfArM-No.";"4036857";"[---]*";;;;;;;;;;"ICD10";"K74.6";"Other and unspecified cirrhosis of liver";"ICD10";"K72.0";"Acute and subacute hepatic failure";"ICD10";"T86.40";"[generalization T86.4: Liver transplant failure and rejection]";"ICD10";"T86.41";"[generalization T86.4: Liver transplant failure and rejection]";;;;"Arm 1";"Intervention: Ilomedin (Iloprost), 1ng/kg BW/min intra-venous (with infusion pump - type Perfusor) continously seven days";"Arm 2";"Control group: Placebo, 1ng/kg BW/min intra-venous (with infusion pump - type Perfusor) continously seven days";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"III";"Yes";"primary graft dysfunction (PDF) after liver transplantation characterized as<br/>presentation of one or more of the following criteria: ALAT or ASAT level > 2000<br/>IU/ml within the first 7 postoperative days, bilirubin ≥ 10 mg/dl on postoperative<br/>day 7; INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function<br/>(INF) defined as graft failure originating from the graft itself, excluding hepatic<br/>artery thrombosis (HAT), biliary complication, recurrent disease or acute rejection<br/>and resulting in retransplantation or patient death within 14 days after initial LT";"- Occurrence of any infection up to day 28 after LT<br/>- Initial non-function (INF) defined as graft failure originating from the graft<br/>itself, excluding hepatic artery thrombosis (HAT), biliary complication,<br/>recurrent disease or acute rejection and resulting in retransplantation or<br/>patient death within 14 days after initial LT<br/>- Clotting factor substitution up to day 28 after LT<br/>- Renal replacement therapy up to day 28 and 180 after LT<br/>- Liver dialysis up to day 28 and 180 after LT<br/>- Graft survival at day 28 and 180 after LT<br/>- Patient survival at day 28 and 180 after LT<br/>- Occurrence of biliary complications at day 28 and 180 after LT<br/><br/>- Length of ICU stay in days up to day 180 after LT (maximum)<br/>- Length of hospital stay in days up to day 180 after LT (maximum)<br/>- Course of ASAT/ALAT, Quick’s value/INR, Factor V and ICG-PDR until day 7<br/>after LT<br/>- Change in SOFA-score from day 1 to day 7 after LT;<br/>Follow-up assessment 270 and 360 days after LT:<br/>- Graft survival<br/>- Patient survival<br/>- Occurrence of biliary complications;<br/>Assessment of safety:<br/>occurrence of bleeding complications, circulatory instability (assessment of<br/>catecholamines administration, mean arterial pressure, heart rate), pulmonary<br/>disturbance (blood-gas analysis, FiO2,PEEP, arterial oxygen saturation, pO2,<br/>pCO2), incidence of AEs and SAEs";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Allgemein, Viszeral- und Gefäßchirurgie";"Jena";"University Medical Center";"Charité Campus Virchow-Klinikum, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie";"Berlin";"University Medical Center";"Klinik für Allgemein-, Viszeral- und Transplantationschirurgie";"Essen";"University Medical Center";"Universitätsmedizin Georg-August-Universität, Klinik für Allgemein- und Viszeralchirurgie, Transplantationschirurgie";"Göttingen";"University Medical Center";"Chirurgische Universitätsklinik, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie";"Heidelberg";"University Medical Center";"Klinikum der Johann Wolfgang Goethe-Universtität, Klinik für Allgemein- und Viszeralchirurgie";"Frankfurt a.M.";"University Medical Center";"Universitätsmedizin der Johannes Gutenberg-Universität, Abteilung für Transplantationschirurgie, Chirurgie von Leber, Pankreas und Gallenwegen";"Mainz";"University Medical Center";"Klinik und Poliklinik für Chirurgie";"Regensburg";"University Medical Center";"Medizinische Hochschule Hannover, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie";"Hannover";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/04/30;"Actual";"430";2014/12/11;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- Full-size liver transplantation<br/>- Informed consent of the patient or legal representative<br/>- Age ≥ 18 years<br/>";"<br/>- Women of child-bearing potential except women with the following criteria:<br/>o post menopausal (12 months natural amenorrhea or 6 month amenorrhea with serum FSH > 40 mlU/ml)<br/>o sterilization 86 weeks after bilateral ovarectomy with or without hysterectomy <br/>o using an effective method of birth control for the duration of trial: implants, injectables, combined oral contraceptives, intra-uterine device (in place for a period of at least 2 months prior to screening) and with negative serum pregnancy test<br/>o sexual abstinence<br/>o vasectomised partner<br/>- Pregnancy/lactation<br/>- Respiratory and/or circulatory instability (noradrenaline > 1 µg/kgBW/min and FiO2 > 0.6) after LT before randomization<br/>- Split liver transplantation/living donor related liver transplantation<br/>- Retransplantation<br/>- Receiving a multi-organ transplantation<br/>- Participation on other clinical trials 30 days prior to randomization <br/>- Known allergic reaction against trial medication <br/>- Conditions in which bleeding complications may be expected from the effect of Iloprost on platelets<br/>- Severe coronary artery disease or unstable angina pectoris<br/>- Myocardial infarction within the past 6 months prior to baseline assessment after acceptance of donor organ<br/>- Acute or chronic heart failure (NYHA II-IV)<br/>- Cardiac arrhythmias relevant for the prognosis<br/>- Suspected pulmonary artery congestion<br/>- Known allergy or intolerance against tacrolimus, mycophenolate mofetil, basiliximab or corticosteroids<br/><br/>";"Primary Sponsor";"Friedrich Schiller Universität Jena -<br/>Universitätsklinikum Jena";"[---]*";"[---]*";"[---]*";"[---]*";"Bachstraße 18";"07740";"Jena";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinikum-jena.de";"Contact for Scientific Queries";"Universitätsklinikum Jena<br/>Klinik für Allgemein-, Viszeral- und Gefäßchirurgie";"Mr.";"Dr.";"Erik";"Bärthel";"Erlanger Allee 101";"07747";"Jena";"Germany";"+49 (0) 3641 932 26 88";"+49 (0) 3641 932 26 02";"avg(at)med.uni-jena.de";"http://www.avc.uniklinikum-jena.de/Klinik+f%C3%BCr+Allgemein__+Viszeral_+und+Gef%C3%A4%C3%9Fchirurgie.html";"Contact for Public Queries";"Universitätsklinikum Jena<br/>Klinik für Allgemein-, Viszeral- und Gefäßchirurgie";"Mr.";"Dr.";"Erik";"Bärthel";"Erlanger Allee 101";"07747";"Jena";"Germany";"+49 (0) 3641 932 26 88";"+49 (0) 3641 932 26 02";"avg(at)med.uni-jena.de";"http://www.avc.uniklinikum-jena.de/Klinik+f%C3%BCr+Allgemein__+Viszeral_+und+Gef%C3%A4%C3%9Fchirurgie.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Astellas Pharma GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Georg-Brauchle-Ring 64-66";"80992";"München";"Germany";"[---]*";"[---]*";"[---]*";"www.astellas.com/de";"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"10115";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Bayer Vital GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"51368";"Leverkusen";"Germany";"[---]*";"[---]*";"[---]*";"www.bayervital.de";"A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation";"PRAISE-Study";"http://www.praise.uniklinikum-jena.de/PRAISE.html";"The clinical course after liver transplantation is essentially determined by the graft function. Poor working grafts lead to an increased risk of complication, e.g.  the occurrence of serious infections. In single cases these infections can become live-threatening. The most serious manifestation of a poor working liver graft is the initial non-function with the requirement of high urgent re-transplantation.<br/><br/>The risk for poor working liver grafts is increased by using organs of lower quality. Due to the lack of organs in Germany, it is necessary to make also use of these organs. It is a major concern to find alternative possibilities in order to  reduce the rate of poor working liver grafts.<br/><br/>The characteristic of the drug Iloprost above others is to inhibit aggregation of platelets and widens blood vessels. Therefore the tissue perfusion (micro-circulation) can be improved. The presented study proves the assumption that application of Iloprost improves the perfusion of the liver graft and therefore lead to a better graft function. This should be reflected in a lower rate of complications. The study participantes receive randomly assigned whether the drug Iloprost or a placebo directly after transplantation for 7 days in total. During these 7 days individual blood samples are taken and liver funcional tests are performed besides the usual routine analysis.  The all over monitoring time of this study takes six months.";"The incidence of primary graft dysfunction (PDF) after liver transplantation (LT) is approximately 25%. Initial non-function (INF) develops in up to 6% of these cases and requires urgent retransplantation. As possible causes several factors are being discussed. These relate to the age of the donor, cold ischemic time or serious steatosis of the graft as potential risk factors. In accordance with these investigations about the incidence of PDF the severity of developing hepatic ischemia/reperfusion injury (IRI) is one of the main reasons for graft dysfunction.<br/>Due to the continuing shortage of donor organs within Germany the transplant centers are forced to accept so called marginal organs. The more criteria of a marginal organ are met, the higher is the risk for the development of a dysfunction of the transplanted liver. Organ dysfunction may deteriorate to complete organ failure and increases perioperative morbidity and mortality after transplantation. Therapeutic strategies for reducing the rate of organ dysfunction and for the treatment of malfunctions with medication are of current clinical relevance. One approach is the systemic application of prostaglandin derivatives.<br/><br/>Many authors reported about the clinical use of the synthetic prostaglandin-I2 (PGI2)-analogue Iloprost. Based on inducing vasodilatation it has been utilized in pulmonary hypertension. Off-label systemically administered iloprost as adjuvant in elective abdominal aortic aneurysm surgery or after revascularisation of acute lower limb ischemia based on improving microcirculation was reported. In these studies the iloprost infusion was associated with significant reduction of morbidity and mortality. <br/><br/>Bärthel et al. (2011) evaluated the impact of iloprost in 80 liver transplanted patients in a prospective, randomized (1:1), open-label, single-center pilot study.<br/>These data indicate that intravenous administered iloprost (1ng/kg BW/min) improves the graft function particularly in the early postoperative period.<br/>These results are encouraging. There is, however, preliminary evidence to suggest beneficial effects in this particular clinical scenario. The clinical outcome after LT is affected by various donor and recipient characteristics. In order to define the specific impact of iloprost on liver graft function, this prospective, multicenter, randomized, doubleblinded, placebo-controlled clinical trial including an appropriate number of patients will be performed. The investigational medicinal product will be iloprost. It will be administered intra-venous continuously over seven days. The placebo group receives the placebo that is administered in the same dosage and application form.<br/>The end of the trial duration for each patient is reached 180 days after LT (after 6 months). The follow up period will be 180 days (6 months) with assessment after 270 and 360 days (9 and 12 months) after LT.<br/><br/>The primary objective of this trial is the rate of PDF after LT. It is evaluated using the following definition: PDF is characterized as presentation of one or more of the following criteria: ALAT or ASAT level > 2000 IU/ml within the first 7 postoperative days; bilirubin ≥ 10 mg/dl on postoperative day 7; INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function (INF) defined as graft failure originating from the graft itself, excluding hepatic artery thrombosis (HAT), biliary complication, recurrent disease or acute rejection and resulting in retransplantation or patient death within 14 days after initial LT.<br/><br/>Based on the results of previous investigations a relative reduction of PDF incidence of<br/>50% by iloprost compared to placebo is expected.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003514";"2015-01-05T12:47:51.347+01:00";
"DRKS00004017";2012/09/13;2009/07/03;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00933374";"ClinicalTrials.gov";"Sponsor-ID";"CRAD001L DE 17T";"Heinrich-Heine University, Duesseldorf";;;;;;;;;;"Free text";"[---]*";"Bladder Cancer";"ICD10";"C67";"Malignant neoplasm of bladder";;;;;;;;;;"Arm 1";"Drug: paclitaxel";"Arm 2";"Drug: RAD001";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"- Response rate; time frame: 3 years<br/>";"- Duration of response; time frame: from first determination of response until progression<br/>- Progression free survival; time frame: 3 years<br/>- overall survival; time frame: 3 years<br/>- safety profile of combination RAD001 and paclitaxel; time frame: 6 month<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Klinik für Urologie, Klinikum rechts der Isar der TU München";"München";"[---]*";"Heinrich-Heine-University of Duesseldorf, Department of Urology";"Duesseldorf";"[---]*";"Universitätsklinik Essen, Klinik für Urologie";"Essen";"[---]*";"Klinik für Urologie, Universitätsklinikum Muenster";"Muenster";"[---]*";"Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes";"Homburg";"[---]*";"Universitätsklinik Hamburg, Medizinische Klinik und Poliklinik Onkologie - Hämatologie";"Hamburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/07/31;"[---]*";"28";2013/09/01;"Multicenter trial";"[---]*";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Patients with histologically proven carcinoma of the urinary tract including urinary<br/>             bladder, ureter, renal pelvis and lower urinary tract. Urothelial carcinoma should be<br/>             the predominant histology<br/><br/>          -  Confirmation of locally relapsed or metastatic disease by imaging. Measurable disease<br/>             according to RECIST- guidelines with ≥1 measurable lesion has to be evident.<br/><br/>          -  If bone is the only metastatic site a quantification of the target lesion(s) using<br/>             MRI is mandatory.<br/><br/>          -  Failure of prior platin- based chemotherapy<br/><br/>          -  Patients may have shown progressive disease within the first 3 months of platin-based<br/>             chemotherapy (primary failure) or progression within 3 months after the end of<br/>             platin-based chemotherapy (early relapse)-Prior therapy with ≤ 4 chemotherapeutic<br/>             drugs<br/><br/>          -  Patients with tumor relapse within 3 months after cystectomy in the neoadjuvant or<br/>             adjuvant setting are not eligible.<br/><br/>          -  ECOG performance status 0-2<br/><br/>          -  Adequate haematological, liver and renal functions.<br/><br/>               -  Neutrophil count > 1500/mm3, haemoglobin > 9 g/dl, platelets ≥ 100.000/ mm3<br/><br/>               -  Serum bilirubin ≤ 1.5 x ULN, ALT and AST ≤ 2.5x ULN. Patients with known liver<br/>                  metastases who have an AST and ALT ≤ 5x ULN.<br/><br/>               -  serum creatinine ≤ 2 x ULN.<br/><br/>          -  Women of childbearing potential must have a negative serum or urine pregnancy test<br/>             within 14 days prior to the first dose of study drug. Female subjects of childbearing<br/>             potential must be using two acceptable methods of contraception, from the time of<br/>             screening and for the duration of the study, through study completion and for 3<br/>             months following study completion<br/><br/>          -  Age > 18 years.<br/><br/>          -  Able to communicate well with the investigator, to understand and comply with the<br/>             requirements of the study. Understand and sign the written informed consent.<br/><br/>          -  Patients must give written informed consent<br/><br/>          -  No concurrent treatment with other experimental drugs or anti-cancer drugs<br/><br/>          -  Another distinguishable malignancy will be permitted<br/>";"-  chemotherapy, radiation therapy or any other anticancer therapy within 4 weeks of the<br/>             first dose of study drug.<br/><br/>          -  Participation in any clinical investigation within 4 weeks prior to initial dosing.<br/><br/>          -  known hypersensitivity to RAD001 or other rapamycin analogs and paclitaxel or other<br/>             taxanes, or to its excipients.<br/><br/>          -  previously received RAD001, other mTOR inhibitors or taxanes or epothilones<br/><br/>          -  known metastasis of central nervous system.<br/><br/>          -  symptomatic pleural effusions or symptomatic ascites.<br/><br/>          -  wide field radiation therapy to up to ≥ 25% of the bone marrow within 4 weeks prior<br/>             therapy.<br/><br/>          -  intravenous radionuclide therapy, e.g. phosphorus (32P), strontium (89SrCl), rhenium<br/>             (186Re)or samarium (153Sm).<br/><br/>          -  Patients who have undergone major surgery within 4 weeks prior to starting study<br/>             drug,open biopsy, or significant traumatic injury, or who have not recovered from the<br/>             side effects of any of the above.<br/><br/>          -  Chronic systemic treatment with corticosteroids corresponding to a prednisone<br/>             equivalent of > 10 mg daily. Patients receiving corticosteroids must be on a stable<br/>             dose for ≥ 4 weeks prior to the first dose of RAD001. Topical or inhaled<br/>             corticosteroids are permitted.<br/><br/>          -  Concomitant medication with strong CYP3A4- inhibitors or CYP3A4- inducers.<br/><br/>          -  active bleeding diathesis.<br/><br/>          -  Neuropathy > grade 1.<br/><br/>          -  any severe and/or uncontrolled medical conditions(unstable angina pectoris,<br/>             symptomatic congestive heart failure, myocardial infarction ≤ 6 months, serious<br/>             uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled<br/>             severe infection,cirrhosis,chronic or persistent active hepatitis)<br/><br/>          -  severely impaired lung function as defined as spirometry and DLCO that is 50% of the<br/>             normal predicted value and/or O2 saturation ≤ 88% at rest on room air<br/><br/>          -  Uncontrolled diabetes<br/><br/>          -  Hepatic impairment with a Child-Pugh score >9<br/>";"Primary Sponsor";"Heinrich-Heine University, Duesseldorf";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Heinrich-Heine-University, Department of Urology";"[---]*";"[---]*";"[---]*";"Peter Albers, Professor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Heinrich-Heine-University, Department of Urology";"[---]*";"[---]*";"[---]*";"Peter Albers, Professor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy";"RAD001";"[---]*";"This is a single arm open- label phase II- trial evaluating safety and efficacy of<br/>      paclitaxel and RAD001 in patients with metastatic urothelial bladder cancer who failed prior<br/>      platin-based systemic therapy.<br/>";"The screening phase for checking eligibility and evaluation of the patient prior start of<br/>      study treatment will last up to 21 days.Tumor histology must be predominant urothelial<br/>      carcinoma and confirmed histological or cytological.Patients who meet the inclusion criteria<br/>      will be treated with paclitaxel 175 mg/m2 every 3 weeks and RAD001 10 mg once daily. Each<br/>      cycle will use the combination of paclitaxel 175 mg/m2 3-weekly with RAD001 10 mg daily<br/>      starting at day 1 of a 21 days treatment cycle. Additional visits after day 1 are performed<br/>      at day 8 and day 15 of each cycle Assessment of safety and toxicity will be performed at<br/>      every visit.<br/><br/>      Patients will be treated until no signs of clinical or radiological progression are evident<br/>      and the study treatment is well tolerated for a maximum of 6 cycles.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004017";"2016-01-20T16:50:19.204+01:00";
"DRKS00004349";2012/08/28;"[---]*";yes;"Approved";"86_12";"Ethik-Kommission der Friedrich-Alexander-Universität Erlangen-Nürnberg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2012-000500-15";"[---]*";"BfArM-No.";"4038173";"[---]*";;;;;;;;;;"ICD10";"E11";"Non-insulin-dependent diabetes mellitus";;;;;;;;;;;;;"Arm 1";"Period 1: Metformin, 850 mg p.o., once daily for 2 days; Glucose syrup, 75 g glucose p.o., once daily for 2 days<br/><br/>Period 2: Metformin, 850 mg p.o., once daily for 2 days; Glucose syrup, 75 g glucose p.o., once daily for 2 days; trimethoprim, 200 mg p.o., twice daily for 5 days<br/><br/>Duration of wash-out period: at least 7, maximal 56 days";"Arm 2";"Period 1: Metformin, 850 mg p.o., once daily for 2 days; Glucose syrup, 75 g glucose p.o., once daily for 2 days; trimethoprim, 200 mg p.o., twice daily for 5 days<br/><br/>Period 2: Metformin, 850 mg p.o., once daily for 2 days; Glucose syrup, 75 g glucose p.o., once daily for 2 days<br/><br/>Duration of wash-out period: at least 7, maximal 56 days";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Other";"Other";"Crossover";"I";"Yes";"Primary pharmacokinetic outcome: The area under the metformin plasma concentration time curve, analysed by LC/MS/MS. Time points of measurements: pre-dose until 24 hours after the second intake of metformin in each period. <br/><br/>Primary pharmacodynamic outcome: The area under the plasma glucose concentration time curve in the oral glucose tolerance test. Time points of measurements: pre-dose until 5 hours after intake of glucose syrup.";"- Other kinetic and dynamic parameters of metformin and trimethoprim in blood and urine (e.g., the area under the concentration time curve for other time intervals, the maximal concentrations, the fraction excreted in the urine, the renal, extrarenal and secretory clearance, the time of maximal concentration)<br/>- The effect of genetic variants on metformin and trimethoprim concentrations and on endogenous substances in blood and urine, e.g., lactate<br/>- Gender aspects of the analyses<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"other";"Institut für Experimentelle und Klinische Pharmakologie und Toxikologie";"Erlangen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/09/07;"Actual";"24";2014/02/27;"Monocenter trial";"National";"Both, male and female";"18";"Years";"60";"Years";"- Healthy male or female<br/>- No clinically relevant findings at screening<br/>- body mass index between 18 and 30 kg/m²<br/>- willing to use contraceptive measures<br/>";"- Clinically relevant deviation of laboratory parameters at screening<br/>- Pathologic deviations in the hemogram at screening<br/>- Fasted plasma glucose of 100 mg/dl or higher at screening<br/>- Anamnestically known glucose malabsorption<br/>- Simultaneous participation in another clinical study according to the German Drug Law<br/>- Use of other medication within 14 days before study start (except for hormonal contraceptives)<br/>- smoking of 5 or more cigarettes per day<br/>- Dependency of alcohol, illegal drugs or medication<br/>- Current, relevant disease or relevant physiologic change<br/>- Blood loss of 200 ml blood or more within 4 weeks before study start<br/>- Contraindication for the use of one of the investigational drugs<br/>- Pregnancy or lactation<br/>- No capacity to consent<br/>- dependence on one of the investigators";"Primary Sponsor";"Friedrich-Alexander-Universität Erlangen-Nürnberg";"Mr.";"Prof. Dr. med. Dr. h.c.";"Jürgen";"Schüttler";"Krankenhausstraße 12";"91054";"Erlangen";"Germany";"+49 (0) 9131 85-22258";"+49 (0) 9131 85-22773";"fabian.mueller@pharmakologie.uni-erlangen.de";"www.uni-erlangen.de";"Contact for Scientific Queries";"Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg";"Mr.";"Prof. Dr. med.";"Martin";"Fromm";"Fahrstraße 17";"91054";"Erlangen";"Germany";"+49 (0) 9131 85 22258";"+49 (0) 9131 85 22773";"fabian.mueller@pharmakologie.uni-erlangen.de";"www.pharmakologie.uni-erlangen.de";"Contact for Public Queries";"Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg";"Mr.";"Dr. med.";"Fabian";"Müller";"Fahrstraße 17";"91054";"Erlangen";"Germany";"+49 (0) 9131 85 22258";"+49 (0) 9131 85 22773";"studien@pharmakologie.uni-erlangen.de";"www.pharmakologie.uni-erlangen.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg";"Mr.";"Prof. Dr. med.";"Martin";"Fromm";"Fahrstraße 17";"91054";"Erlangen";"Germany";"+49 (0) 9131 85 22772";"+49 (0) 9131 85 22773";"martin.fromm@pharmakologie.uni-erlangen.de";"www.pharmakologie.uni-erlangen.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A single-center, randomized, open-label cross-over study to investigate the drug-drug interaction of trimethoprim and metformin in healthy volunteers";"KPE22";"[---]*";"Main purpose of the study is the examination of occurrence and extent of the drug interaction between the drugs trimethoprim and metformin.  <br/><br/>Background: Trimethoprim is an antibiotic that is used mainly in therapy of urinary tract infection. Metformin is a drug that is used for treatment of so called adult onset diabetes. Both metformin and trimethoprim are frequently used drugs, and trimethoprim possibly influences the behaviour (drug concentrations and effect) of metformin in the body.<br/><br/>Potential participants: Healthy adult male and female subjects.<br/><br/>Outcomes: The effect of trimethoprim on concentrations of metformin in blood and urine and therewith on the effects of metformin shall be investigated.<br/><br/>The hypothesis is: We suspect that trimethoprim influences the concentrations of metformin in blood and urin and therewith the therapeutic effects of metformin. Possibly, the extent of this interaction may be influenced by the genes. This means, that the extent of the interaction may vary from person to person depending on the genes.";"Both metformin and trimethoprim are frequently used drugs. We hypothesize that trimethoprim influences both pharmacokinetics and pharmacodynamics of metformin. Furthermore, we hypothesize that the extent of this interaction is influenced by genetic variants. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004349";"2014-03-27T12:02:46.522+01:00";
"DRKS00005040";2013/08/22;2011/04/08;yes;"Approved";"152-11";"Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2009-013701-34";"[---]*";"Primary Registry-ID";"EUCTR2009-013701-34-DE";"EU Clinical Trials Register";;;;;;;;;;"ICD10";"G43";"Migraine";"ICD10";"H81.4";"Vertigo of central origin";"ICD10";"H81.9";"Disorder of vestibular function, unspecified";"ICD10";"R42";"Dizziness and giddiness";;;;"Arm 1";"metoprolol succinate (BelocZok(R)) 95 mg once a day orally for 6 months";"Arm 2";"placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"III";"Yes";"The number of vertigo attacks and the number of headache attacks during the last 3 months of the 6-month treatment period.";"The number of vertigo attacks and the number of headache attacks<br/>during the last 3 months of the total follow-up period of 9 months;<br/><br/>the median duration and severity of vertigo attacks during the last 3<br/>months of the 6-month treatment period and the last 3 months of the<br/>total follow-up period;<br/><br/>the number of headache days per month during the last 3 months of<br/>the 6-month treatment period and the last 3 months of the total follow-<br/>up period;<br/><br/>the changes in the neurological and neuro-orthoptic examination and<br/>handicap / impairment due to vertigo between baseline, 6-month visit<br/>and 9-month visit.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"München";"Medical Center";"[---]*";"Celle";"Medical Center";"[---]*";"Altötting";"University Medical Center";"[---]*";"Tübingen";"University Medical Center";"[---]*";"Essen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/06/20;"Actual";"266";2018/01/03;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"· Patients with diagnosis of probable (1., 4., 5.) or definite (1., 2., 3., 5.) vestibular<br/>migraine according to the criteria of Neuhauser (Neuhauser et al.<br/>2001):<br/>1. episodic vestibular symptoms of at least moderate severity (rotational<br/>vertigo, other illusory self or object motion, positional vertigo, head motion<br/>intolerance, i. e., sensation of imbalance or illusory self or object<br/>motion that is provoked by head motion);<br/>2. migraine according to the IHS criteria;<br/>3. at least one of the following migrainous symptoms during at least two<br/>vertiginous attacks: migrainous headache, photophobia, phonophobia,<br/>visual or other auras;<br/>4. at least one of the following: migraine according to the IHS criteria; migrainous<br/>symptoms during vertigo as specified in 3.; migraine-specific<br/>precipitants of vertigo, e. g. specific foods, sleep irregularities, hormonal<br/>changes; response to antimigraine drugs<br/>5. other causes ruled out by appropriate investigations;<br/>· Between 6 and 30 attacks per 3 subsequent months;<br/>· Subjects with the ability to follow study instructions and likely to attend and<br/>complete all required visits;<br/>· Written informed consent of the subject";"· Patients not able to give consent;<br/>· Other vestibular disorders such as Menière´s disease, phobic postural<br/>vertigo, benign paroxysmal positioning vertigo, vestibular paroxysmia;<br/>· Central disorders such as paroxysmal brainstem attacks, TIAs;<br/>· Contraindications for the treatment with metoprolol such as<br/>o known allergic reaction to the trial drug or other beta receptor<br/>blockers;<br/>o shock, acidosis<br/>o Any bronchospastic disease, e.g. bronchial asthma;<br/>o Sick sinus syndrome, known SA-block, AV-block;<br/>o Bradycardia < 50 bpm at rest, systolic blood pressure < 100<br/>mmHg, end-grade peripheral arterial disease;<br/>o Known severe coronary heart disease or heart failure;<br/>o Concurrend treatment with MAO-inhibitors, sympathomimetic<br/>drugs, Catecholamine-depleting drugs, digitalis glycosides;<br/>· Poorly controlled diabetes mellitus;<br/>· Pheochromocytoma;<br/>· Suspicion of developing thyrotoxicosis;<br/>· Disorders of hemostasis;<br/>· Porphyria;<br/>· Psoriasis;<br/>· Pregnancy or breast-feeding;<br/>· Persistent hypertension with systolic blood pressure > 180 mmHg or diastolic<br/>BP > 110 mmHg (mean of 3 consecutive arm-cuff readings over<br/>20-30 minutes) that cannot be controlled by antihypertensive therapy;<br/>· Life expectancy < 12 months;<br/>· Other serious illness, e.g., severe hepatic, cardiac, or renal failure, acute<br/>myocardial infarction, neoplasm or a complex disease that may confound<br/>treatment assessment;<br/>· Treatment with beta-blockers<br/>· The patient has received any investigational medication within 30 days<br/>prior to administration of study medication or is scheduled to receive an<br/>investigational drug up to 30 days after end of study;";"Primary Sponsor";"Klinikum der Universität München, Campus Großhadern";"[---]*";"[---]*";"[---]*";"[---]*";"Marchioninistraße 15";"81377";"München";"Germany";"[---]*";"[---]*";"[---]*";"www.klinikum.uni-muenchen.de";"Contact for Scientific Queries";"Klinikum der Universität München, Campus Großhadern<br/>Deutsches Schwindel- und Gleichgewichtszentrum (IFB)<br/>Studienzentrale";"Mr.";"Privdoz. Dr. med., MPH";"Otmar";"Bayer";"Marchioninistr. 15";"81377";"München";"Germany";"089-4400-76977 oder 089-5526189-12";"089-4400-78795";"IFB-Studienzentrale@med.uni-muenchen.de";"www.ifb.klinikum.uni-muenchen.de";"Contact for Public Queries";"Klinikum der Universität München, Campus Großhadern<br/>Deutsches Schwindel- und Gleichgewichtszentrum (IFB)<br/>Studienzentrale";"[---]*";"[---]*";"[---]*";"[---]*";"Marchioninistr. 15";"81377";"München";"Germany";"089-4400-76987";"089-4400-78795";"IFB-Studienzentrale@med.uni-muenchen.de";"www.ifb.klinikum.uni-muenchen.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Bonn";"[---]*";"[---]*";"[---]*";"[---]*";"Heinemannstr. 2";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-controlled trial";"PROVEMIG";"http://www.klinikum.uni-muenchen.de/Deutsches-Schwindelzentrum-IFB-LMU/de/Studienzentrum/PROVEMIG_Studie/index.html";"To date there is no prophylactic drug for vestibular migraine shown to be effective in controlled clinical trials. This study investigates, whether there is a prophylactic effect of Metoprolol on attacks in patients with vestibular migraine.";"Primary Objective :<br/>To demonstrate the superiority of Metoprolol Succinate treatment regarding the<br/>number of vertigo attacks and the number of headache attacks per month compared<br/>to placebo.<br/>Secondary Objective:<br/>To analyze whether the superiority of Metoprolol Succinate treatment is kept up<br/>to three months after the last drug intake. To quantitatively describe and compare<br/>the median duration and severity of vertigo attacks, the number of headache days, neurological and neuro-orthoptic examination and the change of<br/>handicap / impairment due to vertigo or dizziness vs. placebo. To check for the<br/>occurrence of the adverse effects reported in the summary of the medical<br/>product characteristics (SmPC) of the drug.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005040";"2019-02-13T10:15:43.482+01:00";
"DRKS00005485";2014/05/07;"[---]*";yes;"Approved";"2013-110";"Ethikkommission der Medizinischen Fakultät der Martin-Luther-Universität Halle Wittenberg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2013-000776-15";"[---]*";;;;;;;;;;;;;"ICD10";"F32";"Depressive episode";"ICD10";"E29";"Testicular dysfunction";;;;;;;;;;"Arm 1";"injection of 1000 mg testosteroneundecanoate (Nebido); 0, 6, 18, 30 weeks after beginning of treatment";"Arm 2";"injection of 4 ml Placebo; 0, 6, 18, 30 weeks after beginning of treatment";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"IV";"No";"score geriatric depression scale (GDS-30) 42 weeks after beginning of treatment";"score of questionnaires (time after beginning of treatment):<br/>1)Geriatric Depression scale (GDS-30), (week -2, week 18, week 42)<br/>2) Ageing Male's Symptom Scale (AMS) (week -2, week 18, week 42)<br/>3) Depression scale of PHQ-D (PHQ-9) (week -2, week 18, week 42)<br/>4) IIEF (International Inventory of erectile function) (week -2, week 18, week 42)<br/>5) BDI-II (Beck Depressions Inventory) (week -2, week 6, week 18, week 30, week 42)<br/>6) time until psychiatric council is necessary (Score of BDI-II >= 20 and/or item 9 BDI-II (suicidality) >=1) (week -2, week 6, week 18, week 30, week 42)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Zentrum für Reproduktionsmedizin und Andrologie";"Halle Saale";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/02/09;"Actual";"112";2015/12/18;"Monocenter trial";"National";"Male";"60";"Years";"[---]*";"no maximum age";"written informed consent; men with age at least 60 years; confirmed late-onset hypogonadism (according to International Society of Andrology 2009); confirmed depressive mood (ICD10 F32.0 - F32.1); either total testosterone level < 12 nmol/l or free testosterone < 225 pmol/l; score GDS-30 >= 13 (within last week)";"taking of Androgens or Anabolics within last 12 months; PSA ≥ 4 ng/ml; pathological finding of prostate (DRE); diagnose or suspicion of tumor of prostate, mamma and liver; Major Depression (ICD10 F32.2 - F32.3); known dementia;	known abuse of alcohol and drugs; <br/>other known psychiatric disease (psychiatric examination) or psychotherapy; BDI-II >=20, item 9 BDI-II (suicidality) >=1); acute or life-threatening disease (estimated expectancy of life < 2 years); chronic disease, possibly affecting security of patient during study (e.g. Haemochromatosis, Dubin-Johnson-Rotor-Syndrome, chronic disease of lung;<br/>Hypersensitivity against IMP or substances of IMP; problems of coagulation with increased risk of bleeding after injection; sleep apnea; Polycythaemia; Haematocrit > 50 %; taking of 5α-Reductase-Inhibitors; Prolactin > 25 ng/ml; benign hyperplasia of prostate with obstruction of bladder neck  (residual urine > 200 ml); BMI > 35 kg/m²; untreated dysfunction of thyroid gland; untreated Diabetes mellitus (HbA1C > 9%); untreated  Epilepsy; untreated Migaine; planned or actual therapy for reproduction; psychiatric or other disease to hinder the patient to understand content of study; unsufficient treatment of hypertension; known insufficiency of heart, liver and kidney; unsufficient treatment of coronary heart disease; known or actual thrombotic event; participation on other clinical trials; taking of Androgens, Anabolics, Clomipramin, Antiandrogens, Estrogens; Corticotropinen (ACTH); Oxyphenbutazon; psychotropic drugs<br/>";"Primary Sponsor";"Marin-Luther-Universität Halle-Wittenberg";"[---]*";"[---]*";"[---]*";"[---]*";"Magdeburgerstr. 8";"06112";"Halle Saale";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Zentrum für Reproduktionsmedizin und Andrologie der Martin-Luther-Universität Halle-Wittenberg";"Mr.";"Prof.";"Hermann";"Behre";"Ernst-Grube-Str. 40";"06120";"Halle Saale";"Germany";"0345 5574782";"0345 5574788";"zra@uk-halle.de";"https://www.medizin.uni-halle.de/index.php?id=34";"Contact for Public Queries";"Zentrum für Reproduktionsmedizin und Andrologie der Universität Halle-Wittenberg";"Mr.";"Prof.";"Hermann";"Behre";"Ernst-Grube-Str. 40";"06120";"Halle Saale";"Germany";"0345 5574782";"0345 5574788";"zra@uk-halle.de";"https://www.medizin.uni-halle.de/index.php?id=34";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Jenapharm GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Otto-Schott-Straße 15";"07745";"Jena";"Germany";"03641 648888";"03641 648889";"maennergesundheit@jenapharm.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Late-onset hypogonadism (LOH) and depressive mood changes - a double blind, placebo-controlled study with intramuscular application of testosterone undecanoate ";"TeLoDe12";"[---]*";"The clinical trial TeLoDe12 is focussed on elderly men suffering from low level of testosterone associated with depressive mood. The aim is to evaluate wether depressive mood can be influenced by Nebido, a testosterone compound with manufacturing authorisation. The trial is designed as controlled and double-blind study. 50 % of population will be treated with Placebo. The duration of treatment is 30 weeks. During this time 4 injections either of Nebido or of placebo will be given to the patients. Primary endpoint is the value of Geriatric Depression Scale (GDS-30) 42 weeks after beginning of treatment.";"The aim of trial is to evaluate wether depressive mood caused by Late-onset hypogonadism ca be influenced by testosterone substitution with testosertone-undecanoate (Nebido). Primary endpoint is the score of Geriatric Depression Scale (GDS-30) 42 weeks after beginning of testosterone substitution.<br/>secondary endponits are<br/>a) score of GDS-30, 18 weeks after beginning of substitution; b) evaluation of symptoms of Late-onset hypogonadism with questionnaires:<br/>Beck Depression Inventory (BDI), Ageing Males’ Symptoms rating scale (AMS), Depression Scale of Patients Health Questionnaire (PHQ-9), International Inventory of erectile function (IIEF). c) time until psychiatric council is necessary (score BDI-II >=20, item 9 BDI-II (suicidality) >=1)";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005485";"2016-08-01T14:11:16.201+02:00";
"DRKS00006178";2014/05/20;2014/01/23;yes;"Approved";"087-14-10032014";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2013-004353-24";"[---]*";"Primary Registry-ID";"EUCTR2013-004353-24-DE";"EUDRA-CT-Datenbank";;;;;;;;;;"Free text";"[---]*";"Obesity, abdominoplasty/lower body lift after bariatric surgery";"ICD10";"Z41";"Procedures for purposes other than remedying health state";;;;;;;;;;"Arm 1";"abdominoplasty / lower body lift using Artiss Fibrin Sealant";"Arm 2";"Standard abdominoplasty / lower body lift ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"IV";"No";"Reduction of the wound drainage volume until 14 days after surgery";"- proportion of patients with a drainage volume <30 ml/day from the first day until 14 days after surgery<br/>- number of “drainage days” until 14 days after surgery<br/>- number of days with a drainage volume >30 ml until 14 days after surgery<br/>- wound drainage volume per day until 14 days after surgery<br/>- length of in-hospital stay<br/>- quality of life measured by Impact of Weight in Quality of Life, Post-Bariatric-Surgery Quality of Life and Weight Bias Internalization Scale to baseline and 12 weeks after surgery<br/>- quality of interpersonal relationships (Realationship Assessment Scale)  to baseline and 12 weeks after surgery<br/>- psychiatric comorbidities assessed by the Patient Health Questionnaire  to baseline and 12 weeks after surgery<br/>- Importance of weight and shape measured by subscales  to baseline and 12 weeks after surgery<br/>- Self-esteem ( Rosenberg Self-Esteem Scale) and the body image ( Figure Rating Scale)  to baseline and 12 weeks after surgery<br/>- Assessment of specific surgical issues / problems (such as postoperative pain, recovery process and satisfaction with treatment)  to baseline and 12 weeks after surgery";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Abteilung für Plastische, Ästhetische und spezielle Handchirurgie am Universitätsklinikum Leipzig AöR;  Liebigstr. 20; 04103 Leipzig";"Leipzig";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/08/08;"Actual";"50";2017/03/03;"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"- age of 18 to 65 years<br/>- Previous bariatric surgery with reaching an equilibrium plateau over 6 months<br/>- planned abdominoplasty / lower body lift<br/>- estmated resection weight >1 kg<br/>- Written informed consent";"-  inoperable from anaesthesiological perspective<br/>-  increased bleeding tendency (ProTime INR<= 70%; PTT >= 38 sec; platelets <= 150.000/mm³)<br/>-  instable diabetes mellitus typ II (HbA1c >8%)<br/>-  known complications after blood transfusion (especially AB0 incompatibility reaction, Rh incompatibility reaction)<br/>- known hypersensitivity to human fibrin, aprotinin, human thrombin, L-histidine, niacinamide<br/>- Women during pregnancy and lactation (positive pregnancy test in women of childbearing age)<br/>- Participation in other clinical trials";"Primary Sponsor";"Universität Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstr. 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum Leipzig AöRDepartment für operative Medizin (DOPM)Abteilung für Plastische, Ästhetische und spezielle Handchirurgie";"Mr.";"Prof. Dr. med.";"Stefan";"Langer";"Liebigstr. 20";"04103";"Leipzig";"Germany";"+49 341 97 17140";"+49 341 97 17139";"stefan.langer@medizin.uni-leipzig.de";"http://www.plastische-chirurgie.uniklinikum-leipzig.de";"Contact for Public Queries";"Universitätsklinikum Leipzig - AöRDepartment für Operative Medizin (DOPM)Abteilung für Plastische, Ästhetische und Spezielle Handchirurgie";"Mr.";"Prof. Dr. med.";"Stefan";"Langer";"Liebigstr. 20";"04103";"Leipzig";"Germany";"+49 341 97 17140";"+49 341 97 17139";"stefan.langer@medizin.uni-leipzig.de";"http://www.plastische-chirurgie.uniklinikum-leipzig.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"BMBF IFB Adipositas-Erkrankungen";"[---]*";"[---]*";"[---]*";"[---]*";"Liebigstr. 21";"04103";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Wound Management in Post-Bariatric Surgery<br/>Investigation for the reduction of the mean drainage volume in patients after abdominoplasty / lower body lift using Artiss Fibrin Sealant in comparison to the standard procedure";"WMPS";"[---]*";"Many patients who have undergone bariatric surgery develop extreme amounts of excess skin due to the pronounced weight loss. This can be corrected using body contouring operations such as abdominoplasty (tightening the abdomen) and the body-lift (tightening abdomen, buttocks and back). When the wound is closed in such operations, the trial will make use of a fibrin sealant to affix tissue layers. The expectation is that the use of the fibrin sealant will reduce the volume of drainage fluid and prevent seroma (a pocket in which lymphatic fluid or serum collects) as compared to the control group.";"The aim of the trial is to assess the effectiveness of the Artiss™ fibrin sealant compared to the standard technique in reducing the volume of wound drainage fluid in patients that have undergone a planned post-bariatric body contouring operation.<br/>The primary endpoint in the volume of wound drainage fluid.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006178";"2018-08-09T16:02:31.079+02:00";
"DRKS00007559";2014/11/25;"[---]*";no;"Approved";"140/13_mm";"Ethik-Kommission der Medizinischen Fakultät der Universität Würzburg";"EUDAMED-No.<br/>(for studies acc. to Medical Devices act)";"CIV-13-05-011241";"[---]*";;;;;;;;;;;;;"ICD10";"A41.8";"Other specified sepsis";"ICD10";"R57.2";"Septic shock";;;;;;;;;;"Arm 1";"Combined therapy with cytokine eliminating hemofiltration using the Selecticure L19 filter and granulocyte/monocyte adsorption with the Immuloc®-sorbent adsorber, continuously during a total of 72 h";"Arm 2";"Therapy according to current standards";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Mortality at day 90";"1. Mortality at day 28<br/>2. Length of stay on Intensive Care Unit<br/>3. median SOFA- and APACHE II- (Sub-)Scores after 5 and 28 days<br/>4. Length of stay in Hospital after study start<br/>5. Daily urine output<br/>6. Length of anuria until hospital dismission<br/>7. Frequency and length of ventilator therapy until day 28<br/>8. Vasopressor drug requirements until day 28<br/>9. Length of renal replacement therapy until day 90<br/>10. Course of defined laboratory parameters<br/>11. Feasability of study therapy / study targets";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Intensivstation";"Würzburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/12/10;"Actual";"128";2016/11/21;"Monocenter trial";"National";"Both, male and female";"18";"Years";"90";"Years";"- Severe sepsis or septic shock,<br/>- Acute, septic renal failure and indication for renal replacement therapy,<br/>- Age ≥18 years,<br/>- Written informed consent of the patient or next of kin or legally authorized person";"- Pregnant or breast-feeding women,<br/>- Age > 90 years,<br/>- bleeding risk due to underlying disease or recently performed surgery,<br/>- known allergies to components of the extracorporeal therapy,<br/>- Contraindications to heparin for anticoagulation including heparin induced thrombocytopenia Type II<br/>- previous severe sepsis during the hospital stay (“re-Sepsis”),<br/>- very poor prognosis (life expectancy < 6 months) due to concomitant disease (except severe sepsis or septic shock),<br/>- Aplasia,<br/>- currently on chemotherapy.";"Primary Sponsor";"eXcorLab GmbH";"Mr.";"Dr.";"Christoph";"Sauvant";"Industrie Center Obernburg";"63784";"Obernburg";"Germany";"06022-812867";"06022-812676";"christoph.sauvant@excorlab.de";"www.excorlab.de";"Contact for Scientific Queries";"eXcorLab GmbH";"Mr.";"Dr.";"Christoph";"Lemke";"Industrie Center Obernburg";"63784";"Obernburg";"Germany";"06022-812867";"06022-812676";"christoph.sauvant@excorlab.de";"www.excorlab.de";"Contact for Public Queries";"eXcorLab GmbH";"Mr.";"Dr.";"Christoph";"Sauvant";"Industrie Center Obernburg";"63784";"Obernburg";"Germany";"06022-812867";"06022-812676";"christoph.sauvant@excorlab.de";"www.excorlab.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"eXcorLab GmbH";"Mr.";"Dr.";"Christoph";"Sauvant";"Industrie Center Obernburg";"63784";"Obernburg";"Germany";"06022-812867";"06022-812676";"christoph.sauvant@excorlab.de";"www.excorlab.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Pilot Trial on the Combined Therapy of Cytokine Filtration and Granulocyte/Monocyte Adsorption in Sepsis";"[---]*";"[---]*";"The study investigates a novel therapy, which removes blood cells and messenger substances from blood of patients with severe sepsis. Study target is the prevention of an overshooting immune response and its complications to beneficially impact on the course of the disease.";"The pilot trial investigates the impact of a combined therapy with highly efficient hemofiltration using a novel, improved cytokine eliminating filtration membrane (Selecticure L19 filter) and granulocyte/monocyte adsorption (Immuloc®-sorbent) on the course of severe sepsis or septic shock. A comparison between patients treated with  study or standard therapy will be made.";"Recruiting stopped after recruiting started ";"Trial results";"fce8e096-49ba-40bd-8831-116bb53111c5";"KSSEP1203_Results DRKS.pdf";"Ergebnisbericht";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007559";"2018-02-16T06:45:14.644+01:00";
"DRKS00009788";2015/12/15;"[---]*";yes;"Approved";"237/15";"Ethik-Kommission der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn";"Universal Trial Number (UTN)";"U1111-1177-6518";"[---]*";;;;;;;;;;;;;"ICD10";"I21";"Acute myocardial infarction";;;;;;;;;;;;;"Arm 1";"STEMI DESolve (bioresorbable vascular scaffolds (BRS) in Patient with ST-Segment myocardial Infarction (STEMI). Every Patient with STEMI and BRS is enrolled in the study. Additional the Patients receive an OCT-examination to evaluate the success of the Stent-Implantation. Patients receive a further angiography after 4-6 Month with OCT-examination to re-evaluate the success of the Stent-Implantation).<br/><br/>";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"IV";"No";"device-oriented composite endpoint within 36 Month (target lesion failure [TLF]), defined as the combination of cardiac death, target vessel MI, or clinically driven target lesion revascularisation (TLR), either percutaneous or surgical. Deaths that could not be attributed to another cause were re-garded as cardiac deaths. OCT subgroup: neointima formation after 4-6 month ";"-TIMI 0, I, II, III Fluss<br/>-Angina Pectoris <br/>-Successfull Stent-Implantationen<br/>-Target vessel failure (cardiac death, target vessel MI, or clinically driven target vessel revascularisation (TVR), and scaffold thrombosis (ST))<br/>-Kidneyinjury<br/>-Rhythm-Events";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinik Bonn";"Bonn";"Medical Center";"Krankenhaus der Barmherzigen Brüder";"Trier";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/03/22;"Actual";"50";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"99";"Years";"-All Patients with STEMI and with a anatomically suitable coronarstatus<br/>-Written agreement of the Patient";"-Intellectual reduction, No suitable coronarstatus (ostial leasion, bifurcation, calc rich leasions) ";"Primary Sponsor";"Universitätsklinikum Bonn";"[---]*";"[---]*";"[---]*";"[---]*";"Sigmund-Freud-Str. 25";"53127";"Bonn";"Germany";"[---]*";"[---]*";"felix.hauptmann@ukb.uni-bonn.de";"www.ukb.uni-bonn.de";"Contact for Scientific Queries";"Krankenhaus der Barmherzigen Brüder Trier";"Mr.";"Dr.";"Hauptmann";"Felix";"Nordallee 1";"54292";"Trier";"Germany";"01736400438";"[---]*";"f.hauptmann@bk-tirer.de";"https://www.bk-trier.de";"Contact for Public Queries";"Brüderkrankenhaus Trier";"Mr.";"Dr.med";"Felix";"Hauptmann";"Nordalle 1";"54292";"Trier";"Germany";"01736400438";"[---]*";"f.hauptmann@bk-trier.de";"https://www.bk-trier.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Bonn";"[---]*";"[---]*";"[---]*";"[---]*";"Sigmund-Freud-Str. 25";"53127";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.ukb.uni-bonn.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Bioresorbable vascular scaffolds in ST-elevation myocardial infarction – OCT-guided implantation and mid-term OCT resultsd<br/>";"DESolve-STEMI-OCT";"[---]*";"The study is designd to evaluate the security of bioresorbable vascular stents (BRS) in Patient with ST-Segment myocardial Infarction (STEMI). Every Patient with STEMI and BRS is enrolled in the study. Additional the Patients receive an further examination (OCT) to evaluate the success of the Stent-Implantation. Patients receive a further angiography after 4-6 Month with OCT-examination to re-evaluate the success of the Stent-Implantation.";"The study is designd to evaluate the security of bioresorbable vascular scaffolds (BRS) in Patient with ST-Segment myocardial Infarction (STEMI). Every Patient with STEMI and BRS is enrolled in the study. Additional the Patients receive an OCT-examination to evaluate the success of the Stent-Implantation. Patients receive a further angiography after 4-6 Month with OCT-examination to re-evaluate the success of the Stent-Implantation.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009788";"2018-08-16T07:21:44.059+02:00";
"DRKS00010871";2016/07/29;"[---]*";yes;"Approved";"5354R";"Ethik-Kommission an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf";;;;;;;;;;;;;;;;"ICD10";"F17.2";"Mental and behavioural disorders due to use of tobacco; Dependence syndrome";"Free text";"[---]*";"Tobacco smoking, Tobacco addiction";;;;;;;;;;"Arm 1";"Intervention ABC: GPs will receive a 3-hour training in delivering brief advice to quit smoking according to the ABC approach (ask, brief advice, cessation support).<br/>Baseline data will be collected in all consecutive smoking patients consulting their GP within 4 weeks following the training (prior to consultation). Quit attempts will be assessed one month later via questionnaires. ";"Arm 2";"Intervention 5A: GPs will receive a 3-hour training in delivering brief advice to quit smoking according to the 5A approach (ask, advice, assess, assist, arrange).<br/>Baseline data will be collected in all consecutive smoking patients consulting their GP within 4 weeks following the training (prior to consultation). Quit attempts will be assessed one month later via questionnaires.";"Arm 3";"Usual care (no training).<br/><br/>Baseline data will be collected in all consecutive smoking patients consulting their GP within 4 weeks simultaneously to the data collection period of the intervention groups. Rates of quit attempts will be collected one month later through questionnaires. <br/>GPs from the control group will be offered training on the approach which has proven to be <br/>most effective or they can choose their preferred method in case of comparable effectiveness after<br/>the completion of last follow-up interviews. ";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Other";"Prevention";"Parallel";"N/A";"N/A";"Quit attempts at 1 month (following consultation), assessed via questionnaires";"Rates of delivery and quality of advice to quit by GPs, triggers of the last quit attempt, use of evidence-based cessation treatments and point prevalence abstinence rates 1, 4, 26 and 52 weeks after consultation.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Doctor's Practice";"[---]*";"North Rhine-Westphalia";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/09/01;"Actual";"1200";2016/12/15;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Smoking tobacco occasionally or regularly, consultation of a GP who participates in the trial (arm 1, 2 or 3)";"Limited literacy, incapability to provide informed consent (e.g., dementia), patients who will not see the GP personally";"Primary Sponsor";"Medizinische Fakultät der Heinrich-Heine-Universität; Medical Faculty of the Heinrich-Heine-University";"[---]*";"[---]*";"[---]*";"[---]*";"Moorenstr. 5";"40225";"Duesseldorf";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Institut für Allgemeinmedizin (ifam)Forschungsschwerpunkt Suchtforschung und Klinische Epidemiologie, Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf; Institute of General Practice, Addiction Research and Clinical Epidemiology, Medical Faculty of the Heinrich-Heine-University Duesseldorf";"Ms.";"Dr.";"Sabrina";"Kastaun";"P.O. 101007";"40001 ";"Duesseldorf";"Germany";"+49 211 81 19527";"+49 211 81 08622";"Sabrina.Kastaun@med.uni-duesseldorf.de";"http://www.uniklinik-duesseldorf.de/allgemeinmedizin";"Contact for Public Queries";"Institut für Allgemeinmedizin (ifam)Forschungsschwerpunkt Suchtforschung und Klinische Epidemiologie, Medizinische Fakultät der Heinrich-Heine-Universität";"Ms.";"Dr.";"Sabrina";"Kastaun";"Postfach 101007";"40001";"Düsseldorf";"Germany";"0211/81-19527";"0211/81-08622";"sabrina.kastaun@med.uni-duesseldorf.de";"http://www.uniklinik-duesseldorf.de/allgemeinmedizin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen;Ministry for Innovation, Science and Research of the German Federal State of North Rhine-Westphalia";"[---]*";"[---]*";"[---]*";"[---]*";"Völklinger Str. 49";"40221";"Duesseldorf";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effectiveness and impact of training general practitioners in delivering the ""5A"" or ""ABC"" approach for brief stop-smoking advice during routine consultations: a pragmatic, cluster randomised controlled trial";"ABC-Trial";"[---]*";"According to clinical guidelines, general practitioners (GP) should routinely provide their smoking patients brief advice to quit and make an offer of help to do so. The delivery of such advice is traditionally based on the ""5A"" approach (ask, advice, assess, assist, arrange). The alternative ""ABC"" approach focusses on cessation support and has several advantages but there is no evidence that it is more effective than usual care or at least as good than 5A in triggering quit attempts. The primary aim is to compare rates of quit attempts in smoking patients after routine consultation with GPs who have been trained in 5A or ABC or have received usual care.<br/><br/>Approximately 30 GP practices in North Rhine-Westphalia (Germany) will be randomised to receive training in delivering 5A or ABC or no training (usual care). Data will be collected in all consecutive smoking patients consulting their GP within 4 weeks following the training. Rates of delivery and quality of advice to quit will be assessed within the first days after consultation (secondary outcomes), quit attempts one month later (primary outcome). Further secondary outcomes include: triggers of the last quit attempt, use of evidence-based cessation treatments and abstinence rates 1, 4, 26 and 52 weeks after consultation. <br/>";"According to clinical guidelines, general practitioners (GP) should routinely provide their smoking patients brief advice to quit and make an offer of help to do so. The delivery of such advice is traditionally based on the ""5A"" Approach (ask, advice, assess, assist, arrange). The alternative ""ABC"" Approach focusses on cessation support and has several advantages but there is no evidence that it is more effective than usual care or at least as good than 5A in triggering quit attempts. The primary aim is to compare rates of quit attempts in smoking patients after routine consultation with GPs who have been trained in 5A or ABC or have received usual care.<br/><br/>A pragmatic, 3-arm cluster randomised controlled trial will be conducted in approximately 30 GP practices in North Rhine-Westphalia, Germany. Practices will be randomised to receive training in delivering 5A or ABC or no training (usual care). Data will be collected in all consecutive smoking patients consulting their GP within 4 weeks following the training. Rates of delivery and quality of advice to quit will be assessed within the first days after consultation (secondary outcomes), quit attempts one month later (primary outcome). Further secondary outcomes include: triggers of the last quit attempt, use of evidence-based cessation treatments and point prevalence abstinence rates 1, 4, 26 and 52 weeks after consultation. Cost-effectiveness of the interventions will be analysed.<br/><br/>The primary data analysis uses a mixed-effects logistic regression model with random effects for cluster, patient-reported attempts to quit since the last GP consultation (any vs. none) as the dependent variable<br/>and group allocation (5A, ABC, control group) as independent variable. This model will be adjusted for potential confounders measured at baseline.<br/><br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010871";"2019-08-22T07:22:37.703+02:00";
"DRKS00000659";2011/01/03;"[---]*";yes;"Approved";"342/10";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";;;;;;;;;;;;;;;;"ICD10";"M54.5";"Low back pain";"ICD10";"M48.99";"[generalization M48.9: Spondylopathy, unspecified]";;;;;;;;;;"Arm 1";"Cryoneurolysis of the affected lumbar facet joints<br/>with 2 x 3 min -60 bis -70° C";"Arm 2";"steroid infiltration of the affected lumbar facet joints with 4 mg dexamethason  ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Crossover";"N/A";"[---]*";"mean, minimal and maximal pain scores on the NAS twelve weeks after cryoneurolysis";"•	quality of life<br/>•	medication use<br/>•	depressivity/anxiety<br/>•	second cryoneurolysis after twelve weeks<br/>•	 mean, minimal and maximal pain scores on the NAS half a year, one year and two years after cryoneurolysis<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/02/09;"Actual";"30";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"•	chronic low back pain<br/>•	twofold lumbar facet joint block with at least 50 % pain reduction on the NAS (numeric analog scale) during the local anaesthetic effect<br/>•	written consent after detailed explanation and enough time for consideration <br/><br/>";"•	radicular pain<br/>•	lumbar instability<br/>•	Coagulopathy<br/>•	steroid intolerance<br/>•	severe insulin-dependent diabetes mellitus <br/>•	medium or major depressive episode <br/>•	dementia<br/>•	considerable psychosocial stress factors<br/>•	whole body pain<br/><br/>";"Primary Sponsor";"Interdisziplinäres Schmerzzentrum<br/>Universitätsklinikum Freiburg";"Mr.";"Dr.med. ";"Tilman ";"Wolter";"Breisacherstr. 64";"79106";"Freiburg";"Germany";"+49/761/2705203";"+49/761/2705013";"tilman.wolter@uniklinik-freiburg.de";"[---]*";"Contact for Scientific Queries";"Interdisziplinäres Schmerzzentrum<br/>Universitätsklinikum Freiburg ";"Mr.";"Dr. med. ";"Tilman";"Wolter";"Bresiacherstr. 64";"79106";"Freiburg";"Germany";"+49/761/2705203";"+49/761/2705013";"tilman.wolter@uniklinik-freiburg.de";"[---]*";"Contact for Public Queries";"Interdisziplinäres Schmerzzenztrum<br/>Universitätsklinikum Freiburg";"Mr.";"Dr. med. ";"Tilman ";"Wolter";"Breisacherstr. 64";"79106";"Freiburg";"Germany";"+49/761/2705203";"+49/761/2705013";"tilman.wolter@uniklinik-freiburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Interdisziplinäres Schmerzzentrum<br/>Universitätsklinikum Freiburg ";"[---]*";"[---]*";"[---]*";"[---]*";"Breisacherstr. 64";"79106";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Cryoneurolysis versus steroid infiltration for treatment of lumbar facet joint syndrome: a randomized controlled double-blind study";"KryoRCT";"[---]*";"Chronic low back pain can be attributed to degeneratieve facet joints changes in 15-52% of the patients. Therapy comprises physiotherapy and analgetic medication. Moreover, infiltration of the facet joint either with local anaesthetics or with steroids (or a combination of both) can lead to pain relief. Besides, local anaesthetic infiltration can also confirm the diagnosis of facet joint pain. If also facet joint infiltrations do not produce a lasting pain relief, procedures aiming at denervation of the facet joint like radiofrequency treatment or cryoneurolysis should be considered. <br/>The aim of our study is to compare the outcome of cryoneurolysis of the facet joint with steroid injections in a randomized, controlled and double blinded manner.   <br/>";"Chronic low back pain is caused by facet joint arthropathy in 15-52% of the cases. Diagnosis is clinical and can be confirmed by diagnostic facet joint injections. Facet joint injections can also be performed with therapetic indication with steroid application. If therapeutic facet joint injections do not have a lasting pain relieving effect, two methods come into consideration for the treatment of lumbar facet joint pain by denervation of the neural supply: radiofrequency lesioning (RF) and cryoneurolysis. Up to now there are no RCTs on cryoneurolysis for lumbar facet joint pain. <br/>The aim of our study is to compare the outcome of cryoneurolysis of the facet joint with facet joint steroid injections in a randomized, controlled and double blinded manner.   <br/><br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000659";"2019-12-16T12:22:40.554+01:00";
"DRKS00004874";2013/10/30;"[---]*";yes;"Approved";"2013-544N-MA";"Medizinische Ethik-Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg";;;;;;;;;;;;;;;;"Free text";"[---]*";"angulated distal forearm fracture";"ICD10";"S52";"Fracture of forearm";;;;;;;;;;"Arm 1";"Immobilization in cast without reduction<br/>";"Arm 2";"Closed reduction and percutaneous K-wire pinning, cast, patients under narcosis";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Cooney-Score after 24 months (dichotomised in ≥90 vs. <90). The Cooney score includes subjective parameters (pain, strength, and activity before and after trauma) as well as objective (flexibility) parameters.";"- Cooney-score after 3 and 12 months;<br/>- patient/parent satisfaction score (ZUF-8 and CHC-SUN modified) after 1, 3, 12 and 24 months;<br/>- grade of radiological displacement at 12/24 months;<br/>- secondary operation (after 24 months);<br/>- secondary reposition (after 24 months);<br/>- secondary K-wire osteosynthesis (after 24 months);<br/>- growth disturbance (after 24 months);<br/>- therapeutic complications (Dindo-Clavien classification, after 24 months)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Kinderchirurgische Klinik";"Mannheim";"Medical Center";"Altonaer Kinderkrankenhaus gGmbH";"Hamburg";"University Medical Center";"Klinik und Poliklinik für Kinderchirurgie Charité";"Berlin";"University Medical Center";"Klinik für Kinderchirurgie";"Greifswald";"Medical Center";"Krankenhaus St. Elisabeth und St. Barbara";"Halle Saale";"University Medical Center";"Klinik für Unfall-, Hand- und Wiederherstellungschirurgie";"Homburg Saar";"Medical Center";"Städtisches Klinikum";"Karlsruhe";"University Medical Center";"Klinik für Unfallchirurgie";"Kiel";"Medical Center";"Kinderchirurgie und -urologie Cnopf'sche Kinderklinik";"Nürnberg";"Medical Center";"Klinik für Unfallchirurgie und Orthopädie Ev. Krankenhaus Paul-Gerhardt-Stift";"Lutherstadt Wittenberg";"Medical Center";"Krankenhaus Bethanien";"Moers";"Medical Center";"Klinikum Memmingen";"Memmingen";"University Medical Center";"Universitätsklinikum Carl Gustav Carus";"Dresden";"University Medical Center";"Universitätsklinikum Gießen und Marburg GmbH";"Marburg";"University Medical Center";"Klinik für Orthopädie und Unfallchirurgie der Albert-Ludwigs-Universität Freiburg";"Freiburg im Breisgau";"Medical Center";"Klinikum Schwabing";"München";"University Medical Center";"Abteilung für Kinderchirurgie der Universitätsmedizin Rostock";"Rostock";"Medical Center";"Berufsgenossenschaftliche Unfallklinik Frankfurt am Main";"Frankfurt a.M.";"Medical Center";"Kaiserswether Diakonie Florence-Nightingale-Krankenhaus";"Düsseldorf";"University Medical Center";"Universitätsklinik für Kinder- und Jugendmedizin ";"Tübingen";2014/04/07;"Actual";"742";2018/08/01;"Multicenter trial";"National";"Both, male and female";"5";"Years";"11";"Years";"- Children 5-11 yrs <br/>- distal forearm fracture<br/>=> 23-M/2-3 or 23-E/1-2 according to AO-classification), <br/>=> angulated radius/forearm fracture in distal third<br/>=> angulated epiphyseolysis with/without metaphyseal wedge<br/>- angulation ≤30°<br/>=> 5-7 yrs angulation 15-30°<br/>=> 8-11 yrs angulation 10-25°<br/>- written informed consent (children and parents)";"- torus fractures;<br/>- complete displacement with shortening;<br/>- other osteosynthesis than K-wire osteosynthesis necessary;<br/>- neurological concomittant diseases;<br/>- metabolic diseases;<br/>- pathological fracture;<br/>- neurovascular injuries;<br/>- presence of another skeletal injury or serious injuries<br/>";"Primary Sponsor";"Ruprecht-Karls-Universität Heidelberg";"Ms.";"Dr.";"Angela";"Kalous";"Grabengasse 1";"69117";"Heidelberg";"Germany";"06221 54-2100 und -2101";"6221 54-2618";"kanzlerin@zuv.uni-heidelberg.de";"http://www.uni-heidelberg.de/einrichtungen/rektorat/angela_kalous.html";"Contact for Scientific Queries";"Universitätsklinikum Mannheim";"Mr.";"Prof. Dr. ";"Lucas M.";"Wessel";"Theodor-Kutzer-Ufer 1-3";"68167";"Mannheim";"Germany";"0621 3835574";"0621 3833823";"lucas.wessel@medma.uni-heidelberg.de";"www.umm.de";"Contact for Public Queries";"Universitätsmedizin MannheimFakultät für Medizin der Universität Heidelberg";"Mr.";"Prof. Dr.";"Lucas M.";"Wessel";"Theodor-Kutzer-Ufer 1-3";"68167";"Mannheim";"Germany";"0621 383 5574";"0621 383 3823";"Lucas.Wessel@medma.uni-heidelberg.de";"www.umm.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Angulated fractures of the distal forearm in children: is remodeling a therapeutic option?";"AFIC";"[---]*";"Children (5-11 yrs) with distal angulated forearm fractures will be corrected spontaneously by remodelling or closed reduction and K-wire pinning. The primary objective of this trial is to assess whether long-term functional outcome (2 yrs) in remodelled patients is not inferior to patients receiving closed reduction and K-wire pinning. ";"Children (5-11 yrs) with distal angulated forearm fractures will be corrected spontaneously by remodelling or closed reduction and K-wire pinning. The primary objective of this trial is to assess whether long-term functional outcome (2 yrs) in remodelled patients is not inferior to patients receiving closed reduction and K-wire pinning. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004874";"2020-01-10T06:31:07.137+01:00";
"DRKS00004917";2013/04/23;2012/12/19;yes;"Approved";"5470/12";"Ethik-Kommission der Fakultät für Medizin der Technischen Universität München";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2012-003630-16";"[---]*";"Primary Registry-ID";"NCT01755520";"ClinicalTrials.gov";"BfArM-No.";"4038824";"[---]*";;;;;;;"MedDRA";"[---]*";"Cardiovascular Diseases [C14], 14.1 100000004866 10003601 Atherosclerosis LLT";"ICD10";"I20-I25";"Ischaemic heart diseases";;;;;;;;;;"Arm 1";"Ticagrelor (Brillique), 2 x 90mg/daily, tablets, 1-0-1";"Arm 2";"ASA (ASS Hexal), 1 x 100mg/daily, tablet, 1-0-0";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"Yes";"Composite of cardiovascular death, myocardial infarction, recurrent revascularization, and stroke at 12 months after coronary artery bypass operation";"Safety endpoint: The incidence of major bleeding at 12 months after coronary artery bypass operation<br/>Incidence of the individual components of the primary endpoint at 12 months after coronary artery bypass operation (cardiovascular death, myocardial infarction, recurrent revascularization, and stroke)";"DE";"Germany";"AT";"Austria";"CH";"Switzerland";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Deutsches Herzzentrum München, Klinik an der TU München";"München";"University Medical Center";"Universitätsklinikum Schleswig-Holstein, Campus Lübeck";"Lübeck";"University Medical Center";"Universitätsklinik Wien";"Wien, Österreich";"University Medical Center";"Universitätsklinikum Gießen";"Gießen";"University Medical Center";"Universitätsklinikum";"Freiburg im Breisgau";"Medical Center";"Klinikum der Stadt Ludwigshafen";"Ludwigshafen am Rhein";"University Medical Center";"Herzzentrum Leipzig GmbH";"Leipzig";"Medical Center";"Herzzentrum Bremen, Klinikum Links der Weser";"Bremen";"University Medical Center";"RWTH Aachen";"Aachen";"Medical Center";"Herz- und Gefäßzentrum";"Bad Bevensen";"Medical Center";"Bad Nauheim";"Kerckhoff-Klinik GmbH";"Medical Center";"Deutsches Herzzentrum Berlin";"Berlin";"University Medical Center";"Universitätsmedizin Göttingen";"Göttingen";"Medical Center";"Asklepios Klinik St.Georg";"Hamburg";"Medical Center";"Klinikum Nürnberg Süd";"Nürnberg";"Medical Center";"Herz- und Kreislaufzentrum Rotenburg a .d. Fulda";"Rotenburg a.d. Fulda";"University Medical Center";"Charité";"Berlin";"Medical Center";"Herzzentrum Brandenburg in Bernau";"Bernau";"University Medical Center";"Universitätsklinikum Jena";"Jena";"University Medical Center";"Universitätsklinikum Schleswig-Holstein, Campus Kiel";"Kiel";2013/04/24;"Actual";"3850";2018/05/19;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1.	Patients 18 years of age or older<br/>2.	Informed, written consent by the patient<br/>3. 	Indication for CABG surgery: <br/>- coronary three vessel disease, or<br/>- left main stenosis, or <br/>- two vessel disease with impaired left ventricular function (<50%)<br/>";"1. Cardiogenic shock, haemodynamic instability<br/>2. Indication for oral anticoagulation or dual antiplatelet therapy that cannot be stopped after CABG<br/>3. Need for concomitant non-coronary surgery (e.g. valve replacement)<br/>4. Contraindication for ASA or Ticagrelor use (e.g. known allergy)<br/>5. Intolerance of or allergy to Ticagrelor or ASA or any of their excipients<br/>6. History of bleeding diathesis within three months prior presentation,<br/>7. History of significant gastrointestinal bleed within 6 months prior presentation<br/>8. History of intracranial hemorrhage<br/>9. History of moderate to severe liver impairment (Child Pugh B or C)<br/>10. Chronic renal insufficiency requiring dialysis<br/>11. Patient with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope)<br/>12. Known, clinically important thrombocytopenia (e.g. <100.000/μl)<br/>13. Known, clinically important anaemia (e.g. <10g/dl)<br/>14. Participation in another investigational drug or device study in the last 30 days<br/>15. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception, one of which must be barrier method, are required); in women with childbearing potential a pregnancy test is mandatory<br/>16. Concomitant oral or intravenous therapy (see examples below) with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers which cannot be stopped for the course of the study<br/>o Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, over 1 liter daily of grapefruit juice.<br/>o Substrates with narrow therapeutic index: cyclosporine, quinidine.<br/>o Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.<br/>17. Life expectancy less than 12 months that may result in protocol non-compliance or a risk for being lost to follow up, active cancer<br/>18. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery)<br/>19. Previous enrolment or randomization of treatment in the present study.";"Primary Sponsor";"Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenKlinik an der Technischen Universität München";"Mr.";"Prof. Dr.";"Heribert";"Schunkert";"Lazarettstr. 36";"80636";"München";"Germany";"089-1218-4073";"089-1218-1539";"schunkert@dhm.mhn.de";"[---]*";"Contact for Scientific Queries";"Klinik für Herz- und Kreislauferkrankungen<br/>DEutsches Herzzentrum München<br/>Klinik an der Technischen Universität München";"Mr.";"Prof. Dr.";"Heribert";"Schunkert";"Lazarettstr. 36";"80636";"München";"Germany";"089-1218-4073";"089-1218-1534";"schunkert@dhm.mhn.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"AstraZeneca GmbH<br/>Unternehmensbereich Medizin";"[---]*";"[---]*";"[---]*";"[---]*";"Tinsdaler Weg 183";"22880";"Wedel";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation<br/>TiCAB– Ticagrelor in CABG<br/>";"TiCAB";"[---]*";"It is expected that ticagrelor (180mg/day) compared with aspirin (ASS, 100mg/day) will significantly reduce cardiovascular event rates in patients with coronary heart disease undergoing coronary bypass operation (CABG). Therefore it is to be investigated whether in patients undergoing coronary bypass operation ticagrelor will lead to a reduction of fatal and non-fatal cardiovascular events in comparison with aspirin.<br/><br/>";"It is expected that ticagrelor (180mg/day) compared with aspirin (ASS, 100mg/day) will significantly reduce cardiovascular event rates in patients with coronary heart disease undergoing coronary bypass operation (CABG). Therefore it is to be investigated whether in patients undergoing coronary bypass operation ticagrelor will lead to a reduction of fatal and non-fatal cardiovascular events in comparison with aspirin.<br/><br/>";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"https://academic.oup.com/eurheartj/article/40/29/2432/5506732";"Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial ";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004917";"2019-09-20T07:10:27.420+02:00";
"DRKS00000181";2009/09/02;"[---]*";no;"Approved";"2008-496-f-A";"Ethik-Kommission der Ärztekammer Westfalen-Lippe und der med. Fakultät der Westfälischen Wilhelms-Universität Münster";"Universal Trial Number (UTN)";"U1111-1111-6195";"[---]*";"EudraCT-Number";"2008-000504-92";"[---]*";"PEI-No.";"749/01";"[---]*";"Sponsor-ID";"APX-PHP-07-008";"Protokoll-Nummer";;;;"ICD10";"A41.9";"Septicaemia, unspecified";"ICD10";"R57";"Shock, not elsewhere classified";;;;;;;;;;"Arm 1";"PHP will be administered by intravenous infusion at a dose rate of 0.25 ml/kg/hr up to a maximum of 150 hours or a total dose of 3,000 mg/kg. The dose rate remains constant throughout the entire infusion. Standard of care using conventional vasopressors can be administered at any time as medically indicated.";"Arm 2";"Placebo (isotonic saline) will be administered by intravenous infusion at a dose rate of 0.25 ml/kg/hr up to a maximum of 150 hours or a total dose of 3,000 mg/kg. The dose rate remains constant throughout the entire infusion. Standard of care using conventional vasopressors can be administered at any time as medically indicated.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Single blind";"Placebo";"Treatment";"Parallel";"III";"[---]*";"28 day all-cause mortality";"All-cause mortality at days 3, 7, 14, and 21 || Survival time || Survivor days in the intensive care unit censored at 28 days || Survivors' hospital length of stay censored at 28 days || Time on mechanical ventilation || Time on pressors || All-cause mortality at days 60 and 90";"AT";"Austria";"BE";"Belgium";"DE";"Germany";"NL";"Netherlands";"ES";"Spain";"GB";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/06/05;"Actual";"454";2011/08/21;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"SIRS Inclusion Criteria:<br/>- Patients with SIRS as characterized by two or more of the following conditions (worst values in a 24 hour period):<br/>a) Either respiratory rate >= 20 breaths/minute, or partial pressure of arterial carbon dioxide (PaCO2) <= 32 torr, or mechanical ventilation;<br/>b) Heart rate >= 90 beats/minute;<br/>c) Either hyperthermia >= 38 ºC or hypothermia <= 36 ºC;<br/>d) Either white blood cell (WBC) >= 12,000 cells/mm3, <= 4,000 cells/mm3, or >= 10% immature (band) forms.<br/>Shock Inclusion Criteria:<br/>Patients with adequate fluid resuscitation and requiring a norepinephrine dose of >= 0.3 mcg/kg/min for at least one hour to maintain a MAP >= 65 mmHg but <= 80 mmHg within the first 36 hours of the initiation of norepinephrine treatment. If a patient reaches the Norephinephrine dose threshold for enrolment, but begins to improve before randomization, then the patient should only be randomized if the Norepinephrine dose is still >=0,2 mcg/kg/min";"- Patients who lack documented Informed Consent signed by the patient or his/her legally authorized representative<br/>- Patients that are pregnant<br/>- Patients less than 18 years old<br/>- Patients with suspicion of or active treatment for coronary artery disease within 60 days of enrollment defined as any of the following: acute myocardial infarction with an abnormal ECG indicative of myocardial infarction or abnormal regional wall motion (echocardiography), unstable angina with abnormal regional wall motion (echocardiography) and/or EF < 35%, coronary revascularization (angioplasty, stenting, coronary bypass graft) if EF < 35%<br/>- Patients who have received a stent within the last 12 months<br/>- Patients with suspicion of or active treatment for malignant arrhythmia within 60 days of enrollment defined as any of the following: ventricular tachycardia, ventricular fibrillation, appropriate defibrillator firing in patient with AICD; Note: A peacemaker is not an exclusion criterion<br/>- Patients with suspicion of or active treatment for congestive heart failure within 60 days of enrollment defined as any of the following: ejection fraction < 35% and LV end-diastolic dimension > 6.0 cm demonstrated by echo or MUGA, or hospitalization primarily for congestive heart failure, or NYHA Class IV congestive heart failure<br/>- Patients with suspicion of or active treatment for aortic valve heart disease within 60 days of enrollment defined as any of the following: aortic valve stenosis with area < 1.0 cm2, or severe aortic insufficiency, or after aortic valve replacement if ejection fraction < 35%<br/>- Patients with stage 3 or 4 solid tumors (TNM classification, group staging),  hematologic malignancies with high tumor burden, CNS cancer (WHO stage 3 and 4) unless significant tumor mass was removed near occurrence of shock<br/>- Patients with dead bowel likely to result in death. After surgical removal of the dead bowel the patient can be enrolled<br/>- Patients receiving/scheduled to receive another investigational drug or have received an investigational drug in the previous 30 days<br/>- Patients with known hypersensitivity to blood products<br/>- Patients with hypovolemic shock from bleeding or other volume loss<br/>- Patients who are likely to die within days for diseases or conditions other than catecholamine-dependent shock (e.g. multiple organ failure that is irreversible as distinct from multiple organ dysfunction that may resolve)<br/>- Patients with Glasgow Coma Score <= 7 at the time of admission and prior to the administration of confounding medications such as narcotics, sedatives or neuromuscular blockers<br/>- Patients that experienced trauma within the past 48 hours <br/>- Patients that experienced burns within the past 48 hours<br/>- Patients with anaphylactic shock";"Primary Sponsor";"Apex Bioscience, Inc.";"[---]*";"[---]*";"[---]*";"[---]*";"109 Connor Drive, Suite 2102";"27514";"Chapel Hill, N.C.";"United States";"[---]*";"[---]*";"[---]*";"[---]*";"Secondary Sponsor";"Curacyte AG";"[---]*";"[---]*";"[---]*";"[---]*";"Grillparzerstr. 14";"81675";"München";"Germany";"+49 (0)89 200 01 42 0";"+49 (0)89 200 01 42 79";"phoenix@curacyte.com";"www.curacyte.eu";"Contact for Scientific Queries";"Erasme University Hospital";"Mr.";"Prof. Dr. med.";"Jean-Louis";"Vincent";"Route de Lennik 808";"1070";"Brussels";"Belgium";"+32 25553380";"[---]*";"jlvincent@ulb.ac.be";"[---]*";"Contact for Public Queries";"Curacyte AG";"Mr.";"Dr. med.";"Erwin";"Böhm";"Grillparzerstr. 14";"81675";"München";"Germany";"+49 (0)89 200 01 42 15";"+49 (0)89 200 01 42 79";"erwin.boehm@curacyte.com";"www.curacyte.eu";;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Curacyte AG";"[---]*";"[---]*";"[---]*";"[---]*";"Grillparzerstr. 14";"81675";"München";"Germany";"+49 (0)89 200 01 42 0";"+49 (0)89 200 01 42 79";"info@curacyte.com";"www.curacyte.eu";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of PHP When Administered by Continuous Infusion in Patients With Catecholamine-Resistant Distributive Shock";"PHOENIX";"[---]*";"PHP (pyridoxalated hemoglobin polyoxyethylene), a chemically modified blood component is a medication being developed to treat patients suffering from distributive shock. Distributive shock can emerge as an extreme and life threatening reaction of the body from a severe systemic infection with pathogens which causes a systemic inflammatory response syndrome (SIRS). Patients with SIRS may have some of the following symptoms: fever, fast heart rate, low blood pressure, breathing difficulties, blood clotting difficulties, kidney failure, or liver failure. When the blood pressure drops so low that drugs are needed to raise it, the patient is in shock. This means that the blood circulation may not provide the organs with as much oxygen as they need and may cause organ damage - which can lead to death - and must be treated quickly. Usually medicines called catecholamines are used to raise the blood pressure. However, not all patients respond to these drugs. These patients may benefit from PHP.  In this study, PHP will be given to patients not responsive to the catecholamine norepinephrine in addition to standard therapy. PHP raises blood pressure by trapping and neutralizing a substance, nitric oxide that causes shock and may work against the shock. The function of lung, liver and kidneys could improve and mortality could be reduced.";"The purpose of this multi-center, randomized, placebo-controlled, phase 3 study is to determine the efficacy and safety of pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) administered by continuous infusion in catecholamine-resistant distributive shock patients. PHP is a human-derived chemically modified hemoglobin (Hb) preparation. PHP selectively scavenges excess nitric oxide (NO) and does so in a catalytic, concentration-dependent reaction that results in the formation of the non-toxic NO metabolite, nitrate. PHP is postulated to reduce excess, toxic levels of NO while allowing critical beneficial levels of the molecule to persist. The efficacy of PHP will be established by demonstrating a reduction of 28-day all-cause mortality. The safety and tolerability of PHP will be monitored continuously throughout the 28-day study.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000181";"2011-11-03T09:16:33.565+01:00";
"DRKS00004048";2012/10/25;2007/08/02;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2007-000323-17";"[---]*";"Primary Registry-ID";"NCT00514917";"ClinicalTrials.gov";"Sponsor-ID";"XRP6976J_3503";"Sanofi-Aventis";"Other Secondary-ID";"2007-000323-17";"[---]*";;;;"Free text";"[---]*";"Prostatic Neoplasms";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Docetaxel";"Arm 2";"Drug: Leuprolide";"Arm 3";"Drug: Bicalutamide";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population; time frame: Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60; PFS was the time from randomization to the date of first documented prostate specific antigen (PSA) progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. PSA progression was determined as: a) During treatment period: a 50 percent (%) increase from baseline, which was confirmed by a second value; b) During follow-up: detectable PSA (defined as PSA greater than or equal to 0.05 nanogram per millimeter [ng/mL]), which was confirmed by consecutive observation (not less than 2 weeks apart). Median PFS was estimated using the Kaplan-Meier method.<br/>- Progression-Free Survival (PFS) Rate at Month 36 in ITT Population; time frame: Month 36; PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.<br/>- Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population; time frame: Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60; PFS was the time from randomization to the date of first documented PSA progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.<br/>- Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population; time frame: Month 36; PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.<br/>";"- Overall Survival (OS): Number of Participants Who Died (All Cause); time frame: Randomization until death due to any cause, assessed up to Month 60; The OS was the time interval from the date of randomization to the date of death due to any cause. OS was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from any cause.<br/>- Cancer-Specific Survival: Number of Participants Who Died (Cancer-Specific); time frame: Randomization until death due to prostate cancer, assessed up to Month 60; The cancer-specific survival was the time from the date of randomization to the date of death due to prostate cancer. Cancer-specific survival was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from prostate cancer.<br/>- Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at End of Treatment (EOT); time frame: Baseline, EOT (up to Month 18); FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better quality of life with fewer symptoms. A score of 156 represents the best outcome.<br/>- Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Trial Outcome Index (TOI) Score at EOT; time frame: Baseline, EOT (up to Month 18); Physical well-being, functional well-being, and prostate cancer concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.<br/>- Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Index Score at EOT; time frame: Baseline, EOT (up to Month 18); MAF scale consists of 16-items to measure 4 dimensions of fatigue during past week: severity (Item 1-2), distress (Item 3), degree of interference in activities of daily living (Item 4-14), and timing (Item 15-16). Item 1-14 are scored on a numeric rating scale from 1 to 10, where higher score indicate more severity/distress/interference. Item 15-16 had multiple choice responses (4 responses each). Scale Index was calculated using Item 1-15, in following steps: 1) Item 15 score converted to 1-10 scale by multiplying the score with 2.5; 2) Average score was calculated from Item 4-14; 3) Finally scale index was calculated by adding Items 1, 2, 3 scores with average score from step 2 and converted score of Item 15 from step 1. Total MAF scale index score ranges 1 (no fatigue) to 50 (severe fatigue).<br/>- Change From Baseline in Erectile Function Domain of International Index of Erectile Function (EF-IIEF) Total Score at EOT; time frame: Baseline, EOT (up to Month 18); EF-IIEF is a 6-item erectile function domain of IIEF. It consists of Question 1, 2, 3, 4, 5, and 15 of IIEF questionnaire. 5 questions are scored from 0 (no activity) to 5 (very high activity) and 1 question is scored from 1 (very low activity) to 5 (very high activity). Total EF-IIEF score ranges from 1 to 30, where higher score indicates high activity.<br/>";"US";"United States";"BE";"Belgium";"CA";"Canada";"CZ";"Czech Republic";"DE";"Germany";"LT";"Lithuania";"PL";"Poland";"SK";"Slovakia";"ES";"Spain";;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Sanofi-Aventis Administrative Office";"Frankfurt";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2007/07/31;"[---]*";"412";2012/09/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Diagnosis of prostate adenocarcinoma pathologically confirmed<br/><br/>          -  History of radical prostatectomy (pre-operative radiation therapy to the prostate or<br/>             pelvis or salvage radiation after radical prostatectomy was allowed)<br/><br/>          -  Demonstration of biochemical progression of disease based on prostate specific<br/>             antigen (PSA) doubling time. The minimum PSA value for eligibility was greater than<br/>             or equal to (>=) 1. PSA doubling time over three values must be equal to (=) 9 months<br/>             with a minimum of 3 weeks between assessments<br/><br/>          -  Serum testosterone >=100 nanogram per deciliter (ng/dL)<br/><br/>          -  Karnofsky performance status (KPS) >=70 percent (%)<br/><br/>          -  Adequate organ function as defined by the following laboratory criteria:<br/><br/>               -  White blood cells >=3500 per cubic millimeter (mm^3)<br/><br/>               -  Absolute neutrophil count (ANC) >=1500 per mm^3<br/><br/>               -  Platelet count >=100,000 per mm^3<br/><br/>               -  Hemoglobin >= 10.0 gram per deciliter (g/dL)<br/><br/>               -  Total Bilirubin less than or equal to (<=) upper limit of normal (ULN) unless<br/>                  due to Gilbert's disease<br/><br/>               -  Creatinine l <= 1.5 milligram per deciliter (mg/dL) or creatinine clearance >=60<br/>                  cubic centimeters per minute<br/><br/>               -  Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline<br/>                  phosphatase within pre-defined ranges<br/><br/>          -  Previous hormonal therapy was allowed provided that the total duration of therapy did<br/>             not exceed 6 months<br/><br/>          -  Man of childbearing potential who was willing to consent to use effective<br/>             contraception while on treatment and for at least 3 months thereafter<br/><br/>          -  Participant who was willing and was able to comply with scheduled visits, treatment<br/>             plans, laboratory tests, and other study procedures<br/>";"-  Clinically significant cardiac disease (New York Heart Association Class III/IV), or<br/>             severe debilitating pulmonary disease<br/><br/>          -  Uncontrolled serious active infection<br/><br/>          -  Anticipated duration of life < 2 years<br/><br/>          -  Less than 5-year history of successful treatment for other cancers or concurrent<br/>             active nonprostate cancer other than nonmelanoma dermatologic tumor<br/><br/>          -  Peripheral neuropathy >=Grade 2<br/><br/>          -  History of hypersensitivity reaction to Docetaxel or other drugs formulated with<br/>             polysorbate 80, leuprolide, or bicalutamide<br/><br/>          -  Prior chemotherapy within the past 10 years (except non-taxane based chemotherapy for<br/>             treatment of other cancers); concurrent treatment on another clinical trial or with<br/>             any other cancer therapy including chemotherapy, immunotherapy, radiotherapy (except<br/>             salvage radiation therapy), chemoembolization therapy, cryotherapy<br/><br/>          -  Other severe acute or chronic medical conditions including psychiatric disease, or<br/>             significant laboratory abnormality requiring further investigation that may cause<br/>             undue risk for the participant's safety, delay or prohibit protocol participation, or<br/>             interfere with the interpretation of study results, and in the judgment of the<br/>             investigator would make the participant inappropriate for entry into this study<br/><br/>          -  Radiographic findings suspicious for metastatic disease in the treating physician's<br/>             clinical judgment. Participant who had radiographically suspicious pelvic lymph nodes<br/>             prior to radial prostatectomy, but who, at the time of enrollment did not have<br/>             suspicious adenopathy was eligible. Participant was eligible even if he/she had<br/>             tumor-containing pelvic adenopathy at the time of surgery as long as at the time of<br/>             enrollment there was no radiographically evident nodal disease in the clinician's<br/>             opinion<br/><br/>          -  Participant was the investigator or any sub-investigator, research assistant,<br/>             pharmacist, study coordinator, other staff or relative thereof directly involved in<br/>             the conduct of the protocol<br/><br/>          -  Participant unlikely to comply with protocol or research tests, for example,<br/>             uncooperative attitude, inability to return for follow-up visits, and unlikelihood of<br/>             completing the study<br/><br/>          -  Participant who participated in another clinical study/received investigational<br/>             product within 30 days of screening<br/><br/>        The above information was not intended to contain all considerations relevant to a<br/>        participant's potential participation in a clinical trial.<br/>";"Primary Sponsor";"Sanofi";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Sanofi";"[---]*";"[---]*";"[---]*";"Barrett Childs, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Sanofi";"[---]*";"[---]*";"[---]*";"Barrett Childs, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy";"Rising PSA";"[---]*";"The primary objective was to evaluate and compare the efficacy of androgen deprivation with<br/>      or without docetaxel as determined by the median progression free survival (PFS) over the<br/>      period of 18-month therapy and at least 18-month follow-up.<br/><br/>      The secondary objectives were:<br/><br/>        -  To assess cancer specific survival;<br/><br/>        -  To compare overall survival between the 2 treatment groups;<br/><br/>        -  To evaluate patient-reported outcomes including quality of life, fatigue, and sexual<br/>           functioning as measured by 3 different assessments.<br/>";"The duration of the study per participant was to be at least 36 months, of which the<br/>      treatment period was 18 months for all participants, followed by at least 18 months<br/>      follow-up period.<br/><br/>      Participants received study treatment for up to 18 months from the time of study therapy<br/>      initiation or less if one of the following occurred: disease progression, unacceptable<br/>      toxicity, death, participant refusal or treatment delay beyond the time frame that is<br/>      permitted for each treatment.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004048";"2016-01-22T15:57:49.055+01:00";
"DRKS00000084";2010/04/21;2010/06/07;yes;"Approved";"PVN 3440";"Ethik-Kommission der Ärztekammer Hamburg";"Universal Trial Number (UTN)";"U1111-1114-7443";"[---]*";"EudraCT-Number";"2009-017374-20";"[---]*";"Primary Registry-ID";"ISRCTN01005546";"(International Standard Randomised Controlled Trial Number Register)";"BfArM-No.";"4036133";"[---]*";;;;"Free text";"[---]*";"antibiotic-associated diarrhoea";"ICD10";"A04.7";"Enterocolitis due to Clostridium difficile";;;;;;;;;;"Arm 1";"bid 250 mg Perenterol forte orally when beginning antibiotic treatment until 1 week after end of antibiotic treatment (duration variable).";"Arm 2";"bid placebo when beginning antibiotic treatment until 1 week after end of antibiotic treatment (duration variable).";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Prevention";"Parallel";"III";"[---]*";"Cumulative incidence of antibiotic-associated diarrhoea (AAD)";"Cumulative incidence of Clostridium difficile-associated diarrhoea (CDAD) || Cumulative incidence of AAD without evidence of an CDAD || Cumulative incidence of a CDAD within all AAD patients || Occurance of an AAD in dependence from initial number of leucocytes and CRP || Occurance of a CDAD in dependence from initial number of leucocytes and CRP || Incidence density of an AAD or rather CDAD || Average duration of an AAD or rather CDAD || Average stool frequency at an AAD or rather CDAD || Cumulative incidence of stopping or changing the initially applied anibiotic therapy";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/07/09;"Actual";"1520";2012/11/01;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Adult, hospitalized patients receiving systemic antibiotic treatment; patient is competent to contract; patient is physically and psychologically able to follow the trial process; written informed consent.";"Allergy against Saccharomyces boulardii; <br/>Central venous catheter; <br/>Immunosuppression; <br/>Chronic diarrhoea; <br/>Regular intake of Saccharomyces boulardii before beginning of the study; <br/>Systemic antimycotic treatment; <br/>Systemic antibiotic treatment within the last 6 weeks; <br/>Missing contraception (failure rate < 1%/year) for the duration of the study at women in childbearing age, pregnancy or breastfeeding women;";"Primary Sponsor";"Bernhard-Nocht-Institut für Tropenmedizin";"[---]*";"[---]*";"[---]*";"[---]*";"Bernhard-Nocht-Str. 74";"20359";"Hamburg";"Germany";"040-42818-0";"040-42818-394";"klinik@bni-hamburg.de";"www.bni-hamburg.de";"Contact for Scientific Queries";"Bernhard-Nocht-Institut für Tropenmedizin";"Mr.";"Dr. med.";"Stephan";"Ehrhardt";"Bernhard-Nocht-Str. 74";"20359";"Hamburg";"Germany";"040-42818-292";"040-42818-293";"ehrhardt@bni-hamburg.de";"www-bni-hamburg.de";"Contact for Public Queries";"Bernhard-Nocht-Institut für Tropenmedizin";"Ms.";"[---]*";"Rebecca";"Hinz";"Bernhard-Nocht-Str. 74";"20359";"Hamburg";"Germany";"040-42818-290";"040-42818-291";"hinz@bni-hamburg.de";"www.bni-hamburg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"BMBF";"[---]*";"[---]*";"[---]*";"BMBF Programm ""Klinische Studien""";"Heinemannstr. 2";"53175";"Bonn";"Germany";"0228-9957-0";"0228-9957-83601";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea. Randomised, double-blind, placebo-controlled trial";"SacBo";"www.clinicaltrial-sacbo.de";"During antibiotic treatment in hospital the occurance of diarrhoea in patients is common. This diarrhoea may be severe and life-threatening. To date, no measures of proven efficacy to prevent the occurence of this diarrhoea exist. The apathogenic yeast, Saccharomyces boulardii, has the potential to prevent this diarrhoea. A clinical trial shall prove the hypothesis that Saccharomyces boulardii prevents diarrhoea in patients when administered alongside an antibiotic.";"Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We designed a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000084";"2012-12-07T14:06:42.877+01:00";
"DRKS00000721";2012/02/22;2011/01/18;yes;"Approved";"4112-11 FF";"Ethik-Kommission der Medizinischen Fakultät der Ruhr-Universität Bochum";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-000290-31";"[---]*";"Primary Registry-ID";"NCT01512446";"Clinical Trials.gov";"BfArM-No.";"4037610";"[---]*";;;;;;;"ICD10";"M81";"Osteoporosis without pathological fracture";"ICD10";"M80";"Osteoporosis with pathological fracture";;;;;;;;;;"Arm 1";"Alendronate 70 mg per week for 24 months";"Arm 2";"Placebo<br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"IIIb";"Yes";"Osteoporotic fractures within 24 months, detected via patient interview and medical reporting";"	<br/>Adverse events, death";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Alfried Krupp Krankenhaus Steele";"Essen";"Doctor's Practice";"[---]*";"Bochum";"Doctor's Practice";"[---]*";"Essen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/02/28;"Actual";"7000";2013/03/08;"Multicenter trial";"National";"Both, male and female";"60";"Years";"[---]*";"no maximum age";"Postmenopausal women or men > 60 years,<br/>DXA T-Score at lumbar spine, total hip or femur neck <-2,0 OR at least one low traumatic vertebral fracture grade 2/3 or multiple low traumatic vertebral fractures regardless of bone density Pretreatment with bisphosphonates for at least four years<br/>Risk for hip and vertebral fractures min. 30% according to DVO-guideline for osteoporosis 2009<br/>Signed informed consent";"Other pharmacological treatment of osteoporosis during the last 48 months, other bone diseases, Malabsorption syndromes, Renal insufficiency with a calculated creatinine clearance < 35 ml/min , Diseases of the esophagus, delayed esophageal clearance, Unrealisability of the intake instructions, Hypocalcemia";"Primary Sponsor";"Evangelisches Krankenhaus Lutherhaus gGmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Hellweg 100";"45276";"Essen";"Germany";"0201- 8050";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Osteologisches Forschungszentrum Essen am Evangelischen Krankenhaus Lutherhaus gGmbH";"Mr.";"Prof. Dr. med. ";"Johannes ";"Pfeilschifter";"Hellweg 100";"45276";"Essen";"Germany";"0201 - 805 1847";"0201 - 805 2185";"johannes.pfeilschifter@krupp-krankenhaus.de";"[---]*";"Contact for Public Queries";"Osteologisches Forschungszentrum Essen";"Ms.";"[---]*";"Inga";"Steinebach";"Hellweg 100";"45276";"Essen";"Germany";"0201 - 805 1979";"0201 - 805 1986";"steinebach@osteo-fz.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Bonn";"[---]*";"[---]*";"[---]*";"[---]*";"Heinemannstr. 2";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Comparison of the effect of an ongoing treatment with alendronate or a drug holiday<br/>on the fracture risk in osteoporotic patients with a bisphosphonate long term therapy";"BILANZ";"[---]*";"Study to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis ";"	<br/>Is a continued treatment with alendronate for another two years after a preceding therapy with bisphosphonates of at least four years able to reduce the incidence of new osteoporotic fractures in patients at high fracture risk compared to a therapy-free interval?";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000721";"2013-12-20T17:30:07.254+01:00";
"DRKS00003246";2013/05/31;"[---]*";yes;"Approved";"12/0351";"Ethik-Kommission des Landes Berlin";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-004463-69";"[---]*";"PEI-No.";"1694/01";"[---]*";;;;;;;;;;"ICD10";"H35.8";"Other specified retinal disorders";;;;;;;;;;;;;"Arm 1";"Three initial monthly Lucentis intravitreal injections (0.5 ml, 10 mg/ml Ranibizumab aqueous solution). Subsequently three more monthly injections if visual acuity drops by > 5 letters from best observed on treatment (including baseline) value.";"Arm 2";"Laser treatment using an Argon Green Laser to the macula and periphery in areas. Additional treatment at intervals of not less than 3 months if visual acuity drops by > 5 letters from best observed on treatment (including baseline) value.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"IIb";"Yes";"Change from baseline in BCVA (Best Corrected Visual Acuity) over 6 months (area under curve / 6 months)";"Change from baseline in macular thickness and the size of areas of macular and peripheral capillary drop out over 6 months (area under the curve / 6 months)<br/><br/>Change from baseline in BCVA, macular thickness and the size of areas of macular and peripheral capillary drop out over 12 months (area under the curve / 12 months)<br/><br/>Proportion of patients with improvement of visual acuity after 6 and 12 months<br/><br/>Rate of vitreous hemorrhages";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Charité";"Berlin";"University Medical Center";"Augenklinik";"Essen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/10/23;"Actual";"60";2016/12/02;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Clinical signs of radiation retinopathy (cotton wool spots, hemorrhages, vascular ischemia)<br/><br/>Visual impairment due to focal or diffuse radiation induced macula edema (ME) in the irradiated eye that is eligible for laser treatment<br/><br/>Age ≥18 years<br/><br/>BCVA less than 20/32";"Concomitant conditions in the study eye which could, in the opinion of the investigator, prevent VA improvement, e.g. tumor recurrence, tumor growth underneath the macula<br/><br/>Endoresection and / or previous vitrectomy<br/><br/>Patients with proliferative retinopathies or macular edema due to reasons other than irradiation: e.g. diabetic retinopathy, vein occlusion, or Irvine-Gass syndrome<br/><br/>Treatment with anti-angiogenic drugs or intravitreal corticosteroids or any other investigational drug within 3 months prior to randomisation<br/><br/>Prior laser photocoagulation treatment within 3 months (focal / grid laser) or 6 months (panretinal) prior to study entry<br/><br/>Known hypersensitivity against local anaesthetics<br/><br/>Known hypersensitivity against iodine";"Primary Sponsor";"Charité Campus Benjamin Franklin";"[---]*";"[---]*";"[---]*";"[---]*";"Hindenburgdamm 30";"12203";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.charite.de";"Contact for Scientific Queries";"Charité University Medicine Berlin<br/>Department of Ophthalmology<br/>";"Ms.";"Prof. Dr. med. ";"Antonia";"Joussen";"Hindenburgdamm 30";"12200";"Berlin";"Germany";"030 450 554 202";"[---]*";"Antonia.Joussen@charite.de";"[---]*";"Contact for Public Queries";"Charité University Medicine Berlin, Department of Ophthalmology";"Ms.";"[---]*";"Sabrina";"Thees";"Hindenburgdamm 30";"12200";"Berlin";"Germany";"+49 30 450 654138";"[---]*";"Sabrina.Thees@charite.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Novartis Pharma GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Roonstr. 25";"90429";"Nürnberg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Investigation of Radiation Retinopathy (Radi-Ret Study)<br/>Subtitle: Influence of Lucentis® on radiation retinopathy after irradiation of choroidal melanoma";"Radi-Ret";"[---]*";"Uveal melanoma is the most common primary intraocular tumour in adults.<br/><br/>Uveal melanoma can be treated with a local ocular radiation therapy.<br/><br/>Possible complications of this therapy involve a reaction of the retinal blood vessels, known as radiation retinopathy.<br/><br/>In this clinical trial, the therapy of radiation retinopathy with laser coagluation will be  compared to Lucentis therapy.";"Comparison of ranibizumab to laser treatment regarding change from baseline in BCVA (Best Corrected Visual Acuity) over a 6-month treatment period for Patients with radiation retinopathy, due to irradiation of uveal melanoma.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003246";"2017-08-02T13:03:45.267+02:00";
"DRKS00003498";2012/01/27;"[---]*";yes;"Approved";"115/2011";"Ethik-Kommission der Universität Witten/Herdecke";;;;;;;;;;;;;;;;"Free text";"[---]*";"Iatrogenic subcutaneous abdominal wound healing disorder";"ICD10";"S31.1";"Open wound of abdominal wall";"ICD10";"T89.03";"[---]*";;;;;;;"Arm 1";"Intervention group: Negative Pressure Wound Therapy (NPWT)";"Arm 2";"Control group: Standard Conventional Wound Therapy (SCWT). Methods of simple and advanced wound treatment according to the therapy recommendations.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Controlled testing of two primary endpoints:<br/>1) Time (number of days) to the achievement of complete wound closure (Time-to-Closure) within 42 days of treatment<br/><br/>2) Number of achieved wound closures within maximum therapy period (Rate-of-Closure) within 42 days of treatment<br/>";"Secondary endpoints related to efficacy:<br/>•	Reduction of wound volume in the course of treatment (over time)<br/>•	Wound infections<br/>•	Relapses<br/>•	Pain<br/>•	Quality of Live<br/><br/>Safety endpoints:<br/><br/>•<br/>Therapeutic AE, Specific therapeutic SAE, Mortalitiy.<br/>Health econonomic endpoints:<br/>1)	Patient-related endpoints / Patient Reported Outcome (PRO)<br/>2)	Consumption of resources in inpatient and outpatient setting and costs (economically orientated outcome parameters)<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Städtisches Klinikum Karlsruhe";"Karlsruhe";"Medical Center";"Städtisches Klinikum";"Neunkirchen";"Medical Center";"Krankenhaus Martha Maria";"Halle/Dölau";"University Medical Center";"[---]*";"Frankfurt a.M.";"Medical Center";"Asklepios Stadtklinik";"Bad Tölz";"Medical Center";"Ortenau Klinikum Offenburg";"Offenburg";"Medical Center";"Asklepios Westklinikum Hamburg";"Hamburg";"Medical Center";"Klinikum Dorothea Christiane Erxleben";"Quedlinburg";"Medical Center";"Asklepios Klinikum Uckermark GmbH";"Schwedt";"Medical Center";"Dr. Horst Schmidt Kliniken GmbH";"Wiesbaden";"Medical Center";"Krankenhaus St. Elisabeth";"Halle Saale";"Medical Center";"Klinikum Darmstadt";"Darmstadt";"Medical Center";"Kliniken der Stadt Köln";"Köln";"Medical Center";"Gemeinschaftskrankenhaus Herdecke";"Herdecke";"University Medical Center";"Universitätsklinikum Schleswig-Holstein";"Lübeck";"Medical Center";"Evangelisches Krankenhaus Paul Gerhard Stift";"Wittenberg";"Medical Center";"Sana Hanse-Klinikum Wismar GmbH";"Wismar";"Medical Center";"Kreiskrankenhaus Blaubeuren";"Blaubeuren";"Medical Center";"Westklinikum Heide";"Heide / Holstein";"Medical Center";"Alexianer Krankenhaus Krefeld GmbH";"Krefeld";2012/07/15;"Actual";"251";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"85";"Years";"Key inclusion criteria:<br/>•	Acute subcutaneous abdominal wound-healing impairment after surgical intervention<br/>•	Sizes of wound opening (maximum diameter ≥ 3 cm)<br/>•	Wound depth ≥ 3 cm<br/>•	Wound surface ≥ 9 cm2<br/>";"Key exclusion criteria:<br/>•	Lack of infrastructure for outpatient continuation of treatment and study-specific interventions<br/>•	Existence of an open abdominal fascia<br/>•	Acute serious organ failure<br/>•	Application of an other active vacuum device at the wound treated during the study conduct within 8 days before screening visit<br/>•	Ongoing chemotherapy / during 3 weeks after chemotherapy<br/>•	Ongoing radiation therapy / during 3 weeks after radiation therapy<br/>Contraindications in accordance with the safety precautions issued by the FDA or the companies<br/>";"Primary Sponsor";"Private Universität Witten/Herdecke gGmbH";"Mr.";"Dr. med.";"Marcus";"Redaèlli";"Alfred-Herrhausen-Str. 50";"58448";"Witten";"Germany";"+49 2302 926-741";"+49 2302 926-745";"marcus.redaelli(at)uni-wh.de";"www.uni-wh.de";"Contact for Scientific Queries";"Private Universität Witten/Herdecke gGmbH";"Mr.";"Dr. med.";"Marcus";"Redaèlli";"Alfred-Herrhausen-Str. 50";"58448";"Witten";"Germany";"+49 2302 926-741";"+49 2302 926-745";"marcus.redaelli(at)uni-wh.de";"www.uni-wh.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"AOK-Bundesverband GbR, Ersatzkassen: Barmer GEK, Techniker Krankenkasse (TK), Deutsche Angestellten-Krankenkasse, KKH_Allianz, HEK - Hanseatische Krankenkasse, hkk, Knappschaft; Kinetic Concepts Incorporated (KCI) & Smith&Nephew";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Randomised controlled study to evaluate the efficacy of the treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) after surgery by application of Negative Pressure Wound Therapy (NPWT) in comparison to Standard Conventional Wound Therapy (SCWT) of the clinical routine";"ISAW";"www.wound-care.de";"The Institute for Research in Operative Medicine as part of the Private University of Witten<br/>/Herdecke is performing a clinical study project to evaluate the efficacy of NPWT for the treatment of postsurgical abdominal wound healing impairments after abdominal surgery. Thereby a comparison between NPWT and SCWT will be drawn.<br/><br/>The main target parameters, time till complete wound closure and number of wound closures among ca. 250 patients during the maximum treatment time of 42 days, the recurrence of wound healing impairments and the changes of wound sizes during course of time will be documented photographically and by computer-based analysis.<br/><br/>Patients with preliminarily closed abdominal wounds, which experience a spontaneous reopening after surgery or with wound healing disorder in the postoperative course or whose wounds will be reopened by the physician in charge will be enrolled in the study. Patients whose wounds can not be closed initially and need further treatment to achieve wound closure will be enclosed in the study likewise. Study therapy will be started with inpatient treatment and will be continued outpatient care, if necessary. Patients with acceptable general condition should be assigned to ambulant treatment as soon as possible.<br/>";"Conduct of a study project with the intention to prove the efficacy and the benefit of NPWT in patient-centered care of ISAW in inpatient and outpatient therapy.<br/><br/>This study project evaluates the therapeutic outcome of the application of a CE-certified technical medical product, based on the principle of the NPWT (intervention group) in comparison to the SCWT of the control group for the treatment of subcutaneous abdominal wound-healing impairments without fascial dehiscence after surgical interventions und will be conducted in medical departments, which offer special structural, personal and scientific qualifications. Negative pressure devices of two companies acting nationwide, whose systems are CE-certified and field-tested, will be applied.<br/><br/>Patients will be stratified according to the assignment to the participating facility (clinic) und according to their wound sizes. Study therapy will be started in hospital and should be continued in an out-patient setting. This clinical trial is designed as a national multi-centric prospective randomised controlled superiority study. The planned number of study centres is 25.<br/><br/>Aim of the study is the comparison of clinical, safety and economic results of NPWT and SCWT in the treatment of postoperative wound-healing impairments without fascial dehiscence. Primary endpoints are the time till complete wound closure within the maximum treatment period of 42 days (lasting for 30 days) and the number of wound closures of each study arm within 42 days. In addition, this study contains the detailed recording of specific covariates and their influences on target parameters.<br/>A blinded computer-based analysis of wound photographs with focus on the primary endpoints (complete wound closure and number of wound closures) and secondary endpoints (changes of wound sizes in the course of time, number of relapses) will be performed.<br/><br/>The study is based on the hypothesis that the application of NPWT for treatment of postoperative abdominal wound-healing impairments with intact fascia results in a decrease of time until achievement of wound closure (with confirmation after 30 days) and for this reason more wound closures can be achieved in the maximum treatment period of 42 days compared to the control therapy. Furthermore it is supposed that the application of NPWT represents an effective und save therapy option for the treatment of postoperative subcutaneous abdominal wound-healing impairments in inpatient and outpatient settings.<br/><br/>Patients will be randomized in a 1:1 ratio to the therapy arm NPWT and the control arm SCWT. The sample size estimation revealed that a maximum of 228 patients (Intention-To-Treat-analysis) has to be enrolled during the active recruitment period to achieve the sample size of 198 participants (Per-Protocol-analysis) necessary for statistical analysis.<br/><br/>Data acquisitions in the context of the evaluation of the primary endpoints and the secondary endpoints in the health economic, patient-related and safety-relevant context will generate reliable data fort he evaluation of efficacy and efficiency of NPWT in the therapy of postoperative abdominal wound-healing impairments in inpatient and outpatient settings. The results analyzed during the study conduct shall be provided until June 2014 to supply a contribution to the final decision of the Gemeinsamer Bundesausschuss (Federal Joint Committee) concerning a possible admission of negative pressure wound closure as a standard service of the statutory health insurance within both medical settings.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003498";"2017-08-10T09:57:51.801+02:00";
"DRKS00003851";2013/04/25;"[---]*";yes;"Approved";"101/12 A-ff";"Ethik-Kommission des Fachbereichs Medizin der Philipps-Universität Marburg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-004361-32";"[---]*";"BfArM-No.";"4038250";"[---]*";;;;;;;;;;"ICD10";"L12.0";"Bullous pemphigoid";;;;;;;;;;;;;"Arm 1";"Best medical treatment (Control intervention):<br/>Arm A (BMT): Clobetasol Cream at an initial dose of 30g/d plus placebo<br/>";"Arm 2";"Experimental intervention:<br/>Arm B (BMT + adjuvant simvastatin): Clobetasol Cream at an initial dose of 30g/d plus Simvastatin at a dose of 40mg/d";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"IIa";"N/A";"•	Yearly accrual rate<br/>•	Proportion of patients compliant with interventional treatment<br/>•	Proportion of patients adhering to planned study visits<br/>";"•	Relapse-free survival (RFS) defined as the time interval from randomisation to relapse or death of the patient (This is the designated primary efficacy endpoint of the phase III trial).<br/>•	Time to control of disease activity (defined as the time interval from randomisation to the time at which new lesions cease to form and established lesions begin to heal or pruritic symptoms start to abate) <br/>•	Time to complete remission on minimal therapy (defined as the absence of new or established lesions or pruritus while patient is receiving minimal therapy for at least 2 months) <br/>•	Duration of complete remission on minimal therapy (defined as the time interval from complete remission on minimal therapy to relapse)<br/>•	Cumulative dose of clobetasol cream<br/>•	Change in clinical severity scores (modified ABSIS – Autoimmune bullous skin disorder intensity score, BPDAI – Bullous Pemphigoid Disease Activity Index)<br/>•	Change in life quality questionnaires (EQ-5D, DLQI, GDS)<br/>•	Serum concentration of autoantibodies during follow-up<br/>•	Serum concentration of pro- and anti-inflammatory cytokines and other parameters during follow-up<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Dermatologie und Allergologie";"Marburg";"University Medical Center";"Klinik für Dermatologie, Venerologie und Allergologie";"Würzburg";"Medical Center";"Zentrum für Dermatologie, Allergologie und Dermatochirurgie Helios-Klinikum";"Wuppertal";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/12/09;"Actual";"30";2014/04/30;"Multicenter trial";"National";"Both, male and female";"55";"Years";"[---]*";"no maximum age";"Inclusion criteria:<br/>•	Patients with newly diagnosed or relapsing bullous or pruriginous pemphigoid: <br/>The diagnosis is based on clinical symptoms typical for active bullous or pruriginous pemphigoid: blisters, urticarial plaques, pruriginous papules or eczematous skin alterations.<br/>The clinical extent of BP at screening must exceed values for  Bullous Pemphigoid Disease Area Index (BPDAI) of ≥ 15 (15 or more of max. 240 without damage) or modified Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) of ≥ 5 (5 or more of max. 150).<br/>Newly diagnosed patients only:<br/>positive direct immunofluorescence (DIF) with linear deposition of IgG and/or C3 at the dermo-epidermal basal membrane zone<br/>All patients:<br/>1. optional: skin biopsy (histological evidence for subepidermal blister formation) <br/>2. IgG reactivity with blister roof of saline-split human skin using indirect immunofluorescence and IgG reactivity against BP180 and/or BP230 by ELISA <br/>•	Male and female patients aged ≥55 years<br/>•	Only confirmed postmenopausal female patients, whose last menorrhoea occurred more than 1 year ago.<br/>• 	Written informed consent by patient or written informed consent of the patient’s legal representative<br/>•	Karnofsky-Index ≥ 30%<br/><br/>";"Exclusion criteria: <br/>•	Predominant or exclusive mucosal involvement<br/>•	Treatment with systemic corticosteroids >10mg prednisolone equivalent if systemic corticosteroids cannot be completely tapered until study visit 1 <br/>•	Treatment with systemic corticosteroids ≤ 10mg prednisolone equivalent for a time period less than four weeks prior to randomisation <br/>•	Hypersensitivity to Simvastatin or other ingredients of the IMPs<br/>•	Treatment with topical calcineurin inhibitors, dapsone, immunosuppressive drugs (azathioprine, mycofenolate mofetil, cyclophosphamide, methotrexate, ciclosporin) or tetracyclines within the past month prior to randomisation<br/>•	Treatment with intravenous immunoglobulins, immunoadsorption or TNF-alpha antagonists within the past 3 months prior to randomisation<br/>•	Treatment with rituximab or leflunomide within the past 12 months prior to randomisation<br/>•	Concurrent treatment with potent CYP3A4-inhibitors (itraconazole, ketoconazole, fluconazole, posaconazole, HIV protease inhibitors (e.g. nelfinavir), erythromycin, clarithromycin, telithromycin, nefazodon) <br/>•	Concurrent treatment with less potent CYP3A4-inhibitors (verapamil, diltiazem, voriconazol, danazol, fibrates, niacin, amiodarone, gemfibrozil, fusidic acid, consumption of grapefruit juice) <br/>•	Treatment with simvastatin or other statins four weeks prior to randomisation<br/>•	Chronic muscle diseases or increase of creatine kinase above 2.5fold of normal value <br/>•	Hereditary muscle diseases in medical history<br/>•	Contact hypersensitivity to clobetasol<br/>•	Renal dysfunction (creatinine clearance<30ml/min according to the Cockcroft and Gault Formula (30)) <br/>•	Untreated hypothyreosis<br/>•	Active liver disease or prolonged increased transaminase levels >3x upper limit of normal and increased total bilirubin>3mg/dl<br/>•	Alcohol dependency<br/>•	poorly controlled diabetes mellitus (glycohaemoglobin > 8,0 %)<br/>•	Inability to apply topical glucocorticoids and to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations<br/>•	Illiteracy or insufficient language skills (German) to complete the questionnaires<br/>•	Simultaneous participation in another clinical trial except if that other trial does not affect the study as approved and documented by the principal investigators<br/>";"Primary Sponsor";"Philipps-Universität Marburg";"[---]*";"[---]*";"[---]*";"[---]*";"Biegenstraße 10";"D-35037";"Marburg";"Germany";"+49-06421-28 66785";"+49-06421-28 66517";"karin.weide@kks.uni-marburg.de";"[---]*";"Contact for Scientific Queries";"Klinik für Dermatologie und Allergologie<br/>Philipps Universität Marburg";"Mr.";"Prof. Dr. med.";"Michael";"Hertl";"Baldinger Straße ";"35043 ";"Marburg";"Germany";"+49-6421-5866280";"+49-6421-5862902";"hertl@med.uni-marburg.de";"[---]*";"Contact for Public Queries";"Klinik für Dermatologie und Allergologie<br/>Philipps Universität Marburg";"Ms.";"Dr. med.";"Melika";"Behzad";"Baldinger Straße";"35043";"Marburg";"Germany";"+49-6421-58 66281";"+49-6421-58 62902";"behzad@med.uni-marburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Klinik für Dermatologie und Allergologie<br/>Philipps Universität Marburg";"Mr.";"Prof. Dr. med.";"Michael";"Hertl";"Baldinger Straße ";"35043";"Marburg";"Germany";"+49-6421-5866280";"+49-6421-5862902";"hertl@med.uni-marburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid<br/><br/>A prospective multi-centre randomised double-blind placebo-controlled <br/>pilot study<br/>";"SICOPEM";"[---]*";"The SICOPEM study pilot study will  investigate if the relapse-free interval of patients with bullous pemphigoid who are treated with topical corticosteroids can be prolonged by additional application of simvastatin capsules.";"The aim of the pilot study is to gather data about recruitment potential, compliance to the interventional treatment, and adherence to planned study visits in order to decide about the feasibility of a phase III trial that will investigate, whether the relapse-free interval of patients suffering from bullous pemphigoid and treated with high-potent topical corticosteroids can be prolonged by additional oral application of simvastatin 40 mg daily.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003851";"2016-08-22T09:56:57.634+02:00";
"DRKS00004009";2012/06/25;2005/09/12;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00191477";"ClinicalTrials.gov";"Sponsor-ID";"6138";"Eli Lilly and Company";"Other Secondary-ID";"B9E-MC-S274";"[---]*";;;;;;;"Free text";"[---]*";"Bladder Neoplasms";"ICD10";"C67";"Malignant neoplasm of bladder";;;;;;;;;;"Arm 1";"Drug: Gemcitabine";"Arm 2";"Drug: Placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"III";"[---]*";"- Recurrence-Free Survival (RFS); time frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)<br/>";"- Time to Recurrence; time frame: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)<br/>- Recurrence-Free Survival (RFS) in Subgroups; time frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)<br/>- Tumor Recurrence Type; time frame: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physici";"Reinfeld";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2004/01/31;"[---]*";"355";2008/06/01;"Multicenter trial";"[---]*";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Clinical evidence of superficial transitional cell carcinoma of the bladder<br/><br/>          -  Males or females at least 18 years of age<br/><br/>          -  Karnofsky Performance Status greater than or equal to 70%<br/><br/>          -  Patient compliance and geographic proximity that allow adequate follow-up<br/><br/>          -  Female patients with reproductive potential must use a reliable contraceptive method<br/>             if appropriate (for example, intrauterine device [IUD], birth control pills, or<br/>             barrier device) during the study. Female patients with reproductive potential must<br/>             have a negative serum pregnancy test within 7 days of study enrollment.<br/><br/>          -  Signed informed consent.<br/>";"-  Clinical evidence of muscle-invasive or locally advanced bladder cancer<br/><br/>          -  Clinical evidence of upper urinary tract tumor<br/><br/>          -  Distant metastases<br/><br/>          -  Other malignancies within the last 2 years, except non-melanotic skin tumors,<br/>             carcinoma in situ of the cervix or organ-confined prostate cancer after curative<br/>             therapy<br/><br/>          -  Severe concomitant psychiatric disease<br/><br/>          -  Febrile, active infection<br/><br/>          -  Other serious concomitant disorders that would compromise the safety of the patient<br/>             or his/her ability to complete the study according to the protocol, at the discretion<br/>             of the investigator (for example, unstable angina pectoris, uncontrolled diabetes<br/>             mellitus)<br/>";"Primary Sponsor";"Eli Lilly and Company";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Eli Lilly and Company";"[---]*";"[---]*";"[---]*";"Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Eli Lilly and Company";"[---]*";"[---]*";"[---]*";"Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder";"[---]*";"[---]*";"A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the<br/>      efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately<br/>      after transurethral resection of the bladder tumor.<br/>";"[---]*";"Recruiting stopped after recruiting started ";"Further trial documents";"[---]*";"http://www.lillytrials.com";"Lilly Clinical Trial Registry";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004009";"2016-01-19T16:59:45.163+01:00";
"DRKS00004696";2013/03/01;"[---]*";yes;"Approved";"EA1/211/10";"Ethik-Kommission der Charité -Universitätsmedizin Berlin-";;;;;;;;;;;;;;;;"ICD10";"G80.0";"Spastic quadriplegic cerebral palsy";"ICD10";"J18.0";"Bronchopneumonia, unspecified";;;;;;;;;;"Arm 1";"Breathing synchronized electrical stimulation of the abdominal muscles. The stimulation is applied for 30 minutes twice a day over a period of 90 days.";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Prevention";"Single (group)";"N/A";"N/A";"Pneumonia rate over the period of abdominal stimulation (90 days)";"mortality, days in hospital, weaning, period of ventilation";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Unfallkrankenhaus Berlin";"Berlin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/11/30;"Actual";"14";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"Men and women<br/>SCI paralysis C4 - Th3<br/>Paralysis not older than 4 weeks, with no extubation, the period is due to the treatment of the underlying disease.<br/>BMI <35<br/>Age 18 - 80 years<br/>Intensive monitoring obligation<br/>Mandatory ventilation at baseline<br/>Consent by the patient";"lack of consent<br/>pulmonary disease (COPD)<br/>progressive Disease<br/>impossibility to place electrodes abdominal<br/>pregnancy<br/>pacemaker or similar implants interfere with the electrical stimulation";"Primary Sponsor";"Unfallkrankenhaus Berlin";"Mr.";"PD Dr. med.";"Rainer";"Seidl";"Warenerstrasse 7";"12683";"Berlin";"Germany";"030 5681 4301";"030 5681 4303";"ROSeidl@ukb.de";"www.ukb.de";"Contact for Scientific Queries";"Unfallkrankenhaus Berlin";"Mr.";"PD Dr. med.";"Rainer";"Seidl";"Warenerstrasse 7";"12683";"Berlin";"Germany";"030 5681 4301";"030 5681 4303";"ROSeidl@ukb.de";"www.ukb.de";"Contact for Public Queries";"Unfallkrankenhaus Berlin";"Mr.";"Dr. med.";"Andreas";"Niedeggen";"Warnerstrasse 7";"12683";"Berlin";"Germany";"030 5681 3401";"030 5681 3403";"Andreas.Niedeggen@ukb.de";"www.ukb.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"DGUV – Forschungsförderung";"[---]*";"[---]*";"[---]*";"[---]*";"Alte Heerstasse 111";"53757";"St. Augustin";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prospective study on breathing synchronized electrical stimulation of the abdominal muscles in patients with acute and chronic tetraplegia";"AbdomenStim";"www.abdomenstim.de";"Central problem in the care of patients with acute paralysis of the cervical cord is the long-term prevention of complications in the lungs (pneumonia). By the injury, the ability to breathe and cough worse.<br/>A preliminary study (proof of concept), we want to check if a breath-dependent stimulation of the abdominal muscles leads to better breathing and coughing, and thus reduced the number of lung infections. In the study we are using electricity stimulate the abdominal muscles when you exhale, so that they contract. Breathing out, we measure directly the ventilators or by an additional mask over his face. We begin with this therapy as soon as possible after the accident so that your muscles do not usually reverses. The stimulation is done twice a day for 30 minutes over a period of 90 days. The aim is to look to improve if the number of lung inflammation and other respiratory parameters.";"Central problem in the care of patients with paralysis of the throat and upper chest Marks is to secure the airway and the long-term prevention of complications such as pneumonia.<br/>The objective of the proposed research project is to reduce the number of complications in the primary steady progress after the accident. This with the help of an electrical stimulation of the abdominal muscles to the expiration and the cough . The respiration is measured on the respiratory ventilator or by means of a face mask. The stimulation is applied for 30 minutes twice a day over a period of 90 days. Endpoint of the study is the number of pneumonia. The study design provided 14 patients is examined, 9 should stay beyond the period of stimulation without pneumonia.";"Recruiting stopped after recruiting started ";"Trial results";"209796d7-a958-4c3c-ba91-d1e3db8a219e";"Abschlußbericht AbdomenStim kurz.pdf";"Abschlußbericht zur Stude";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004696";"2018-02-13T10:13:42.119+01:00";
"DRKS00004909";2013/05/13;"[---]*";yes;"Approved";"20/13";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";;;;;;;;;;;;;;;;"Free text";"[---]*";"cancer pain, opioid specific side effects";"ICD10";"T88.7";"Unspecified adverse effect of drug or medicament";"ICD10";"R52.9";"Pain, unspecified";;;;;;;"Arm 1";"Valoron (tilidine/naloxone), 2x 100/8mg/day p.o. (prolonged-release tablet), for 4 days";"Arm 2";"Tramadol (tramadol), 2x 100mg/day p.o. (prolonged-release tablet), for 4 days<br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Treatment";"Parallel";"N/A";"No";"nausea on a numeric rating scale from 0-10, daily documented per questionnaire for probands and investigators, over a period of 4 days";"other side effecs on a numeric rating scale from 0-10, documented daily per questionnaire for probands and investigators, over a period of 4 days<br/>pain on a numeric rating scale from 0-10, documented daily per questionnaire for probands and investigators, over a period of 4 days";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinikum Freiburg";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/05/13;"Actual";"150";2014/12/31;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"cancer pain patients with moderate to severe pain, age > 18 years, sufficient mental, physical and linguistic abilities to cooperate at the study, signed informed consent";"contraindication for tilidine or tramadol (allergy against a component of tilidine or tramadol, pregnancy or lactation, severe hepatic or renal impairment (CHILD C; GFR < 15ml/min), seizure disorder, drug abuse, taking of MAO-inhibitors), acute interventional pain (e.g. postoperative pain), indication for pain therapy with opioids of WHO step 3";"Primary Sponsor";"Universitätsklinikum Freiburg - Anästhesiologie";"Mr.";"Dr. med.";"Klaus";"Offner";"Hugstetter Strasse 55";"79106";"Freiburg";"Germany";"004976127041540";"004976127026290";"klaus.offner@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/anaesthesie/live/klinik/schmerzdienst.html";"Contact for Scientific Queries";"Universitätsklinikum Freiburg - Anästhesiologie";"Mr.";"Dr. med.";"Klaus";"Offner";"Hugstetter Straße 55";"79106";"Freiburg im Breisgau";"Germany";"004976127041540";"004976127026290";"klaus.offner@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/anaesthesie/live/klinik/schmerzdienst.html";"Contact for Public Queries";"Universitätsklinikum Freiburg - Anästhesiologie";"Mr.";"Dr. med.";"Klaus";"Offner";"Hugstetter Straße 55";"79106";"Freiburg im Breisgau";"Germany";"004976127041540";"004976127026290";"klaus.offner@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/anaesthesie/live/klinik/schmerzdienst.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Freiburg - Anästhesiologie";"Mr.";"Dr. med.";"Klaus";"Offner";"Hugstetter Straße 55";"79106";"Freiburg im Breisgau";"Germany";"004976127041540";"004976127026290";"klaus.offner@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/anaesthesie/live/klinik/schmerzdienst.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Side effects of Tramadol and Tilidine in Cancer Pain Patients – A prospective randomized double blinded clinical trial<br/>";"TiTaN<br/>";"[---]*";"Usually cancer pain is treated according to the three-step WHO pain ladder. Opioids are an import component of this pain ladder. The study drugs tilidine and tramadol are ranked among the mild opioids. Since decades both drugs are approved and commonly used in clinical practice. However both have been used randomly for the treatment of cancer pain for there are little studies comparing and quantifying effects and adverse reactions of both drugs directly. This is what our study is aiming for. Especially the occurrence of sickness, nausea and vomiting shall be compared. Furthermore other side effects and the analgesic effects of tilidine and tramadol are checked against each other.<br/>Study objective is to find the drug with less adverse effects to give an informed therapy recommendation. <br/>";"The study is ment to compare the side effects of tilidine and tramadol in the treatment of cancer pain. Objective is to find the drug with the better side effects profile.<br/>Tilidine and tramadol have been used in clinical practice since the 1970s. But there are little studies comparing effects and adverse reactions of both drugs. <br/>Anyhow we expect clinical relevant differences - particularly regarding the side effect of sickness, nausea and vomiting.<br/>Therefor two hypotheses are established: 1) There is a difference between tilidine and tramadol regarding their nauseating and vomiting effects. 2) Tilidine and Tramadol show further differences in their side effects profile as well as in their analgesic effects. <br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004909";"2015-07-13T16:41:22.138+02:00";
"DRKS00004915";2013/05/10;"[---]*";yes;"Approved";"1784-2013";"Ethikkommission der Medizinischen Hochschule Hannover";;;;;;;;;;;;;;;;"Free text";"[---]*";"Acute Coronary Syndrome, i.e. STEMI or NSTE-ACS";"ICD10";"I21";"Acute myocardial infarction";;;;;;;;;;"Arm 1";"Patients of the intervention group receive intersectoral pharmaceutical care: detailled pre-discharge counselling according to a multimodal concept serves as main intervention. Further counselling is offered during the follow-up telephone calls after 6 and 12 moneths, respectively. In-patient and out-patient care by physicians remains completely unaffected by the interventions.";"Arm 2";"Patients of the control group will be cared of solely by physicians. Follow up telephone calls only serve to collect data.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Supportive care";"Parallel";"N/A";"N/A";"Patient-reported medication adherence 12 months post-discharge as measured by the German Version of the Morisky Medication Adherence Scale / 8-item Version";"Key secondary endpoint: patient-reported physical functioning as key dimension of health-related quality of life, as measured with the German Version of the Physical Funktioning Scale of the SF-12v2® Health Survey 12 months post-discharge.<br/><br/>Further secondary endpoints:<br/>A. MACCE incidence: incidence and time up to a possible major adverse cardiac or cerebrovascular event during follow-up, i.e. non-fatal reinfarction, any repeat target lesion revascularisation (TLR), cerebrovascular accident or cardiac death.<br/>B. Patient's diesease and drug related knowledge: essential content of the in-patient educative session will be assessed with a short self-designed questionnaire at discharge.<br/>C. Patient satisfaction: satisfaction with drug related counselling will also be assessed at discharge unsing the drug information scale of the German Hamburger Fragebogen zum Krankenhausaufenthalt.<br/>D. Health-related quality of life in the dimensions Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health as measured by the SF-12v2® Health Survey 12 months post-discharge.<br/>E. Categorial interpretation of medication adherence: patient-reported medication adherence 12 months post-discharge will be interpreted according to the adherence categories by Morisky et al.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Medizinische Hochschule Hannover";"Hannover";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/05/27;"Actual";"200";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"a. patients 18 yrs. of age or older<br/>b. acute coronary syndrome as confirmed admission diagnosis, i.e. st-segment elevated myocardial infarction (STEMI), non st-segment elevated myocardial infaction (NSTEMI) or unstable angina pectoris (UA).<br/>c. informed consent";"a. restricted cognitive abilities, i.e. patients who are not able to care for themselves (patients with neurological/psychiatric disorders, patients receiving care or live in a nursing home)<br/>b. patients with terminal renal impairment who receive blood dialysis regularly<br/>c. patients under antineoplastic treatment<br/>d. patients not capable of sufficient knowledge of German language";"Primary Sponsor";"Klinik für Kardiologie & Angiologie<br/>der Medizinischen Hochschule Hannover";"Mr.";"Prof. Dr. med.";"Andreas";"Schäfer";"Carl-Neuberg-Str. 1";"30625";"Hannover";"Germany";"0511/532-5240";"[---]*";"schaefer.andreas@mh-hannover.de";"[---]*";"Contact for Scientific Queries";"Medizinische Hochschule Hannover";"Mr.";"[---]*";"Jan";"Fodor";"OE 8500, Carl-Neuberg-Str. 1";"30625";"Hannover";"Germany";"0151/75005550";"[---]*";"fodor.jan@mh-hannover.de";"[---]*";"Contact for Public Queries";"Medizinische Hochschule Hannover";"Mr.";"[---]*";"Jan";"Fodor";"OE 8500, Carl-Neuberg-Str. 1";"30625";"Hannover";"Germany";"0151/75005550";"[---]*";"fodor.jan@mh-hannover.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Zentralapotheke<br/>der Medizinischen Hochschule Hannover";"Ms.";"Dr. rer. biol. hum.";"Heike";"Alz";"Carl-Neuberg-Str. 1";"30625";"Hannover";"Germany";"0511/532-3130";"0511/532-18529";"alz.heike@mh-hannover.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Pharmaceutical Care of patients during and after hospitalisation for Acute Coronary Syndrome";"PHAIRPLAY";"[---]*";"Our main attempt is to investigate, to which extent patients who suffered a heart attack can benefit from additional counselling by a pharmacist within and after their hospital stay. Beside, we would like to find out, how the patients' health state develops as well as how they are able to cope with their medical therapy during the first year after their heart attack.<br/>In order to answer these questions, we offer the opportunity to patients who suffered a heart attack to take part in our study at the Clinic for Cardiology & Angiology of Hanover Medical School:<br/>Patients who will be chosen for our Innovative Study Group by lot receive, in addition to the standard care by physicians, couselling by a pharmacist concerning their medication before being discharged. In the course of one year, two follow-up interviews will take place, i.e. after 6 and 12 months, respectively, which will be conducted via telephone. During these interviews, additional counselling will be offered, and, at the same time, data relevant to the study will be collected.<br/>Being chosen by lot for the Traditional Study Group, these patients will exclusively experience care by medical staff. Study data will be collected - equally to the Innovative Study Group - during the patient's stay in hospital as well as during two telephone interviews after 6 and 12 months, respectively.<br/>In our study, neither any physical examinations will take place nor any new drugs will be tested.";"In our study, we aim to evaluate the benefit of pharmaceutical care for patients who suffered an acute coronary syndrome by performing a randomised controlled interventional trial. Additionally, the current state of drug supply for these patients will be researched.<br/>As patient outcomes are considerably impaired within the first year after index hospitalisation, a multimodal intersectoral intervention for boosting patients' adherence and persistence was tailored to the needs of this patient collective. The study is to reveal the extent up to which pharmaceutical care contributes to an ameliorated patient outcome.<br/><br/>Core intervention of our programme is an in-patient counselling session. Futhermore, patients of the intervention group will be provided with additional couselling within the follow-up after 6 and 12 months post-discharge, respectively. However, patients of the control group receive care and couselling by physicians only.<br/>Endpoint will be assessed by patient-reported outcomes. Primary endpoint is the patient-reported medication adherence, while health-related quality of life serves as key secondary endpoint.<br/><br/>Data will be collected by use of standardised psychometric instruments. As by default no medical out-patient follow-up care is provided, the follow-up will be conducted in a remote mode via telephone as well as being merged with the follow-up intervention in the case of the intervention group.";"Recruiting stopped after recruiting started ";"Abstract";"[---]*";"[---]*";"Krankenhauspharmazie 34(4): 201-2 (2013).";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004915";"2015-06-22T12:45:20.064+02:00";
"DRKS00005039";2013/08/23;2010/08/13;yes;"Approved";"128-10 fed";"Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2009-013702-14";"[---]*";"Primary Registry-ID";"2009-013702-14";"EU-CTR";;;;;;;;;;"ICD10";"H81.2";"Vestibular neuronitis";;;;;;;;;;;;;"Arm 1";"betahistine dihydrochloride (Vasomotal(R)) 3 times 48 mg per day orally up to 4 weeks";"Arm 2";"placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"II-III";"Yes";"""Total sway path"" (length per time) on a compliant foam-padded posturography <br/>platform for postural control on day 3 and 10 after randomization<br/><br/>Peak slow phase velocity of the spontaneous <br/>nystagmus on day 3 and 10 after randomization";"""subjective visual vertical"" on day 1, 3, 10, 28 and 56 after randomization<br/><br/>slow phase velocity of nystagmus  provoked by caloric irrigation on day 1 and 56 after randomization<br/><br/>handicap / impairment due to vertigo or dizziness assessed by the Dizziness Handicap Inventory (questionnaire) on day 1, 10, 28 and 56 after randomization";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"München";"Medical Center";"[---]*";"Altötting";"University Medical Center";"[---]*";"Essen";"University Medical Center";"[---]*";"Tübingen";"University Medical Center";"[---]*";"Lübeck";"Medical Center";"[---]*";"Augsburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/12/17;"Actual";"210";2016/06/10;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"• Patient has a history of acute/sub-acute (i.e., within minutes to hours) on-set of severe prolonged rotatory vertigo, nausea, and postural imbalance;<br/>• the clinical examination reveals horizontal-rotatory spontaneous nystag-mus (fast phase) toward the unaffected ear without evidence of a central vestibular lesion, and a pathological head-impulse test (i.e., turning the head of the patient rapidly to the right and left while observing provoked compensatory eye movements) that reveals an ipsilateral deficit of the horizontal semicircular canal (Halmagyi & Curthoys 1988);<br/>• caloric irrigation shows hypo-/unresponsiveness of the horizontal canal of the affected ear, i.e., the maximum slow phase velocity during caloric irri-gation with 30°C and 44°C water should be less than 3°/s on the affected side and the asymmetry between the two sides is >25 percent according to “Jongkees’s vestibular paresis formula” (Jongkees et al. 1962; Fife et al. 2000); and<br/>• there is a displacement of the subjective visual vertical toward the affected ear without any vertical divergence of the eyes, i.e., without vertical devia-tion of one eye above the other (Cnyrim et al. 2008).<br/>• Written informed consent";"• Patients not able to give consent;<br/>• a history of vestibular dysfunction before the acute symptom onset or ves-tibular symptoms beginning more than 3 days before patients were re-cruited;<br/>• additional cochlear symptoms, i.e., tinnitus or acute hearing loss before, during, or after the onset of vertigo;<br/>• central ocular motor or central vestibular dysfunction;<br/>• any other brainstem or cerebellar signs or symptoms or abnormal findings on the MRI in the brainstem or cerebellum in diffusion-weighted images or hyperintense lesions in T2-weighted images in combination with contrast enhancement in T1-weighted images;<br/>• other known vestibular disorders such as vestibular migraine, Menière´s disease/syndrome, phobic postural vertigo, benign paroxysmal positioning vertigo;<br/>• central disorders such as paroxysmal brainstem attacks;<br/>• contraindications for treatment with betahistine-dihydrochloride such as bronchial asthma, pheochromocytoma,<br/>• pregnancy or breast-feeding,<br/>• severe dysfunction of liver or kidney, ulcer of the stomach or duodenum,<br/>• treatment with other antihistaminic drugs;<br/>• known severe coronary heart disease or heart failure;<br/>• persistent hypertension with systolic blood pressure > 180 mmHg or dias-tolic BP > 110 mmHg that cannot be controlled by antihypertensive thera-py;<br/>• life expectancy < 3 months, other serious illness, e.g., severe hepatic, cardiac or renal failure, acute myocardial infarction, neoplasm or a com-plex disease that may confound treatment assessment.<br/>• The patient has received any investigational medication within 30 days prior to administration of trial medication or is scheduled to receive an in-vestigational drug up to 30 days after end of trial.<br/>• The patient was previously admitted to this trial or simultaneous participa-tion in another clinical trial or participation in any clinical trial involving anadministration of investigational medicinal product within 30 days prior to clinical trial beginning.";"Primary Sponsor";"Klinikum der Universität München, Campus Großhadern";"[---]*";"[---]*";"[---]*";"[---]*";"Marchioninistraße 15";"81377";"München";"Germany";"[---]*";"[---]*";"[---]*";"www.klinikum.uni-muenchen.de";"Contact for Scientific Queries";"Klinikum der Universität München, Campus Großhadern<br/>Deutsches Schwindel- und Gleichgewichtszentrum (IFB)<br/>Studienzentrale";"Mr.";"Privdoz. Dr. med., MPH";"Otmar";"Bayer";"Marchioninistraße 15";"81377";"München";"Germany";"089-5526189-12 oder 089-4400-76977";"[---]*";"IFB-Studienzentrale@med.uni-muenchen.de";"www.ifb.klinikum.uni-muenchen.de";"Contact for Public Queries";"Klinikum der Universität München, Campus Großhadern<br/>Deutsches Schwindel- und Gleichgewichtszentrum (IFB)<br/>Studienzentrale";"[---]*";"[---]*";"Studienzentrale";"DSGZ";"Marchioninistr. 15";"81377";"München";"Germany";"089-4400-76977";"089-4400-78795";"IFB-Studienzentrale@med.uni-muenchen.de";"www.ifb.klinikum.uni-muenchen.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Bonn";"[---]*";"[---]*";"[---]*";"[---]*";"Heinemannstr. 2";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial";"BETAVEST";"[---]*";"To date there is no approved drug treatment available for patients with acute vestibular failure.<br/>Research question: Do patients receving betahistin show better/faster recovery from acute unilateral vestibular failure.";"Primary Objective: To demonstrate medium-term and short-term superiority of betahistine treatment regarding recovery of postural control or  spontaneous nystagmus as compared to placebo.<br/>Secondary Objectives:  <br/>To establish a  patient-oriented endpoint “time to recovery  from acute symp-toms of acute vestibular neuritis” for phase III trials and to demonstrate faster recovery after betahistine treatment than after placebo. (Key secondary objective)  <br/>To analyze whether superiority of betahistine treatment is kept up to the end of treatment. To quantitatively describe/compare recovery over time vs. placebo and to determine optimal treatment duration. To shed light on the underlying mechanisms (i. e., peripheral vs. central compensation). To check for the occurrence of the adverse effects reported in the summary of the medical product characteristics (SmPC) of the drug. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005039";"2019-03-04T12:53:50.480+01:00";
"DRKS00005346";2013/10/04;"[---]*";yes;"Approved";"S-145/2013";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";"Universal Trial Number (UTN)";"U1111-1148-6198";"[---]*";;;;;;;;;;;;;"Other";"[---]*";"F20.- schizophrenia";;;;;;;;;;;;;"Arm 1";"motor-cognitive therapy , a manualized combination of cognitive elements combined with kinesitherapy and physical training as well as psychoeducation over 18 treatment sessions provided in 3 sessions per week (50 min.) with a minimun overall duration of 6 weeks";"Arm 2";"standard kinesitherapy over 18 treatment sessions provided in 3 sessions per week (50 min.) with a minimun overall duration of 6 weeks";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"-negative symptoms of schizophrenia (PANSS)<br/>-social functioning (GAF und SOFS Rating)<br/><br/>after 18 treatment sessions compared to baseline assessment prior to intervention";"-positive symptoms of schizophrenia (PANSS).<br/>-executive functioning (Tower-Test, Labyrinth-Test, Corsi Block-Test).<br/>- ability to recognize the intentions of others („Theory of Mind“, TOM-task, Schnell et al. 2011).<br/>after 18 treatment sessions compared to baseline assessment prior to intervention";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Universitätsklinikum Heidelberg Klinik für Allgemeine Psychiatrie";"Heidelberg";"Medical Center";"Zentrum für Psychiatrie Nordbaden";"Wiesloch";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/10/07;"Actual";"128";2016/04/01;"Multicenter trial";"National";"Both, male and female";"18";"Years";"55";"Years";"patients with a schizophrenia spectrum psychosis (DSM-IV 295.xx, ICD-10 F20.x) aged between 18 and 55 years, capable to give consent ";"other disorders due to brain disease, damage and dysfunction, major depressive episode,<br/>mental retardation, other chronic mental disorders, current substance abuse, serious medical conditions impairing physical exercise (e.g. angina pectoris, COPD)";"Primary Sponsor";"Klinik für Allgemeine PsychiatrieUniversitätsklinikum Heidelberg";"Mr.";"PD Dr. med.";"Knut";"Schnell";"Vossstr.2";"69115";"Heidelberg";"Germany";"062215637804";"06221565998";"knut.schnell@med.uni-heidelberg.de";"http://www.klinikum.uni-heidelberg.de/Klinik-fuer-Allgemeine-Psychiatrie.8791.0.html";"Contact for Scientific Queries";"Universitätsklinikum Heidelberg, Allgemeine Psychiatrie";"Ms.";"Dipl.-Psych.";"Kirsten";"Guba";"Voßstraße 2";"69115";"Heidelberg";"Germany";"06221 5636528";"[---]*";"kirsten.guba@med.uni-heidelberg.de";"[---]*";"Contact for Public Queries";"Universitätsklinikum HeidelbergAllgemeine Psychiatrie";"Ms.";"Dipl.-Psych.";"Kirsten";"Guba";"Voßstraße 2";"69115";"Heidelberg";"Germany";"06221 5636528";"[---]*";"kirsten.guba@med.uni-heidelberg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"Dietmar Hopp Stiftung gGmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Raiffeisenstraße 51";"68789";"St. Leon-Rot";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Integration by movement - a motor-cognitive therapy for patients with psychotic disorders";"[---]*";"[---]*";"The objective of the study is to evaluate the efficacy of a new specific, manualized combination of psychotherapy and kinesitherapy for group-therapy applied in the early treatment of patients with schizophrenic psychosis. Being integrated into the regular treatment the program consists of a combination of cognitive elements combined with kinesitherapy and physical training as well as psychoeducation of proven effectiveness for every single element. The aim of the study is to test, whether the new treatment will effect in a greater improvement of social functioning and greater reduction of negative symptoms of schizophrenia compared to common unspecific kinesitherapy as usual.";"The objective of this randomized, observer blinded, prospective bicentric study is to evaluate the efficacy of a new specific, manualized combination of psychotherapy and kinesitherapy for group-therapy applied in the early treatment of patients with schizophrenic psychosis. Being integrated into the regular treatment the program consists of a combination of cognitive elements combined with kinesitherapy and physical training as well as psychoeducation of proven effectiveness for every single element. The planned sample comprises 128 Patients with a schizophrenia spectrum psychosis (DSM-IV 295.xx, ICD-10 F20.x) aged between 18 and 55 years currently treated in one of two Psychiatric Departments (Klinik für Allgemeine Psychiatrie Heidelberg and Psychiatrisches Zentrum Nordbaden). The sample will be stratified for dose of antipsychotics at the time of allocation to the trial. After 18 treatment sessions (50 min.) we will test by group comparison to the common unspecific kinesitherapy as usual (n=64) , if the new treatment (n=64) will result in:<br/>Primary Hypotheses: <br/>-greater improvement of social functioning (GAF und SOFS Rating)<br/>-greater reduction of negative symptoms of schizophrenia (PANSS)<br/>Secondary Hypotheses:	<br/>-greater reduction of positive symptoms of schizophrenia (PANSS).<br/>-greater improvement of executive functioning (Tower-Test, Labyrinth-Test, Corsi Block-Test).<br/>- greater improvement in recognizing the intentions of others („Theory of Mind“, TOM-task, Schnell et al. 2011).<br/>Exploratory Analysis:<br/>- Is there a correlation between changes of executive functions, mentalising (tToM) capabilities, psychosocial functioning and quality of life?<br/> - What is the correlation between the extent of positive- and negative symptoms and therapy-effects on social-cognitive and executive functions?<br/>- What is the relation between positive and negative symptoms with attributional style (bias) und jumping to conclusions?<br/>- has the new treatment a greater effect on attributional style (bias) and jumping to conclusions?<br/>- Which domains of social functions will be changed by the treatment?<br/>";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005346";"2016-06-16T10:46:00.783+02:00";
"DRKS00008009";2015/04/13;"[---]*";yes;"Approved";"46-15";"Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München";;;;;;;;;;;;;;;;"ICD10";"F32";"Depressive episode";"ICD10";"F33";"Recurrent depressive disorder";;;;;;;;;;"Arm 1";"open label: Treatment with citalopram/escitalopram in standard dosage, additionnally 20 treatments with transcranial direct current stimulation of the left dorsolateral prefrontal cortex in 10 days (2mA, 2x30 min/day).";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"No";"Primary endpoint is with completion of 20th tDCS, 10 working days after begin of the study. First measurement (baseline) takes place before first stimulation at day 0 with assessment of HAMD. Second measurement (final measurement) takes place after completion of the 20th stimulation with the assessment of the percentual reduction of depression severtiy in the Hamilton Depression Rating Scale (HAMD)";"Feasability and tolerability of 20 stimulations with the Comfort Rating Questionnaire (CRQ) immediatey after completion of tDCS (20th stimulation, day 10).";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Ludwig-Maximilians-Universität, Psychiatrische Klinik";"München";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/04/10;"Actual";"100";2018/03/01;"Monocenter trial";"National";"Both, male and female";"18";"Years";"75";"Years";"depressive syndrome, independent from diagnosis. HAMD>8. informed consent.";"gravidity. other severe psychiatric disorder, substance abuse, acute suicidality. brain/skull trauma. Severe neurologic or somatic disease, epilepsy. metal implants in head/neck. Cancer. Intolerability or former loss of efficacy of citalopram/escitlopram.";"Primary Sponsor";"Psychiatrische Klinik";"Mr.";"Dr.";"Ulrich";"Palm";"Nußbaumstr. 7";"80336";"München";"Germany";"089/4400-55881";"[---]*";"ulrich.palm@med.uni-muenchen.de";"http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Psychiatrie-und-Psychotherapie/de/forschung/tms/schwerpunkte/tdcs.html";"Contact for Scientific Queries";"Psychiatrische Klinik";"Mr.";"Dr.";"Ulrich";"Palm";"Nußbaumstr. 7";"80336";"München";"Germany";"089/4400-55881";"[---]*";"ulrich.palm@med.uni-muenchen.de";"http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Psychiatrie-und-Psychotherapie/de/forschung/tms/schwerpunkte/tdcs.html";"Contact for Public Queries";"Psychiatrische Klinik";"Mr.";"Dr.";"Ulrich";"Palm";"Nußbaumstr. 7";"80336";"München";"Germany";"089/4400-55881";"[---]*";"ulrich.palm@med.uni-muenchen.de";"http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Psychiatrie-und-Psychotherapie/de/forschung/tms/schwerpunkte/tdcs.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Psychiatrische Klinik";"Mr.";"Dr.";"Ulrich";"Palm";"Nußbaumstr. 7";"80336";"München";"Germany";"089/4400-55881";"[---]*";"ulrich.palm@med.uni-muenchen.de";"http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Psychiatrie-und-Psychotherapie/de/forschung/tms/schwerpunkte/tdcs.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Antidepressant and additional transcranial electrial cortex stimulation";"AzteK";"[---]*";"Treatment of depressive disorders with standardized antidepressant medication (citalopram, escitalopram) and transcranial direct current stimulation during a two-week inpatient stay. Transcranial direct current stimulation modulates brain activity and stimulates hypoactive brain regions. Antidepressant medication and brain stimulation are supposed to provoke synergistic effects to improve depressive symptoms rapidly and efficiently.";"Anodal transcranial direct current stimulation has shown efficacy in several studies als an add-on treatment to antidepressant medication. In this open-label study, a two-week short intervention program will be evaluated and implemented with standard antidepressant medication and intensive transcranial direct current stimulation of the left dorsolateral prefrontal cortex (2mA, 2x30 min/day).";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"https://www.ncbi.nlm.nih.gov/pubmed/30314900";"Treatment of major depression with a two-step tDCS protocol add-on to SSRI: Results from a naturalistic study";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008009";"2018-10-26T09:03:48.589+02:00";
"DRKS00011023";2016/09/02;"[---]*";yes;"Approved";"4897-08/16";"Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2016-002388-33";"[---]*";;;;;;;;;;;;;"ICD10";"B99";"Other and unspecified infectious diseases";;;;;;;;;;;;;"Arm 1";"Therapeutic drug monitoring of piperacillin in patients with fever during neutropenia following myelosuppressive cytostatic chemotherapy. Upon randomization piperacillin/tazobactam (4.0/0.5 g) is injected as a bolus over 15-30 min. Four hours after administration piperacillin plasma level will be measured and the dose adjusted, as follows:<br/># Pip plasma level >64 mg/l -- Pip/Taz dosage 3x 4.0/0.5 daily<br/># Pip plasma level 48-63 mg/l -- Pip/Taz dosage 4x 4.0/0.5 daily<br/>Pip plasma level <48 mg/l -- Pip/Taz dosage 3x 8.0/1.0 daily. Dose adjustment will be made during the first 3 days of drug administration; thereafter therapy will continue with the last adjusted dose.";"Arm 2";"Patients with fever during neutropenia following myelosuppressive cytostatic chemotherapy. Upon randomization piperacillin/tazobactam (4.0/0.5 g) is injected as a bolus over 15-30 min. No Therapeutic drug monitoring will be conducted in the course of treatment.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"IV";"No";"Persistent afebrility (yes/no), defined as absence of fever over 5 consecutive days without changes of the antimicrobial therapy. The proportions of afebrile patients in the groups with and without therapeutic drug monitoring will be compared.";"•Mortality over 30 days<br/>•Infection-related mortality over 30 days<br/>•Duration and cumulative dose of antibiotic therapy<br/>•Number of dose adjustments per treatment cycle<br/>•Duration of combined therapy with anti-infectious agents<br/>•Number of in-hospital antibiotic-free days<br/>•Necessity of ICU treatment<br/>•Duration of in-hospital sojourn <br/>•Cost of antibiotic treatment<br/>•Pharmakokinetics (PK) / Pharmakodynamics (PD) - Indices (e.g. antibiotic concentration >4x MIC 100% )<br/>•Number of antibiotic-free days during neutropenia phase<br/>•Infection successfully treated<br/>•Progression to SIRS/Sepsis <br/>•Occurrence of antibiotic-resistant pathogens<br/>•Rate of super-infection with a different pathogen<br/>•Safety (untoward effects)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Universitätsklinikum Jena, Klinik für Innere Medizin II";"Jena";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/10/19;"Actual";"208";2018/06/06;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"•Fever (defined as 1 episode >38,3°C or 2 episodes >38,0°C within 2 hours) in neutropenia (defined as WBC < 1 Gpt/l or neutrophile granulocytes <0,5Gpt/l) following myelosuppressive chemotherapy<br/>•imminent or ongoing therapy with Piperacillin/Tazobactam (Pip/Taz)<br/>•signed informed consent<br/>";"•Age < 18 years <br/>•Pregnancy/Breastfeeding<br/>•Women at prolific age without dependable contraception <br/>•Patients unable to consent<br/>•Medical history-documented hypersensitivity toward beta-lactam antibiotics or components of the study drug formulation (Pip/Taz)<br/>•Treatment with Pip/Taz at daily dose >18g within the last 24 hours before randomization<br/>•Participation in another interventional clinical trial<br/>•Prior participation in the current trial (TARGET-FN)<br/>•Impaired liver function (Child-Pugh C)<br/>•Renal failure (eGFR <40ml/min)<br/>•Infectious condition that requires a defined different antibiotic therapy (e.g. endocarditis)<br/>•Life expectancy < 90 days<br/>";"Primary Sponsor";"Universitätsklinikum Jena";"[---]*";"[---]*";"[---]*";"[---]*";"Bachstraße 18";"07740";"Jena";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinikum-jena.de";"Contact for Scientific Queries";"Universitätsklinikum Jena,Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkologie";"Ms.";"Prof. Dr. med.";"Marie";"von Lilienfeld-Toal";"Am Klinikum 1";"07747";"Jena";"Germany";"+4936419324210";"+4936419324657";"marie.von_lilienfeld-toal@med.uni-jena.de";"www.uniklinikum-jena.de";"Contact for Public Queries";"Universitätsklinikum Jena,Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkologie";"Ms.";"Prof. Dr. med.";"Marie";"von Lilienfeld-Toal";"Am Klinikum 1";"07747";"Jena";"Germany";"+4936419324210";"+4936419324657";"marie.von_lilienfeld-toal@med.uni-jena.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung - Dienstsitz Berlin";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"10117";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Therapeutic drug Monitoring (TDM) of piperacillin in patients with fever in neutropenia in the course of myelosuppressive cytostatic chemotherapy";"TARGET-FN<br/><br/>";"[---]*";"Bone-marrow-suppressing chemotherapy in cancer patients results in strongly decreased leukocyte production and enhanced vulnerability to infections. Infections are the predominant cause of treatment-associated mortality in cancer patients receiving chemotherapy. Fever becomes manifest in some 80% of such patients during the phase of bone marrow suppression; in most cases it is considered a sign of systemic infection. Timely administration of broad spectrum antibiotics, especially the combination piperacillin/tazobactam, is recommended and leads in ca. 50% of the cases in stable fever reduction. Non-responsiveness to this therapy can be ascribed in the majority of the patients to sub-optimal antibiotic dosage; this assumption has been confirmed in an own pilot study. However, there are certain concerns of simply increasing the dose of the antibiotic, based on recent evidence pertaining to its untoward effects. Also in view of the unknown nature of the causal pathogen at the time of introduction of the therapy, it appears plausible to use a tailored approach  consisting in continuous optimization of the drug dose, thus achieving plasma levels of the drug that are sufficient to suppress symptoms of infection. Dose adjustment will be conducted during the first 3 days upon introduction of antibiotic therapy under consideration of plasma drug levels measured 4 hours following administration.";"In ca. 80% of the patients undergoing myelosuppressive chemotherapy fever during the phase of neutropenia is considered a typical sign of systemic infection. Infections are the predominant cause of treatment-associated mortality in cancer patients. Besides secondarily increasing mortality, fever during neutropenia is associated with significant increase of in-hospital treatment duration and cost. In the first instance, for the attending physician fever may serve as the only sign of an imminent life-threatening infection. Thus, in view of the present immunosuppression in patients with neutropenia, early introduction of empirical treatment with broad-spectrum antibiotics is indicated. One of the most frequently used combinations is piperacillin/tazobactam (Pip/Taz); however, its use results in stable afebrility in only 50% of the patients. Sub-therapeutic drug plasma levels are considered a possible cause for non-responsiveness to this treatment; this assumption was confirmed in own studies with ICU patients. These data support the view that insufficient dosage might be a cause for the failure of empirical antibacterial therapy with Pip/Taz. While dose escalation appears plausible with regard of the side-effect profile of the drug, recent data indicate that it exerts suppressive effects on the innate immune responsiveness and, thus, might further enhance the susceptibility to secondary infections. Therapeutic drug monitoring (TDM) has a proven record as an individualized method in drug therapy, especially in drugs with a narrow therapeutic index. This approach has been barely examined with regard to penicillins. The antimicrobial effects of beta-lactam-antibiotics are time-dependent; thus, it is recommended to maintain plasma levels above the minimal inhibitory concentration (MIC) over at least 50% of the time interval between successive doses. Lack of knowledge about the causal pathogen at the time of introduction of the therapy also urges to consider achievement of such doses that warrant maintenance of MIC for the most dangerous putative pathogen. Dose optimization by means of individual dosage algorithms based on intermittent drug plasma level determinations are feasible and can be elaborated with a few blood samples. Further benefits of this approach and intended pathogen immunophenotyping consist in avoidance of beta-lactam antibiotic overdosage and further immune system suppression with resultant increased infection vulnerability. Using a multivariate model based on fever recording during neutropenia will minimize time-dependent bias. Finally, the cost effectiveness of TDM-based Pip/Taz dosage will be examined. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011023";"2018-10-11T10:58:03.314+02:00";
"DRKS00012330";2017/04/13;"[---]*";no;"Approved";"EA1/027/17";"Ethik-Kommission der Charité -Universitätsmedizin Berlin-";"Sponsor-ID";"CEF/022616";"Cefak-Nr.";;;;;;;;;;;;;"Free text";"[---]*";"increased blood glucose/HbA1c/oGTT-levels";;;;;;;;;;;;;"Arm 1";"investigational product PDM022616; Food Supplement; ingredients: plant extract, Mineral, trace element; 3x1 capsule per day with meals for 16 weeks; prediabetic persons";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Prevention";"Single (group)";"N/A";"N/A";"blood sample: HbA1c at all visits, lab analysis";"blood sample: blood Glucose, oGTT, Insulin - all visits, lab Analysis; crp - begin and end, lab Analysis.<br/>Further parameter: Body weight, waist circumference, blood pressure.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"other";"Studienzentrum";"Berlin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/04/26;"Actual";"35";2017/11/17;"Monocenter trial";"National";"Both, male and female";"30";"Years";"65";"Years";"- BMI 25-34.9 kg/m2<br/>- HbA1c 5.7-6.4% (39-47 mmol/mol) at V1 <br/>- Subject’s agreement to comply with study procedures<br/>- Stable concomitant medications (if any) for at least last 3 months prior to V1 <br/>and during the study<br/>- Stable body weight (≤3 kg difference) for the last 3 months prior to V1<br/>- Regular intake of three main meals (breakfast, lunch and dinner)<br/>- Women of childbearing potential: <br/>a. negative pregnancy testing (beta human chorionic gonadotropin test in <br/>urine) at V1<br/>b. commitment to use contraception methods during the study";"1.  Known sensitivity to the components of the investigational product<br/>2.  Pathological electrocardiogram (ECG)<br/>3.  Psychotic disorders within the last 6 months prior to V1<br/>4.  History and/or presence of clinically significant disease, which per investigator's judgement  could  interfere  with  the  results  of  the  study  or  the  safety  of  the subject, e.g.:<br/>a.  eating disorders such as anorexia<br/>b.  untreated or non-stabilized thyroid disorder<br/>c.  untreated or non-stabilized hypertension  <br/>d.  significant gastrointestinal diseases  <br/>e.  spleen disorder<br/>f.  known severe acute or chronic immunological disorders such as AIDS (or HIV positive)<br/>g.  severe acute or chronic infection<br/>h.  any  other  known  significant  or  serious  condition/disease  that  renders subjects ineligible (e.g. history of malignancy within the past 5 years prior to V1, any clinically significant cardiovascular, renal, liver, lung disease <br/>etc.)<br/>5.  Clinical symptoms of diabetes type 2<br/>6.  Suspected diabetes type 1<br/>7.  Known congenital disorders of glycosylation<br/>8.  Known polycystic ovarian syndrome (female subjects)<br/>9.  Use of drugs/supplements which could interfere with the results of the study as per investigator's judgement (e.g. anti-diabetic therapy, products for reduction of blood glucose levels, products with a possible impact on glycemic control) within the last month prior to V1 and during the study<br/>10. Blood transfusion within the last 12 weeks before V1<br/>11. Blood donation within the last 6 month before V1<br/>12. Previously known hemoglobinopathy (HbS, HbC, HbD, HbH, HbF or HbE)<br/>13. Anemia (Hb ≤11 g/dL)<br/>14. Recent change in diet and lifestyle (within the last 4 weeks prior to V1)<br/>15. Deviation of safety laboratory parameter(s) at V1 (except for Hb and HbA1c) that is: <br/>a.  clinically significant or<br/>b.  >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)<br/>16. History of or current abuse of drugs, alcohol or medication in the last 6 months prior to V1<br/>17. Participation in another study during the last 30 days prior to V1 and during the study<br/>18. Women of child-bearing potential: pregnant or breast-feeding<br/>18. Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures   ";"Primary Sponsor";"Cefak KG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"87437";"Kempten";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"analyze&realize GmbH";"Mr.";"Prof. Dr.";"Ralf";"Uebelhack";"Weißenseerweg 111";"10369";"Berlin";"Germany";"030-40008123";"030-40008501";"ruebelhack@analyze-realize.com";"[---]*";"Contact for Public Queries";"analyze&realize GmbH";"Mr.";"Prof. Dr. ";"Ralf";"Uebelhack";"Weißenseerweg 111";"10369";"Berlin";"Germany";"030-40008123";"030-40008501";"ruebelhack@analyze-realize.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Cefak KG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"87437";"Kempten";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Pilot study to evaluate the benefit and tolerability of PDM022616 on blood glucose levels in subjects with prediabetes";"CEF/022616";"[---]*";"Pilot study to evaluate the benefit and tolerability of the Food Supplement PDM022616 on blood glucose levels in subjects with prediabetes within 16 weeks";"Single-arm, monocentric pilot study to evaluate the benefit and tolerability of the Food Supplement PDM022616 on blood glucose levels in subjects with prediabetes within 16 weeks";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012330";"2019-07-25T08:11:44.483+02:00";
"DRKS00010537";2016/06/15;"[---]*";yes;"Approved";"23038/2016/11";"Ethikkommission der Landesärztekammer Thüringen";;;;;;;;;;;;;;;;"ICD10";"M16.1";"Other primary coxarthrosis";;;;;;;;;;;;;"Arm 1";"With this study are being researched the characteristics of the ""optimys"" hip stem and the RM pressfit cup. The study is expected to take 2 years. <br/>Target of the study is to capture and follow up 50 patients in the orthopedic clinic ""Marienstift"" in Arnstadt to check the safety and effectiveness of a hip prosthesis. <br/> ";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"N/A";"Target of the study is to capture and follow up 50 patients in the orthopedic clinic ""Marienstift"" in Arnstadt to check the safety and effectiveness of a hip prosthesis.<br/>Follow up after 3, 6 and 18 month using the Harris HIP Score und the WOMAC.";"Measurement sintering of the stem using Single image X-ray Analysis (EBRA)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Marienstift Arnstadt, Fachklinik für Orthopädie";"Arnstadt";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/03/01;"Actual";"50";2019/01/24;"Monocenter trial";"National";"Both, male and female";"18";"Years";"99";"Years";"All patients with a primaryhip osteoarthritis , who receive a hip arthroplastic using the optimys hip stem and the RM pressfit cup.<br/>The patients have to be treatet in the ""I.V. program"" of the health insurance.<br/>";"no ""I.V.-Treatment"" of the health insurance<br/>";"Primary Sponsor";"Orthopädische FachklinikMarienstift Arnstadt";"Mr.";"Dr. med.";"Heiko";"Spank";"Wachsenburgallee 12";"99310";"Arnstadt";"Germany";"+ 49 (0) 3628 720151";"+ 49 (0) 3628 720153";"boerner@ms-arn.de";"http://www.marienstift-arnstadt.de/";"Contact for Scientific Queries";"Mathys Orthoädie GmbH";"Ms.";"[---]*";"Natividad";"Zeleny";"Seilfahrt 99";"44809";"Bochum";"Germany";"+49 (0)1705722702";"+ 49 (0) 58859100";"natividad.zeleny@mathysmedical.com";"www.mathysmedical.com";"Contact for Public Queries";"Mathys Orthopädie GmbH";"Ms.";"[---]*";"Natividad";"Zeleny";"Seilfahrt 99";"44809";"Bochum";"Germany";"+49 (0)1705722702";"+49 (0) 55859100";"natividad.zeleny@mathysmedical.com";"www.mathysmedical.com";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Mathys Orthopädie GmbH";"Mr.";"[---]*";"Norbert";"Reichel";"Seilfarth 99";"44808";"Bochum";"Germany";"023458859500";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"clinical study with the optimys hipstem and the RM pressfit cup";"[---]*";"[---]*";"Prospective clinical and radiographic follow-up after Implantation of the optimys hip stem and the RM pressfit Cup. Follow up after 3, 6 and 18 month using the Harris HIP Score and the WOMAC.<br/>Target of the study is to capture and follow up 50 patients in the orthopedic clinic ""Marienstift"" in Arnstadt to check the safety and effectiveness of a hip prosthesis.<br/>Follow up after 3, 6 and 18 month using the Harris HIP Score und the WOMAC.";"Prospective clinical and radiographic follow-up after Implantation of the optimys hip stem and the RM pressfit Cup. Follow up after 3, 6 and 18 month using the Harris HIP Score and the WOMAC.<br/>Measurement sintering of the stem using Single image X-ray Analysis (EBRA)";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010537";"2019-05-20T11:00:22.697+02:00";
"DRKS00000598";2010/11/23;"[---]*";yes;"Approved";"168/10";"Ethik-Kommission der Medizinischen Fakultät der Universität Würzburg";"Universal Trial Number (UTN)";"U1111-1117-5671";"[---]*";;;;;;;;;;;;;"Free text";"[---]*";"estradiol homeostasis and associated effects in breast tissue";;;;;;;;;;;;;"Arm 1";"Supplement: commercially avialable isoflavone-rich soy extract (Novasoy)<br/>Dose: 1 - 1,3 mg isoflavone (genistein +<br/>daidzein, aglyca + glycoside)/kg body weight/day.<br/>Application: Prior to surgery once daily as capsule at diner for seven consecutive days.<br/>";"Arm 2";"Placebo: mannitol<br/>Dose: 1 - 1,3 mg mannitol/kg body weight/day.<br/>Application: Prior to surgery once daily as capsule at diner for seven consecutive days.<br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Basic research/physiological study";"Parallel";"[---]*";"[---]*";"Endpoint: biotransformation of estradiol and isoflavonen in the mammary gland.<br/>Time point: 1 day after last application. <br/>Method: GC- and LC/MS/MS.";"Endpoints: cellular response zu altered estradiol biotransformation (genotoxicity, cell proliferation and differentiation in the mammary gland).<br/>Time point: 1 day after the las application.<br/>Method: real-time PCR, immunohistology.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Doctor's Practice";"[---]*";"Würzburg und Umgebung";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/10/01;"Actual";"100";2018/05/25;"Monocenter trial";"National";"Female";"18";"Years";"[---]*";"no maximum age";"cosmetically motivated breast reduction surgery";"Pathological changes in the breast tissue, family history of breast cancer, soy allergy";"Primary Sponsor";"Lehrstuhl für Lebensmittelchemie, <br/>Institut für Pharmazie und Lebensmittelchemie,  Universität Würzburg";"Ms.";"Prof. Dr.";"Leane";"Lehmann";"Am Hubland";"97074";"Würzburg";"Germany";"+49 (931) 31-85481";"+49 (931) 31-85484";"leane.lehmann@uni-wuerzburg.de";"http://www.lmc.chemie.uni-wuerzburg.de/";"Contact for Scientific Queries";"Lehrstuhl für Lebensmittelchemie, <br/>Institut für Pharmazie und Lebensmittelchemie, <br/>Universität Würzburg";"Ms.";"Prof. Dr.";"Leane";"Lehmann";"Am Hubland";"97074";"Würzburg";"Germany";"+49 (931) 31-85481";"+49 (931) 31-85484";"leane.lehmann@uni-wuerzburg.de";"http://www.lmc.chemie.uni-wuerzburg.de/";"Contact for Public Queries";"Universitätsklinikum WürzburgChirurgie II";"Ms.";"Dr.";"Iva";"Neskova";"Oberdürrbacher Str. 6";"97080";"Würzburg";"Germany";"0931-20137028";"[---]*";"neshkova_i@ukw.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"53170";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Impact of tissue specific isoflavone profiles on the formation, activation, and action of 17β-estradiol in the female mammary gland";"[---]*";"[---]*";"Soy isoflavones could impact cellular processes involved in the formation of breast cancer. However, up to now there is only little scientific insight about the underlying molecular mechanisms in the human mammary gland. Women of full age, undergoing cosmetic breast reduction surgery receive daily isoflavone rich soy extracts or placebo for seven consecutive days prior to surgery. The mammary gland tissue will be examined for tissue levels of isoflavones and estrogens as well as markers for cellular response to isoflavone exposure.";"Soy isoflavones could impact cellular processes involved in the formation of breast cancer. However, up to now there is only little scientific insight about the underlying molecular mechanisms in the human mammary gland. The female sex hormone 17beta-estradiol is essential for the formation of breast cancer: it regulates cell proliferation and differentiation and is precursor for mutagenic quinones.  This internvention study will investigate to what extent soy isoflavones affect processes accounting for breast tumor formation.<br/>Women of full age, undergoing cosmetic breast reduction surgery receive daily isoflavone rich soy extracts or placebo for seven consecutive days prior to surgery. The mammary gland tissue will be examined for tissue levels of isoflavones and estrogens and their biotransformation products as well as markers for genotoxic stress, cell proliferation and differentiation.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000598";"2020-01-31T06:29:44.630+01:00";
"DRKS00005183";2013/08/02;"[---]*";no;"Approved";"EK-BR-37/13-1";"Ethikkommission bei der Sächsischen Landesärztekammer";;;;;;;;;;;;;;;;"ICD10";"K58";"Irritable bowel syndrome";;;;;;;;;;;;;"Arm 1";"Verum (natural humic acid - Activomin®): intake of capsules orally (400mg per capsule) over 28 days (day 1-10: 3x2 capsules daily, day 11-28: 3x1 capsule daily)";"Arm 2";"placebo (rice flour colored with sepia): intake of capsules orally over 28 days (day 1-10: 3x2 capsules daily, day 11-28: 3x1 capsule daily)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"N/A";"N/A";"Change of IBS-Scores (Irritable Bowel Syndrome-Score, Francis 1997) and therefore the improvement of the subject state while having gastrointestinal dysfunctions on day 28 compared to day 0 (Baseline)";"Safety:<br/>- adverse events <br/>- rescue medication according to patient diary<br/>- number of patients with premature termination of the trial<br/>efficacy: before and after comparison (day 0 and day 28) for<br/>- Bristol Stool Form Scale <br/>- IBS-QOL for documentation of quality of life<br/>- Quality of life (SF-36)<br/>- further explorative endpoints<br/> ";"DE";"Germany";"AT";"Austria";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Doctor's Practice";"[---]*";"Leipzig";"Doctor's Practice";"[---]*";"Dresden";"Doctor's Practice";"[---]*";"Wien";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/01/10;"Actual";"78";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"• irritable bowel syndrome - diarrhea-predominant  (RDS-D) --> according to ROM III criteria (diarrhea / pain)<br/>• male and female patients ≥ 18 years<br/>• patients, who are willing and able to realise the study visits (e.g. no planned holidays)<br/>• patients, who are willing and able to complete the patient diary<br/>• last to weeks (screening phase) at least two times complaints (pain, discomfort) per week <br/>• willing to forgo medications of the forbidden medication list<br/>• Written informed consent";"• irritable bowel syndrome -  obstipation-predominant  (RDS-O) <br/>• diagnosed, inflammatory bowel disease, as Morbus Crohn, Colitis ulcerosa, chronic inflammatory bowel disease<br/>•  clinical reference to colon cancer (colonoscopy without pathological findings from the last 5 years for patient > 55 years)<br/>• clinical reference to an acute infection<br/>• history of known chronic gastritis or inflammatory bowel diseases<br/>• history of known coeliac<br/>• history of known lactose intolerance <br/>• patients with serious diseases in connection with vital medications<br/>• naturopathic measures regarding irritable bowel syndrome during the last 6 months before screening<br/>• current regular intake of medications influencing motility  <br/>• addiction<br/>• history of known hypersensitivity compared to the substances / medical product <br/>• participation in other interventional trials during the last 4 weeks before screening<br/>• knowing pregnancy";"Primary Sponsor";"WH Pharmawerk Weinböhla GmbH";"Mr.";"Dr.";"Svent";"Haufe";"Poststr. 58";"01689";"Weinböhla";"Germany";"035243 – 387-0";"035243 – 387-28";"kontakt@pharmawerk-weinboehla.de";"[---]*";"Contact for Scientific Queries";"WH Pharmawerk Weinböhla GmbH";"Mr.";"Dr.";"Svent";"Haufe";"Poststr. 58";"01689";"Weinböhla";"Germany";"035243 – 387-0";"035243 – 387-28";"kontakt@pharmawerk-weinboehla.de";"[---]*";"Contact for Public Queries";"Gastroenterologie und Hepatologie <br/>am Johannisplatz<br/>Dres. Kuchta, Wegner & Prof. Schiefke";"Mr.";"Prof. Dr.";"Ingolf";"Schiefke";"Johannisplatz 1";"04103";"Leipzig";"Germany";"0341/ 9112471";"0341/ 9117940";"schiefke@gastropraxis-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"WH Pharmawerk Weinböhla GmbH";"Mr.";"Dr.";"Svent";"Haufe";"Poststr. 58";"01689";"Weinböhla";"Germany";"035243 – 387-0";"035243 – 387-28";"kontakt@pharmawerk-weinboehla.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"irritable bowel syndrome – improvement to the clinical situation by the use of humic acid";"WH67® - irritable bowel syndrome";"[---]*";"The humic acid WH67®, broken down from lignite, will be used as medical device in a cellulose capsule. Because of its high molecular structure this capsule remains almost completely after administration in the gastrointestinal tract. The humic acids bond in the intestinal tract for example noxious substances which are egested again via the gut. The clinical trial should prove the main effect of the medical device Activomin® - improvement of the subject state while having gastrointestinal dysfunctions - at the indication of irritable bowel syndrome. For this purpose patients with irritable bowel syndrome will be recruited into the clinical trial. After a 2 week break of medication intake they receive the medical device or placebo for 28 days. During the first 10 days the patients take 2 capsules three times a day. From day eleven to day twenty eight 1 capsule will be taken three times a day. The follow-up will be performed until day 56 after first intake of the medical device or respectively placebo. ";"The humic acid WH67®, broken down from lignite, will be used as medical device in a cellulose capsule. Because of its high molecular structure this capsule remains almost completely after administration in the gastrointestinal tract. The humic acids bond in the intestinal tract for example noxious substances which are egested again via the gut. The clinical trial should prove the main effect of the medical device Activomin® - improvement of the subject state while having gastrointestinal dysfunctions - at the indication of irritable bowel syndrome. It will be examined if there is an improvement of the IBS symptomatic by treatment with the medical product Activomin®. For this purpose patients with irritable bowel syndrome will be recruited into the clinical trial. After a 2 week break of medication intake they receive the medical device or placebo for 28 days. During the first 10 days the patients take 2 capsules three times a day. From day eleven to day twenty eight 1 capsule will be taken three times a day. The follow-up will be performed until day 56 after first intake of the medical device or respectively placebo. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005183";"2016-08-12T08:46:55.240+02:00";
"DRKS00004154";2013/01/21;2009/01/27;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-004338-26";"[---]*";"Primary Registry-ID";"NCT00831233";"ClinicalTrials.gov";"Sponsor-ID";"FE200486 CS28";"Ferring Pharmaceuticals";"Other Secondary-ID";"2008-004338-26";"[---]*";;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Degarelix";"Arm 2";"Drug: Goserelin";"Arm 3";"Drug: Bicalutamide";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12; time frame: After treatment of 12 weeks compared to Baseline; The IPSS is a tool commonly used to assess the severity of lower urinary tract symptoms (LUTS), and to monitor the progress of the disease once treatment has been initiated. The participant completes a questionnaire containing 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5. The total score is then classified according to the following scale: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.<br/>";"- Change From Baseline in Total IPSS at Weeks 4 and 8; time frame: After treatment of 4 and 8 weeks compared to Baseline; The IPSS is a tool commonly used to assess the severity of lower urinary tract symptoms (LUTS), and to monitor the progress of the disease once treatment has been initiated. The participant completes a questionnaire containing 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5. The total score is then classified according to the following scale: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.<br/>- Change From Baseline in Maximum Urine Flow (Qmax) at Each Visit; time frame: After treatment of 4, 8 and 12 weeks compared to Baseline; Uroflowmetry was used to quantify the maximum urine flow (Qmax; mL/sec)<br/>- Change From Baseline in Residual Volume (Vresidual) at Each Visit; time frame: After treatment of 4, 8 and 12 weeks compared to Baseline; Uroflowmetry was used to quantify the residual volume (Vresidual; mL)<br/>- Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12; time frame: After 12 weeks treatment compared to Baseline; TRUS is a method of measuring the size of the prostate.<br/>- Number of Participants With Testosterone <=0.5 Nanograms/Milliliter at Each Visit; time frame: After treatment of 4, 8 and 12 weeks compared to Baseline<br/>- Percentage Change From Baseline in Prostate-specific Antigen (PSA) Concentration at Each Visit; time frame: After treatment of 4, 8 and 12 weeks compared to Baseline<br/>- Change From Baseline in Quality of Life (QoL) Related to Urinary Symptoms at Each Visit; time frame: After treatment of 4, 8 and 12 weeks compared to Baseline; The IPSS questionnaire included an additional single question to assess the participant's QoL in relation to his urinary symptoms. The question was: 'If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?' The possible answers to this question ranged from 'delighted' (a score of '0') to 'terrible' (a score of '6'). The figures in the tables present the change (ie decrease) in IPSS QoL score, i.e. the bigger the decrease the better QoL.<br/>- Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight; time frame: Baseline to 12 weeks of treatment; This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value.<br/>- Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables; time frame: Baseline to 12 weeks of treatment; The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) levels of safety laboratory variables. Only the laboratory variables that had at least on participant with one abnormal value are presented, many more variables were included in the trial.<br/>";"DE";"Germany";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Facharztpraxis für Urologie";"Bamberg";"[---]*";"Gemeinschaftspraxis";"Borken";"[---]*";"Universitätsklinikum Dresden";"Dresden";"[---]*";"Euromed Clinic";"Fürth";"[---]*";"Urologische Gemeinschaftspraxis";"Hamburg";"[---]*";"Gemeinschaftspraxis";"Köln";"[---]*";"VITURO Gesellschaft für Klinische Studien";"Leipzig";"[---]*";"Klinikum Offenbach GmbH";"Offenbach";"[---]*";"Urologische Klinik Planegg";"Planegg";"[---]*";"Wuppertaler Gemeinschaftspraxis";"Wuppertal";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/04/30;"[---]*";"42";2010/07/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Patient has given written informed consent before any trial-related activity is<br/>             performed<br/><br/>          -  Has a confirmed prostate cancer in which this type of treatment is needed.<br/>";"-  Previous treatment for prostate cancer<br/><br/>          -  Previous trans-urethral resection of the prostate<br/><br/>          -  Current use of 5-alpha reductase inhibitor or α-adrenoceptor antagonist.<br/><br/>          -  Patients in need of external beam radiotherapy to be started at the same time as<br/>             hormone therapy<br/><br/>          -  Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT<br/>             interval over 450 msec., Torsades de Pointes or use of certain medications with<br/>             potential risk)<br/><br/>          -  History of severe untreated asthma, anaphylactic reactions, or severe urticaria<br/>             and/or angioedema.<br/><br/>          -  Hypersensitivity towards any component of the investigational product<br/><br/>          -  Other previous cancers within the last five years with the exception of prostate<br/>             cancer and some types of skin cancer.<br/><br/>          -  Clinical disorders other than prostate cancer including but not limited to renal,<br/>             haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric<br/>             disease, alcohol or drug abuse or other conditionals as judged by the investigator.<br/>";"Primary Sponsor";"Ferring Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Ferring Pharmaceuticals";"[---]*";"[---]*";"[---]*";"Clinical Development Support";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Ferring Pharmaceuticals";"[---]*";"[---]*";"[---]*";"Clinical Development Support";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer";"[---]*";"[---]*";"The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower<br/>      urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a<br/>      standard drug hormonal treatment worked on the same symptoms. The advancement/worsening of<br/>      prostate cancer may be associated with LUTS and the symptoms may impact the ability to<br/>      urinate normally and thereby the quality of life for these patients.<br/><br/>      Patients were randomly selected (like flipping a coin) to receive either degarelix or<br/>      standard hormone therapy (combination of goserelin and bicalutamide) for a 3 month treatment<br/>      period. During this period the relief of urinary symptoms was evaluated via a questionnaire<br/>      filled in by patients and addressing the severity and frequency of their symptoms.<br/>";"[---]*";"Recruiting stopped after recruiting started ";"Trial results";"[---]*";"[---]*";"Anderson J, Al-Ali G, Wirth M, Gual JB, Gomez Veiga F, Colli E, van der Meulen E, Persson BE. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013;90(3):321-8. doi: 10.1159/000345423. Epub 2012 Dec 15.; 23258223";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004154";"2016-01-26T16:18:35.109+01:00";
"DRKS00004038";2012/07/19;2007/12/18;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00578097";"ClinicalTrials.gov";"Sponsor-ID";"Y-79-52120-126";"Ipsen";;;;;;;;;;"Free text";"[---]*";"Overactive Bladder";"ICD10";"N32.8";"Other specified disorders of bladder";;;;;;;;;;"Arm 1";"Drug: Botulinum type A (Dysport®)";"Arm 2";"Other: Placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo|Other";"Treatment";"Parallel";"II";"[---]*";"- Number of episodes of urgency and frequency of micturition.; time frame: Week 12<br/>";"- The number of episodes of urgency, frequency of micturition, and frequency of nocturia.; time frame: All timepoints<br/>- Severity of urgency.; time frame: All timepoints<br/>- Maximum flow rate and post-micturition residual volume (PMRV).; time frame: Day 4 and Week 6<br/>- Standard International Continence Society (ICS) urodynamic parameters.; time frame: Week 12<br/>- Quality of Life (QoL).; time frame: All timepoints<br/>- Safety; time frame: All timepoints<br/>- Extension study - Duration of effect as determined by the persistence of a positive response.; time frame: All timepoints<br/>- Extension study - The number of episodes of urgency, frequency of micturition, and frequency of nocturia.; time frame: All timepoints<br/>- Extension study - Severity of urgency.; time frame: All timepoints<br/>- Extension study Quality of Life (QoL); time frame: All timepoints<br/>- Extension study safety.; time frame: All timepoints<br/>";"BE";"Belgium";"CZ";"Czech Republic";"FR";"France";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Medizinische Einrichtungen der RWTH";"Aachen";"[---]*";"Praxis für Urologie";"Bad Kreuznach";"[---]*";"Praxis für Urologie";"Emmendingen";"[---]*";"Praxis für Urologie";"Günzburg";"[---]*";"Praxis für Urologie";"Lahr";"[---]*";"Beckenboden Zentrum München";"München";"[---]*";"Städtisches Klinikum Neunkirchen gGmbH";"Neunkirchen";"[---]*";"Krankenhaus St. Trudpert";"Pforzheim";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/02/27;"[---]*";"81";2009/12/01;"Multicenter trial";"International";"Female";"18";"Years";"75";"Years";"-  The subject has a diagnosis of idiopathic overactive bladder, without incontinence.<br/><br/>          -  The subject has ≥ 3 urgency episodes over the course of the 3 days immediately<br/>             preceding the Baseline visit.<br/><br/>          -  The subject has ≥ 24 episodes of micturition over the course of the 3 days<br/>             immediately preceding the Baseline visit.<br/>";"-  Bladder outlet obstruction (on urodynamic assessment).<br/><br/>          -  Post-Micturition Residual Volume > 150 ml (ultrasound assessment).<br/><br/>          -  Evidence of a urinary tract infection at Screening or Baseline in the study.<br/><br/>          -  Active or history of interstitial cystitis, malignancy of the bladder or urothelial<br/>             tract, a carcinoma in situ (non malignant melanoma is allowed) bladder and/or kidney<br/>             stones.<br/>";"Primary Sponsor";"Ipsen";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Ipsen";"[---]*";"[---]*";"[---]*";"Benjamin Zakine, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Ipsen";"[---]*";"[---]*";"[---]*";"Benjamin Zakine, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase II, International, Multi-centre, Prospective, Randomised, Parallel-group, Double-blind, Dose-ranging, Placebo-controlled, 12-week, Study to Assess the Efficacy and Safety of a One Injection Cycle With Either Botulinum Toxin Type-A (Dysport® 125, 250 or 500 Units) or Placebo Followed by an Optional 6-month Extension Phase in the Symptomatic Treatment of Micturition Urgency and Frequency in Continent Female Subjects Suffering From Idiopathic Overactive Bladder.";"[---]*";"[---]*";"The purpose of this study is to determine the optimal dose of botulinum toxin type A<br/>      injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and<br/>      quality of life of continent women suffering from idiopathic overactive bladder.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004038";"2016-01-22T16:24:03.185+01:00";
"DRKS00005123";2013/07/02;2011/09/26;yes;"Approved";"2012-414M-MA";"Medizinische Ethik-Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg";"Primary Registry-ID";"NTR3080";"Netherlands Trial Register";;;;;;;;;;;;;"Free text";"[---]*";"Anastomotic Leakage after colorectal surgery";;;;;;;;;;;;;"Arm 1";"The Sponsor wants to enroll overall 616 patients in this study. Each group (Intervention group vs. Control group) should include 313 patients.<br/>Procedure: After the physician has decided to make an anastomosis during the surgery the patient will be randomized either to the intervention group (with C-Seal application) or to the control group (without C-Seal application).<br/>If the patient will be assigned to the intervention group the C-Seal will be used. It will be stapled to the anastomosis during the operation.<br/>After surgery and after the discharge of the hospital two follow-up visits will be conducted either by phone call or within a routine visit at the hospital.<br/><br/>";"Arm 2";"The operation within the control group will be conducted according the local standard but without the C-seal.<br/>In general, the overall study will be conducted without any additional visits or burden for the patients. All steps and procedures will be done due to the local requirements.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Treatment";"Parallel";"N/A";"N/A";"The primary outcome is the incidence of anastomotic leakage leading to invasive treatment within 30 days after the primary operation.";"Secondary Outcomes:<br/>- Number of dismantled anastomoses<br/>- Grade A, B or C Anastomotic Leakage<br/>- Interval between the primary operation and the diagnosis of Anastomotic Leakage<br/>- Pain Score at day 3 postoperatively on a visual analogue scale<br/>- Number of ostomies created<br/>- Late anastomotic leakage (diagnosed 30 days after the primary operation)<br/>- Number of ostomies present after one year<br/>- Total duration of hospital stay including readmissions for (serious) adverse events and/or stoma closure<br/>- Interval between the primary operation and the excretion of the C-Seal through the anus<br/>- Other complications";"DE";"Germany";"NL";"Netherlands";"AT";"Austria";"ES";"Spain";"IT";"Italy";"FR";"France";"UK";"United Kingdom";"PT";"Portugal";;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Visceral-, Transplantations- und Thoraxchirurgie";"Innsbruck";"Medical Center";"Klinikum rechts der Isar, TUM";"München";"University Medical Center";"Chirurgische Klinik";"Mannheim";"Medical Center";"Krankenhaus Nordwest Frankfurt";"Frankfurt a.M.";"University Medical Center";"Universitätsklinikum Hamburg Eppendorf";"Hamburg";"Medical Center";"Hop Beaujon";"Frankreich, Paris-Clichy";"Medical Center";"C.H.U. de Bordeaux/ St André";"Bordeaux";"Medical Center";"CHU Lille ";"Lille";"Medical Center";"Hopital Universitaire Hautepierre";"Strasbourg";"Medical Center";"C.H.U. de Toulouse-Rangueil";"Toulouse";"Medical Center";"S Andrea Hospital Sapienza Roma";"Rom";"Medical Center";"Molinette Hospital ";"Torino";"University Medical Center";"Instituto Portugese de Oncology";"Portugal, Porto";"Medical Center";"Hospital Clinico San Carlos, Madrid";"Spain, Madrid";"Medical Center";"Meander Medisch Centrum";"Netherlands, Amersfoort";"Medical Center";"AMC";"Netherlands, Amsterdam";"Medical Center";"Gelre Ziekenhuis";"Netherlands, Apeldoorn";"Medical Center";"Rijnstate";"Netherlands, Arnheim";"Medical Center";"Wilhelmina Ziekenhuis";"Netherlands, Assen";"Medical Center";"Amphia";"Netherlands, Breda";2011/10/15;"Actual";"616";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- The patient will receive a colorectal anastomosis by means of stapling<br/>- Elective surgery<br/>- Age: 18 or older<br/>- American Society of Anesthesiologist (ASA) classification 1,2 or 3<br/>- The patient did receive preoperative oral mechanical bowel preparation";"- There are clinical signs of peritonitis<br/>- The patient underwent major surgical or interventional procedures in the last 30 days prior to this study or surgical or interventional procedures are planned within 30 days of entry in this study<br/>- There are psychological, familial, sociological conditions which could hampering compliance with the study protocol or follow-up schedule<br/>- Patient is randomized in this trial before";"Primary Sponsor";"University Medical Center Groningen<br/>Department of Abdominal Surgery";"Mr.";"[---]*";"Klaas";"Havenga";"P.O. Box 30.001";"9700 RB";"Groningen";"Netherlands";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"University Medical Center Groningen<br/>Department of Abdominal Surgery";"Mr.";"[---]*";"Klaas";"Havenga";"P.O. Box 30.001";"9700 RB";"Groningen";"Netherlands";"+3150-3611505";"+3150-3614873";"K.havenga@umcg.nl";"[---]*";"Contact for Public Queries";"University Medical Center Groningen<br/>Department of Abdominal Surgery";"Ms.";"[---]*";"Ilsalien";"Bakker";"P.O. Box 30.001";"9700 RB";"Groningen";"Netherlands";"+316-31623612; +3150-3611505";"+3150-3614873";"i.s.bakker@umcg.nl";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"University Medical Center Groningen<br/>Department of Abdominal Surgery";"Ms.";"[---]*";"Ilsalien";"Bakker";"P.O. Box 30.001";"9700 RB";"Groningen";"Netherlands";"+316-31623612; +3150-3611505";"+3150-3614873";"i.s.bakker@umcg.nl";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Colorectal anastomosis protected by a biodegradable drain fixed to the anastomosis by a circular stapler: a randomised, controlled, multicenter trial.";"The C-Seal Study";"http://www.csealtrial.com/";"The main objective of this trial is to find out wether the use of a C-Seal leads to fewer suture leakages after surgery of the large intestine or rectum. <br/>Due to a medical problem with an intestine, part of the large intestine or rectum will need to be removed. Both ends will be sutured to create a functioning passage. This new connection is called an intestinal suture. One possible complication is leakage of this intestinal suture. The contents of the intestine will leak into the abdominal cavity. This can lead to peritonitis. The chance of leakage in intestinal sutures located close to the anus is approximately 10 %.<br/>In order to reduce the likelihood of leakage of an intestinal suture, a biodegradable drain (a kind of thin tube) with a thin wall has been developed - The C-Seal. This drain is placed over the intestinal suture in the intestine during surgery. The drain will decompose automatically, so it does not need to be removed.<br/>Before you undergo surgery, your doctor will discuss the procedure with you. The surgical procedure will be done in the usual way. Lots will be drawn to determine whether or not you will receive the C-Seal. <br/>In either case the connection between the large intestine and the rectum will be made using a surgical stapler. In patients who receive a C-Seal, the intestinal connection will be made and then C-Seal will be joined to the connection using those staples. After surgery, a small portion of the drain will protrude from your anus. As it is made of a soft material, it will cause very little discomfort to you.<br/>Before you leave the hospital, the drain will be shortened, so that it will not cause any discomfort at all to you once you are back home. The drain will disintegrate after 2 to 4 weeks. When it does, you may find some pieces of it in your faces.<br/>The efficacy of the C-Seal will be evaluated after your hospital discharge as well as after 30 days and after 1 year after operation by phone call or routine hospital visit.<br/>All patients aged 18 years of above who must undergo a non-urgent surgical procedure involving an intestinal suture due to an intestinal complaint are asked to participate in this trial.";"Anastomotic leakage (AL) is a major complication in colorectal surgery. The incidence of AL in colorectal anastomoses is about 10 %. In order to reduce the incidence of anastomotic leakage, the C-Seal is developed.<br/>This intraluminal biodegradable drain is developed to prevent extravasation of intracolonic content to the peritoneal cavity in case of an anastomotic dehiscence.<br/>The primary endpoint/outcome is the incidence of anastomotic leakage leading to invasive treatment within 30<br/>days after the primary operation.<br/>The following hypotheses will be examined:<br/>H(0): There is no difference in percentage of Leakage between the C-seal group and the control group (or a higher<br/>percentage of Leakage in the C-seal group).<br/>H(1): The percentage of Leakage in the C-seal group is lower than in the control group.<br/>Your doctor will discuss the operation/procedure in detail with you. The surgical procedure will be done in the usual way. Lots will be drawn to determine whether or not you will receive the C-Seal. <br/>In either case the connection between the large intestine and the rectum will be made using a surgical stapler. In patients who receive a C-Seal, the intestinal connection will be made and then C-Seal will be joined to the connection using those staples. After surgery, a small portion of the drain will protrude from your anus. As it is made of a soft material, it will cause very little discomfort to you.<br/>Before you leave the hospital, the drain will be shortened, so that it will not cause any discomfort at all to you once you are back home. The drain will disintegrate after 2 to 4 weeks. When it does, you may find some pieces of it in your faces.<br/>The efficacy of the C-Seal will be evaluated after your hospital discharge as well as after 30 days and after 1 year after operation by phone call or routine hospital visit.<br/>All patients aged 18 years of above who must undergo a non-urgent surgical procedure involving an intestinal suture due to an intestinal complaint are asked to participate in this trial.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005123";"2014-06-13T11:48:20.842+02:00";
"DRKS00004071";2012/10/31;2004/08/19;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00090025";"ClinicalTrials.gov";"Sponsor-ID";"XL119-001";"Helsinn Healthcare SA";;;;;;;;;;"Free text";"[---]*";"Biliary Tract Cancer";"ICD10";"C24.9";"Malignant neoplasm: Biliary tract, unspecified";"ICD10";"C23";"Malignant neoplasm of gallbladder";;;;;;;"Arm 1";"Drug: becatecarin";"Arm 2";"Drug: 5-Fluorouracil Plus Leucovorin";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Treatment";"Parallel";"III";"[---]*";"- To compare survival duration for XL119 and 5-FU/LV treated subjects; time frame: time to death<br/>";"- To determine time to progressive disease for XL119 and 5-FU/LV treated subjects, to evaluate clinical benefit for XL119 and 5-FU/LV treated subjects, and to assess the safety profile of XL119; time frame: time to progressive disease<br/>";"US";"United States";"BE";"Belgium";"CA";"Canada";"FR";"France";"DE";"Germany";"HU";"Hungary";"IT";"Italy";"PL";"Poland";"RU";"Russian Federation";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;"[---]*";"Charite Berlin der Humbold Universitat";"Berlin";"[---]*";"Heinrich-Heine-Universitat-Dusseldorf";"Dusseldorf";"[---]*";"Allgem. Krankenhaus St. Georg";"Hamburg";"[---]*";"Medizinische Hochschule Hannover";"Hannover";"[---]*";"Universitätsklinikum Johannes Gutenberg";"Mainz";"[---]*";"Technischen Universitat Munchen";"Munich";"[---]*";"Klinikum Grosshadern der Ludwig Maximilians Universitaet";"Munich";"[---]*";"Universitätsklinikum Tübingen";"Tübingen";"[---]*";"Universitatsklinikum Ulm";"Ulm";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2004/09/30;"[---]*";"248";2006/11/01;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Male and female subjects with advanced histologically confirmed biliary cancer<br/>             (gallbladder cancer or cholangiocarcinoma) that is not amenable to conventional<br/>             surgical approach<br/><br/>          -  18 years or older<br/><br/>          -  Life expectancy of at least 12 weeks<br/><br/>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score less than 3<br/><br/>          -  Willing and able to sign informed consent<br/><br/>          -  Sexually active men and women must use an accepted and effective method of<br/>             contraception (including barrier contraception with spermicide)<br/><br/>          -  Women of child-bearing age must have a negative pregnancy test<br/><br/>          -  Laboratory criteria<br/>";"-  Prior chemotherapy (excluding chemotherapy given as adjuvant treatment completing<br/>             more than 6 months prior to entry into study)<br/><br/>          -  Unstable angina, or class III or IV New York Heart Association heart disease<br/><br/>          -  Central nervous system metastases<br/><br/>          -  Uncontrolled diabetes mellitus<br/><br/>          -  Uncontrolled seizure disorder<br/><br/>          -  Major surgery, chemotherapy, immunotherapy, or radiotherapy during the 28 days<br/>             preceding the first study treatment<br/><br/>          -  Need for concomitant anticancer therapy (chemotherapy, immunotherapy, or radiation)<br/>             or other investigational agents during study participation or 28 days prior to study<br/>             participation<br/><br/>          -  Pregnant or breast-feeding<br/><br/>          -  A known history of human immunodeficiency virus (HIV) infection<br/>";"Primary Sponsor";"Helsinn Healthcare SA";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Case Western Reserve University - Cleveland";"[---]*";"[---]*";"[---]*";"Afshin Dowlati, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Case Western Reserve University - Cleveland";"[---]*";"[---]*";"[---]*";"Afshin Dowlati, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery";"[---]*";"[---]*";"The main purpose of this study is to determine if XL119 is more effective than the<br/>      combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of<br/>      subjects with advanced biliary tumors.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004071";"2015-01-27T14:09:02.978+01:00";
"DRKS00000580";2010/10/07;"[---]*";yes;"Approved";"180-10-12072010-ff";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2009-017347-33";"[---]*";"BfArM-No.";"4036362";"[---]*";;;;;;;;;;"MedDRA";"[---]*";"10000886, akute myeloische Leukämie, acute myeloid leukemia";"ICD10";"C92.0";"Acute myeloid leukaemia";;;;;;;;;;"Arm 1";"Dosis evaluation phase:<br/><br/>Dose level 1:<br/>1. cycle: Clofarabine 10mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/>2. cycle: Clofarabine 15mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/>3. cycle: Clofarabine 20mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/>4. cycle: Clofarabine 30mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/><br/>Dose level 2:<br/>1. cycle: Clofarabine 15mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/>2. cycle: Clofarabine 20mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/>3. cycle: Clofarabine 30mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/><br/>Dose level 3 and target dose for induction therapy with Clofarabine and low dose AraC:<br/><br/>1. cycle: Clofarabine 20mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/>2. cycle: Clofarabine 30mg/m2, i.v., days 1-5, Ara-C 20mg/m2, s.c., days 1-14.<br/><br/><br/>Consolidation therapy with Clofarabine and low dosw AraC:<br/><br/>1 to 4 cycles: Clofarabine 15mg/m2, i.v., days 1-3, Ara-C 20mg/m2, s.c., days 1-7.<br/>";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"I-II";"[---]*";"Adverse and serious adverse events during induction therapy, Adverse and serious adverse reactions during induction therapy, Adverse Reactions CTC grade 4 (AR4)";"Response after induction therapy: assessed at d21 of the last cycle of induction therapy of the patient, with the following response categories: complete remission (CR), complete remission with incomplete recovery (CRi), partial response (PR), resistant disease (RD), death during induction therapy.<br/><br/>Overall survival (OS): defined as time from the date of enrollment to the day of death from any cause.<br/><br/>Event-free survival (EFS): defined as time from the date of enrolment to the day of induction failure treatment, or relapse after CR or death from any cause. Patients not known to have experienced any of these events will be censored on the day they were last examined.<br/><br/>Relapse-free survival (RFS): defined as time from the date of achievement of a complete remission to the day of relapse or death from any cause. Patients not known to have experienced any of these events will be censored on the day they were last examined. RFS is defined only for patients achieving CR.<br/><br/>Allogeneic hematopoietic cell transplantation performed after reaching CR at the end of induction therapy (yes/no).<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/03/03;"Actual";"60";2013/08/25;"Multicenter trial";"National";"Both, male and female";"60";"Years";"[---]*";"no maximum age";"1.	Diagnosis of AML as defined by WHO <br/>2.	Primary or secondary AML<br/>3.	Age ≥60 years<br/>4.	Not eligible for standard/”curative” chemotherapy as described at the end of this section in refer-ence tables in section 4.3.<br/>5.	Adequate renal and hepatic functions as indicated by ALL of the following laboratory values:<br/>a.	Serum creatinine <=1.0 mg/dL (<=88,4 µmol/l) or<br/>if serum creatinine >1.0 mg/dL (>88,4 µmol/l), then the estimated glomerular filtration rate (GFR) must be >60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2)  = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is black)<br/>b.	Serum bilirubin ≤1.5 mg/dL (17,1 µmol/l) × upper limit of normal (ULN) <br/>c.	Aspartate transaminase (AST)/ alanine transaminase (ALT) <=2.5 × ULN<br/>d.	Alkaline phosphatase <=2.5 × ULN<br/>6.	Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent. <br/>7.	Written informed consent (ICF)<br/>";"1.Diagnosis of AML M3<br/>2.Current concomitant chemotherapy, radiation therapy, or immunotherapy other than described in the trial protocol.<br/>3.Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry. The patient must have recovered from all acute toxicities from any previous therapy.<br/>4.Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.<br/>5.Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).<br/>6.Hypersensitivity to Clofarabine, AraC or one of their components.<br/>7.Pregnant or nursing women.<br/>8.Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.<br/>9.Have had a diagnosis of another malignancy, unless the patient has been disease-free for at least 3 years following the completion of curative intent therapy, with the following exceptions:<br/>9a.Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.<br/>9b.Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.<br/>10.Psychiatric illness that would prevent granting of informed consent.<br/>11.Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C.<br/>12.Ongoing drug abuse.<br/>13.Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner) during the conduct of the trial. Patients using hormonal methods of contraception must be informed about possible influences of the study drug on contraception.<br/>14.Concomitant participation in other clinical trials: <br/>During the verification of the in- and exclusion criteria the trial physician checks, if the patient is participating in any other interventional clinical trials following the AMG at the same time. Should this be the case, the patient will not be included. Simultaneously the patient declares not to take part in any parallel interventional clinical trials following the AMG by signing the informed consent sheet.";"Primary Sponsor";"Universität Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstr. 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universität Leipzig<br/>Department für Innere Medizin<br/>Selbstständige Abteilung für Hämatologie,<br/>Internistische Onkologie und Hämostaseologie<br/>";"Mr.";"Prof. Dr. med. Dr. h.c.";"Dietger";"Niederwieser";"Johannisallee 32a";"04103";"Leipzig";"Germany";"+49-341 97-13050";"+49-341 97-13139";"dietger.niederwieser@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Universität Leipzig<br/>Department für Innere Medizin<br/>Selbstständige Abteilung für Hämatologie,<br/>Internistische Onkologie und Hämostaseologie<br/>";"Mr.";"Prof. Dr. med. Dr. h.c.";"Dietger";"Niederwieser";"Johannisallee 32a";"04103";"Leipzig";"Germany";"+49-341 97-13050";"+49-341 97-13139";"dietger.niederwieser@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Genzyme Europe B.V.";"[---]*";"[---]*";"[---]*";"[---]*";"Gooimeer 10";"1411 DD";"Naarden";"Netherlands";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional<br/>Chemotherapy<br/>";"Clofarabine";"[---]*";"This trial is performed in several trial centres in Germany with the target to assess the safety, feasibility and efficacy of a combination induction chemotherapy of Clofarabine and low-dose AraC in older patients with AML who are not eligible for conventional chemotherapy.<br/>To investigate the feasibility of this induction therapy, three different dose levels are initiated subsequently.<br/>To determine the efficacy of the combination therapy, the therapeutic achievements of each patient are followed.<br/><br/>Age has a strong impact on outcome in acute myeloid leukemia, with a gradual and consistent decline in survival with increasing age. Many older patients cannot be treated with curative intention because of comorbidities and/or increased toxicity of induction and consolidation chemotherapy. Older patients mostly do not tolerate chemotherapy as well as younger patients.<br/>These observations indicate the poor outcome in elderly patients with AML and the need for more effective and less toxic treatment approaches.<br/>Progress concerning rates of overall survival and complete remissions in curative treatment of elderly patients with AML can be obtained only using less toxic and more efficient drugs. Considering studies evaluating Clofarabine as single agent and the results of other trials, the treatment with Clofarabine in combination with AraC as described in this protocol seems promising concerning these objectives.<br/><br/>The trial treatment consists of a maximum of 4 induction cycles and up to 4 consolidation cycles. Every induction cycle comprises five days of Clofarabine and 14 days of AraC administration. Every consolidation cycle consists of three days of Clofarabine and seven days of AraC administration.<br/>After the last administration of trial therapy there will be a follow up phase of 13 months.<br/><br/>Patients may participate in this trial if ALL of the following criteria are met:<br/>1.	Diagnosis of AML as defined by WHO <br/>2.	Primary or secondary AML<br/>3.	Age ≥60 years<br/>4.	Not eligible for standard/”curative” chemotherapy as defined in the trial protocol<br/>5.	Adequate renal and hepatic functions<br/>6.	Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent. <br/>7.	Written informed consent (ICF)<br/><br/>This trial is designed to assess safety and feasibility (tolerability) of the induction treatment with Clofarabine in combination with low dose AraC. This is reflected by the evaluation of this trial. The hypotheses are, that the treatment with Clofarabine in combination with low dose AraC is less toxic and that this treatment is effective for older patients who are not eligible for standard/curative chemotherapy.<br/>Therefor the occurrence of adverse events will be documented and the response to the induction therapy is assessed.";"This is a prospective open-label Phase I / II multicentre trial to assess the safety and feasibility of Clfarabine in combination with low-dose AraC in patients not eligible for conventional chemotherapy.<br/><br/>The trial starts with a dose escalation phase with regard to the dose of Clofarabine. Three cohorts of 3-6 patients will be included in the dose escalation phase. All further patients will be treated at the dose level resulting from the dose escalation phase. Patient recruitment will continue until a total of 60 patients are included.<br/><br/>During the dose evaluation phase, the investigational treatment consists of a maximum of four (dose level 1), three (dose level 2) resp. two (dose level 3) induction and a maximum of four consolidation cycles of the combined therapy with Clofarabine and low-dose AraC.<br/><br/>The dose escalation algorithm is based on the incidence of adverse reactions with CTC Grade 4 (AR4) during the individually first induction cycle. Dose evaluation can be based only on informative patients with respect to AR4. That means that patients who die within 14 days of the individually first induction cycle from other than treatment-related causes,will not be counted for the dose evaluation.<br/><br/>The trial starts with the enrolment of 3 patients on dose level 1. Depending on the results of the first three informative patients, the further procedure is:<br/><br/>If in the first three informative patients there is no case of adverse reactions CTC grade 4 (AR4), the study will be continued with dose level 2.<br/>If there is one case of AR4 in the first three informative patients on dose level 1, another three patients are treated on this dose level. If there are less than two cases of AR4 in the first six informative patients, the trial will be continued with dose level 2. If there are two or more cases of AR4 in the first six informative patients, the DMC will be informed and decides on the further course of the trial<br/><br/>If there are two or three cases of AR4 in the first three informative patients, the DMC will be informed and decides on the further course of the trial.<br/><br/>Dose level 2 starts with the enrolment of another 3 patients. The further procedure is:<br/><br/>If in the first three informative patients on dose level 2 there is no case of adverse re-actions CTC grade 4 (AR4), the study will be continued with dose level 3.<br/>If there is maximally one case of AR4 in these three informative patients on dose level 2, another three patients are treated on this dose level. If there are less than two cases of AR4 in the first six informative patients, the trial will be continued with dose level 3. If there are two or more than two cases of AR4 the first six informative patients, the final dose level is dose level 1. If there are two or three cases of AR4 in these three informative patients, the final dose level is dose level 1<br/><br/>Dose level 3 starts with the enrolment of another 3 patients. The further procedure is: If there is maximally one case of AR4 in three informative patients on dose level 3, another three patients are treated on this dose level. If there are less than two cases of AR4 in the first six informative patients, the final dose level is dose level 3. If there are two or more cases of AR4 in the first six informative patients, the final dose level is dose level 2. If there are two or more cases of AR4 in these three patients, the final dose level is dose level 2.<br/>The final dose level will be maintained until a total of 60 patients have been enrolled into the trial.<br/><br/>Every induction cycle comprises five days of Clofarabine where the dosage depends on the dose level the patient is allocated to and 14 days of AraC administration. Every consolidation cycle consists of three days of Clofarabine (15 mg/m2/day) and seven days of AraC administration. AraC will be given in all induction and all consolidation cycles at a dose of 20 mg/m2 per day.<br/><br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000580";"2013-09-27T15:19:53.076+02:00";
"DRKS00004615";2013/01/15;"[---]*";yes;"Approved";"S-061/2003";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";;;;;;;;;;;;;;;;"ICD10";"N97.0";"Female infertility associated with anovulation";;;;;;;;;;;;;"Arm 1";"Injection of seminal plasma into the cervix";"Arm 2";"Injection of sodium chloride into the cervix";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Treatment";"Parallel";"N/A";"[---]*";"Clinical pregnancy, at least amniotic sac. Thereby earliest ultrasound at 6+0 weeks of pregnancy";"/";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Abteilung Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitätsfrauenklinik ";"Heidelberg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2007/04/01;"Actual";"422";2012/02/28;"Monocenter trial";"National";"Female";"18";"Years";"43";"Years";"infertility, IVF therapy";"male urogenital infection";"Primary Sponsor";"Abteilung Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik";"Mr.";"Prof. Dr.";"Thomas";"Strowitzki";"Vossstrasse 9";"69115";"Heidelberg";"Germany";"0049-6221-567910";"[---]*";"thomas.strowitzki@med.uni-heidelberg.de";"[---]*";"Contact for Scientific Queries";"Abteilung Gynäkologische Endokrinologie und Reproduktionsmedizin, Universitäts-Frauenklinik";"Mr.";"Prof. Dr.";"Michael";"von Wolff";"Effingerstrasse 102";"3010";"Bern";"Switzerland";"0041-31-6321301";"[---]*";"Michael.vonWolff@insel.ch";"[---]*";"Contact for Public Queries";"Abteilung Gynäkologische Endokrinologie und Reproduktiosnmedizin, Universitäts-Frauenklinik";"Mr.";"Prof. Dr.";"Michael";"von Wolff";"Effingerstrasse 102";"3010";"Bern";"Switzerland";"0041-31-6321303";"[---]*";"Michael.vonWolff@insel.ch";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Abteilung Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik";"Mr.";"Prof. Dr.";"Thomas";"Strowitzki";"Vossstrasse 9";"69115";"Heidelberg";"Germany";"0049-6221-567910";"[---]*";"thomas.strowitzki@med.uni-heidelberg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Intrauterine instillation of diluted seminal plasma in in vitro fertilization – a double-blind, placebo controlled, randomized study";"[---]*";"[---]*";"At the time of oocyte aspiration in In vitro Fertilization (IVF) therapies, diluted seminal plasma of the patients partner or placebo (sodium chloride) is injected into the cervix. Thereby sexual intercourse is imitated, which does not take place in IVF therapies.  The goal is to increase the pregnancy rate.<br/><br/><br/>";"At the time of oocyte aspiration in In vitro Fertilization (IVF) therapies, diluted seminal plasma of the patients partner or placebo (sodium chloride) is injected into the cervix ti imitate sexual intercourse is imitated. The therapy is aimed to increase the pregnancy rate. <br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004615";"2013-07-23T13:09:06.353+02:00";
"DRKS00005476";2013/11/27;"[---]*";no;"Approved";"2012-475-f-M";"Ethik-Kommission der Ärztekammer Westfalen-Lippe und der med. Fakultät der Westfälischen Wilhelms-Universität Münster";"EUDAMED-No.<br/>(for studies acc. to Medical Devices act)";"CIV-12-10-008944";"[---]*";;;;;;;;;;;;;"ICD10";"C71";"Malignant neoplasm of brain";;;;;;;;;;;;;"Arm 1";"NanoTherm monotherapy";"Arm 2";"NanoTherm combination therapy with HFSRT (hypofractionated stereotactic radiotherapy)";"Arm 3";"HFSRT monotherapy ";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Run-in phase: number of subjects with stable disease (SD) or better at 3 months after start of treatment<br/>Main study: mOS-2: median overall survival after start of treatment for first recurrence<br/><br/>";"Main study: <br/>mOS-1: median overall survival from primary diagnosis<br/>OS-12: overall survival at 12 months from randomization into the study<br/><br/>mPFS: median progression-free survival from enrollment/ randomization into the study<br/>PFS-6: PFS rate at 6 months from enrollment/ randomization into the study<br/><br/>Tumor response: percentage of subjects with SD or better during the 1-year assessment period<br/>Quality of life (QoL): via health-related QoL scales, EORTC-QLQ-C30, version 3 and the Brain Cancer Module 20 (BCM20) questionnairesMGMT promoter methylation status: percentage of MGMT+ and MGMT- subjects and their correlation to efficacy <br/>Secondary safety endpoints:<br/>AEs, TEAEs, SAEs, laboratory parameters, KPS, physical and neurological examination, vital signs<br/><br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Münster";"University Medical Center";"[---]*";"Düsseldorf";"University Medical Center";"[---]*";"Köln";"University Medical Center";"[---]*";"Gießen";"University Medical Center";"Charite";"Berlin";"University Medical Center";"[---]*";"Kiel";"University Medical Center";"[---]*";"Frankfurt a.M.";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/03/25;"Actual";"269";2015/03/05;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"• Radiographically (MRI) according to RANO criteria and histologically (evidence of vital tumor tissue) confirmed first progression of a histologically proven WHO grade IV glioma after primary therapy <br/>• Primary standard radiochemotherapy using TMZ followed by adjuvant TMZ chemotherapy, OR radiotherapy alone, AND at least 6 months off radiotherapy<br/>• Supratentorial tumor localization with or without prior surgery for recurrence<br/>• One tumor focus OR multiple foci in conjunction with the primary tumor or the resection cavity<br/>• Maximal volume of all contrast-enhancing tumor: 25 mL<br/>• At least one contrast-enhanced tumor residue (25 mL max.) not involving the contralateral site, and measurable according to modified Macdonald criteria<br/>• Primary irradiation dose: 54 Gy ≤ x ≤ 60 Gy<br/>• Age ≥18 years<br/>• Karnofsky performance score ≥60%<br/>• Life expectancy of ≥3 months, excluding any severe diseases interfering with the performance, evaluation, and outcome of the clinical investigation<br/>• Laboratory values as specified:<br/>◦ WBC ≥3x 109/L<br/>◦ ANC ≥1.5x 109/L<br/>◦ Platelets ≥100 x 109/L<br/>◦ aPTT 26 – 36 s<br/>◦ Quick value 70 – 120% / INR 0.9 – 1.2<br/>◦ Hb ≥10.0 g/dl (≥5.6 mmol/l)<br/>◦ AST or ALT ≤3x ULN, unless attributed to anti-convulsants<br/>◦ Alkaline phosphatase ≤2.5x ULN<br/>◦ Total bilirubin ≤1.5x ULN<br/>◦ Serum creatinine ≤2.0x ULN<br/>◦ GFR ≥60 mL/min<br/>◦ TSH: 0.3  mU/L < x < 3.5 mU/L <br/>• Able to undergo contrast-enhanced MRI and PET-CT <br/>• Women of childbearing potential must have a negative serum pregnancy test<br/>• Signed informed consent<br/><br/>";"• Irremovable metallic material within 40 cm from the rim of the magnetic field, e.g. dental fillings, crowns, implants, or staples/clips <br/>• Cardiac pacemaker, implanted defibrillator, neurostimulator, electric field supply, or other electronic implants<br/>• Hypersensitivity to the iron oxide nanoparticles or any of the ingredients of NanoTherm (aminosilanes, iron oxide, methanol) <br/>• Previous (within 30 days prior to enrollment / randomization) and concurrent treatment during the treatment phase with other investigational drug/s or device/s<br/>• Previous and concurrent treatment with antiangiogenic drugs<br/>• Pregnancy or breastfeeding<br/>";"Primary Sponsor";"MagForce AG";"[---]*";"[---]*";"[---]*";"[---]*";"Max-Planck-Straße 3";"12489";"Berlin";"Germany";"+49 30 308 380 0";"+49 30 308 380 99";" info@magforce.com";"http://www.magforce.de/kontakt.html";"Contact for Scientific Queries";"MagForce AG";"Mr.";"Dr.";"Claus";"Thielert";"Bunsenstrasse 7";"82152";"Martinsried";"Germany";"+49 89 954 77 95 60";"+49 30 308 380 66";"studies@magforce.com";"http://www.magforce.de/kontakt.html";"Contact for Public Queries";"Clinical Project Management, MF 1001, MagForce AG";"[---]*";"[---]*";"[---]*";"[---]*";"Bunsenstrasse 7";"82152";"Martinsried";"Germany";"+49 89 95 477 95 60";"+49 89 95 477 95 66";"studies@magforce.de";"www.magforce.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"MagForce AG";"[---]*";"[---]*";"[---]*";"[---]*";"Max-Planck-Straße 3";"12489";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.magforce.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"MF 1001: Open-label, randomized, controlled study to determine the efficacy and safety of NanoTherm® monotherapy and NanoTherm® in combination with radiotherapy versus radiotherapy alone in recurrent / progressive glioblastoma.";"MF 1001";"[---]*";"MF 1001 is a study to investigate NanoTherm Therapy® in patients with recurrent glioblastoma, a malignant brain tumor.<br/><br/>What is the NanoTherm Therapy? <br/>The NanoTherm Therapy generates heat inside the tumor. It consists of 5 medical devices: iron oxide nanoparticles (NanoTherm®), the NanoActivator® to generate an alternating magnetic field, a temperature monitor and a catheter for actual temperature measurement, and a software (NanoPlan®), which simulates the temperature distribution in the treatment area. <br/>During the first step of the therapy, the iron oxide nanoparticles are injected directly into the tumor in a small surgery. Afterwards, the nanoparticles are activated in an alternating magnetic field (NanoActivator). The activated nanoparticles produce heat, which either kills or sensitizes the tumor cells for a concurrent radiotherapy or chemotherapy. In this study, a radiotherapy is given in parallel. <br/>In a previous clinical study, the NanoTherm Therapy showed a favorable safety profile with a prolonged overall survival rate in combination with radiation therapy. Based on this study, the NanoTherm Therapy was CE-certified all over Europe.<br/><br/>Why this study is undertaken?<br/>The objective of this study is to validate the safety and efficacy of the NanoTherm Therapy in recurrent glioblastoma. In up to 269 patients, it is investigated whether the NanoTherm monotherapy or the combination of NanoTherm Therapy and an optimized radiation therapy are equally effective or even more effective than the optimized radiation therapy alone. Moreover, two components of the therapy are specifically investigated: the nanoparticles in a higher concentration and a new thermometry catheter. <br/>The scope of this trial is to develop a more effective tumor therapy and accomplish a longer survival time and less side effects with the NanoTherm Therapy alone or in combination with radiotherapy.<br/>";"This clinical investigation is an open-label, controlled, multicenter study in patients with recurrent progressive glioblastoma. In a run-in phase, the efficacy and safety of NanoTherm monotherapy is evaluated. In the following main study, the efficacy and safety of NanoTherm monotherapy (when effective in the run-in phase) and NanoTherm Therapy in combination with a hypofractionated stereotactic radiotherapy (HFSRT) is investigated versus the HFSRT monotherapy. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005476";"2017-02-20T12:23:19.162+01:00";
"DRKS00005740";2014/03/14;"[---]*";no;"Approved";"BB 124/10";"Ethikkommission an der Medizinischen Fakultät der Ernst-Moritz-Arndt-Universität Greifswald";;;;;;;;;;;;;;;;"ICD10";"K02";"Dental caries";;;;;;;;;;;;;"Arm 1";"Filling with a conventional Glasionomer (Fuji IX GP fast + Fuji Coat LC), 40 fillings";"Arm 2";"Filling with a modified Glasionomer + Coat (EQUIA System, Fuji IX GP Extra in combination with G-Coat Plus), 40 fillings<br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Differences in degree of wear and fillings fracture between both products over a five year period according to a calibrated evaluation based on FDI standard (Hickel et al 2010) beginning from Baseline.";"Failure rate of all fillings.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Zentrum für Zahn-, Mund- und Kieferheilkunde";"Greifswald";"University Medical Center";"Abteilung für Zahnerhaltungskunde LMU München";"München";"University Medical Center";"Medizinisches Zentrum für ZMK";"Marburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/04/12;"Actual";"240";2015/12/18;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. Dentate patients (no partial or full dentures, proximately three opposing zones with occlusal contacts of natural teeth in the posterior region), 2. fillings quantity is limited on the multi-surface fillings, 3. the cavity size is limited at 50% of the width of teeth, the proximal walls on the distances of the cusp tip.";"1. Patients with CMD dysfunction or malfunction, 2. signs of occlusal abrasion, hyperfunction, clenching will be excluded from the study. CMD-Screening, 3. Patients who withheld their paticipation will be excluded from the study, 4. none one-surface fillings, none completed or partially cusp replacements.";"Primary Sponsor";"GC Europe N.V.";"Mr.";"[---]*";"Piyush";"Khandelwal";"Interleuvenlaan 33";"3001";"Leuven";"Belgium";"+32 16 74 51 32";"+32 16 74 51 40";"p.khandelwal@gceurope.com";"www.gceurope.com";"Contact for Scientific Queries";"GC Europe N.V.";"Mr.";"[---]*";"Piyush";"Khandelwal";"Interleuvenlaan 33";"3001";"Leuven";"Belgium";"+32 16 74 51 32";"+32 16 74 51 40";"p.khandelwal@gceurope.com";"www.gceurope.com";"Contact for Public Queries";"Poliklinik f. Prothetik und Werkstoffkunde<br/>Ernst-Moritz-Arndt-Universität";"Mr.";"OA Dr.";"Thomas";"Klinke";"Rotgerberstrasse 8";"17487";"Greifswald";"Germany";"03834-867140";"03834-867148";"klinke@uni-greifswald.de";"www.uni-greifswald.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"GC Europe N.V.";"[---]*";"[---]*";"[---]*";"[---]*";"Interleuvenlaan 33";"3001";"Leuven";"Belgium";"[---]*";"[---]*";"[---]*";"www.gceurope.com";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"The clinical success of the permanent posterior filling alternative Equia-additional cohort.";"[---]*";"[---]*";"Study to compare the higher survival rate of a modified glasionomer system compared towards a conventional Glasionomer in combination with a coating material. A participation of a minimum of three dental clinics is assigned.";"A prospective clinical trial as cohort study according to MPG phase IV to compare the survival rate of Equia (Fuji IX GP Extra in combination with G-Coat Plus) with Fuji IX (GIC Fuji IX GP fast in combination with Fuji Coat LC) as filling material for posterior teeth.";"Recruiting stopped after recruiting started ";"Further trial documents";"29bf4e69-ad25-41e5-906a-807291f54ef9";"Abstract192_2012_IADR.pdf";"Weitere Studiendokumente/ further trial documents";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005740";"2018-04-13T12:00:12.982+02:00";
"DRKS00006126";2014/05/19;"[---]*";yes;"Approved";"213/14";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"Universal Trial Number (UTN)";"U1111-1156-0412";"[---]*";;;;;;;;;;;;;"Free text";"[---]*";"osteoarthritis";"ICD10";"M17";"Gonarthrosis [arthrosis of knee]";;;;;;;;;;"Arm 1";"Arm 1: Intervention group. Subjects age 30-67 with diagnosed (preferentially) medial osteoarthritis of the knee. Kinematics, Kinetics and neuromuscular control are tested in pre- and post measurements in several conditions: walking, running, stair climbing, stair descending, each with and without the knee sleeve. Relevant personal and disease-related data are assessed by questionnaires. Subjects are subsequently asked to wear the knee sleeve for 6 at least 6 hours/day and during all physical activity for 8 weeks. Subjects are provided with information about the sleeve at the first measurement and through an information sheed. ";"Arm 2";"Arm 2: Control group. Subjects age 30-67 with diagnosed (preferentially) medial osteoarthritis of the knee. Kinematics, Kinetics and neuromuscular control are tested in pre- and post measurements in several conditions: walking, running, stair climbing, stair descending, each with and without the knee sleeve. Relevant personal and disease-related data are assessed by questionnaires. During the 8-weeks-intervention, subjects are asked to not wear any kind of knee sleeve.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Basic research/physiological study";"Parallel";"N/A";"N/A";"After 8 week knee support the reduction of knee joint load will be compared to a no-treatment control group.<br/>Knee joint load is determined by kinematic and kinetic parameters (adduction, adduction moment, joint stiffness)<br/>Knee joint controll is determined of muscles surrounding the joint (electromyography) and an additional angle reproduction test.<br/>";"After 8 week knee support changes in subjective pain will be compared to a no-treatment control group.<br/>Changes in subjective pain will be investigated in relation to changes in knee joint load.<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Orthopädie und Unfallchirurgie";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/05/20;"Actual";"40";2014/12/16;"Monocenter trial";"National";"Both, male and female";"30";"Years";"67";"Years";"Male and female subjects, medically diagnosed moderate to severe (preferably) medial knee osteoarthritis (Kellgren-Lawrence Grade >2) and pain dominantly in the medial compartment (visual analog scale). Static varus alignment of the knee. Age between 30-67.";"Disability to go or to run contingent on health problems, neurological diseases, artificial ankle, knee or hip joint, knee support during last 6 months. ";"Primary Sponsor";"Institut für Sport und Sportwissenschaft der Albert-Ludwigs-Universität Freiburg";"Mr.";"Prof. Dr.";"Albert";"Gollhofer";"Schwarzwaldstraße 175";"79117";"Freiburg";"Germany";"+49 761 203-4510";"+49 761 203-4534";"albert.gollhofer@sport.uni-freiburg.de";"[---]*";"Contact for Scientific Queries";"Institut für Sport und Sportwissenschaft der Albert-Ludwigs-Universität Freiburg";"Mr.";"[---]*";"Raphael";"Schween";"Schwarzwaldstraße 175";"79117";"Freiburg";"Germany";"+49 761 203-4529";"+49 761 203-4534";"raphael.schween@sport.uni-freiburg.de";"[---]*";"Contact for Public Queries";"Institut für Sport und Sportwissenschaft der Albert-Ludwigs-Universität Freiburg";"Mr.";"[---]*";"Raphael";"Schween";"Schwarzwaldstraße 175";"79117";"Freiburg";"Germany";"+49 761 203-4529";"+49 761 203-4534";"raphael.schween@sport.uni-freiburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Bauerfeind AG";"Mr.";"Dr.";"Uwe";"Berendt";"Triebeser Straße 16";"07937";"Zeulenroda-Triebes";"Germany";"+49 36628-66 1720";"+49 36628-66 1718";"uwe.berendt@bauerfeind.com";"www.bauerfeind.com";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Evatuation of long-term biomechanical effects of an elastic knee sleeve in subjects with moderate to severe medial knee osteoarthritis ";"[---]*";"[---]*";"This study tests if wearing an elastic knee sleeve for 8 weeks influendes gait characteristics in subjects with medial knee osteoarthritis. Prior studies have shown that the acute effect of a knee sleeve was reduced knee adduction during gait. A subsequent longitudinal study confirmed this tendency but failed to reach statistical significance. In the present study, the inclusion criteria for subject have been narrowed in order to prevent those subjecs from participating who, even without a sleeve, have little or no functional impairment and therefore presumably cannat benefit from a sleev. <br/>Subject undergo a pre and post test where gait characteristics and joint proprioception are assessed with biomechanical tests with and without the sleeve. Between these two tests, there is an 8 week period during which subjects of the intervention grour are supposed to wear the sleeve at least 6 hours each day. Subjects of the control group must not wear a sleeve during this time.";"Osteoarthritis of the knee causes pain and impairs function of the respective joint. The consequence is an impairment of gait kinematics and neuromascular activation of the whole body and specifically the lower extremity (Block & Shakoor, 2010; Ornetti et al., 2010). A prior study at the Department of Sport Sciece of the University of Freiburg showed that wearing an elastic knee sleeve immediately influenced gait kinematics and kinetics (Schween et al., in prep.; Ethics vote No. 107/12). Based on these results, a subsequent longitudinal study tested if the observed effects would prevail during an 8-weeks intervention (184/13). Gait kinematics and kinetics were assessed in subjects with unilateral knee osteoarthritis in a pre and post measurement. The focus was on the frontal plane. The results showed tendencies in the same direction as the effects found by Schween et al. (in prep.). Specifically, the knee adduction moment was reduced by an average of 5%. However, these tendencies failed to reach statistical significance. A retrospective view of the two prior studies at our department indicates that the effects of a knee sleeve depend strongly on the individual impairment of knee function in general and knee function in the test situation in particular. More specifically: the longitudinal study inlcuded several subjects that showed no or little functional impaiment during baseline-testing without a knee sleeve already. We reason that the knee sleeve could not have further improved pain or function in these subjects in the test situation. Therefore, we keep the hypothesis that a knee sleeve can improve function, and particularly lateral differences in gait biomechanics, over a longer period. The aim of the current study therefore is to again test whether the effects found by Schween et al. (in prep.) prevail during an 8-weeks intervention. Based on experience from the earlier longitudinal study, we try to reduce the floor-effect described above by narrowing the inclusion criteria for the sleeve. Specifically, we want to prevent subjects from participating that show no or little functional impairment at baseline. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006126";"2015-01-07T11:52:36.399+01:00";
"DRKS00006286";2016/09/01;"[---]*";yes;"Approved";"257/14";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"Universal Trial Number (UTN)";"U1111-1137-8734";"[---]*";;;;;;;;;;;;;"ICD10";"R15";"Faecal incontinence";"ICD10";"[---]*";"[---]*";;;;;;;;;;"Arm 1";"Two-stage procedure: direct implantation of the quad-lead electrode without first implanting a test-electrode";"Arm 2";"Three-stage procedure";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"The implantation rate is higher in the two-step procedure compared to the three-step procedure";"Quality of life (questionnaire)<br/>fecal incontinence (questionnaire)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/01/30;"Planned";"20";2016/08/22;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";">= 18 years<br/>-fecal incontinence refractory to conservative therapy<br/>-Egilibility for SNS<br/>-sphincter defect < 180°";"rectal prolapse<br/>neuropathy<br/>Scleroderma<br/>borreliosis<br/>erectile dysfunction<br/>diarrhea, liquid stool <br/>anticoagulants (ASS, Clopidogrel, Marcumar)<br/>allergy to local anesthetics";"Primary Sponsor";"Universitätsklinikum Freiburg<br/>Department Chirurgie<br/>Klinik für Allgemein- und Viszeralchirurgie";"Mr.";"Dr.";"Matthias";"Goos";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270-24010";"+49 761 270-28080";"matthias.goos@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/de.html";"Contact for Scientific Queries";"Universitätsklinikum Freiburg<br/>Department Chirurgie<br/>Klinik für Allgemein- und Viszeralchirurgie";"Mr.";"Dr. ";"Matthias";"Goos";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270-24010";"+49 761 270-28080";"matthias.goos@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/de.html";"Contact for Public Queries";"Universitätsklinikum Freiburg<br/>Department Chirurgie<br/>Klinik für Allgemein- und Viszeralchirurgie";"Mr.";"Dr.";"Matthias";"Goos";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270-24010";"+49 761 270-28080";"matthias.goos@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/de.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Freiburg<br/>Department Chirurgie<br/>Klinik für Allgemein- und Viszeralchirurgie";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270-24010";"+49 761 270-28080";"[---]*";"http://www.uniklinik-freiburg.de/de.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Two versus three-stage, CT-controlled sacral nerve stimulation for the treatment of fecal incontinence";"[---]*";"[---]*";"Sacral nerve stimulation is a method to treat fecal incontinence. An electrode is places through the sacral foramen and the nerves that enable fecal continence are controlled by a pace maker.<br/>The known procedure is to first implant a test electrode. If an improvement of fecal incontinence can be achieved the permanent electrode will be implanted. There is a risk of treatment failure due to dislocation of the test electode. In case of negative testing the permanent electrode will not be implanted. Secondly, it can occour that improvement of fecal incontinence cannot be repeated after removal of the testing electrode. The aim of this study is to investigate the treatment of fecal incontinence by directly implanting a permanent electrode.";"The development of SNS mus be regarded as a mulestone in the treatment of fecal incontinece. And while the indication is constantly expanding, not evera SNS-implantation is successful. SNS must be tested in in different steps to evaluate its effectiveness in the individual patient. The eamination of the nerve plexus can be regarded as periphere nerve evaluation (PNE). With PNE, the accessibility and the ability of stimulation can be examined in a uni - or bilateral way in S2-S3.<br/>During the test phase the patient keeps a stool diary in order to evaluate the effectiveness of the test electrode. There is no guaranty that positive results that were achieved using the test electrode can be repeated wth the permanent electrode. The implantation rate varies between 56 and 70%, in some trials 54%-84%. One part of the negative test results can be trace back to a dislocation of the test electrode that is a simple whire electrode. The permanent electrode possesses fine blades that prohibit dislocation.<br/>The problem of electrode dislocation is known in the urological context and led to the two-stage-procedure - the permanent Quad-Lead electrode is directly implanted, without haven a test phase. If successful, the pacemaker is going to be installed, if not, the electrode will be removed. With this two-step procedure, the implantation rate could be increased and the critical replacement of the whire test electrode is omitted. For the application of this method no data of RCT is available.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006286";"2017-04-20T09:50:55.446+02:00";
"DRKS00011614";2017/03/13;"[---]*";yes;"Approved";"149/16";"Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2016-002735-16";"[---]*";;;;;;;;;;;;;"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;;;;"Arm 1";"Abbiraterone acetat (Zytiga®) in combination with prednisone or prednisolone. Therapy and obbservation are done according to the expert information of the registered product Zytiga®. The only intervention are the additional blood draws to measure CTCs and the AR-V7-status.";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Prognosis";"Single (group)";"III";"No";"Radiologic progression-free survival under therapy with  Zytiga® as first line therapy with consideration of the AR-V7-status and the number of CTCs.";"1. Number of CTCs at three time points: baseline prior to therapy start with Zytiga®, after 12 weeks ± 1 week therapy with Zytiga® and at radiologic progression <br/>2. AR-V7-status at three time points: baseline prior to therapy start with Zytiga®, after 12 weeks ± 1 week therapy with Zytiga® and at radiologic progression <br/>3. PSA development under first line therapy with Zytiga®<br/>4. OS under first line therapy with Zytiga®<br/>5. Life Quality:<br/>- pain scale: VAS/NRS<br/>- FACT-P, Functional Assessment of Cancer Therapy-Prostate<br/>- QLQ-C30<br/>- EORTC Quality of Life Questionnaire-Cancer<br/>6. Documentation of toxicities";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinik für Urologie und Kinderurologie";"Magdeburg";"Doctor's Practice";"[---]*";"Berlin";"Doctor's Practice";"[---]*";"Magdeburg";"Doctor's Practice";"[---]*";"Magdeburg";"Doctor's Practice";"[---]*";"Bernburg";"Medical Center";"Marienkrankenhaus Bergisch Gladbach, Klinik für Urologie";"Bergisch Gladbach";"Doctor's Practice";"[---]*";"Lutherstadt Eisleben ";"Doctor's Practice";"[---]*";"Reutlingen";"Doctor's Practice";"[---]*";"Wuppertal";"Doctor's Practice";"[---]*";"Wilhelmshaven";"Doctor's Practice";"[---]*";"Mettmann";"Doctor's Practice";"[---]*";"Herzberg";"Medical Center";"Diakonie Klinikum Stuttgart";"Stuttgart";;;;;;;;;;;;;;;;;;;;;;2017/03/16;"Actual";"140";2018/09/30;"Multicenter trial";"National";"Male";"18";"Years";"[---]*";"no maximum age";"1. Signed informed consent<br/>2. Age ≥ 18 years<br/>3. Patients with metastasic castration-resistant prostate carcinoma (mCRPC), ≤ 3 months, for who a therapeutic decision is to be taken<br/>4. ≥ 5 Bone metastases in bone scintigraphy and/or visceral metastases in CT and/or MRT and/or PSMA-PET/CT (≤ 8 weeks) and/or patients with only non-regional lymph node metastases (outside the small pelvis), if at least 5 metastases with an extent of 5 cm each or extensive lymph node conglomerates are present <br/>5. No or mild pain symptoms <br/>6. ECOG 0-1<br/>7. Tumor progression under hormone therapy with LHRH-agonists/antagonists or maximum androgen blockade (MAB), respectively<br/>8. Tumor progression: three times PSA increase (after stopping antiandrogens with previous MAB and no therapy with bicalutamide and flutamide in the last 4-6 weeks, time between  measurements one week each, at least 25% increase of PSA, Basic value > 1ng/ml) and/or increase of metastases (in lymph nodes and/or bones and/r visceral organs) as per imaging (CT and/or MRT and/or bone scintigraphy and/or PSMA-PET/CT), referred to the last documented time<br/>9. Testosteron in the castration area (≤ 0.2 ng/ml)<br/>10. Palliative radiation and/or bone surgery must be at least  4 weeks ago<br/>11. Minimal baseline CTC value ≥ 2 <br/>";"1. Brain metastases<br/>2. Severe liver impairment (ALT und AST >50% ULN); child Pugh class C<br/>3. Severe neurological diseases<br/>4. Previous therapy with androgen receptor targeted substances like Abirateron and Enzalutamid<br/>5. A previous therapy in the primary, castration-naïve status with up to 6 cycles Docetaxel (see DGU guideline 2017) is allowed, a previous therapy with Docetaxel in castration-resistant status is not allowed<br/>6. Hypersensitivity against the active compound or one of the other components listed in section 6.1 of the expert Information of Zytiga®<br/>7. Participation in another clinical trial in the last 4 weeks";"Primary Sponsor";"Medizinische Fakultät";"Mr.";"Prof. Dr. med.";"H.-J.";"Rothkötter";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"+49-391-6715750";"+49-391-6715749";"hermann-josef.rothkoetter@med.ovgu.de";"[---]*";"Contact for Scientific Queries";"Universitätsklinik für Urologie und Kinderurologie";"Mr.";"Prof. Dr. med.";"Martin";"Schostak";"Leipziger str. 44";"39120";"Magdeburg";"Germany";"+49-391-6715036";"+49-391-6715094";"martin.schostak@med.ogvu.de";"[---]*";"Contact for Public Queries";"ONKODATAMED GmbH (CRO)";"Ms.";"[---]*";"Anne-Katrin";"Ullner";"Friedenstr. 58";"15366";"Neuenhagen";"Germany";"+49-3342-4268910";"+49-3342-4268920";"anne-katrin.ullner@onkodatamed.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Janssen-Cilag GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Johnson & Johnson Platz 1";"41470";"Neuss";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®)";"STAR-V7";"[---]*";"Zytiga® is registered in combination with Prednison or Prednisolon for treatment of metastatic castration-resistant prostate carzinoma in adult men, who have none or only light symptoms of the disease following failure of conventional hormone therapy (androgen deprivation therapy) and in whom  chemotherapy is not yet clinically indicated.<br/>In this study the routine treatment of metastatic prostate carcinnoma is complemented by the following blood exminations.<br/>Circulating tumor cells. these are cancer cells, which are derived from the main tumor or a metstasis and can be found in little amounts in the blood. Not only the baseline number of circulating tumor cells prior to therapy start, but also the treatment-dependent change of the frequency give indication for the course if the disease. Measurement of circulating tumor cells during and after therapy can therefore provide useful information for the treatment, because in comparison to the usual PSA tests they allow an earlier evaluation, if the therapy is effective. The procedure has been reviewed by the American health authority FDA and approved for patients with breast-, colon- and prostate cancer. <br/><br/>AR-V7 status: AR-V7 stands for ""androgen receptor splice variant 7"". The so-called r-v7 status of circulating cancer cells seems to allow a prediction of the efficacy of the therapy in patients with testtosterone deprivation therapy, especially with the new active ingredients  Enzalutamid or Abirateronacetat (Zytiga®). Thus, these examinations can provide useful approaches for the individual therapy of cancer patients.<br/>";"In patients with mCRPC in whom PSA change alone are barely significant for success of therapy and survival, there is an urgent need for reviewing the efficacy of therapies.<br/><br/>The monitoring of circulating tumor cells during and after therapy could provide useful information for the clinical management of a personalized therapy. In clinical trials it was already shown that tumor cells found in circulating blood can allow a prognosis for progression-free and overall survival. Besides, the numbers of circulating tumor cells provided an earlier evaluation of therapy response compared to the usual PSA test. <br/><br/>The cliinical benefit of monitoring changes of circulating tumor cells with therapy as efficacy-response-surrogate-biomarker is currently tested with new antihormonal survival-prolonging therapies like Enzalutamid (Xtandi®)  and Abirateron (Zytiga®). The molecular characterization of circulating tumor cells could provide useful insight for the individual therapy of cancer patients, as circulating tumor cells are discussed as predictative biomarker. <br/><br/>The AR-V7 status of tumor cells seems to allow a prediction of the therapy response in patients under ADT (androgen deprivation therapy) with Enzalutamid or Abirateron. Only recently a connection between AR-V7 expression in circulating tumor cells and therapeutic resistance could be shown. Approximately 15 to 25% of patients with mCRPC under first-line therapy with Abirateron or Enzalutamid are affected. However, this finding requires a prospective validation on a large scale. <br/><br/>It is assumed that the number of circulating tumor cells and the AR-V7 status at the beginning and during the treament can predict the progression-free survival without threshold value and that the distribution of cells in the circulation and the AR-V7 status are a characteristic associated with the tumor independent of the extent of the disease. <br/><br/>According to already existing examinations CTCS can be expected in about 70% of the mCRPC patients, of which about 30% will be AR-V7-positive. <br/><br/>In this study the frequecy of the positive AR-V7 status as well as the changes of the numbers of circulating tumor cells are to be evaluated for the first time in a larger cohort in Germany. In addition new knowledge about survival and life quality under first-line therapy with Abirateronacetat (Zytiga®) with regard to CTCs and AR-V7 status should be generated. For the first time data on the AR-V7 conversion rate under first-line therapy with Abirateronacetat (Zytiga®) will be collected. <br/><br/>A protocol amendment was approved by the ethics committee on the 8th of Jan 2018 and by Bfarm on the 2nd of Jan 2018. Recruitment period is hence extended until Dec 2018.";"Recruiting stopped after recruiting started ";"Trial results";"fb23dfb2-1ae2-4dfa-8ba4-57ab1572e8e3";"STAR-V7_Abschlussbericht_12122019.pdf";"Ergebnisbericht STAR-V7";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011614";"2019-12-21T09:14:43.742+01:00";
"DRKS00007125";2015/05/19;"[---]*";yes;"Approved";"30/15";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"Universal Trial Number (UTN)";"U1111-1163-5436";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2014-005473-36";"[---]*";"BfArM-No.";"4040407";"[---]*";;;;;;;"ICD10";"E78.0";"Pure hypercholesterolaemia";;;;;;;;;;;;;"Arm 1";"Male patients with (possible) familial hypercholesterolemia between 18 and 75 years.<br/>First timepoint: The patients are not under the influence of medication affection the fat metabolism (e.g. statins).<br/>Second timepoint: The patients took Atorvastatin for 3-4 month.";"Arm 2";"Healthy, male probands without a disorder of the fat metabolism. These probands are age-matched to the FH-patients.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Control group receives no treatment";"Basic research/physiological study";"Parallel";"N/A";"No";"ApoB, TG, FC and CE distribution in the LDL and their subfractions";"activity of the following enzyms: LCAT, CETP, PLTP, LP-PLA2. HDL functionality-test. Concentration of the lipids: TG, CE, free cholesterol (FC) and phospholipids (PL) in all lipoprotein-subfractions concentration of the apolipoproteins: ApoA1, Apolipoprotein-A2, Apolipoprotein B-100, Apolipoprotein-E, Apolipoprotein-CII, Apolipoprotein-CIII and Lipoprotein Lp(a) in all lipoprotein subfractions";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Institut für Klinische Chemie und Laboratoriumsmedizin/Lipidambulanz";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/10/09;"Actual";"30";2020/02/05;"Monocenter trial";"National";"Male";"18";"Years";"75";"Years";"inclusion criteria for FH: <br/>• written consent <br/>• positive Simon Broome criteria (possible and definitely)<br/>• no lipid-lowering therapy in the 6 weeks before inclusion <br/>         <br/>inclusion criteria control subjects:<br/>• written consent <br/>• Patients without disorder of LDL metabolism, proven by< 200 mg/dl cholesteryl, < 150 mg/dl triglycerides and <160 mg/dl LDL-cholesteryl in fasting plasma <br/>• no relevant internistic deseases and no lipidlowering therapy in the 6 weeks before inclusion";"1.Active Liver-disease or impairment of liver function with GOT and/or GPT > 2 x value of the Upper Limit of Normal= (ULN) <br/>2.mid-level or severe renal insufficiency<br/>3.TSH not im reference range<br/>4.uncontrolled aterial hypertension: Diastolic RR ≥ 105 mmHg and/or systolic RR ≥ 160 mmHg <br/>5.lipid-lowering therapy within the last 6 weeks before the screening<br/>6.Smoker, alcohol abuse or other drug abuse<br/>7.blood donation within the last 6 weeks before the screening<br/>8.Patients with a adverse acute disease<br/>9. HbA1c > 6.5% <br/>10.Other important striking internistic diseases, which may alter the lipidmetabolism <br/><br/>";"Primary Sponsor";"Universitätsklinikum Freiburg Institut für klinische Chemie und Laboratoriumsmedizin";"Mr.";"Prof. Dr.";"Karl";"Winkler";"Hugstetter Str. 55";"79106";"Freiburg i. Br.";"Germany";"+49 761 270-35160";"+49 761 270-34440";"karl.winkler@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/zentrallabor/live/index.html";"Contact for Scientific Queries";"Universitätsklinikum Freiburg Institut für klinische Chemie und Laboratoriumsmedizin";"Mr.";"Prof. Dr.";"Karl";"Winkler";"Hugstetter Str. 55";"79106";"Freiburg i. Br.";"Germany";"+49 761 270-35160";"+49 761 270-34440";"karl.winkler@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/zentrallabor/live/index.html";"Contact for Public Queries";"Universitätsklinikum Freiburg Institut für klinische Chemie und Laboratoriumsmedizin";"Ms.";"Dr. med";"Brigitte";"König";"Hugstetter Str. 55";"79106";"Freiburg i. Br.";"Germany";"+49 761 270-77210";"+49 761 270-34440";"brigitte.koenig.zentrallabor@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/zentrallabor/live/index.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Freiburg Institut für klinische Chemie und Laboratoriumsmedizin";"Mr.";"Prof. Dr.";"Karl";"Winkler";"Hugstetter Str. 55";"79106";"Freiburg i. Br.";"Germany";"+49 761 270-35160";"+49 761 270-34440";"karl.winkler@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/zentrallabor/live/index.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects";"[---]*";"[---]*";"A high level of cholesterol is an important risk factor for cardiovascular diseases. Patients with familial hypercholesterolemia (FH) have a disordered LDL-metabolism, and a higher risk to suffer a cardiovascular disease. Further it is known that the composition of lipoproteins in FH patients is different compared to the corresponding composition in healthy probands.<br/>In this study certain parameters of the fat metabolism are measured. Out of this data we try to describe the LDL metabolism in healthy humans as well as in FH-Patients with an mathematical model. The lipidmetabolism-parameters are measured before and after administration of the statin 'Atorvastatin' in the FH-patients.<br/>";"In this case-control study without therapeutical intervention 2 collectives are considered: A group of male patients with (possible) familial hypercholesterolemia without lipidlowering medication and a group of male age-matched participants without a disorder of lipometabolism and without relevant internistic deseases.<br/>Based on lipoprotein composition and certain enzyme activities, which are related to lipoproteins, we try to make an in silico -estimation of the lipoprotein metabolism. We focus on the function of LDL-lipoproteins in intracellular cholesterol transport. Further the influence of the drug 'Atorvastatin' on the lipid-metabolism in the FH-patients is studied. Atorvastatin is an often used drug for people with FH.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007125";"2020-02-17T15:12:27.077+01:00";
"DRKS00007787";2015/05/13;2015/05/13;yes;"Approved";"312/14 (FF-MC)";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2013-004879-13";"[---]*";"Primary Registry-ID";"NCT02484339";"ClinicalTrials.gov";;;;;;;;;;"ICD10";"C61";"Malignant neoplasm of prostate";"ICD10";"C79.5";"Secondary malignant neoplasm of bone and bone marrow";;;;;;;;;;"Arm 1";"EBRT (external beam radiotherapy) and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity";"Arm 2";"EBRT and best supportive care until progression or intolerable toxicity";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"II";"Yes";"Time to radiological progression-free survival defined as time from randomization to radiological progression according to the “Recommendations of the Prostate Cancer Clinical Trials Working Group” published by Scher et al. (JCO 2008) (based on new lesions in bone scan and CT /MRI or death";"1. Overall survival<br/>2. Time to local progression in any of the EBRT treated bone metastases of CRT vs. HIRT treatment techniques<br/>3. Time to distant bone metastasis progression outside the RT target volumes<br/>4. Time to SRE (using the same criteria as in ALSYMPCA)<br/>5. Pain control (weekly visual analog score and “Brief pain inventory short form”)<br/>6. Disease Control Rate (DCR); Response rates (CR, PR, SD according to RECIST criteria)<br/>7. PSA response, time to PSA response and time to PSA normalization<br/>8. Bone ALP response, time to bone ALP response<br/>";"DE";"Germany";"FR";"France";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Universitätsklinikum Freiburg";"Freiburg im Breisgau";"University Medical Center";"""Carl Gustav Carus"", TU Dresden";"Dresden";"University Medical Center";"Univ.medizin Mainz, Klinik u. Poliklinik f. Nuklearmed.";"Mainz";"University Medical Center";"Klinikum der Univ. München";"München";"University Medical Center";"[---]*";"Tübingen";"University Medical Center";"[---]*";"Würzburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/12/01;"Actual";"274";2017/05/30;"Multicenter trial";"International";"Male";"18";"Years";"85";"Years";"1. Has provided written informed consent. Subjects must be able to understand and be willing to sign the written informed consent form (ICF). A signed ICF must be appropriately  obtained prior to the conduct of the any trial- specific procedure. Enrollment (entry) in the study is defined as the signing of the informed consent. Age ≥ 18 and ≤ 85 years<br/>2. Patients with progressive castration resistant prostate cancer (CRPC) with 1-5 bone metastases for whom Radium-223 dichloride  constitutes first-line cytostatic treatment<br/>3. Primary tumor (and its local recurrence, if applicable) controlled by effective local treatment<br/>4. If diagnosed, pelvic lymph node metastases controlled by effective local treatment<br/>5. At least 1 not previously locally treated skeletal metastasis on bone scan without non-bone distant metastases (e.g. lung, liver, and/or brain metastases) and without pathologically enlarged lymph nodes above the pelvis<br/>6. Progressive disease is defined either by: <br/>  - The appearance of new bone lesions. If progression is based on new lesion(s) on bone scan only without an increase in prostate specific antigen (PSA), PSA values from 3 assessments within the last 6 months must be provided;          OR <br/>  - In the absence of new bone lesions by 2 consecutive increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA ≥5 ng/mL <br/>7. Life expectancy of at least 6 months.<br/>8. Zubrod (WHO/ECOG) Performance Status (PS) 0 or 1<br/>9. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of therapy:<br/>- Hemoglobin > 10.0 g/dl<br/>- Absolute neutrophil count (ANC) >1,500/µl<br/>- Platelet count >100,000/μl<br/>- Total bilirubin < 1.5 times the institutional upper limit of normal (ULN)<br/>- ALT and AST < 2.5 x institutional upper limit of normal (ULN)<br/>- Serum creatinine < 2 x upper limit of normal.<br/>10. Patient has or has had symptoms (e. g. pain or micro-fractions) from bone metastases<br/>";"Excluded medical conditions:<br/>1. More than 5 not previously locally treated bone metastases as diagnosed by bone scintigraphy; <br/>2. Visceral or lymph node metastases above the pelvis as assessed by computed tomography (CT) (or other imaging modality) ;<br/>3. History of HIV infection or chronic hepatitis B or C<br/>4. Active clinically serious infections (> grade 2 NCI-CTC version 4.03)<br/>5. History of organ allograft<br/>6. Patients undergoing renal dialysis<br/>7. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study if not in complete remission for at least 5 years since date of diagnosis treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.<br/>8. Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results<br/>9. Imminent or history of spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI) <br/>10. Any other serious illness or medical condition, such as but not limited to:  <br/>- Cardiac failure New York Heart Association (NYHA) III or IV <br/>- Crohn’s disease or ulcerative colitis <br/>- Bone marrow dysplasia <br/>11. Fecal incontinence <br/>12. Any condition that is unstable or could jeopardize the safety of the patient and his compliance in the study<br/>13. Known allergy to Radium-223 dichloride (i.e. to active substance or one of the constituents)<br/><br/>Excluded therapies and medications, previous and concomitant: <br/>1. Anticancer chemo- or targeted therapy for CRPC (e.g. docetaxel or cabazitaxel)<br/>2. Radiotherapy for prostate cancer manifestations other than study treatment if not given with curative intent to prostate fossa and/or pelvic lymph nodes<br/>3. Major surgery within 4 weeks of study entry.<br/>4. Systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride) for the treatment of bone metastases<br/>5. Autologous bone marrow transplant or stem cell rescue within 4 months of study entry<br/>6. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity  such as febrile neutropenia when clinically indicated or at the discretion of the investigator;  however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2  months prior to the study entry or during the study]<br/>7. Investigational drug therapy outside of this trial during or within 4 weeks of study entry<br/>";"Primary Sponsor";"Universitätsklinikum Freiburg";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Strasse 49";"79095";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinik-freiburg.de";"Contact for Scientific Queries";"Universitätsklinikum Freiburg";"Ms.";"Prof. Dr. med.";"Ursula";"Nestle";"Hugstetter Strasse 49";"79095";"Freiburg";"Germany";"0761 270-94630";"[---]*";"alpha-radiotherapy@uniklinik-freiburg.de";"www.uniklinik-freiburg.de";"Contact for Public Queries";"Universitätsklinikum Freiburg";"Mr.";"Dr. med.";"Daniel";"Schnell";"Hugstetter Strasse 49";"79095";"Freiburg";"Germany";"0761 270-94630";"[---]*";"alpha-radiotherapy@uniklinik-freiburg.de";"www.uniklinik-freiburg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Freiburg";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Strasse 49";"79095";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinik-freiburg.de";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Bayer Healthcare";"[---]*";"[---]*";"[---]*";"[---]*";"BV-PH-MED-ONC/INF";"51368";"Leverkusen";"Germany";"[---]*";"[---]*";"[---]*";"healthcare.bayer.de";;;;;;;;;;;;;;;"Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. external beam radiotherapy alone in the treatment of advanced castration resistant prostate carcinoma with limited bone metastases ";"α-RT";"[---]*";"Phase II open-label study to evaluate the efficacy and safety of an external beam radiotherapy with or without a following Radium-223 dichloride therapy in the treatment of advanced castration resistant prostate carcinoma with 1-5 bone metastases. A possible improvement in the therapy of the castration resistant prostate cancer (flare-up of the disease after or under an anti-hormonal treatment) is investigated. Since decades the external radio beam therapy of bone metastases is an established and effective option for the treatment of bone metastases. The effectiveness of Radium-223 dichloride has been proven in another study. Both, external beam radiotherapy an Radium-223 dichloride cause cell death, mainly of tumor cells. With the combination of both methods we expect a mutually reinforcing effect on the control of the tumor disease.";"Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. external beam radiotherapy alone in the treatment of advanced castration resistant prostate carcinoma with limited bone metastases ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007787";"2020-01-14T06:36:38.024+01:00";
"DRKS00005651";2014/01/21;2013/06/03;yes;"Approved";"3698-02/13";"Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2010-019181-91";"[---]*";"Primary Registry-ID";"NTR4011";"Nederlands Trial Register";;;;;;;;;;"ICD10";"C67";"Malignant neoplasm of bladder";"Free text";"[---]*";"bladder";"Free text";"[---]*";"urothelial carcinoma";;;;;;;"Arm 1";"Induction cycle BCG-full dose(2x10^8 bis 3x10^9 lliving units)   ; weeks 1 through 6 plus maintenance cycles at months 3, 6 and 12 (wks 1,2,3); total 15 full dose BCG instillations";"Arm 2";"Induction cycle BCG-full dose (2x10^8 bis 3x10^9 living units)  (reduced frequency); weeks 1, 2 and 6 plus maintenance cycles at months 3, 6 and 12 (weeks 1, 3);<br/>in total 9 full dose BCG instillations";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"Yes";"- time to first recurrence (3 to 5 years)";"- number and grade of recurrent tumors <br/>(3 to 5 years)<br/>- rate of progression to a higher stage (T2 or higher) , (3 to 5 years)<br/>- incidence and severity of side effects (3 to 5 years)<br/>";"DE";"Germany";"NL";"Netherlands";"FR";"France";"BE";"Belgium";"ES";"Spain";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Doctor's Practice";"[---]*";"Braunschweig";"Doctor's Practice";"[---]*";"Aachen";"Doctor's Practice";"[---]*";"Herzberg/Seesen";"University Medical Center";"[---]*";"Jena";"Doctor's Practice";"[---]*";"Kiel";"Doctor's Practice";"[---]*";"Winsen";"Doctor's Practice";"[---]*";"Wilhelmshaven";"Doctor's Practice";"[---]*";"Würselen";"University Medical Center";"[---]*";"Dresden";"Doctor's Practice";"[---]*";"Duisburg";"Doctor's Practice";"[---]*";"Hamburg";"Doctor's Practice";"[---]*";"Kempen";"University Medical Center";"[---]*";"Lübeck";"Medical Center";"[---]*";"Weiden";"University Medical Center";"[---]*";"Ulm";"Doctor's Practice";"[---]*";"Berlin";"Doctor's Practice";"[---]*";"Erkrath";"Doctor's Practice";"[---]*";"Köln";"Doctor's Practice";"[---]*";"München-Pasing";"Doctor's Practice";"[---]*";"Langenfeld";2013/12/18;"Actual";"824";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. Presence of high grade (Ta-T1) urothelial papillary carcinoma of the bladder with or without CIS<br/>1.1. Tumors can be primary or recurrent<br/>1.2. Tumors can be single or multiple<br/>2a. In case of a Ta high grade tumor in the initial resection, a re-TUR can be performed at the discretion of the investigator. Initial resection or re-TUR must include the deep resection or cold cup biopsy (deep enough to obtain muscle tisssue) of the (initial) tumor site(s)<br/>2b. In case of a T1 high grade tumor in the initial resection, a re-TUR should be performed at weeks 4-8 after initial resection, which must include the deep resection or cold cup biopsy (deep enough to obtain muscle tisssue) of the initial tumor site(s)<br/>3. Re-re-TUR should be performed at weeks 4-8 after re-TUR in case of histological detection of T1 low/high grade tumor in the re-TUR, which must include the deep resection or cold cup biopsy (deep enough to obtain muscle tisssue) of the initial tumor site(s)<br/>4. Histopathologically confirmed absence of T1 low/high grade tumor(s) in the re-TUR specimen and/or re-re-TUR specimen<br/>5. All visible papillary tumors must be completely resected<br/>6. If the patient is male, he must use a condom during sexual intercourse during the first week after BCG treatment. If the patient is female, and of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 3 months after the last BCG treatment.<br/>7. Signed and dated informed consent form.<br/>8. Patient is clinically fit enough to receive BCG bladder instillations.<br/>";"1. Any previous intravesical BCG therapy<br/>2. Presence of primary CIS only.<br/>3. Presence of histopathologically proven muscle invasive urothelial carcinoma of the bladder at first or (re-)re-TUR surgical specimens<br/>4. Presence of any tumors in upper urinary tract or in the prostatic urethra at any time<br/>5. Presence of any other histological type of resected tumor other than urothelial carcinoma on the first or second resection<br/>6. Presence of another malignancy within 5 years except for basal cell carcinoma of the skin or localised prostate cancer in active surveillance<br/>7. Presence of pregnancy or lactation<br/>8. Presence of active tuberculosis, any form of immunodeficiency (eg HIV + serology, transplant recipients) and/or any other contraindication of BCG therapy<br/>9. Patients who have received any systemic cytostatic agents or multi-instillation intravesical chemotherapy in the 3 months prior to randomisation. Early postoperative (within 6 hours of resection) single dose chemotherapy is allowed after the first resection. However, it should not be given after (re-)re-TUR if the patient is considered eligible for this study.<br/>10. Patients with uncontrollable UTI";"Primary Sponsor";"European Association of Urology";"[---]*";"[---]*";"[---]*";"[---]*";"Mr. E.N. van Kleffensstraat 5";"6842";"CV ARNHEM";"Netherlands";"026/38 90 680";"026/38 90 674";"[---]*";"[---]*";"Contact for Scientific Queries";"Klinik und Poliklinik für UrologieUniversitätsklinikum Jena";"Mr.";"Prof. Dr.";"Marc-Oliver";"Grimm";"Am Klinikum 1";"07747";"Jena";"Germany";"03641/9 329901";"03641/9 329902";"marc-oliver.grimm@med.uni-jena.de";"http://www.urologie.uniklinikum-jena.de/Urologische+Klinik.html";"Contact for Public Queries";"Klinik und Poliklinik für UrologieUniversitätsklinikum Jena";"Mr.";"Prof. Dr.";"Marc-Oliver";"Grimm";"Am Klinikum ";"07747";"Jena";"Germany";"03641/9329901";"03641/9329902";"marc-oliver.grimm@med.uni-jena.de";"http://www.urologie.uniklinikum-jena.de/Urologische+Klinik.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"Deutsche Krebshilfe e.V.";"[---]*";"[---]*";"[---]*";"[---]*";"Buschstr. 32";"53113";"Bonn";"Germany";"0228/72 99 00";"0228/72 99 011";"deutsche@krebshilfe.de";"www.krebshilfe.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of  Intravesical BCG Instillations <br/>Versus Reduced Number of Intravesical Instillations with Standard Dose of BCG. <br/>";"NIMBUS";"http://www.uroweb.org/research/projects/";"Intravesical instillation of BCG is a widely accepted strategy to prevent recurrence of non muscle invasive bladder cancer. The most accepted treatment schedule is induction of BCG: weeks 1 through 6 plus maintenance (weeks 1,2,3) at months 3,6 and 12, but it is unknown how many administrations are really necessary. Scientific evidence prones to the hypothesis that after an initial sensitization to BCG antigens has occurred the number of instillations can be reduced for a proper anamnestic immune response resulting in similar clinical efficacy and potentially less side-effects and costs. <br/>The primary objective of this study is to identify if reduced number of BCG instillations are not inferior to standard number and dose intravesical BCG treatment in patients with high grade NMIBC. The primary endpoint for inferiority analysis is time to first recurrence.<br/>The secondary objectives are to identify if number and grade of recurrent tumors, rate of progression to a higher stage (T2 or higher) of the disease and safety, specifically the presence of treatment related toxicity > grade 2 differ between the two study arms. <br/>With the protocol amended final Version 5-DE, Nov 15th 2018 in- and exclusion criteria were adapted and the recruitment period was extended.";"Intravesical instillation of BCG is a widely accepted strategy to prevent recurrence of non muscle invasive bladder cancer. The most accepted treatment schedule is induction of BCG: weeks 1 through 6 plus maintenance (weeks 1,2,3) at months 3,6 and 12, but it is unknown how many administrations are really necessary. Scientific evidence prones to the hypothesis that after an initial sensitization to BCG antigens has occurred the number of instillations can be reduced for a proper anamnestic immune response resulting in similar clinical efficacy and potentially less side-effects and costs. <br/>The primary objective of this study is to identify if reduced number of BCG instillations are not inferior to standard number and dose intravesical BCG treatment in patients with high grade NMIBC. The primary endpoint for inferiority analysis is time to first recurrence.<br/>The secondary objectives are to identify if number and grade of recurrent tumors, rate of progression to a higher stage (T2 or higher) of the disease and safety, specifically the presence of treatment related toxicity > grade 2 differ between the two study arms. <br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005651";"2020-01-06T13:07:48.182+01:00";
"DRKS00000287";2009/12/09;2009/07/09;yes;"Approved";"301/09";"Ethik-Kommission der Universität Ulm";"Universal Trial Number (UTN)";"U1111-1112-8086";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2009-013956-62";"[---]*";"Primary Registry-ID";"99665363";"ISRCTN";"Sponsor-ID";"DEMIJO";"Universitätsklinikum Ulm";;;;"ICD10";"F32.0";"Mild depressive episode";"ICD10";"F32.1";"Moderate depressive episode";;;;;;;;;;"Arm 1";"SJW (600mg/d up to 900mg/d) orally; duration of intervention per patient: 12 weeks";"Arm 2";"placebo orally; duration of intervention: 12 weeks";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Other";"Parallel";"IV";"[---]*";"Assessment of efficacy of SJW (Neuroplant® 300mg N) compared with PBO in the acute treatment of adolescents who meet criteria for mild to moderate MDD.<br/>Primary efficacy endpoint: CGI-I dichotomized 1-2 vs. >= 3 at week 12";"Further measures of efficacy, safety and pharmacokinetics of SJW. Additionally quality of life and social functioning after treatment with SJW.<br/>Key secondary endpoint(s): Improvement in CDRS-R total score and other psychometric scales indicating improvement of symptoms of depression and social functioning at week 6 and 12, hyperforin kinetics at week 6, metabolizer pheno-type<br/>Assessment of safety: Adverse Events (AEs) by monitoring and usual documentation acc. GCP, Adverse Event questionnaires (PAERS, C-SSRS), SHBQ for self-harming/suicidal ideations or attempts";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/11/03;"Actual";"238";2012/08/29;"Multicenter trial";"National";"Both, male and female";"12";"Years";"17";"Years";"Participant is able to understand the study and its procedures according to his or her age. Caregivers have to be able to understand the study, the study procedures, individual consequences for their child. <br/>Written consent and assent of the caregivers and participants which is dated by the caregivers/participants before any study exam or procedure is conducted.<br/>Adolescents with mild to moderate MDD <br/>Symptoms of depression stable for about 6 weeks before entering the trial. <br/>Female patients must test negative for pregnancy during screening at baseline-visit. Furthermore, female patients must agree to abstain from sexual activity or to use a reliable method of birth control as determined by the investigator during the study.";"Other psychiatric disorders<br/>Acute risk of suicide in the opinion of the investigator at Visit 1<br/>Other non-psychiatric disorders as specified as follows:<br/>diagnosis of epilepsy, any intracranial disease<br/>Q above 80<br/>Start of psychotherapy<br/>Treatment with other AD or psychopharmacologically active substances<br/>Contraindications or hypersensitivity to SJW<br/>Treatment with drugs that interact with SJW or CYP3A4";"Primary Sponsor";"Universitätsklinikum Ulm<br/>Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie";"[---]*";"[---]*";"[---]*";"[---]*";"Steinhövelstr. 5";"89075";"Ulm";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Vivantes Klinikum im FriedrichshainKlinik für Kinder- u. Jugendpsychiatrie, Psychotherapie und Psychosomatik";"Mr.";"Professor Dr. med.";"Michael";"Kölch";"Landsberger Allee 49, Haus 8 ";"10249";"Berlin";"Germany";"+49(0)30 130 23 8001";"+49(0)30 130 2923 8001";"Michael.Koelch@vivantes.de";"http://www.vivantes.de/seelische-gesundheit/kliniken-fuer-kinder-und-jugendliche";"Contact for Public Queries";"Universitätsklinikum Ulm<br/>Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie";"Mr.";"Professor Dr. med.";"Michael";"Kölch";"Steinhövelstr. 5";"89075";"Ulm";"Germany";"0731 - 500 61608";"0731 - 500 61602";"michael.koelch@uniklinik-ulm.de";"www.uniklinik-ulm.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Projektträger im DLR <br/>Gesundheitsforschung";"[---]*";"[---]*";"[---]*";"[---]*";"Heinrich-Konen-Str. 1";"53227";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.";"DEMIJO";"[---]*";"Labelled as a phytopharmacon in Germany, SJW has not been put through controlled clinical trials to demonstrate its efficacy, safety and recommended dose in minors in order to obtain its license according to German regulatory procedures. Therefore SJW is labelled for the use in children and adolescents, it is the most frequent prescribed antidepressant in children and adolescents, but efficacy and safety has not been proven as it would be required in case of a synthetic antidepressant. Therefore a sound RCT on SJW in adolescents is a public health imperative in Germany.";"This is a Phase 4, multicenter, randomized, double-blind, PBO-controlled, study in adolescents aged 12 to 17 years meeting DSM-IV-TR defined criteria for mild to moderate major depressive disorder (MDD). Safety and efficacy of orally delivered SJW (Neuroplant® 300mg N) will be assessed. The study consists of 2 periods: Period I is a screening period; Period II is a 12-week double-blind acute therapy period. The total duration of the study is approximately 38 weeks. The total number of randomly assigned patients in this study is anticipated to be approximately 216, with approximately 108 assigned to each of 2 arms: SJW (Neuroplant® 300mg N) and PBO.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000287";"2013-10-15T12:26:33.600+02:00";
"DRKS00003549";2012/02/10;"[---]*";yes;"Approved";"133/11";"Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-001765-41";"[---]*";"BfArM-No.";"4037761";"[---]*";;;;;;;;;;"MedDRA";"[---]*";"10027475 (LLT): Metastatic breast cancer";"ICD10";"C50.9";"Malignant neoplasm: Breast, unspecified";;;;;;;;;;"Arm 1";"BIBW 2992 (Afatinib), 40 mg/day oral use (tablet), daily and vinorelbine, 25 mg/m² days 1 & 8 every 21 days, intravenous infusion over 10-15 minutes.<br/><br/>Duration of treatment continuously, this means, stop only in case of progression or start of a new treatment (or withdrawal of informed consent to participate in the study).";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"N/A";"The primary objective is to determine the 6-month progression free survival rate.";"Secondary endpoints: Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1), Safety, Time-to-Progression (TTP), and Overall Survival (OS).";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Frauenklinik";"Magdebug";"Doctor's Practice";"[---]*";"Berlin";"Doctor's Practice";"[---]*";"Hamburg";"Doctor's Practice";"[---]*";"Hildesheim";"Medical Center";"Onkologisches Zentrum Süd, Vivantes Tumorzentrum";"Berlin";"Doctor's Practice";"[---]*";"Bottrop";"Medical Center";"Klinik für Frauenheilkunde und Geburtshilfe";"Chemnitz";"Medical Center";"Onkologisches Zentrum Regensburg";"Regensburg";"University Medical Center";"Universitätsfrauenklinik";"Düsseldorf";"Medical Center";"St. Marien Amberg Frauenklinik und Brustzentrum";"Amberg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/07/13;"Actual";"40";2013/09/25;"Multicenter trial";"National";"Female";"18";"Years";"[---]*";"no maximum age";"1. Female patients ≥ 18 years<br/>2. Histologically confirmed diagnosis of intermediate HER2-overexpressing breast cancer<br/>3. Stage IV metastatic disease<br/>4. Must have received anthracycline-based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer<br/>5. Must have received one first-line chemotherapy for metastatic breast cancer<br/>6. Must have (archived) tumour tissue sample available for central re-assessment of HER2 status and prove to be intermediate HER2-positive. HER2 intermediate status is defined as IHC 2+ and FISH-negativity.<br/>7. Must have at least one measurable lesion according to RECIST 1.1. Patient with only skin lesions will not be eligible.<br/>8. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.<br/>9. Life expectancy of at least six (6) months.<br/>10. Written informed consent that is consistent with ICH-GCP guidelines. <br/>11. Must be eligible for treatment with BIBW 2992 and vinorelbine.<br/>";"1. Prior treatment with EGFR/HER2-targeted tyrosine kinase inhibitors, i.e. lapatinib<br/>2. Prior treatment with vinorelbine <br/>3. Known pre-existing interstitial lung disease<br/>4. Radiotherapy, chemotherapy, hormone therapy, immunotherapy or surgery (other than biopsy) within 4 weeks (2 weeks for hormone therapy) prior to start of treatment with BIBW 2992 and vinorelbine.<br/>5. Active brain metastases <br/>6. Any other current malignancy or malignancy diagnosed within the past five (5) years (other than non-melanomatous skin cancer and in situ cervical cancer).<br/>7. Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom, e.g. Crohn's disease, malabsorption or CTC grade ≥ 2 diarrhoea of any aetiology.<br/>8. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of ≥3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to start of study treatment.<br/>9. Cardiac left ventricular function with resting ejection fraction of less than 50 %.<br/>10. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.<br/>11-15. Laboratory values according to specified ranges.<br/>16. Women of childbearing potential, unwilling to use a medically acceptable method of contraception during the trial<br/>17. Pregnancy or breast-feeding.<br/>18. Patients unable to comply with the protocol.<br/>19. Known hepatitis B infection, known hepatitis C infection or known HIV carrier.<br/>20. Known or suspected active drug or alcohol abuse.<br/>21. Requirement for treatment with any of the prohibited concomitant medications <br/>22. Any contraindications for therapy with vinorelbine or BIBW 2992.<br/>23. Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.<br/>24. Use of any investigational drug within 4 weeks of start of treatment.<br/>";"Primary Sponsor";"Universitätsklinikum Magdeburg";"[---]*";"[---]*";"[---]*";"[---]*";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"[---]*";"[---]*";"[---]*";"www.med.uni-magdeburg.de";"Contact for Scientific Queries";"Universitätsklinikum Magdeburg<br/>Klinische Studienzentrale (CSC)";"Mr.";"Dr.";"Christian";"Glier";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"0049 391 67-21839";"[---]*";"christian.glier@med.ovgu.de";"www.med.uni-magdeburg.de";"Contact for Public Queries";"Universitätsklinikum Magdeburg<br/>Frauenklinik";"Mr.";"Dr.";"Joachim";"Bischoff";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"0049 391 67 17301";"[---]*";"Joachim.Bischoff@med.ovgu.de";"www.med.uni-magdeburg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Boehringer Ingelheim Pharma GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"55216";"Ingelheim";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines";"[---]*";"[---]*";"The purpose of the trial is to investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine chemotherapy.<br/><br/>Patients with metastatic breast cancer and HER2 overexpressing by immunohistochemy (2+) and negative HER2 in-situ hybridisation after failure of first-line therapy for metastatic disease and having received anthracyclines may participate.<br/><br/>Continuous treatment with BIBW 2992 (one tablet daily) and vinorelbine (infusion on days 1 and 8, every 21 days) in the absence of disease progression or adverse events.<br/><br/>The primary objective is to determine the 6-month progression free survival rate.<br/>";"To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2 IHC 2+, HER2 FISH-negative , metastatic breast cancer after failure of first-line therapy for metastatic disease and having received anthracyclines.<br/><br/>Primary endpoint: Progression Free Survival (PFS).<br/><br/>Secondary endpoints: Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1), Safety, Time-to-Progression (TTP), and Overall Survival (OS).<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003549";"2013-10-02T23:17:11.380+02:00";
"DRKS00006236";2014/06/18;"[---]*";yes;"Approved";"66/14";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"EUDAMED-No.<br/>(for studies acc. to Medical Devices act)";"CIV-14-02-011880";"[---]*";;;;;;;;;;;;;"ICD10";"E10.74";"[generalization E10.7: Insulin-dependent diabetes mellitus; With multiple complications]";"ICD10";"E14";"Unspecified diabetes mellitus";;;;;;;;;;"Arm 1";"Standard therapy  complemented Shock Wave Therapy.<br/>In this trial the standard treatment of the diabetic foot syndrome is complemented by shock wave therapy  to improve the wound healing. By the combination therapy the wounds can heal within a shorter period.The expected effect of the extra corporals shock wave therapy (ESWT) is a decrease of wounds' size and an improvement in the healing process.";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"No";"Assessment whether ESWT with the linear focused device FBL10x5G2 improves secondary wound healing:<br/>- measurement of the wound area by photo planimetry (in % and mm2)<br/>- analyzing the rate of wound healing as reduction of the lesion divided by the initial area (in percent) in the treatment and follow up period (in %)";"- percentage of comlete wound closure .<br/>- tissue oxygenation and microvascular blood flow at wound border and within the wound by O2C measurement<br/>- tissue temperature of the wound bed outside and within the wound by thermography (IR-Kamera Fluke Ti25).<br/>-bactericidal effect: change in microbial count/ swab culture<br/>-percentage of change in pain symptoms on VAS scale 1 – 10<br/>- increased angiogenesis and increased growth factors in wound biopsy ";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/04/17;"Actual";"15";2018/03/31;"Monocenter trial";"National";"Both, male and female";"19";"Years";"[---]*";"no maximum age";"patients with diabetic foot syndrome:<br/>-chronic wound since at least 4 weeks<br/>- Wagner stage 1-2<br/>-ABI (ankle-brachial-index) 0.7-1.2<br/>- Patients with Diabetic mellitus receive a therpaiy HbA1c<=7,5%<br/>- appropriate pressure relief<br/>General inclusion criteria:<br/>-signed declaration of informed consent and data protection<br/>-males and females<br/>-older than 18 years<br/>";"-Presence of an ABI (=Ankle Brachial Index) of < 0.7 > 1,2<br/>- patient with malignant disease<br/>- Wagner stage 3-5<br/>- osteitis/Osteomyelitis in wound region<br/>- untreated wound infektion (leukocytes>12 000/miicroliter)<br/>- General exclusion criteria:<br/>- pregnancy<br/>- participation in other clinical studies either concurrently or within the last 30 days <br/>- Noncompliance (Patient does not wear the shoes, does not carry out local therapy or terminates it,<br/>- Evidence of any major life-threatening or serious medical condition (sytemic infection) <br/>- Heart pacemaker and implanted defibrillator";"Primary Sponsor";"Leitender Ärztliche Direktor Universitätsklinikum Freiburg";"Mr.";"Prof. Dr.";"J.R.";"Siewert";"HugstetterStr. 49";"79106";"Freiburg";"Germany";"0761-270-18060";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Abteilung für Allgemein und Viszeralchirurgie Chirurgische Universitätsklinik Freiburg";"Mr.";"Dr.";"Bernd";"Jänigen";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270-27690";"+49 761 278970";"bernd.jaenigen@uniklinik-freiburg.de";"[---]*";"Contact for Public Queries";"Abteilung für Allgemein und Viszeralchirurgie Chirurgische Universitätsklinik Freiburg";"Mr.";"Dr.";"Bernd";"Jänigen";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270-27690";"+49 761 278970";"bernd.jaenigen@uniklinik-freiburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Fa. Richard Wolf GmbH";"Mr.";"[---]*";"Werner";"Krauss";"Pforzheimer Str. 32";"75438";"Knittlingen";"Germany";"+49 7043 35 4334";"+49 7043 35 1255";"Werner.Krauss@richard-wolf.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Extracorporeal Shock Wave Therapy for secondary wound healing of diabetic foot syndrome – ESWT";"ESWT";"[---]*";"The standard treatment of the diabetic foot syndrome contains the optimal setting of the blood glucose, improvement of a circulatory disorder and a standardized local therapy like pressure discharge of the wound, <br/>wound cleansing and humid treatment of wound. Thereby about 60% of the wounds heal within 20 weeks. In this trial the basic treatment is complemented by shock wave therapy to improve the wound healing. By the combination therapy  the wounds can heal within a shorter period. <br/>The expected effect of the extra corporals shock wave therapy (ESWT) is a decrease of wounds' size and an improvement in the healing process.";"This study was planned to investigate the opportunity of introducing the ESWT in the treatment of chronic wounds. Patients with diabetic foot syndrome will be treated additional with the linearly focused shock wave (FBL10x5G2, medical cart PiezoDerm, Fa. Richard Wolf). The extracorporeal shock wave therapy (ESWT) is an established, very effective method of treatment. High-energy sound waves are produced and passed on tissues by a tube.<br/>The standard treatment of the diabetic foot syndrome contains the optimal setting of the blood glucose, improvement of a circulatory disorder and a standardized local therapy like pressure discharge of the wound, <br/>wound cleansing and humid treatment of wound. Thereby about 60% of the wounds heal within 20 weeks. In this trial the basic treatment is complemented by shock wave therapy to improve the wound healing. By the combination therapy  the wounds can heal within a shorter period. <br/>The expected effect of the extracorporeal shock wave therapy (ESWT) is a decrease of wounds' size and an improvement in the healing process. The linear focused device FBL10x5G2 is  licensed since the end of 2013 especially also for diabetic ulcers.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006236";"2018-08-08T10:44:38.847+02:00";
"DRKS00006359";2015/11/25;"[---]*";yes;"Approved";"172/14";"Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg";"Universal Trial Number (UTN)";"U1111-1163-9410";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2013-004414-18";"[---]*";;;;;;;;;;"ICD10";"K72.7";"[generalization K72: Hepatic failure, not elsewhere classified]";;;;;;;;;;;;;"Arm 1";"Rifaximin 550mg 1-0-1 per os for 90 days";"Arm 2";"550mg rifaximin bid 1-0-1 po for 90 days in combination with lactulose three to four times 7,5 - 15 ml up to 30-60 ml daily (to pass 2-3 semisoft stools/day) for 3 months";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"IV";"Yes";"Primary efficacy variable: neurocognitive function measured in CFF( Critical Flicker Test), NCT(Number Cancellation Test),VEP (Visually Evoked Potentials)<br/><br/><br/>Treatment Phase (EOT):<br/>Screening,<br/>Visit1 after 30 days +/-3 days,<br/>Visit 2 after 60 days +/-3 days,<br/>Visit 3 after 90 days +/-3 days,<br/><br/> <br/>Follow up after 120 days:<br/>Visit 5 6 weeks after end of Treatment (EOT)<br/>Visit 6 12 weeks after end of Treatment (EOT)  = end of study<br/>";"Secondary efficacy variable: -  EEG, quality of life and Health-Related Quality of Life (ECOG performance status and HR-QOL - EORTC QLQ C30)- changes in gut microbiome - influence of infection with H. pylori <br/><br/><br/>Visite:4  120 Tagen after end of Treatment (EOT)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Gastroentrologie, Hepatologie und Infektiologie";"Magdeburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/03/17;"Actual";"60";2016/11/05;"Monocenter trial";"National";"Both, male and female";"18";"Years";"90";"Years";"1. Male and female individuals 18 - 90 years of age at the time of enrollment who are mentally competent, willing and able to understand the nature and risks of the proposed study, and able to sign the consent form prior to study entry; <br/>2. Individuals with a projected life expectancy of 6 months or longer; <br/>3. Individuals who are able to comply with all study procedures and requirements; <br/>4. Female subjects with childbearing potential who have negative pregnancy test during screening period.<br/>5. diagnosis of liver cirrhosis, established either by histology or by typical signs in transabdominal ultrasound in combination with signs of portal hypertension (ascites, enlarged spleen, fundic or esophageal varices)<br/>6. presence of minimal hepatic encephalopathy (MHE)<br/>";"Individuals with one of the following medical conditions: <br/>1. Documented underlying allergic condition against rifaximin or lactulose<br/>2. Underlying blindness or eye axis deviation or red- green- color- blindness<br/>3. Individuals with a projected life expectancy of less than 6 months  <br/>4. overt hepatic encephalopathy<br/>5. antibiotic treatment within 28 days before study entry or during the study<br/>6. Individuals who are not in sufficient health status as determined by the outcome of medical history, physical assessment, and clinical judgment of the investigator.<br/>7. Individuals who are not able to follow the required study procedures for the whole period of the study.<br/>8. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject´s ability to participate in the trial.<br/>9. Individuals who are planned to be hospitalized or undergo surgery during the study period.<br/>10. Individuals who have participated in another clinical study within 30 days prior enrollment into the study.<br/>11. Individuals with ongoing drug- or alcohol abuse that, in the opinion of the investigator, would interfere with the safety of the subject or the evaluation of the study objectives.<br/>12. Individuals who are member of the research staff or have relatives who are member of the research staff.<br/>13. Female subjects with childbearing potential who have positive pregnancy test during screening period. Female subjects no use of common contraceptive methods. Pregnant and lactating women.<br/>14. Individuals with a medical history or any illness that may, in the opinion of the investigator, pose additional risk to the subject due to participation in the study.<br/>";"Primary Sponsor";"Medizinische Fakultät der Otto-von-Guericke Universität";"Mr.";"Prof. Dr. med  ";"Hermann-Josef";"Rothkötter";"Leipziger Str.44";"39218";"Magdeburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Medizinische Fakultät der Otto-von-Guericke-Universität, Klinik für Gastroenterologie, Hepatologie und Infektiologie";"Ms.";"Dr. med.";"Kerstin";"Schütte";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"0391 67-13249";"0391 67-13105";"kerstin.schütte@med.ovgu.de";"[---]*";"Contact for Public Queries";"Medizinische Fakultät der Otto-von-Guericke-Universität, Klinik für Gastroenterologie, Hepatologie und Infektiologie";"Mr.";"Dr. med.";"Christian";"Schulz";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"0391 67-13150";"0391  67-13105";"christian.schulz@med.ovgu.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"NORGINE";"[---]*";"[---]*";"[---]*";"[---]*";"Im Schwarzenborn 4";"35041";"Schwarzenborn";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Minimal hepatic encephalopathy (MHE) – influence of therapy with rifaximin on MHE and on the intestinal microbiome in patients with liver cirrhosis – the RiMINI-Trial ";"RiMINI";"[---]*";"Primary objectives:<br/>to compare continuous antibiotic therapy with rifaximin  combined with lactulose with continuous therapy with rifaximin alone in patients with MHE concerning neurocognitive function<br/><br/>Secondary objectives:<br/>to analyze the intestinal microbiome of the upper GI-tract in cirrhotic patients with minimal hepatic encephalopathy before, during and after therapy with rifaximin alone and before, during and after therapy with rifaximin combined with lactulose<br/><br/>60 Patients with minimal hepatic encephalopathy will receive either a treatment with continuous rifaximin or a combination of continuos rifaximin and lactulose and will be compared with respect to neurocognitive function";"Background<br/><br/>Minimal hepatic encephalopathy (MHE) is present in 30 to 84% of patients with liver cirrhosis (1). 531 patients with liver cirrhosis were treated in our department within 12 months and, based on clinical tests +/- hyperammonemia, 16,4 % ( n= 87) of these patients suffered from manifest hepatic encephalopathy. HE significantly affects neurocognitive functions leading to impaired quality of life, already if present in subclinical stages. <br/>Diagnosis of MHE is established by psychometric tests (e.g. number connection test, figure connection test, picture completion test). Objective and sensitive methods to assess MHE are visual evoked potentials and critical flicker frequency analysis (CFF). <br/><br/>A continuous therapy with rifaximin in combination with lactulose significantly reduces the risk of overt HE, recurrence and HE-related hospitalisations in randomized double-blind placebo-controlled clinical trials (1-3). The drug is approved for the therapy of overt HE in Germany. A therapy with lactulose has been shown to improve cognitive functions in patients with liver cirrhosis. It has not been addressed in prospective clinical trials so far, if a monotherapy with rifaximin is as effective as a combination therapy with rifaximin and lactulose in the treatment of MHE.<br/>Rifaximin is a minimally absorbed gut-selective antibiotic and thus impacts on gut microbiome. The role of the gut microbiome in the pathophysiology of hepatic encephalopathy is still little understood. Changes in gut microbiome of the upper gastrointestinal tract as result of therapy with rifaximin have not been addressed in clinical studies so far.<br/><br/><br/>Primary objective: To compare continuous antibiotic therapy with rifaximin combined with lactulose with continuous therapy with rifaximin alone in patients with MHE concerning neurocognitive function  <br/>Secondary objective:To analyze the intestinal microbiome of the upper GI-tract in cirrhotic patients with minimal hepatic encephalopathy before, during and after therapy with rifaximin alone and before, during and after therapy with rifaximin combined with lactulose   <br/><br/>References<br/>(1)    Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175-83.<br/>(2)    Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081.<br/>(3)    Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-3555.<br/><br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006359";"2018-02-28T10:19:02.822+01:00";
"DRKS00007817";2015/02/16;"[---]*";yes;"Approved";"27/13";"Ethik-Kommission bei der Ärztekammer des Saarlandes";"Universal Trial Number (UTN)";"U1111-1167-2354";"[---]*";;;;;;;;;;;;;"ICD10";"F32";"Depressive episode";"ICD10";"B18.2";"Chronic viral hepatitis C";;;;;;;;;;"Arm 1";"The intervention group receives the probiotic strains (lactobacillus helveticus and Bifidobacterium Longum) p.o. once a day for 60 days. At 30 and 60 days, patients will be assessed for severity of depressive and stress symptoms using the BDI-II and the PSS.";"Arm 2";"The control group receives an identical placebo p.o. once a day for 60 days.<br/>At 30 and 60 days, patients will be assessed for severity of depressive and stress symptoms using the BDI-II and the PSS.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"N/A";"N/A";"change in depression score using BDI-II from baseline to 30 and 60 days (after probiotic I placebo supplementation). ";"- changes in intestinal flora after 30 and 60 days of probiotic/placebo supplementation <br/>- changes in serum LFTS (ALT, AST, AP, GGT, Bilirubin, Albumin) after 30 and 60 days of a probiotic/placebo supplementation";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Saarland University Medical Center";"Homburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/07/10;"Actual";"30";2016/04/17;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Patients with the chronic hepatitis C virus infection and depression";"- Severe hepatic encephalopathy (i.e. CCF score <35 Hz)<br/>-Women who are pregnant or breastfeeding <br/>-Immunocompromised patients (as assessed by noting those taking immunosuppressive treatment or those with a known HIV infection)<br/>-Receiving depression-focused psychotherapy less than eight weeks of screening<br/>-Another diagnosis of mental illness <br/>-At risk of / or actively suicidal (assessed with BDI-II and by a pyschiatrist if needed)<br/>-Interferon therapy<br/>-Cirrhosis (ie, Fibroscan score > 16)<br/>-Intake of pre or probiotic products within previous four weeks<br/>-Participation in a clinical trial with investigational drug/device during past month before enrolment <br/>";"Primary Sponsor";"Lallemand Health Solutions, Institute Rosell Inc.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"H4P 2R2";"Montreal";"Canada";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Saarland University Medical Center, Department of Internal Medicine II";"Ms.";"Dr.";"Caroline";"Stokes";"Kirrberger Str. 1";"66421";"Homburg";"Germany";"+4968411623222";"[---]*";"caroline.stokes@uks.eu";"[---]*";"Contact for Public Queries";"Saarland University Medical Center, Department of Internal Medicine II";"Ms.";"Dr.";"Caroline";"Stokes";"Kirrberger Str. 1";"66421";"Homburg";"Germany";"+4968411623222";"[---]*";"caroline.stokes@uks.eu";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Lallemand Health Solutions, Institute Rosell Inc.";"[---]*";"[---]*";"[---]*";"[---]*";"6100, avenue Royalmount";"H4P2R2";"Montreal";"Canada";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Probiotic supplementation in patients with chronic liver disease, resulting from the hepatitis C virus ";"ProbioC";"[---]*";"Patients with chronic liver disease/hepatitis C virus infection frequently present with depressive symptoms, the prevalence of which appears to be higher compared to chronic liver disease of other aetiologies. This intervention study investigates whether probiotic supplementation improves depressive symptoms in patients with the chronic hepatitis C virus. <br/><br/>Our hypothesis: probiotic supplementation improves depressive symptoms in patients with the chronic hepatitis C virus infection.";"Patients with chronic liver disease are at increased risk for depressive and cognitive disorders, which have a strong influence on the quality of life. Pharmacological treatments for depression are not always effective, and some patients are not willing to take psychiatric drugs because they fear the side effects. Experimental studies have shown specific strains of intestinal bacteria to positively influence brain neurotransmitters which are implicated in depression. Moreover, clinical studies have shown that psychological distress and depressive symptoms can be alleviated by probiotic supplementation. Dysbiosis has been confirmed in patients with chronic liver disease and the hepatitis C virus infection. Treatment with antidepressants needs to be avoided in certain patients, because of the risk of adverse liver-related effects. We therefore want to perform a controlled study to investigate the role of probiotic supplementation for 60 days in depressive symptoms in patients with chronic hepatitis C virus infection.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007817";"2019-05-20T11:00:43.999+02:00";
"DRKS00007994";2015/06/11;"[---]*";no;"Approved";"112/2014";"Ethik-Kommission der Universität Witten/Herdecke";;;;;;;;;;;;;;;;"Free text";"[---]*";"Sleep Related Breathing Disorders (SRBDs), Patients with the indication for first-time initiation of BiLevel therapy. ";"ICD10";"G47.3";"Sleep apnoea";;;;;;;;;;"Arm 1";"Application of the TriLevel pressure profile during one half (split-night) of a treatment night with polysomnography in a sleep laboratory.";"Arm 2";"Application of the BiLevel pressure profile during one half (split-night) of a treatment night with polysomnography in a sleep laboratory.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Other";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Crossover";"N/A";"N/A";"Primary outcome parameters for the evaluation of therapeutic efficacy of the auto-Bi-/TriLevel therapy night are the apnea-hypopnea index (AHI) and the percentage of total sleep time (TST) with an oxygen Saturation < 90% (SpO2<90% in %TST). <br/>";"Outcome parameters of the split-night comparison of the Bi- and TriLevel pressure profile are the obstructive apnea index (oAI) and the percentage of total sleep time (TST) with an oxygen saturation < 90% (SpO2<90% in %TST). In addition the following outcome parameters are of relevance for the comparison: tidal volume, breaths per minute (bpm), pressure parameters  (IPAP, EEPAP, EPAP),<br/>leakage and relative inspiration time (Ti/T).  The outcome parameters and laboratory reports regarding evtl. manual changes of therapeutic parameters will provide information regarding the comparison of the Bi- and TriLevel pressure profile. ";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"HELIOS Klinik Hagen-Ambrock";"Hagen";"Medical Center";"Evangelisches Krankenhaus Herne";"Herne";"Medical Center";"Städtisches Klinikum Karlsruhe ";"Karlsruhe";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/04/01;"Actual";"80";2016/01/15;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Diagnosis of obstructive, mixed or complex sleep apnea; indication for first-time initiation of BiLevel therapy within clinical routine, time to first time diagnosis ≤ 6 months; Age ≥ 18 years; signed informed consent ";"Missing signed informed consent form; Concurrent participation in another study that influences the initiation of BiLevel therapy by specifications of device settings or titration procedure; Acute cardiac decompensation; Severe arrhythmia; Severe hypotension, particularly in combination with intravascular volume depletion; Severe epistaxis; High risk of barotrauma; Severe chronic/decompensated pulmonary conditions; Pneumothorax or pneumomediastinum; Pneumocephalus; Cranial trauma; Status following brain surgery or surgical intervention on the pituitary gland or the middle/inner ear; Acute sinus infection (sinusitis), middle ear infection (otitis media) or perforated eardrum; Dehydration; In each case the decision whether to use this therapy device lies with the doctor in charge. ";"Primary Sponsor";"Heinen + Löwenstein GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Arzbacher Straße 80";"56130";"Bad Ems";"Germany";"+49 (0) 2603 9600-0";"+49 (0) 2603 9600-50";"[---]*";"www.hul.de";"Contact for Scientific Queries";"HELIOS Klinik Hagen - Ambrock";"Mr.";"PD Dr. med.";"Georg";"Nilius";"Ambrocker Weg 60";"58091";"Hagen";"Germany";"+49 2331 974 2000";"+49 2331 974 2009";"georg.nilius@helios-kliniken.de";"www.helios-kliniken.de/hagenambrock";"Contact for Public Queries";"Pneumologisches InstitutHELIOS Klinik Hagen";"Ms.";"[---]*";"Ulrike";"Domanski";"Ambrocker Weg 60";"58091";"Hagen";"Germany";"+49 2331 974 2080";"+49 2331 974 52080";"ulrike.domanski@helios-kliniken.de";"http://www.helios-kliniken.de/klinik/hagen-ambrock.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Heinen + Löwenstein GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Arzbacher Straße 80";"56130";"Bad Ems";"Germany";"+49 (0) 2603 9600-0";"Telefax +49 (0) 2603 9600-50";"[---]*";"www.hul.de";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Weinmann Geräte für Medizin GmbH + Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"Kronsaalsweg 40";"22525";"Hamburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"Extended validation of the auto-Bi/TriLevel therapy modes prismaLINE";"prismaLINE auto-Bi/TriLevel Studie";"[---]*";"In the treatment of sleep related breathing disorders (SRBDs) distinct forms of therapy with positive airway pressure (PAP) are applied.  During BiLevel therapy pressure levels differ between expiration and inspiration and are applied by means of a respiratory mask. Application of different pressure levels during expiration and inspiration enables administration of ventilatory support as well as treatment of respiratory disturbances during sleep. In recent years BiLevel devices with auto-regulation have become established on the market. These devices detect the respiratory flow as well as breathing disturbances and adjust the applied therapeutic pressure and device behavior according to treatment needs. This study aims at investigating the efficacy of the auto-adaptive regulation of an auto-BiLevel device during treatment initiation in sleeb laboratory settings. In addition an extension of the classic BiLevel pressure profile is evaluated. ";"Auto-BiLevel therapy is an established treatment form for sleep related breathing disorders (SRBDs). Among other indications, BiLevel therapy is applied for treatment of patients with obstructive sleep apnea (OSA) and high pressure needs. It is further used for treatment of patients with mixed or complex sleep apnea as well as hypoventilation, e.g. obesitas hypoventilation syndrome (OHS) or overlap patients. BiLevel devices of the prismaLINE platform (Weinmann) provide the option to apply an auto-adaptive regulation.  An additional option is the possibility to apply an extension of the classic BiLevel pressure profile, the TriLevel pressure profile. During TriLevel treatment application of the critical therapeutic pressure for obstruction treatment is constrained to the end-expiratory phase, which is susceptible to the generation of obstructions. Therapy pressure at beginning of expiration is decreased up to 4hPa. This aims at increasing therapy comfort and at reducing average and peak therapeutic pressure. In this national multicenter clinical trial the therapeutic efficacy of the applied pressure profiles of the auto-BiLevel therapy modes (prismaLINE platform, Weinmann) is further validated. In addition, this study aims at obtaining further information regarding the quality of event-recognition, the pressure ramp to inspiration and trigger behavior at different respiratory profiles and artifact situations.  A secondary aim is the exploratory comparison of the Bi- and TriLevel pressure-profile regarding the efficacy of obstruction treatment and ventilatory efficacy. To do so, a randomized split-night application of each pressure profile is addministered.  In total, the acquisition of minimal 80 up to maximal 150 patients is planned. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007994";"2017-05-17T09:07:04.200+02:00";
"DRKS00012593";2017/11/24;"[---]*";yes;"Approved";"477/16S";"Ethik-Kommission der Fakultät für Medizin der Technischen Universität München";;;;;;;;;;;;;;;;"Free text";"[---]*";"dietary behaviour<br/>";"Free text";"[---]*";"Anthropometric and biological parameters of health<br/><br/>";;;;;;;;;;"Arm 1";"Interventiongroup: Usage of a personalised and automatised smartphone application (personalised recipe recommendations, self-monitoring of progress, personalised feedback about critical nutrients, etc) over a 6-months period.";"Arm 2";"Control group: Population-based nutrition recommendations in PDF and printed form at the start, after 3 and after 6 months of the study.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Prevention";"Parallel";"III";"[---]*";"Healthy Eating Index (evaluated by Food Frequency Questionnaire after 0, 3 and 6 months)<br/><br/>Nutrient intake (evaluated by Food Frequency Questionnaire after 0, 3 and 6 months)<br/><br/>Body weight, height, waist and hip circumference (self-measurements after 0, 3 and 6 months)<br/><br/>Physical activity (evaluated by Baecke questionnaire after 0, 3 and 6 months)<br/><br/>Blood biomarkers (evaluated using Dried Blood Spots after 0, 3 and 6 months)<br/><br/>";"Evaulation of the mobile application (e.g. drop-out rates, frequency and intensity of app usage, satisfaction of the different features of the app) using a feedback questionnaire after 6 months and using data logging of the app during the entire study period<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"other";"[---]*";"Whole Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/10/23;"Actual";"344";2018/03/06;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Owner of an Android Smartphone<br/>Owner of a body scale<br/>Body Mass Index between 25 and 40 kg/m2<br/>Absence of food allergies or intollerances<br/>Generally healthy<br/>";"Untreated chronic diseases<br/>Chronic diseases related to nutrition<br/>";"Primary Sponsor";"Lehrstuhl für Ernährungsphysiologie der Technischen Universität München ";"Ms.";"Prof.";"Hannelore";"Daniel";"Gregor-Mendel-Str. 2";"85354";"Freising";"Germany";"08161 71 3400";"[---]*";"hannelore.daniel@tum.de";"http://www.nutrition.tum.de/startseite/";"Contact for Scientific Queries";"Lehrstuhl für Ernährungsphysiologie der Technischen Universität München";"Ms.";"M.Sc.";"Mira";"Madenach";"Gregor-Mendel-Str. 2";"85354";"Freising";"Germany";"+49 8161 71 2329";"[---]*";"mira.madenach@tum.de";"http://www.nutrition.tum.de/groups/png/madenach/";"Contact for Public Queries";"Lehrstuhl für Ernährungsphysiologie der Technischen Universität München";"Ms.";"M.Sc.";"Mira";"Madenach";"Gregor-Mendel-Str. 2";"85354";"Freising";"Germany";"+49 8161 71 2329";"[---]*";"info@nutrilize.de";"https://www.nutrilize.de/wordpress/?page_id=140";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Bonn";"[---]*";"[---]*";"[---]*";"[---]*";"Heinemannstr. 2";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Personalised Nutrition and Communication - Evaluation of an automised personalised nutrition application for optimization of nutrition behaviour<br/>";"[---]*";"https://www.nutrilize.de<br/><br/>";"As part of the enable cluster, a project funded by the Federal Ministry for Education and Research (BMBF), nutritionists and computer scientists of the Technical University Munich (TUM) have developed the nutritional app ""Nutrilize"". In a 6-months study it will be evaluated whether a personalized dietary advice with the help of this app can positively influence the nutritional habits of the users.";"Nutrition has a substantial influence on health and plays an important role in the development of chronic diseases such as, diabetes mellitus and cardiovascular disease. Nutritional recommendations, as a preventive measure, are often based on general population policies, without addressing individual factors. In the EU-funded project Food4Me, initial approaches to personalized nutrition were made, which are further developed in this subproject of the BMBF-sponsored enable cluster project. A mobile nutrition application, which is based on the concept of Food4Me, which is newly developed by us, is to be tested for its effectiveness to optimize the dietary habits individually. For this purpose, healthy subjects with a BMI between 25 and 40 kg/m2 are invited to participate in a 6-month randomized control study, in which they are to use the mobile nutritional application we have created. Participants record their dietary habits and physical activity in a digital diary and provide information on their food preferences and anthropometry. In addition, they will collect blood samples in the form of Dried Blood Spots (DBS) at home and send them to us for the analysis of biomarkers. On the basis of these personal data, the mobile application will then algorithmically recommend recipes and resources that address the individual needs of the participants. In addition, the participants can follow the course of their food intake, their energy requirements, their physical activity, their weight etc. in the application (self-tracking).";"Recruiting stopped after recruiting started ";"Further trial documents";"fa86c187-7b97-4525-849f-b5dcaf73f55d";"Teilnehmerinformation Hauptstudie.pdf";"Teilnehmerinformation";"Further trial documents";"f5dc5e71-0ddb-487a-8412-db0df08ecc88";"Einverständniserklärung Hauptstudie.pdf";"Einverständniserklärung";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012593";"2018-06-06T14:23:02.864+02:00";
"DRKS00012484";2017/05/26;"[---]*";yes;"Approved";"23/3/17";"Ethik-Kommission der Medizinischen Fakultät der Georg-August-Universität Göttingen";;;;;;;;;;;;;;;;"ICD10";"I60";"Subarachnoid haemorrhage";"ICD10";"I61";"Intracerebral haemorrhage";"ICD10";"I62";"Other nontraumatic intracranial haemorrhage";"ICD10";"I63";"Cerebral infarction";"ICD10";"I64";"Stroke, not specified as haemorrhage or infarction";"Arm 1";"Additionally to standard therapy, group 1 receives an intensive upper limb strength training with an intensity of 80 % of the maximum force (determined with the 1RM = one repetition maximum). It is a sixty-minute circuit training, 3 times per week, for 3 weeks (a total of nine training units). It includes five standardized functional exercises, performed in three series, each with about 10 repetitions. The resting time between the exercises and series is 120 seconds. The resting time between training units is 24 hours. The training includes unilateral, active and functional exercises. Heavy objects and elastic bands are used to rise resistances systematically. The standard rehabilitation for the arm includes mobilization, stretching, arm and hand motor training, strengthening exercises, robot- and device-supported function training and activity training.";"Arm 2";"Additionally to standard therapy, group 1 receives a functional arm training with an intensity of 40 % of the maximum force (determined with the 1RM = one repetition maximum). It is a sixty-minute circuit training, 3 times per week, for 3 weeks (a total of nine training units). It includes five standardized functional exercises (the same as in group 1), performed in three series, each with about 10 repetitions. The resting time between the exercises and series is 120 seconds. The resting time between training units is 24 hours. The training includes unilateral, active and functional exercises. Objects or elastic bands must be gripped and moved over different distances. During training the number of repetitions increased - from initially ten to 18 in the last training unit (in each training one repetition is added). The standard rehabilitation for the arm includes mobilization, stretching, arm and hand motor training, strengthening exercises, robot- and device-supported function training and activity training. ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"The primary endpoint is grip strength. It is measured by a hand-held dynamometer (unit: kilogram). The measurement takes place immediately before and after the three weeks of training.";"The Upper Extremity Fugl-Meyer assessment (0 to 66 points) measures sensorimotor impairments.<br/><br/>The Box & Block Test assesses the dexterity of arm activities. The number of cubes successfully transported in one minute (0 – 150 pieces) will be documented.<br/><br/>Motricity Index (0 – 100 points) measures upper extremity strength of representative arm movements after stroke<br/><br/>With the Goal Attainment Scale, individual goals of the patient can be evaluated in a standardized way. The attainment of participatory goals is assessed with a five-stage scale (-2 to +2 points).<br/><br/>The Modified Ashworth Scale (0 - 5 points) measures changes in muscle tone and reflex activity.<br/><br/>The measurement takes place immediately before and after the three weeks of training.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Asklepios Kliniken Schildautal Seesen, Klinik für Neurologische Rehabilitation";"Seesen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/05/29;"Actual";"78";2018/05/01;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Subacute stroke patients with a Barthel Index > 29<br/>Sitting Balance Score greater than or equal to 2<br/>ability to put the paretic arm from the lap on a table <br/>Medical Research Council score of 2 - 4 in shoulder abduction, elbow flexion or finger flexion<br/>Passive range of motion: shoulder abduction, flexion and elbow flexion at least 90 °, touch of the fingers with the thumb, submaximal finger extension<br/>Apraxia Screen of TULIA score of at least 5";"4 points on the Modified Ashworth Scale<br/>pain of the affected arm with greater than 5 points on a pain scale<br/>armparesis caused of other neuromuscular or neurological disorders and / or syndromes <br/>manifest hereditary diseases (Such as cardiac insufficiency (> NYHA 1), angina pectoris, myocardial infarction within 120 days before the beginning of the study, cardiomyopathy, hypertension (WHO grade 2 systole 160-179 mmHg and diastole 100-109 mmHg) or difficultly controllable cardiac arrhythmia)<br/>inflammation or infections that are associated with fever, bad condition, or insulation";"Primary Sponsor";"Asklepios Kliniken Schildautal Seesen";"Ms.";"[---]*";"Susan";"Högg";"Karl-Herold-Straße 1";"38723";"Seesen";"Germany";"05381 74 2301";"[---]*";"s.hoegg@asklepios.com";"https://www.asklepios.com/seesen/";"Contact for Scientific Queries";"Asklepios Kliniken Schildautal Seesen";"Ms.";"[---]*";"Susan";"Högg";"Karl-Herold-Straße 1";"38723";"Seesen";"Germany";"05381 74 2301";"[---]*";"s.hoegg@asklepios.com";"https://www.asklepios.com/seesen/";"Contact for Public Queries";"Asklepios Kliniken Schildautal Seesen";"Ms.";"[---]*";"Susan";"Högg";"Karl-Herold-Straße 1";"38723";"Seesen";"Germany";"05381 74 2301";"[---]*";"s.hoegg@asklepios.com";"https://www.asklepios.com/seesen/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Asklepios Kliniken Schildautal Seesen";"Ms.";"[---]*";"Susan";"Högg";"Karl-Herold-Straße 1";"38723";"Seesen";"Germany";"05381 74 2301";"[---]*";"s.hoegg@asklepios.com";"https://www.asklepios.com/seesen/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Upper limb strength training in subacute stroke patients. A randomized controlled trial.";"[---]*";"[---]*";"This study´s objective is to investigate the savety and the effectiveness of a resistance arm training in subacute stroke patients. We will separate patients into two groups. Group 1 will receive (additionally to standard therapy) an intensive upper limb strength training with rising resistances. Group 2 will receive (additionally to standard therapy) a functional arm training with a rising number of repetitions. Training will be performed for 3 weeks. Patients will be examined before and directly after training for arm function, activities of daily living and participatory goals. Side effects will be systematically recorded.";"Prospective two-armed randomized controlled trail; pre-post-design<br/>Subacute stroke patients will be randomized into two groups: <br/>intervention group: intensive upper limb strength training with rising resistances;<br/>Control group: functional arm training with increasing repetitions<br/>Training will be performed 3 times per week for 3 weeks.<br/>Measures: T0 baseline, T1 post-treatment, primary outcome is grip strength, side effects will be systematically recorded in the training protocol<br/>Patients and assessors are blinded for group affiliation";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012484";"2019-09-10T18:51:40.521+02:00";
"DRKS00005127";2013/07/03;"[---]*";yes;"Approved";"S-327/2012";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";;;;;;;;;;;;;;;;"ICD10";"C79.3";"Secondary malignant neoplasm of brain and cerebral meninges";"ICD10";"C43";"Malignant melanoma of skin";;;;;;;;;;"Arm 1";"helical Tomotherapy of the whole brain (10x3Gy) with integrated boost to the brain metastases (10x5Gy) and hippocampal-sparing";"Arm 2";"conventional whole-brain radiotherapy 10x3Gy";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Toxicity quantified by absolute frequencies and percentages of side effects according to CTC Criteria Version 4. Follow-up visits every ~2 months for in total 1 year";"imaging response, local and loco-regional progression-free survival, overall survival and quality of life<br/>Imaging response will be evaluated according to the RECIST criteria and represented by percentages. Kaplan-Meier curves will be plotted and Cox-regression analyses will be conducted to investigate possible factors influencing survival. QoL will be measured with the EORTC-QoL-Q C30 and brain module BN-20, and results will be summarized by median, minimum and maximum scores, and represented by box plots. Follow-up visits (as previously mentioned in section primary endpoint) every ~2 months for 1 year";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Abt. für Strahlentherapie";"Heidelberg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/08/16;"Actual";"50";2017/07/31;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"• histologically confirmed malignant melanoma (MM)<br/>• MR-imaging confirmed >1 cerebral metastases (in case of resection, >1 remaining metastases)<br/>• age ≥ 18 years of age<br/>• Karnofsky Performance Score >/=60<br/>• For women with childbearing potential, (and men) adequate contraception.<br/>• Ability of subject to understand character and individual consequences of the clinical trial <br/>• Written informed consent (must be available before enrolment in the trial)<br/>";"• refusal of the patients to take part in the study<br/>• previous radiotherapy of the brain <br/>• Patients who have not yet recovered from acute high-grade toxicities of prior therapies<br/>• Known carcinoma < 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy<br/>• Pregnant or lactating women<br/>• Participation in another clinical study or observation period of competing trials, respectively<br/>• MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants)<br/>";"Primary Sponsor";"Universitätsklinikum Heidelberg";"[---]*";"[---]*";"[---]*";"[---]*";"Im Neuenheimer Feld 672";"69120";"Heidelberg";"Germany";"[---]*";"[---]*";"[---]*";"www.klinikum.uni-heidelberg.de";"Contact for Scientific Queries";"Abteilung für Strahlentherapie";"Mr.";"PD Dr.";"Florian";"Sterzing";"INF 400";"69120";"Heidelberg";"Germany";"06221-56-8202";"06221-56-5353";"florian.sterzing@med.uni-heidelberg.de";"[---]*";"Contact for Public Queries";"Abteilung für Strahlentherapie";"[---]*";"[---]*";"Studiensekretariat";"der Strahlentherapie";"INF 400";"69120";"Heidelberg";"Germany";"06221-56-8202";"[---]*";"strahlentherapie@med.uni-heidelberg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum Heidelberg";"[---]*";"[---]*";"[---]*";"[---]*";"Im Neuenheimer Feld 672";"69120";"Heidelberg";"Germany";"[---]*";"[---]*";"[---]*";"www.klinikum.uni-heidelberg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Whole brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma – a randomized trial";"BRAIN-RT";"[---]*";"Comparison of a conventional whole-brain radiotherapy in patients with brain metastases from malignant melanoma with a special radiation therapy technique (helical Tomotherapy) with dose escalation to the single brain metastases.";"Patients with malignant melanoma (MM) may develop cerebral metastases, requiring radiotherapeutic treatment. In patients with 1-3 intracerebral lesions, stereotactic radiosurgery (SRS) has been established as a treatment option. For patients with 4 or more lesions, whole brain radiotherapy (WBRT) is considered the standard treatment. In certain patients with cerebral metastases, radiation treatment using whole brain helical tomotherapy with integrated boost and hippocampal-sparing may be indicated. <br/>The present trial aims to exploratory investigate the treatment response to ‘conventional whole brain radiotherapy ’and ‘whole brain helical tomotherapy with integrated boost and hippocampal-sparing’ in melanoma patients.<br/>The primarily investigated endpoint is treatment toxicity. Secondary endpoints include imaging response, local and loco-regional progression-free survival, overall survival and quality of life.<br/>";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"https://doi.org/10.2147/CMAR.S204729";"Vollpublikation";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005127";"2020-01-03T13:35:50.248+01:00";
"DRKS00011616";2017/07/11;"[---]*";no;"Approved";"S15(a)/2017";"Ethik-Kommission der Landesärztekammer Brandenburg";;;;;;;;;;;;;;;;"Free text";"[---]*";"unspecific subfertility in men";"Free text";"[---]*";"childlessness";;;;;;;;;;"Arm 1";"Verum Group: Taking AM019016 (verum), dietary food, 3 capsules once a day to a meal with some liquid, oral intake, over 12 weeks. Ingredients: Vitamin D, E, C, B12, B6, B2, Folic Acid, L-Carnithine, L-Arginine, Coenzyme Q10, Zinc, Selenium, Beta Carotene, Copper, Pigrafert (combination of pine bark, grape seed, green tea extract).";"Arm 2";"Placebo group: Taking AM019016 (placebo), 3 capsules once a day with a meal with some liquid, oral intake, over 12 weeks. Ingredients Placebo: maltodextrin, release agent magnesium salts of feed fatty acids and dye E171 and hydropropylmethylcellulose in the capsule shell. Free of gluten and lactose. ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"N/A";"N/A";"Parameters for the assessment of the benefit by  preparation and evaluation of spermograms according to the WHO criteria (2010, 5th edition):<br/> <br/>Change in progressive motility (visit 1 vs. visit 2) <br/>Change of sperm concentration (visit 1 vs. visit 2) Change of sperm morphology (visit 1 vs. Visite 2) Change of sperm total (Visite 1 vs. Visite 2) <br/>Change in total motility (visit 1 vs. Visite 2) <br/>Change of the ejaculate volume (visit 1 vs. Visite 2) <br/>Occurrence of pregnancy during the study and about 3 months after visit 2 <br/>Global evaluation of the benefit by the physician (to visit 2) on a scale with the four assessment points ""very good"", ""good"", ""moderate"" and ""bad"".";"Parameters for the assessment of tolerability: <br/>Adverse events and serious adverse advents during the clinical trial <br/><br/>Global evaluation of the tolerability by the physician and subjects using a scale with the four assessment points ""very good"", ""good"", ""moderate"" and ""bad"" at final visit.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Doctor's Practice";"[---]*";"Kleinmachnow";"Doctor's Practice";"[---]*";"Berlin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/08/23;"Actual";"200";2019/03/03;"Multicenter trial";"National";"Male";"18";"Years";"[---]*";"no maximum age";"1. Men with existing unfulfilled child wish<br/>2. Uspecific (idiopathic) subfertility diagnosed by an already existing sperm analysis (may not be older than four weeks) and whilst observing a sexual abstinence period of at least 2 days to a amaxium of 7 days; according to WHO reference values (2010, 5th Edition):<br/>- < 39 million total number of spermatozoa per ejaculate sample and / or<br/>- < 32 % progressive motile spermatozoa<br/>4. Readiness to comply with at least 2 to a maximum of 7 Days of sexual abstinence before creating a Spermogram<br/>5. Consent to take a dietary food for three months<br/><br/>A written consent of the subject after written and oral enlightenment by the doctor about nature, scope, importance, potential benefits and possible risks of the clinical trial is the prerequisite for participation in the clinical trial.";"1. Presumed or established organic causes of subfertility<br/>2. azoospermia, aspermia, anejaculation<br/>3. Varicocele of the testis, assessment according to medical examination discretion<br/>4. Urogenital infections such as e.g. Prostatitis, epididymitis, Orchitis, sexually transmitted diseases<br/>5. Known relevant endocrine disorders, e.g.<br/>Hypogonadotropic hypogonadism (assessment according to Medical discretion)<br/>6. Operational interventions in the past:<br/>- Orchidopexy in cryptorchid or hoddentorsion, varicocele surgery, hodentrauma, pelvine, inguinal or scrotal surgical procedures<br/>- any surgical intervention during the last 6 months before the start of the study and planned interventions during the study<br/>7. Systemic disorders that could influence the outcome of the study, assessment by medical judgment (e.g., diabetes, renal failure, hepatic impairment, malignancy, obesity)<br/>8. Pesticide exposure in the past and present<br/>9. Ingestion of substances or other forms of therapy that could influence the study result  according to medical discretion, eg:<br/>- Medication, e.g. Anabolic agents, sulfasalazines, alpha-blockers, cimetidine and aldosterone antagonists, androgens, 6 months before study initiation and during the study<br/>- Regular intake of dietary supplements / supplementary balanced diets in the last 6 months before the start of the study and during the study (with the exception of the study preparation)<br/>- Applied therapy to improve sperm quality in the last 6 months before the start of the study and during the study<br/>- Application of antioxidants in the last 6 months before study start and during the study<br/>10. Known intolerance / allergic reactions to the ingredients of the investigational medicinal product<br/>11. Significant changes in the patient's lifestyle, especially regarding medication intake, diet, smoking, alcohol last month Study start and during the study<br/>12. Drug, alcohol and / or drug abuse<br/>13. Simultaneous participation in another clinical trial or participate in such an event within the last 30 days<br/>14. Signs that the subject's is expected to fail test plan (E.g. lack of co-operation)<br/>";"Primary Sponsor";"Active Bio Life Science GmbH";"Mr.";"[---]*";"Jörn";"Seidenschnur";"Lilienthalstr. 6";"12529";"Schönefeld";"Germany";"+49(0)30-6891 6761";"+49(0)30-6891 6763";"joern.seidenschnur@amitamin.com";"[---]*";"Contact for Scientific Queries";"Urologische Praxis";"Mr.";"Dipl. med.";"Holger";"Baumgraß";"Förster-Funke-Allee 104";"14532";"Kleinmachnow";"Germany";"+49(0)33203 58 50";"+49(0)33203 58 529";"holger.baumgrass@t-online.de";"[---]*";"Contact for Public Queries";"Urologische Praxis";"Mr.";"Dipl. med.";"Holger";"Baumgraß";"Förster-Funke-Allee 104";"14532";"Kleinmachnow";"Germany";"+49(0)33203 58 50";"+49(0)33203 58 529";"holger.baumgrass@t-online.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Active Bio Life Science GmbH";"Mr.";"[---]*";"Jörn";"Seidenschnur";"Lilienthalstr. 6";"12529";"Schönefeld";"Germany";"+49(0)30-6891 6761";"+49(0)30-6891 6763";"joern.seidenschnur@amitamin.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Randomized, Placebo-Controlled, Double-Blind, Multi-Centre Pilot Study to Investigate the Effect of AM019016 on male spermatogenesis in Subjects with diagnosed unspecific (idiopathic) subfertility.";"ABL/019016<br/>";"[---]*";"Assessment of the tolerability and benefit of AM019016 on the sperm quality in subjects with present unspecific restricted fertility.";"Investigation of the effect and benefit of AM019016 on spermatogenesis in male subjects with diagnosed unspecific subfertiliy.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011616";"2020-02-11T11:46:36.027+01:00";
"DRKS00005792";2014/05/06;"[---]*";yes;"Approved";"S-579/2013";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";;;;;;;;;;;;;;;;"ICD10";"I63";"Cerebral infarction";;;;;;;;;;;;;"Arm 1";"best medical care";"Arm 2";"endovascular thrombectomy using a stent-retriever and best medical care";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Degree of disability after stroke assessed by modified Rankin Scale (mRS)  outcome at 90 days poststroke";"Good neurological outcome with 90-day mRS≤2 or 90-day NIHSS score improvement ≥10 from baseline<br/>Excellent neurological outcomes with 90-day mRS≤1<br/>Infarct volume at 30 (-/+ 6) hours (CT or MRI).<br/>Difference of infarct volume from infarct volume as predicted by pretreatment imaging<br/>Functional health status and quality of life 90 (±14) days after stroke (EQ-5D)<br/>For the endovascular treatment group successful recanalization will be defined as TICI 2b or 3.";"DE";"Germany";"AT";"Austria";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"RWTH Aachen";"Aachen";"Medical Center";"Universitätsklinikum Knappschaftskrankenhaus Bochum";"Bochum";"Medical Center";"Vivantes Klinikum Neukölln";"Berlin";"University Medical Center";"Klinikum Dortmund";"Dortmund";"University Medical Center";"Universitätsklinkum Erlangen";"Erlangen";"University Medical Center";"Universitätsklinkum Essen";"Essen";"Medical Center";"Alfried Krupp Krankenhaus";"Essen";"University Medical Center";"Universitätsklinikum Freiburg";"Freiburg im Breisgau";"University Medical Center";"Universitätsmedizin Göttingen";"Göttingen";"Medical Center";"Asklepios Klinik Altona";"Hamburg";"University Medical Center";"Universitätsklinikum Hamburg-Eppendorf";"Hamburg";"University Medical Center";"UniversitätsKlinikum Heidelberg";"Heidelberg";"University Medical Center";"Uniklinik Köln";"Köln";"Medical Center";"Landes-Nervenklinik Wagner-Jauregg";"Linz";"University Medical Center";"Klinikum der Universität München";"München";"University Medical Center";"Klinikum rechts der Isar der Technischen Universität München ";"München";"Medical Center";"Knappschaftskrankenhaus Recklinghausen";"Recklinghausen";"University Medical Center";"Universitätsklinikum Würzburg";"Würzburg";"Medical Center";"Klinikum Augsburg";"Augsburg";;;;2014/04/20;"Actual";"600";2015/05/05;"Multicenter trial";"International";"Both, male and female";"18";"Years";"80";"Years";"Moderate to severe stroke (NIHSS>7 and <26)<br/><br/>Ineligibility for iv tPA and no prior iv tPA therapy<br/><br/>Premorbid mRS 0-1<br/><br/>Life expectancy > 6 Months<br/><br/>Treatment can be accomplished within 8 hours after stroke onset<br/>Informed consent by the patient, legal guardian, or independent physician<br/><br/>Imaging criteria:<br/>Occlusion of the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by MRA or CTA<br/>CT and CBV map on CTP or DWI with an ASPECT score of 7-10";"Patient is eligible for and receives IV tPA according to licensing criteria<br/>Patient with an INR of >3<br/>Patient is an active participant in another drug or device treatment trial for any disease state,<br/>or patient is expected to start participation in another drug or device treatment trial while<br/>enrolled in this protocol, unless approved by Sponsor.<br/>Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations.<br/>Patient has carotid dissection, high grade stenosis ≥ 70% proximal to occlusion that requires stenting, or excessive tortuosity to gain access to occlusion, as determined by MRA/ CTA of neck and head.<br/>Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access)<br/>Patient has history of contraindication for contrast medium.<br/>Patient is known to have infective endocarditis<br/>CT scan or MRI with evidence of: Mass effect or intracranial tumor, or hypodensity on<br/>unenhanced CT and CBV drop on CBV maps on CTP, or, alternatively as per institutional<br/>standard, restricted diffusion on DWI with an ASPECT score of 6 or less<br/>Female of childbearing potential who is known to be pregnant and/or lactating or who has a<br/>positive pregnancy test on admission.<br/>Patients anticipated life expectancy is less than 6 Months.";"Primary Sponsor";"UniversitätsKlinikum HeidelbergNeurologische KlinikAbteilung Neuroradiologie";"Mr.";"Prof. Dr.";"Martin";"Bendszus";"Im Neuenheimer Feld 400";"69120";"Heidelberg";"Germany";"06221 567566";"06221-564629";"thrill@med.uni-heidelberg.de";"http://www.klinikum.uni-heidelberg.de/Willkommen.112254.0.html";"Contact for Scientific Queries";"UniversitätsKlinikum HeidelbergNeurologische KlinikAbteilung Neuroradiologie";"Mr.";"Prof. Dr.";"Martin";"Bendszus";"Im Neuenheimer Feld 400";"69120";"Heidelberg";"Germany";"06221 567566";"06221-564629";"thrill@med.uni-heidelberg.de";"http://www.klinikum.uni-heidelberg.de/Willkommen.112254.0.html";"Contact for Public Queries";"UniversitätsKlinikum HeidelbergNeurologische KlinikAbteilung Neuroradiologie";"Mr.";"Prof. Dr.";"Martin";"Bendszus";"Im Neuenheimer Feld 400";"69120";"Heidelberg";"Germany";"06221 567566";"06221-564629";"thrill@med.uni-heidelberg.de";"http://www.klinikum.uni-heidelberg.de/Willkommen.112254.0.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Covidien LPNeurovascular business";"[---]*";"[---]*";"[---]*";"[---]*";"9775 Toledo Way";"92618";"Irvine, CA";"United States";"[---]*";"[---]*";"[---]*";"[---]*";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Stryker / Concentric Medical, Inc.USA";"[---]*";"[---]*";"[---]*";"[---]*";"301 East Evelyn Avenue";"94041";"Mountain View, CA";"United States";"001877 471 0075";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"Thrombectomy in patients ineligible for iv tPA";"THRILL";"[---]*";"The primary objective of the THRILL study is to test efficacy and safety of thrombectomy (removal of a blood clot) with stent-retrievers  in acute stroke patients as compared to best medical care alone. Patients are eligible for the study if a they have suffered the occlusion (blockage) of a large intracranial vessel up to 8 hours of symptom onset and are not eligible for a medical treatment with a lytic agent (IV-tPA). ";"This study is a prospective, open label, blinded endpoint (PROBE), binational (Germany and Austria), two-arm, randomized, controlled, postmarket study to compare the safety and effectiveness of stent-retrievers as a device class group as compared to best medical care alone in the treatment of acute ischemic stroke (AIS) in patients who are not eligible for IV-tPA up to 8 hours of symptom onset.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005792";"2019-02-01T09:25:32.273+01:00";
"DRKS00004110";2012/10/08;2007/02/08;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00435448";"ClinicalTrials.gov";"Sponsor-ID";"TH-CR-202";"Threshold Pharmaceuticals";;;;;;;;;;"Free text";"[---]*";"Benign Prostatic Hyperplasia";"Free text";"[---]*";"Enlarged Prostate";"ICD10";"N40";"Hyperplasia of prostate";;;;;;;"Arm 1";"Drug: Lonidamine";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Factorial";"III";"[---]*";"- International prostate symptom score (I-PSS)<br/>";"- Qmax on uroflowmetry<br/>- Post micturitional residue<br/>- Volume of the prostate<br/>- PSA<br/>";"DE";"Germany";"HU";"Hungary";"IT";"Italy";"PL";"Poland";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Vivantes Klinikum am Urban, Klinik für Urologie";"Berlin";"[---]*";"ClinPharm International GmbH & Co KG--Chemnitz";"Chemnitz";"[---]*";"ClinPharm International GmbH & Co KG--Dresden";"Dresden";"[---]*";"niversitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Urologie";"Dresden";"[---]*";"Gemeinschaftspraxis Jacobi - Hellmis";"Duisburg";"[---]*";"ClinPharm International GmbH & Co KG--Frankfurt/Main";"Frankfurt";"[---]*";"ClinPharm International GmbH & Co KG--Gorlitz";"Gorlitz";"[---]*";"Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Urologie";"Hamburg";"[---]*";"Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Urologie und Kinderurologie";"Kiel";"[---]*";"Universitätsklinik Köln, Klinik und Poliklinik für Urologie";"Köln";"[---]*";"ClinPharm International GmbH & Co KG--Leipzig";"Leipzig";"[---]*";"ClinPharm International GmbH & Co KG--Magdeburg";"Magdeburg";"[---]*";"Urologische Universitätsklinik, Klinikum Mannheim gGmbH, Fakultät für Klinische Medizin Mannheim";"Mannheim";"[---]*";"Klinik für Urologie und Kinderurologie, Klinikum Marburg";"Marburg";"[---]*";"Urologische Klinik und Poliklinik der Technischen Universität München, Klinikum Rechts der Isar";"München";"[---]*";"Klinikum der Universität München, Urologische Klinik und Poliklinik";"München";"[---]*";"Urologische Klinik, Klinikum Landkreis Neumarkt i.d.Obf.";"Neumarkt";"[---]*";"Klinik für Urologie, Eberhard-Karls-Universität Tübingen";"Tubingen";"[---]*";"Wuppertaler Gemeinschaftspraxis für Dermatologie, Gynäkologie und Urologie";"Wuppertal";;;;2005/06/30;"[---]*";"480";2006/12/01;"Multicenter trial";"International";"Male";"50";"Years";"80";"Years";"-  Capable of understanding the purpose and risks of the study and sign a statement of<br/>             informed consent<br/><br/>          -  Male 50-80 years of age<br/><br/>          -  Presence of LUTS (lower urinary tract symptoms) for at least 3 months<br/><br/>          -  Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc<br/><br/>          -  Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)<br/><br/>          -  I-PSS (International prostate symptom score) > 12<br/><br/>          -  PSA > 1.0 ng/mL<br/><br/>          -  Must ensure and consent to use medically acceptable methods of contraception<br/>             throughout the entire study with sexual partners of childbearing potential<br/><br/>          -  Able to comply with the prescribed treatment protocol and evaluations<br/>";"-  Prior treatment for BPH with alpha-blockers and/or herbal supplements in the past 2<br/>             weeks (alpha-blockers and herbal supplements for the treatment of BPH are not allowed<br/>             during the study). Prior treatment with 5-alpha-reductase inhibitors is allowed if<br/>             discontinued at least 3 months prior to enrollment.<br/><br/>          -  Prior surgery of the prostate (except biopsies; subject is eligible to enroll one<br/>             month after full recovery from prostate biopsy.)<br/><br/>          -  Current or past evidence of malignant disease of the prostate or prostatic<br/>             intraepithelial neoplasia (for subjects with PSA between 4 - 10 ng/mL, prostate<br/>             cancer must be ruled out to the satisfaction of the Principal Investigator. Subjects<br/>             with PSA >10 ng/mL are excluded.)<br/><br/>          -  Active urinary tract infections (UTI)<br/><br/>          -  Active cardiac, renal or hepatic disease as evidenced by:<br/><br/>               1. Serum creatinine > 1.8 mg/dL<br/><br/>               2. ALT or AST > 2.5x the upper limit of normal at screen<br/><br/>               3. History of active myocardial infarction,unstable cardiac arrhythmias or stroke<br/>                  within 6 months prior to screening<br/><br/>               4. Uncontrolled congestive heart failure<br/><br/>          -  Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)<br/><br/>          -  Use of systemic teriods for any reason (systemic steroid usage is not allowed during<br/>             the study). Inhaled and/or topical steroids are allowed.<br/><br/>          -  Concurrent participation or participation in an investigational drug study within the<br/>             past 30 days prior to screening<br/><br/>          -  Concomitant disease or condition that could interfere with the conduct of the study,<br/>             or would in the opinion of the investigator,pose an unnaceptabele risk to the subject<br/>";"Primary Sponsor";"Threshold Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Fakultät für Klinische Medizin Mannheim";"[---]*";"[---]*";"[---]*";"Peter Alken, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Fakultät für Klinische Medizin Mannheim";"[---]*";"[---]*";"[---]*";"Peter Alken, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia";"[---]*";"[---]*";"The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared<br/>      to placebo in subjects with symptomatic BPH.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004110";"2016-01-25T16:08:29.855+01:00";
"DRKS00005000";2013/08/15;2012/12/11;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2012-001815-21";"[---]*";"Primary Registry-ID";"NCT01749306";"ClinicalTrials.gov";"Sponsor-ID";"EB01-ABH001";"Shire Regenerative Medicine, Inc.";"Other Secondary-ID";"2012-001815-21";"[---]*";;;;"Free text";"[---]*";"Epidermolysis Bullosa";"ICD10";"L12.0";"Bullous pemphigoid";;;;;;;;;;"Arm 1";"Biological: ABH001";"Arm 2";"Other: Control wound treatment";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Other";"Treatment";"Parallel";"III";"[---]*";"- Reduction in wound surface area; time frame: 24 weeks<br/>";"- Change in wound pain and wound itch; time frame: 24 weeks<br/>- Patient global impression of change (PGIC); time frame: 24 weeks<br/>- Clinician global impression of change (CGIC); time frame: 24 weeks<br/>- Proportion of subjects achieving reduction in wound surface area; time frame: 24 weeks<br/>- Time to reduction of wound surface area and duration of reduction; time frame: 24 weeks<br/>- Durability of wound healing; time frame: 24 weeks<br/>- Incidence, relatedness and severity of adverse events; time frame: Up to 48 Weeks<br/>";"US";"United States";"AT";"Austria";"CA";"Canada";"FR";"France";"DE";"Germany";"PL";"Poland";"PT";"Portugal";"ES";"Spain";;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"University of Freiburg (Studiensekretariat Hautklinik Universitätsklinikum Freiburg - Hautklinik)";"Freiburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/12/31;"[---]*";"21";"[---]*";"Multicenter trial";"International";"Both, male and female";"[---]*";"no minimum age";"[---]*";"no maximum age";"1. The subject or legal guardian must have read, understood and signed an Institutional<br/>             Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form and<br/>             must be able to and willing to follow study procedures and instructions<br/><br/>          2. Male and female subjects.<br/><br/>          3. Stable nutritional status.<br/><br/>          4. Subjects with a confirmed diagnosis of generalized Epidermolysis Bullosa (EB)<br/><br/>          5. Cutaneous wounds meeting the following criteria:<br/><br/>               1. Anatomical location: arms, legs, thorax, or back above the waistline and below<br/>                  the neck.<br/><br/>               2. Documented age (duration) of the wound(s).<br/><br/>               3. One or more wounds capable of potentially meeting the following wound selection<br/>                  criteria at the end of the observation period:<br/><br/>             i. Two clinically non-infected cutaneous wounds with no clinically meaningful change<br/>             in wound size during the observation period.<br/><br/>             ii. Two matched wounds.<br/><br/>          6. Negative urine pregnancy test for women of child-bearing potential.<br/><br/>          7. Female subjects of childbearing potential and male subjects of procreative capacity<br/>             must agree to use an effective method of contraception.<br/>";"1. Pregnant or nursing women.<br/><br/>          2. Diagnosis of non-genetic generalized EB.<br/><br/>          3. Localized, active clinical infection of study wounds.<br/><br/>          4. Diseases or conditions that could interfere with the assessment of safety and<br/>             efficacy of the study treatment and compliance of the subject with study<br/>             visits/procedures.<br/><br/>          5. Known allergy to bovine products.<br/><br/>          6. Known allergy to silver products.<br/><br/>          7. Systemic infection at the time of enrolment in the study.<br/><br/>          8. Currently receiving or have received oral steroid therapy within the previous 4<br/>             weeks.<br/><br/>          9. Taking, or have participated in other clinical studies involving gene therapy, stem<br/>             cell therapy, recombinant DNA/protein therapy.<br/><br/>         10. Received ABH001, or other biologic or cell therapy for the treatment of EB in the<br/>             study wound sites within the previous 3 months.<br/><br/>         11. Hypersensitivity to any of the therapeutic agents.<br/><br/>         12. History of malignant skin disease.<br/>";"Primary Sponsor";"Shire Regenerative Medicine, Inc.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"H&E Enterprises";"[---]*";"[---]*";"[---]*";"Alan Arbuckle, MD, FAAD, FAAP";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"H&E Enterprises";"[---]*";"[---]*";"[---]*";"Alan Arbuckle, MD, FAAD, FAAP";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa";"[---]*";"[---]*";"The purpose of this study is to evaluate the efficacy and safety of ABH001 in the treatment<br/>      of patients with epidermolysis bullosa who have wounds that are not healing.<br/><br/>      It is hypothesized that ABH001 may initiate and continue wound healing in patients with<br/>      epidermolysis bullosa.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005000";"2016-02-19T16:42:42.252+01:00";
"DRKS00004078";2012/08/23;2010/11/16;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2010-021434-55";"[---]*";"Primary Registry-ID";"NCT01242748";"ClinicalTrials.gov";"Sponsor-ID";"FE200486 CS35A";"Ferring Pharmaceuticals";"Other Secondary-ID";"2010-021434-55";"[---]*";;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Degarelix";"Arm 2";"Drug: Goserelin acetate";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Hazard Ratio of Prostate-specific Antigen (PSA) Progression-free Survival (PFS) Failure Rates During 3 Years' Treatment Between Degarelix and Goserelin; time frame: From baseline to 3 years; PSA PFS failure is defined as either PSA failure (defined as increase in serum PSA of 50%, and at least 5 ng/mL, compared to nadir, measured on two consecutive occasions at least 2 weeks apart) or death, whichever is first. The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of no PSA-PFS.<br/>";"- Hazard Ratio of PFS Failure Rates During 3 Years Treatment Between Degarelix and Goserelin; time frame: From baseline to 3 years; PFS failure is defined as either PSA failure, introduction of additional therapy related to prostate cancer (radiation, anti-androgens or second-line treatment), or death, whichever is first. The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of no PFS failure.<br/>- Hazard Ratio of PSA Failure Rates During 3 Years Treatment Between Degarelix and Goserelin; time frame: From baseline to 3 years; PSA failure is defined as increase in serum PSA of 50%, and at least 5 ng/mL, compared to nadir, measured on two consecutive occasions at least 2 weeks apart. The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of no PSA failure.<br/>- Hazard Ratio of Testosterone Escape Rates During 3 Years' Treatment Between Degarelix and Goserelin; time frame: From baseline to 3 years; Testosterone escape is defined as serum levels >0.5 ng/mL. The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of no testosterone escape.<br/>- Hazard Ratio of the Rates of Introduction of Additional Therapy Related to Prostate Cancer During 3 Years' Treatment Between Degarelix and Goserelin; time frame: From baseline to 3 years; Additional therapy related to prostate cancer included radiation, anti-androgens and second-line treatment. The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of no additional therapy related to prostate cancer.<br/>- Hazard Ratio of Mortality Rates During 3 Years' Treatment Between Degarelix and Goserelin; time frame: From baseline to 3 years; The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of death.<br/>- Serum Levels of Testosterone During 3 Years' Treatment With Degarelix or Goserelin; time frame: Baseline and after 1, 6, 12, 19, and 22 months; Median testosterone levels are presented as absolute values in nanograms per milliliter (ng/mL) at baseline and after 1, 6, 12, 19, and 22 months. One month equals 28 days. After 22 months, only a limited number of samples were analysed.<br/>- Serum Levels of Prostate-specific Antigen (PSA) During 3 Years' Treatment With Degarelix or Goserelin; time frame: Baseline and after 1, 6, 12, 19, and 22 months; Median PSA levels are presented as absolute values in nanograms per milliliter (ng/mL) at baseline and after 1, 6, 12, 19, and 22 months. One month equals 28 days. After 22 months, only a limited number of samples were analysed.<br/>";"US";"United States";"BE";"Belgium";"CA";"Canada";"CZ";"Czech Republic";"FI";"Finland";"DE";"Germany";"HU";"Hungary";"MX";"Mexico";"NL";"Netherlands";"PL";"Poland";"RO";"Romania";"UA";"Ukraine";"UK";"United Kingdom";;;;;;;;;;;;;;;"[---]*";"Gemeinschaftspraxis Rudolph & Wörner";"Kirchheim";"[---]*";"Urologische Studienpraxis";"Nürtingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/10/31;"[---]*";"288";2012/01/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Has given written consent prior to any trial-related activity is performed. (A<br/>             trial-related activity is defined as any procedure that would not have been performed<br/>             during the normal management of the patient).<br/><br/>          -  Has completed the CS35 trial.<br/>";"-  Has been withdrawn from the CS35 trial.<br/><br/>          -  Has had end of trial visit in CS35 prior to approval of the CS35A protocol.<br/>";"Primary Sponsor";"Ferring Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Ferring Pharmaceuticals";"[---]*";"[---]*";"[---]*";"Clinical Development Support";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Ferring Pharmaceuticals";"[---]*";"[---]*";"[---]*";"Clinical Development Support";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy";"[---]*";"[---]*";"A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot<br/>      with the established therapy Zoladex 3 month implant in patients with prostate cancer.<br/>";"CS35A was an open-label, multicentre, comparative non-inferiority extension trial to the<br/>      Phase 3 CS35 trial (NCT00946920).<br/><br/>      In the main CS35 trial, participants were randomised 2:1 to treatment with degarelix or<br/>      goserelin, respectively. All participants who completed the main CS35 trial after initiation<br/>      of the CS35A trial were eligible to enrol into this extension trial, provided that their<br/>      treatment could continue uninterrupted. Patients entering the CS35A trial continued with the<br/>      same 3-monthly treatment as they received in CS35 (i.e. degarelix 480 mg or goserelin 10.8<br/>      mg).<br/><br/>      It was intended that patients enrolled in the CS35A trial would receive treatment with<br/>      degarelix or goserelin at 3-month intervals for a period of 40 months (including 13 months'<br/>      treatment in CS35). It was, however, decided to prematurely terminate the CS35A trial due to<br/>      an insufficient number of patients being enrolled. Maximum exposure of treatment was 111<br/>      weeks (in both treatment arms).<br/><br/>      The baseline characteristics are based on the CS35A Full Analysis Set (FAS)defined as all<br/>      participants who received at least one dose of degarelix or goserelin acetate during CS35A<br/>      and had at least one efficacy assessment after dosing. All efficacy analyses were performed<br/>      for the CS35/CS35A FAS defined as all participants who received at least one dose of<br/>      degarelix or goserelin acetate during CS35 and had at least one efficacy assessment after<br/>      dosing. All safety analyses were performed for the CS35/CS35A Safety analysis set, which<br/>      included all patients who received at least one dose of degarelix or goserelin acetate<br/>      during CS35.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004078";"2016-01-25T14:41:58.087+01:00";
"DRKS00006417";2014/11/04;2012/10/24;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01732549";"ClinicalTrials.gov";"Sponsor-ID";"8-55-58102-002";"Ipsen";;;;;;;;;;"Free text";"[---]*";"Metastatic Castrate Resistant Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Tasquinimod";"Arm 2";"Drug: Placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"II";"[---]*";"- Time to radiological progression free survival [PFS]; time frame: Every 8 weeks, up to 3.5 years; The time from the date of randomisation to the date of radiological progression or death due to any cause.<br/>";"- Overall survival; time frame: Every 8 weeks, up to 3.5 years; Overall survival is defined as the time from randomisation to death due to any cause<br/>- Time to progression free survival [PFS] on next-line therapy (PFS 2); time frame: Every 8 weeks, up to 3.5 years; The time from the date of randomisation to the date of radiological progression free survival [PFS] on next-line therapy (PFS 2) or death due to any cause.<br/>- Symptomatic PFS; time frame: Every 8 weeks, up to 3.5 years; Symptomatic PFS is defined as the time from the date of randomisation to the date of symptomatic progression or death due to prostate cancer, whichever occurs first (symptomatic progression as assessed by Brief Pain Inventory [BPI] and analgesic use)<br/>- Safety profile of tasquinimod; time frame: Every 8 weeks, up to 3.5 years; Number of subjects reporting adverse events<br/>";"BE";"Belgium";"CZ";"Czech Republic";"DK";"Denmark";"FR";"France";"DE";"Germany";"HU";"Hungary";"IT";"Italy";"LT";"Lithuania";"PL";"Poland";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;"[---]*";"[---]*";"Aachen";"[---]*";"[---]*";"Essen";"[---]*";"[---]*";"München";"[---]*";"[---]*";"Nürtingen";"[---]*";"[---]*";"Tübingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/01/31;"[---]*";"140";2015/05/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Histologically documented prostate cancer with evidence of metastatic disease on<br/>             radiological evaluation, with or without symptoms (defined according to the BPI<br/>             scale, with use of analgesics or narcotics)<br/><br/>          -  Has received a first line docetaxel based chemotherapy (as a monotherapy) every 3<br/>             weeks schedule of administration with corticosteroids for a minimum of 6 cycles with<br/>             a cumulative dose ≥360 mg/m2. Any combination with investigational or non<br/>             investigational agent is prohibited<br/><br/>          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1<br/><br/>          -  Docetaxel-related adverse effects must have been resolved to NCI-CTCAE v4.03 (Common<br/>             Toxicity Criteria for Adverse Effects) Grade ≤1. Chemotherapy-induced alopecia and<br/>             Grade 2 peripheral neuropathy are allowed<br/><br/>          -  No progressive disease at the end of docetaxel treatment defined according to RECIST<br/>             criteria, no new lesion(s) assessed by bone scan and no elevated prostate specific<br/>             antigen (PSA) for the three last tests with PSA3≤PSA2≤PSA1. The time between each PSA<br/>             test should be preferably at least 14 days, however, a minimum of 7 days is<br/>             acceptable.<br/><br/>        Note: PSA value can be rounded to the nearest whole number if PSA>10 ng/mL. If the PSA3<br/>        value is above the PSA2, a fourth PSA test will be performed. The PSA4 value should be<br/>        below or equal to PSA2<br/><br/>          -  Last dose of docetaxel administered between 21 and 42 days before randomisation<br/><br/>          -  Chemical or surgical castration verified by levels of serum testosterone ≤50 ng/dL<br/>             (1.75 nmol/L)<br/>";"-  Has concurrent use of other anticancer agents or treatments, with the following<br/>             exceptions: ongoing treatment with luteinising hormone-releasing hormone agonists or<br/>             antagonists, denosumab or bisphosphonate (e.g., zoledronic acid) is permitted if<br/>             started ≥4 weeks prior to Screening. Ongoing treatment should be kept at a stable<br/>             dose regimen<br/><br/>          -  Has ongoing treatment with warfarin<br/><br/>          -  Had prior radiation therapy since starting docetaxel. Exceptions may be made for<br/>             palliative non-myelosuppressive radiation therapy administered more than 2 weeks<br/>             prior to randomisation<br/><br/>          -  Had prior strontium, samarium or radium therapy or prior treatment with tasquinimod,<br/>             or any agents with antiangiogenic properties<br/><br/>          -  Has ongoing treatment with corticosteroids at >10 mg/day prednisolone equivalent<br/><br/>          -  Has prostate cancer pain that warrants the initiation of radiotherapy or chemotherapy<br/><br/>          -  Has known brain or epidural metastases. Patients with previous medullary cord<br/>             compression without any neurological deficit could be included<br/><br/>          -  Has a history of other malignancies, except adequately treated non-melanoma skin<br/>             cancer or other solid tumours curatively treated, without evidence of disease for >5<br/>             years<br/>";"Primary Sponsor";"Ipsen";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Ipsen";"[---]*";"[---]*";"[---]*";"Nathalie Germann, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Ipsen";"[---]*";"[---]*";"[---]*";"Nathalie Germann, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy";"[---]*";"[---]*";"The purpose of this study is to confirm that tasquinimod used as maintenance therapy is<br/>      active and tolerable in patients with metastatic castrate-resistant prostate cancer not<br/>      progressing after a first chemotherapy with docetaxel.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006417";"2016-01-29T16:11:55.657+01:00";
"DRKS00010225";2016/03/31;"[---]*";no;"Approved";"198/15";"Ethik-Kommission des Fachbereichs Medizin der Justus-Liebig-Universität Gießen";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2015-001975-30";"[---]*";;;;;;;;;;;;;"Free text";"[---]*";"Aortic valve replacment";"ICD10";"Z95.2";"Presence of prosthetic heart valve";;;;;;;;;;"Arm 1";"Rivaroxaban-based strategy<br/>• Rivaroxaban 10 mg once-daily AND Acetylsalicylic Acid (ASA) 75-100 mg once-daily<br/>• Rivaroxaban 10 mg once-daily<br/>Whether Rivaroxaban is given alone or in combination with ASA  depends on the time point after the TAVI. <br/>If new-onset atrial fibrillation (NOAF) occurs:<br/>• Rivaroxaban 20 or 15 mg once-daily AND ASA 75-100 mg once-daily<br/>• Rivaroxaban 20 or 15 mg once-daily<br/><br/>All medications are tablets and to be taken orally. Since this is an event driven study the study duration can only be given as an estimation, which will be approximately two years, but this can also be shorter like only one year. <br/>";"Arm 2";"Antiplatelet-based strategy<br/>• Clopidogrel hydrogen sulfate (clopidogrel) 75 mg once-daily AND ASA 75-100 mg once-daily<br/>• ASA 75-100 mg once-daily<br/><br/>If NOAF occurs:<br/>• Vitamin K antagonist (VKA) with a target international normalized ratio (INR) 2-3 AND ASA 75-100 mg once-daily<br/>• VKA (target INR 2-3)<br/><br/>All medications are tablets and to be taken orally. Since this is an event driven study the study duration can only be given as an estimation, which will be approximately two years, but this can also be shorter like only one year. <br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"No";"The primary comparison will be to test the superiority of a rivaroxaban-based strategy to an antiplatelet-based strategy with respect to the primary efficacy endpoint. This comparison is preceded by a non-inferiority test that must be satisfied.<br/>Further, non-inferiority of a rivaroxaban-based strategy to an antiplatelet-based strategy towards the primary safety endpoint will be tested.<br/><br/>Primary Efficacy Endpoint: death or first adjudicated thromboembolic event (DTE) defined as the composite of all-cause death and adjudicated any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), or non-CNS systemic embolism.<br/>Primary Safety Endpoint: primary bleeding event (PBE) defined as the composite of adjudicated life-threatening, disabling or major bleeding, classified according to the valve academic research consortium (VARC) definitions following the bleeding academic research consortium (BARC) classification.<br/>";"The secondary efficacy objectives are to compare the effects of the rivaroxaban-based strategy and antiplatelet-based strategy with respect to the net-clinical-benefit, defined as the composite of death or first thromboembolic events and life-threatening, disabling, or major bleeding events classified according to the VARC definitions following the BARC classification.<br/>Whereas the secondary safety objectives are safety criteria with respect to bleeding (thrombolysis in myocardial infarction [TIMI] major or minor bleeds, international society on thrombosis and haemostasis [ISTH] major bleeding, and BARC 2, 3, or 5 bleeds).";"AT";"Austria";"BE";"Belgium";"CA";"Canada";"CZ";"Czech Republic";"DK";"Denmark";"FR";"France";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"NO";"Norway";"PL";"Poland";"ES";"Spain";"SE";"Sweden";"CH";"Switzerland";"UK";"United Kingdom";"US";"United States";;;;;;;;;"Medical Center";"Klinikum Fulda, Med. Klinik I";"Fulda";"University Medical Center";"Klinik f. Kardiologie, Angiologie und Pneumolgie";"Magdeburg";"Medical Center";"Herz-Zentrum Bodensee";"Konstanz";"Medical Center";"Segeberger Kliniken GmbH";"Bad Segeberg";"Medical Center";"St. Johannes Hospital, Med. Klinik I";"Dortmund";"Medical Center";"Deutsches Herzzentrum München, Klinik an der Technischen Universität München";"München";"University Medical Center";"Med. Klinik II-Kardiologie, Angiologie";"Erlangen";"Medical Center";"Kerckhoff Klinik GmbH";"Bad Nauheim";"Medical Center";"Zentralklinik Bad Berka GmbH";"Bad Berka";"University Medical Center";"Charité Centrum 11, Klinik und Poliklinik SP Kardiologie, Angiologie, Chartéplatz 1";"Berlin";"University Medical Center";"Universitätsmedizin der Johannes Gutenberg-Universität Mainz, II Med. Klinik, Kardiologie und Angiologie";"Mainz";"University Medical Center";"Klinikum der Univerität Regensburg, Klinik und Poliklin9ik für Innere Medizin II";"Regensburg";"University Medical Center";"Universitätsklinikum Bonn, Med. Klinik u. Poliklinik II";"Bonn";"University Medical Center";"Klinik III für Innere Medizin/Herzzentrum";"Köln";"University Medical Center";"Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik für Kardiologie, Hindenburgdamm 30";"Berlin";"University Medical Center";"Universitäres Herzzentrum-Universitätsklinikum Eppendorf";"Hamburg";"University Medical Center";"MHH, Klinik für Kardiologie/Angiologie";"Hannover";"University Medical Center";"Klinikum der Eberhard-Karls-Universität Tübingen, Med. Klinik III";"Tübingen";"Medical Center";"Herz- und Kreislaufzentrum Rotenburg a. d. Fulda";"Rotenburg a. d. Fulda";"Medical Center";"Mediclin Herzzentrum Lahr/Baden GmbH& Co. KG";"Lahr";2016/03/17;"Actual";"1520";2018/11/16;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Key inclusion criteria:<br/>• Successful TAVR of a native aortic valve stenosis<br/>• By iliofemoral or subclavian access<br/>• With any approved/marketed device<br/>• Written informed consent (IC)<br/>";"Key exclusion criteria:<br/>• Atrial fibrillation (AF), current or previous, with an ongoing indication for oral anticoagulant treatment<br/>• Any other indication for continued treatment with any oral anticoagulant (OAC)<br/>• Known bleeding diathesis (such as but not limited to active internal bleeding, clinically significant bleeding, platelet count ≤ 50,000/mm3 at screening, hemoglobin level < 8.5 g/dL, active peptic ulcer or known gastrointestinal (GI) bleeding, history of intracranial hemorrhage or subdural hematoma)<br/>• Any indication for dual-antiplatelet therapy (DAPT) for more than 3 months after randomization (such as coronary, carotid or peripheral stent implantation)<br/>• Clinically overt stroke within the last 3 months<br/>• Planned coronary or vascular intervention or major surgery<br/>• Severe renal impairment (eGFR < 30 mL/min/1.73 m2) or on dialysis, or post-TAVR unresolved acute kidney injury with renal dysfunction stage 2 or higher<br/>• Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy.<br/>Screening, IC and randomization:<br/>Subjects are screened for inclusion after TAVR. Consenting subjects must be randomized within 2-7 days (1-7 days after protocol amendment) after a successful TAVR and before hospital discharge.<br/>";"Primary Sponsor";"Bayer AG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"D-13353";"Berlin";"Germany";"+49 30 468 193460";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"St.-Johannes-Hospital";"[---]*";"[---]*";"[---]*";"[---]*";"Johannesstr. 9-13";"44137";"Dortmund";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Cardialysis";"Ms.";"[---]*";"Sanne";"Rijnders";"Westblaak 98";"3012 KM";"Rotterdam";"Netherlands";"+31(0)10 240 24 54";"[---]*";"GALILEO@cardialysis.nl";"www.cardialysis.com";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Bayer AG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"13348";"Berlin";"Germany";"030 468 193460";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes.";"GALILEO";"http://www.cardialysis.com/galileo";"Narrowing of the aortic valve opening, called aortic stenosis, which is <br/>treated with Transcatheter aortic valve replacement, implanted by vascular catheterization in the aortic valve.  Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oralanticoagulant)<br/>may reduce this risk, without increasing bleeding risk.<br/>";"The secondary efficacy objectives are to compare the effects of the <br/>rivaroxaban-based strategy and antiplatelet-based strategy with respect to the net-clinical-benefit, defined as the composite of death or first thromboembolic events and life-threatening, disabling, or major bleeding events classified according to the VARC definitions following the BARC classification.<br/>Whereas the secondary safety objectives are safety criteria with respect to bleeding (thrombolysis in myocardial infarction [TIMI] major or minor<br/>bleeds, international society on thrombosis and haemostasis [ISTH] major bleeding, and BARC 2, 3, or 5 bleeds). ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010225";"2019-03-01T10:52:43.928+01:00";
"DRKS00003619";2012/04/18;2011/04/19;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01341158";"ClinicalTrials.gov";"Sponsor-ID";"5021000";"University Hospital Tuebingen";;;;;;;;;;"Free text";"[---]*";"Locoregional Metastases in Malignant Melanoma Stages IIIB/C";"ICD10";"C43";"Malignant melanoma of skin";;;;;;;;;;"Arm 1";"Drug: human interferon-α";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"- Overall response rate; time frame: after 4 weeks of treatment; Overall response rate (clinical and radiological) after 4 weeks of treatment (CR + PR) according to immune-related response criteria (irRC)<br/>";"- Disease control rate; time frame: after 4 weeks of treatment; Disease control rate (CR + PR +SD) according to irRC<br/>- Rate of histopathological complete responses; time frame: after 4 weeks of treatment; Rate of histopathological complete responses<br/>- Tolerability; time frame: after 4 weeks of treatment; Assessment of numbers of adverse events<br/>- Differences in gene expression in metastatic tissue before/after treatment; time frame: after 4 weeks of treatment<br/>- Dose dependency of effects; time frame: after 4 weeks of treatment<br/>- Changes of serum markers and PBMC subsets before/after treatment (optional translational side studies); time frame: after 4 weeks of treatment<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätshautklinik Tübingen";"Tübingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/04/30;"[---]*";"42";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. Histologically proven cutaneous melanoma<br/><br/>          2. Clinical stage IIIB or IIIC (AJCC 2010)<br/><br/>          3. ≥ 18 years of age<br/><br/>          4. Presence of at least two metastases, not more than 10 metastases, and completely<br/>             resectable<br/><br/>          5. Measurable disease (at least one lesion that can be accurately measured in two<br/>             perpendicular diameters, with both dimensions at least 10 mm x 10 mm for spiral CT<br/>             and 5 mm x 5 mm for locoregional metastases assessed by ultrasound or digital<br/>             photography)<br/><br/>          6. ECOG performance status of 0/1<br/><br/>          7. Patients with previous adjuvant recombinant interferon-α treatment of any dose are<br/>             eligible if (i) treatment was stopped at least 1 month before start of treatment and<br/>             (ii) no progression occurred during interferon-α treatment.<br/><br/>          8. No childbearing potential or negative pregnancy test within 14 days before inclusion<br/>             in women with child bearing potential Women with childbearing potential must be using<br/>             an effective method of contraception (Pearl-Index < 1, e.g. oral contraceptives,<br/>             other hormonal contraceptives [vaginal products, skin patches, or implanted or<br/>             injectable products], or mechanical products such as an intrauterine device or<br/>             barrier methods [diaphragm, spermicides]) throughout the study and for up to 3 months<br/>             after the last dose of investigational product, in such a manner that the risk of<br/>             pregnancy is minimized.<br/><br/>             No men of fathering potential or men of fathering potential must be using an<br/>             effective method of contraception to avoid conception throughout the study and for up<br/>             to 3 months after the last dose of investigational product, in such a manner that the<br/>             risk of pregnancy is minimized.<br/><br/>          9. Signed and dated informed consent informed consent before the start of specific<br/>             protocol procedures<br/>";"1. Mucous membrane or ocular melanoma<br/><br/>          2. Any evidence of distant metastasis (e.g. whole body CT-scan including brain scan<br/>             within 4 weeks before inclusion)<br/><br/>          3. Patients with severe cardiac disease (e.g. NYHA Functional Class III or IV,<br/>             myocardial infarction within 6 months before inclusion, ventricular tachyarrhythmia<br/>             requiring ongoing treatment, unstable angina pectoris).<br/><br/>          4. ALAT or ASAT > 2 x ULN<br/><br/>          5. Total bilirubin > 2 x ULN<br/><br/>          6. Creatinine > 2 x ULN<br/><br/>          7. Evidence or history of depression. If this condition can not be ruled out, the<br/>             patient should be transferred to a psychiatrist for consultation and further<br/>             assessment before inclusion.<br/><br/>          8. Patients with seizure disorders requiring anticonvulsant therapy<br/><br/>          9. Any of the following abnormal baseline hematologic/laboratory values:<br/><br/>             Hb < 10g/dl WBC < 3.0x109 /l Platelets < 100x109 /l<br/><br/>         10. Presence of active autoimmune disease<br/><br/>         11. Concurrent systemic glucocorticoids or any other systemic immunosuppressive therapy<br/><br/>         12. Unwilling or unable to comply with the requirements of the protocol<br/><br/>         13. Known infection with HBV, HCV, HIV<br/><br/>         14. Pregnant or lactating women<br/><br/>         15. Unwillingness or inability to employ an effective barrier method of birth control<br/>             throughout the study and for up to 3 months after end of treatment in female or male<br/>             patients<br/><br/>         16. Known or suspected allergy to human interferon alpha or any ingredient of the IMP.<br/><br/>         17. Any  thyroid dysfunctions not responsive to therapy<br/><br/>         18. Presence of chronic hepatitis with decompensated liver cirrhosis<br/><br/>         19. Immunosuppression in patients with transplantation<br/><br/>         20. Evidence or history of bleeding diathesis or coagulopathy<br/>";"Primary Sponsor";"University Hospital Tuebingen";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"[---]*";"[---]*";"[---]*";"[---]*";"Claus Garbe, Prof. Dr.";"[---]*";"[---]*";"[---]*";"[---]*";"+49 (0) 7071/ 298 7110";"[---]*";"claus.garbe@med.uni-tuebingen.de";"[---]*";"Contact for Public Queries";"[---]*";"[---]*";"[---]*";"[---]*";"Claus Garbe, Prof. Dr.";"[---]*";"[---]*";"[---]*";"[---]*";"+49 (0) 7071/ 298 7110";"[---]*";"claus.garbe@med.uni-tuebingen.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Neoadjuvant Treatment of Locoregional Metastases in Malignant Melanoma (AJCC Stage IIIB/C) With Multiferon: a Phase IIa DeCOG Trial";"[---]*";"[---]*";"The current clinical trial shall clarify the efficacy, safety and biologic effects of<br/>      neoadjuvant treatment with natural interferon-α (Multiferon) in patients with locoregional<br/>      metastases of melanoma in stage IIIB/C.<br/>";"The study is an open label, multicenter phase IIa clinical trial which is designed as a<br/>      pilot project in order to establish the efficacy and tolerability of Multiferon as a<br/>      neoadjuvant treatment of locoregional metastases. Patients will be treated subsequently in<br/>      cohorts characterized by different doses (3 - 9 - 18 MIU) to analyze dosage dependent<br/>      effects.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003619";"2017-10-25T14:41:37.787+02:00";
"DRKS00006293";2014/07/03;"[---]*";no;"Approved";"2014-148-f-S";"Ethik-Kommission der Ärztekammer Westfalen-Lippe und der med. Fakultät der Westfälischen Wilhelms-Universität Münster";"Universal Trial Number (UTN)";"U1111-1158-9113";"[---]*";;;;;;;;;;;;;"ICD10";"C43";"Malignant melanoma of skin";"ICD10";"C44";"Other malignant neoplasms of skin";;;;;;;;;;"Arm 1";"After tumor excision wound treatment with Hyalomatrix (Anika Therapeutics S.r.l) followed by autologous skin graft";"Arm 2";"After tumor excision open wound treatment with Aqaucel (Convatec) followed by autologous skin graft";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"No";"Skin transplant take rate 1 week after grafting, as well as after 6-12 months. Scar evaluation with POSAS scar scale and high resolution skin ultrasound examination";"Pain during wound dressing after tumor excision with visual analog pain scale (VAS)<br/>scar quaulity (POSAS scar scale) 6-12 months after skin grafting";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Fachklinik Hornheide";"Münster";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/07/14;"Actual";"52";2016/04/30;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Skin Tumor in need of excision and skin transplantation";"Persons aged under 18, Wound infection before surgery, missing informed consent";"Primary Sponsor";"ATG-Med, AT Technologies GmbH";"Mr.";"[---]*";"Tolga";"Halici";"Schwanen 10";"42929";"Wermelskirchen";"Germany";"021968820913";"021968820919";"tolga.halici@atg.eu.com";"www.atg.eu.com";"Contact for Scientific Queries";"Fachklinik HornheideAbteilung für Plastische und Ästhetische Chirurgie, Handchirurgie";"Mr.";"Dr. med";"Albrecht";"Krause-Bergmann";"Dorbaumstr. 300";"48157";"Münster";"Germany";"0251-3287-441";"0251-3287-445";"pl-chir@fachklinik-hornheide.de";"www.fachklinik-hornheide.de";"Contact for Public Queries";"Fachklinik HornheideAbteilung für Plastische und Ästhetische Chirurgie, Handchirurgie";"Mr.";"Dr. med";"Albrecht";"Krause-Bergmann";"Dorbaumstr. 300";"48157";"Münster";"Germany";"0251-3287-441";"0251-3287-445";"pl-chir@fachklinik-hornheide.de";"www.fachklinik-hornheide.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"AT Technologies GmbH";"Mr.";"[---]*";"Tolga";"Halici";"Schwanen 10";"42929";"Wermelskirchen";"Germany";"02196-8820913";"021968820919";"tolga.halici@atg.eu.com";"www.atg.eu.com";"Institutional budget, no external funding (budget of sponsor/PI)";"Fachklinik HornheideAbteilung für Plastische und Ästhetische Chirurgie, Handchirurgie";"Mr.";"Dr. med";"Albrecht";"Krause-Bergmann";"Dorbaumstr. 300";"48157";"Münster";"Germany";"0251-3287-441";"0251-3287-445";"pl-chir@fachklinik-hornheide.de";"www.fachklinik-hornheide.de";;;;;;;;;;;;;;;"Comparison of wound treatment and wound healing with a hyaluronic acid-containing matrix vs. hydrofibre and skin transplant healing rates for defect coverage after resection of skin tumors";"[---]*";"http://www.fachklinik-hornheide.de/Studien-der-Plastischen-Chirur.371.0.html";"Background: In this study the results of different wound therapeutics in so called open wound therapy followed by autologous skin grafting are compared after the excision of skin tumors.<br/>What is done? Who are potential participants?<br/>All adults aged 18 years onwards, in need of excision of a skin tumor and skin grafting can participate in the study.<br/>Aims of the study:<br/>Evidence based evaluation of two different methods for the promotion of granulation tissue and dermal regenaration. So far there is no proof that bio-inductive hyaluronic acid based dermal subsitutes initiates a better wound healing process in comparison to hydrofibre wound dressings. The effects of hyaluronic acid and hydrofibres in wound healing and the molecular processes will be examined.<br/>The wound therapeutics to be compared are Hyalomatrix (Anika Wound Therapeutics S.r.l.) and Aquacel Hydrofibre (Convatec).<br/>Hypothesis: The use of Hyalomatrix leads to less scarring and a better skin texture be promoting coordinatetd cell growth in the three dimensional stuctrue of the hyaluronic acid fibres.";"The results of wound treatment after excision of skin tumours with two different wound therapeutics are compared.The are a bio inductive, hyaluronic acid based three dimensional dermal substitute (Hylomatix, Anika Wound therapuetics S.r.l.)  and a hydrofibre (Aquacel extra, Convatec) <br/><br/>Objective analysis of the results is achieved with skin ultrasound photo documentation, visual pain scale and the POSAS scar scale.<br/><br/>Histo-pathological examinations will by performed to morphologically evaulate and quantify wound healing and angiogenesis aspects.<br/>H&E colouring and Antibodies against endothelium as well as the markers CD34 und SMA will be used. The fibrillar collagen is quantified by EvG colouring.<br/> ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006293";"2016-05-27T20:36:00.275+02:00";
"DRKS00006766";2016/08/09;2014/09/16;yes;"Approved";"09/11";"Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg";"Universal Trial Number (UTN)";"U1111-1161-8388";"[---]*";"Other Secondary-ID";"00006631";"DIMDI-Registriernummer";;;;;;;;;;"Free text";"[---]*";"chronic alcohol dependence ";"ICD10";"F10.2";"Mental and behavioural disorders due to use of alcohol; Dependence syndrome";;;;;;;;;;"Arm 1";"Implantation of the stimulation electrode<br/><br/>Intervention phase:<br/>12 weeks with activated stimulation electrode<br/>12 weeks with switched off stimulation electrode<br/><br/>From week 25 permanent activation of the stimulation electrode";"Arm 2";"Implantation of the stimulation electrode<br/><br/>Intervention phase:<br/>12 weeks with switched off stimulation electrode<br/>12 weeks with activated stimulation electrode<br/><br/>From week 25 permanent activation of the stimulation electrode";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Crossover";"N/A";"N/A";"Primary endpoint: relapse of alcohol abuse (patient interviews)<br/>first evaluation<br/>12 weeks after activation: new evaluation; after conversion of the stimulation<br/>24 weeks after activated stimulation: new evaluation<br/>1 year after activated stimulation: new evaluation<br/>2 years after activated stimulation: new evaluation";"Secondary endpoint: Improvement of cognitive memory function<br/>What are the effects of stimulation in the nucleus accumbens on motivational and cognitive processes of patients with chronic alcohol dependence? implementation of following tests: Psychometric testing 3 , 6 and 12 months after implantation : • VLMT - Verbal Learning Test ( using different parallel forms ) • D2 - concentration test • sense memory ( retell stories parallel form ) • I STAI - State Trait Anxiety Inventory (State ) • BDI II - Beck Depression Inventory • LDH - Lifetime Drinking History • SVF - coping questionnaire • I-SEE- Inventory for the Measurement of Self-Efficacy and Externality• Urica - University of Rhode Island Change Assessment ( questionnaire for the assessment of treatment motivation ) • ADS - Alcohol Dependence Scale • AUQ - Alcohol Urge Questionnaire • Fagerström - Test for Nicotine Dependence • CGI - Clinical Global Impression • OCDS - Obsessive Compulsive Drinking Scale • ACQ - Alcohol Craving Questionnaire<br/><br/>In addition, the 12 - month follow-up : • SCID- II - Structured Clinical Interview for DSM - IV • HAWIE - Hamburg - Wechsler Intelligence Test for Adults <br/>first evaluation<br/>12 weeks after activation: new evaluation; after conversion of the stimulation<br/>24 weeks after activated stimulation: new evaluation<br/>1 year from activated stimulation: new evaluation<br/>2 years from activated stimulation: new evaluation<br/><br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Magdeburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/10/01;"Actual";"15";2017/01/16;"Monocenter trial";"National";"Both, male and female";"18";"Years";"65";"Years";"1. Alcoholabusus ICD-10 and DSM-IV<br/>2 Male and female individuals 18-65 years of age<br/>3. No alcohol at least 10 days after completion of detoxification<br/>4 Since 4 weeks no sedative drugs (benzodiazepines, clomethiazole)<br/>5. Therapies without lasting success: including medical detoxification, inpatient or partial inpatient long-term treatment ≤ 8 weeks psychotherapies<br/>6. Relapse prevention medication (acamprosate, naltrexone, disulfiram or other)<br/>7. Therapies must be documented<br/>8. in last 12 months about 6 months ""drinking days""<br/>9. Patients are mentally competent, willing and able to sign <br/>10. Patients must have sufficient knowledge of German<br/><br/><br/>";"1. medical history cerebral seizures except by alcohol withdrawal<br/>2. severe neurological or internal medical comorbidity<br/>3. coagulopathy<br/>4. other acute, severe, requiring treatment psychiatric disorders of Axis I (according to criteria of DSM IV)<br/>5. personality disorder according SCID-II<br/>6. cardiac or pulmonary disease with risk of anesthesia (ASA value> 3)<br/>7. participation in other clinical studies 30 days before inclusion<br/>8. medical history of significant brain vascular malformations, head injury or neurosurgical operations<br/>9. cerebral changes in current CT / MRI<br/>10. pacemaker or an implantable defibrillator<br/>11. possible need an MRI scan after inclusion in the study<br/>12. pregnancy or lactation or women wishing to become pregnant<br/>13. planned inpatient or partial inpatient long-term therapy<br/>14. mental retardation (HAWIE IQ <70)<br/>15. legal care or patient of a psychiatric facility<br/>16. medical history drug use (current drug abuse) or drug addiction (past drug dependence) - except nicotine.<br/>";"Primary Sponsor";"Otto-von-Guericke-Universität MagdeburgMedizinische Fakultät, Klinik für Stereotaktie";"Mr.";"Prof. ";"Hermann-Josef Rothkötter";"[---]*";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"0391 6724780";"0391 6715898";"martina.beckmann@med.ovgu.de";"[---]*";"Contact for Scientific Queries";"Klinik für Stereotaktische Neurochirurgie";"Mr.";"Prof. Dr. med";"Jürgen";"Voges";"Leipziger Str.44";"39120";"Magdeburg";"Germany";"0391 6724780";"0391 6715898";"Voges, Jürgen (juergen.voges@med.ovgu.de)";"[---]*";"Contact for Public Queries";"Klinik für Stereotaktische Neurochirurgie";"Ms.";"[---]*";"Martina";"Leucke";"Leipziger Str. 44";"39120";"Magdeburg";"Germany";"0391 6714413";"[---]*";"martina.leucke@med.ovgu.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effects of stimulation in the nucleus accumbens on motivational and cognitive processes of patients with chronic alcohol dependence";"ESNachA";"[---]*";"Patients who are alcoholics get a new therapy, because the have known not helpful. It is applied an operating method where electrodes are implanted. These stimulate the addiction center in the brain. This electrical stimulation, the activity changes in this area. This should disappear in the long term addiction.<br/>By coincidence, the stimulator is in half of all study participants switched off after three months. After another three months, this is finally and permanently activated. The other half of the study participants is first turned three months then activated for the next three months. This group will remain on permanently even after the expiry of six months. Doctor and patient do not know which patient is assigned to which group.<br/>";"We have conducted in the past two years in five patients with refractory alcohol addiction a therapeutic trial with THS in Nacc , which has led to a massive reduction in relapse frequency and in two cases to total abstinence This approach is based on the idea that alcoholism is a special form of obsessive-compulsive disorder , and that with treatment-resistant obsessive-compulsive disorder , the high-frequency DBS can achieve a significant clinical improvement in the shell of Nacc ; Moreover, it was observed by another research group in a patient as an incidental finding , a reduction of his alcohol addiction among Nacc stimulation. <br/><br/>While these results are encouraging, but need for a confirmation , on the other hand a thorough scientific investigation. For if the desired stimulation effect can confirm , it follows that motivation and motivated action of these patients be influenced. We can not judge whether and to what extent these effects selectively affect addictive behavior currently , however ; possibly the intensity and breadth motivational behavior are generally in the long run stimulation changed with potentially significant consequences. <br/>The planned in the clinical trial cognitive experiments therefore focused on the effect of stimulation of the Nacc on motivational and cognitive processes. ";"Recruiting stopped after recruiting started ";"Trial results";"9342eb0d-0041-4a85-83bb-b5105105c0fa";"Abschlussbericht_Final_20190605_oU.pdf";"Abschlussbericht";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006766";"2019-06-06T08:19:54.058+02:00";
"DRKS00007802";2015/02/24;"[---]*";yes;"Approved";"413-14-17112014";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2014-000346-30";"[---]*";;;;;;;;;;;;;"ICD10";"C93.1";"Chronic myelomonocytic leukaemia";"ICD10";"C92.0";"Acute myeloblastic leukaemia [AML]";;;;;;;;;;"Arm 1";"The oral dose of 25 mg INC424 bid will be administered continuously until: disease progression; unacceptable toxicity; death; discontinuation from the study for any other reason. <br/>Dose escalation to 50 mg INC424  bid p.o. is forseen in patients with inadequate response (stable disease or progressive disease ). In patients with AML following 2 weeks of therapy. In patients with CMML a reduction of 50% monocytes is expected. If monocytes reduction is ≤50% or blast count is stable or increasing, dose is increased to 50 mg bid p.o.<br/>If after further 14 days no response is obtained the therapy will be continued with azacitidine 75 mg/m2 sc qd for 7d and 25 mg bid INC424. After further 14 days and still no response the dose of INC424 is increased to 50 mg bid p.o. in combination with azacitidine 75 mg/m2 sc qd for 7d  if the patient has no dose limiting toxicity. If the patient does not respond to the therapy or if unacceptable toxicity due to study medication happens, which do not allow the continuation of the treatment, study treatment will be discontinued and the best standard threrapy will be applied. The study medication will be applied max. for one year, aferwards a one year follow-up will be performed.";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Other";"Open (masking not used)";"Other";"Treatment";"Other";"I-II";"Yes";"Phase I<br/>Tolerability and safety of INC424 alone or in combination with azacitidine at day 56 after treatment of 4 patients.<br/>The following clinical and laboratory parameters will be collected to evaluate study drug safety and toxicity (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths):<br/>•	duration and severity of all grade adverse events (AEs) by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE V4.03)<br/>•	performing physical exams (PE)<br/>•	evaluating changes in vital signs (VS)<br/>•	ECOG performance status<br/>•	electro and echocar-diograms<br/>•	serum chemistry and hematology results<br/>•	Grade 3 and 4 AEs, Serious Adverse Events (SAEs)<br/>•	Frequency of dose interruptions and discontinuations due to AEs.<br/>Phase II (after one year treatment of the last patient) - Hematological response defined as:   <br/>-	CR, CRi, PR, SD in post-myeloproliferative AML (blastic transfor-mation)<br/>-	Monocyte count (periphery) and Blast count (bone marrow) reduction in CMML";"• Dose limiting toxicity (DLT) during study therapy (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths)<br/>• Leukemia Free Survival one year after start of trial therapy<br/>• Overall survival one year after start of trial therapy <br/>• Progression free survival one year after start of trial therapy<br/>• Transfusion requirement during study therapy (on day 1 of every treatment period (28 days) of study treatment (max. 12 months)<br/>• Effect on Bone Marrow Fibrosis during study therapy (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths)<br/>• Response according to cytogenetics (normal and multiaberrant karyotype) during study therapy (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths)<br/>• Duration of hospitalization for any reason during study therapy (on day 1 of every treatment period (28 days) of study treatment (max. 12 months)<br/>• Incidence of treatment failure according to IWG response criteria during study therapy (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths).<br/>• Correlation of study endpoints (on day 1 of every treatment period (28 days) of study treatment (max. 12 months) with the points achieved at the time of diagnosis according to the following questionnaire: instrumental activities of daily living (iADLs, “Instrumentelle Aktivitäten des täglichen Lebens” and EORTC QLQ-C30 Version 3.0)<br/>• Correlation of study endpoints (on day 1 of every treatment period (28 days) of study treatment (max. 12 months) with the Eastern Cooperative Oncology Group (ECOG) Performance Status at the time of diagnosis <br/>• Comparison of response and survival of patients treated with INC424 as monotherapy and in combination with azacitidine with historical patient populations treated with the conventional chemotherapy<br/>• Response according to JAK2, flt3, npm1 Mutation during study therapy (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths)<br/>• Number of patients undergoing stem cell Transplantation up to end of follow-up (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths)<br/>• Safety of INC424 ± azacitidine (Grade IV toxicities and feasibility of the combination) during study therapy (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths)<br/>The following clinical and laboratory parameters will be collected to evaluate study drug safety and toxicity (on days 15, 28, 42, 56, 84 and all 28 days up to max. 12 moths):<br/>•	duration and severity of all grade adverse events (AEs) by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE V4.03)<br/>•	performing physical exams (PE)<br/>•	evaluating changes in vital signs (VS)<br/>•	ECOG performance status<br/>•	electro and echocar-diograms<br/>•	serum chemistry and hematology results<br/>•	Grade 3 and 4 AEs, Serious Adverse Events (SAEs)<br/>•	Frequency of dose interruptions and discontinuations due to AEs.<br/>• Quality of Life (on day 1 of every treatment period (28 days) of study treatment (max. 12 months):<br/>- Change in ECOG PS from baseline to each visit where measured<br/>- EORTC QLQ-C30 from baseline to each visit where measured<br/>- Change in iADL from baseline to each visit where measured";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Dept. of Hematology, Oncology and Hemostasiology";"Leipzig";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/06/15;"Actual";"40";2018/02/28;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1.	Patients must be diagnosed with postmyeloproliferative AML according to the 2008 World Health Organization criteria (Appendix A), irrespective of JAK2 mutation status or diagnosed with CMML with a white-blood-cell count above 13×10⁹ cells /L.<br/>2.	Patients must give written informed consent according to local guidelines prior to any screening procedures.<br/>3.	Patients must not be eligible for another ongoing INC424 clinical trial. <br/>4.	Male or female patients ≥18 years<br/>5.	Patients with adequate liver function defined as direct bilirubin ≤ 2.0 x ULN, and ALT ≤ 2.5 x ULN.<br/>6.	Patients with adequate renal function defined as serum creatinine<br/>≤ 2 x ULN.<br/>7.	Patients with an Eastern Cooperative Oncology Group (ECOG) perfor-mance status of 0, 1, or 2 (Appendix A).<br/>8.	Women of childbearing potential must have had a negative serum preg-nancy test within 72 hours prior to the administration of study drug. They must agree to use effective contraceptive methods (doctors approved contraception) throughout the study and for 3 months following the date of the last dose of study medication. Female patients who are more than 2 years postmenopausal or have had a hysterectomy will not be consid-ered of childbearing potential. Males with female partner of childbearing potential must agree to use effective contraceptive methods (doctors ap-proved con-traception)  throughout the study and should avoid fathering a child for 3 months fol-lowing the date of the last dose of study medica-tion. Adequate forms of contraception are double-barrier methods (con-doms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depot, or injectable contraceptives, intrauterine devices, and tubal ligation.<br/>9.	Patients must have recovered or stabilized sufficiently from adverse drug reactions associated with prior treatments before beginning treatment with INC424.";"1.	Any diagnosis of malignant disease within the previous 12 months (ex-cluding treated early stage squamous or basal cell carcinoma with no complications) <br/>2.	Impairment of gastrointestinal (GI) function or GI disease that may signifi-cantly alter the absorption of INC424 (e.g., ulcerative diseases, uncon-trolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).<br/>3.	Hepatic tumors in the medical history<br/>4.	Patients with known active hepatitis A, B, C or who are HIV-positive.<br/>5.	Patients with coagulation parameters (PT, PTT) ≥1.5 x ULN.<br/>6.	Patients with known hypersensitivity to INC424 or to its excipients or known or suspected hypersensitivity to azacitidine or mannitol.<br/>7.	Patients with serious concomitant medical illness:<br/>a.	history of severe congestive heart failure [grade ≥ 3 according to CTCAE] or<br/>b.	clinically unstable ischemia or <br/>c.	acute myocardial infarction in the previous six months or<br/>d.	pulmonary hypertension [grade > 3 according to CTCAE] or<br/>e.	severe cardiac arrythmias [grade > 3 according to CTCAE] or<br/>f.	chronic pulmonary diseases [grade > 3 according to CTCAE] or<br/>g.	uncontrolled hypertension or<br/>h.	uncontrolled diabetes or<br/>i.	uncontrolled severe infections [grade > 3 according to CTCAE] or<br/>j.	any other severe or uncontrolled medical illness<br/>8.	Psychiatric illness that would prevent granting of informed consent<br/>9.	Patients receiving ongoing treatment with another investigational medica-tion or having been treated with an investigational medication within 30 days of study drug treatment.<br/>10.	Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until termination of gestation, con-firmed by a positive βHCG laboratory test (> 5 mIU/mL).<br/>11.	Patients with any concurrent condition that, in the Investigator’s opinion, would jeopardize the safety of the patient or compliance with the protocol.";"Primary Sponsor";"Universität Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstr. 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum AöRDepartment für Innere MedizinHämatologie, Internistische Onkologie und Hämostaseologie";"Mr.";"Prof.";"Dietger";"Niederwieser";"Johannisallee 32A";"04103";"Leipzig";"Germany";"+49 341 97-13051";"+49 341 97-13159";"dietger.niederwieser@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Universitätsklinikum AöRDepartment für Innere MedizinHämatologie, Internistische Onkologie und Hämostaseologie";"Mr.";"Prof.";"Dietger";"Niederwieser";"Johannisallee 32A";"04103";"Leipzig";"Germany";"+49 341 97-13051";"+49 341 97-13159";"dietger.niederwieser@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Novartis Pharma GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Roonstraße 25";"90429";"Nürnberg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Celgene International Sarl";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"2017 ";"Boudry";"Switzerland";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"An open-label, multicenter, study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML ";"JAKVIDA";"[---]*";"At this time, there is no standard medical treatment for patients with post- myeloproliferative AML (acute myeloid leukemia) as consequence of a myeloproliferative disorde or chronic myelomonocytic leukemia (CMML). This study is intended to provide efficacy and safety of INC424/Ruxolitinib monotherapy or in combination with Azacitidine.The study drug INC424 is indicated for the treatment of symptoms in adult patients with diseases of the hematopoietic system in the bone marrow. Azacitidine is indicated for CMML with 10 – 29% of bone marrow blasts and for AML with 20 – 30% blasts. Due to the mechanism of action of INC424 an improvement of the response is expected in patients with AML and CMML. Patients with post- myeloproliferative AML or chronic myelomonocytic leukemia (CMML) meeting all inclusion and exclusion criteria for this study will be treated with the drug INC424 or with the combination of INC424 and Azacitidine. Depending on the response to the study therapy it will be decided which therapy will be administered for a maximum of one year followed by a one year follow-up phase.";"The study is an explorative, prospective, open-label, one-arm, multicenter, phase I/II study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007802";"2019-01-02T13:01:24.859+01:00";
"DRKS00008531";2015/06/17;"[---]*";yes;"Approved";"13-050";"Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln";;;;;;;;;;;;;;;;"Free text";"[---]*";"Esophageal carcinoma";"ICD10";"C15";"Malignant neoplasm of oesophagus";;;;;;;;;;"Arm 1";"Interventiongroup: The interventiongroup will have a single bout of aerobic exercise about 12 h befor tumorresection. The will performe a step-protocoll on a bycicle-ergometer. Load starts at 20 watt and will be increased every 3 minutes with 10 watts. With that protocoll a long duration and a high intensity will be ensured.";"Arm 2";"Controlgroup: The controlgroup will not perform any exercise. They will stay in rest for 30 minutes at least 12 hours befor tumorresection.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Control group receives no treatment";"Basic research/physiological study";"Parallel";"N/A";"N/A";"Primary outcome is the nk-cell-cytotoxicity. Before, after and 12 h after the single bout of exercise blood will be drawn. From this blood samples nk-cells will be isolated and used in cytotoxicity assays with the cell line K562 as target cell.";"Secondary edpoints are the characterization of NK-cells and the tumorinfiltration by NK-cells.<br/>For the characterization blood will be drawn (befor, after and 12 h after exercise) and the NK-cells will be investigated for their subgroups (CD56bright and CD56dim) and for the degranulation marker CD107a by flow cytometry.<br/>The tumor tissue will be removed and analysed for NK-cell infiltration by imunohistochemistry. Therefore the NK-cells will be stained by CD56 and CD57.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinik Köln";"Köln";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/10/06;"Actual";"24";2018/12/31;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Esophageal carcinoma, befor Operation (tumoe removal), medical innocuousness for the sport intervention";"Age < 18 years, therapy befor operatione (chemotherapy or radiation), medical contraindications for exercise";"Primary Sponsor";"Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung für molekulare und zelluläre Sportmedizin";"Mr.";"Prof. Dr.";"Wilhelm";"Bloch";"Am Sportpark Müngersdorf 6";"50933";"Köln";"Germany";"0221 4982 5380";"0221 4982 8370";"w.bloch@dshs-kolen.de";"www.dshs-koeln.de";"Contact for Scientific Queries";"Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung für molekulare und zelluläre Sprotmedizin";"Mr.";"[---]*";"Alexander";"Schenk";"Am Sportpark Müngersdorf 6";"50933";"Köln";"Germany";"0221 4982 5450";"0221 4982 8370";"a.schenk@dshs-koeln.de";"[---]*";"Contact for Public Queries";"Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung für molekulare und zelluläre Sprotmedizin";"Mr.";"[---]*";"Alexander";"Schenk";"Am Sportpark Müngersdorf 6";"50933";"Köln";"Germany";"0221 4982 5450";"0221 4982 8370";"a.schenk@dshs-koeln.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung für molekulare und zelluläre Sportmedizin";"Mr.";"Prof. Dr.";"Wilhelm";"Bloch";"Am Sportpark Müngersdorf 6";"50933";"Köln";"Germany";"0221 4982 5380";"0221 4982 8370";"w.bloch@dshs-koeln.de";"www.dshs-kolen.de";"Institutional budget, no external funding (budget of sponsor/PI)";"Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und SPortmedizin, Abteilung für molekulare und zelluläre Sportmedizin";"Mr.";"PD. Dr.";"Freerk T.";"Baumann";"Am Sportpark Müngersdorf 6";"50933";"Köln";"Germany";"0221 4982 4821";"0221 4982 8370";"f.baumann@dshs-kolen.de";"www.dshs-koeln.de";;;;;;;;;;;;;;;"Influence of acute physical activity on the NK-cell cytotoxicity of esophageal cancer patients";"[---]*";"[---]*";"Former investigations give first hints that physical activity has a positive influence on the development of several cancer types, cancer-related mortality as well as cancer recurence. The way physical activity promotes these influences is not understood  yet. As a possible mechanism a sports related activation of the body owns cancer defense by natural killer cells is discussed. Natural killer cells belong to the immune system and have the ability to recognize and  kill cancer cells.<br/>This study should investigate, if a single bout of aerobic exercise could improve the ability of natural killer cells to kill cancer cells and promote a migration of natural killer cells into the tumor tissue of esophageal cancer patients (This study is an amendment of the study DRKS00005037). Therefore, 24 esophageal carcinoma patients should be included before surgical tumor removal. Patients will be randomized in an intervention and a control group. The intervention group performs an intensive bout of aerobic exercise 10-14 hours before tumor removal. The control group stays in rest during the same time interval. Before, after and 12 hours after the bout of exercise or rest blood is drawn. The blood samples are used for isolation of natural killer cells and analyzing of tumor cell killing. Further the natural killer cells will be characterized in respect for subgroups. After the tumor removal the tissue is investigated for intratumoral natural killer cells.<br/>With these investigations it should be shown if a single bout of aerobic exercise could improve the ability of natural killer cells to kill tumor cells and if it could promote a migration of natural killer cells into the tumor tissue.<br/>";"The literature shows a positive influence of physical activity on cancer specific mortality. Furthermore, physical activity could improve the risk for primary cancers and relapses. The knowledge about the underlying mechanisms is still sparse. An exercise induced activation of the body owns cancer defense by natural killer cells is discussed as one such mechanism. Therefore, this study investigates the influence of a single bout of aerobic exercise on natural killer cell cytotoxcity and the tumorinfiltration by natural killer cells (Amendment of the study DRKS00005037).<br/>For this purpose 24 esophageal cancer patients before surgical tumor resection and without neoadjuvant therapy should be included. Patients will be randomized into an intervention and a control group. The intervention group will perform a single bout of aerobic exercise on a bicycle ergometer 10-14 hours before tumor resection. In the same time interval, the control group will stay in rest. Before, after and 12 hours after exercise or rest blood will be drawn. Natural killer cells will be isolated from the blood samples and the cytotoxicity will be measured. Additionally,  a characterization of natural killer cells in respect to their subsets will be done. Finally, the removed tumor tissue will be analyzed for intratumoral natural killer cells.<br/>With these analyses it will be shown, if a single bout of aerobic exercise can influence the natural killer cell cytotoxicity and the migration into the tumor tissue. <br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008531";"2019-08-13T11:32:42.735+02:00";
"DRKS00006176";2014/05/21;"[---]*";yes;"Approved";"022/14-ff";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";;;;;;;;;;;;;;;;"ICD10";"C32.9";"Malignant neoplasm: Larynx, unspecified";"ICD10";"Z90";"Acquired absence of organs, not elsewhere classified";;;;;;;;;;"Arm 1";"use of Phonax(R) voice prothesis";"Arm 2";"use of Provox II(R) voice prothesis";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Number of voice protheses per year in the course of a three year follow-up with a maximum duration of stay of one year per prothesis.";"•3 year loco-regional control (staging, recurrence of tumor)<br/>•symptomscore related to breathing-/ speaking- and swallowing ability <br/>•complication rate related to the protheses /mediaclly documented (inspection of tracheostom, tracheoskopy with optics, way of insuffiziency, promblems with the fistula) during the 3 years of follow-up.<br/>•funktioning of the voice protheses: PLTT (Post Laryngektomie Telefon Test), VHI (Voice Handicap Index), sound holding period 12, 24 and 36 months post surgery<br/>•biofilm-parameterp: analysis of the voice prothesis after explantation by swab and microbiological analyses <br/>•patient's quality of life (questionaires) 12, 24 and 36 monaths post surgery<br/>•primary placement of the voice prothesis (questionaire for the surgeon)<br/>•replacement of the voice prothesis (questionaire for the physician)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde";"Leipzig";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/10/01;"Actual";"58";2018/07/11;"Monocenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"•histologically verified, primary resectable Larynx/Hypopharynxcarcinoma<br/>•indikation for laryngectomy with primary creation of a  tracheo esophageal fistula<br/>•planned curative resection (R0-resection)<br/>•stage II/IV A ollowing UICC (without T1) <br/>•low to slightly enhanced risk of anesthesia<br/>•adequate bone marrow-, liver- and kindneyfunction<br/>•Karnofsky-Index ≥70%<br/>•Age 18-80 Years<br/>•written informed consent<br/>";"•tumorspezifc pre-treatment (chemotherapy, radiation therapy)<br/>•Metachrone or synchrone malignom (exception: basaliom or low-risk prostatecarcinoma) [In case of a controlled tumor at a different location with a treatment free intervall of more than 5 years, inclusion might be possible after consultation of the co-ordinating investigator]<br/>•life expectancy < 6 months<br/>•acute infection or fever<br/>•anamnestic HIV-infection or othe immune suppression<br/>•serious cardio-pulmonary concomittant disease (heart insufficiency grade III and IV following NYHA scale, myocardial infarction, angina pectoris, respiratoric insufficiency serious Asthma bronchiale, COPD (FEV1 <35%))<br/>•chronic disease with permanent therapy (uncontrolled Diabetes, rheumatoide Arthritis) particularly steroid therapy<br/>•other concomittant diseases, which exclude the patient from the trial from the perspective of the trial physician<br/>•analphabetism<br/>•intolerance regarding the materials of the voice protheses <br/>•experienced low patient's compliance<br/>•regular follow-up impossible (e. g. patient lives outside of Germany)<br/>•lack of or patial legal capcity of the patient<br/>•participation in another clinical trial or  application of a not yet registered substancewithin 30 days before trial start<br/>•pregnant or nursing<br/>•fertile female patients (< 2 years after the last spontaneous menstruation) without effective contraception (implants, injections, oral contraceptives, intrauterine devices, vasectomized partner)<br/>";"Primary Sponsor";"Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde Leipzig";"Mr.";"Prof. Dr. med.";"Andreas";"Dietz";"Liebigstrasse 12, Haus 1";"04103";"Leipzig";"Germany";"(03 41) 97 - 2 1700";"(03 41) 97 - 2 17 09";"andreas.dietz@medizin.uni-leipzig.de";"[---]*";"Contact for Scientific Queries";"Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde Leipzig";"Mr.";"Prof. Dr. med.";"Andreas";"Dietz";"Liebigstrasse 12, Haus 1";"04103";"Leipzig";"Germany";"(03 41) 97 - 2 1700";"(03 41) 97 - 2 17 09";"andreas.dietz@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Klinik und Poliklinik für Hals-, Nasen-, OhrenheilkundeSektion Phoniatrie und Audiologie";"Ms.";"Dr. med.";"Sylvia";"Meuret";"Liebigstrasse 12, Haus 1";"04103";"Leipzig";"Germany";"(03 41) 97 - 2 1800";"(03 41) 97 - 2 18 09";"sylvia.meuret@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"HEIMOMED GmbH & Co. KG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"50170";"Kerpen";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Prospective, randomized clinical trial for the comparison of the voice protheses Phonax® and Provox II®";"Phonax";"[---]*";"Randomized prospectiv clinical trial for the comparison of twp voice protheses: Phonax and Provox II.<br/>After a complete laryngectomie (removal of the larynx) the patient often receives a voice protheses for voice rehabilitation. This trial will compare the two above mentioned protheses with respect to their functioning, patient satisfaction as well as with respect to potential complications.";"This trial willcompare the most frequently used voice protheses in Europe, Provox II (ATOS Medical GmbH) with the voice prothesis Phonax with respect to their duration of stay, functionality, compliation rate and handling with respect to placement and replacement of the protheses.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006176";"2020-01-23T08:36:17.687+01:00";
"DRKS00006330";2015/05/18;"[---]*";yes;"Approved";"44/15 (FF-MC)";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2014-000180-41";"[---]*";;;;;;;;;;;;;"ICD10";"A04.9";"Bacterial intestinal infection, unspecified";;;;;;;;;;;;;"Arm 1";"Patients will be treated with colistin ( 4 x 2 million units/day) and  rifaximin (2 x 400 mg/day) for 3 weeks.";"Arm 2";"Patients with no active drug treatment (watch & wait, control group).";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Control group receives no treatment";"Treatment";"Parallel";"II";"Yes";"3GCREB eradication defined as: no evidence for colonization with 3GCREB by preferably rectal swab and/or stool cultures performed at end of treatment visit (=visit 3) and at 1-2 weeks after end of treatment visit (=visit 4). ";"- early (rapid) 3GCREB decolonization (days 8-12 after treatment initiation=visit 2); <br/>- late (sustained) 3GCREB decolonization (week 9 after end of treatment visit =visit 5); <br/>- any infection which requires antibiotic therapy<br/>- infection originating from gastrointestinal tract microflora (including urinary tract infection) which requires antibiotic therapy; <br/>- intestinal carriage of colistin- and rifaximin-resistant 3GCREB;";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinikum Freiburg";"Freiburg im Breisgau";"University Medical Center";"Universitätsklinikum Leipzig";"Leipzig";"University Medical Center";"Universität zu Kön";"Köln";"University Medical Center";"Philipps-Universität Marburg";"Marburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/11/16;"Actual";"174";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. Written informed consent obtained according to international guidelines and local laws;<br/>2. Male or female patients aged 18 or older;<br/>3.Patients with at least two episodes of infection<br/>-during the last 12 months,<br/>-each time requiring specific antibiotic therapy and<br/>-due to the same species of 3GCREB (ESBL and/or AmpC enterobacteria) but not necessarily with identical susceptibility test results. <br/>A second infection WITHOUT microbiological documentation can be accepted if<br/>-it can be considered as relapsing infection with the same clinical focus based on clinical judgement<br/>-and there has been no other relevant pathogen for this episode<br/>-and the episode required antibiotic treatment considered adequate and clinically effective<br/>4. Patients with current colonization with the same species of 3GCREB as in (3)<br/>- on two occasions within three weeks before day 0 of the study (i.e. day -21 to -1).<br/>- proven by two cultures taken at least one week apart from each other, with the second culture taken within one week before day 0 of the study (i.e. day -7 to -1)<br/>- with the first culture taken from any site (e.g. sputum, wound,urinary tract, rectal swab, stool)*<br/>- and the second being a rectal swab, alternatively stool**<br/>- absence of antibiotic therapy, except<br/>- if treatment stop is planned before day 0 of the trial<br/>- short-term therapy for uncomplicated urinary tract infection (oral fosfomycin, norfloxacin, trimethoprim or trimethoprim-sulfamethoxazole for 3 days or less, or nitrofurantoin for no more than 5 days);<br/>5. Specific inclusion criteria for patients with a history of recurrent urinary tract infections: Result of a current urine culture (done 3 weeks before day 0 of the study) has to be on hand. Result of urine culture which was routinely performed during medical care of a patient will be accepted;<br/>6. Ability to understand the nature of the trial and the trial related procedures and to comply with them;<br/><br/>* Result of culture which was routinely performed during medical care of a patient will be accepted;<br/>** To obtain at least one baseline culture sample for analysis in the Microbiology Reference Center (see<br/>section 7.6.11), results of cultures routinely performed cannot be accepted";"1. Patients with rapidly fatal underlying disease (i.e. McCabe category 3);<br/>2. Patients with severe diarrhea (defined as >5 bowel movements per day with loose stools) in the last three days;<br/>3. Patients with severe nausea/vomiting;<br/>4. Patients with inability to swallow;<br/>5. Patients who received recent (last 3 weeks) treatment with oral colistin and/or rifaximin;<br/>6. Patients with expected low compliance with drug regimen;<br/>7. Simultaneous participation in other interventional trials which could interfere with this trial and/or participation within the last 30<br/>days before the start of this trial (except for registry and diagnostic trials);<br/>8. Patients with contraindications to the study drugs such as known intolerance of the study drugs (including other rifamycin derivatives like rifampin/rifampicin, rifabutin and rifapentine);<br/>9. Co-medication with ibrutinib (recently approved tyrosine kinase inhibitor for treatment of patients with B cell lymphomas);<br/>10. Known or persistent abuse of medication, drugs or alcohol;<br/>11. Persons who are in a relationship of dependence/employment with the sponsor or the investigator;<br/><br/>Specific exclusion criteria for female patients:<br/>1. Current or planned pregnancy, nursing period;<br/>2. Failure to use one of the following safe methods of contraception: female condoms, diaphragm or coil, each used in combination<br/>with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception.";"Primary Sponsor";"Universitätsklinikum Freiburg";"[---]*";"[---]*";"[---]*";"[---]*";"Hugstetter Strasse 49";"79095";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinik-freiburg.de";"Contact for Scientific Queries";"Universitätsklinikum Freiburg";"Mr.";"Prof. Dr.";"Winfried";"Kern";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"0761 270 18190";"0761 270 18200";"winfried.kern@uniklinik-freiburg.de";"www.uniklinik-freiburg.de";"Contact for Public Queries";"Universitätsklinikum Freiburg, Abteilung Infektiologie";"Mr.";"Dr.";"Marc Fabian";"Küpper";"Hugstetter Str. 55";"79106";"Freiburg";"Germany";"+49 761 270 37620";"+49 761 270 37620";"marc.kuepper@uniklinik-freiburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung Dienstsitz Berlin";"[---]*";"[---]*";"[---]*";"[---]*";"Friedrichstraße 130 B";"10117";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Carriage of 3GCREB in patients at risk for relapsing infection: randomized<br/>controlled trial of intestinal decolonization with colistin plus rifaximin<br/><br/>";"Eradicate";"[---]*";"decolonization treatment with oral non-absorbable drugs to see if the treatment is superior to watch & wait in eradicating bacteria from the intestinal tract and prevent infection";"Decolonization treatment with oral non-absorbable drugs to compare if it is superior to watch & wait in eradicating 3GCREB from the intestinal tract and prevent infection";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006330";"2020-01-31T07:30:28.828+01:00";
"DRKS00011572";2017/03/14;2016/01/29;yes;"Approved";"415/15-ff";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2015-002212-32";"[---]*";"Primary Registry-ID";"NCT02669680";"ClinicalTrials.gov ";;;;;;;;;;"ICD10";"K72.0";"Acute and subacute hepatic failure";"Free text";"[---]*";"acute-on-chronic liver failure";;;;;;;;;;"Arm 1";"Application of G-CSF (Filgrastim) in combination with standard care of acute-on-chronic liver failure<br/>(G-CSF subcutaneously, 5 μg/kg daily  on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses)<br/>";"Arm 2";"Standard care of acute-on-chronic liver failure";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Transplant-free survival up to 90 days (death or transplant count as events)";"•	Overall survival at 360 days<br/>•	Transplant-free survival at 360 days<br/>•	Complications of ACLF within 90 days/within 360 days (hepatorenal syndrome, variceal bleeding, ascites, hepatic encephalopathy)<br/>•	Infections within 90 days/within 360 days (proven infection necessitating systemic use of antibiotics)<br/>•	Liver function during the course of treatment and follow-up (MELD-Score, Child-Pugh-Score)<br/>•	Duration of initial hospital stay<br/><br/>Assessment of safety:<br/>In addition to the complications of ACLF listed above, further AEs and SAEs will be assessed. Laboratory values reflecting liver function as well as infection related parameters will be monitored during the course of treatment and follow-up.<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Allgemeine Innere Medizin 1";"Kiel";"University Medical Center";"Medizinische Klinik Abteilung I";"Tübingen";"University Medical Center";"Klinik u. Poliklinik für Gastroenterologie u. Rheumatologie";"Leipzig";"University Medical Center";"Medizinische Klinik und Poliklinik I";"Bonn";"University Medical Center";"Klinik für Gastroenterologie und Hepatologie - Zentrum für Innere Medizin";"Essen";"University Medical Center";"Klinik f. Gastroenterologie u. Hepatologie am Abdominalzentrum";"Köln";"University Medical Center";"Klinik für Gastroenterologie, Hepatologie, Infektiologie";"Düsseldorf";"Medical Center";"St. Georg";"Leipzig";"University Medical Center";"Innere Medizin II, Gastroenterologie, Hepatologie, Endokrinologie";"Saarland";"University Medical Center";"Medizinische Klinik III";"Aachen";"Medical Center";"St. Josefs-Hospital";"Wiesbaden";"University Medical Center";"Medizinische Klinik 1";"Frankfurt a.M.";"University Medical Center";"Medizinische Klinik - Abt. IV Gastroenterologie/ Hepatologie";"Heidelberg";"University Medical Center";"Innere Medizin II";"Freiburg im Breisgau";"University Medical Center";"Klinik für Gastroenterologie, Hepatologie, Endokrinologie";"Hannover";"University Medical Center";"Innere Medizin IV, Gastroenterologie, Hepatologie, Infektiologie";"Jena";"University Medical Center";"Charité";"Berlin";"University Medical Center";"1. Medizinische Klinik";"Mainz";;;;;;;2016/02/29;"Actual";"292";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Acute-on-chronic liver failure according to the criteria defined by the CANONIC study [Moreau 2013] / age >= 18 years / Informed consent";"Prior not curatively treated or active malignancies / sickle cell disease / septic shock, defined by the following symptom complex: bacteraemia AND SIRS AND shock / WBC-count of > 50 x 109/L / known HIV infection / known intolerance to filgrastim / pregnancy, lactation or insufficient contraception / participation in other interventional clinical trials";"Primary Sponsor";"Universität Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstr. 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum LeipzigSektion Hepatologie; Abteilung für Innere Medizin, Neurologie, Dermatologie";"Mr.";"Prof.";"Thomas";"Berg";"Liebigstraße 20";"04103";"Leipzig";"Germany";"+49 341 97 12331";"+49 341 97 12339";"thomas.berg@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Universitätsklinikum Leipzig AöRSektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum";"Mr.";"Prof.";"Thomas";"Berg";"Liebigstr. 20";"04103";"Leipzig";"Germany";"+49 341 97 12331";"[---]*";"thomas.berg@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A<br/>multicentre randomized trial<br/>";"GRAFT";"[---]*";"[---]*";"ACLF is a condition with dismal prognosis, for which apart from OLT (liver transplantation) no therapeutic options exist. A treatment approach that helps to recover from this acute intercurrent event and hereby improves the very poor short-term survival would be of major clinical importance. Stem cells play a major role in the process of hepatic regeneration. Their mobilization from the bone marrow due to G-CSF in patients with liver failure could be demonstrated in several phase I/II trials. Although an impact on the hepatic regenerative capacity was obvious, the results for clinical endpoints like patients´ survival and liver function were controversial [Di Campli 2007, Lorenzini 2008, Gaia 2006, Spahr 2008]. This was most likely due to the fact, that the observation period was limited and the power was inadequate for these endpoints. Recently two small randomized trials have shown the potential of G-CSF in this patient population markedly improving patients´ outcome [Garg 2012, Duan 2013]. However, these results need to be confirmed in a large multicenter Trial.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011572";"2019-09-10T18:41:10.274+02:00";
"DRKS00004194";2013/08/06;2012/04/04;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2011-000756-42";"[---]*";"Primary Registry-ID";"NCT01571895";"ClinicalTrials.gov";"Partner Registry-ID";"AIFA Codice: 10006567";"[---]*";"Sponsor-ID";"MEX0111";"Dompé s.p.a.";"Other Secondary-ID";"2011-000756-42";"[---]*";"Free text";"[---]*";"Bullous Pemphigoid";"ICD10";"L12.0";"Bullous pemphigoid";;;;;;;;;;"Arm 1";"Drug: DF2156A";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"- Total number of blisters from baseline; time frame: day 0/1 (pre-dose), 8 and 15; Total number of blisters from baseline<br/>- Modified ABSIS score change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; ABSIS score will be measured according to the pemphigus scoring sheet [Rosenbach, 2009] adjusted to the clinical manifestation in BP patients, as per specifications in protocol.<br/>- Physician Global Assessment (PGA) score measured on a 0-10 scale [Rosenbach, 2009]. Percent change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; PGA score will be measured according to the following scale:<br/>0<br/>1 2 3 4 5 6 7 8 9 10 Perfect Worst health skin condition imaginable<br/>The following guidelines will help standardize PGA:<br/>0: no lesions 2: almost cleared, no functional impairment 4: few lesions / low functional impairment 6: moderate 8: severe / extensive 10: life-threatening<br/>- Pruritus measured on a 10 cm visual analogue scale. Absolute value change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; Pruritus will be measured according to the following scale:<br/>0 10 No pruritus Worst pruritus I can imagine<br/>- Eosinophil blood count. Percent change from baseline; time frame: screening and day 15<br/>- Percentage of patients with treatment failure (drug discontinuation due to disease worsening); time frame: day 8<br/>- Percentage of patients completely free from blisters; time frame: day 15<br/>- Number of patients who are still free from blisters without requiring any systemic or topical rescue treatment - Optional; time frame: Day 30<br/>- Vital signs (blood pressure and heart rate); time frame: Italy: screening and day 15 (or withdrawal)___Ger: screening, day 1, 3, 5 and day 15 (or withdrawal)<br/>- Routine laboratory tests (haematology, clinical chemistry); time frame: screening and day 15 (or withdrawal)<br/>- QTcF. Change from baseline; time frame: Italy: day 0/1 (pre-dose), day 1, 5, 8 and 15___Ger:day 0/1 (pre-dose), day 1, 3, 5, 8 and 15<br/>- Incidence of Adverse Events and Serious Adverse Events; time frame: throughout the study up to day 15 or 30<br/>- Blisters percent change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; Blisters percent change from baseline<br/>- Modified ABSIS score percent change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; ABSIS score will be measured according to the pemphigus scoring sheet [Rosenbach, 2009] adjusted to the clinical manifestation in BP patients, as per specifications in protocol.<br/>- Physician Global Assessment (PGA) score measured on a 0-10 scale [Rosenbach, 2009]. Absolute value change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; PGA score will be measured according to the following scale:<br/>0<br/>1 2 3 4 5 6 7 8 9 10 Perfect Worst health skin condition imaginable<br/>The following guidelines will help standardize PGA:<br/>0: no lesions 2: almost cleared, no functional impairment 4: few lesions / low functional impairment 6: moderate 8: severe / extensive 10: life-threatening<br/>- Pruritus measured on a 10 cm visual analogue scale. Percent change from baseline; time frame: day 0/1 (pre-dose), 8 and 15; Pruritus will be measured according to the following scale:<br/>0 10 No pruritus Worst pruritus I can imagine<br/>- Eosinophil blood count. Absolute number change from baseline; time frame: screening and day 15<br/>- Number of patients with treatment failure (drug discontinuation due to disease worsening); time frame: day 8<br/>- Number of patients completely free from blisters; time frame: day 15<br/>- QTcF. Absolute value; time frame: Italy: day 0/1 (pre-dose), day 1, 5, 8 and 15___Ger:day 0/1 (pre-dose), day 1, 3, 5, 8 and 15<br/>";"- Plasma levels of DF2156A and its major metabolites (DF2227 and DF2108) at steady state conditions; time frame: day 5 and 8<br/>";"DE";"Germany";"IT";"Italy";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Department of Dermatology - Universitäts-Hautklinik; Hauptstraße 7";"Freiburg";"[---]*";"Klinik für Dermatologie, Allergologie und Venerologie - Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Ratzeburger Allee 160";"Lübeck";"[---]*";"Klinik für Dermatologie und Allergologie - Philips Universität; Baldingersstraße - 35037";"Marburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/07/31;"[---]*";"[---]*";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Male and female patients aged >50 years.<br/><br/>          -  Patients with newly diagnosed or relapsing bullous pemphigoid based on clinical<br/>             diagnosis to be confirmed by direct immunofluorescence and indirect<br/>             immunofluorescence on salt-spit skin (or BP180 and/or BP230 ELISA). Confirmation by<br/>             laboratory tests will be obtained ideally before or anyway within one week after<br/>             enrolment.<br/><br/>        For the purpose of this study, clinical relapses are defined as re-appearance of clinical<br/>        symptoms after the patient had attained remission lasting for more than 3 months without<br/>        immunosuppressive treatment. In patients with relapsing BP, clinical diagnosis will be<br/>        confirmed by indirect immunofluorescence or BP180 and/or BP230 ELISA only.<br/><br/>          -  Patients with mild to moderate active blistering disease (total number of blisters<br/>             between 1 and 30) whether associated or not with urticarial/eczematous lesions.<br/><br/>          -  Patients with modified ABSIS score ≤50<br/><br/>          -  Patients free from any systemic treatments that may affect the course of the disease<br/>             with the following off-period prior to enrolment:<br/><br/>               1. 3 weeks: steroids, dapsone, tetracyclines, nicotinamide,<br/><br/>               2. 3 months: azathioprine, mycofenolate mofetil, cyclophosphamide, methotrexate,<br/>                  intravenous immunoglobulins, immunoadsorption, TNF antagonists<br/><br/>               3. 12 months: rituximab, leflunomide<br/><br/>          -  Patients free from any topical treatments other than topical antibiotics and<br/>             antiseptics in the 4 days prior to enrolment.<br/><br/>          -  Patients able to comply with the protocol procedures for the duration of the study,<br/>             including scheduled follow-up visits and examinations.<br/><br/>          -  Patients able to provide informed consent.<br/>";"-  Patients with a Karnofsky rating score <40%.<br/><br/>          -  Patients with mucosal involvement.<br/><br/>          -  Patients with moderate to severe renal impairment as per calculated creatinine<br/>             clearance (CLcr) < 50 mL/min according to the Cockcroft-Gault formula<br/>             (Cockcroft-Gault , 1976).<br/><br/>          -  Patients with hepatic dysfunction defined by increased ALT/AST > 3 x upper limit of<br/>             normal (ULN) and increased total bilirubin > 3 mg/dL [>51.3 μmol/L].<br/><br/>          -  Patients with hypoalbuminemia defined as serum albumin < 3 g/dL.<br/><br/>          -  Patients with a baseline (day 0/1, pre-dose) QTcF > 470 msec.<br/><br/>          -  Patients who had a myocardial infarction in the 6 months prior to enrolment.<br/><br/>          -  Patients on treatment with phenytoin, warfarin, sulphonylurea hypoglycemics (e.g.<br/>             tolbutamide, glipizide, glibenclamide/glyburide, glimepiride, nateglinide) and high<br/>             dose of amitriptyline (> 50 mg/day).<br/><br/>          -  Patients with known hypersensitivity to non-steroidal antiinflammatory drugs.<br/><br/>          -  Patients using any investigational agent within 12 months prior to enrolment.<br/><br/>          -  Pregnant or breast feeding women. Unwillingness to use effective contraceptive<br/>             measures up to 2 months after the end of study drug administration (females and<br/>             males).<br/><br/>        Additional Exclusion Criteria for Germany only:<br/><br/>          -  Patients with hypokalemia defined as serum potassium < 3.5 mmol/L.<br/><br/>          -  Patients with clinically relevant bradycardia (heart rate < 50 beats/min)<br/><br/>          -  Patients with a complete left bundle branch block.<br/><br/>          -  Patients with a history of uncontrolled or labile hypertension<br/><br/>          -  Patients with a history of congestive heart failure.<br/><br/>          -  Patients with a history of cardiomyopathy.<br/><br/>          -  Patients with unstable angina pectoris.<br/><br/>          -  Patients with a personal or family history of congenital or documented acquired QT<br/>             interval prolongation.<br/><br/>          -  Patients with a significant atrial or ventricular arrhythmia or symptomatic<br/>             arrhythmia in the past.<br/>";"Primary Sponsor";"Dompé s.p.a.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"I Divisione di Dermatologia, Istituto Dermopatico dell'Immacolata, IRCCS; Via Monti di Creta 104 - 00167 Roma, Italy";"[---]*";"[---]*";"[---]*";"Biagio Didona, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"I Divisione di Dermatologia, Istituto Dermopatico dell'Immacolata, IRCCS; Via Monti di Creta 104 - 00167 Roma, Italy";"[---]*";"[---]*";"[---]*";"Biagio Didona, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.";"[---]*";"[---]*";"The study will be a phase 2, multicentre, single arm, pilot study. It has been designed to<br/>      determine if DF2156A has sufficient activity to warrant its further development.<br/><br/>      A total of twelve (12) BP patients will be involved, who will be administered DF2156A orally<br/>      at the dose of 150 mg twice a day for a maximum of 14 days.<br/><br/>      Recruitment will be competitive among the study sites, until the planned number of patients<br/>      is enrolled. Competitive recruitment has been chosen to increase the speed of recruitment<br/>      and to account for any unexpected occurrence at a site that negatively impact enrolment<br/>      rate.<br/><br/>      The single arm design has been chosen as an appropriate tool for this pilot phase 2 study,<br/>      considering that BP is a rare disease where a placebo control is not acceptable. Moreover,<br/>      as there is no spontaneous acute recovery from the active blistering condition, any<br/>      improvement in patient outcome can be attributed to a positive effect of the Investigational<br/>      Product.<br/><br/>      Each patient will be involved in the study for a screening period, for 14 days of treatment,<br/>      for all required measurements up to hospital discharge (planned on day 8+1 of treatment) and<br/>      for one assessment occasion on day 15+1, either during hospital stay or after hospital<br/>      discharge (out-patient visit). An optional post-treatment visit might be scheduled at day<br/>      30+3.<br/><br/>      The objective of this clinical trial is to evaluate whether DF2156A has a potential in<br/>      improving the clinical outcome in patients with active blistering BP to warrant its further<br/>      development. The safety of DF2156A in the specific clinical setting will be also evaluated.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004194";"2017-03-16T09:17:02.286+01:00";
"DRKS00010314";2016/04/20;2011/12/20;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01497171";"ClinicalTrials.gov";"Sponsor-ID";"11-000247";"Emanuel Trabuco";;;;;;;;;;"Free text";"[---]*";"Pelvic Organ Prolapse";"ICD10";"N81.1";"Cystocele";;;;;;;;;;"Arm 1";"Procedure: Elevate Mesh";"Arm 2";"Procedure: Anterior Colporrhaphy";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"IV";"[---]*";"- Comparison of the Proportion of Subjects in Each Group, Who Achieve Anatomic Success at 12 Month Follow-up.; time frame: 12 months; Anatomical success will be measured using a composite index including: lack of specific prolapse symptoms, no interval treatment and no observed prolapse beyond 1 cm from the hymen.<br/>";"[---]*";"DE";"Germany";"US";"United States";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"St. Hedwig's Krankenhaus";"Berlin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/11/30;"[---]*";"5";2013/05/01;"Multicenter trial";"International";"Female";"21";"Years";"80";"Years";"-  Women with symptomatic pelvic organ prolapse who opt for a vaginal repair<br/><br/>          -  Require both apical and anterior compartment repairs<br/><br/>          -  Willing to return for follow-up visit<br/><br/>          -  Understand and have signed informed consent to undergo randomization<br/><br/>          -  Need both an apical and anterior repair<br/><br/>          -  All trial participants who have a uterus will require a hysterectomy<br/>";"-  Known or suspected vulvodynia<br/><br/>          -  Known or suspected interstitial cystitis<br/><br/>          -  History of chronic pelvic pain<br/><br/>          -  Current pregnancy<br/><br/>          -  Desire to maintain fertility<br/><br/>          -  History of reconstructive pelvic surgery with synthetic mesh<br/><br/>          -  History of radical pelvic surgery<br/><br/>          -  History of pelvic radiation therapy<br/><br/>          -  Currently undergoing treatment for a malignancy<br/><br/>          -  Medically poor candidates for surgery<br/>";"Primary Sponsor";"Emanuel Trabuco";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Mayo Clinic";"[---]*";"[---]*";"[---]*";"Emanuel Trabuco, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Mayo Clinic";"[---]*";"[---]*";"[---]*";"Emanuel Trabuco, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Safety and Efficacy of Transvaginal Mesh Colposuspension for Anterior Vaginal Prolapse: the Elevate vs. Anterior Colporrhaphy Trial";"[---]*";"[---]*";"This study is designed to compare the safety and efficacy of a commercially available mesh<br/>      kit used for surgical repair of anterior vaginal wall prolapse with traditional suture<br/>      repair surgery.<br/>";"This is a multicenter, double blinded, randomized controlled trial, comparing Elevate®<br/>      System with Interpro® Lite™, Anterior and Apical Prolapse Repair System (American Medical<br/>      Systems) and Anterior Colporrhaphy (anterior suture repair) in women with symptomatic pelvic<br/>      organ prolapse, who have opted to have surgical repair.<br/><br/>      The goals of the study are to compare both efficacy and safety of the two procedures and to<br/>      compare the surgical impact of mesh and suture repairs on vaginal function.<br/><br/>      The principal investigator is from Mayo Clinic in Rochester, Minnesota. Mayo Clinic will<br/>      serve as the data gathering and coordination site for this multicenter trial.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010314";"2016-04-20T14:54:43.198+02:00";
"DRKS00011454";2016/12/22;"[---]*";yes;"Approved";"562/16";"Ethikkommission der Christian-Albrechts-Universität zu Kiel";;;;;;;;;;;;;;;;"Free text";"[---]*";"Mukositis/Periimplantitis";;;;;;;;;;;;;"Arm 1";"Testgroup: Scaling and Rootplaning (SRP) with hand instruments and powered dives (scaler) as well as PDT at each visit after reevaluation (each 3 months during the observation time of one year). ";"Arm 2";"Controlgroup: Scaling and Rootplaning (SRP) with hand instruments and powered dives (scaler) at each visit after reevaluation (each 3 months during the observation time of one year). ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"No";"At baseline and after 12months:<br/>MBL: marginal bone loss - clinical record<br/>";"At baseline and each 3months-visit during 12months:<br/>BOP%: percentage of bleeding on probing - clinical record<br/>PPD: pocket probing depth in mm - clinical record<br/>Peri-implant bacteria profile - clincal record";"DE";"Germany";"CN";"China";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Department for Periodontology and Department of Oral Surgery";"Kiel (D)";"University Medical Center";"Department of Oral Surgery";"Shanghai (China), Zhejiang (China)";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2018/09/03;"Actual";"54";2018/12/21;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- ages≥18.<br/>- Subjects with at least one implant with peri-implantitis. The peri-implantitis is defined as: PPD of 4-6mm combined with BOP+, and bone loss of 2-4mm on peri-apical radiographs (taken by paralleling technique with splints for reproducible X-rays) compared to the time point of restoration placement.<br/>- Availability for the 12 month duration of the study<br/>- Signed Informed Consent Form.<br/>";"- Subject with severe systemic diseases. (e.g. uncontrolled hypertension, uncontrolled diabetes, severe coagulation disorder, acute hepatitis, acute nephritis and myocardial infarction history less than 6 months).<br/>- Pregnant or lactating females<br/>- Patients have history of periodontitis<br/>- Patients have history of receiving bisphosphonate therapy<br/>- Peri-implant mucositis defined as the absence of radiographic marginal bone loss between restoration placement and pre-screening review<br/>- Subjects treated for >2 weeks with any medication known to affect soft tissue condition (e.g. phenytoin, calcium antagonists, cyclosporin, Coumadin and non-steroidal anti-inflammatory drugs) within 1 month of the prescreening examination<br/>- Allergy to dye phenothiazine chlorid (“Toloniumchlorid or Toluidinblue“) or mouth rinse with chlorhexidine<br/>- Unwilling to participate in the study.";"Primary Sponsor";"Klinik für Mund-, Kiefer- und Gesichtschirurgie im UKSH, Campus Kiel";"Mr.";"Prof.";"Jörg";"Wiltfang";"Arnold-Heller-Str. 3 (Haus 26)";"24105";"Kiel";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Klinik Zahnerhaltung und Parodontologie im UKSH, Campus Kiel";"Mr.";"PD Dr.";"Christian";"Graetz";"Arnold-Heller-Str. 3 (Haus 26)";"24105";"Kiel";"Germany";"043150026201";"043150026204";"christian.graetz@uksh.de";"http://www.uni-kiel.de/konspar/";"Contact for Public Queries";"Klinik für Zahnerhaltung und Parodontologie im UKSH, Campus Kiel";"Mr.";"PD Dr.";"Christian";"Graetz";"Arnold-Heller-Str. 3 (Haus 26)";"24105";"Kiel";"Germany";"043150026201";"043150026204";"christian.graetz@uksh.de";"http://www.uni-kiel.de/konspar/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Klinik für Mund-, Kiefer- und Gesichtschirurgieim UKSH, Campus Kiel";"[---]*";"[---]*";"[---]*";"[---]*";"Arnold-Heller-Str. 3 (Haus 26)";"24105";"Kiel";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Anti-infective effect of non-surgical treatment with and without photodynamic therapy on peri-implantitis: a pilot multicenter prospective randomized controlled clinical trial";"[---]*";"[---]*";"[---]*";"The aim of the present pilot RCT over twelve months observation time is to investigate the effect of photodynamic thearpy (PDT) on initial peri-implantitis and the optimal frequency of PDT on peri-implant disease. The study will be a multicenter prospective examiner-blinded, randomized, parallel clinical trial with 2 arms (1 test group and control). The examiners will be blinded. 54 subjects with at least one implant with peri-implantitis, ages≥18, will be entered into study. The subjects will be from 3 institutions in Germany (Clinic for Conservative Dentistry and Periodontology & Department of Oral Surgery, UKSH) and two in China (Department of Oral and Maxillo-facial Implant, Shanghai 9th People’s Hospital, Medical School of Shanghai Jiaotong University; Department of Implantology, Stomatology Hospital affiliated to School of Medicine, Zhejiang University) recruited. The peri-implantitis is defined as: PPD of 4-6mm combined with BOP+, and bone loss of 2-4mm on peri-apical radiographs (reproducible). In both groups a conventional treatment of the peri-implantitis will be done with plastic curettes or plastic work tips with ultra-sonic system to perform the mechanical debridement. Then in the test group, the addition PDT will be performed by a designed and in practice well incorporated system (HELBO® Photodynamic Systems, bredent medical GmbH & Co KG, Walldorf, Deutschland) with a wavelength of 660nm and a power density of 100mW. The dye phenothiazine chloride (HELBO® Photodynamic Systems, bredent medical GmbH & Co KG, Walldorf, Deutschland) will be applied sub-mucosally from the bottom to the top of the peri-implant pockets and exposed to the laser light. In both groups the treatment will be repeated at each follow-up visit during 12month observation time after the clinical (each 3month: bleeding on robing, PPD,  peri-implant bacteria profile) and radiographic assessment (baseline and 12month: marginal bone loss). <br/>";"Recruiting stopped after recruiting started ";"Approval of ethics comm. (mandatory for transfer to Studybox)";"ae5fe123-6da3-4807-bca2-a28728ea8884";"Ethikvotum_PDP_Periimpl_526_16.pdf";"positives Votum Kiel";"trial protocol (mandatory for transfer to Studybox)";"de8af44b-dadb-4976-81e3-f18d1e86a577";"PDT_peri-implantitis_Ethik_21_11_16.docx";"Studienprotokoll";;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011454";"2019-01-03T11:16:14.038+01:00";
"DRKS00005002";2013/08/06;2012/09/17;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01688882";"ClinicalTrials.gov";"Sponsor-ID";"CQGE031X2202";"Novartis Pharmaceuticals";;;;;;;;;;"Free text";"[---]*";"Bullous Pemphigoid";"ICD10";"L12.0";"Bullous pemphigoid";;;;;;;;;;"Arm 1";"Drug: QGE031";"Arm 2";"Drug: Placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"II";"[---]*";"- Change in the Clinical Global Assessment of Change from Baseline to Week 12; time frame: 12 weeks<br/>";"- Change in the Clinical Global Assessment of Change from Baseline to Week 6; time frame: 6 weeks<br/>- Change from baseline in the Investigator Global Assessment over 48 weeks; time frame: Baseline, every 2 weeks up to 12 weeks, every 4 weeks up to 24 weeks, every 8 weeks up to 48 weeks<br/>- Safety of QGE031 over 48 weeks; time frame: Baseline, ever 2 weeks up to 12 weeks, every 4 weeks up to 24 weeks, every 8 weeks up to 48 weeks<br/>";"US";"United States";"AT";"Austria";"FR";"France";"DE";"Germany";"JP";"Japan";"TW";"Taiwan, Province of China";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Novartis Investigative Site";"Dresden";"[---]*";"Novartis Investigative Site";"Freiburg";"[---]*";"Novartis Investigative Site";"Marburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/01/31;"[---]*";"42";2015/03/01;"Multicenter trial";"International";"Both, male and female";"20";"Years";"80";"Years";"-  Patients diagnosed with bullous pemphigoid<br/><br/>          -  Stable dose of prednisone at or above 10mg per day but no greater than 1 mg/kg/day<br/><br/>          -  Weigh between 40-120kg<br/><br/>          -  total IgE level up to 5000 IU/mL<br/>";"-  Use of rituximab within 1 year<br/><br/>        Other protocol-defined inclusion/exclusion criteria may apply<br/>";"Primary Sponsor";"Novartis Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Novartis Pharmaceuticals";"[---]*";"[---]*";"[---]*";"Novartis Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Novartis Pharmaceuticals";"[---]*";"[---]*";"[---]*";"Novartis Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment";"[---]*";"[---]*";"To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous<br/>      pemphigoid.  Efficacy will be assessed as a reduction of disease activity.  How QGE031 is<br/>      broken down by the body and the impact it has on different blood and tissue markers will<br/>      also be explored.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005002";"2016-02-26T12:24:11.523+01:00";
"DRKS00003686";2012/05/15;2008/09/26;"[---]*";"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00761280";"ClinicalTrials.gov";"Sponsor-ID";"AP 12009-G005";"Antisense Pharma";;;;;;;;;;"Free text";"[---]*";"Anaplastic Astrocytoma";"Free text";"[---]*";"Glioblastoma";"ICD10";"C71";"Malignant neoplasm of brain";;;;;;;"Arm 1";"Drug: trabedersen";"Arm 2";"Drug: temozolomide";"Arm 3";"Device: Drug delivery system for administration of AP 12009";"Arm 4";"Procedure: Placement of Drug Delivery System";"Arm 5";"Drug: carmustine";"Arm 6";"Drug: lomustine";;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Survival rate; time frame: 24 months<br/>";"- Progression rate; time frame: 10, 12, 14, 16, 18, 21, and 24 months<br/>- Time to death (months)<br/>- Overall response rate<br/>- Tumor control rate<br/>- Duration of response<br/>- Time to progression (months)<br/>- Survival rate; time frame: 12, 18, 21, 27, and 30 months; 3 and 4 years<br/>- Quality of Life (EORTC QLQ-C30, Independent Living Score [ILS])<br/>";"US";"United States";"AR";"Argentina";"AT";"Austria";"BR";"Brazil";"CA";"Canada";"FR";"France";"DE";"Germany";"HU";"Hungary";"IN";"India";"KR";"Korea, Republic of";"MX";"Mexico";"PL";"Poland";"RU";"Russian Federation";"ES";"Spain";"TW";"Taiwan, Province of China";"UK";"United Kingdom";;;;;;;;;"[---]*";"Klinik und Poliklinik für Neurochirurgie";"Frankfurt/M.";"[---]*";"Universitätsklinikum Freiburg";"Freiburg";"[---]*";"Neurochirurgische Klinik an der Universität Ulm am Bezirkskrankenhaus Günzburg";"Günzburg";"[---]*";"Universitätklinikum Hamburg-Eppendorf, Klinik für Neurochirurgie";"Hamburg";"[---]*";"Medizinische Hochschule Hannover Neurochirurgische Klinik";"Hannover";"[---]*";"Universitätsklinik Heidelberg Neurologische Klinik";"Heidelberg";"[---]*";"Universitätsklinikum Leipzig, Neurochirurgische Klinik";"Leipzig";"[---]*";"Otto-von-Guericke-Universität, Klinik für Neurochirurgie";"Magdeburg";"[---]*";"Klinik und Poliklinik für Neurochirurgie";"Münster";"[---]*";"Klinik und Poliklinik für Neurologie";"Regensburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/12/31;"[---]*";"180";2012/06/01;"Multicenter trial";"International";"Both, male and female";"18";"Years";"70";"Years";"-  The patient has provided written informed consent prior to any study-related<br/>             procedure.<br/><br/>          -  The patient is at least 18 years of age and equal to or below 70 years.<br/><br/>          -  The patient has a present diagnosis of AA or secondary GBM.<br/><br/>          -  The patient has a measurable lesion (> 1 ccm in volume, central MRI review).<br/><br/>          -  The lesion (or sum of lesions) does not exceed 50 ccm in volume (central MRI review).<br/><br/>          -  The tumor is localized supratentorially (central MRI review).<br/><br/>          -  All patients have recurrent or refractory disease, i.e. disease has progressed after<br/>             prior surgery and radiotherapy at any time of the disease course or stage. Secondary<br/>             GBM patients have progressed after a previous diagnosis of A and/or AA.<br/><br/>          -  The patient has not received more than one chemotherapy regimen. Radiation with<br/>             concomitant chemotherapy, followed by adjuvant chemotherapy, is considered as one<br/>             chemotherapy regimen.<br/><br/>          -  The patient is eligible for chemotherapy.<br/><br/>          -  The patient is on a maximum dose of 4 mg/day dexamethasone or equivalent doses for<br/>             other corticosteroids, which has been stable or decreasing for at least 3 weeks prior<br/>             to Screening.<br/><br/>          -  The patient is male or a non-pregnant, non-lactating female.<br/><br/>          -  Females of childbearing potential must have a negative beta-HCG pregnancy test at<br/>             Screening.<br/><br/>          -  Females of childbearing potential and males must practice strict birth control.<br/><br/>          -  The patient must have recovered from acute toxicity caused by any previous therapy.<br/><br/>          -  The patient has a life expectancy of at least 3 months.<br/><br/>          -  The patient has a Karnofsky Performance Status of at least 70%.<br/><br/>          -  The patient shows adequate organ functions as assessed by the following screening<br/>             laboratory values:<br/><br/>               1. Adequate renal function determined by serum creatinine and urea < 2 times the<br/>                  upper limit of        normal<br/><br/>               2. Adequate liver function with ALT, AST and AP < 3 times the upper limit of<br/>                  normal, and bilirubin       < 2.5 mg/dL<br/><br/>               3. INR < 1.5 and aPTT < 1.5 x ULN<br/><br/>               4. Hemoglobin > 9 g/dL<br/><br/>               5. Platelet count > 100 x 10E9/L<br/><br/>               6. WBC > 3 x 10E9/L<br/><br/>               7. ANC > 1.5 x 10E9/L (or WBC > 3.0 x 10E9/L)<br/>";"-  Patient unable or not willing to comply with the protocol regulations.<br/><br/>          -  The investigator deems it necessary to surgically (re-)resect the present tumor<br/>             (NOTE: the patient might still be eligible for randomization at a later timepoint).<br/><br/>          -  Tumor surgery, tumor debulking, or other neurosurgery within 3 months prior to<br/>             randomization. If a ≤48-hour routine post-surgery MRI (in accordance with study<br/>             specifications) qualifies the patient for study participation, the patient can be<br/>             randomized 30 ± 7 days post-surgery.<br/><br/>          -  Radiotherapy or stereotactic (gamma knife) radiosurgery within 3 months prior to<br/>             randomization.<br/><br/>          -  Prior interstitial brachytherapy of the brain with permanent implants. Prior<br/>             interstitial brachytherapy of the brain with removable implants within 3 months prior<br/>             to randomization.<br/><br/>          -  Chemotherapy, hormone therapy, or any other therapy with established or suggested<br/>             anti-tumor effects within 4 weeks (nitrosoureas: 6 weeks) prior to randomization.<br/><br/>          -  Prior anti-TGF-beta 2 targeted therapy.<br/><br/>          -  Screening MRI shows a mass effect caused by the tumor defined as significant<br/>             compression of the ventricular system and/or a midline shift (≥ 3 mm, central MRI<br/>             review). Compression of the ventricular system and/or a midline shift ≥ 3 mm only due<br/>             to the presence of (a) cyst(s) or scarring processes does not exclude an individual<br/>             from the study.<br/><br/>          -  Participation in another clinical study with another investigational medicinal<br/>             product within 30 days prior to randomization.<br/><br/>          -  History of a second independent malignant disorder within 5 years, except for<br/>             carcinoma in situ of the cervix and basal cell carcinoma.<br/><br/>          -  Presence of poorly controlled seizures.<br/><br/>          -  Clinically relevant cardiovascular abnormalities such as uncontrolled hypertension,<br/>             congestive heart failure, unstable angina, or poorly controlled arrhythmia.<br/>             Myocardial infarction within 6 months prior to randomization.<br/><br/>          -  Known HIV, HBV or HCV infection.<br/><br/>          -  Acute viral, bacterial, or fungal infection.<br/><br/>          -  Acute medical problems that may be considered to become an unacceptable risk, or any<br/>             conditions, which might be contraindications for starting study treatment.<br/><br/>          -  Presence of high risk for pulmonary toxicities, defined as:<br/><br/>               1. Lung function: vital capacity ≤ 70%<br/><br/>               2. Status following sequential or concomitant thoracic irradiation<br/><br/>               3. Increased risk for a pulmonary toxicity induced by BCNU (Carmustine) or CCNU<br/>                  (Lomustine). Risk factors include smoking, presence of a respiratory condition,<br/>                  pre-existing radiographic pulmonary abnormalities, exposure to agents that cause<br/>                  lung damage.<br/><br/>          -  History of allergies to reagents used in this study, history of celiac disease.<br/><br/>          -  Drug abuse or extensive use of alcohol.<br/><br/>          -  Clinically relevant psychiatric disorders / legal incapacity or a limited legal<br/>             capacity.<br/><br/>          -  Concomitant treatment with yellow fever vaccine.<br/>";"Primary Sponsor";"Isarna Therapeutics GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Montreal Neurological Institute and Hospital";"[---]*";"[---]*";"[---]*";"Rolando Del Maestro, MD, PhD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Montreal Neurological Institute and Hospital";"[---]*";"[---]*";"[---]*";"Rolando Del Maestro, MD, PhD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.";"SAPPHIRE";"[---]*";"In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared<br/>      to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed<br/>      recurrent or refractory anaplastic astrocytoma (WHO grade III) or secondary glioblastoma<br/>      (WHO grade IV).<br/>";"The purpose of this study is to compare the safety and efficacy of the 10 µM concentration<br/>      of AP 12009 and standard chemotherapy (temozolomide, BCNU, CCNU) in adult patients with<br/>      recurrent or refractory anaplastic astrocytoma (AA, WHO grade III) or secondary glioblastoma<br/>      (GBM, WHO grade IV). AP 12009 (trabedersen) is a phosphorothioate antisense<br/>      oligodeoxynucleotide specific for the mRNA of human Transforming Growth Factor beta 2<br/>      (TGF-beta-2), which is applied intratumorally. The growth factor TGF-beta plays a key role<br/>      in malignant progression of various tumors by inducing proliferation, invasion, metastasis,<br/>      angiogenesis, and escape from immunosurveillance. In patients with high-grade glioma, the<br/>      TGF-beta-2 overexpression is associated with disease stage, clinical prognosis, and the<br/>      immunodeficient state of the patients. Main objective of the study is to determine survival<br/>      (rate) and tumor response.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003686";"2017-12-06T10:43:37.409+01:00";
"DRKS00005165";2013/08/06;2012/07/18;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01650805";"ClinicalTrials.gov";"Sponsor-ID";"AP24534-12-301";"Ariad Pharmaceuticals";;;;;;;;;;"Free text";"[---]*";"Chronic Myeloid Leukemia";"ICD10";"C92.1";"Chronic myeloid leukaemia";;;;;;;;;;"Arm 1";"Drug: ponatinib";"Arm 2";"Drug: imatinib (Gleevec/ Glivec)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Treatment";"Parallel";"III";"[---]*";"- Major Molecular response (MMR) rate; time frame: 12 months after first dose; To compare the efficacy of ponatinib with imatinib as measured by major molecular response (MMR) rate at 12 months (1 month or cycle = 28 days)<br/>";"- MMR rate; time frame: 5 years after first dose; To compare the efficacy of ponatinib with imatinib, as measured by MMR rate, at 5 years<br/>- <10% BCR-ABL^IS rate; time frame: 3 months after first dose; To compare the proportion of patients achieving a ratio of <10% BCR-ABL to ABL transcript levels at 3 months, as measured by the international scale (<10% BCR-ABL^IS), in patients administered ponatinib versus those administered imatinib<br/>- Complete cytogenetic response (CCyR) rate; time frame: 12 months after first dose; To compare, according to treatment with ponatinib versus imatinib, the CCyR rate at 12 months<br/>- Progression-free survival; time frame: Up to 8 years after the last patient's first dose; To compare, according to treatment with ponatinib versus imatinib, progression-free survival<br/>- Overall survival; time frame: Up to 8 years after the last patient's first dose; To compare, according to treatment with ponatinib versus imatinib, overall survival<br/>";"US";"United States";"AU";"Australia";"AT";"Austria";"BE";"Belgium";"CA";"Canada";"CZ";"Czech Republic";"FI";"Finland";"FR";"France";"DE";"Germany";"HK";"Hong Kong";"IT";"Italy";"KR";"Korea, Republic of";"NL";"Netherlands";"NZ";"New Zealand";"PL";"Poland";"PT";"Portugal";"PR";"Puerto Rico";"SG";"Singapore";"SK";"Slovakia";"ES";"Spain";"[---]*";"Universitätsklinikum Aachen, AÖR, Site #513";"Aachen";"[---]*";"Charite - Universitatsmedizin Berlin, Site #701";"Berlin";"[---]*";"Universitatsklinikum Carl Gustav Carus an der TU Dresden, Site #526";"Dresden";"[---]*";"Universitatsklinikum Freiburg, Site #527";"Freiburg";"[---]*";"Universitatsklinikum Hamburg-Eppendorf, Site #524";"Hamburg";"[---]*";"Universitatsklinikum Jena, Site #946";"Jena";"[---]*";"Universitatsklinikum Koln-AOR, Site #525";"Koln";"[---]*";"Universitat Heidelberg, CML - Studienzentrale III. Medizinische Klinik, Site #947";"Mannheim";"[---]*";"Klinikum rechts der Isar, Site #949";"Munchen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/06/30;"[---]*";"528";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. CP CML within 6 months of diagnosis<br/><br/>               -  CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus<br/>                  promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv)<br/>                  ≥100 × 10^9/L platelets (≥100,000/mm^3); (v) No evidence of extramedullary<br/>                  disease except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or<br/>                  BP-CML<br/><br/>          2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22)<br/>             Philadelphia chromosome<br/><br/>               -  (a)Variant translocations are only allowed provided they are assessable for<br/>                  cytogenetic response utilizing conventional cytogenetic techniques; (b)<br/>                  Conventional chromosome banding must be performed; AND (c) A minimum of 20<br/>                  metaphases must be assessable at entry<br/><br/>          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2<br/><br/>          4. Adequate hepatic function as defined by the following criteria:<br/><br/>             (a) Total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's<br/>             syndrome; (b) Alanine aminotransferase (ALT) ≤2.5 × ULN; AND (c) Aspartate<br/>             aminotransferase (AST) ≤2.5 × ULN<br/><br/>          5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN<br/><br/>          6. Adequate pancreatic function as defined by serum lipase and amylase ≤1.5 × ULN<br/>";"1. Received prior imatinib therapy<br/><br/>          2. Received prior dasatinib therapy<br/><br/>          3. Received prior nilotinib therapy<br/><br/>          4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or<br/>             radiation therapy with the exception of anagrelide or hydroxyurea<br/><br/>          5. Major surgery within 28 days prior to initiating therapy<br/><br/>          6. History of bleeding disorder unrelated to CML<br/><br/>          7. History of acute pancreatitis within 1 year of study or history of chronic<br/>             pancreatitis<br/><br/>          8. History of alcohol abuse<br/><br/>          9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)<br/><br/>         10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically<br/>             including, but not restricted to:<br/><br/>               1. Myocardial infarction, within 6 months prior to randomization<br/><br/>               2. Unstable angina within 6 months prior to randomization<br/><br/>               3. Congestive heart failure within 6 months prior to randomization<br/><br/>               4. History of clinically significant (as determined by the treating physician)<br/>                  atrial arrhythmia or any ventricular arrhythmia<br/><br/>               5. Any history of ventricular arrhythmia<br/><br/>               6. Cerebrovascular accident or transient ischemic attack within 6 months prior to<br/>                  randomization<br/><br/>               7. Any history of peripheral arterial occlusive disease requiring revascularization<br/><br/>               8. Any  history of venous thromboembolism including deep venous thrombosis or<br/>                  pulmonary embolism<br/><br/>         11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).<br/>             Patients with hypertension should be under treatment on study entry to effect blood<br/>             pressure control<br/><br/>         12. Taking medications that are known to be associated with Torsades de Pointes<br/><br/>         13. Ongoing or active infection.  The requirement for intravenous (IV) antibiotics is<br/>             considered active infection<br/><br/>         14. Known history of human immunodeficiency virus (HIV).  Testing is not required in the<br/>             absence of history<br/><br/>         15. Pregnant or breastfeeding<br/><br/>         16. Malabsorption syndrome or other gastrointestinal illness that could affect oral<br/>             absorption of study drugs<br/><br/>         17. Diagnosed with or received anticancer therapy for another primary malignancy within 3<br/>             years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)<br/><br/>         18. Any condition or illness that, in the opinion of the Investigator, would compromise<br/>             patient safety or interfere with the evaluation of the drug<br/>";"Primary Sponsor";"Ariad Pharmaceuticals";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase";"[---]*";"[---]*";"The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients<br/>      with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.<br/>";"This multicenter, international, phase 3 trial will test the hypothesis that ponatinib is an<br/>      effective treatment for newly diagnosed CP-CML patients when compared with standard<br/>      imatinib.<br/><br/>      Patients will be randomized in a 1:1 fashion, stratified by Sokal risk score at diagnosis<br/>      (low, intermediate, high), to receive once daily oral administration of either ponatinib or<br/>      imatinib. Efficacy measures include molecular, cytogenetic, and hematologic response rates<br/>      at various timepoints; time to, duration of, and durability of responses; and survival<br/>      follow-up. Safety measures include clinical laboratory testing, adverse event monitoring,<br/>      vital signs, physical exams, ECGs, and ECHOs. Other measures include two patient-reported<br/>      health outcomes questionnaires (FACT-Leu and EQ-5D-5L), determination of mutation status,<br/>      and, for ponatinib only, measurement of steady-state plasma concentration. Accrual is<br/>      expected to take approximately 2 years, and patients will be followed for survival for up to<br/>      8 years after the last patient's first dose; therefore, patient participation may last up to<br/>      10 years.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005165";"2014-08-22T10:10:24.957+02:00";
"DRKS00005146";2013/09/03;"[---]*";yes;"Approved";"EA01/026/13";"Ethik-Kommission der Charité -Universitätsmedizin Berlin-";;;;;;;;;;;;;;;;"ICD10";"G80.0";"Spastic quadriplegic cerebral palsy";"ICD10";"J18.0";"Bronchopneumonia, unspecified";;;;;;;;;;"Arm 1";"The patients received standard respiratory therapy with physiotherapy, inhalation and suction. In addition, a stimulation of the abdominal muscles twice a day depending on exhalation breath. The stimulation must be done at least 7 times per week interruptions in the study by surgery or holiday may not exceed 7 days of the week. The patient is placed 30 ° upright during stimulation . It will be placed 8 electrodes (4x9cm) on the abdomen for each stimulation.<br/> The intensity of the stimulation is checked at the beginning of each week and determined by the patient indicating the intensity that they can endure. The stimulation is carried out according to the protocol: 10 minutes of exercise (60% stimulation intensity) - 4 breaths with cough intensity (100% Stimulationsin intensity) - 3 minutes rest (0%, no stimulation) - 10 minutes of exercise (60% stimulation intensity) - 4 breaths with cough intensity (100% Stimulationsin intensity).";"Arm 2";"The patients received a standard therapy with respiratory physiotherapy, inhalation and suction.<br/>The placebo group receives a sham stimulation The patient can be connected to the stimulation device and also asked verbally, depending on their breathing to a deeper breathing or coughing.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Placebo";"Prevention";"Parallel";"N/A";"N/A";"Number of acute pneumonia by CDC definition during the treatment period.<br/>There is a daily clinical examination of the patient by the study doctor to signs of infection and signs of pulmonary complication. If it is suspected further investigations (X-ray, sputum, antibiogram according to CDC criteria) are introduced<br/>Pneumonia must be confirmed by the clinical investigator who is not informed about the therapy process (blinding) (four-eyes principle).";"To check the influence of stimulation of the abdominal muscles on the circulatory regulation, a modified Schellong test is performed. The investigation is carried out every second day in the morning before the start of therapy. At the beginning the blood pressure is measured every minute over a period of 5 minutes. Following the rearrangement takes place in the highest possible upright seating position and re-measuring the blood pressure every minute for five minutes. This is followed by the abdominal stimulation.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"BG-Klinik";"Hamburg";"Medical Center";"BG-Klinik";"Berlin";"Medical Center";"BG-Klinik";"Murnau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/07/01;"Actual";"228";2014/09/30;"Multicenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"Men and women;<br/>neurological level  C4-C8;<br/>ASIA (Amercian Spinal Injury Assication) Typ A, B;<br/>Paralysis not older than 6 weeks;<br/>Body Mass Index <35;<br/>Age 18-80 years;<br/>Consent by the patient";"Lack of consent;<br/>Acute pneumonia (CDC definition);<br/>Known pulmonary disease (COPD> VI °);<br/>Heart failure class III;<br/>Progressive disease, tumor;<br/>Lack of opportunity to place abdominal electrodes;<br/>pregnancy;<br/>Pacemaker or similar implants which interfere with electrical stimulation";"Primary Sponsor";"Zentrum für Klinische Forschung, Unfallkrankenhaus Berlin";"[---]*";"[---]*";"[---]*";"[---]*";"Warenerstrasse 7";"12683";"Berlin";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Unfallkrankenhaus Berlin";"Mr.";"PD Dr. med.";"Rainer";"Seidl";"Warenerstrasse 7";"12683";"Berlin";"Germany";"030 5681 4301";"030 5681 4303";"ROSeidl@ukb.de";"www.ukb.de";"Contact for Public Queries";"Unfallkrankenhaus Berlin";"Mr.";"Dr. med.";"Andreas";"Niedeggen";"Warnerstrasse 7";"12683";"Berlin";"Germany";"030 5681 3401";"030 5681 3403";"Andreas.Niedeggen@ukb.de";"www.ukb.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"DGUV – Forschungsförderung";"[---]*";"[---]*";"[---]*";"[---]*";"Alte Heerstasse 111";"53757";"St. Augustin";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Open-label, multicenter, prospective, randomized trial of breath-synchronized electrical abdominal stimulation in patients with acute tetraplegia";"Multi AbdomenStim<br/><br/>";"www.abdomenstim.de";"Central problem in the care of patients with paralysis of the cervical and upper thoracic cord is the long-term prevention of pulmonary complications. In a preliminary study a stimulator concept could be developed and evaluated in a pilot study that seems to be able to reduce the number of pulmonary complications, improve rehabilitation to accelerate and the quality of life of patients immediately after an injury and long term.<br/>In a prospective study, the efficiency of the new method should be tested in a comparative study of three German centers. This should be divided into two groups for a period of three years and a total of 228 patients treated either by today's conventional therapy or in addition to a breath-dependent abdominal muscle stimulation. This is the currently developed in the preliminary study and evaluated system are used.<br/>If t is possible to reach a reduction of complications in the planned abdominal stimulation this means an acceleration of the treatment in addition to a significant cost reduction of the relief for the patient.";"Central problem in the care of patients with quadriplegia is the long-term prevention of pulmonary complications. In a preliminary study, a respiratory-related abdominal stimulation was developed and pilot study be evaluated.<br/>In an open, prospective, randomized study, the new method should be tested in a comparative study of three German centers. This should be randomized with acute Teraplegie into two groups over a period of three years and a total of 228 patients treated with either conventional respiratory therapy, or in addition to a breath-dependent abdominal muscle stimulation. Patients will receive either a functional electrical stimulation or sham stimulation.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005146";"2018-02-13T09:15:03.440+01:00";
"DRKS00009758";2016/06/16;"[---]*";yes;"Approved";"15-6363-BO";"Ethik-Kommission der Medizinischen Fakultät der Universität Duisburg-Essen";;;;;;;;;;;;;;;;"Free text";"[---]*";"We do not include any specific psychiatric diagnosis. We include all inpatients or day patients at admission in the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Duisburg-Essen (see inclusion criteria).<br/>";"ICD10";"E55";"Vitamin D deficiency";;;;;;;;;;"Arm 1";"Vitamin D supplementation, 2640 IE Vitamin D q.d. ( = 3 tablets Vitamin D à 880 IE in the morning/ day) based on the current practice of the pediatric endocrinologists in chronically ill children and adolescents for 28 days plus treatment as usual with regard to the respective psychiatric disease.";"Arm 2";"No vitamin D supplementation, corresponding to the vitamin D supplementation 3 placebo tablets q.d. in the morning, for 28 days plus treatment as usual with regard to the respective psychiatric disease.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Other";"Parallel";"N/A";"N/A";"Depression score measured via BDI-II after 28 days";"25(OH)-Vitamin D serum level after 28 days;<br/>impulsiveness measured via Barratt Impulsiveness Scale (BIS-11) after 28 days, depression score measured via DISYPS-II depression questionnaire (for parents and children) after 28 days";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, LVR-Klinikum Essen, Kliniken und Institut der Universität-Duisburg-Essen";"Essen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/06/15;"Actual";"200";2018/05/16;"Monocenter trial";"National";"Both, male and female";"11";"Years";"18";"Years";"In- or day patient child- and adolescent psychiatric admission, age: 11-18.9 years, BDI-II score > 13, 25(OH)-vitami D level < 30nmol/L (12 ng/ml), written informed consent of children/adolescents and their parents.";"Current severe somatic disease, hypocalcemia, parathormon (Plasma) > 130ng/ml,  IQ < 70, contraindication or refusal of a vitamin D supplementation.";"Primary Sponsor";"Universitätsklinikum Essen AöR; Universität Duisburg-Essen, Campus Essen – Med. Fakultät –";"Mr.";"[---]*";"Thorsten";"Kaatze";"Hufelandstr. 55";"45147";"Essen";"Germany";"0201 / 7 23 - 2601";"0201 7 23 - 5913";"Thorsten.Kaatze@uk-essen.de";"www.uk-essen.de";"Contact for Scientific Queries";"Klinik für Kinder- und Jugendpsychiatrie, -psychosomatik und -psychotherapie, Universitätsklinikum (UKM) Münster";"Mr.";"PD Dr.";"Manuel";"Föcker";"Schmeddingstraße 50";"48149";"Münster";"Germany";"0251 83 53544";"0251 83 52275";"manuel.foecker@ukmuenster.de";"https://www.ukm.de/index.php?id=kjp_uebersicht";"Contact for Public Queries";"Klinik für Kinder- und Jugendpsychiatrie,-psychosomatik und -psychotherapie, Universitätsklinikum (UKM) Münster";"Mr.";"PD.Dr.";"Manuel";"Föcker";"Schmeddingstraße 50";"48149 ";"Münster";"Germany";"0251 83 53544";"0251 83 52275";"manuel.foecker@ukmuenster.de";"https://www.ukm.de/index.php?id=kjp_uebersicht";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters,LVR-Klinikum Essen, Kliniken der Universität Duisburg-Essen";"Mr.";"Prof. Dr.";"Johannes";"Hebebrand";"Wickenburgstr. 21";"45147";"Essen";"Germany";"0201 8707 466";"0201 8707 302";"johannes.hebebrand@uni-due.de";"www.rk-essen.lvr.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effect of an untreated vitamin D deficiency on depressive symptoms in child and adolescent psychiatric patients  – a randomized controlled trial.";"[---]*";"[---]*";"Vitamin D is important for bone formation and bone health in general. Only a minor portion of the required vitamin D is ingested with food, the major part is synthesized by means of sunlight in the human skin. Many people in Central and Northern Europe show up with vitamin D deficiency, based on relative low sun light intensity and insufficient sunlight exposure. Vitamin D insufficiency can be detected by analyzing vitamin D levels in blood serum. A low vitamin D status will have a negative impact on bone health, causing increased frequencies of fractures and bone deformations. Thus a supplementation e.g. via Vitamin D tablets is indicated. Epidemiological studies revealed also an association with cardiovascular health. It is also known that many patients with depressive symptomatology show up with a too low Vitamin D status.<br/>This clinical study should evaluate, whether a non-supplementation with vitamin D3 in case of vitamin D deficiency < 30nmol/l (=12.5 ng/ml) compared to a supplementation will show inferiority for the non-supplementation group versus the supplementation group with regard to the depressive symptomatology (measured with Beck Depression Inventory [BDI-II]) in children and adolescents in a 28 day lasting placebo controlled study.";"Vitamin D is a hormon with a potential impact on mental health. Vitamin D deficiency seems to be associated with major depression. Cross-sectional as well as prospective cohort studies revealed an association between a low vitamin D status and an increased risk to suffer from depressive symptomatology. Some – not all – randomized controlled trials showed an antidepressant effect of a vitamin D supplementation in adult patients with depressive symptoms. Assessment of vitamin D status of depressed patients is not part of current routine diagnostic. <br/>We hypothesize that the placebo group of vitamin D deficient and depressed children and adolescents is inferior with regard to depressive symptomatology compared to the supplementation group (vitamin D3 for 28 days).<br/>This double blind, randomized controlled trial will enroll 200 in- and day-patients in a child and adolescent psychiatric department with a 25(OH) vitamin D level < 30nmol/l (12 ng/ml) and a Beck Depressions Inventory (BDI-II) score > 13. The patients will be randomized into a supplementation and a non-supplementation group. Both study-arms will receive treatment-as-usual with regard to the respective psychiatric disease. The participants of the supplementation group will additionally receive 2640 I.E. Vitamin D q.d. for 28 days, the participants of the non-supplementation group the respective placebos.";"Recruiting stopped after recruiting started ";"trial protocol (mandatory for transfer to Studybox)";"[---]*";"[---]*";"Föcker M, Antel J, Grasemann C, Führer D, Timmesfeld N, Öztürk D, Peters T, Hinney A, Hebebrand J, Libuda L. Effect of an vitamin D deficiency on depressive symptoms in child and adolescent psychiatric patients - a randomized controlled trial: study protocol. BMC Psychiatry. 2018 Mar 1;18(1):57. doi: 10.1186/s12888-018-1637-7";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009758";"2019-06-19T13:18:48.557+02:00";
"DRKS00009874";2016/01/29;"[---]*";yes;"Approved";"232/15";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";;;;;;;;;;;;;;;;"Free text";"[---]*";"major chronic depression";"ICD10";"F33";"Recurrent depressive disorder";;;;;;;;;;"Arm 1";"<br/>Intervetniongroup: 3 weeks inpatient CBASP treatment (2 single therapy sessions of 50 min per week) with following videoconference based outpatient CBASP treatment for 9 weeks  (2 single therapy sessions of 50 min per week).<br/>";"Arm 2";"Historical comparison group from existing data of patients who participated in a classical 12 weeks inpatient CBASP treatment  (2 single therapy sessions of 50 min per week plus 2 h of CBASP-group therapy per week) .<br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Historical";"Health economics";"Other";"N/A";"N/A";"- Questionnaire on feasibility and acceptance. Completed by patients and therapists<br/>- Hamilton Rating Scale for Depression (HAMD-24; Hamilton, 1960) T0, T1, T2, T3 (T0 : at admission to station , T1 : at discharge from station , T2 : at end of outpatient therapy , follow-up ( T3 ) : 3 months after completion of outpatient therapy (end of study)";"- Structured Clinical Interview for DSM-IV Disorders (T0).<br/>- Childhood Trauma Questionnaire (T0).<br/>- Beck Depression Inventory (T0-T3).<br/>- Clinical Global Impression Scale (T1-T2).<br/>- Global Assessment of Functioning Scale (T1-T2).<br/>- World Health Organization Quality of Life Instrument (T0-T3).<br/>- Impact Message Inventory-R (therapist-patient-relationship) (T1-T2).<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Psychiatrie und Psychotherapie";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/10/06;"Actual";"30";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"70";"Years";"- diagnosis of Chronic Depression <br/>- Hamilton Rating Scale of Depression (HRSD-24) score>20 <br/>- in ongoing medical/psychiatric care <br/>- age 18-70 years <br/>- fluent in German language<br/>- technical requirements (Internet access)<br/>- informed consent<br/>- treatment resistance (no response to two or more adequate trials of antidepressants and/or no response to at least two health-insurance-reimbursed psychotherapies with at least 22 sessions each).<br/>";"- history of bipolar disorder<br/>- substance addiction (less than 3 months clean)<br/>-  antisocial or borderline personality disorder<br/>- severe autism<br/>- organic brain disorders<br/>- severe physical illness<br/>- acute risk of suicide or suicide attempt within the last 12 months";"Primary Sponsor";"Klinik für Psychiatrie und Psychotherapie. Uniklinik Freiburg";"Mr.";"Dr.";"Lars";"Hölzel";"[---]*";"79104";"Freiburg";"Germany";"0761-270-69840";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum FreiburgKlinik für Psychiatrie und Psychotherapie";"Ms.";"Dr.";"Nicole";"Ower";"Hauptstr. 5";"79104";"Freiburg";"Germany";"0761-27069841";"0761-27069890";"Nicole.ower@uniklinik-freiburg.de";"https://www.uniklinik-freiburg.de/psych.html";"Contact for Public Queries";"Universitätsklinikum FreiburgKlinik für Psychiatrie und Psychotherapie";"Ms.";"Dr.";"Nicole";"Ower";"Hauptstr. 5";"79104";"Freiburg";"Germany";"0761-27069841";"0761-27069890";"Nicole.ower@uniklinik-freiburg.de";"https://www.uniklinik-freiburg.de/psych.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Ministerium für Wissenschaft, Fortschung und Kunst Baden-Württemberg";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"70029";"Stuttgart";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum FreiburgKlinik für Psychiatrie und Psychotherapie";"Mr.";"Dr.";"Lars";"Hölzel";"[---]*";"79104";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"Brief inpatient treatment continued by videoconference based psychotherapy for patients with chronic major depression";"CBASP-VCP";"[---]*";"Aim of the project is to test the feasibility and acceptability of a combined treatment consisting of 3 week inpatient CBASP (Cognitive Behavioral Analysis System of Psychotherapy) -treatment and a 9 week outpatient CBASP-treatment using videoconference technology. During inpatient treatment patients undergo a medical and psychiatric examination and if necessary, medication is optimized according to the actual guide lines. Psychotherapeutic treatment starts and patients are introduced to the videoconference technique. After discharge the same therapist continues treatment via videoconference. A local ambulant psychiatrist will be involved in the treatment of the patient. Data collection will take place at four study centers at the same time. <br/>The pilot data sould provide the necessary data-base for the application of a larger randomized-controlled trial to conduct a cost-benefit-analysis in comparison to clinical routine treatment.";"Aim of the project is to test the feasibility and acceptability of a combined treatment consisting of 3 week inpatient CBASP (Cognitive Behavioral Analysis System of Psychotherapy) -treatment and a 9 week outpatient CBASP-treatment using videoconference technology. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009874";"2017-07-31T14:07:55.678+02:00";
"DRKS00010791";2016/07/04;"[---]*";yes;"Approved";"62/2016";"Ethik-Kommission der Universität Witten/Herdecke";;;;;;;;;;;;;;;;"ICD10";"K62.1";"Rectal polyp";;;;;;;;;;;;;"Arm 1";"Altemeier's procedure (perineal rectosigmoidectomy)";"Arm 2";"Transtar procedure (perineal stapled prolapse resection (PSP))";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"The primary endoint is quality of life as measured with the PAC-QoL questionnaire (Patient Assessment of Constipation-Quality of Life). Using analysis of variance (ANOVA) for repeated measures, the primary hypothesis compares pre- and postoperative PAC-QoL summary scores after 0, 1, 6 and 12 months.";"Length of resected specimen; duration of surgery; complications; length of hospital stay; reoperation rate; time until return to normal activity; pain (in rest and during defecation)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Helios St.Elisabeth Klinik Oberhausen";"Oberhausen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2016/08/01;"Actual";"30";2016/08/30;"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Indication for elective surgery due to second- or third-degree rectal prolapse; <br/>age ≥18 Jahre ";"Pregnancy;<br/>planned simulatenous surgery;<br/>non-elective surgery;<br/>severe comorbidity with one-year life expectancy <75%;<br/>missing written informed consent";"Primary Sponsor";"Helios St.Elisabeth Klinik Oberhausen";"Mr.";"Prof. Dr.";"Mike Ralf";"Langenbach";"Josefstr. 3";"46045";"Oberhausen";"Germany";"0208-85064001";"[---]*";"ob-allgemeinchirurgie@helios-kliniken.de";"[---]*";"Contact for Scientific Queries";"Helios St.Elisabeth Klinik Oberhausen";"Mr.";"Prof. Dr.";"Mike Ralf";"Langenbach";"Josefstr. 3";"46045";"Oberhausen";"Germany";"0208-85064001";"[---]*";"ob-allgemeinchirurgie@helios-kliniken.de";"[---]*";"Contact for Public Queries";"Helios St.Elisabeth Klinik Oberhausen";"Mr.";"Prof. Dr.";"Mike Ralf";"Langenbach";"Josefstr. 3";"46045";"Oberhausen";"Germany";"0208-85064001";"[---]*";"ob-allgemeinchirurgie@helios-kliniken.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Helios St.Elisabeth Klinik Oberhausen";"Mr.";"PD Dr.";"Mike Ralf";"Langenbach";"Josefstr. 3";"46045";"Oberhausen";"Germany";"0208-85064001";"[---]*";"ob-allgemeinchirurgie@helios-kliniken.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Surgical therapy of second- or third-degree rectal prolapse using either the Altemeier or the Transtar technique: a randomised trial";"[---]*";"[---]*";"Rectal prolapse is defined as a protrusion of the large intestine through the anus, which can cause obstipation, bleeding, pain and incontinence. In patients with advanced disease (stage II or III), surgical therapy is indicated, often including a removal of parts of the large intestine. In the present study, patients with rectal prolapse undergo one of two different types of surgical resection, with the decision being left to random assignment. The aim of the study is to find out whether one of the surgical techniques is better than the other.";"Surgical therapy for second- or third-degree rectal prolapse often includes transanal rectal resection. As described by Altemeier already in 1952, the classical surgical procedure is to resect the protruded part of the rectosigmoid and to anastomize the remainder with the anus. Alternatively, transanal rectosigmoidal resection can be performed with a stapler. This technique is called transtar technique, as it requires the use of a specific stapler (Contour® Transtar™; Ethicon Endo-Surgery, Cincinnati, OH). The study aims at comparing the two procedures.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010791";"2019-03-04T08:31:03.872+01:00";
"DRKS00009822";2016/01/13;"[---]*";yes;"Approved";"473-15 fed";"Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2014-000861-32";"[---]*";;;;;;;;;;;;;"ICD10";"J84.1";"Other interstitial pulmonary diseases with fibrosis";"ICD10";"J68.4";"Chronic respiratory conditions due to chemicals, gases, fumes and vapours";;;;;;;;;;"Arm 1";"Pirfenidone Esbriet (2403 mg/d) = 9 capsules daily for 48 weeks";"Arm 2";"Treatment with placebo ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"II";"No";"Absolute change in percent predicted FVC from baseline to week 48";"Key secondary endpoints: Time to disease worsening, progression-free survival as well as selected measures of pulmonary function, quality of life questionnaires and safety parameters.";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen Medizinische Klinik und Poliklinik II ";"Gießen";"University Medical Center";"Medizinische Klinik und Poliklinik V";"München-Großhadern";"University Medical Center";"Thoraxklinik-Heidelberg gGmbH";"Heidelberg";"Medical Center";"LungenClinic  Abteilung für Pneumologie";"Grosshansdorf";"University Medical Center";"Medizinische Hochschule Klinik für Pneumologie";"Hannover";"University Medical Center";"Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum  Essen gGmbH Abteilung Pneumologie-Allergologie";"Essen";"Medical Center";"Zentralklinik  Bad Berka Klinik für Pneumologie";" Bad Berka";"University Medical Center";"Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I Abteilung für Pneumologie";"Leipzig";"Medical Center";"Lungenfachklinik Immenhausen";"Immenhausen";"Medical Center";"Fachkrankenhaus Coswig GmbH; Zentrum für Pneumologie, Allergologie, Beatmungsmedizin, Thorax- und Gefäßchirurgie";"Coswig";"University Medical Center";"Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin";"Nürnberg";"University Medical Center";"Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B";"Greifswald";"Medical Center";"HELIOS Klinikum Emil von Behring Berlin-Zehlendorf, Klinik für Pneumologie";"Berlin";"Medical Center";"Evangelische Lungenklinik Berlin, Klinik für Pneumologie";"Berlin";"Medical Center";"Klinik Donaustauf, Zentrum für Pneumologie, Psychosomatische Medizin und Psychotherapie";"Donaustauf";"University Medical Center";"Universitätsklinikum des Saarlandes Klinik für Innere Medizin V - Pneumologie";"Homburg-Saar";"Medical Center";"Klinikum Würzburg Mitte gGmbH, Standort Missioklinik Innere Medizin Pneumologie";"Würzburg";"University Medical Center";"Universitätsklinikum Hamburg-Eppendorf II. Medizinische Klinik und Poliklinik (Pneumologie)";"Hamburg";"Medical Center";"Katholisches Klinikum Koblenz - Montabaur Klinik für Innere Medizin/Pneumologie, Schlaf- und Beatmungsmedizin ";"Koblenz";"University Medical Center";"Klinik für Kardiologie, Pneumologie und Angiologie Universitätsklinikum Düsseldorf";"Düsseldorf";2016/04/05;"Actual";"374";2018/10/04;"Multicenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"Confident diagnosis of progressive, non-IPF lung fibrosis due to ALF, CVDLF, chronic HP or fNSIP:<br/>1. Clinical symptoms consistent with ALF, CVDLF, chronic HP or fNSIP, including the insidious onset of otherwise unexplained dyspnea on exertion prior to diagnosis<br/>2. Diagnosis of either ALF, CVDLF, chronic HP or fNSIP based on diagnostic criteria outlined in Table 1, at least 9 months before randomization<br/>3. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective methods of contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study. If abstinence is not practiced, then one of the two methods of birth control should be an oral contraceptive (e.g., oral contraception and a spermicide)<br/>Table 1 Diagnostic criteria for ALF, CVDLF, chronic HP and fNSIP<br/><br/>(patients need to fulfil all of the listed diagnostic criteria within one of the categories)<br/>Asbestos-induced lung fibrosis<br/>• Existence of asbestos-specific pleural changes in HRCT (pleural plaques)<br/>• Reticular changes in HRCT and restrictive lung function pattern<br/>• History of asbestos exposure<br/>• Absence of an alternative explanation for fibrotic lung disease<br/>• Absence of extensive pleural plaques and/or effusion <br/>Lung fibrosis associated with collagen / vascular diseases<br/>• Diagnosis of progressive systemic sclerosis (PSS), mixed connective tissue disease (MCTD), rheumatoid arthritis (RA), Sjörgen’s syndrome, polymyositis/dermatomyositis on the basis of extrapulmonary symptoms and corresponding proof of auto-antibodies<br/>• Reticular changes in HRCT and restrictive lung function pattern<br/>• Absence of an alternative explanation for fibrotic lung disease<br/>Chronic Hypersensitivity Pneumonitis<br/>• Previous or current respiratory symptoms (dyspnea, coughing) with a <br/>temporal or spatial relation to a causative antigen exposure<br/>• Proof of precipitating antibody and/or lymphocytic alveolitis (>30%)<br/>• HRCT consistent with chronic HP<br/>• Restrictive lung function pattern<br/>• Absence of an alternative explanation for fibrotic lung disease<br/>Fibrotic NSIP<br/>• Histological diagnosis of a fibrotic NSIP pattern by open lung biopsy or <br/>cryobiopsy<br/>• HRCT consistent with fibrotic NSIP<br/>• Restrictive lung function pattern<br/>• Absence of an alternative explanation for fibrotic lung disease, especially no clinical suspicion of CVD<br/>4. 18 ≤  Age ≤ 80 years<br/>Disease Severity and Progression:<br/>5. Progressive disease in absence of a particular treatment (ALF) or despite a previous or concomitant treatment as outlined in protocol chapter 7.11. Progression prior to study entry must be proven by calculating the slope of a set of at least 3 previous FVC measurements within at least 6 months and at maximum 24 months before screening, showing a (eventually extrapolated) FVC decline of at least 5% (abs. pred.) per year<br/>6. Percent predicted FVC ≥40%, but < 90% at the Screening Visit (before randomization)<br/>7. Percent predicted, hemoglobin (Hb)-corrected carbon monoxide diffusing capacity/carbon monoxide transfer capacity (DLCO) ≥10%, but < 90% at the Screening Visit<br/>8. Distance walked ≥150 meters, with O2 saturation >83% on ≤ 6L/min of O2<br/>Informed Consent and Protocol Adherence:<br/>9. Able to understand and sign a written informed consent form<br/>10. Able to understand the importance of adherence to study treatment and the study protocol, including the concomitant medication restrictions throughout the study period<br/>Lung transplantation:<br/>11. Patients being considered or on the waiting list for lung transplantation are eligible for participation only if their estimated waiting time is longer than the study period. At the time these patients are placed on the list the date and reason for this placement and the LAS should be collected";"Disease-Related Exclusions:<br/>1. Not a suitable candidate for enrolment or unlikely to comply with the requirements of this study, in the opinion of the investigator<br/>2. May not survive the study period, in the opinion of the investigator<br/>3. Premature withdrawal from a randomized clinical trial in the previous 2 years for any reason other than Sponsor decision or current participation in a clinical drug trial<br/>4. Obvious additional obstructive lung disease, as evident from a) forced expiratory volume in the first second (FEV1)/FVC ratio <0.7 after administration of bronchodilator at Screening Visit , OR b) bronchodilator response defined by an increase of ≥12% and an increase of ≥ 200 mL in the FEV1 after bronchodilator use compared to the value seen before bronchodilator at the Screening Visit, OR c) residual volume (RV) >140% of predicted (before administration of bronchodilator)<br/>5. Other explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis and cancer<br/>6. Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis<br/>7. In the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 52 weeks after randomization<br/>8. Unable to undergo pulmonary function testing<br/>Medical Exclusions:<br/>9. Any history of malignancy likely to result in death or significant disability or likely to require significant medical or surgical intervention within the next 2 years. This does not include minor surgical procedures for localized carcinoma (e.g. basal cell carcinoma)<br/>10. Any condition other than lung fibrosis which, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years<br/>11. History of advanced cirrhosis or clinically significant liver disease<br/>12. History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months, including but not limited to the following:<br/>• Myocardial infarction, unstable angina pectoris, coronary artery bypass surgery, or coronary angioplasty<br/>• Congestive heart failure requiring hospitalization<br/>• Uncontrolled arrhythmias<br/>• Asthma or chronic bronchitis requiring hospitalization in the last 6 months<br/>13. Any condition, which, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone<br/>14. Poorly controlled diabetes (defined by glycosylated hemoglobin [HbA1C] >10 %)<br/>15. Pregnancy or lactation<br/>16. History of alcohol or substance abuse in the past 2 years<br/>17. History of any condition or habit associated with altered consciousness and a risk of aspiration in the past 2 years<br/>18. Family or personal history of long QT Syndrome<br/>19. Treatment with either one of the following medications: fluvoxamine (any time), any investigational drug, Stable treatment with PH-specific medication for less than 12 weeks. For individual cases, exemptions can be made after consultation with the Coordination Investigator (LKP) and/or the deputy Coordinating Investigator.<br/>20. Severe pulmonary hypertension with PVR values > 900 dyn<br/>21. Smoking<br/>Laboratory Exclusions:<br/>22. Any of the following liver function test criteria above specified limits: total bilirubin >2.5 upper limit of normal (ULN); aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) >2.5 ULN; alkaline phosphatase >2.5 ULN<br/>Concomitant Therapy Exclusions:<br/>23. Severe liver failure<br/>24. Prior use of pirfenidone. <br/>25. Hypersensitivity/allergy against pirfenidone or any component of the IMP<br/>26. History of angioedema in relation to prior use of pirfenidone<br/>27. Severe renal failure defined as GFR < 30ml/min and/or need for dialysis<br/>28. Concomitant therapy with potential interaction to study drug according to SmPC<br/>29. Patients are excluded, if more than 15 mg prednisolon equivalent are applied per day, or if a pre-existent steroid and/or immunosuppressant therapy has been modified within the last 3 months and/or if such therapy would be needed to be changed during the study period. In that case, dosing has to be adjusted and patient must be re-checked for eligibility 3 months after the last dose adjustment<br/>";"Primary Sponsor";"Justus-Liebig Universität Giessen ";"[---]*";"[---]*";"[---]*";"[---]*";"Ludwigstraße 23";"35390 ";"Gießen ";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Philipps-Universität Marburg Koordinierungszentrum für Klinische Studien";"Mr.";"[---]*";"Christoph";"Dupuy Backofen";"Karl-von-Frisch-Str. 4";"35043 ";"Marburg";"Germany";"+49 (0) 6421 286 6526";"+49 (0) 6421 286 6517";"christoph.dupuy@kks.uni-marburg.de";"www.kks.uni-marburg.de";"Contact for Public Queries";"Medizinische Klinik und Poliklinik V Klinikum der Universität München LMU";"Mr.";"Prof. Dr. med.";"Jürgen";"Behr";"Marchioninistrasse 15";"81377";"München";"Germany";"(0) 89-44007 5310";"+49 (0) 89-44007 8608";"juergen.behr@med.uni-muenchen";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsches Zentrum für Lungenforschung- DZL-Geschäftsstelle -";"Ms.";"Dr.";"Sylvia ";"Weißmann (Kommissarische Geschäftsführerin)";"Aulweg 130";"35392 ";"Gießen";"Germany";"+49 (0)641 - 99-42411";"+49 (0)641 - 99-42419";"s.baumgarten@dzl.de";"www.dzl.de";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Roche Pharma AG";"[---]*";"[---]*";"[---]*";"[---]*";"Emil-Barell-Str. 1";"79639";"Grenzach-Wyhlen";"Germany";"[---]*";"[---]*";"[---]*";"www.roche.de/about/standorte/grenzach.html";;;;;;;;;;;;;;;"Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) -<br/>A randomized, double-blind, placebo-controlled, parallel group,multi-center, phase II trial";"RELIEF";"[---]*";"The aim of the study is to investigate whether treatment with pirfenidone can improve lung function in patients with progressive, non-IPF lung fibrosis. To this end, patients will be randomly assigned to treatment with pirfenidone (intervention) or placebo (control). Treatment lasts for 48 weeks. The success of each treament will be assessed by the forced vital capacity (FVC), which is defined as the total volume expired forcefully with greatest force and speed after a maximal inspiration. Pirfenidone will be considered as effective if the FVC between start and end of treatment in the intervention group impoves much more than in the control group.";"To assess the safety and efficacy of treatment with pirfenidone compared to placebo in patients with progressive, non-IPF lung fibrosis. Patients will be randomly assigned to the control (placebo) arm and intervention arm (pirfenidone) in a 1:1 ratio. Treatment lasts for 48 weeks.<br/><br/><br/><br/>Indications for inclusion:<br/><br/>1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosis<br/><br/>Primary efficacy analysis and population:<br/>Primary endpoint: Absolute change in percent predicted FVC from baseline to week 48<br/><br/>H0: “no difference in primary endpoint  between the pirfenidone and placebo group”<br/><br/>H1: “difference in primary endpoint  between the pirfenidone and placebo group”<br/><br/>The null hypothesis is tested against the alternative hypothesis at a two-sided significance level of 5 % using a rank analysis of covariance (ANCOVA) model with a classification effect for treatment and indication and baseline FVC as a covariate. Data will be analyzed in the intent-to-treat (IIT) population.<br/>Safety:<br/>Safety data will be summarized using descriptive statistical methods.<br/>Secondary endpoint(s):<br/>Secondary outcomes will be analyzed using appropriate statistical methods.<br/>There is one planned interim analysis for efficacy.<br/><br/>Amendment Nr. 3, EK Votum Az.: 473-15 fed from 01.02.2018 Exclusion criterion Nr. 19 is added.<br/>Time for stable treatment with ph-spez. therapy is in med view of the LKP with 12 weeks adequate   ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009822";"2019-09-25T07:23:04.815+02:00";
"DRKS00008923";2015/07/29;"[---]*";yes;"Approved";"KEK-ZH-Nr: 2014-0658";"Kantonale Ethikkommission Zürich<br/>Stampfenbachstraße 121<br/>8090 Zürich<br/>Switzerland<br/>http://www.kek.zh.ch/internet/gesundheitsdirektion/kek/de/home.html<br/>";;;;;;;;;;;;;;;;"Free text";"[---]*";"Degenerative Mitral Regurgitation";"ICD10";"I34.0";"Mitral (valve) insufficiency";;;;;;;;;;"Arm 1";"MitraClip® system";"Arm 2";"Mitral valve surgery (repair or replacement)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"IV";"N/A";"- Safety: <br/>30-day safety superiority (ITT analysis)<br/>The study is powered to show superiority for safety of an endovascular treatment strategy with the MitraClip® as compared to a surgical treatment strategy. The primary safety endpoint is a Major Adverse Event Composite (MAE) including all-cause death, prolonged ventilation (>48h), renal failure, stroke and need for non-elective cardiovascular or thoracic surgery (defined as any kind of cardiovascular and thoracic surgery performed within 30 days from the index procedure and non anticipated prior to the procedure). The analysis of the primary safety endpoint is a test of superiority for the proportion of subjects free from the composite of safety events in the Device vs. the Surgery group at 30 days.<br/><br/>- Efficacy:<br/>12-month efficacy non-inferiority (ITT analysis)<br/>The study is powered to show non-inferiority for clinical efficacy of an endovascular treatment strategy with the MitraClip® as compared to a surgical treatment strategy. The primary effectiveness endpoint is a test of non-inferiority for the proportion of responders in the Device vs. the Surgery group at 12 months. Patients are defined as responders if they are alive with at least a 1-grade improvement in NYHA Functional Class at 12 months over baseline and have not experienced a HF hospitalization within 12 months of randomization (MitraClip® procedure or Surgery).";"- Safety:<br/>overall rate of Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs) until 12 months<br/><br/>- Efficacy:<br/>MR (Mitral Regurgitation) Severity reduction at 6 and 12 months in the MitraClip® and Surgery groups<br/>NYHA class changes at 6 and 12 months in the MitraClip® and Surgery groups<br/>Change in 6MWT (6 Minute walking test) in 6 and 12 months in the MitraClip® and Surgery groups<br/>Change in Quality of life (MLWHF and SF36) at 1, 6 and 12 months in the MitraClip® and Surgery groups<br/>Heart failure hospitalization rate in the post randomization in the MitraClip® and Surgery groups<br/>Days alive and out of hospital in the 12 months post-randomisation in the MitraClip® and Surgery groups<br/>Hospital resources utilisations: length of stay post-procedure, ICU beds occupant, need for rehabilitation services";"CH";"Switzerland";"DE";"Germany";"IT";"Italy";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Zürich";"Medical Center";"Inselspital";"Bern";"University Medical Center";"[---]*";"Hamburg";"Medical Center";"St. Georg";"Hamburg";"Medical Center";"Helios Klinikum";"Siegburg";"University Medical Center";"Herzzentrum Großhadern";"München";"University Medical Center";"[---]*";"Köln";"University Medical Center";"[---]*";"Bonn";"University Medical Center";"[---]*";"Lugano";"University Medical Center";"[---]*";"Rome";"University Medical Center";"[---]*";"Milan";"University Medical Center";"[---]*";"Catania";;;;;;;;;;;;;;;;;;;;;;;;;2015/08/11;"Actual";"294";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- Severe (4+) DMR (degenerative mitral regurgitation), or 3+ DMR<br/>- NYHA Functional Class III or IV<br/>- Mitral valve anatomy should be suitable for both MitraClip® and Mitral valve surgery (repair or replacement)<br/>- Subjects meet the following conditions:<br/>Age >=18 and high or intermediate risk with STS calculated mortality (using the repair calculator) >=3% and <=10% or as determined by the local Heart Team (which should include a surgeon and a cardiologist), based on the evidence that STS risk calculator may not identify possible risk factors<br/>- Patient is operable<br/>- Signed by the subject and dated approved informed consent prior to any study related procedure<br/>- Available and able to return to study site for post-procedural follow-up examination";"- Patient incapable to approve the informed consent or Emergency Cases<br/>- functional mitral valve pathology<br/>- evolving endocarditis or active endocarditis in the last 3 months<br/>- heavily calcified leaflets<br/>- subjects in whom transesophageal echocardiography is contraindicated<br/>- subjects in whom transseptal catheterisation is contraindicated<br/>- presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year<br/>- currently participating in the study of an investigational drug or device<br/>- untreated clinically significant CAD requiring revascularisation<br/>- any percutaneous coronary, carotid, endovascular intervention or carotid surgery within 30 days or any coronary or endovascular surgery within 3 months<br/>- prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure<br/>- concomitant and significant aortic or tricuspid valve pathology<br/>- CVA or TIA within 6 months or severe carotid stenosis (>70% assessed by Ultrasound)<br/>- contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately managed with premedication";"Primary Sponsor";"Klinikdirektor, Klinik für Herz- und Gefäßchirurgie";"Mr.";"Professor Doktor";"Francesco";"Maisano";"Raämistrasse 100";"8091";"Zürich";"Switzerland";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Klinikdirektor, Klinik für Herz- und Gefäßchirurgie";"Mr.";"Professor Doktor";"Francesco";"Maisano";"Raämistrasse 100";"8091";"Zürich";"Switzerland";"+41 44 255 32 98";"[---]*";"sponsor@hiride.eu";"[---]*";"Contact for Public Queries";"Klinikdirektor, Klinik für Herz- und Gefäßchirurgie";"Mr.";"Professor Doktor";"Francesco";"Maisano";"Raämistrasse 100";"8091";"Zürich";"Switzerland";"+41 44 255 32 98";"[---]*";"sponsor@hiride.eu";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Manufacterer of MitraClip®";"[---]*";"[---]*";"[---]*";"Abbott AG";"Neuhofstraße 23";"6340";"Baar";"Switzerland";"+41 417684333";"[---]*";"[---]*";"[---]*";"Institutional budget, no external funding (budget of sponsor/PI)";"Klinikdirektor, Klinik für Herz- und Gefäßchirurgie";"Mr.";"Professor Doktor";"Francesco";"Maisano";"Raämistrasse 100";"8091";"Zürich";"Switzerland";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: a Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy";"""HiRiDe"" Trial";"[---]*";"The study is comparing MitraClip® to Surgical therapy in high and intermediate risk patients, who should be older than 18 years, and shall evaluate safety and efficacy of MitraClip® vs. surgery in high-risk patients. The patients will be randomised (MitraClip® or Surgery). The Study Follow-Up includes 4 visits after procedure (hospital discharge, 1, 6, 12 months post-procedure).<br/>A substantial amendment has been submitted to the ECs including the following changes:<br/>- high and intermediate risk patients are allowed to participate in the trial<br/>- the inclusion criteria "">=75"" changes to "">=18""<br/>- Inclusion criteria: STS score between 3 and 10% OR heart team (including cardiologist and heart surgeon) decide to include the patient<br/>- patient is operable<br/>- patients incapable to approve the informed consent and emergency cases are excluded";"Two-arm, multi-centre, randomised prospective study comparing MitraClip® to Surgical therapy in high and intermediate risk patients. Patients should be older than 18 years and intermediate and high-risk is defined by the Society of Thoracic Surgeons score (for MV repair) >= 3% and <= 10% or intermediate or high-risk as determined by the local Heart Team (which should include a Surgeon and a Cardiologist), based on the evidence that STS risk calculator may not identify all possible risk factors. Patients are selected upon clinical conditions and severity of MR. Anatomical feasibility is assessed by ECHO, according to the IFU (instructions for use).<br/>The purpose of the trial is to evaluate safety and efficacy of MitraClip® vs. surgery in high and intermediate risk patients with DMR. Study Follow-Up includes the following visits after procedure: Hospital discharge, 1, 6, 12 months post-procedure.<br/>Primary Endpoints are the 30-day safety superiority (ITT analysis) and the 12-month efficacy non-inferiority (ITT analysis) of the MitraClip®. The overall rate of Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs) until 12 months and the MR Severity reduction at 6 and 12 month in the MitraClip® and Surgery groups are Secondary Endpoints";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008923";"2016-09-14T09:59:39.328+02:00";
"DRKS00008770";2015/10/02;2015/05/08;yes;"Approved";"PV4679";"Ethik-Kommission der Ärztekammer Hamburg";"Primary Registry-ID";"NCT02454543";"ClinicalTrials.gov";"Sponsor-ID";"G-RAMPP_MK-2014";"Martini-Klinik am UKE GmbH";;;;;;;;;;"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;;;;"Arm 1";"Arm 1 = Intervention arm<br/>Hormonal therapy plus radical prostatectomy with extended lymphadenectomy plus, if appro-priate, radiotherapy of the operation area (secondary<br/>hormonal therapy, osteoprotective med-ication, chemotherapy is possible)";"Arm 2";"Arm 2: = Standard therapy in accordance with Guideline = Hormonal therapy (secondary hormonal therapy, osteoprotective medication,<br/>chemotherapy is possible).";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"The primary objective is the tumour-specific survival time, defined as the time from randomization until death due to the underlying prostate cancer. In the event of death due to other causes, the time up to death is assessed as a concurrent event. For patients still living at the end of the follow-up the time from the randomization up to the last contact is entered as censored observation.";"1. Development of a castration-resistant stage:<br/>The evaluation of the period of time prior to the development of a castration-resistant stage (definition as per EAU Guidelines 2012)<br/>- Serum testosterone level <50 ng/dl (<1.7 nmol/l)<br/>- Three consecutive increases in serum PSA measured at an interval of 1 week, 2 of which must lie >50% above the nadir<br/>- Growth of metastases: enlargement or new occurrence of ≥2 bone or soft tissue metastases<br/><br/>2. Clinical progression-free survival time:<br/>A further secondary objective is the time interval from randomization to clinical progression. Clinical progression is defined by the diagnosis of new bone or soft tissue metastases. A clinical progression is confirmed or excluded by imaging tests (skeletal scintigraphy, CT, MRT or choline PET). They are performed in accordance with the guidelines if there is an increase in the PSA value of ≥ 2ng/ml compared with the reference PSA value.<br/>For patients without clinical progression, who are still living at the end of the follow-up, the time from randomization up to the last clinical examination is entered as censored observation.<br/><br/>3. Overall survival:<br/>The overall survival time is defined as the time from randomization until death. For patients still living at the end of the follow-up, the time from randomization up to the last contact is entered as censored observation.";"DE";"Germany";"AT";"Austria";"SE";"Sweden";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Martini-Klinik am UKE GmbH";"Hamburg";"Medical Center";"St. Marien-Krankenhaus, Abteilung für Urologie und Kinderurologie";"Ahaus";"Medical Center";"St. Vincenz Krankenhaus, Klinik für Urologie";"Datteln";"Medical Center";"Klinikum Dortmund, Urologie";"Dortmund";"University Medical Center";"Klinik und Poliklinik für Urologie";"Dresden";"Medical Center";"Urologie und Kinderurologie";"Geestland/Langen";"Medical Center";"St. Antonius-Hospital, Klinik für Urologie, Kinderurologie & urologische Onkologie";"Gronau";"Medical Center";"Klinikum Großburgwedel, Klinik für Urologie";"Burgwedel";"University Medical Center";"Klinik für Urologie und Kinderurologie";"Homburg/Saar";"University Medical Center";"Urologische Klinik und Poliklinik";"Jena";"University Medical Center";"Klinik für Urologie und Kinderurologie";"Kiel";"Medical Center";"KliLu, Urologische Klinik";"Ludwigshafen am Rhein";"University Medical Center";"Klinik für Urologie";"Lübeck";"Medical Center";"Klinikum Lüneburg, Klinik für Urologie";"Lüneburg";"University Medical Center";"Klinik für Urologie und Kinderurologie";"Magdeburg";"Medical Center";"Kreisklinikum Calw-Nagold, Klinik für Urologie Nagold ";"Nagold";"University Medical Center";"Urologie";"Oldenburg";"Medical Center";"Krankenhaus St. Josef, Urologie";"Regensburg";"Medical Center";"Klinikum Traunstein, Urologie";"Traunstein";"University Medical Center";"Urologie";"Tübingen";2015/05/01;"Actual";"500";2018/12/18;"Multicenter trial";"International";"Male";"18";"Years";"74";"Years";"1. Patients with newly diagnosed prostate cancer which has been confirmed by histological examination (within the last 6 months prior to randomization)<br/>2. At least one and at most 5 bone metastases in imaging tests (bone scintigraphy, CT, MRT or PET) at diagnosis with no evidence of visceral metastasis. Patients with evidence of lymph node metastasis (N1) are allowed<br/>3. PSA ≤ 200 ng/ml at diagnosis (without systemic therapy)<br/>4. Asymptomatic or mild symptomatic disease<br/>5. Locally resectable tumour stage<br/>6. ECOG Performance Status 0-1<br/>7. Submission of the patient’s written declaration of informed consent following explanation<br/>8. Age ≥ 18 - ≤ 75 years<br/>9. Full legal capacity and compliance of the patient";"1. Contraindications to radical prostatectomy (locally non-resectable disease, increased anaes-thesia risk with corresponding comorbidity)<br/>2. Evidence of more than 5 bone metastases<br/>3. Pain management with opioid analgesics<br/>4. Evidence of visceral metastases or brain metastases<br/>5. Neuroendocrine and/or small cell differentiation in the histology of the biopsy<br/>6. Charlson Comorbidity Index > 2<br/>7. ECOG Performance Status >1<br/>8. Myocardial infarction or stroke within the last 6 months<br/>9. Existing major cardiovascular (grade III - IV according to NYHA), pulmonary (pO2 <60 mmHg), renal, hepatic or haematopoietic (e.g. severe bone<br/>marrow aplasia) disease<br/>10. Severe psychiatric disorders in persons housed by a judicial or administrative arrangement in an institution<br/>11. Simultaneous participation in another clinical study with interventional character of the meta-static prostate cancer";"Primary Sponsor";"Martini-Klinik am UKE GmbH";"Mr.";"Professor";"Markus";"Graefen";"Martinistraße 52";"20246";"Hamburg";"Germany";"040 741053115";"040 741052745";"graefen@uke.de";"http://www.martini-klinik.de";"Contact for Scientific Queries";"Martini-Klinik am UKE GmbH";"Mr.";"Professor";"Markus";"Graefen";"Martinistraße 52";"20246";"Hamburg";"Germany";"040 741053115";"040 741052745";"graefen@uke.de";"http://www.martini-klinik.de";"Contact for Public Queries";"Martini-Klinik am UKE GmbH";"Ms.";"Dipl. Pflegew. (FH)";"Anke";"Renter";"Martinistraße 52";"20246";"Hamburg";"Germany";"040 741053115";"040 741052745";"renter@martini-klinik.de";"http://www.martini-klinik.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Martini-Klinik";"Mr.";"Prof. Dr.";"Markus";"Graefen";"Martinistraße 52";"20246";"Hamburg";"Germany";"040 741053115";"040 741052745";"graefen@uke.de";"www.martini-klinik.de";"Private sponsorship (foundations, study societies, etc.)";"Förderverein Hilfe bei Prostatakrebs e.V.";"Mr.";"[---]*";"Ernst-Günther";"Carl";"Thomas Mann Str. 40";"53111";"Bonn";"Germany";"0228 33889500";"[---]*";"info@fhbp.de";"www.fhpp.de";;;;;;;;;;;;;;;"Multicentric, prospective, randomized study to evaluate the effect of standard drug therapy with or without radical prostatectomy (RP) in patients with limited bone metastatic prostate cancer";"g-RAMPP";"https://www.martini-klinik.de/fuer-aerzte/studien/studienuebersicht/g-rampp-studie/";"The objective of the study is to answer the question whether the progress of disease in patients with a limited bone metastasis can be influenced favourably by radical prostatectomy. In addition, the influence of radical prostatectomy on the quality of life will be determined.";"More recent data has shown that performing local therapy with lymphogenic metastatic prostate cancer has resulted in a definite benefit in carcinomaspecific and overall survival. The analysis of this data has led to a change of paradigm in the treatment of lymphogenic metastatic prostate cancer (Isbarn Deutsches Ärzteblatt 2013). Patients with low lymphogenic metastatic load and low comorbidity are therefore frequently given local therapy. In a retrospective review of patients with lympho-genic metastatic prostate cancer, who were either treated by means of systemic standard therapy or standard therapy plus radical prostatectomy, a highly significant benefit is shown for the patient group which was operated on (Engel et al., Eur Urol 2012). The 5 and 10 year overall survival rate in this cohort was 84% and 64% respectively following performance of RP and with standard therapy without RP was 60% and 28% respectively.<br/><br/>Our own working group was able to confirm this clear survival benefit in the lymphogenic metastatic stage for patients who had been operated on: in a matched pair analysis the clinically progression-free survival rate after 5 and 10 years was 77% and 61% respectively after additional RP and 61% and 31% respectively with standard therapy alone (p=0.005). The same trend was found for cancer-specific survival (84% and 76% with additional RP versus 81% and 46% with standard therapy alone (p=0.001) (Steuber et al., BJUI 2011).<br/><br/>The impressive improvements in the survival rates of lymphogenic metastatic prostate cancer through local therapy compared with systemic drug therapy alone suggests that patients with distant metastases could potentially also benefit from local therapy. Besides possible effects on tumour control, the RP could also be beneficial with regard to a local progression of the prostate cancer (rectal infiltration, infiltration of the bladder). This could lead to an improvement in the quality of life in the course of the disease. On the other hand, radical prostatectomy is associated with potential side-effects (e.g. urinary incontinence in approximately 5 – 10% of patients as well as the usual possible side-effects, such as thrombosis, embolism, disturbances to wound healing etc.), which can lead to a loss in terms of quality of life. ";"Recruiting stopped after recruiting started ";"Background literature";"[---]*";"[---]*";"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014 Jan;65(1):124-37. doi: 10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6.; 24207135";"Background literature";"[---]*";"[---]*";"Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol. 1997 May;157(5):1731-5.; 9112515";"Background literature";"[---]*";"[---]*";"Isbarn H, Huland H, Graefen M. Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancers. Dtsch Arztebl Int. 2013 Jul;110(29-30):497-503. doi: 10.3238/arztebl.2013.0497. Epub 2013 Jul 22.; 24000298";"Background literature";"[---]*";"[---]*";"Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, Oberneder R, Rothenberger KH, Stief CG, Hölzel D. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010 May;57(5):754-61. doi: 10.1016/j.eururo.2009.12.034. Epub 2010 Jan 20.; 20106588";"Background literature";"[---]*";"[---]*";"Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.; 20942833";"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008770";"2020-02-06T07:36:48.935+01:00";
"DRKS00012534";2017/06/27;"[---]*";yes;"Approved";"208/17";"Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München";"Other Secondary-ID";"MOH_2019-03-12_006018";"registered at the Ministry Of Health in Israel";;;;;;;;;;;;;"Free text";"[---]*";"Side effects of H. pylori treatment: diarrhea, constipation, abdominal pain, bloating etc.";"ICD10";"B98.0";"Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters";;;;;;;;;;"Arm 1";"Intervention group with probiotic tablets 2x a day for 3 weeks (during two weeks of Helicobacter treatment and a week thereafter). Probiotic tablet is a food supplement (not a drug) containing L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475. <br/><br/>Other ingredients are: Bulking agent (isomalt), flavor enhancer (citric acid), Lactobacillus reuteri DSM 17938 and Lactobacillus reuteri ATCC PTA 6475, palm oil, mint flavoring and mandarin flavoring. This food supplement is currently freely on sale under the name “Gastrus®” of Biogaia, Sweden.<br/>";"Arm 2";"Control group with placebo tablets 2x a day for 3 weeks (during two weeks of Helicobacter treatment and a week thereafter). Placebo tablet is a dummy or pretend tablet. It contains no probiotics, only maltodextrin and mandarin flavoring. ";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Prevention";"Parallel";"N/A";"N/A";"Incidence of diarrhea during the 3 weeks intervention period defined as percentage of patients developing diarrhea. Diarrhea is defined as increased frequency (>3 stools per day) with loose consistency (equal to Bristol stool scale (BSS) of 5 or 6) or >1 watery stool per day (BSS 7). ";"(1) Incidence of other adverse events (abdominal pain, bloating, nausea, vomiting, bad (metallic) taste during the 3 weeks intervention period.<br/>(2) Duration and severity of diarrhea during the 3 weeks intervention period in days.<br/>(3) Percentage of patients with an intake of drugs from triple therapy less than 80% during the 2 week treatment period.<br/>(4) Percentage of patients with successful H. pylori eradication at follow up at visit 4.<br/>";"DE";"Germany";"PT";"Portugal";"ES";"Spain";"SI";"Slovenia";"IL";"Israel";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Dr. von Haunersches Kinderspital, Klinikum der Universität München (AöR)";"Munich, Germany";"University Medical Center";"National Institute of Health, University Hospital Santa Maria";"Lisbon, Portugal";"University Medical Center";"São João Hospital Centre";"Porto, Portugal";"Medical Center";"Hospital “ 12 de Octubre “";"Madrid, Spain";"Medical Center";"Hospital Puerta de Hierro-Majadahonda";"Madrid, Spain";"University Medical Center";"University Children´s Hospital";"Ljubljana, Slovenia";"Medical Center";"Kaplan Medical Center";"Rehovot, Israel";"University Medical Center";"University Medical Centre Maribor";"Maribor, Slovenia";"Medical Center";"Hospital de Dona Estefânia";"Lisbon, Portugal";"Medical Center";"Schneider Children's Medical Center  ";"Tel Aviv, Israel";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2018/04/01;"Actual";"220";2019/07/01;"Multicenter trial";"International";"Both, male and female";"5";"Years";"18";"Years";"(a) Male or female patients aged between 5 - 18 years. <br/>(b) Minimal body weight of 15 kg. <br/>(c) H. pylori infection confirmed by positive culture and results of susceptibility testing for clarithromycin and metronidazole. <br/>(d) No previous therapy for H. pylori infection.<br/>(e) Screening diary completed with ≥ 6/7 days.<br/>(f) Written informed consent by parents/care giver and patients (6-11 years and 12-17 years).<br/>";"(a) Significant acute or chronic gastrointestinal or other disease interfering with assessment of symptoms.<br/>(b) Known allergies to used antibiotics, proton pump inhibitors or probiotics.<br/>(c) Having received treatment with antibiotics or bismuth compounds during the previous 30 days.<br/>(d) Having received proton pump inhibitors during the previous two weeks.<br/>(e) Having received probiotic therapy during the previous 14 days. <br/>(f) Being infected with a strain resistant to clarithromycin and metronidazole (double resistant).<br/>(g) Severe acquired or primary immunodeficiency.<br/>(h) Diarrhea as defined in the study protocol for at least 2 days documented on the screening diary.<br/>";"Primary Sponsor";"Klinikum der Universität München, Campus Innenstadt";"[---]*";"[---]*";"[---]*";"[---]*";"Lindwurmstraße 2a";"81337";"München";"Germany";"[---]*";"[---]*";"[---]*";"www.klinikum.uni-muenchen.de";"Contact for Scientific Queries";"Dr. von Haunersches Kinderspital, Abt. Pädiatrische Gastroenterologie & Hepatologie, Klinikum der Universitaet Muenchen (AöR)";"Ms.";"Prof. Dr. med.";"Sibylle";"Koletzko";"Lindwurmstr. 4";"80337";"München";"Germany";"+4989440057854";"+4989440057898";"Sibylle.Koletzko@med.uni-muenchen.de";"http://www.klinikum.uni-muenchen.de/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital/";"Contact for Public Queries";"Dr. von Haunersches Kinderspital, Abt. Pädiatrische Gastroenterologie & Hepatologie, Klinikum der Universitaet Muenchen (AöR)";"Ms.";"[---]*";"Thu Giang";"Le Thi";"Lindwurmstr. 4";"80337";"München";"Germany";"+4989440057854";"+4989440057898";"tlethi@med.lmu.de";"http://www.klinikum.uni-muenchen.de/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Biogaia AB";"[---]*";"[---]*";"[---]*";"[---]*";"Kungsbroplan 3, P.O. Box 3242";"SE 103-64";"Stockholm";"Sweden";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Effect of a probiotic combination on anti-Helicobacter pylori treatment related adverse effects in children - a multicenter double blind RCT";"HeliP Study";"[---]*";"a.) Patient, who was diagnosed with stomach inflammation caused by Helicobacter pylori (H. pylori) bacterium, will have to take at least two different antibiotics plus an acid suppressing drug (PPI) for two weeks. Under this treatment, side effects like diarrhea, constipation, abdominal pain, and bloating often occur. <br/><br/>With this study, we aim to investigate whether the additional intake of probiotics tablets during two weeks of Helicobacter treatment and a week thereafter can prevent or reduce these uncomfortable, but mostly harmless side effects. <br/><br/>b.) In the study, patients will be assigned by chance to a treatment group or a control group with placebo (without probiotics). These two groups will be compared with each other. In order not to influence the evaluation, patient, researcher, and study staff will not know whether the patient will get tablets with or without probiotics.<br/>";"Infection with Helicobacter pylori (H. pylori) is still a very common bacterial infection in humans, despite the worldwide significant decrease in incidence and prevalence recorded in recent years (1). Infection with H. pylori is mostly acquired during early childhood, and in low prevalence countries such as European countries, infected family members, particularly the mothers, are the main source of infection. Chronic inflammation of the gastric mucosa can cause peptic erosions and ulcerations, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. In addition, extra gastric complications, such as iron-deficiency anemia, may be induced by H. pylori infection. <br/>The new guidelines of the European and North American societies of Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN) recommend in anti - H. pylori infected children that H. pylori infection should be confirmed by positive culture, when treatment will be offered. The H. pylori treatment should be tailored according to antibiotics susceptibility testing and should be administered for 14 days (2). Hence, patient, who was diagnosed with stomach inflammation caused by Helicobacter pylori (H. pylori) bacterium, will have to take at least two different antibiotics plus an acid suppressing drug (PPI) for two weeks. Adverse events such as diarrhea, nausea, taste disturbance, and abdominal pain are frequent during eradication therapy and mainly due to antibiotics, with diarrhea being the most common one.  <br/>The use of probiotics in combination with a treatment regimen guided by antibiotic susceptibility testing may decrease side effects, improve compliance for H. pylori treatment protocols and hopefully to raise the eradication rates (2). Among several probiotics, Lactobacillus sp. have especially demonstrated a positive effect on reduction of adverse effects and anti- H. pylori properties (3). The combination of two Lactobacillus reuteri strains, DSM 17938 and ATCC PTA 6457, are probiotics as dietary supplement and has been proposed as better option in increasing H. pylori eradication rate, due to additional anti-inflammatory properties of the second strain (4). Francavilla et al. showed in a RCT in 100 adults, that probiotics concomitantly administrated with an eradication therapy decreases serum gastrin level, increases, although not significantly, H. pylori eradication rate, and significantly decreases antibiotic associated adverse effects, i.e. diarrhea, abdominal pain, bloating and epigastric pain compared to placebo (5). The study included only adult patients infected with H. pylori. So far no data are available on the beneficial effects of probiotics on adverse effects and eradication rate of an anti-H. pylori therapy in a pediatric population. <br/>In this study, we aim to investigate whether the additional intake of probiotics tablets containing L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475 during two weeks of Helicobacter treatment and a week thereafter can prevent or reduce side effects of the H. pylori treatment with antibiotics, reduce the rate of non-adherence to triple therapy and improve H. pylori eradication rates of triple therapy.<br/>This study was designed as a multicenter, double blind, randomized, placebo controlled trial, stratified in 2 groups by antibiotics susceptibility testing for clarithromycin and metronidazole.<br/>(1) Sustmann A, Okuda M, Koletzko S. Helicobacter pylori in children. Helicobacter 2016 Sep;21 Suppl 1:49-54.<br/>(2) Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011 Aug;53(2):230-43.<br/>(3) Alsahli M, Michetti P. Lactobacilli for the management of Helicobacter pylori. Nutrition 2001 Mar;17(3):268-9.<br/>(4) Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010 Nov;299(5):G1087-G1096.<br/>(5) Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol 2014 May;48(5):407-13.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012534";"2020-03-23T14:53:40.221+01:00";
"DRKS00009666";2015/11/13;2008/05/08;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00676650";"ClinicalTrials.gov";"Sponsor-ID";"A6181120";"Pfizer";;;;;;;;;;"Free text";"[---]*";"Prostatic Neoplasms";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Prednisone";"Arm 2";"Drug: sunitinib";"Arm 3";"Drug: Placebo";"Arm 4";"Drug: Prednisone";;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"III";"[---]*";"- Overall Survival (OS); time frame: Baseline up to 32 months; OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4.<br/>";"- Progression-Free Survival (PFS); time frame: Baseline, every 8 weeks up to 123 weeks; PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02<br/>- Percent of Participants With Objective Response (OR); time frame: Baseline, every 8 weeks up to 123 weeks; OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response.<br/>- Duration of Response (DR); time frame: Baseline, every 8 weeks up to 123 weeks; Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cause - the date of the first CR or PR that was subsequently confirmed plus 1 divided by 7.02. DR calculated for the subgroup of participants with a confirmed objective tumor response<br/>- Change From Baseline in Pain Severity; time frame: Day 1 through Day 7 every 28 days (every cycle) up to 29 months; Pain severity recorded on a numerical scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Higher scores indicated greater level of pain. The pain score for each cycle averaged for the 7 days.<br/>- Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P); time frame: Baseline, every 4 weeks up to 123 weeks; FACT-P is a validated, self-administered instrument used to assess health-related quality of life and prostate cancer-specific symptoms. Scores ranged from 0 (not at all) to 4 (very much). It is 27-item FACT-General and 12 items for the prostate cancer specific concerns. The 27 items in FACT-G are grouped into 4 domains: physical well-being, social/family well-being, emotional well-being and functional well-being. The 12 prostate cancer symptoms items focus on pain (3 items), urination problems (3 items), sexual functions (2 items), weight loss, appetite, overall comfort, and bowel movement.<br/>- Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility Score; time frame: Baseline, every 4 weeks up to 123 weeks; EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (""confined to bed""). Overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction.<br/>";"AU";"Australia";"BE";"Belgium";"BR";"Brazil";"CA";"Canada";"CN";"China";"CZ";"Czech Republic";"DK";"Denmark";"FI";"Finland";"FR";"France";"DE";"Germany";"IL";"Israel";"IT";"Italy";"KR";"Korea, Republic of";"PE";"Peru";"PL";"Poland";"PT";"Portugal";"SK";"Slovakia";"ES";"Spain";"SE";"Sweden";"TW";"Taiwan, Province of China";"[---]*";"Pfizer Investigational Site";"Berlin";"[---]*";"Pfizer Investigational Site";"Homburg/Saar";"[---]*";"Pfizer Investigational Site";"Kempen";"[---]*";"Pfizer Investigational Site";"Leipzig";"[---]*";"Pfizer Investigational Site";"Muenchen";"[---]*";"Pfizer Investigational Site";"Muenster";"[---]*";"Pfizer Investigational Site";"Tuebingen";"[---]*";"Pfizer Investigational Site";"Ulm";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/07/31;"[---]*";"873";2011/12/01;"[---]*";"[---]*";"Male";"18";"Years";"[---]*";"no maximum age";"-  Histologically or cytologically confirmed adenocarcinoma of the prostate.<br/><br/>          -  Progressive, metastatic castration-resistant prostate cancer after failure of<br/>             docetaxel chemotherapy (resistant or intolerant).<br/><br/>          -  Progressive disease based on PSA progression, RECIST, or positive bone scan.<br/><br/>          -  ECOG 0 or 1.<br/>";"-  Prior treatment with sunitinib and/or more than 1 prior chemotherapy regimen in the<br/>             metastatic disease setting.<br/><br/>          -  Chemotherapy within 3 weeks.<br/><br/>          -  Impending complications from bone metastases.<br/><br/>          -  Ongoing urinary obstruction.<br/><br/>          -  Cardiac dysfunction, QTc >470 msec.<br/><br/>          -  CNS involvement.<br/>";"Primary Sponsor";"Pfizer";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Pfizer";"[---]*";"[---]*";"[---]*";"Pfizer CT.gov Call Center";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Pfizer";"[---]*";"[---]*";"[---]*";"Pfizer CT.gov Call Center";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen";"SUN 1120";"[---]*";"This study will compare the safety and efficacy of sunitinib in combination with prednisone<br/>      versus placebo and prednisone in patients that have metastatic castration-resistant prostate<br/>      cancer that has progressed after treatment with a docetaxel-containing chemotherapy regimen.<br/>      This is a second-line study.<br/>";"[---]*";"Recruiting stopped after recruiting started ";"Further trial documents";"[---]*";"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181120&StudyName=Sunitinib%20Plus%20Prednisone%20In%20Patients%20With%20Metastatic%20Castration-Resistant%20Prostate%20Cancer%20After%20Failure%20Of%20Docetaxel%20Chemotherapy";"To obtain contact information for a study center near you, click here.";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009666";"2016-08-22T17:31:34.865+02:00";
"DRKS00004405";2012/10/12;2012/10/26;yes;"Approved";"184/12";"Ethik-Kommission bei der Ärztekammer des Saarlandes";"Primary Registry-ID";"NCT01717677";"clinicaltrials.gov";"Sponsor-ID";" 2011-PCA-01";" Klinik für Urologie  und Kinderurologie der Universität des Saarlandes";"Sponsor-ID";" 2011-PCA-01";"Klinik für Strahlentherapie und Radioonkologie der Universität Ulm";;;;;;;"Free text";"[---]*";"prostate cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"radical prostatectomy ";"Arm 2";"percutaneous radio therapy";"Arm 3";"continuous Seed-Implantation";"Arm 4";"Active Surveillance";;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)|Control group receives no treatment";"Treatment";"Parallel";"N/A";"N/A";"Prostate cancer-specific survival, minimal observation time of 13 years for last study patient";"- Overall survival,  minimal observation time of 13 years for last study patient<br/>- Time to onset of hormone therapy<br/>- Occurrence of the first progression in hormone therapy<br/>- Quality of life on EORTC-QLQ-C30 with additional modul PCA (EORTCQLQ-<br/>PR25) as well as HADS-D at timepoints basline, before and 3 Mon. after therapy as well as after 1, 2, 3, 5, 7, 10 and 13 years<br/>- Complications / side effects of therapy";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"60-100 Prüfzentren ";"[---]*";"University Medical Center";"Universitätsklinikum";"Hamburg/Saar";"University Medical Center";"Universitätsklinikum";"Ulm";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/10/22;"Actual";"7600";"[---]*";"Multicenter trial";"National";"Male";"18";"Years";"75";"Years";"1) Newly diagnosed adenocarcinoma of the prostate confirmed by punching biopsy method/ histology (punch biopsy according to standardized protocol)<br/><br/>2) At least 8 randomized biopsies; in case of modern imaging methods a minimum of 6 biopsies have to be taken. Lesion targeted biopsies only are not sufficient.<br/><br/>3) Initiation of therapy within 6 months after histological confirmation<br/><br/>4) Locally limited carcinoma <= cT2a, NX or N0 M0 (A tumor detected with needle biopsy in one or both lobes which is neither palpable nor visible in imaging is classified as T1c)<br/><br/>5) PSA <= 10 ng / ml<br/><br/>6) Gleason score = <7a (3 +4)<br/><br/>7) For Gleason 7 tumors: Proportion of tumored punching in the total number of the extracted stamping (see punching Protocol) <= 33% and the largest contiguous tumor stove <= 5 mm<br/><br/>8) Men aged 18-75 years<br/><br/>9) ECOG performance status 0 or 1<br/>";"1) Lack of patient suitability for surgery, radiation* or Active Surveillance<br/><br/>2) Timely Op because of BPH e.g. TURP, HIFU, cryotherapy in the anamnesis<br/><br/>3) Timely radiotherapy of the pelvis<br/><br/>4) Life expectancy < 10 years<br/><br/>5) ASA > 4<br/><br/>6) IPSS-Score > 18*<br/><br/>7) Residual urine > 50 ml*<br/><br/>8) Prostate volume on transrectal ultrasound* > 60 cm3<br/><br/>9) Prostate large median lobe* visible in the TRUS<br/><br/>10) Floride chronic intestinal inflammation in the rectum area*<br/><br/>11) Application of Alpha-reductase inhibitors (finasteride, dutasteride) within 6 month before biopsy because of their influence on the PSA level <br/><br/>12) Other active malignancy within the past 5 years (except are superficial basal cell carcinoma or  non-muscle invasive bladder cancer)<br/><br/>13) Patients that are not able to consent<br/><br/>14) Lack of written informed consent";"Primary Sponsor";"Klinik für Urologie  und Kinderurologie der Universität des Saarlandes";"Mr.";"Prof. Dr.";"Michael";"Stöckle";"Kirrberger Straße";"66424";"Homburg an der Saar";"Germany";"06841/162-47 02";"06841/162-47 95";"michael.stoeckle@uks.eu";"[---]*";"Primary Sponsor";"Klinik für Strahlentherapie und Radioonkologie der Universität Ulm";"Mr.";"Prof. Dr.";"Thomas";"Wiegel";"Albert-Einstein-Allee 23";"89081";"Ulm";"Germany";"0731-50056101";"0731-50056110";"thomas.wiegel@uniklinik-ulm.de";"[---]*";"Contact for Scientific Queries";"Deutsche Krebsgesellschaft e.V.";"Ms.";"[---]*";"Roswitha";"Bussar-Maatz";"Kuno-Fischer-Str. 8";"14057";"Berlin";"Germany";"030-322932946";"030-322932946";"studienzentrale@prefere.de";"[---]*";"Contact for Public Queries";"Deutsche Krebsgesellschaft e. V.";"Ms.";"[---]*";"Roswitha";"Bussar-Maatz";"Kuno-Fischer-Str. 8";"14057";"Berlin";"Germany";"030-322932946";"030-322932946";"studienzentrale@prefere.de";"[---]*";;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"Deutsche Krebshilfe e.V.";"[---]*";"[---]*";"[---]*";"[---]*";"Buschstr. 32";"53113";"Bonn";"Germany";"0228/72 99 00";"0228/72 99 011";"deutsche@krebshilfe.de";"www.krebshilfe.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Preference based randomized trial for evaluation of four treatment modalities in prostate cancer with low or ""early intermediate"" risk";"PREFERE";"http://www.prefere.de";"The study will compare four possible therapy options for treatment of newly diagnosed prostate cancer with low or early intermediate risk including patients preferences.<br/>That for the following hypotheses will be proofed:<br/>- Radiotherapy is not relevantly worse than operation therapy in time to prostatecancer-related deaths.<br/>- Permanent seeds inplantation therapy is not relevantly worse than operation therapy in time to prostatecancer-related deaths.<br/>- Active Surveillance will not lead to a relevantly worsening of time to prostatecancer-related deaths compared to operation therapy.<br/>That for, newly diagnosed patients with prostatecancer will be randomised into one of the four therapyarms. Within that, patients have the possibility to refuse for a maximum of two therapy arms before randomisation according to their own preferences.<br/>";"4arms preference based Study to compare four therapy options in prostate cancer with low or early intermediate risk; Amendment 3 (study protocol version 5.0): Change of inclusion and exclusion criteria";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004405";"2017-02-07T10:19:58.218+01:00";
"DRKS00005443";2013/11/12;2013/06/24;yes;"Approved";"2013-06-19";"Ethikkommission des Landes Bremen";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2012-001006-24";"[---]*";"Primary Registry-ID";"EUCTR2012-001006-24-DE";"EUCTR";;;;;;;;;;"ICD10";"E14.30";"[generalization E14.3: Unspecified diabetes mellitus; With ophthalmic complications]";"ICD10";"H35.8";"Other specified retinal disorders";;;;;;;;;;"Arm 1";"initial vitrectomy with ILM-peeling with intraoperative andministration of Ranibizumab 0,5 mg intravitreally. After vitrectomy, 2 further injections of 0,5 mg Ranibizumab every 4 weeks will be performed, according to the label of Ranibizumab (Lucentis ®). After the first 3 obligatory treatments with Ranibizumab, examination will be performed every 4 weeks. Further injections will be given, according to the label of Ranibizumab (Lucentis ®), if indicated.";"Arm 2";"Three initial injections of 0,5 mg Ranibizumab every 4 weeks will be performed, according to the label of Ranibizumab (Lucentis ®). After the first 3 obligatory treatments with Ranibizumab, examination will be performed every 4 weeks. Further injections will be given, according to the label of Ranibizumab (Lucentis ®), if indicated";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"IV";"No";"Number of injections of study drug during the first year of treatment<br/><br/>Mean change from baseline in BCVA at month 12 (visit 13)<br/>Visual acuity measured by ETDRS-charts";"Proportion of patients with a vision acuity loss of fewer than 15 letters at month 12 (visit 13) compared with baseline<br/>- - - Proportion of patients with a vision acuity loss of more than 15 letters at month 12 (visit 13) compared with baseline (visual acuity measured by ETDRS-charts)<br/>- - - Proportion of patients with a treatment-free interval of at least 3 months duration at any time point following visit 3 (at month 2)<br/>- - - Drop out rates<br/>- - - Rate of non-responders<br/>- - - Retinal lesions <br/>- - - Changes in retinal thickness from baseline at month 4 and 12 (visit 13) via Optical Coherence Tomography (OCT)<br/>- - - AEs<br/>- - - Quality of Life at visit 1 (before treatment) and visit 13 (month 12); questionnaire VFQ25.<br/><br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Augenklinik Universitätsallee";"Bremen";"Medical Center";"DRK Kliniken Berlin Westend, Klinik für Augenheilkunde";"Berlin";"Medical Center";"Städtisches Klinikum Dessau, Augenklinik";"Dessau";"Medical Center";"Augenärzte am St. Franziskus-Hospital";"Münster";"Medical Center";"Augenklinik Gelsenkirchen";"Gelsenkirchen";"University Medical Center";"Universitätsmedizin Göttingen, Augen- und Poliklinik";"Göttingen";"Medical Center";"St. Joseph-Stift";"Bremen";"Medical Center";"St. Gertrauden-Krankenhaus, Augenheilkunde";"Berlin ";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/04/07;"Actual";"110";2016/08/01;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Patients aged 18 years and older<br/>- - - Diabetes mellitus type 2 (insulin-dependent diabetes mellitus (IDDM) and noninsulin-dependent diabetes mellitus (NIDDM))<br/>- - - Clinical significant diabetic macular edema (diffuse or focal)<br/>- - - Visual acuity (decimal) reduced by diabetic macular edema to ≤ 0,3 and ≥ 0,05 (LogMar ≤ 1,3 and ≥ 0,5) stated by EDTRS charts.<br/>- - - Signed informed consent<br/><br/>";"The investigator is clinically not convinced about vitrectomy being indicated or the possible side effects outweigh the possible positive effects of vitrectomy<br/>- - - Diabetes mellitus type 1<br/>- - - Visual acuity of the study eye (decimal) > 0,3 (LogMar < 0,5)<br/>- - - Visual acuity of the study eye (decimal) < 0,05 (LogMar > 1,3)<br/>- - - Central retinal thickness stated by SD-OCT < 250 µm<br/>- - - Any clouding of optical media influencing the evaluation of the retina<br/>- - - Previous focal laser coagulation of the macula in the study eye within 3 months prior to baseline<br/>- - - Previous treatment of diabetic macular edema involving intravitreal steroids or VEGF blockers within 3 months prior to baseline<br/>- - - Previous vitrectomy in the study eye<br/>- - - Previous cataract surgery in the study eye within 3 months prior to baseline<br/>- - - Pseudophakia with opening of the posterior capsule by surgery or YAG laser capsulotomy within 3 months prior to baseline<br/>- - - History of glaucoma (including or excluding local or systemic therapy) in either eye<br/>- - - Uveitis or extraocular inflammation in either eye<br/>- - - Pseudoexfoliative syndrome<br/>- - -  Known ocular ischemia syndrome in either eye (occlusion of extraocular arteries, influencing the vascularisation of the study eye)<br/>- - - Retinal venous occlusion in the study eye<br/>- - - History of retinal detachment (including or excluding any therapy) in either eye<br/>- - - Tractive retinal detachment due to diabetic epiretinal proliferation in the study eye<br/>- - - Intravitreal hemorrhage interfering with the assessment of the posterior pole in the study eye prior to baseline<br/>- - - Active malignancies (history of successful treated malignancies is not an exclusion criterion)<br/>- - - History of cerebral vascular accident or myocardial infarction within 12 months prior to baseline<br/>- - - Diabetes mellitus with HbA1c > 10 % or if it can be expected that the patient’s diabetes cannot be controlled adequately during the trial <br/>- - - Uncontrolled arterial Hypertension defined as a systolic value of > 180 mmHg and/or a diastolic value of > 110 mmHg<br/>- - - Systemic therapy with steroids or anticoagulative therapy with coumarin derivatives or heparin (Aspirin or Clopidogrel is allowed)<br/>- - - History of allergy to fluorescein or ranibizumab<br/>- - - Women who are pregnant or planning a pregnancy<br/>- - - Women who are breast feeding<br/>- - - Inability to comply with study or follow-up procedures<br/><br/>";"Primary Sponsor";"Augenklinik Universitätsallee";"Mr.";"Dr. med.";"Andreas";"Schüler";"Parkallee 301";"28213";"Bremen";"Germany";"++49-0421-5665-200";"++49-0421-5665-349";"a.schueler@retina.to";"[---]*";"Contact for Scientific Queries";"Augenklinik Universitätsallee";"[---]*";"Dr. med.";"Andreas";"Schüler";"Parkallee 301";"28213";"Bremen";"Germany";"++49-0421-5665-200";"++49-0421-5665-349";"a.schueler@retina.to";"[---]*";"Contact for Public Queries";"Institut für Pharmakologie";"[---]*";"Dipl. biol.";"Kerstin";"Graumann";"St.-Juergen-Str.1";"28177";"Bremen";"Germany";"++49-0421-497-3206";"++49-0421-497-3326";"k.graumann@pharmakologie-bremen.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Novartis Pharma GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"Roonstr.25";"90429";"Nürnberg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Ranibizumab and Vitrectomy in the Therapy of Diabetic Macular Edema";"RAVIT-DME";"[---]*";"Treatment of Diabetic Macular Edema, swelling of the central retina causing impaired vision or blindness<br/><br/>Previous therapies<br/>- treatment by laser photocoagulation <br/>- Intravitreal injections of VEGF-inhibitors (Ranibizumab, Bevacizumab)<br/>- Vitrectomy incl. ILM-peeling (internal limiting membrane)<br/><br/><br/>Hypotheses:<br/>Vitrectomy in combination with  intravitreal injections of Ranibizumab is superior to exclusively used intravitreal injections of Ranibizumab characterized by fewer injections necessary to maintain the therapeutic effect.<br/><br/>Vitrectomy in combination with intravitreal injections of Ranibizumab is not inferior with regard to the mean change of BCVA (Best Corrected Visual Acuity) from baseline to month 12)<br/><br/>The study is designed to evaluate the efficacy of vitrectomy inc. ILM-peeling plus Ranibizumab administered intravitreally in comparison to Ranibizumab administered intravitreally in respect to the number of doses of Ranibizumab and the change of visual acuity 12 months after first treatment and other secondary clinical outcome parameters.<br/><br/><br/><br/>";"Treatment of Diabetic Macular Edema, swelling of the central retina causing impaired vision or blindness<br/><br/>Previous therapies<br/>- treatment by laser photocoagulation <br/>- Intravitreal injections of VEGF-inhibitors (Ranibizumab, Bevacizumab)<br/>- Vitrectomy incl. ILM-peeling<br/><br/>Hypotheses:<br/>Vitrectomy in combination with  intravitreal injections of Ranibizumab is superior to exclusively used intravitreal injections of Ranibizumab characterized by fewer injections necessary to maintain the therapeutic effect.<br/><br/>Vitrectomy in combination with intravitreal injections of Ranibizumab is not inferior with regard to the mean change of BCVA  from baseline to month 12<br/><br/>The study is designed to evaluate the efficacy of vitrectomy inc. ILM-peeling plus Ranibizumab administered intravitreally in comparison to Ranibizumab administered intravitreally in respect to the number of doses of Ranibizumab and the change of visual acuity 12 months after first treatment and other secondary clinical outcome parameters.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005443";"2017-10-19T09:16:00.828+02:00";
"DRKS00008985";2015/09/23;"[---]*";yes;"Approved";"445/12-bk ";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";;;;;;;;;;;;;;;;"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;;;;"Arm 1";"Airwaymanagement with laryngeal tube suction LTS II";"Arm 2";"Airwaymanagement with endotracheal tube";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"N/A";"N/A";"Successfull ventilation with LTS II";"Aspiration<br/>Ease and time of insertion<br/>Soar throat, dysphagia, difficulties in swallowing<br/>Conditions as rated by the responsible surgeon";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Anästhesiologie und Intensivtherapie";"Leipzig";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/04/23;"Actual";"100";2015/05/04;"Monocenter trial";"National";"Male";"18";"Years";"[---]*";"no maximum age";"Patients undergoing endoscopic prostate resection";"ASA  > II<br/>Age < 18y<br/>BMI > 30<br/>missing informed consent<br/>elevated risk for aspiraton of gastric content<br/>participation in another interventional clinical trial";"Primary Sponsor";"Universität Leipzig, medizinische Fakultät";"[---]*";"[---]*";"[---]*";"[---]*";"Liebigstr. 27b";"04103";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"www.uniklinikum-leipzig.de";"Contact for Scientific Queries";"Universitätsklinikum Leipzig";"Mr.";"PD Dr.";"Sven";"Bercker";"Liebigstrasse 20";"04229";"Leipzig";"Germany";"0341 97 17700";"0341 97 17709";"sven.bercker@medizin.uni-leipzig.de";"http://www.kai-uniklinik-leipzig.de";"Contact for Public Queries";"Universitätsklinikum Leipzig";"Mr.";"PD Dr.";"Sven";"Bercker";"Liebigstrasse 20";"04103";"Leipzig";"Germany";"0341 97 17700";"0341 97 17709";"sven.bercker@medizin.uni-leipzig.de";"http://www.kai-uniklinik-leipzig.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universität Leipzig, medizinische Faultät";"[---]*";"[---]*";"[---]*";"[---]*";"Liebigstrasse 27b";"04103";"Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Laryngeal tube suction II or endotracheal intubation for laparoscopic radical prostatectomy in a head down position: A randomised controlled trial.";"[---]*";"[---]*";"The aim of the study is to evaluate fesability, safety and patient comfort during airway management with the laryngeal tube suction II (LTS II) in patients undergoing laparoscopic prostate resection.  In this study two groups of patients were compared: Patients who were ventilated with an LTS II and patients who were ventilated with a concentional tracheal tube. ";"The laryngeal tube suction II (LTS II) is a supraglottic airway device (SAD) with a gastric drainage tube and enhanced seal properties when compared to other SAD. Therefore, it is in use in prehospital emergency airway management and has been proposed in situations with an elevated risk for aspiration. In the presented study we investigated the safety and efficacy of airway management and controlled mechanical ventilation with a LTS II in comparison with endotracheal intubation (ET) for radical endoscopic prostate surgery. In 28 patients who were randomized for LTS II the device had to be switched to ET mainly due to airway leakage and problems with mechanical ventilation. Additionally, we detected engorgement in 3 patients and a higher but not significant incidence of severe sore throat in the LTS II group. We therefore concluded that LTS II should not be used for airway management in patients undergoing radical endoscopic prostate surgery. ";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"[---]*";"Eur J Anaesthesiol. 2016 Oct 27. [Epub ahead of print]";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00008985";"2017-02-28T13:22:50.942+01:00";
"DRKS00010738";2016/07/15;"[---]*";yes;"Approved";"2016-33";"Ethikkommission der Medizinischen Fakultät der Martin-Luther-Universität Halle Wittenberg";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2015-002602-36";"[---]*";;;;;;;;;;;;;"ICD10";"H91";"Other hearing loss";;;;;;;;;;;;;"Arm 1";"Prednisolone, 250 mg/day i.v., for 5 days (+ Placebo p.o. 10 days)";"Arm 2";"Dexamethasone, 40 mg/day p.o., for 5 days (+ Placebo i.v. 5 days/ p.o. 5 days)";"Arm 3";"Prednisolone, 60 mg/day  p.o., für 5 days & Prednisolone in tapering doses (2 x 40 mg and 3 x 20 mg), for 5 days (+ Placebo i.v. in the first 5 days)";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)";"Treatment";"Parallel";"II-III";"Yes";"Average change in hearing thresholds (pure-tone average of the 3 most affected contiguous frequencies)";"-average change in pure tone hearing level (3PTA0,5-2kHz [Fletcher- Typ] und 4PTA0,5-4kHz) 30 days after enrolment<br/>-percentage of patients with complete, partial or no improvement of hearing<br/>-average change in percentage of ear-specific masked monosyllabic words understood correctly at 65 and 80 dB SPL<br/>-patient self evaluation, quality of life and communication competence (patient questionnaires SF-12, HHIE)<br/>-percentage of patients needing a hearing aid/ cochlear implant<br/>-percentage of patients with new or worsened arterial hypertension at day 5 (office blood pressure >140 mmHg syst. or >90 mmHg diast. or both)<br/>-percentage of patients with altered glucose tolerance at day 5 (to be detected by HOMA-IR)<br/>-need for rescue therapy<br/>-occurrence and extent of tinnitus one and six month after enrolment";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Halle Saale";"University Medical Center";"[---]*";"Jena";"Medical Center";"[---]*";"Berlin";"Medical Center";"[---]*";"Gera";"University Medical Center";"[---]*";"Regensburg";"University Medical Center";"[---]*";"Magdeburg";"University Medical Center";"[---]*";"Greifswald";"Medical Center";"[---]*";"Dessau";"Medical Center";"[---]*";"Nordhausen";"University Medical Center";"[---]*";"Lübeck";"Medical Center";"[---]*";"Stuttgart";"University Medical Center";"[---]*";"Bochum";"Medical Center";"[---]*";"Halberstadt";"University Medical Center";"[---]*";"Leipzig";"University Medical Center";"[---]*";"Ulm";"University Medical Center";"[---]*";"Freiburg im Breisgau";"Doctor's Practice";"[---]*";"Starnberg";"University Medical Center";"[---]*";"Essen";"Medical Center";"[---]*";"Bad Lippspringe";"University Medical Center";"[---]*";"Rostock";2016/11/28;"Actual";"312";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"80";"Years";"-female and male adults (18-80 years)<br/>-unilateral sensorineural hearing loss<br/>-sudden onset of hearing loss (occurring within 24 hours)<br/>-unknown etiology (no other ear or CNS disease)<br/>-change in hearing threshold due to ISSHL of 30 dB or higher compared to a pre-event audiogram, the audiogram of the unaffected ear, or the ISO) for the 3 most affected contiguous frequencies in the affected ear but not less then 50 dB absolute threshold as average of the 3 most affected contiguous frequencies between 0,25 und 8 kHz <br/>-enrolment and treatment within 7 days from onset";"-recurrent ISSHL at the affected side (< 12 months)<br/>-known other otologic cause of ISSHL (e.g.: middle ear disease; vestibular schwannoma; known fluctuating hearing loss; Meniere’s disease) <br/>-absolute hearing threshold as average of the 3 most affected contiguous frequencies between 0,25 und 8 kHz < 50 dB HL <br/>-certain systemic diseases (treatment for or chronically active infection such as HIV, hepatitis C or B, tuberculosis, hard to balance diabetes mellitus, ongoing immunosuppressive treatment for rheumatic or chronic inflammatory disease, unstable atherosclerotic disease, heart failure >NYHA II, suicidality, severe osteoporosis, active peptic ulcer, uncontrolled (syst. >180 mmHg or diast. >100 mmHg) arterial hypertension) <br/>-treated mental disorders or after surgical interventions in the last 6 weeks: inclusion only after critical evaluation by the investigator <br/>-pre-treatment of ISSHL with glucocorticosteroids or hyperbaric oxygen <br/>-conductive deafness (air-bone gap 4PTA0,5-4kHz >10 dB)<br/> -pregnancy or lactation";"Primary Sponsor";"Martin-Luther-Universität Halle-Wittenberg";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"06097";"Halle (Saale)";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie";"Mr.";"Prof.";"Stefan";"Plontke";"Ernst-Grube-Str. 40";"06120";"Halle (Saale)";"Germany";"+49 3455571784";"[---]*";"stefan.plontke@uk-halle.de";"[---]*";"Contact for Public Queries";"Universitätsklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie oder Prüfärzte am jeweiligen Standort,";"Mr.";"Prof.";"Stefan";"Plontke";"Ernst-Grube-Str. 40";"06120";"Halle (Saale)";"Germany";"+49 3455571784";"[---]*";"stefan.plontke@uk-halle.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Bundesministerium für Bildung und Forschung ";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.bmbf.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Efficacy and safety of high dose glucocorticosteroid treatment for<br/>idiopathic sudden sensorineural hearing loss";"HODOKORT";"http://hodokort-studie.hno.org/";"According to recent studies, in Germany the annually cases of sudden idiopathic sensorineural hearing loss has been estimated to be 160 to 400 per 100.000. Idiopathic sudden sensorineural hearing loss (ISSHL) is one of the most frequent causes of sensorineural hearing loss. Although sensorineural hearing impairment can be partially compensated by hearing aids (HA) or cochlear implants (CI), hearing without these aids is better with respect to sound quality and communication ability. In addition, tremendous costs for society are associated with communication disorders in general and with both aids, specifically. Systemic steroids are widely used worldwide as standard of care for primary therapy of ISSHL. However, scientific data did not demonstrate a clear efficacy of any of these therapies. The German ISSHL-Guideline recommends high dose steroid (250mg Prednisolone or equivalent steroid dose) for primary therapy of ISSHL, which has not been proven so far in high-quality scientific studies. This three-armed trial is aimed to compare standard dose with two types of high-dose steroids for systemic therapy with respect to their efficacy in improving hearing, and thus communication ability in patients with idiopathic sudden sensorineural hearing loss. It is to be tested, if high-dose treatments show superiority as compared to standard treatment.<br/>In the course of a protocol amendment, the following changes were made in October 2017: - adjustment or clarification of the inclusion / exclusion criteria. The amendment was approved by the ethics committee of the Medical Faculty of the Martin-Luther-University Halle Wittenberg on 05.10.2017.";"According to recent studies, in Germany the incidence of sudden idiopathic sensorineural hearing loss has been estimated to be 160 to 400 per 100.000. Idiopathic sudden sensorineural hearing loss (ISSHL) is one of the most frequent causes of sensorineural hearing loss. Although sensorineural hearing impairment can be partially compensated by hearing aids (HA) or cochlear implants (CI), generic hearing is better with respect to sound quality and communication ability. In addition, tremendous costs for society are associated with communication disorders in general and with both, HAs and CI, specifically. Systemic steroids are widely used worldwide as standard of care for primary therapy of ISSHL. However, their assessment in reviews, meta-analysis and RCTs did not demonstrate a clear efficacy of any of these therapies. The German ISSHL-Guideline recommends high dose steroid (250mg Prednisolone or equivalent steroid dose) for primary therapy of ISSHL, which has not been proven so far in RCTs. The rationale for the treatment of ISSHL using high dose steroids is only based on retrospective cohort studies. This three-armed trial is aimed to compare standard dose with two types of high-dose steroids for systemic therapy with respect to their efficacy in improving hearing, and thus communication ability in patients with idiopathic sudden sensorineural hearing loss.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010738";"2020-05-07T13:20:00.580+02:00";
"DRKS00004128";2012/10/12;2010/03/31;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01097707";"ClinicalTrials.gov";"Sponsor-ID";"10373";"Eli Lilly and Company";"Other Secondary-ID";"I1A-MC-BPAE";"[---]*";;;;;;;"Free text";"[---]*";"Benign Prostatic Hyperplasia";"ICD10";"N40";"Hyperplasia of prostate";;;;;;;;;;"Arm 1";"Drug: LY500307";"Arm 2";"Drug: Placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"II";"[---]*";"- Change from baseline to 24 week endpoint in International Prostate Symptom Score (IPSS) total score; time frame: Baseline, 24 weeks<br/>";"- Change from baseline to 24 week endpoint in Total Prostate Volume (TPV); time frame: Baseline, 24 weeks<br/>- Change from baseline to 24 weeks endpoint in Peak Urinary Flow Rate (Qmax); time frame: Baseline, 24 weeks<br/>- Change from baseline to 24 week endpoint in International Prostate Symptom Score-Quality of Life Index (IPSS-QoL); time frame: Baseline, 24 weeks<br/>- Change from baseline to 24 week endpoint in International Prostate Symptom Score storage, voiding and nocturia subscores; time frame: Baseline, 24 weeks<br/>- Change from baseline to 24 week endpoint in Prostate Specific Antigen (PSA); time frame: Baseline, 24 weeks<br/>- Change in fasting total testosterone; time frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28-32 weeks<br/>- Change in Lipid Profile; time frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28-32 weeks<br/>";"US";"United States";"AU";"Australia";"CA";"Canada";"FR";"France";"DE";"Germany";"GR";"Greece";"IT";"Italy";"RU";"Russian Federation";;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Bad Bergzabern";"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Berlin";"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Hamburg";"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Holzminden";"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Marburg";"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Oranienburg";"[---]*";"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.";"Reutlingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/04/30;"[---]*";"414";2011/10/01;"Multicenter trial";"International";"Male";"45";"Years";"[---]*";"no maximum age";"-  Present at screening with a history of BPH for >6 months.<br/><br/>          -  Have an IPSS greater than or equal to 13 at screening.<br/><br/>          -  Have a Total Prostate Volume by Transrectal ultrasound greater than or equal to 30 mL<br/>             at screening.<br/><br/>          -  Show signs of bladder outlet obstruction as defined by a peak urinary flow rate<br/>             (Qmax) greater than or equal to 4 and less than or equal to 15 mL/sec (from a prevoid<br/>             total bladder volume [assessed by ultrasound] of greater than or equal to 150 to less<br/>             than or equal to 550 ml and a minimum voided volume of 125 ml) at screening.<br/><br/>          -  Have a PSA greater than or equal to 1.4 and less than or equal to 10 ng/mL at<br/>             screening.<br/><br/>          -  Demonstrate a Post Void Residual less than or equal to 300 mL by ultrasound at<br/>             screening.<br/><br/>          -  Have not received the following treatments within the specified time period:<br/><br/>               1. Finasteride or dutasteride for at least 6 months prior to screening.<br/><br/>               2. Any alpha-adrenergic antagonists for at least 4 weeks prior to screening.<br/><br/>               3. Any other non-experimental BPH therapy (including an herbal preparation) for at<br/>                  least 4 weeks prior to screening.<br/><br/>               4. Any other experimental or off-label BPH therapy such as injectable therapies<br/>                  with a protracted effect for at least 6 months prior to screening.<br/><br/>               5. Any overactive bladder treatment for at least 4 weeks prior to screening.<br/><br/>               6. Any Erectile Dysfunction treatment which may include oral phosphodiesterase type<br/>                  5 inhibitors or devices for at least 4 weeks prior to screening.<br/><br/>          -  Have a morning fasting Total Testosterone concentration greater than or equal to 300<br/>             ng/dL at screening.<br/><br/>          -  If hyperlipidemic, based on history, be on stable statin treatment as determined by<br/>             the investigator for at least 2 months prior to screening.<br/>";"-  Have completed or withdrawn from this study or have completed or withdrawn from any<br/>             other study investigating LY500307.<br/><br/>          -  Have any history of BPH-related invasive procedures (for example, Transurethral<br/>             Resection of the Prostate, open prostatectomy, and minimally invasive procedures that<br/>             include thermal-based therapies, transurethral microwave treatment, transurethral<br/>             needle ablation, and stents).<br/><br/>          -  Have active cardiovascular disease as evidenced by the following:<br/><br/>               1. Recent Myocardial infarction, unstable angina, stroke or Transient ischemic<br/>                  attach within 6 months of screening.<br/><br/>               2. Recent coronary intervention that includes coronary artery bypass surgery,<br/>                  percutaneous coronary artery intervention, or stent placement within 6 months of<br/>                  screening.<br/><br/>               3. Recent history of positive stress tests without any written documentation of<br/>                  effective intervention within 6 months of screening.<br/><br/>               4. Evidence of heart disease categorized as greater than or equal to Class III<br/>                  functional classification of NYHA within 6 months of screening.<br/><br/>          -  Have known or suspected history of prostate cancer, breast cancer, or other<br/>             clinically significant neoplastic disease (other than squamous cell or basal cell<br/>             carcinoma of skin).<br/><br/>          -  Have a history of deep venous thrombosis or pulmonary embolism disease.<br/><br/>          -  Have moderate to severe renal insufficiency.<br/><br/>          -  Have a hemoglobin A1c (HbA1c) greater than 9.0%.<br/><br/>          -  Are on testosterone replacement therapy, or drugs that influence the<br/>             hypothalamus-pituitary-gonadal axis.<br/><br/>          -  Are on pharmacological treatment other than statins for hyperlipidemia.<br/>";"Primary Sponsor";"Eli Lilly and Company";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Eli Lilly and Company";"[---]*";"[---]*";"[---]*";"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Eli Lilly and Company";"[---]*";"[---]*";"[---]*";"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)";"[---]*";"[---]*";"The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic<br/>      Hyperplasia (BPH)<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004128";"2016-01-26T15:30:03.015+01:00";
"DRKS00003674";2012/05/08;2009/10/14;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2009-013435-38";"[---]*";"Primary Registry-ID";"NCT01009593";"ClinicalTrials.gov";"Sponsor-ID";"M10-963";"Abbott";"Other Secondary-ID";"2009-013435-38";"[---]*";;;;"Free text";"[---]*";"Hepatocellular Carcinoma Non-resectable";"Free text";"[---]*";"Hepatocellular Carcinoma Recurrent";"Free text";"[---]*";"Carcinoma, Hepatocellular";"Free text";"[---]*";"Liver Diseases";"Free text";"[---]*";"Neoplasms by Histologic Type";"Arm 1";"Drug: ABT-869";"Arm 2";"Drug: Sorafenib";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Overall Survival; time frame: From randomization until patient death; assessed monthly<br/>";"- Time To Progression (TTP); time frame: From randomization until patient progression; assessed every 6 weeks<br/>- Overall Response Rate (ORR); time frame: Assessed Every 6 weeks<br/>";"US";"United States";"AR";"Argentina";"AU";"Australia";"AT";"Austria";"BE";"Belgium";"CA";"Canada";"CL";"Chile";"CN";"China";"CZ";"Czech Republic";"DK";"Denmark";"EG";"Egypt";"FR";"France";"DE";"Germany";"GR";"Greece";"HK";"Hong Kong";"IT";"Italy";"JP";"Japan";"KR";"Korea, Republic of";"MY";"Malaysia";"MX";"Mexico";"[---]*";"Site Reference ID/Investigator# 23267";"Berlin";"[---]*";"Site Reference ID/Investigator# 23845";"Bochum";"[---]*";"Site Reference ID/Investigator# 23266";"Frankfurt am Main";"[---]*";"Site Reference ID/Investigator# 23268";"Freiburg";"[---]*";"Site Reference ID/Investigator# 23269";"Mainz";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/01/31;"[---]*";"1100";2012/07/01;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Inclusion Criteria<br/><br/>          -  Histologic or cytologic diagnosis with unresectable or metastatic HCC<br/><br/>          -  Child Pugh Class A<br/><br/>          -  ECOG performance status 0-1<br/><br/>          -  Adequate hematologic, hepatic, and renal function<br/><br/>       ";" Exclusion Criteria<br/><br/>          -  Prior systemic (administered intravenously or orally rather than locoregionally)<br/>             treatment for HCC<br/><br/>          -  Prior local therapy (including liver-directed therapy) within 4 weeks from entry<br/><br/>          -  Untreated brain or meningeal metastases<br/><br/>          -  Current treatment on another clinical trial<br/><br/>          -  Pregnancy or breastfeeding<br/>";"Primary Sponsor";"Abbott";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Abbott";"[---]*";"[---]*";"[---]*";"Justin Ricker, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Abbott";"[---]*";"[---]*";"[---]*";"Justin Ricker, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)";"[---]*";"[---]*";"The primary objective of this study is to assess the overall survival (OS) of oral linifanib<br/>      given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per<br/>      standard of care in subjects with advanced or metastatic HCC.<br/>";"The IDMC recommended discontinuation of the study, and, the protocol was amended to end<br/>      study treatment.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003674";"2017-10-30T16:49:16.356+01:00";
"DRKS00011761";2017/02/20;2016/10/30;yes;"Approved";"S-264/2016";"Ethik-Kommission I der Medizinischen Fakultät Heidelberg";"Primary Registry-ID";"NCT02948764";"clinicaltrials.gov";;;;;;;;;;;;;"ICD10";"C50.0";"Malignant neoplasm: Nipple and areola";"ICD10";"C50.8";"Malignant neoplasm: Overlapping lesion of breast";;;;;;;;;;"Arm 1";"single arm study: the vacuum assisted biopsy (VAB, = index test) as well as the surgery (=reference test) will both be performed on every patient";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Other";"Blinded";"Other";"Diagnostic";"Other";"N/A";"No";"Primary endpoint is the false negative rate (=FNR). The false negative rate (FNR) will be calculated as the quotient of the number of cases with “pCR in VAB” and residual tumor in surgical specimen (false negative VAB results), divided by the total number of cases with residual tumor in surgical specimen in the cohort of the confirmatory primary outcome analysis. The primary endpoint will be assessed the pathologic report (comparison of pathologic result of the biopsy with the pathological result of surgical specimen).";"Negative predictive value (NPV), positive predictive value (PPV), sensitivity, specificity. The secondary endpoints will be analysed descriptively for the whole cohort and different subgroups: (1) Tumor biology, (2) clinical response, (3) assessment of representiveness, (4) trial sites, (5) guidance method (mammography / ultrasound).";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsfrauenklinik";"Ulm";"Medical Center";"Brustzentrum Bielefeld-Herford / Operativer Standort Franziskus Hospital Bielefeld";"Bielefeld";"University Medical Center";"Universitäts-Frauenklinik Rostock am Klinikum Südstadt Rostock";"Rostock";"University Medical Center";"Brustzentrum der Technischen Universität München";"München";"University Medical Center";"Department für Frauengesundheit Tübingen";"Tübingen";"University Medical Center";"Klinikum der LMU München";"München";"Medical Center";"Mammazentrum Hamburg am Krankenhaus Jerusalem";"Hamburg";"Medical Center";"AGAPLESION Markus Krankenhaus";"Frankfurt a.M.";"University Medical Center";"Brustzentrum Universitätsklinikum Köln";"Köln";"University Medical Center";"Brustzentrum am Universitätsklinikum Halle";"Halle Saale";"Medical Center";"Marienhospital";"Witten";"University Medical Center";"Brustzentrum der Universitätsfrauenklinik Heidelberg";"Heidelberg";"University Medical Center";"Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin";"Berlin";"University Medical Center";"Schleswig- Holstein, Campus Lübeck";"Lübeck";"University Medical Center";"Universitätsfrauenklinik Kiel";"Kiel";"Medical Center";"Klinikum Frankfurt Höchst";"Frankfurt a.M.";"Medical Center";"Klinik für Senologie, Klinik Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH";"Essen";"Medical Center";"VISIORAD";"Pinneberg";;;;;;;2017/03/08;"Actual";"600";"[---]*";"Multicenter trial";"National";"Female";"18";"Years";"[---]*";"no maximum age";"Female patients with primary breast cancer after Neoadjuvant Chemotherapy (NACT) treatment<br/>which has been performed for at least 12 weeks and resulted in cPR or cCR (see below); <br/><br/>>/=18 years; <br/><br/>any cT and cN stage, except cT4 stages; <br/><br/>any routine breast cancer surgical intervention planned according to guidelines (breast<br/>conservation or mastectomy); <br/><br/>residual intramammary target lesion or clip marker is visible in ultrasound and / or mammography; <br/><br/>diagnosis of imaging complete or partial response according to RECIST 1.1 by at least<br/>mammography or ultrasound, according to local routine); <br/><br/>inclusion of only one breast per patient, in bilateral cancer one breast can be included; <br/><br/>in case of multicentric disease: confirmation of the same tumorbiological subtype defined by<br/>immunohistology in at least 2 lesions; <br/><br/>ability of subject to understand character and individual consequences of the clinical trial; <br/><br/>written informed consent (must be available before enrolment in the trial)<br/>";"palliative or recurrent breast cancer; <br/><br/>in case of clip marker = target lesion: dislocation of marker (>5mm distance to the initial lesion<br/>border at the time of clip placement); <br/><br/>contraindication for VAB or associated procedures (e.g. local anesthesia); <br/><br/>pregnancy and lactation; <br/><br/>held in an institution by legal or official order; <br/><br/>legally incapacitated";"Primary Sponsor";"Universitätsklinikum Heidelberg";"[---]*";"[---]*";"[---]*";"[---]*";"Im Neuenheimer Feld 672";"69120";"Heidelberg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Brustzentrum der Universitätsfrauenklinik Heidelberg";"Mr.";"Professor";"Jörg";"Heil";"Im Neuenheimer Feld 440";"69120";"Heidelberg";"Germany";"+49 6221 567906";"+49 6221 5633681";"joerg.heil@med.uni-heidelberg.de";"[---]*";"Contact for Public Queries";"Brustzentrum der Universitätsfrauenklinik Heidelberg";"Mr.";"Professor";"Jörg";"Heil";"Im Neuenheimer Feld 440";"69120";"Heidelberg";"Germany";"+49 6221 567906";"+49 6221 5633681";"joerg.heil@med.uni-heidelberg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"RESPONDER Trial - Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy after Neoadjuvant Chemotherapy in Breast Cancer";"[---]*";"/";"Chemotherapy before surgery (=neoadjuvant chemotherapy, NACT) is nowadays a standard therapeutical approach in many breast cancer cases. Due to improved medicines, many tumors respond increasingly well to this therapy. Thus, chemotherapy even leads to a complete eradication of the tumor (= pathological complete response, pCR) with increasing frequency. <br/><br/>Unfortunately, it is still not possible to diagnose such a complete tumor remission after the neoadjuvant chemotherapy and before surgery. At present, surgery is therefore indispensable for a reliable diagnosis. However, the question arises whether surgery is still necessary for the therapy of the cancer in cases of complete tumor remission. In order to study this question further, another reliable, diagnostic method needs to be developed.<br/><br/>We carried out different studies on this subject at the Department of Gynecology of the University Hospital Heidelberg. Those showed exceptionally good results for the so-called vacuum-assisted biopsy. We now aim to confirm those preliminary results in a national trial including 600 patients. According to the study design, a vacuum-assisted biopsy will be performed on participants after neoadjuvant chemotherapy and before surgery. As we aim to evaluate the diagnostic accuracy of the vacuum-assisted biopsy, the resulst of the histopathological evaluation of the biopsy specimen will be compared to the results of the evaluation of the surgical specimen.<br/><br/>Potential participants of the study are patients with breast cancer treated by neoadjuvant chemotherapy and showing either complete or partial response in clinical examination.";"Chemotherapy before surgery (=neoadjuvant chemotherapy, NACT) is increasingly used in breast cancer treatment. Moreover, a pathological complete response (pCR) in the breast (=ypT0), meaning that no tumor cells are present after NACT, is achieved with increasing frequency. This scenario provokes the widely debated issue if local treatment (surgery and / or radiotherapy) is actually beneficial in patients with pCR. Should those procedures prove not to serve any therapeutic purpose, patients deserve to be spared its’ potential, negative effects. <br/><br/>However, before this question regarding the therapeutic benefit of local treatment can be investigated, it is essential that a reliable diagnosis of a pCR is possible without the histopathological evaluation of the surgical specimen. Up to date, imaging methods as ultrasound, mammography, or breast MRI do not provide us with a valid prediction of a pCR. <br/><br/>This multicenter, confirmative, clinical trial aims to confirm that a pCR after NACT can be validly diagnosed by using vacuum-assisted, minimal invasive biopsy techniques (VAB). The VAB will be performed after NACT and before standard surgical treatment. The study will include 600 patients with at least partial response in breast imaging in order to confirm that less than 5% of the patients with a residual after NACT are falsely classified as having no residual tumor (=pCR) by the VAB. <br/><br/>";"Recruiting stopped after recruiting started ";"trial protocol (mandatory for transfer to Studybox)";"7d5aa5f7-7dbd-4ba2-afd1-8c8623091b32";"20161118_Trial protocol_RESPONDER_final_V4.0_final_clean.pdf";"Studienprotokoll, öffentlich sichtbar";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011761";"2019-06-03T13:05:08.335+02:00";
"DRKS00004455";2012/10/11;"[---]*";yes;"Approved";"79/12";"Ethik-Kommission der Universität Ulm";"EudraCT-Number<br/>(for studies acc. to Drug Law)";"2011-006250-90";"[---]*";"BfArM-No.";"4038111";"[---]*";;;;;;;;;;"ICD10";"C73";"Malignant neoplasm of thyroid gland";;;;;;;;;;;;;"Arm 1";"Oral intake of 400 mg Sorafenib (Nexavar) bid  (2 x 2 tbl./d) until disease progression or unacceptable toxicity. Afterwards follow-up for overall survival.";"Arm 2";"Oral intake of Placebo bid (2 x 2 tbl./d) plus best supportive care until documented disease progression.  After unblinding subjects will receive Sorafenib 400 mg bid (2 x 2 tbl./d) until further disease progression. Afterwards follow-up for survival.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Double or multiple blind";"Placebo";"Treatment";"Parallel";"II";"N/A";"Progression-free survival (PFS) measured as time from randomization to disease progression or death based on RECIST v1.1 evaluation or based on Tumour marker progress (CEA or calcitonin) in the first section of the study between the sorafenib treated patients and the placebo group (prior to cross-over to sorafenib).";"Secondary endpoints are the comparisons of sorafenib and placebo group (for each tratment period - both after randomisation and after cross-over) with regard to:<br/>•	Time To Progression (TTP)<br/>•	DCR (CR + PR + SD rate) in first period of the study before cross-over<br/>•	Overall Response Rate (ORR = CR rate + PR rate) in first period<br/>•	Response duration in first period<br/>•	Overall Survival (OS)<br/>•	PFS after cross-over (only descriptive analysis)<br/>•	TTP after cross-over<br/>•	DCR after cross-over <br/>•	Overall Response Rate (ORR = CR rate + PR rate) after cross-over<br/>•	Safety<br/>•	Patient reported outcomes (PROs), defined as health-related quality of life  (FACT-G and EQ-5D)";"DE";"Germany";"AT";"Austria";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik für Nuklearmedizin, Klinik für Innere Medizin";"Ulm";"University Medical Center";"Klinik für Innere Medizin";"Aachen";"University Medical Center";"Klinik für Endokrinologie und Stoffwechselerkrankungen";"Essen";"University Medical Center";"Medizinische Klinik I";"Heidelberg";"University Medical Center";"Klinik und Poliklinik für Nuklearmedizin";"Würzburg";"University Medical Center";"Medizinische Klinik und Poliklinik II/Endokrinologie";"München";"Medical Center";"The Royal Marsden NHS Foundation Trust, Head and Neck Unit";"Surrey";"Medical Center";"Krankenhaus Barmherzige Schwestern, Klinik für Nuklearmedizin";"Linz";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/10/19;"Planned";"110";2013/04/22;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"•	Histologically confirmed medullary thyroid carcinoma (C-cell thyroid carcinoma)<br/>•	Recurrent or persistent local disease and/or distant metastases not suitable for local curative treatment (surgery or radiation therapy) assessed by Investigator<br/>•	No more than one prior line of systemic therapy (including no more than 1 prior line with a targeted drug, e.g. kinase inhibitor)<br/>•	Best available supportive care to control (endocrine) symptoms according to current standards established for at least 8 weeks before study entry  <br/>•	At least one defined lesion in CT or MRI evaluable for RECIST (v1.1), no older than 42 days from planned treatment start, or at least one defined lesion in CT or MRI not evaluable by RECIST in combination with elevated tumour markers with minimum initial levels of 150 pg/ml for calcitonin or 5 x UILN for CEA (e.g., in case of bone metastases)<br/>•	Progression within previous 12 months (according to RECIST 1.1 criteria or tumour marker progression (calcitonin or CEA referred to normal Reference Ranges from Site Lab) can be used as a basis for the assessment of disease progression); tumour marker doubling time must be no longer than 12 months (30) and a minimum initial level of 150 pg/ml for calcitonin or 5 x UILN for CEA, respectively, need to be present. The tumour marker doubling time should be estimated using the calculator at the ATA-website: http://www.thyroid.org/professionals/calculators/CDTC.php <br/>•	Hb > 8g/dl, WBC >3.000 cells/mm³ (ANC > 1.500 cells/mm³), platelets > 100.000 cells/mm³, bilirubin < 2mg/dl, Alanine aminotransaminase (ALT) and Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (referred to normal Reference Ranges from Site Lab)<br/>•	Performance status: WHO ≤ 2; Karnofsky index ≥ 50%<br/>•	Patients should have sufficient renal function, as determined by serum creatinine <1.5 mg/dl and CrCL > 30ml/min<br/>•	PT-INR and PTT < 1.5 x upper limit of normal (referred to normal Reference Ranges from Site Lab) [Patients who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]<br/>•	No acute infections at the time of therapy initiation <br/>•	Staging studies (MRT or CT and Calcitonin or CEA) completed within four weeks of protocol randomisation<br/>•	Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. <br/>•	Women and men of childbearing potential must agree to use adequate contraception (barrier method of birth control) <br/>•	Patient is able to understand the study procedures, voluntarily agrees to participate in the study and has given a signed and dated written informed consent prior to study participation.<br/>";"•	Unresolved toxicity (i.e. neurotoxicity) attributed to any prior therapy higher than NCI-CTCAE (version 4) Grade 2 (excluding cases of alopecia)<br/>•	Patients with history of allergic or hypersensitivity reaction to study drug or placebo or their excipients or with a history of allergic reactions attributed to compounds with similar composition to any of the study drug or placebo.<br/>•	Current participation in another investigational trial <br/>•	Patients with significant cardiovascular disease, such as myocardial infarction < 6 months, unstable coronary artery disease (anginal symptoms at rest), new-onset angina within 3 months before randomization, or chronic heart failure (New York Heart Association grade III or IV)<br/>•	Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy other than beta-blockers or digoxin<br/>•	Congenital long QTc syndrome, history of drug induced QTc prolongation, or QTc interval unmeasurable or more than 450 ms<br/>•	Abnormal serum electrolytes such as potassium, magnesium and calcium<br/>•	Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal management<br/>•	Major surgery, open biopsy, or significant traumatic injury within 30 days prior to randomization<br/>•	Non-healing wound, ulcer, or bone fracture<br/>•	Evidence or history of bleeding diathesis or coagulopathy disorder<br/>•	Hemorrhage/bleeding event ≥ Grade 3 within 3 months prior to first dose of study drug<br/>•	Thrombotic or embolic events including transient ischemic attacks within the past 6 months<br/>•	Subjects with symptomatic brain metastases or Subjects with brain metastases under corticosteroid treatment. Previous or concurrent cancer that is distinct in primary site or histology from thyroid cancer within 5 years prior to randomization EXCEPT cervical cancer in situ, treated basal cell carcinoma and superficial bladder tumours [Ta (Non invasive tumour), Tis (Carcinoma in situ) and T1 (Tumour invades lamina propria)] <br/>•	Pregnant or breast-feeding patients<br/>•	Patients with uncontrolled infections <br/><br/>•	Known human immunodeficiency virus (HIV) infection or infection with hepatitis B or C<br/>•	Immunosuppression<br/>•	Subjects with seizure disorder requiring medication (such as steroids or anti¬epileptics)<br/>•	Subjects undergoing renal dialysis<br/>•	Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results<br/>•	Any malabsorption condition<br/>•	Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study";"Primary Sponsor";"EANM Forschungs GmbH/ EANM Research Ltd.";"Ms.";"M.A.";"Andrea";"Bauer";"Hollandstraße 14 / Mezzanine";"A-1020";"Wien";"Austria";"+43 1212 8030";"+43 2121 80309";"earl@eanm.org";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum Ulm<br/>Klinik für Nuklearmedizin";"Mr.";"Prof. Dr. med.";"Markus";"Luster";"Albert-Einstein-Allee 23";"D-89081";"Ulm";"Germany";"+49 731 500 61357";"+49 731 500 61309";"markus.luster@uniklinik-ulm";"[---]*";"Contact for Public Queries";"ABX-CRO GmbH";"Mr.";"Dipl.-Med.";"Ingo";"Weigmann";"Blasewitzer Straße 78 - 80";"D-01307";"Dresden";"Germany";"+49 351 21444 277";"+49 351 21444 15";"weigmann@abx-cro.com";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Private sponsorship (foundations, study societies, etc.)";"EANM Forschungs GmbH / EANM Research Ltd.";"Ms.";"M.A.";"Andrea";"Bauer";"Hollandstraße 14 / Mezzanine";"A-1020";"Wien";"Austria";"+43 1212 8030";"+43 2121 80309";"earl@eanm.org";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Randomized, double-blind, placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).";"[---]*";"[---]*";"The aim of this study is to evaluate the effectiveness and safety of the drug sorafenib in patients with medullary thyroid carcinoma (MTC) when administered over multiple treatment cycles. The extent to which sorafenib can inhibit the progress of the disease is of particular importance. Furthermore, the tolerability and the effect of sorafenib on quality of life are examined. ";"This is a randomized, double-blind, placebo controlled, multicentre, phase II study designed to evaluate the efficacy and safety of Sorafenib versus placebo in subjects with locally advanced, defined as recurrent, persistent and/or metastatising medullary thyroid cancer. 110 subjects will be randomized to receive either Sorafenib or placebo in a blinded fashion. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004455";"2013-05-16T14:02:48.548+02:00";
"DRKS00012546";2017/07/17;"[---]*";yes;"Approved";"46_17 B";"Ethik-Kommission der Friedrich-Alexander-Universität Erlangen-Nürnberg";;;;;;;;;;;;;;;;"ICD10";"I20-I25";"Ischaemic heart diseases";"ICD10";"F30-F39";"Mood [affective] disorders";;;;;;;;;;"Arm 1";"Participants receive treatment as usual and immediately access to a guided (e-coach; trained psychologists) internet- and mobile-based cognitive-behavioral selfhelp-programm against depression; the program consists of 7 lessons, 6 out of 9 optional lessons and one booster session after four weeks; participants work on 1-2 lessons per week and will receive feedback after each lesson by e-coaches (trained psychologists); main components of the program include psychoeducation, behavioural activation, problem solving and cognitive restructuring.";"Arm 2";"waitlist control group: participants will receive standard care and get access to the same program as the intervention group after a waiting time (ca. 2 months); participants in the waitlist control group will work on the program without guidance.";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Control group receives no treatment";"Treatment";"Parallel";"N/A";"N/A";"feasibility: recruitment strategies (quantification of recruitmentstrategies, drop-out) acceptance (ZUF-8 , time of measurement: T2, adverse events (INEP , time of measurement: T2(=2 months after randomization), adherence (discontinuation rate, time of measurement: T2)<br/><br/>T2=2 months after randomisation";"depressive symptom severity (PHQ-9, T1 and T2), anxiety  severity (GAD-7, T1 and T2), quality of life (AQoL, T1 and T2) and fear of progression (PA-F, T1 and T2), disease-specific strains (CSS-classification (questionnaire (=self-report), T1 and T2)<br/><br/>T1=Measurement after screening (T0)<br/>T2=2 months after randomisation";"DE";"Germany";"AT";"Austria";"CH";"Switzerland";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"other";"[---]*";"Online";"Medical Center";"Rehabilitationseinrichtungen, Beratungsstellen, Praxen";"Baden-Württemberg, Bayern, Niedersachsen";"other";"Fachgesellschaften, Vereine";"Deutschland, Österreich, Schweiz";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/06/21;"Actual";"50";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"diagnosis of a coronary artery disease, <br/>PHQ-9 score ≥ 5;<br/>access to internet";"Acute suicidality; concurrent or life-time diagnosis of schizophrenia, psychosis or bipolar disorder";"Primary Sponsor";"Abteilung für klinische Psychologie und Psychotherapie, Institut für Psychologie und Pädagogik,Universität Ulm, Deutschland";"Mr.";"Prof. Dr.";"Harald";"Baumeister";"Albert-Einstein-Allee 47";"89069 Ulm";"Ulm";"Germany";"[---]*";"[---]*";"harald.baumeister@uni-ulm.de";"https://www.uni-ulm.de/in/psy-klips/";"Contact for Scientific Queries";"Abteilung für klinische Psychologie und Psychotherapie, Institut für Psychologie und Pädagogik,Universität Ulm";"Ms.";"M.Sc.";"Eileen";"Bendig";"Albert-Einstein-Allee 47";"89069";"Ulm";"Germany";"0731 5032807";"[---]*";"eileen.bendig@uni-ulm.de";"https://www.uni-ulm.de/in/psy-klips/";"Contact for Public Queries";"Abteilung für klinische Psychologie und Psychotherapie, Institut für Psychologie und Pädagogik,Universität Ulm";"Ms.";"M.Sc.";"Eileen";"Bendig";"Albert-Einstein-Allee 47";"89069";"Ulm";"Germany";"0731 5032807";"[---]*";"widecad-studie@uni-ulm.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Abteilung für klinische Psychologie und Psychotherapie, Institut für Psychologie und Pädagogik,Universität Ulm";"Mr.";"Prof. Dr.";"Harald";"Baumeister";"Albert-Einstein-Allee 47";"89069";"Ulm";"Germany";"[---]*";"[---]*";"harald.baumeister at uni-ulm.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"WIDeCAD: a guided internet- and mobile-based self-help intervention for patients facing coronary artery disease (CAD) and depression - a randomized controlled pilot trial";"WIDeCAD";"[---]*";"Many people facing coronary artery disease suffer from depression. The present study aims at evaluating the feasibility and effectiveness of an online-training against depression in patients with coronary artery disease. Participants will be randomly assigned to one of two groups. Participants can take part either immediately or after a waiting time. Different aspects of feasibility as well as changes in depression severity, anciety severity, quality of life, fear of progression as well as disease-specific risc factors as outcomes.";"Background: A strong association between coronary artery disease (CAD) and comorbid depression has been consistently reported. Depression in patients facing CAD is widespread and hightens the risk of cardiovascular morbidity and mortality. Depression is an additional burden to CAD-patients. Evidence shows that depressive symptoms worsens adherence to treatment as well as outcomes of patients with CAD. Restricted resources in the health care sector and limited improvements in relation to CAD and comorbid depression health care possibilities require innovative approaches to overcome the mental health care gap for people with CAD. The use of time- and place-independent internet- and mobile-based interventions is an innovative approach for this target group. Barriers to mental-health care are still high for patients, including mobility and stigmatization. Advantages of this innovative treatment option are high availability, low-treshold access, easy application and low perceived stigmatization. The present trial aims at evaluating the feasibility and potential effectiveness of a guided internet- and mobile-based intervention for the treatment of depression („WIDeCAD“) in patients with CAD and depressive symptoms. <br/>Methods: A parallel group randomized controlled pilot trial will be conducted. Recruitment of N=50 patients facing CAD and depressive symptoms (PHQ≥5) takes place from June to July 2017. Suitable participants will be randomly assigned to either the intervention group (n=25) or a waitlist control group (n=25). Participants in the intervention group receive immediately access to guided self-help intervention. The programm is based on cognitive-behavioral therapy and consists of seven regular sessions, a booster session and individual selectable add-on modules with different thematic focus. Participants in the waitlist control group receive standard medical care and get access to the unguided self-help intervention after the final assessment. Primary outcomes are markers of feasibility. Secondary outcomes will be assessed at baseline and post-intervention and include changes in patient-reported depressive symptoms(PHQ-9), anxiety symptoms (GAD-7), quality of life (AQol) and fear of progression (PA-F). Effectiveness will be estimated by means of intention-to-treat principle.<br/>Discussion: This study contributes evidence to the research of internet- and mobile-based interventions for patients with CAD and depression, where evidence is currently relatively scarce. Findings and data regarding feasibility and patient outcomes will inform decisions on the progression to a future definitive randomized controlled trial.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012546";"2019-11-12T06:36:44.838+01:00";
"DRKS00004090";2012/08/09;2009/11/30;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01023269";"ClinicalTrials.gov";"Sponsor-ID";"1.02.7004";"Medtronic International Trading Sarl";;;;;;;;;;"Free text";"[---]*";"Neurogenic Overactive Bladder";"Free text";"[---]*";"Urinary Incontinence";"Free text";"[---]*";"Detrusor Overactivity";"ICD10";"R32";"Unspecified urinary incontinence";"ICD10";"N32.8";"Other specified disorders of bladder";"Arm 1";"Device: InterStim Therapy";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Other";"Treatment";"Crossover";"IV";"[---]*";"- The mean difference in functional bladder capacity, as measured by the the average voiding volume per episode, between stimulation ON for 4 weeks and OFF for 4 weeks.; time frame: 8 weeks after neurostimulator implant<br/>";"- Urge Urinary Incontinence, as measured using the number of leaks or notice of leaks, will be compared between stimulation ON for 4 weeks and stimulation off for 4 weeks.; time frame: 8 weeks from neurostimulator implant<br/>";"BE";"Belgium";"FR";"France";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Marienhospital Herne, Klinikum der Ruhr-Universitaet Bochum";"Herne";"[---]*";"Klinik für Urologie Oberarzt-Sekretaria";"Tübingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/12/31;"[---]*";"17";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Incomplete upper motor neuron lesion<br/><br/>          -  Detrusor overactivity<br/><br/>          -  Two leaks or two notices of leaks per day<br/><br/>          -  Mean functional bladder capacity (volume voided per episode) of ≥100 ml<br/>";"-  Complete spinal lesion or complete bilateral lesion of sacral / pudendal nerves.<br/><br/>          -  Degenerative disease of the central nervous system<br/>";"Primary Sponsor";"Medtronic International Trading Sarl";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Ospedale Niguarda Ca' Granda, Milan, Italy";"[---]*";"[---]*";"[---]*";"Michele Spinelli, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Ospedale Niguarda Ca' Granda, Milan, Italy";"[---]*";"[---]*";"[---]*";"Michele Spinelli, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder";"ACCEPTANCE";"[---]*";"The study is designed to demonstrate that treatment with low level stimulation of the<br/>      bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.<br/>";"The Medtronic InterStim device delivers stimulation therapy for the treatment of chronic<br/>      intractable (functional) disorders of the pelvis and lower urinary or intestinal tract<br/>      through the sacral nerve or the pudendal nerve systems.<br/><br/>      This trial is designed to demonstrate that neuromodulation of the pudendal nerve will<br/>      effectively treat patients with neurogenic overactive bladder. Symptoms of urinary<br/>      incontinence are compared when stimulation is switched on for 4 weeks to stimulation<br/>      switched off for 4 weeks. After the eight week crossover period, all patients receive<br/>      treatment and are followed up within the study for 12 months post implant.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004090";"2016-01-25T15:00:54.317+01:00";
"DRKS00003807";2012/07/03;2007/05/14;yes;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2006-005970-26";"[---]*";"Primary Registry-ID";"NCT00473486";"ClinicalTrials.gov";"Sponsor-ID";"2006-005970-26";"University Hospital Muenster";"Other Secondary-ID";"KKS / INNERE_A / NSCLC2006";"[---]*";;;;"Free text";"[---]*";"Carcinoma, Non-Small-Cell Lung";"ICD10";"C34";"Malignant neoplasm of bronchus and lung";;;;;;;;;;"Arm 1";"Drug: pemetrexed, carboplatin, sorafenib";"Arm 2";"Drug: pemetrexed, carboplatin, placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo|Active control (effective treament of control group)";"Treatment";"Parallel";"I-II";"[---]*";"- Ph.1: Identify the recommended phase II dose of sorafenib for combination therapy with carboplatin and pemetrexed; time frame: July 2008<br/>- Ph.2: Compare the PFS of carboplatin/pemetrexed + sorafenib or carboplatin/pemetrexed + placebo in patients with stage IIIb or IV non-small cell lung cancer; time frame: May 2009<br/>";"- Ph.1: Determine dose limiting toxicity; time frame: July 2008<br/>- Ph 1: Determine the safety profile of the combination treatment; time frame: July 2008<br/>- Ph 1: descriptive analysis of efficacy; time frame: July 2008<br/>- Ph.2: Compare PFS of carboplatin/pemetrexed + sorafenib or carboplatin/pemetrexed + placebo in patients with stage IIIb or IV NSCLC; time frame: May 2009<br/>- Ph 2: Assess time to progression in patients treated with either regimen; time frame: May 2009<br/>- Ph 2: Determine the overall survival in patients treated with either regimen; time frame: May 2009<br/>- Ph 2: Determine the objective response rate (CR, PR), disease control rate (CR,PR,SD), time to response and duration of response; time frame: May 2009<br/>- Ph 2: Identify surrogate markers from the tumor biopsy or resection specimen from the time of diagnosis that predict response; time frame: May 2009<br/>- Ph 2: Assess Quality of Life of patients treated with either regimen; time frame: May 2009<br/>- Ph 2: Assess feasibility and toxicity profile of this regimen; time frame: May 2009<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"University of Muenster, Dept. of Medicine, Hematology / Oncology";"Muenster";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2007/05/31;"Planned";"12";2010/01/01;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Histologically or cytologically confirmed NSCLC<br/><br/>          -  Locally advanced (stage IIIB with malignant pleural or pericardial effusion)  or<br/>             metastatic (stage IV) NSCLC<br/><br/>          -  No prior systemic chemotherapy<br/><br/>          -  Prior local radiotherapy is allowed if it is completed at least 3 weeks prior to the<br/>             first dose of study medication; also concomitant palliative radiotherapy to an<br/>             existing bone lesion for pain control is allowed<br/><br/>          -  Prior surgery is allowed if it is performed at least 4 weeks prior to the first dose<br/>             of study medication and patient should be fully recovered.<br/><br/>          -  Must have measurable disease with at least one lesion with a longest diameter<br/>             measured as ≥ 2 cm with conventional techniques or as ≥ 1 cm with spiral CT<br/><br/>          -  Age ≥18 years old<br/><br/>          -  ECOG performance score (PS) 0-1<br/><br/>          -  Life expectancy of at least 12 weeks<br/><br/>          -  Adequate bone marrow, renal and hepatic function<br/><br/>               -  hemoglobin ≥ 9.0 g/dl<br/><br/>               -  absolute neutrophil count  ≥1,500/mm3<br/><br/>               -  platelet count ≥ 100,000/mm3<br/><br/>               -  total bilirubin ≤ 1.5 times the upper limit of normal<br/><br/>               -  ALT and AST ≤ 2.5 times the upper limit of normal (≤ 5 x upper limit of normal<br/>                  for patients with liver involvement)<br/><br/>               -  INR ≤ 1.5 and aPTT within normal limits<br/><br/>               -  serum creatinine ≤ 1.5 the upper limit of normal<br/><br/>          -  Patients with creatinine clearance ≥ 45 mL/min<br/><br/>          -  Not pregnant or nursing patients<br/><br/>          -  Women of childbearing potential must have a negative serum pregnancy test performed<br/>             within 7 days prior to the start of treatment<br/><br/>          -  Women of childbearing potential and men must agree to use adequate contraception<br/>             (barrier method of birth control) prior to study entry and for the duration of study<br/>             participation. Men should use adequate birth control for at least six months after<br/>             the last administration of sorafenib<br/><br/>          -  Signed informed consent prior to any study specific procedures<br/><br/>          -  Compliance and geographic proximity that allow adequate follow-up<br/>";"-  Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents,<br/>             experimental therapy (treatment within the last 30 days with a drug that has not<br/>             received regulatory approval for any indication at the time of study enrollment),<br/>             adjuvant, or neo-adjuvant therapy for NSCLC<br/><br/>          -  Any participation in a clinical trial 30 days prior to study entry and concomitantly<br/>             to the study<br/><br/>          -  Cardiac disease: Congestive heart failure > class II NYHA. Patients must not have<br/>             unstable angina (angina symptoms at rest) or new-onset angina (began within the last<br/>             3 months) or myocardial infarction within the past 6 months<br/><br/>          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy<br/><br/>          -  Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic<br/>             pressure > 90 mm Hg, despite optimal medical management<br/><br/>          -  Documented brain metastases (unless the patient is > 6 months from definitive therapy<br/>             for brain metastases, has a negative imaging study within 4 weeks of study entry and<br/>             has been off corticosteroids for at least 4 weeks before study enrolment). Brain<br/>             imaging (CT scan/MRI) is required in symptomatic patients to rule out brain<br/>             metastases, but is not required in asymptomatic patients.<br/><br/>          -  Patients with seizure disorder requiring medication (such as steroids or<br/>             antiepileptics)<br/><br/>          -  Known HIV infection or chronic hepatitis B or C<br/><br/>          -  Active clinically serious infections > CTCAE Grade 2<br/><br/>          -  Presence of clinically significant third-space fluid collections, for example,<br/>             ascites or pleural effusions that cannot be controlled by drainage or other<br/>             procedures prior to study enrolment<br/><br/>          -  Pulmonary hemorrhage/bleeding event >= CTCAE Grade 2 within 4 weeks of first dose of<br/>             study drug<br/><br/>          -  Any other hemorrhage/bleeding event > =Grade 3 within 4 weeks of first dose of study<br/>             drug<br/><br/>          -  Evidence or history of bleeding diathesis or coagulopathy<br/><br/>          -  Therapeutic anticoagulation with vitamin K antagonists such as phenprocoumon,<br/>             warfarin, or with heparins or heparinoids. Low dose anticoagulation is permitted<br/><br/>          -  Serious, non-healing wound, ulcer, or bone fracture<br/><br/>          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first<br/>             dose of study drug<br/><br/>          -  Known or suspected allergy to sorafenib, carboplatin or pemetrexed<br/><br/>          -  Previous or current cancer that is distinct in primary site or histology from NSCLC<br/>             except cervical cancer in-situ, treated basal cell carcinoma, superficial bladder<br/>             tumors (Ta and Tis) or any cancer curatively treated > 3 years prior to study entry<br/><br/>          -  Substance abuse, medical, psychological or social conditions that may interfere with<br/>             the patients participation in the study<br/><br/>          -  Significant weight loss (> or equal 10% body weight during preceeding 6 weeks)<br/><br/>          -  Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other<br/>             than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for<br/>             long-acting agents, such as piroxicam)<br/><br/>          -  Inability or unwillingness to take folic acid, vitamin B12 supplementation or<br/>             corticosteroids<br/><br/>          -  Recent (within 30 days of enrolment) or concurrent yellow fever vaccination<br/><br/>          -  Serious concomitant systemic disorder that, in the opinion of the investigator, would<br/>             compromise the patient's ability to adhere to the protocol.<br/>";"Primary Sponsor";"University Hospital Muenster";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum Münster, Med. Klinik und Poliklinik A, Hämatologie, Onkologie und Pneumologie and Uniklinik Frankfurt Innere Medizin, Hämatologie/Onkologie, 60590 Frankfurt";"[---]*";"[---]*";"[---]*";"Christian Brandts, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Universitätsklinikum Münster, Med. Klinik und Poliklinik A, Hämatologie, Onkologie und Pneumologie and Uniklinik Frankfurt Innere Medizin, Hämatologie/Onkologie, 60590 Frankfurt";"[---]*";"[---]*";"[---]*";"Christian Brandts, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"A Randomized (PhaseII), Double-blind, Multicenter Phase I/II Trial of Pemetrexed, Carboplatin Plus or Minus Sorafenib in the First-line Treatment of Patients With Stage IIIb or IV Non-Small Cell Lung Cancer";"PECASO";"[---]*";"The majority of patients with advanced NSCLC treated with standard platinum based<br/>      chemotherapy regimens ultimately develop disease progression. Active therapies with improved<br/>      toxicity profiles are clearly needed in this setting. The primary objective of this trial is<br/>      to assess the toxicity profile and to determine the effect on progression free survival and<br/>      time to progression in patients with advanced NSCLC treated with sorafenib in addition to<br/>      carboplatin and pemetrexed.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003807";"2015-09-15T14:16:17.504+02:00";
"DRKS00007722";2015/03/03;"[---]*";yes;"Approved";"4147-07/14 ";"Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät";;;;;;;;;;;;;;;;"ICD10";"I60-I69";"Cerebrovascular diseases";"ICD10";"G81.1";"Spastic hemiplegia";;;;;;;;;;"Arm 1";"repetitive peripheral magnetic stimulation (rPMS)  (interventiongroup):<br/>daily stimulation (mo-fr) for three weeks; <br/>Muscles of the upper arm and forearm are stimulated with a butterfly coil; <br/>The patient takes a sitting position with raised feet in the wheelchair or on a chair with backrest; <br/>The arm is placed to be stimulated or maintained by the therapist; <br/>magnetic stimulator: Magstim Rapid²;<br/>Instruction: Patients are asked to relax and observe their arm<br/>";"Arm 2";"peripheral electrical stimulation (controlgroup):<br/>daily stimulation (mo-fr) for three weeks<br/>Muscles of the upper arm and forearm are stimulated with electrodes; <br/>The patient takes a sitting position with raised feet in the wheelchair or on a chair with backrest; <br/>The arm is placed to be stimulated or maintained by the therapist; <br/><br/>Electrical device: wellcare digi stim<br/><br/>Instruction: Patients are asked to relax and observe their arm<br/>";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Treatment";"Parallel";"N/A";"N/A";"group difference in Fugl-Meyer-Score three weeks post stimulation";"<br/>group difference in Katz Index of Independence of daily living scale (ADL) score after six months";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Moritz Klinik";"Bad Klosterlausnitz";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2014/09/23;"Actual";"80";"[---]*";"Monocenter trial";"National";"Both, male and female";"[---]*";"no minimum age";"[---]*";"no maximum age";"subacute stroke (incident not longer than six months back);<br/>spastic hemiparesis (at least modified ashworth scale 1);<br/>a slight function in the fingers or hand (at least 1 point in the Fugl-Meyer-test in subscore C)";"Epilepsy, implantated metal in the stimulation area,<br/>implantated medical devices, dysfunctional speech comprehension, pregnancy, ";"Primary Sponsor";"Moritz Klinik Bad Klosterlausnitz";"[---]*";"[---]*";"[---]*";"[---]*";"Hermann Sachse Straße 46";"07639";"Bad Klosterlausnitz";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Moritz Klinik";"Ms.";"[---]*";"Kristin";"Pohl";"Hermann-Sachse-Straße 46";"07639";"Bad Klosterlausnitz";"Germany";"036601/49418";"[---]*";"kristin.pohl@moritz-klink.de";"[---]*";"Contact for Public Queries";"Moritz Klinik Bad Klosterlausnitz";"Ms.";"[---]*";"Kristin";"Pohl";"Hermann-Sachse-Straße 46";"07639";"Bad Klosterlausnitz";"Germany";"036601/49418";"[---]*";"kristin.pohl@moritz-klinik.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Moritz Klinik";"[---]*";"[---]*";"[---]*";"[---]*";"Hermann-Sachse-Straße 46";"07639";"Bad Klosterlausnitz";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"The effect of repetitive peripheral magnetic stimulation in stroke-rehabilitation: A randomized controlled trial";"[---]*";"[---]*";"In this study, the effectiveness of repetitive peripheral magnet stimulation (rPMS) is compared to peripheral electrical stimulation.<br/>rPMS improves the functional status of a paretic hand/arm and spasticity after stroke. Since now it is unclear how effective rPMS is.<br/>Patients were randomly assigned to “magnetic stimulation group” or “electrical stimulation group.<br/>The stimulation is applied every day from monday to friday for 3 weeks. In regular intervals (before therapy, after one week, after two weeks after interventionperiod and after six months) assessments were performed for the function of the upper limb and mobility to find out how effective rPMS is.<br/>We hypothesized that rPMS is the more effective stimulation method to improve lost functions in the affected upper limb and the activities of daily living.";"Repetitive peripheral magnetic stimulation (rPMS) is a stimulation method with strong and rapidly changed magnetic fields that's applicated on a muscle to produce repetitive muscle contractions.<br/>The first rPMS trials by patients after stroke were performed in the 90s by the research group by Albrecht Struppler. These first trials indicated an improvement of voluntary activity, spasticity and perception after rPMS.<br/>In this randomized-controlled trial the effect of rPMS will be examined in patients after stroke. The patients are randomly assigned in the intervention group(magnetic stimulation) and the control group (electrical stimulation). The intervention /controllintervention be applied daily (mon-fri) over three weeks.<br/>To investigate the short- and long-term effects the assessments will be evaluated at different times: T0 (baseline), T1(after the first week), T2 (after second week), post (directly after intervention period) and 6mon (six months after stimulation). Standardized assessments will be applied at these times.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007722";"2015-03-11T12:00:27.983+01:00";
"DRKS00005455";2015/03/26;2013/09/17;yes;"Approved";"13/0296 - EK";"Ethik-Kommission des Landes Berlin";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2012-004442-15";"[---]*";"Primary Registry-ID";"EUCTR2012-004442-15-DE";"EUCTR";;;;;;;;;;"Free text";"[---]*";"Hepatitis C-Patienten mit Leberzirrhose ";"ICD10";"B18.2";"Chronic viral hepatitis C";"ICD10";"K74";"Fibrosis and cirrhosis of liver";;;;;;;"Arm 1";"Peginterferon alpha 2a (Pegasys); Ribavirin (Copegus); Telaprevir (Incivo) - according to current guidelines";"Arm 2";"Peginterferon alpha 2a (Pegasys); Ribavirin (Copegus); Telaprevir (Incivo) - according to current guidelines<br/>+ Silibinin (Legalon SIL) infusions over 10 days 20 mg/kg body weight";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"IIa";"No";"To compare the rates of RVR – rapid virological response, defined as HCV RNA ≤ LOQ (limit of quantification), defined as ≤ 15 IU/mL at week four of an antiviral treatment with telaprevir, peginterferon alpha and ribavirin – between patients who either receive infusions of silibinin during the first ten consecutive working days of antiviral treatment or no infusions";"Efficacy:<br/>- The rate of patients with undetectable HCV RNA at treatment week 12, 24 and 48 and week 12 and 24 of the follow-up period.<br/>- Rate of patients with normalized ALT levels after treatment week 4, 12 and 48, as well as the time interval between the start of therapy and the first evidence of ALT normalization.<br/>- Description of the viral kinetics:<br/>- The time to the first reachment of negative HCV RNA levels (≤ LOQ)<br/>- The number of silibinin infusions for the initial reaching negative HCV RNA levels (≤ LOQ) (arm A),<br/>- The, area under curve 'of the HCV RNA decline at week 4<br/>- The decrease in HCV RNA per infusion<br/>Tolerability and safety:<br/>- SAR / AR-rates<br/>- Rate of patients with decompensated liver function during the study.<br/>- In the case of information are obtained to the development of resistance associated with the administration of telaprevir or silibinin, further laboratory parameters will be analyzed";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"[---]*";"Leipzig";"Doctor's Practice";"[---]*";"Berlin";"University Medical Center";"[---]*";"Tübingen";"University Medical Center";"[---]*";"Frankfurt a.M.";"University Medical Center";"[---]*";"Heidelberg";"University Medical Center";"[---]*";"Essen";"University Medical Center";"[---]*";"Köln";"University Medical Center";"[---]*";"Regensburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/12/12;"Actual";"40";2014/03/03;"Multicenter trial";"National";"Both, male and female";"18";"Years";"70";"Years";"- Male or female patients aged between 18 and 70 years<br/>• A signed consent form<br/>• Chronic hepatitis C genotype 1 infection, confirmation of genotype in screening<br/>• compensated liver cirrhosis (Child-Pugh A), assessed by:<br/>Liver histology: Metavir 4 in a liver biopsy (regardless of the time of performing the biopsy)<br/>Or<br/>non-invasive elastography: Fibroscan © measurement> 14.5 kPa with an IQR of less than 20% of the value in kPa and a success rate of at least 85%. The Fibroscan test should not be older than 6 months to screening.<br/>• ""null response"" to prior treatment with peginterferon alpha and ribavirin, one of the following criteria must be met: <1 log10 decrease at week 4 and / or <2 log10 reduction in HCV RNA at week 12 of treatment, or an absolute virus number of ≥ 30,000 IU / ml at treatment week 12<br/>• Female patients who are infertile or if of childbearing age: to have a negative pregnancy test, to have to agree to refrain from sexual intercourse or to use two recognized methods of contraception including a barrier method <br/>or<br/>Male patients who are infertile or to have to agree to refrain from sexual intercourse or to use two recognized methods of contraception including a barrier method ";"1. Chronic hepatitis C with non-genotype 1 infection or mixed infection containing a genotype 2, 3, 4, 5 or 6<br/>2. Detection of resistance associated viral mutations (RAV) in a population based sequencing analysis of the hepatitis C virus NS3/4A region at screening. RAVs are defined as any detected mutation: V36A/G/M, T54A/S, R155G/K/M/T und A156F/N/S/T/V. <br/>3. Positiv testing for HIV-1 or HIV-2 antibodies, positive testing for HBs-Ag at screening<br/>4. Evidence of liver disease due to causes other than hepatitis C infection<br/>5. Decompensated liver disease or history of decompensated liver disease: Ascites, bleeding from esophageal varices, portal vein thrombosis, spontaneous bacterial peritonitis, hepatic encephalopathy. <br/>6. Total bilirubin levels of > 1.8 mg/dL (> 1.5*ULN); INR > 1.26. <br/>7. Combined: albumin levels < 30 g/L and thrombocyte count < 100/nL (Fontaine et al. 2013)<br/>8. Hematologic lab values out of acceptable ranges:<br/>• Thrombocyte count <80/nL.<br/>• Hemoglobin <12.0 g/dL for men and <11.0 g/dL for women.<br/>• Absolute neutrophil count (ANC) of <1/nL<br/>9. Active or suspected nonhepatic malignancy or history of malignancy within the last 5 years – patients with hepatocellular carcinoma that is solely localized to the liver can be included at the judgement of the investigator.<br/>10. Impaired renal function defined as creatinine levels - female: > 1.8 mg/dL; male: > 2.0 mg/dL <br/>11. Impaired thyroid gland function – TSH  outside 0.2 – 4.5 mU/L <br/>12. Body Mass Index <16 or >35 kg/m2.<br/>13. Female patients who are pregnant or breast feeding or male patients whose female partner is pregnant.<br/>14. History of alcohol or drug abuse (except cannabis) within the past 12 months.<br/>15. History of severe or uncontrolled psychiatric disease, especially depression, including a prior suicidal attempt.<br/>16. Active autoimmune disease, including autoimmune hepatitis; i.e. ANA-Titers > 1:320 at screening.<br/>17. Organ transplantation (exception: cornea or hair transplant)<br/>18.	Poor or restricted access to the venous system – patients will receive an i.v. catheter at all silibinin visits.<br/>19. Usage of any investigational drugs within 30 days prior to enrolment<br/>20. Any condition or comorbidity that is listed as contra-indicative for the use of Peginterferon, Ribavirin or Telaprevir – for a detailed list refer to the current SmPC of the respective medication. <br/>21. Inadmissible concomitant medication that is known to be a strong inducer, inhibitor or substrate of cytochrome p450 subtype 3A4. A detailed list of prohibited medication is provided in Section 5.3.5.<br/>22. Known allergies to any of the used study medication or their additives. <br/>23. Persons that are imprisoned due to judicial or administrative order<br/>";"Primary Sponsor";"Universität Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstr. 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Universitätsklinikum Leipzig AöRSektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum";"Mr.";"Prof.";"Thomas";"Berg";"Liebigstr. 20";"04103";"Leipzig";"Germany";"Telefon:   +49 341 97 12330";"[---]*";"Thomas.berg@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Universitätsklinikum Leipzig AöRSektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum";"Mr.";"Prof.";"THomas";"Berg";"Liebigstr. 20";"04103";"Leipzig";"Germany";"Telefon:   +49 341 97 12330";"[---]*";"thomas.berg@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Janssen Pharmaceutica NV ";"[---]*";"[---]*";"[---]*";"[---]*";"Turnhoutseweg, 30, ";"2340";"Beerse";"Belgium";"[---]*";"[---]*";"[---]*";"[---]*";"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Roche Pharma AG, Grenzach";"[---]*";"[---]*";"[---]*";"[---]*";"Emil-Barell-Str. 1";"79630";"Grenzach-Wyhlen";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;"High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety <br/>";"HISTORY";"[---]*";"Patients with liver cirrhosis and non-response to previous therapy (peginterferon alpha and ribavirin) show in a triple therapy with the addition of a so-called protease inhibitor in only 14% permanently therapeutical success. In this case, patients with advanced liver disease will be the greatest clinical benefit from a successful hepatitis C virus elimination.<br/>The study investigated the efficacy and safety of quadruple therapy of telaprevir, peginterferon alpha-2a and ribavirin and an additional dose of silibinin-dose infusions over the first ten business days of therapy. Silibinin infusions are starting in the active treatment arm A with beginning of therapy and in the control arm B silibinin infusions can be offered at week 4 of therapy, when the current treatment has not been successful.";"Patients with liver cirrhosis and virologic non- response to previous therapy ( peginterferon alpha and ribavirin) show in a triple therapy with the addition of an HCV -specific protease inhibitor in only 14 % a virological response. Patients with advanced liver disease have the greatest clinical benefit from a successful hepatitis C virus ( HCV) elimination .<br/>The study evaluated the antiviral efficacy and safety of quadruple therapy with telaprevir , peginterferon alpha- 2a and ribavirin and an additional dose of silibinin infusions over the first ten business days of therapy. Silibinin infusions are randomized to the active treatment arm A at the beginning of therapy - versus the control arm B. In control arm B patients are offered silibinin infusions at week 4 of therapy, when the previous virologic response is not sufficient.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005455";"2019-08-29T07:05:33.411+02:00";
"DRKS00009331";2015/09/07;"[---]*";yes;"Approved";"100_15 B";"Ethik-Kommission der Friedrich-Alexander-Universität Erlangen-Nürnberg";;;;;;;;;;;;;;;;"ICD10";"M81";"Osteoporosis without pathological fracture";"ICD10";"M62.5";"Muscle wasting and atrophy, not elsewhere classified";"Free text";"[---]*";"pain intensity and volume at different regions";;;;;;;"Arm 1";"Usual Care prevention protocol according to § 20 SGB IX: Two periods of 10 weeks of supervised conventional group exercise once a week for 60 min. (i.e. predominately  resistance-type)  with intermittent 10 weeks of rest over 12 months.<br/>CA-/Vit-D-supplementation according to dietary intake.";"Arm 2";"See study arm 1 + DVD-video-exercise.<br/>Additionally to the group sessions, participants performed one home training session of 30 min/week Subjects were guided by a video. During the intermittent rest periods (10 weeks) subjects performed 3 corresponding sessions per week.<br/>Intervention: 12 months<br/>CA-/Vit-D-supplementation according to dietary intake.";"Arm 3";"See study arm 2 + whole body vibration (WBV). During the supervised phases of 10 weeks the exercise protocol was comparable to study arm 2; however during the intermittent rest periods, 2 home-trainings sessions (video-guided, see study arm 2) and 2 WBV-sessions with 15 min were performed.<br/>Intervention 12 months.<br/>CA-/Vit-D-supplementation according to dietary intake.<br/>";"Arm 4";"Non-training control, that maintained there life-style during the intervention period of 12 months. <br/>However, participants were provided with calcium/Vitamin D (all groups) and theory sessions of healthy aging.";;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)|Control group receives no treatment";"Prevention";"Parallel";"N/A";"N/A";"Bone Mineral Density (BMD) at lumbar spine (LS) and hip;<br/>Appendicular skeletal muscle mass (ASMM);<br/><br/>BMD at LS and hip via regional DXA-scan at baseline and after 12 months;<br/>ASMM via DXA-total body scan at baseline, after 6 and 12 months;<br/>";"Total and regional fat and fat free mass (DXA);<br/>cross sectional area and density of the medial thigh (computed tomography: CT);<br/>maximum strength (isokinetic assessment); functional capacity (e.g. balance tests, gait speed);   <br/>endurance (time under load, VO2max);<br/>pain intensity and frequency at different skeletal sites (lower back, big joints via standardized questionnaire).";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"wissenschaftliches Institut";"Erlangen-Nürnberg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2020/01/01;"Planned";"200";"[---]*";"Monocenter trial";"National";"Female";"[---]*";"no minimum age";"[---]*";"no maximum age";"female, postmenopausal<br/>osteopenia (-1> T-Score<-2,5 SD) at lumbar spine or hip<br/>untrained (</=1 session/week of exercise)";"relevant cardiovascular diseases<br/>used medication and/or suffered from diseases affecting our primary end-points <br/>absence for more than 2 weeks during the intervention period<br/>(very) low physical capacity (≤75 Watt bicycle ergometry)<br/>ineligibility for group exercise<br/>contraindications for whole body vibration according to the supplier <br/>";"Primary Sponsor";"Universitätsklinikum Erlangen";"[---]*";"[---]*";"[---]*";"[---]*";"Maximiliansplatz 2";"91054";"Erlangen";"Germany";"[---]*";"[---]*";"[---]*";"www.uk-erlangen.de";"Contact for Scientific Queries";"Friedrich Alexander Universität Erlangen-Nürnberg; Institut für Medizinische Physik,";"Mr.";"Professor Dr.";"Wolfgang";"Kemmler";"Henkestrasse 91";"91052";"Erlangen";"Germany";"09131 8523999";"09131 8522824";"wolfgang.kemmler@imp.uni-erlangen.de";"http://www.imp.uni-erlangen.de/";"Contact for Public Queries";"Friedrich Alexander Universität Erlangen-Nürnberg, Institut für Medizinische Physik,";"Mr.";"Professor Dr.";"Wolfgang";"Kemmler";"Henkestrasse 91";"91052";"Erlangen";"Germany";"09131 8523999";"09131 8522824";"wolfgang.kemmler@imp.uni-erlangen.de";"http://www.imp.uni-erlangen.de/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Friedrich Alexander Universität Erlangen-Nürnberg, Institut für Medizinische Physik,";"Mr.";"Professor Dr.";"Wolfgang";"Kemmler";"Henkestrasse 91";"91052";"Erlangen";"Germany";"09131 8523999";"09131 8522824";"wolfgang.kemmler@imp.uni-erlangen.de";"http://www.imp.uni-erlangen.de/";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Optimizing currant exercise strategies of public compulsory health insurances for musculoskeletal prevention. A randomized controlled pilot study with postmenopausal women";"OPS";"[---]*";"Due to the menopausal transition bone and muscle in women are negatively affected in a relatively early phase of live, which may result in pain, decreases in functional capacity and loss of independence with advancing age. Regular exercise improves musculoskeletal parameters and is thus considered as an important component of osteoporosis and sarcopenia prevention or treatment. Actually, the corresponding exercise programs of compulsory health insurances (CHI) focus on intermitted programs over 10-12 weeks, with a single session/week and at most applied twice per year. This proceeding, however, is in conflict with the current finding that training frequencies lower than two sessions per week are ineffective or suboptimal to address musculoskeletal parameters (i.e. bone and muscle) in untrained middle- and high-aged females. Thus, the aim of this randomized, controlled pilot exercise trial was to determine whether (1) the present exercise strategy of the CHIs are generally effective to generate positive effects on osteoporosis and sarcopenia parameters and whether (2) adjuvant time- and cost-efficient modern training methods (i.e. video guided home exercise, whole-body vibration) may enhance the effectivity of low-frequency exercise programs. <br/>Apart from the scientific evaluation of the project, we further aimed for increasing the applicability and attractiveness of whole-body vibration technology and home- or job-based video-animated exercise programs.<br/>";"Due to the menopausal transition bone and muscle in women are negatively affected in a relatively early phase of live, which may result in pain, decreases in functional capacity and loss of independence with advancing age. Regular exercise improves musculoskeletal parameters and is thus considered as an important component of osteoporosis and sarcopenia prevention or treatment. Actually, the corresponding exercise programs of compulsory health insurances (CHI) focus on intermitted programs over 10-12 weeks, with a single session/week and at most applied twice per year. This proceeding, however, is in conflict with the current finding that training frequencies lower than two sessions per week are ineffective or suboptimal to address musculoskeletal parameters (i.e. bone and muscle) in untrained middle- and high-aged females. Thus, the aim of this randomized, controlled pilot exercise trial was to determine whether (1) the present exercise strategy of the CHIs are generally effective to generate positive effects on osteoporosis and sarcopenia parameters and whether (2) adjuvant time- and cost-efficient modern training methods (i.e. video guided home exercise, whole-body vibration) may enhance the effectivity of low-frequency exercise programs. <br/>Apart from the scientific evaluation of the project, we further aimed for increasing the applicability and attractiveness of whole-body vibration technology and home- or job-based video-animated exercise programs.<br/>";"Recruiting stopped after recruiting started ";"Further trial documents";"806f659d-f3c5-4e74-9f81-758e5aa4c589";"Ethikantrag_OPS_IMP.pdf";"Ausführlich Beschreibung des Vorhabens (Ethikantrag Deutsch)";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009331";"2019-12-13T07:31:15.840+01:00";
"DRKS00003997";2013/01/09;2007/02/22;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00439192";"ClinicalTrials.gov";"Sponsor-ID";"ELB245201-06";"elbion AG";;;;;;;;;;"Free text";"[---]*";"Overactive Bladder";"Free text";"[---]*";"Urinary Incontinence";"ICD10";"N32.8";"Other specified disorders of bladder";"ICD10";"R32";"Unspecified urinary incontinence";;;;"Arm 1";"Drug: ELB245";"Arm 2";"Drug: Tolterodine";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo|Active control (effective treament of control group)";"Treatment";"Parallel";"II";"[---]*";"- mean number of micturitions<br/>";"- OAB related measures<br/>- urgency measures<br/>- Quality of life<br/>";"DE";"Germany";"PL";"Poland";"SE";"Sweden";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Private Gynecological Practice";"Alzey";"[---]*";"Private Urologic Practice";"Berlin";"[---]*";"Private Urologic Practice";"Berlin";"[---]*";"Private Urologic Practice";"Borken";"[---]*";"Private Urologic Practice";"Duisburg";"[---]*";"Private Urologic Practice";"Duisburg";"[---]*";"Private Urologic Practice";"Essen";"[---]*";"Private Urologic Practice";"Greifswald";"[---]*";"Private Urologic Practice";"Hamburg";"[---]*";"Private Urologic Practice";"Hamburg";"[---]*";"Private Urologic Practice";"Homburg Saar";"[---]*";"Private Urologic Practice";"Kleinblittersdorf";"[---]*";"Private Urologic Practice";"Marburg";"[---]*";"Private Urologic Practice";"Muelheim";"[---]*";"Private Urologic Practice";"Munich";"[---]*";"Private Urologic Practice";"Mühlacker";"[---]*";"Private Urologic Practice";"Oberursel";"[---]*";"Private Urologic Practice";"Stuttgart";;;;;;;2007/02/27;"[---]*";"275";2007/08/01;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Male or female outpatients at least 18 years of age<br/><br/>          -  Symptoms of OAB for a minimum of 3 consecutive months prior to study entry; severity<br/>             of OAB (as defined by patient reported symptoms) for a minimum of one month prior to<br/>             study entry<br/><br/>          -  Ability to use a toilet independently and without difficulty<br/><br/>          -  No treatment with any medication against OAB during the 4 weeks prior to study entry<br/><br/>          -  Written informed consent<br/>";"-  Breastfeeding women, pregnant women or women who intend to become pregnant during the<br/>             study or women of childbearing potential who are sexually active and not practicing a<br/>             highly reliable method of birth control<br/><br/>          -  Any local pathology, that might cause the bladder symptoms<br/><br/>          -  Significant stress urinary incontinence or mixed stress/urgency incontinence<br/><br/>          -  Any neurological disease affecting bladder function or muscle strength<br/><br/>          -  Patient history of any lower urinary tract surgery or previous pelvic irradiation<br/><br/>          -  Local administration of botulinum toxin within the last 9 months in the lower urinary<br/>             tract<br/><br/>          -  Start or change of a behavioral bladder training program<br/><br/>          -  Post voiding residual volumes larger than 250ml or symptoms of clinically relevant<br/>             bladder outlet obstruction<br/><br/>          -  Nocturial polyuria<br/><br/>          -  History of liver disease and/or impaired liver function<br/><br/>          -  Cholestasis<br/><br/>          -  Chronic alcohol or drug abuse<br/><br/>          -  Evidence of significantly impaired renal function (<br/><br/>          -  Diabetes mellitus (type I or II) with significant peripheral neuropathy and/or<br/>             polyuria<br/><br/>          -  Inflammatory bowel disease such as Crohn's disease, or ulcerative colitis<br/><br/>          -  Uncontrolled narrow angle glaucoma<br/><br/>          -  Chronic use of carbamazepine or paracetamol<br/><br/>          -  Participation in any drug study in the preceding 3 months<br/><br/>          -  Concomitant treatment with strong CYP3A4 inhibitors<br/><br/>          -  History or evidence of relevant cardiovascular or cerebrovascular disorders<br/>";"Primary Sponsor";"elbion AG";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Dept. Pharmacology & Pharmacotherapy, AMC, University of Amsterdam";"[---]*";"[---]*";"[---]*";"Martin Michel, Prof.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Dept. Pharmacology & Pharmacotherapy, AMC, University of Amsterdam";"[---]*";"[---]*";"[---]*";"Martin Michel, Prof.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)";"[---]*";"[---]*";"This study is designed to determine the efficacy of escalating doses of ELB245 versus<br/>      placebo , when administered to patients with OAB and to compare the efficacy of escalating<br/>      doses of ELB245 versus the standard treatment tolterodine, when administered to patients<br/>      with OAB.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003997";"2016-01-19T16:22:25.760+01:00";
"DRKS00005053";2015/03/13;"[---]*";yes;"Approved";"296/13";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";;;;;;;;;;;;;;;;"ICD10";"N50.1";"Vascular disorders of male genital organs";"ICD10";"N50.8";"Other specified disorders of male genital organs";;;;;;;;;;"Arm 1";"not applicable for steps 1,2,3 (step 1 - physical specification of a flexible microoptical system for endoscopic inspection of the human seminal tract, step 2 - test on human cadaver, step 3 - laboratory investigation of endoluminal inspection of ductus deferens in porcine model)<br/>step 4: clinical tests on patients with hematosperia and/or as a part of transurethral resektion of the prostate (during this procedure certain structures of the male seminal duct are damaged irreversibelly)";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Basic research/physiological study";"Single (group)";"N/A";"N/A";"Feasibility of microoptical, flexible endoscopy of the male seminal duct in human cadaver model and in patients";"clinical side effects after microoptical inspection of the human seminal duct";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Kliniik für Urologie";"Freiburg im Breisgau";"Medical Center";"Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie";"Giessen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2015/05/18;"Actual";"10";"[---]*";"Multicenter trial";"National";"Male";"18";"Years";"90";"Years";"Hematospermia, BPS";"Women, absence of consent, history of surgical interventions on genital tract";"Primary Sponsor";"Uniklinikum FreiburgDepartment ChirurgieKlinik für Urologie";"Mr.";"PD Dr.";"Arkadiusz";"Miernik";"Hugstetterstr. 55";"79106";"Freiburg";"Germany";"004976127028910";"004976127028780";"arkadiusz.miernik@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/urologie";"Contact for Scientific Queries";"Uniklinikum FreiburgDepartment ChirurgieKlinik für Urologie";"Mr.";"PD Dr.";"Arkadiusz";"Miernik";"Hugstetterstr. 55";"79106";"Freiburg";"Germany";"004976127028910";"004976127028780";"arkadiusz.miernik@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/urologie";"Contact for Public Queries";"Uniklinikum FreiburgDepartment ChirurgieKlinik für Urologie";"Mr.";"PD Dr.";"Arkadiusz";"Miernik";"Hugstetterstr. 55";"79106";"Freiburg";"Germany";"004976127028910";"004976127028780";"arkadiusz.miernik@uniklinik-freiburg.de";"http://www.uniklinik-freiburg.de/urologie";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Universitätsklinikum FreiburgDepartment ChirurgieKlinik für Urologie";"Mr.";"PD Dr.";"Arkadiusz";"Miernik";"Hugstetterstr. 55";"79106";"Freiburg";"Germany";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Pilot study for flexible edoscopic examination and endoluminal occlusion of the saminal duct";"FlexEndo-SemDuct";"[---]*";"The presented research aims the development of an optical system, which allows an endoscopic inspection of the entire seminal duct (ejaculatory duct, vas deferens and seminal vesica). In the first phase, the construction of a proper flexible optics attached to a high-resolution visualization system is targeted. So far, the inspection of the seminal tract was limited by the use of rigid instruments (mostly thin ureterorenoscopes). With regard to the recent technical progress of the optical technologies there are real chances to build such instruments. <br/>Currently there are small-sized, flexible optical system for industrial applications on the market. Those instruments are narrow enough to be potentially able to inspect the entire seminal tract.<br/>The aim of the research project is to develop and optimize such endoscopes for human use. For this purpose the first step is to create and describe the technical and physical properties of such systems. The second step are cadaver studies on the human seminal duct (University of Giessen, Department of Urology & Anatomy Institute). In addition we investigate how the optics can be applied in terms of endoluminal occlusion of the seminal duct for fertility control. <br/>Here different materials are inserted to the vas deferens (porcine model) to occlude their lumen. Subsequently, the density of the different materials is tested and evaluated in the lab. Finally, we investigate a CE approved, small-sized optical system for its applicability to endoscopically examine the human seminal duct. <br/>";"Four-stage analysis on the medical applicability of a new, miniaturized, flexible optical system for endoscopy of the seminal tract. <br/>Step 1: investigation and physical characterization of the optics<br/>Step 2: Test on human cadaver<br/>Step 3: Investigation whether the new optics are suitable for optical control of endoluminal occlusion of the seminal duct for fertility control (lab study on a porcine genital tract model).<br/>Step 4: Clinical test of a CE approved small-sized flexible endoscopy system on male patients with hematospermia and/or as a part of transurethral resection of the prostate.<br/>";"Recruiting stopped after recruiting started ";"Abstract";"[---]*";"https://www.ncbi.nlm.nih.gov/pubmed/27166434";"Flexible Vesiculovasoscopy Using a Microoptical System in a Human Cadaver Model: An Experimental Approach for Atraumatic Endoscopy of the Seminal Tract";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005053";"2017-05-12T09:43:02.061+02:00";
"DRKS00005048";2014/07/30;"[---]*";yes;"Approved";"240/13";"Ethik-Kommission der Albert-Ludwigs-Universität Freiburg";;;;;;;;;;;;;;;;"Free text";"[---]*";"All diseases needing palliative care.";;;;;;;;;;;;;"Arm 1";"The exercise program consists of a strength- (KE) and a balance-endurance-flexibility-training (GABE) and has a length of 6 weeks. All exercises should be executed not exceeding 13-14 point on Borg Scale (range 6-20).<br/>KE is performed three times per week (35 minutes) and GABE two times (25-30 minutes).<br/>";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"N/A";"De Morton Mobility Index (DEMMI); questionnaire: mobility; measurement after 3 and 6 weeks ///<br/>Caregiver:<br/>IRES-24; questionnaire: health status and physical functioning; measurement after 3 and 6 weeks";"All measurements on week 3 and 6:<br/>Patients:<br/>- QLQ-C30; questionnaire: quality of life<br/>- balance path length for Rombergstand via force plate<br/>- 6 Minute Walk Test (6MWT); distance walked<br/>- Barthel Index (BI); questionnaire: activities of daily living<br/>- Five Times Sit to Stand Test (FTSS) on a force plate; repetitions<br/>- Hand grip strength; Newton<br/>- Qualitative interviews after intervention (nur bei T2)<br/> /// Caregiver: - balance path length for Rombergstand via force plate<br/>- Hand grip strength; Newton<br/>- 30s chair stand test; repetitions";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Klinik für Palliativmedizin & Strahlenklinik";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2013/12/11;"Actual";"25";"[---]*";"Monocenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Inclusion criteria of palliative care patients:<br/>- palliative patients<br/>- ≥ 18 years<br/>- life expectancy 6-12 months<br/>- ECOG: ≤ 2<br/>- numerical rating scale for pain ≤ 3<br/>- adequate cognitive status<br/>";"Exclusion criteria:<br/>- neurological or orthopaedic diseases<br/>- osseous metastases<br/>- heart diseases: NYHA III-IV<br/>- hypertensive emergency last 12 months<br/>- bleeding tendency<br/>- dyspnea during movement (VRS ≥ 2)<br/>";"Primary Sponsor";"Klinik für Palliativmedizin, Universitätsklinikum Freiburg";"Ms.";"Prof. Dr.";"Gerhild";"Becker";"Robert-Koch-Straße 3";"79106";"Freiburg";"Germany";"+49 761 270-95412";"+49 761 270-95414";"gerhild.becker@uniklinik-freiburg.de";"http://www.universitaetsklinikum-freiburg.de/palliativmedizin/live/index.html";"Contact for Scientific Queries";"Klinik für Palliativmedizin, Universitätsklinikum Freiburg";"Ms.";"[---]*";"Helga";"Jäger";"Robert-Koch-Straße 3";"79106";"Freiburg";"Germany";"+49 761 270-34439";"[---]*";"helga.jaeger@uniklinik-freiburg.de";"https://www.uniklinik-freiburg.de/palliativmedizin.html";"Contact for Public Queries";"Klinik für Palliativmedizin, Universitätsklinikum Freiburg";"Ms.";"[---]*";"Helga";"Jäger";"Robert-Koch-Straße 3";"79106";"Freiburg";"Germany";"+49 761 270-34439";"[---]*";"helga.jaeger@uniklinik-freiburg.de";"https://www.uniklinik-freiburg.de/palliativmedizin.html";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Klinik für Palliativmedizin";"Ms.";"Prof";"Gerhild";"Becker";"Robert-Koch-Straße 3";"79232";"March";"Germany";"[---]*";"[---]*";"gerhild.becker@uniklinik-freiburg.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Training intervention with Palliative Patients (TiPP) - pilot study";"TiPP";"[---]*";"Palliative patients tend often to move too little due to different reasons. This circumstance leads to loss of musculature at an early stage and thus to a reduction of mobility, independence and quality of life, finally.<br/>Very little studies exist which evaluate a systematic exercise program with palliative patients. From these few investigations we know that for the most palliative patients training is effective and can be appraised to be safe.<br/>Hence, this study should contribute to approve the feasibility of a soft training and to outline the effect on mobility.<br/>";"There are numerous research papers that deal with exercise and cancer. Up to now, the field of palliative care is only affected marginally therefrom (Lowe 2011a; Cramp und Byron-Daniel 2012).<br/>Palliative care patients have plenty of defacing symptoms such as loss of musculature, cachexia, motoric immobility, fatigue, pain, dyspnea, nausea, insomnia, depression and constipation (Jäger 2012; Strömgren et al. 2006). Especially the decrease of physical abilities impairs the mobility, autonomy and the quality of life of advanced cancer patients (Helbostad et al. 2009; Lowe et al. 2009b; Cohen und Leis 2002).<br/><br/><br/>The effect of systematic exercise programs is widely unexplored for palliative patients. Thus, no physical activity guidelines exist for this population (Lowe et al., 2009b). The few existing studies indicate positive effects with regard to physical functioning and psychic factors (e. g. emotional status). These results should be confirmed in future studies (Lowe 2011b; Oldervoll et al. 2011; Oldervoll et al. 2006). The immense research deficit in the German-speaking countries is, that there’s no interventional study yet which investigates the effect of a systematic exercise program (e. g. on physical functioning) with palliative patients.<br/><br/><br/><br/><br/>An analysis of needs by Lowe (2010) shows the perceived importance of physical activity and the interest of palliative patients concerning a home-based exercise program. Moreover, the caregiver plays a crucial role for the patient. Caregivers experience physical and psychic stress, however, they are a determining factor for the patients’ quality of life. Caregivers tend to neglect their selves and, de facto, receive little support by the health care system (Blum und Sherman 2010; Glajchen 2004; Haley 2003; Le et al. 2003). That’s why they are included in this study. The IRES-24 is used as primary outcome for caregivers in order to capture different facets of health related quality of life (Meffert und Gerdes [im Druck]; Wirtz et al. 2005). In addition, it stands to reason, that caregivers can contribute in enhancing the patients’ compliance regarding the home-based program which has to be carried out together.<br/>Jordhoy (2007) acknowledges in a systematic review, that physical function plays an inferior role in questionnaires which measure quality of life in palliative patients.<br/>This pilot study is going to test the feasibility and the effect of this exercise program.<br/>";"Recruiting stopped after recruiting started ";"Paper";"[---]*";"http://www.ncbi.nlm.nih.gov/pubmed/26419844";"publication: doi: 10.1186/s13104-015-1523-z";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005048";"2020-03-05T14:34:43.320+01:00";
"DRKS00011036";2017/01/16;"[---]*";yes;"Approved";"410/16-ff";"Ethikkommission an der Medizinischen Fakultät der Universität Leipzig";"EUDAMED-No.<br/>(for studies acc. to Medical Devices act)";"CIV-16-10-017085";"[---]*";;;;;;;;;;;;;"ICD10";"E66";"Obesity";"ICD10";"E11";"Type 2 diabetes mellitus";;;;;;;;;;"Arm 1";"endoscopically implanted duodenal-jejunal bypass liner (EndoBarrierTM) to reduce weight for 12 months";"Arm 2";"intragastric balloon to reduce weight for 6 months";"Arm 3";"Sham control with gastroscopy";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control (effective treament of control group)|Control group receives no treatment";"Treatment";"Parallel";"N/A";"N/A";"successful weight loss 12 months after removal of the medical product<br/>(Note: The scheduled removal of the intragastric balloon is after 6 months, the EndoBarrier after 12 months. The primary EP is determined for the intragastric balloon and the sham-control after 18 months, and for the endo barrier after 24 months.)";"- Percentage weight loss 12 months after removal<br/>- successful weight loss (≥10%) and percentage weight loss after 6 months<br/>- successful weight loss (≥10%) and percentage weight loss at removal of medical product<br/>- remission and reduction of concomitant diseases at removal and 12 months after removal<br/>- change of the HbA1c-value at initial values >6,5% at removal and 12 months after removal<br/>- changes in quality of life (SF-36), physical activity (IPAQ) and body composition (BIA (Bioelectrical impedance analysis)) after 6, 12 and 24 months<br/>- complication rate of the endoscopic procedures in the periods 0-6 months or removal, 6-12 months or removal and time after removal<br/>- comparison of “success”12 months after removal (success is defined as excess weight loss of et least 25%)";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Klinik und Poliklinik für Gastroenterologie und Rheumatologie";"Leipzig";"Medical Center";"Klinikum Bogenhausen, Klinik für Gastroenterologie, Hepatologie und Gastroenterologische Onkologie";"München";"Medical Center";"Krankenhaus Sachsenhausen, Innere Medizin, Gastroenterologie";"Frankfurt a.M.";"University Medical Center";"Klinik für Innere Medizin II, Abteilung für Endokrinologie und Diabetologie";"Freiburg im Breisgau";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/04/28;"Actual";"150";2020/01/31;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"- Age ≥ 18 years<br/>- BMI ≥ 35 or BMI ≥ 30 kg/m² with obesity related co-morbidities such as diabetes<br/>- Dietary consultation was received, but was ineffective<br/>- written informed consent<br/>- indication for long-tern PPI-therapy";"- malignant disease<br/>- peptic ulcer<br/>- large hiatus hernia<br/>- gastrointestinal disease<br/>- previous gastric or bariatric surgery<br/>- high risk of gastrointestinal bleeding<br/>- symptomatic gallstones<br/>- contraindication for general anaesthesia<br/>- contraindication for devices according to manufacturer<br/>- contraindication for proton pump inhibitors (PPIs)<br/>- non controlled GERD (gastroesophageal reflux disease)<br/>- suspected lack of compliance<br/>- drug or alcohol abuse<br/>- pregnant or nursing women  <br/>- fertile women without appropriate contraceptive measures while participating in the trial   <br/>- participation in other interventional trials<br/>- psychological/mental or other inabilities to supply required information (e.g. fill out the questionnaire or follow dietary recommendations due to dementia, language difficulties)";"Primary Sponsor";"Universität Leipzig";"[---]*";"[---]*";"[---]*";"[---]*";"Ritterstr. 26";"04109";"Leipzig";"Germany";"[---]*";"[---]*";"[---]*";"www.uni-leipzig.de";"Contact for Scientific Queries";"Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig";"Mr.";"Prof. Dr. med.";"Albrecht";"Hoffmeister";"Liebigstr. 20";"04103";"Leipzig";"Germany";"+49 341 97 12251";"+49 341 97 12226";"albrecht.hoffmeister@medizin.uni-leipzig.de";"[---]*";"Contact for Public Queries";"Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig";"Mr.";"Prof. Dr. med.";"Albrecht";"Hoffmeister";"Liebigstr. 20";"04103";"Leipzig";"Germany";"+49 341 97 12251";"-49 341 97 12226";"albrecht.hoffmeister@medizin.uni-leipzig.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)";"Deutsche Forschungsgemeinschaft";"[---]*";"[---]*";"[---]*";"[---]*";"Kennedyallee 40";"53175";"Bonn";"Germany";"[---]*";"[---]*";"[---]*";"www.dfg.de";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A multi-centred, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs intragastric balloons vs a sham procedure";"WET";"[---]*";"The morbidly overweight (obesity) is a high risk factor for various diseases. Because of physical limitations, this can lead to a reduced quality of life and psychological problems.<br/>For a large percentage of these patients, the conservative options such as diet, exercise and psychotherapy do not lead to a sufficient success or can this success not long be maintained. One way to support weight loss offer both medical devices used in this study. These are the gastric balloon and the duodenal-jejunal bypass liner. Both products are introduced via a non-surgical method and removed after 6 or 12 months. The gastric balloon reduced the capacity of the stomach and thereby leads after a short time to a weight reduction. Through the bypass liner the digestion of food is delayed due to a barrier between food and the intestine and may also result in a reduction of appetite. This leads to a rapid and sustained weight loss. In conjunction with a healthy diet and permanent changes in lifestyle, both products can help to keep the body weight under control even after the removal of the implants.<br/>The aim of this study is to find out how successful these therapies support weight loss and which of these methods is this more effective. In addition, interested in how long the achieved weight loss can be maintained.";"The two interventions will be deployed as per standard clinical routine. This is both ethically desirable and leads to results that can be better generalized. The balloon cannot be left in place for more than 6 months for safety reasons. The liner is removed while being well tolerated at 12 months and for the clinical trial, we consider a premature removal of the liner after only 6 months not desirable.<br/>The liner is implanted using general anaesthetic, whereas only a sedative is used for the balloon and sham groups. The sham “procedure” involves only a diagnostic gastroscopy. Experience with gastroscopies shows that very many patients are unable to distinguish between an anaesthetic and sedative, meaning that blinding is feasible. The patients from all three arms will wake up and not know which of the procedures was performed. <br/>After 6 months, all patients will be sedated and receive a gastroscopy, which will be used for explantation of the balloon in that arm. After 12 months, all patients will again be sedated and receive a gastroscopy, which will be used for explantation of the liner in that arm. <br/>The physicians performing study visits are blinded. If the physician feels that the patient’s safety or treatment relies on knowledge of the intervention, then the patient will be referred to the gastroscopist for further treatment.<br/>All three arms will receive proton pump inhibitors and dietary counselling, oriented to what is recommended for the liner – the more restrictive of the diets.";"Recruiting stopped after recruiting started ";"trial protocol (mandatory for transfer to Studybox)";"1042f8bc-ec83-4280-bb90-5de7f5582779";"WET_Pruefplan_final2.0_2016-12-15.pdf";"Prüfplan / Trial protocol";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011036";"2020-05-06T10:05:55.847+02:00";
"DRKS00012414";2017/05/08;"[---]*";no;"Approved";"A 2016-0154";"Ethik-Kommission an der Medizinischen Fakultät der Universität Rostock";;;;;;;;;;;;;;;;"ICD10";"H40.1";"Primary open-angle glaucoma";"ICD10";"H40.5";"Glaucoma secondary to other eye disorders";;;;;;;;;;"Arm 1";"Implantation of iStent inject (two trabecular micro-bypass stents) and a suprachoroidal iStent supra stent via a micro incision";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"N/A";"No";"≥ 20% Reduction in IOP at Month 12: A subject will be considered a responder if they meet all the criteria for the primary efficacy endpoint defined as:<br/>•observed at the Month 12 visit,<br/>•12-month mean diurnal IOP reduced by ≥ 20% vs. baseline mean diurnal IOP,<br/>•no use of ocular hypotensive medication for ≥ 4 weeks immediately prior to the 12-month visit,<br/>•no secondary surgical interventions to control IOP (e.g., laser trabeculoplasty, trabeculectomy, stent, shunt or valve placement) prior to the 12-month visit, and<br/>•no postoperative procedure to reposition or remove stents prior to the 12-month visit<br/>";"Month 12 IOP ≤ 18 mmHg: A subject will be considered a responder if they meet all the criteria for the secondary efficacy endpoint defined as:<br/>•observed at the Month 12 visit,<br/>•12-month mean diurnal IOP ≤ 18 mmHg<br/>•no use of ocular hypotensive medication for ≥ 4 weeks immediately prior to the 12-month visit,<br/>•no secondary surgical interventions to control IOP (e.g., laser trabeculoplasty, trabeculectomy, stent, shunt or valve placement) prior to the 12-month visit, and<br/>•no postoperative procedure to reposition or remove stents prior to the 12-month visit<br/>";"DE";"Germany";"CH";"Switzerland";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"University Medical Center";"Universitätsaugenklinik";"Rostock";"Medical Center";"Augenklinik am Wittenbergplatz";"Berlin";"Medical Center";"Augenklinik der Städtische Kliniken";"Karlsruhe";"Medical Center";"Charlottenklinik";"Stuttgart";"Medical Center";"Schlossparkklinik";"Berlin";"Medical Center";"Augenklinik Ahaus";"Ahaus";"University Medical Center";"Universitätsaugenklinik";"Heidelberg";"Medical Center";"Augenklinik Berlin Marzahn";"Berlin";"Medical Center";"Bürgerhospital, Augenklinik";"Frankfurt a.M.";"Medical Center";"Universitätsspital";"Zürich";"Doctor's Practice";"[---]*";"Düsseldorf";;;;;;;;;;;;;;;;;;;;;;;;;;;;2017/05/31;"Actual";"50";"[---]*";"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"Screening Exam Inclusion Criteria:<br/>•Phakic patients or pseudophakic patients with posterior chamber intraocular lenses (PC-IOLs)<br/>•Primary open-angle glaucoma or pseudoexfoliative glaucoma<br/>•C/D ratio ≤ 0.9<br/>•Visual field defects (with mean deviation no worse than – 12db), or nerve abnormality characteristic of glaucoma<br/>•Subject on two topical ocular hypotensive medications<br/>•Medicated IOP of ≥ 18 mmHg and ≤ 30 mmHg<br/>•BCVA 20/80 or better<br/>•Normal angle anatomy as determined by gonioscopy<br/>•Absence of peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities that could impair placement of stents<br/>•Able and willing to attend scheduled follow-up exams for 24 months postoperatively<br/>•Able and willing to provide written informed consent on the approved Informed Consent Form<br/><br/>Baseline Exam Inclusion Criteria:<br/>•Subject has completed appropriate medication washout<br/>•Mean diurnal IOP ≥ 21 mmHg and ≤ 45 mmHg after washout of ocular hypotensive medications<br/>";"Screening Exam Exclusion Criteria:<br/>•Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs)<br/>•Prior stent implantation<br/>•Prior ALT<br/>•Prior SLT within 90 days of screening visit<br/>•Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders<br/>•Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma<br/>•Ineligibility for ocular hypotensive medication washout period as determined by the investigator such as:<br/>•visual field status would be placed at risk by washout period<br/>•unmedicated IOP after washout period would be expected to exceed upper limit of 45 mmHg<br/>•Any active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis)<br/>•Clinically significant corneal dystrophy (e.g., bullous keratopathy, Fuch’s dystrophy); any guttata<br/>•Corneal surgery (prior or anticipated) of any type (including LASIK, LASEK, PRK, etc.) that may interfere with IOP measurement reliability<br/>•Corneal opacities or disorders that would inhibit visualization of the nasal angle<br/>•Congenital or traumatic cataract<br/>•Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition<br/>•Elevated episcleral venous pressure such as associated with: <br/>oactive thyroid orbitopathy<br/>ocavernous sinus fistula<br/>oSturge-Weber syndrome<br/>oorbital tumors<br/>oorbital congestive disease<br/>•Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)<br/>•Chronic ocular inflammatory disease or presence of active ocular inflammation (e.g., uveitis, iritis, iridocyclitis, retinitis)<br/>•Any pathology for which, in the investigator’s judgment, the following would be either at risk or contraindicated:<br/>•stent implantation<br/>•compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up visits)<br/>•Fellow eye BCVA worse than 20/200<br/>•Fellow eye actively enrolled in this trial <br/>•Concurrent participation in another clinical trial involving an investigational drug/device, or participation in such a trial within the past 30 days.<br/>• Pregant or lactating women<br/><br/>Baseline Exam Exclusion Criteria:<br/>•Subject did not complete medication washout<br/>•Mean IOP < 21 mmHg or > 45 mmHg after ocular hypotensive medication washout<br/>";"Primary Sponsor";"Glaukos Corp";"Ms.";"Dr.";"Sally";"Tucker";"229 Avenida Fabricante";"CA 92672";"San Clemente";"United States";"+44 1582 460292";"[---]*";"stucker@glaukos.com";"www.glaukos.com";"Contact for Scientific Queries";"Glaukos Corp";"Ms.";"Dr.";"Sally";"Tucker";"229 Avenida Fabricante";"CA 92672";"San Clemente";"United States";"+44 1582 460292";"[---]*";"stucker@glaukos.com";"www.glaukos.com";"Contact for Public Queries";"Glaukos GmbH";"Mr.";"Dr.";"Harald";"Fuchs";"Gustav-Stresemann-Ring 1";"65189";"Wiesbaden";"Germany";"0151 40718030";"0611.9777.4404";"hfuchs@glaukos.com";"www.glaukos.com";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Commercial (pharmaceutical industry, medical engineering industry, etc.)";"Glaukos Corp";"[---]*";"[---]*";"[---]*";"[---]*";"229 Avenida Fabricante";"CA 92672";"San Clemente";"United States";"001 949.367.9600 ext 227";"001 949.297.4540";"stucker@glaukos.com";"www.glaukos.com";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Prospective Evaluation of Mild to Moderate Open-Angle <br/>Glaucoma Subjects Treated with Second GenerationTrabecular Micro-bypass Stents and One Suprachoroidal Stent<br/>A multicenter study according to MPG §23.b<br/>";"GCF-041";"[---]*";"Glaucoma might lead to blindness due to an increased intraocular pressure (IOP). Usually antigalucomatous eye drops are used for treatment. If these (also combinations of 2 or more agents) are not sufficient, a surgical intervention is indicated. A rather new method is the micro-invasive glaucoma surgery which allows for a safe and atraumatic implantation of so called bypass stents, i.e. small tubes which ab interno (no connection to the eye surface) lead to an improved aqueous outflow and an IOP reduction. The iStent inject is implanted into the trabecular meshwork, through which the aqueous is usually drained. The iStent bypasses the blocked tissue. In this study, patients with mild to moderate glaucoma (glaucomatous damage already present) will be implanted with 2 iStent inject The objective of this study is to evaluate, if a parallel implantation of an iStent supra (which is implanted in the suprachoroidal area and provides an additional aqueous outflow) provides a continuous IOP reduction over 24 months and if the patients need less medication. The IOP and the number of medication will be measured at several time points during the 24 month follow-up period and compared with the baseline values before and after washout of the medication.";"Evaluation of the intraocular pressure (IOP) lowering effect and safety of the additional implantation of an iStent supra in patients with mild or moderate glaucoma which are scheduled for implantation of 2 iStent inject. <br/>The iStent inject (two trabecular micro-bypass stents) and one and a suprachoroidal iStent supra stent will be implanted into each study eye.  The iStent inject is designed to create a patent bypass through the trabecular meshwork to Schlemm’s canal to restore physiologic aqueous outflow and continuously lower intraocular pressure.  The iStent supra is designed to create a patent lumen from the anterior chamber into the suprachoroidal space intended to enhance uveoscleral outflow and reduce intraocular pressure.The study population will consist of 50 eyes of 50 subjects with mild-moderate open-angle glaucoma at up to 10 investigational sites.  All subjects will be followed for 24 months with several time points at which IOD is measured and the number of medication is counted.";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00012414";"2020-02-12T09:00:35.735+01:00";
"DRKS00005760";2017/05/10;2011/04/11;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-003800-73";"[---]*";"Primary Registry-ID";"NCT01334892";"ClinicalTrials.gov";"Sponsor-ID";"12011.201";"Pari Pharma GmbH";;;;;;;"Free text";"[---]*";"Bronchiolitis Obliterans";"ICD10";"J84";"Other interstitial pulmonary diseases";"ICD10";"Z94.2";"Lung transplant status";;;;;;;"Arm 1";"Drug: Cyclosporine Inhalation Solution";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo|Active control (effective treament of control group)";"Prevention";"Parallel";"II-III";"[---]*";"- The primary objective is to compare cumulative BOS-free survival of patients recieving L-CsA or placebo.; time frame: 2 years; BOS stage 1 and higher is considered as BOS for the primary endpoint.<br/>";"- Cumulative mean incidence of BOS 12, 18 and 24 months after first IMP administration; time frame: 2 years; Further secondary objectives are to compare further efficacy and safety data from L-CsA versus placebo. Evaluation of IMP pharmacokinetic (PK) data in whole blood samples and bronchoalveolar lavage (BAL)are included in the outcome measure.<br/>The main safety evaluation is the incidence of treatment-emergent AEs including clinically relevant laboratory parameters and vital signs<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"PARI Pharma GmbH";"Graefelfing";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/12/31;"[---]*";"130";2014/12/01;"[---]*";"[---]*";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"1. Patient's written informed consent<br/><br/>          2. Received a single lung, bilateral lung or heart/lung transplantation between 6 weeks<br/>             and 26 weeks prior to first IMP administration.<br/><br/>          3. Male or female, 18 years of age<br/><br/>          4. Capable of self-administration of medications<br/><br/>          5. Capable of understanding the purpose and risk of the clinical  trial<br/><br/>          6. Received the following immunosuppressive agents and dosages for  maintenance therapy:<br/><br/>               1. Tacrolimus and<br/><br/>               2. Mycophenolate mofetil (MMF) 1 to 3 g/day and<br/><br/>               3. Prednisone or any other steroid therapy; tapered down<br/><br/>          7. Female patients with childbearing potential must have a negative urine pregnancy test<br/>             prior to first IMP administration.<br/><br/>          8. Estimated life expectancy > 6 month<br/>";"1. Any previous episode of bronchiolitis obliterans (BO) or  bronchiolitis obliterans<br/>             syndrome (BOS) of grade 1 or higher<br/><br/>          2. Any active invasive bacterial, viral or fungal infection<br/><br/>          3. Received systemic maintenance immunosuppressive therapy other than   listed in the<br/>             inclusion criteria<br/><br/>          4. Received any systemic or topical ciclosporin A within<br/><br/>          5. Received any systemic or topical Rosuvastatin<br/><br/>          6. Current mechanical ventilation<br/><br/>          7. Received a lung re-transplantation<br/><br/>          8. Pregnant or breast feeding woman<br/><br/>          9. Has known hypersensitivity to ciclosporin A<br/><br/>         10. Has a serum creatinine value of more than 265 µmol/L (3 mg/dL)<br/><br/>         11. Unlikely to comply with visits, inhalation procedures or  spirometric measurements<br/><br/>         12. Receipt of an investigational drug within 4 weeks prior to first administration of<br/>             IMP<br/><br/>         13. Any co-existing medical condition that in the investigator's  judgement<br/><br/>         14. Psychiatric disorders or altered mental status<br/><br/>         15. Patient was previously enrolled in the present clinical trial<br/>";"Primary Sponsor";"Pari Pharma GmbH";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients";"[---]*";"[---]*";"Immunosuppression is a key intervention in patients with solid organ transplant and is<br/>      usually achieved by combination therapy with systemic CsA or tacrolimus with azathioprine,<br/>      mycophenolate mofetil (MMF), or corticoids. However, the outcomes after lung transplantation<br/>      are poor when compared with those after heart, kidney, or liver transplantation, with a<br/>      survival rate of only 55% for recipients of lung transplants.<br/><br/>      Additional application of aerosolised L-CsA should suppress T-cell activation in the lung<br/>      tissue and subsequently BOS development.  The overall purpose of this phase-II/III study is<br/>      to obtain efficacy and safety data of L-CsA in the prevention of BOS.<br/>";"Preventive therapeutic intervention by L-CsA is primarily aimed to suppress T-lymphocyte<br/>      suppression and inflammatory responses and secondly to prevent fibrotic effects making it<br/>      more likely to be effective in early stages of BOS. Early development of BOS, which mostly<br/>      will not be diagnosed, and acute organ rejections are strongly patho-physiological<br/>      associated. Prevention of the very early development of chronic rejection by L-CsA post LTX<br/>      may be the ideal starting point for IMP application.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005760";"2017-05-10T09:28:02.532+02:00";
"DRKS00004099";2012/10/09;2012/03/02;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01551407";"ClinicalTrials.gov";"Sponsor-ID";"PC B202/11";"PhotoCure";;;;;;;;;;"Free text";"[---]*";"Bladder Cancer";"ICD10";"C67";"Malignant neoplasm of bladder";;;;;;;;;;"Arm 1";"Drug: Hexvix";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Diagnostic";"Single (group)";"II";"[---]*";"- Number of lesions; time frame: An average of 15 min (during cystoscopy)<br/>";"- Drug related adverse events; time frame: From time of drug instillation until 24 hours after cystoscopy<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"LMU Munich";"Munich";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2011/12/31;"[---]*";"34";2012/06/01;"[---]*";"[---]*";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"The patients should be indicated for a transurethral resection of the bladder (TURB) based<br/>        on an outpatient cystoscopy and fulfil the following inclusion criteria:<br/><br/>          -  Patients with multiple bladder tumors, defined as ≥2 lesions, based on an outpatient<br/>             cystoscopy.<br/><br/>          -  Patients with known urinary urge symptoms or patients who have problems or pain<br/>             holding back the urine for a time longer than 30 minutes.<br/><br/>          -  Age 18 years or above<br/>";"-  Patients with known tumors in the prostatic urethra or distal urethra<br/><br/>          -  Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed<br/>             resulting in marked amounts of blood in the urine, which may interfere with<br/>             fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded<br/>             if in the investigator's opinion, rinsing during cystoscopy will alleviate the<br/>             possible interference with fluorescence cystoscopy).<br/><br/>          -  Patient with porphyria.<br/><br/>          -  Hypersensitivity to the active substance or to any of the excipients of the solvent<br/><br/>          -  Participation in other clinical studies with investigational drugs either<br/>             concurrently or within the last 30 days.<br/><br/>          -  Women of child-bearing potential meaning that only post-menopausal women, women who<br/>             had their ovaries removed, and women who are otherwise physically unable to bear<br/>             children can be included.<br/><br/>          -  Patients who have received BCG or chemotherapy within three months prior to study<br/>             inclusion.<br/><br/>          -  Conditions associated with a risk of poor protocol compliance.<br/><br/>          -  Patient is the investigator or any sub investigator, research assistant, pharmacist,<br/>             study coordinator, other staff or relative thereof directly involved in the conduct<br/>             of the protocol<br/><br/>          -  Mental condition rendering the subject unable to understand the nature, scope, and<br/>             possible consequences of the clinical study.<br/><br/>          -  Patients unlikely to comply with protocol<br/>";"Primary Sponsor";"Photocure";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Department of Urology, LMU Munich, Germany";"[---]*";"[---]*";"[---]*";"Alexander Karl, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Department of Urology, LMU Munich, Germany";"[---]*";"[---]*";"[---]*";"Alexander Karl, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Open Prospective Within Patient, Phase IIa Study of Hexvix Flexible Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer After 30 Minutes Instillation of Hexvix in Patients With Known or Suspicion of Bladder Cancer";"[---]*";"[---]*";"The objective of the study is to compare Hexvix® flexible cystoscopy and white light<br/>      flexible cystoscopy in the detection of histological confirmed bladder tumor lesions defined<br/>      as dysplasia; CIS; Ta; T1; and ≥ T2 after 30 minutes intravesical instillation of Hexvix®.<br/>";"This study is an open, prospective, within patient, controlled, multi-center, Phase IIa<br/>      study in patients with bladder cancer.<br/><br/>      The bladder of all patients will be instilled with 50 mL Hexvix® 8 mM solution and evacuated<br/>      after 30 minutes. After bladder evacuation, the bladder will be examined under white light<br/>      cystoscopy using the Karl Storz flexible videocystoscope. Tumors visible under white light<br/>      will be mapped. Then the bladder is evaluated with blue light and lesions seen by blue light<br/>      will be mapped. Biopsies of all visible tumors will be taken using both white and blue light<br/>      prior to resection of all lesions.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004099";"2016-01-25T15:23:11.292+01:00";
"DRKS00004117";2012/10/09;2009/05/07;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00911027";"ClinicalTrials.gov";"Sponsor-ID";"BR1-127";"Bracco Diagnostics, Inc";;;;;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Contrast-enhanced ultrasound guided biopsy";"Arm 2";"Procedure: ultrasound guided systematic biopsy";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Other";"Diagnostic";"Crossover";"III";"[---]*";"- Determination of potentiality of SonoVue to guide prostate biopsy increasing detection rate of malignant lesions of 6% points (absolute terms) compared to detection rate of conventional systematic biopsy on patients candidates to a bioptic procedure.; time frame: Day 1<br/>";"- Evaluation of the rate of patients negative to the systematic biopsy among the population that will not receive the targeted biopsy; time frame: Day 1<br/>- Assessment of potentiality of SonoVue guided biopsy to increase % of positive bioptic cores compared to % of positive cores obtained with systematic biopsy, intra-patient in the population of the patients that received both bioptic procedures.; time frame: Day 1<br/>- Evaluation of the Gleason Score of bioptic samples and its relationship with the contrast enhanced signal assessment scores.; time frame: Day 1<br/>";"AT";"Austria";"BE";"Belgium";"FR";"France";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Institut für Radiologie der Charité";"Berlin";"[---]*";"Martini-Klinik, Prostate Cancer Center";"Hamburg";"[---]*";"Urologische Klinik und Poliklinik";"Munich";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/02/27;"[---]*";"282";2011/03/01;"Multicenter trial";"International";"Male";"40";"Years";"[---]*";"no maximum age";"-  Male patient, age ≥ 40 years old<br/><br/>          -  Optimization part only: Diagnosis of prostate cancer<br/><br/>          -  Main part: Suspected prostate cancer scheduled for first biopsy and tPSA ≤ 10 ng/mL<br/>             OR already submitted to one systematic bioptic procedure with negative results<br/>             currently under follow up procedure due to a persistent indication.<br/><br/>          -  Written Informed Consent and willing to comply with protocol requirements<br/>";"-  Documented acute prostatitis or urinary tract infections<br/><br/>          -  Known allergy to sulphur hexafluoride micro bubbles<br/><br/>          -  Any clinically unstable cardiac condition within 7 days prior to SonoVue®<br/>             administration such as:<br/><br/>          -  evolving or ongoing myocardial infarction<br/><br/>          -  typical angina at rest within the previous 7 days<br/><br/>          -  significant worsening of cardiac symptoms within the previous 7 days<br/><br/>          -  recent coronary artery intervention or other factors suggesting clinical instability<br/>             (e.g., recent deterioration of ECG, laboratory or clinical findings)<br/><br/>          -  acute cardiac failure, class III/IV cardiac failure<br/><br/>          -  severe cardiac rhythm disorders<br/><br/>          -  right-to-left shunts<br/><br/>          -  Severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory<br/>             distress syndrome<br/><br/>          -  Bioptic procedure within 30 days before admission into this study (this exclusion<br/>             criterion is only for the main part of the study)<br/><br/>          -  Determined by the Investigator that the patient is clinically unsuitable for the<br/>             study<br/><br/>          -  Participation in a concurrent clinical trial or in another trial within the past 30<br/>             days<br/><br/>          -  Repeated participation in this trial (the patient should not be enrolled twice in the<br/>             present study)<br/>";"Primary Sponsor";"Bracco Diagnostics, Inc";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Bracco Diagnostics, Inc";"[---]*";"[---]*";"[---]*";"Maria L Storto, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Bracco Diagnostics, Inc";"[---]*";"[---]*";"[---]*";"Maria L Storto, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase III Study to Compare SonoVue Guided Prostate Biopsy With Systematic Biopsy in the Detection of Prostate Malignant Lesions in Patients With Suspected Prostate Cancer";"[---]*";"[---]*";"This is a phase III European multicenter, open label, prospective study to assess the<br/>      diagnostic accuracy of the use of SonoVue contrast agent to guide prostate biopsies in<br/>      comparison with the current practice of ultrasound guided systematic biopsy. The trial will<br/>      involve 15-20 European Centers.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00004117";"2016-01-25T16:24:26.332+01:00";
"DRKS00010313";2016/04/14;2015/06/05;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT02480010";"ClinicalTrials.gov";"Sponsor-ID";"BO17004";"Hoffmann-La Roche";;;;;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Pertuzumab";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"[---]*";"Treatment";"Parallel";"II";"[---]*";"- Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab; time frame: Screening, Every 3 weeks up to Week 24; Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines. All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response. The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA. Confirmatory value could not be 50% higher compared to first drop in PSA. The date of response was the date the first 50% (or greater) decline was observed. Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values. Non-response was defined as neither PD nor Response.<br/>";"- Time to Disease Progression; time frame: Screening, Every 3 weeks up to a maximum of 18 months; Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events. 1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.<br/>- Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria; time frame: Screening, Weeks 6, 12, 24, 36 and 48; Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline. The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.<br/>- Time to Response; time frame: Screening, Every 3 weeks for a maximum of 18 months; Time to response was the date of the first documentation of PSA response.<br/>- Duration of Response According to PSA Levels; time frame: Baseline, Every 3 weeks for a maximum of 18 months; Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml). The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.<br/>- Duration of Response According to RECIST Criteria; time frame: Baseline, Weeks 6, 12, 24, 36 and 48; For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death. Participants who never progressed or died were censored at their last tumor measurement.<br/>- Percentage of Participants Without Progression; time frame: Screening, Weeks 3, 6, 9 and 12; Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.<br/>- Time to Prostate Cancer Pain Progression; time frame: Every 3 weeks up to a maximum of 18 weeks; Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.<br/>- Overall Survival; time frame: Screening, Every 3 weeks up to a maximum of 18 months; Overall survival was defined as the interval of time in weeks between start of treatment and day of death. Participants who did not die while being followed were censored at the last time that they were known to be alive.<br/>- Time to Treatment Failure; time frame: Every 3 weeks up to a maximum of 18 weeks; Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment. Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.<br/>- Change From Baseline in Bone Alkaline Phosphatase; time frame: Screening, Weeks 6, 12, 24, 36 and 48; Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase. Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).<br/>- Change From Baseline in N-Telopeptide; time frame: Screening, Weeks 6, 12, 24, 36 and 48; In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX).<br/>- Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (µg*day/mL)<br/>- AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.<br/>- Maximum Plasma Concentration of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. Cmax is measured as micrograms per mL (μg/mL).<br/>- Time to Maximum Plasma Concentration (Tmax) of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. tmax is the time at which the Cmax is observed.<br/>- Terminal Elimination Half-Life (t1/2) of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; t1/2 is the time in days required for the concentration of the drug to reach half of its original value<br/>- Serum Clearance of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).<br/>- Volume of Distribution at Steady State of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.<br/>- Mean Residence Time (MRT) of Pertuzumab; time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1; MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.<br/>";"FR";"France";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"[---]*";"Berlin";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2003/09/30;"[---]*";"68";2005/09/01;"Multicenter trial";"International";"Male";"19";"Years";"[---]*";"no maximum age";"-  Adults greater than (>) 18 years of age<br/><br/>          -  Histologically documented adenocarcinoma of the prostate resistant to hormone<br/>             therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal<br/><br/>          -  Prostate-specific antigen (PSA) values at least 20 ng/mL among those with<br/>             asymptomatic or mildly symptomatic disease<br/><br/>          -  Karnofsky performance status (KPS) at least 80 percent (%)<br/><br/>          -  Castrate testosterone less than (<) 50 ng/dL<br/><br/>          -  Life expectancy at least 12 weeks<br/><br/>          -  Left ventricular ejection fraction (LVEF) at least 50%<br/><br/>          -  Adequate hematologic, hepatic, and renal function<br/>";"-  Prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer<br/><br/>          -  Systemic corticosteroids within 1 month prior to Screening<br/><br/>          -  Bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any<br/>             investigational agent with 28 days of study drug<br/><br/>          -  Prior cumulative doxorubicin dose of > 360 mg/m^2 or equivalent<br/><br/>          -  Central nervous system (CNS) or pulmonary metastases<br/><br/>          -  Other malignancies, except adequately treated basal or squamous cell skin cancer<br/><br/>          -  Significant cardiovascular disease<br/><br/>          -  Active/uncontrolled concurrent illness or infection<br/><br/>          -  Major surgery or traumatic injury within 4 weeks of study drug<br/>";"Primary Sponsor";"Hoffmann-La Roche";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Hoffmann-La Roche";"[---]*";"[---]*";"[---]*";"Clinical Trials";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Hoffmann-La Roche";"[---]*";"[---]*";"[---]*";"Clinical Trials";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"An Open Label, Phase II, Multicenter Study to Evaluate the Efficacy and Safety of a Recombinant Humanized Antibody to HER2 (Pertuzumab) Administered Every 3 Weeks to Patients With Hormone-Refractory Prostate Cancer Who Have Not Been Treated With Chemotherapy";"[---]*";"[---]*";"This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in<br/>      participants with hormone-refractory prostate cancer who have had no previous chemotherapy.<br/>      Participants will be enrolled in two stages, the first (Cohort A) at a lower 420-mg dose and<br/>      the second (Cohort B) at a higher 1050-mg dose based upon observations in Cohort A. Up to 50<br/>      participants may enter either cohort, for a total enrollment between 46 and 73 participants<br/>      across 9 study centers.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010313";"2017-05-09T11:35:10.862+02:00";
"DRKS00003817";2012/05/09;2009/11/25;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT01021423";"ClinicalTrials.gov";"Sponsor-ID";"CC-5013-MCL-003";"Celgene Corporation";;;;;;;;;;"Free text";"[---]*";"Mantle Cell Lymphoma";"Free text";"[---]*";"Non-Hodgkin's Lymphoma";"ICD10";"C83.8";"Other non-follicular lymphoma";;;;;;;"Arm 1";"Drug: Lenalidomide";"Arm 2";"Other: Placebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"[---]*";"Treatment";"Parallel";"III";"[---]*";"- Progression-free Survival (PFS); time frame: up to 7 years; PFS is defined as the time from randomization into the study to the first observation of disease progression or death due to any cause.  Progression, as defined by the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), is any new lesion or increase by 50% of previously involved sites from nadir.<br/>Study terminated prematurely. Analysis not conducted.<br/>";"- Overall Survival; time frame: up to 7 years; Overall survival was defined as the time from randomization to death from any cause.<br/>Study terminated prematurely. Analysis not conducted.<br/>- Participants With Treatment Emergent Adverse Events (TEAEs); time frame: up to 9 months; Participants with treatment-emergent adverse events (TEAEs) during the treatment period plus 30 days.  A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.<br/>The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.<br/>- Time to Progression; time frame: up to 7 years; Time to progression was defined as the time from the date of randomization until the first date of documented disease progression.<br/>Study terminated prematurely. Analysis not conducted.<br/>- Time to Treatment Failure; time frame: up to 2 years; Time to treatment failure was defined as the time from randomization until the date at which a participant was removed from treatment due to progression, toxicity, refusal or death or received another Non-Hodgkin Lymphoma (NHL) therapy, whichever occurs first.<br/>- Participants With a Tumor Response; time frame: up to 7 years; Number of participants with a measurable tumor at time of randomization who achieve a response.  Complete response (CR) is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms if present before therapy.  Partial response (PR) is defined as the regression of measurable disease and no appearance of new sites of disease.  For full definitions, please refer to the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson 2007).<br/>Study terminated prematurely. Analysis not conducted.<br/>";"US";"United States";"CZ";"Czech Republic";"FR";"France";"DE";"Germany";"IL";"Israel";"IT";"Italy";"PL";"Poland";"PT";"Portugal";"RU";"Russian Federation";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;"[---]*";"Universitätsklinikum Essen Zentrum für Innere Medizin";"Essen";"[---]*";"Universitätsklinikum Freiburg - Medizinische Klinik - Abteilung Innere Medizin I: Hämatologie und Onkologie";"Freiburg";"[---]*";"UKG Universitätsklinikum Göttingen Zentrum Innere Medizin Hämatologie / Onkologie";"Göttingen";"[---]*";"Asklepios Klinik St. Georg - Abteilung für Hämatologie und Stammzelltransplantation";"Hamburg";"[---]*";"Städtisches Klinikum Karlsruhe - Hämatologie / Onkologie Karlsruhe";"Karlsruhe";"[---]*";"Klinikum der Universität München - Großhadern, Medizinische Klinik III";"München";"[---]*";"Universitaetsklinikum Tuebingen";"Tuebingen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2010/04/30;"[---]*";"9";2011/03/01;"Multicenter trial";"International";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Histologically-proven mantle cell non-Hodgkin's lymphoma,<br/><br/>          -  One of the following first-line induction chemotherapy regimens with rituximab:  (1)<br/>             combination regimen containing all of the following components: cyclophosphamide,<br/>             vincristine, adriamycin and a glucocorticoid; (2)  Fludarabine containing regimen<br/>             such as FC (fludarabine, cyclophosphamide)<br/><br/>          -  Achieved a PR or better response after the first-line induction chemotherapy regimen<br/>             (assessed by 2007 Revised Response Criteria for Malignant Lymphoma)<br/><br/>          -  ECOG performance status score of ≤ 2<br/><br/>          -  Willing to follow pregnancy precaution<br/>";"-  Patients who have received more than 1 line of induction chemotherapy;<br/><br/>          -  Patients who have received less than 4 cycles of R-CHOP, R-CHOP-like, or R-FC are<br/>             ineligible;<br/><br/>          -  Patients who achieved stable disease or progressive disease as best response with<br/>             first line-induction chemotherapy;<br/><br/>          -  Any of the following laboratory abnormalities:<br/><br/>          -  Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5*10^9/L)<br/><br/>          -  Platelet count < 60,000/mm^3 (60*10^9/L)<br/><br/>          -  Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT)) > 3.0<br/>             times upper limit of normal (ULN), except in patients with documented liver<br/>             involvement by lymphoma<br/><br/>          -  Serum bilirubin > 1.5 times ULN, except in case of Gilbert's Syndrome and documented<br/>             liver involvement by lymphoma<br/><br/>          -  Calculated creatinine clearance (i.e. Cockcroft-Gault formula) of < 30 mL /min<br/><br/>          -  Active or any history of central nervous system (CNS) lymphoma or leptomeningeal<br/>             involvement by lymphoma<br/><br/>          -  Subjects at high risk for deep vein thrombosis (DVT) not willing to take DVT<br/>             prophylaxis<br/><br/>          -  Known seropositive for or active viral infection with human immunodeficiency virus<br/>             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)<br/>";"Primary Sponsor";"Celgene Corporation";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Medizinische Klinik III der Universität München";"[---]*";"[---]*";"[---]*";"Martin Dreyling, Prof. Dr";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Medizinische Klinik III der Universität München";"[---]*";"[---]*";"[---]*";"Martin Dreyling, Prof. Dr";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma";"RENEW";"[---]*";"A study to evaluate the efficacy of lenalidomide as maintenance therapy after completion of<br/>      first-line combination chemotherapy in patients with mantle cell lymphoma (MCL) who are not<br/>      candidates for transplantation and have achieved partial response (PR) or complete response<br/>      (CR).<br/><br/>      This study was prematurely terminated by the sponsor in light of new unpublished data that<br/>      rendered the current design of the study no longer clinically relevant. A study design with<br/>      the control arm of no active treatment was no longer appropriate. The termination of the<br/>      trial was not based on any safety concerns in the study.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003817";"2015-01-27T14:02:01.371+01:00";
"DRKS00009648";2015/11/11;2002/11/04;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00048659";"ClinicalTrials.gov";"Sponsor-ID";"598-CL-008";"Astellas Pharma Inc";;;;;;;;;;"Free text";"[---]*";"Hormone-Refractory Prostate Cancer";"Free text";"[---]*";"Prostatic Neoplasms";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;"Arm 1";"Drug: YM598";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"[---]*";"Treatment";"Parallel";"II";"[---]*";"[---]*";"[---]*";"AU";"Australia";"BE";"Belgium";"FR";"France";"DE";"Germany";"IE";"Ireland";"NL";"Netherlands";"PL";"Poland";"ES";"Spain";"UK";"United Kingdom";"US";"United States";;;;;;;;;;;;;;;;;;;;;"[---]*";"Krankenhause am Urban, Urologie Dieffenfachstr";"Berlin";"[---]*";"Dept Urology University of Essen";"Essen";"[---]*";"Urologische Klinik der MHH";"Hannover";"[---]*";"Klinikum Mannheim Urology";"Mannheim";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"[---]*";"[---]*";2004/06/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"[---]*";"[---]*";"Primary Sponsor";"Astellas Pharma Inc";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy";"[---]*";"[---]*";"The purpose of this study is to determine if patients who take YM598 in addition to<br/>      mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated<br/>      with prostate cancer metastases in the bone.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009648";"2015-12-14T15:18:47.012+01:00";
"DRKS00009658";2015/11/12;2001/04/10;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00014586";"ClinicalTrials.gov";"Sponsor-ID";"EORTC-30991";"European Organisation for Research and Treatment of Cancer - EORTC";"Other Secondary-ID";"EORTC-GU-30991";"[---]*";;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: bicalutamide";"Arm 2";"Drug: goserelin acetate";"Arm 3";"Procedure: orchiectomy";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"[---]*";"Other";"Treatment";"[---]*";"III";"[---]*";"[---]*";"[---]*";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Center of Operative Urology Bremen";"Bremen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2001/01/31;"[---]*";"110";"[---]*";"[---]*";"[---]*";"Male";"[---]*";"no minimum age";"80";"Years";"DISEASE CHARACTERISTICS:<br/><br/>          -  Histologically confirmed prostate cancer<br/><br/>               -  T1-3, any G (any Gleason), N0 or NX<br/><br/>          -  High risk defined as G3 or Gleason more than 6 or PSA more than 20 ng/mL and unfit or<br/>             unwilling to undergo local curative therapy OR<br/><br/>          -  Low risk defined as G1-2 or Gleason less than 7 and PSA no more than 20 ng/mL and no<br/>             prior local curative therapy<br/><br/>          -  Asymptomatic (pain score of 0)<br/><br/>          -  PSA no more than 100 ng/mL (no more than 25 times normal)<br/><br/>          -  No metastatic disease by chest x-ray, bone scan (if PSA more than 10 ng/mL or 2.5<br/>             times normal), and pelvic CT (if chance of lymph node metastases is at least 5% by<br/>             Partin tables)<br/><br/>          -  No bone disease that would interfere with diagnosis of metastatic disease<br/><br/>        PATIENT CHARACTERISTICS:<br/><br/>        Age:<br/><br/>          -  80 and under<br/><br/>        Performance status:<br/><br/>          -  WHO 0-2<br/><br/>        Life expectancy:<br/><br/>          -  Not specified<br/><br/>        Hematopoietic:<br/><br/>          -  Not specified<br/><br/>        Hepatic:<br/><br/>          -  Not specified<br/><br/>        Renal:<br/><br/>          -  Not specified<br/><br/>        Other:<br/><br/>          -  No other malignancy within the past 5 years except adequately treated basal cell skin<br/>             cancer<br/><br/>          -  No psychological, personal, sociological, or geographical condition that would<br/>             preclude study<br/><br/>        PRIOR CONCURRENT THERAPY:<br/><br/>        Biologic therapy<br/><br/>          -  Not specified<br/><br/>        Chemotherapy<br/><br/>          -  Not specified<br/><br/>        Endocrine therapy<br/><br/>          -  Not specified<br/><br/>        Radiotherapy<br/><br/>          -  Not specified<br/><br/>        Surgery<br/><br/>          -  Not specified<br/>";"[---]*";"Primary Sponsor";"European Organisation for Research and Treatment of Cancer - EORTC";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Center of Operative Urology Bremen";"[---]*";"[---]*";"[---]*";"Gerald H.J. Mickisch, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Center of Operative Urology Bremen";"[---]*";"[---]*";"[---]*";"Gerald H.J. Mickisch, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Randomized Phase III Step-Up Study On Initial Antiandrogen Monotherapy In Comparison With Watchful Waiting In Asymptomatic T1-3 Any G (Any Gleason) NO or Nx M0 Prostate Cancer Patients Without Local Treatment With Curative Intent";"[---]*";"[---]*";"RATIONALE: Testosterone can stimulate the growth of cancer cells. Bicalutamide and goserelin<br/>      may fight prostate cancer by reducing the production of testosterone. It is not yet known<br/>      which hormone therapy regimen is most effective for prostate cancer.<br/><br/>      PURPOSE: Randomized phase III trial to compare the effectiveness of bicalutamide with that<br/>      of observation followed by bicalutamide plus either goserelin or orchiectomy for patients<br/>      who have prostate cancer.<br/>";"OBJECTIVES:<br/><br/>        -  Compare the overall and cancer-specific survival of patients with prostate cancer<br/>           treated with bicalutamide alone followed by bicalutamide with either goserelin or<br/>           bilateral orchiectomy vs observation followed by bicalutamide with either goserelin or<br/>           bilateral orchiectomy.<br/><br/>        -  Compare the time to first and second clinical progression in patients treated with<br/>           these regimens.<br/><br/>        -  Compare the quality of life, including potency, of patients treated with these<br/>           regimens.<br/><br/>      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to<br/>      participating center, tumor differentiation grade (G3 or Gleason more than 6 vs other<br/>      values), T category, comorbidity (i.e., chronic disease) (yes vs no), potency (yes vs no),<br/>      type of chosen hormonal ablation (goserelin vs orchiectomy), PSA level (less than 10 ng/mL<br/>      vs 10-20 ng/mL vs 20-100 ng/mL), and N status (N0 vs NX). Patients are randomized to one of<br/>      two treatment arms.<br/><br/>        -  Arm I: Patients receive oral bicalutamide once daily. At first symptomatic disease<br/>           progression, patients also receive goserelin subcutaneously once every 28 or 84 days or<br/>           undergo bilateral orchiectomy. At second disease progression, patients discontinue<br/>           bicalutamide.<br/><br/>        -  Arm II: Patients are observed until first symptomatic disease progression. At first<br/>           disease progression, patients receive bicalutamide with either goserelin or bilateral<br/>           orchiectomy as in arm I. Patients discontinue bicalutamide as in arm I.<br/><br/>      Quality of life is assessed at baseline, every 6 months for 6 years, at each disease<br/>      progression, and then annually thereafter.<br/><br/>      Patients are followed annually.<br/><br/>      PROJECTED ACCRUAL: Approximately 1266 patients (633 per treatment arm) will be accrued for<br/>      this study within 5 years.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009658";"2016-01-15T16:51:33.092+01:00";
"DRKS00009663";2015/11/12;2009/09/10;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-007460-42";"[---]*";"Primary Registry-ID";"NCT00975299";"ClinicalTrials.gov";"Sponsor-ID";"13991";"Bayer";"Other Secondary-ID";"2008-007460-42";"[---]*";;;;"Free text";"[---]*";"Diagnostic Imaging";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: BAY86-4367";"Arm 2";"Drug: BAY86-4367";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Non-randomized controlled trial";"Open (masking not used)";"Other";"Diagnostic";"Parallel";"I";"[---]*";"- Visual assessment of lesions; time frame: Day of study drug administration<br/>";"- Quantitative analysis of BAY86-4367 uptake into lesions (Standardized Uptake Values = SUVs); time frame: Day of study drug administration<br/>- Electrocardiogram (ECG); time frame: At least 3 times within 8 days after treatment<br/>- Blood pressure; time frame: At least 3 times within 8 days after treatment<br/>- Serum protein; time frame: At least 3 times within 8 days after treatment<br/>- Serum creatinine; time frame: At least 3 times within 8 days after treatment<br/>- Serum GOT (Glutamat-Oxalacetat-Transaminase); time frame: At least 3 times within 8 days after treatment<br/>- Adverse events collection; time frame: At least 3 times within 8 days after treatment<br/>";"DE";"Germany";"CH";"Switzerland";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"[---]*";"München";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/09/30;"[---]*";"16";2010/10/01;"Multicenter trial";"International";"Male";"45";"Years";"[---]*";"no maximum age";"-  Healthy volunteers:<br/><br/>               -  males, >/=50 and <= 65 years of age<br/><br/>          -  Cancer patients:<br/><br/>               -  males >/= 45 years of age<br/><br/>               -  patients with recurrent prostate cancer had a positive choline PET/CT for<br/>                  detection, or staging, or restaging of cancer, evaluation of the primary<br/>                  prostate cancer detection rate with BAY 86-4367 in comparison to histology as<br/>                  standard of truth (choline PET/CT is optional).<br/>";"-  Exclusion criteria for all healthy volunteers and patients:<br/><br/>               -  Concurrent severe and/or uncontrolled and/or unstable other medical disease<br/>                  (e.g. poorly controlled diabetes, congestive heart failure, myocardial<br/>                  infarction within 12 months prior to planned injection of BAY 86-4367, unstable<br/>                  and uncontrolled hypertension, chronic renal or hepatic disease, severe<br/>                  pulmonary disease) which could compromise participation in the study<br/><br/>               -  Known sensitivity to the study drug or components of the preparation.<br/>";"Primary Sponsor";"Bayer";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Bayer";"[---]*";"[---]*";"[---]*";"Bayer Study Director";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Bayer";"[---]*";"[---]*";"[---]*";"Bayer Study Director";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Open-label, Multicenter PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY86-4367 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 40 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers";"[---]*";"[---]*";"Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography)<br/>      images obtained after a single intravenous injection of BAY86-4367 in patients with cancer<br/>";"[---]*";"Recruiting stopped after recruiting started ";"Further trial documents";"[---]*";"http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm";"Click here and search for drug information provided by the FDA.";"Further trial documents";"[---]*";"http://www.fda.gov/medwatch/safety.htm";"Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.";"Further trial documents";"[---]*";"http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php";"Click here to find results for studies related to marketed products.";;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009663";"2016-01-15T16:57:07.691+01:00";
"DRKS00009650";2015/11/12;2006/10/06;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2006-001671-38";"[---]*";"Primary Registry-ID";"NCT00385827";"ClinicalTrials.gov";"Sponsor-ID";"CR012346";"Centocor, Inc.";"Other Secondary-ID";"C0328T07";"[---]*";"Other Secondary-ID";"2006-001671-38";"[---]*";"Free text";"[---]*";"Cancer, Prostate";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: Mitoxantrone";"Arm 2";"Drug: Siltuximab";"Arm 3";"Drug: Prednisone";;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"II";"[---]*";"- Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); time frame: Baseline up to 12 weeks after last dose administration; An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.<br/>- Part 2: Progression Free Survival (PFS); time frame: Randomization, Week 12, then every 9 weeks until 1 month after last dose administration, then every 3 months until disease progression or death, up to 2 years; The PFS is the time from the date of randomization until the first documented sign of progression (at least a 20 percent increase in the sum of the longest diameter [LD] of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new target or non-target lesions as per Response Evaluation Criteria in Solid Tumors [RECIST] or 3 or more new skeletal lesions on bone scan with confirmation of second bone scan or with clinical deterioration) or death, whichever occurs first.<br/>";"- Time to Clinical Deterioration (TtCD); time frame: Start of treatment (Part 1)/Randomization (Part 2), Week 1 of each cycle up to 1 month after last dose administration, and thereafter every 3 months until clinical deterioration or death, up to 2 years; The TtCD is defined as the time from the start of treatment (for participants in Part 1) or randomization (for participants in Part 2) until the first documented clinical deterioration (consists of pain requiring palliative (intended to relieve pain) intervention (a treatment given during the course of a research study), or death due to any cause, whichever occurs earlier.<br/>- Number of Participants With Palliative Response; time frame: Start of treatment (Part 1)/Randomization (Part 2), Week 1 of each cycle up to 1 month after last dose administration, and thereafter every 3 months up to 2 years; Palliative response was defined as a 2-point or greater reduction from baseline pain, without a categorical increase in prescribed disease-related analgesic (drug used to control pain) use or at least a categorical decrease in disease-related analgesic use without a concomitant (given at the same time) increase in pain. Each component required confirmation at least 3 weeks later.<br/>- Number of Participants With Prostate Specific Antigen (PSA) Response; time frame: Start of treatment (Part 1)/Randomization (Part 2), Week 1 of each cycle up to 1 month after last dose administration, and thereafter every 3 months until disease progression, up to 2 years; The PSA response is defined as at least a 50% reduction in PSA from the Baseline value, confirmed by a second PSA value at least 3 weeks after initial documentation of PSA response.<br/>- Overall Survival (OS); time frame: Start of treatment (Part 1)/Randomization (Part 2) until death, up to 2 years; The OS is defined as the time from the date of start of treatment (for participants in Part 1) or randomization (for participants in Part 2) to death due to any cause. For participants who were alive at the time of analysis, OS was censored at the last contact date.<br/>";"AT";"Austria";"BE";"Belgium";"FR";"France";"DE";"Germany";"ES";"Spain";"UK";"United Kingdom";"US";"United States";;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"[---]*";"Berlin";"[---]*";"[---]*";"Cologne";"[---]*";"[---]*";"Kassel";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2006/11/30;"[---]*";"106";2008/11/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Histologically (the study of tissue under the microscope) or cytologically (the study<br/>             of cells) confirmed adenocarcinoma (a malignant epithelial tumor with a glandular<br/>             organization) of the prostate<br/><br/>          -  Radiologically (Gamma and Computed Topography [CT] scans) documented metastatic<br/>             disease<br/><br/>          -  At least 6 weeks of treatment with 1 prior docetaxel-based chemotherapy for<br/>             metastatic Hormone Refractory Prostate Cancer (HRPC)<br/><br/>          -  Disease progression, during or within 6 months of stopping of prior docetaxel-based<br/>             therapy, based on one of the following: serum Prostate Specific Antigen (PSA)<br/>             progression, defined as a rise in at least 2 consecutive serum PSA values, each<br/>             obtained at least 1 week apart or radiologic disease progression: if disease<br/>             progression is shown by bone scan only, then disease progression is defined by the<br/>             appearance of 2 or more new bone lesions (abnormal area of tissue, such as a wound,<br/>             sore, rash, or boil)<br/><br/>          -  Orchiectomy (surgery to remove one or both testicles) or testosterone less than 50<br/>             nanogram per decilliter (ng/dL) by means of pharmacological/chemical castration<br/>";"-  No evidence of a brain tumor<br/><br/>          -  No more than 1 line of chemotherapy for metastatic prostate cancer<br/><br/>          -  No prior mitoxantrone treatment<br/><br/>          -  Prior malignancy (other than prostate cancer) except adequately treated superficial<br/>             bladder cancer, basal cell or squamous cell carcinoma (type of cancer) of the skin,<br/>             or other cancer for which the subject has been disease-free for atleast 3 years<br/><br/>          -  No Human Immunodeficiency Virus (HIV) (a life-threatening infection that you can get<br/>             from an infected person's blood or from having sex with an infected person)<br/>             seropositivity or hepatitis (inflammation of the liver) B or C infection<br/>";"Primary Sponsor";"Centocor, Inc.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Centocor, Inc.";"[---]*";"[---]*";"[---]*";"Centocor, Inc. Clinical Trial";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Centocor, Inc.";"[---]*";"[---]*";"[---]*";"Centocor, Inc. Clinical Trial";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)";"[---]*";"[---]*";"The purpose of this study is to assess the safety and efficacy of siltuximab administered in<br/>      combination with mitoxantrone and prednisone in participants with metastatic (spread of<br/>      cancer cells from one part of the body to another) hormone-refractory (not responding to<br/>      treatment) prostate cancer (abnormal tissue that grows and spreads in the body) (HRPC).<br/>";"This is a 2-part, open-label (all people know the identity of the intervention) multicenter<br/>      (when more than 1 hospital or medical school team work on a medical research study), Phase 2<br/>      study to evaluate the safety and efficacy of the combination of siltuximab plus mitoxantrone<br/>      versus mitoxantrone in participants with metastatic HRPC who have received 1 prior<br/>      Docetaxel-based chemotherapy (treatment of disease, usually cancer, by chemical agents)<br/>      regimen (pattern of giving treatment). Part 1 of the study is single arm where participants<br/>      will receive mitoxantrone, prednisone and siltuximab. Part 2 of the study is randomized<br/>      portion (the study drug is assigned by chance), consisting of 2-arms. The experimental arm<br/>      will consist of treatment with mitoxantrone, prednisone and siltuximab. The control arm will<br/>      consist of treatment with mitoxantrone and prednisone. Mitoxantrone will be administered at<br/>      a dose of 12 milligram per square meter (mg/m^2) intravenously (into a vein) as a 30-minute<br/>      infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1 of each<br/>      3-week cycle, until disease progression or unacceptable toxicity (any harmful effect of a<br/>      drug) or up to 10 cycles (a maximum total dose of approximately 120 mg/m^2). Siltuximab will<br/>      be administered at a dose of 6 mg/kilogram intravenously as a 2-hour infusion, starting Day<br/>      1 of Cycle 1 to continue every 2 weeks until disease progression or unacceptable toxicity or<br/>      up to a maximum of 1 year. All participants will receive prednisone 5 mg twice daily<br/>      starting with the first administration of Mitoxantrone. The duration of treatment will be a<br/>      maximum of 12 months for cumulative dose. Radiologic assessments will be performed on Week<br/>      12 after the first study agent dosing, then every 9 weeks until the end of treatment and<br/>      then once every 3 months until documented disease progression. Tumor (a mass in a specific<br/>      area) response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST)<br/>      criteria. There will be short-term follow-up visits (conducted monthly for 2 months),<br/>      followed by long-term follow-up visits (conducted once every 3 months). Participants' safety<br/>      will also be monitored throughout the study.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009650";"2016-08-10T15:27:07.825+02:00";
"DRKS00009654";2015/11/12;2002/12/03;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00050297";"ClinicalTrials.gov";"Sponsor-ID";"598-CL-004";"Astellas Pharma Inc";;;;;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: YM598";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Other";"Treatment";"Parallel";"II";"[---]*";"[---]*";"[---]*";"BE";"Belgium";"CZ";"Czech Republic";"FR";"France";"DE";"Germany";"PL";"Poland";"ES";"Spain";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Haingasse 22";"Bad Homburg";"[---]*";"Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus";"Dresden";"[---]*";"Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße";"Marburg";"[---]*";"Krummbogen 15";"Marburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"[---]*";"[---]*";2004/02/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"[---]*";"[---]*";"Primary Sponsor";"Astellas Pharma Inc";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer";"[---]*";"[---]*";"The purpose of this study is to determine the optimal dosage of YM598 for slowing down<br/>      disease progression in patients with rising PSA after initial therapy for localized prostate<br/>      cancer.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009654";"2015-12-14T15:20:30.118+01:00";
"DRKS00009660";2015/11/12;2004/08/16;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00089856";"ClinicalTrials.gov";"Sponsor-ID";"G-0029";"Cell Genesys";"Other Secondary-ID";"(VITAL-1)";"[---]*";;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Biological: Immunotherapy with allogeneic prostate vaccine";"Arm 2";"Drug: Chemotherapy (Taxotere and prednisone)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Survival; time frame: 0<br/>";"- Bone pain and bone related events; time frame: 0<br/>";"BE";"Belgium";"CA";"Canada";"FR";"France";"DE";"Germany";"NL";"Netherlands";"SE";"Sweden";"UK";"United Kingdom";"US";"United States";;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Universitatsklinikum Aachen Urologie";"Aachen";"[---]*";"der Technischen Universitat Dresden";"Dresden";"[---]*";"Universitatsklinik um Essen";"Essen";"[---]*";"Universitatsklinik um des Saarlande";"Homburg/Saar";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2004/07/31;"[---]*";"626";2008/10/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the<br/>             prostate<br/><br/>          -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy<br/><br/>          -  Detectable metastases<br/><br/>          -  Any Gleason score<br/><br/>          -  ECOG performance status 0-2<br/>";"-  Prior treatment with chemotherapy<br/><br/>          -  Prior Immunotherapy<br/><br/>          -  Prior treatment with gene therapy<br/><br/>          -  Significant cancer related pain<br/>";"Primary Sponsor";"Cell Genesys";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve";"[---]*";"[---]*";"The purpose of this study is to compare the duration of survival between GVAX® immunotherapy<br/>      for prostate cancer and chemotherapy treatment in patients with prostate cancer who no<br/>      longer respond to hormone therapy, who have documented metastases, and who have not been<br/>      treated with chemotherapy in the past.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009660";"2016-01-15T16:53:58.784+01:00";
"DRKS00003697";2012/05/03;"[---]*";yes;"Approved";"12/1/12";"Ethik-Kommission der Medizinischen Fakultät der Georg-August-Universität Göttingen";"Universal Trial Number (UTN)";"U1111-1130-2408";"[---]*";;;;;;;;;;;;;"ICD10";"N80";"Endometriosis";;;;;;;;;;;;;"Arm 1";"excision of endometriotic lesions only";"Arm 2";"excision of endometriotic lesions plus application of Hyalobarrier®";"Arm 3";"excision of the endometriotic lesions with the help of the Jet Grasper";"Arm 4";"excision of the endometriotic lesions with the help of the Jet Grasper plus application of Hyalobarrier®";;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Active control";"Treatment";"Parallel";"N/A";"N/A";"Adhesion development in the area of the tubo-ovarian unit (assessment during a Second-look-laparoscopy 3 month after the first laparoscopy)";"duration of surgery, adhesion score of 23 anatomical sites (assessment during a Second-look-laparoscopy 3 month after the first laparoscopy), assessment of pain before the initial laparoscopy, before the second look laparoscopy(SLL), 3, 6 and 9 month after SLL; pregnancy rate 12 month after SLL, number of bleedings that require coagulation in the area of the tubo-ovarian unit, overall number of bleedings that require coagulation";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Medical Center";"Pius-Hospital, Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie";"Oldenburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2012/06/11;"Actual";"64";2012/09/08;"Monocenter trial";"National";"Female";"18";"Years";"[---]*";"no maximum age";"Women over 18 years with endometriosis-associated pain, like dysmenorrhea, dyspareunia, lower abdominal pain, low-back pain, rectal pain, defecation pain (only one criterion needs to be fulfilled for study inclusion); Participants are in good general health except for endometriosis related problems; Except for endometriosis, no existence of an obvious diseases which could cause chronic pain or which could cause abdominal pain; The participant must have an urgent desire to have children and must agree not to take contraceptive agents during a period of one year after the second look laparoscopy;  Participants must be able to give their consent and must understand the risks associated with a participation in the study; There must be a signed and dated informed consent which was accepted by the local ethic committee; Endometriosis in the area of the tubo-ovarian unit";"Existent pregnancy including ectopic pregnancy; Identification of other causes for the discomfort; Chronic diseases, except endometriosis, which require continuous pain therapy; Previous application of GnRH analogues 6 month prior to study; Concurrent use of systemic corticosteroids, antineoplastic agents and/or radiation; Planned additional general surgical procedures during the operation for removal of the endometriotic lesions; Absence of endometriosis at laparoscopy; Partial resection of the bowel or urinary bladder for removal of endometriosis ";"Primary Sponsor";"Pius-Hospital Oldenburg,<br/>Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie";"Mr.";"Prof. Dr. Dr. med.";"Rudy Leon";"De Wilde";"Georgstraße 12";"26121";"Oldenburg";"Germany";"0441 2291501";"0441 2291525";"gyn-sekretariat@pius-hospital.de";"[---]*";"Contact for Scientific Queries";"Pius-Hospital Oldenburg, Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie";"Mr.";"Prof. Dr. Dr. med.";"Rudy Leon";"De Wilde";"Georgstraße 12";"26121";"Oldenburg";"Germany";"0441 2291501";"0441 2291525";"gyn-sekretariat@pius-hospital.de";"[---]*";"Contact for Public Queries";"Pius-Hospital Oldenburg, Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie";"Mr.";"Prof. Dr. Dr. med.";"Rudy Leon";"De Wilde";"Georgstraße 12";"26121";"Oldenburg";"Germany";"0441 2291501";"0441 2291525";"gyn-sekretariat@pius-hospital.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Institutional budget, no external funding (budget of sponsor/PI)";"Pius-Hospital Oldenburg,<br/>Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie";"Mr.";"Prof. Dr. Dr. med.";"Rudy Leon";"De Wilde";"Georgstraße 12";"26121";"Oldenburg";"Germany";"0441 2291501";"0441 2291525";"gyn-sekretariat@pius-hospital.de";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Randomised, controlled clinical study with patients with endometriosis and the desire to have children – Comparison between peritoneal ablation by excision only and excision with the help of the Jet Grasper as well as the use of an adhesionbarrier";"[---]*";"[---]*";"The main purpose of the study is to investigate the development of adhesions after excision of endometriosis. Half of the patients will receive traditional endometriosis treatment with the excision of the endometriotic lesions only. The other half will be treated with a new instrument, the Jet Grasper (KARL STORZ GmbH & Co. KG, Tuttlingen, Germany), which was developed to remove endometriosis with the help of aquadissection (separation of tissue with water pressure). With the use of aquadissection a less traumatic operation could be possible. Through a reduction of the surgical trauma, the development of adhesions could be reduced. Half of the patients also receive a gel which can reduce adhesion formation (Hyalobarrier®). Further study objectives are the investigation in the development of different types of endometriosis-associated pain over a period of one year (survey will be conducted every three month) and the registration of the pregnancy rate one year after completion of treatment. Potential study participants are women with endometriosis-associated pain and with an urgent desire to have children. It will be investigated in the study if the use of the Jet Grasper will lead to less tissue damage during the operation and if this will result in less adhesion development. Additionally, it will be investigated if the different treatment options will result in a difference in the reduction of endometriosis-associated pain and if the use of the Jet Grasper and the use of Hyalobarrier® will increase pregnancy rates. ";"The development of adhesion formation is influenced by the extent of the surgical trauma. A new instrument, the Jet Grasper, was developed to reduce the surgical trauma during endometriosis excision. The Jet Grasper is a laparoscopic forceps with an integrated irrigation function which facilitates the use of aquadissection for tissue preparation. With the specific use of aquadissection for peritoneal ablation prior to the excision of endometriotic lesions, the excision is less traumatic which could result in a reduced use of electrocoagulation. This can potentially lead to a decreased adhesion formation as a reduced use of electrocoagulation leads to a reduction of the peritoneal trauma. The application of Hyalobarrier® could have an additional positive effect. As endometriosis and adhesions are often associated with pain and infertility, the investigation of these parameters is also an objective of the study. The reduction of adhesion formation through the reduction of the surgical trauma could result in an increased pregnancy rate. ";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003697";"2013-11-20T12:15:35.657+01:00";
"DRKS00009652";2015/11/12;2005/08/19;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00133224";"ClinicalTrials.gov";"Sponsor-ID";"G-0034";"Cell Genesys";"Other Secondary-ID";"VITAL-2";"[---]*";;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine";"Arm 2";"Drug: Chemotherapy (docetaxel and prednisone)";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control (effective treament of control group)";"Treatment";"Parallel";"III";"[---]*";"- Survival; time frame: 0<br/>";"- Time to disease progression. Time to pain progression.; time frame: 0<br/>";"BE";"Belgium";"CA";"Canada";"FR";"France";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"PL";"Poland";"SE";"Sweden";"UK";"United Kingdom";"US";"United States";;;;;;;;;;;;;;;;;;;;;"[---]*";"Universitatsklinikum Aachen";"Aachen";"[---]*";"Charite Campus Mitte";"Berlin";"[---]*";"Krankenhaus Am Urban";"Berlin";"[---]*";"Universitatsklinikum Carl Gustav Carus An Der";"Dresden";"[---]*";"Klinikum der Johann Wolfgang Goethe-Universitat";"Frankfurt am Main";"[---]*";"Urologische Klinik und Poliklinik der Johannes Gutenberg Universitat Mainz";"Mainz";"[---]*";"Klinikum Mannheim";"Mannheim";"[---]*";"Urologische Klinik und Poliklinik";"Munchen";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2005/07/31;"[---]*";"408";"[---]*";"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"Inclusion Criteria:<br/><br/>          -  Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the<br/>             prostate<br/><br/>          -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy<br/><br/>          -  Detectable metastases<br/><br/>          -  ECOG performance status ≤2 (Performance status of 3 if due to bone pain)<br/><br/>          -  Any Gleason score<br/><br/>          -  Only one prior treatment with systemic chemotherapy<br/><br/>          -  No prior treatment with gene therapy<br/><br/>          -  No prior immunotherapy for prostate cancer<br/><br/>          -  Taxane naïve<br/><br/>          -  Experiencing cancer-related pain<br/>";"[---]*";"Primary Sponsor";"Cell Genesys";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain";"[---]*";"[---]*";"The primary objective of this study is to compare the duration of survival between patients<br/>      receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus<br/>      patients receiving docetaxel and prednisone treatment in patients with prostate cancer who<br/>      no longer respond to hormone therapy, who have documented metastases with pain. Patients may<br/>      have had up to one prior non-taxane chemotherapy treatment.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009652";"2016-01-15T16:46:37.755+01:00";
"DRKS00003757";2012/05/02;2009/09/14;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00977132";"ClinicalTrials.gov";"Sponsor-ID";"Valena-Study";"Heinrich-Heine University, Duesseldorf";;;;;;;;;;"Free text";"[---]*";"Myelodysplastic Syndrome MDS";"ICD10";"D46";"Myelodysplastic syndromes";;;;;;;;;;"Arm 1";"Drug: Valproic aicd";"Arm 2";"Drug: Lenalidomide";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"- hematologic success; time frame: 5 years<br/>";"- toxicity and safety; time frame: 5 years<br/>- Progression free survival; time frame: 5 years<br/>- overall survival; time frame: 5 years<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizini";"Freiburg";"[---]*";"Universitätsklinikum Ulm, Klinik für Innere Medizin III";"Ulm";"[---]*";"Georg-August-Universität,Universitätsklinikum - Abteilung Hämatologie und Onkologie";"Goettingen";"[---]*";"Heinrich-Heine-University Duesseldorf, Department of Hematology, Oncology and Clinical Immunology";"Duesseldorf";"[---]*";"St. Johannes Hospital Duisburg";"Duisburg";"[---]*";"Universitätsklinikum Carl Gustav Carus an der TU Dresden, Medizinische Klinik und Poliklinik I";"Dresden";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/10/31;"[---]*";"80";"[---]*";"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Cytologically/histologically confirmed primary myelodysplastic syndrome (pMDS) with a<br/>             favorable risk profile, i.e., low or intermediate I risk group according to IPSS<br/>             (<10% blasts, no unfavorable karyotype)<br/><br/>          -  platelet count ≥50.000/µl<br/><br/>          -  absolute neutrophil count  ≥1.000/µl<br/><br/>          -  age ≥18 years at the time of signing the informed consent form<br/><br/>          -  Karnofsky performance status > 50%<br/><br/>          -  written informed consent to participate<br/><br/>          -  erythropoietin level > 200 mU/ml or failure of previous therapy with erythropoietin<br/><br/>          -  patients in whom allogeneic bone marrow transplantation, treatment with growth<br/>             factors or immune therapy is not possible due to medical or biologic reasons or<br/>             patients in whom such a therapy would be possible but who do not agree to such a<br/>             therapy for personal reasons<br/><br/>          -  females of childbearing potential (FCBP, see page 23) must agree to one reliable form<br/>             of contraception or to practice complete abstinence from heterosexual intercourse<br/>             during the following time periods related to this study: 1) for at least 4 weeks<br/>             before starting study drug; 2) while participating in the study, even during<br/>             treatment interruptions; and 3) for at least 4 weeks after discontinuation from the<br/>             study.<br/>";"-  patients with 5q deletion<br/><br/>          -  MDS treated with experimental therapy or chemotherapy within 4 weeks prior to start<br/>             of treatment with study drugs<br/><br/>          -  previous treatment of MDS with valproic acid or lenalidomide as monotherapy patients<br/>             suitable for chemotherapy, therapy with growth factors or allogeneic bone marrow<br/>             transplantation and who are willing to start such a therapy<br/><br/>          -  hypersensitivity to thalidomide<br/><br/>          -  insufficient liver function (bilirubin, AST or ALT > 2 x ULN)<br/><br/>          -  hepatic disease [details see full protocol]<br/><br/>          -  markedly impaired renal function (serum creatinine > 2mg/dl)<br/><br/>          -  pregnancy, breast feeding, lactation, refusal to use safe contraceptive methods<br/>             during the study<br/><br/>          -  psychiatric disease or addiction with impaired ability to act and make decisions<br/>             according to one's free will<br/><br/>          -  participation in another interventional study 4 weeks prior to or during this study<br/><br/>          -  known hypersensitivity or allergies to one of the study drugs or their ingredients<br/><br/>          -  plasmatic coagulation disorder<br/>";"Primary Sponsor";"Heinrich-Heine University, Duesseldorf";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Department of Hematology, Oncology and Clinical Immunology";"[---]*";"[---]*";"[---]*";"Norbert Gattermann, Professor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Department of Hematology, Oncology and Clinical Immunology";"[---]*";"[---]*";"[---]*";"Norbert Gattermann, Professor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile";"VALENA";"[---]*";"As part of a palliative therapy concept, feasibility, toxicity, and effectiveness of<br/>      treatment with the combination of Valproic acid and lenalidomide in Myelodysplastic Syndrome<br/>      patients with a favorable risk profile will be investigated.<br/>";"Treatment will be administered as continuous therapy, i.e. it should be taken on each day as<br/>      described below without treatment interruption as long as no criteria for termination of<br/>      treatment are met. After two years the primary endpoint will be evaluated. Non-responders<br/>      will be taken off study after 4 months of therapy. Patients who relapse after an initial<br/>      response to study treatment can receive one attempt to re-start therapy after a short<br/>      duration of discontinuation.<br/><br/>      Treatment with Valproic Acid starts at day 1. The dose of Valproic Acid is slowly increased.<br/>      In the morning of day 13 trough level of Valproic Acid will be checked. The target range<br/>      will be 50-110 µg/l. The dose of Valproic Acid will be adjusted depending on the trough<br/>      level.<br/><br/>      In the first eight weeks of therapy weekly controls of Valproic Acid levels are required.<br/>      Thereafter, Valproic Acid levels will be checked every four weeks.<br/><br/>      The planned dose of lenalidomide is 10 mg/day, orally as continuous therapy. Dosing will be<br/>      in the morning at approximately the same time each day. Capsules may be taken before or<br/>      after a meal. In the course of the study the dose will be adjusted to the results of the<br/>      blood count.<br/><br/>      Only one cycle of study drug (28 days) will be supplied to the patient every four weeks.<br/><br/>      Patients experiencing adverse events may need study treatment modifications.<br/><br/>      During treatment with study medication weekly control visits for the detection of adverse<br/>      events are required during the first eight weeks, thereafter the patient must be seen every<br/>      four weeks.<br/><br/>      Therapeutic success is evaluated in 4-weekly intervals. Bone marrow will be examined after<br/>      12 weeks and after 48 weeks or in case of premature study termination<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003757";"2015-09-08T11:32:32.844+02:00";
"DRKS00003639";2012/04/30;2010/09/10;yes;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-003997-17";"[---]*";"Primary Registry-ID";"NCT01200212";"ClinicalTrials.gov";"Sponsor-ID";"GBG 43";"German Breast Group";;;;;;;"Free text";"[---]*";"Breast Cancer";"ICD10";"C50";"Malignant neoplasm of breast";;;;;;;;;;"Arm 1";"Drug: Taxane, Avastin";"Arm 2";"Drug: Taxane, Avastin, Xeloda";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"Active control";"Treatment";"Parallel";"III";"[---]*";"- Progression free survival (PFS); time frame: 10 month; The PFS time is defined as time from randomization to locoregional or systemic recurrence, second malignancy or death due to any cause; censored observations will be the last date of: ""death"", ""last tumor assessment"", ""last follow up date"" or ""last date in drug log""<br/>";"- To determine the objective response rate in both arms; time frame: End of Study<br/>- To determine the duration of response in both arms.; time frame: End of Study<br/>- To determine the Time to Progression (TTP) in both arms.; time frame: End of Study<br/>- To determine the clinical benefit defined as CR, PR, or stable disease ≥ 24 weeks in both arms.; time frame: End of Study<br/>- To determine the overall survival rate 3 years after ""Last Patient In"".; time frame: End of Study<br/>- To determine PFS and TTP response rates in patient's ≥ age 65.; time frame: End of Study<br/>- To determine the toxicity and compliance in both arms.; time frame: End of Study<br/>- To determine the predictive value of serum markers such as VEGF; time frame: End of Study<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"GBG Forschungs GmbH";"Neu-Isenburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/07/31;"[---]*";"432";2012/10/01;"[---]*";"[---]*";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  ECOG performance status 0-2<br/><br/>          -  Histological confirmed carcinoma of the breast with no over expression of HER2<br/><br/>          -  Locally advanced or metastatic stage of disease not suitable for surgery or<br/>             radiotherapy alone<br/><br/>          -  Patients must have either measurable or non-measurable target lesions according to<br/>             RECIST criteria (phase III). Complete staging work-up within 4 weeks prior to<br/>             registration. All patients must have chest X-ray (PA and lateral), abdominal<br/>             ultrasound or CT scan or MRI, and bone scan. In case of positive bone scan, bone<br/>             X-ray is mandatory. Other tests may be per- formed as clinically indicated<br/><br/>          -  The following previous systemic treatment are eligible:<br/><br/>          -  (neo)adjuvant chemotherapy (except if capecitabine was included) However if<br/>             (neo)adjuvant chemotherapy was anthracycline based, the maximum cumulative dose of<br/>             prior anthracycline therapy must not exceed 360 mg/m2 for doxorubicin and 720 mg/m2<br/>             for epirubicin. If taxanes or capecitabine were part of (neo)adjuvant treatment, a<br/>             treatment-free interval of > 6 months is requested<br/><br/>          -  adjuvant endocrine therapy.<br/><br/>          -  palliative endocrine treatments<br/><br/>          -  treatment with bisphosphonates<br/><br/>          -  treatment with immunotherapies<br/><br/>          -  Patient has to be fully recovered from previous radiotherapy. At least one measurable<br/>             lesion must be completely outside the radiation field or there must be pathologic<br/>             proof of progressive disease<br/><br/>          -  Absolute neutrophil count ≥ 2000 cells/ul, platelet count ≥ 100,000 cells/ul.<br/><br/>          -  Bilirubin ≤ 1.5x the upper limit of normal for the institution (ULN); elevation of<br/>             transaminases and alkaline phosphatase <2.5x ULN or <5x ULN for patients with liver<br/>             metastases<br/><br/>          -  Creatinine ≤ 1,25x ULN or creatinin-clearance > 50 ml/min (according to Cockroft<br/>             Gault). Urine dipstick for proteinuria <2+. Patients discovered to have ≥2+<br/>             proteinuria on dipstick urinalysis should undergo a 24 hour urine collection and must<br/>             demonstrate ≤1 g of protein in 24 hours<br/><br/>          -  Negative pregnancy test (urine or serum) within 14 days prior to registration for all<br/>             women of childbearing potential<br/><br/>          -  Patients must be available and compliant for treatment and follow-up. Patients<br/>             registered on this trial must be treated and followed up at the participating or a<br/>             cooperating site<br/>";"-  Known hypersensitivity reaction to the compounds or incorporated substances or known<br/>             dihydropyrimidine dehydrogenase deficiency<br/><br/>          -  Previous chemotherapy for metastatic disease, concurrent immunotherapy or hormonal<br/>             therapy (antihormonal, contraceptive and/or replacement therapy). Bisphosphonates may<br/>             be continued<br/><br/>          -  Life expectancy of less than 3 months<br/><br/>          -  Serious intercurrent medical or psychiatric illness that may interfere with the<br/>             planned treatment (including AIDS and serious active infection).<br/><br/>          -  Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease,<br/>             angina pectoris requiring antianginal medication, previous history of myocardial<br/>             infarction, evidence of transmural infarction on ECG,  un- or poorly controlled<br/>             arterial hypertension (i.e. BP >150/100 mmHg under treatment with two<br/>             antihypertensive drugs), rhythm abnormalities requiring permanent treatment,<br/>             clinically significant valvular heart disease-<br/><br/>          -  Currently active infection<br/><br/>          -  Active peptic ulcer, incomplete wound healing or unhealed bone fracture<br/><br/>          -  Previous thromboembolic events, known hemorrhagic diathesis, coagulopathy with<br/>             increased bleeding risk, or treatment with anticoagulants Current or recent (within<br/>             10 days of first dose of bevacizumab) use of acetylic acid (>325mg/day) or<br/>             clopidogrel (> 75mg/day)<br/><br/>          -  Disease significantly affecting gastrointestinal function, e.g. mal- absorption<br/>             syndrome, resection of the stomach or small bowel, ulcerative colitis; abdominal<br/>             fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of<br/>             enrolment<br/><br/>          -  Major surgery within the last 28 days or anticipation of the need for major surgery<br/>             during study treatment with bevacizumab. No minor surgeries including insertion of an<br/>             indwelling catheter within 24 h prior to randomization<br/><br/>          -  Parenchymal brain metastases, unless adequately controlled by surgery and/or<br/>             radiotherapy with complete resolution of symptoms and discontinuation of all steroids<br/><br/>          -  History of other malignancy within the last 5 years which could affect the diagnosis<br/>             or assessment or outcome of metastatic breast cancer<br/><br/>          -  Concurrent treatment with other experimental drugs; participation in another clinical<br/>             trial with any investigational drug within 30 days prior to study entry<br/><br/>          -  Treatment with sorivudine or derivates e.g. brivudine<br/><br/>          -  Pregnant or lactating patients. Patients of childbearing potential must implement<br/>             adequate non-hormonal contraceptive measures (barrier methods, intra uterine<br/>             contraceptive devices, sterilization) during study treatment<br/>";"Primary Sponsor";"German Breast Group";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"German Breast Group";"[---]*";"[---]*";"[---]*";"Hans-Joachim Lück, Prof. Dr.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"German Breast Group";"[---]*";"[---]*";"[---]*";"Hans-Joachim Lück, Prof. Dr.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer";"TABEA";"[---]*";"The purpose of this study is to determine whether<br/><br/>        -  Paclitaxel and bevacizumab showed improved PFS compared to paclitaxel alone. Recent<br/>           results of the AVADO study report a similar result for the combination of docetaxel and<br/>           bevacizumab. The AVADO study furthermore confirmed the dose of 15 mg/kg BW of<br/>           bevacizumab.<br/><br/>        -  As in metastatic breast cancer (MBC) poly-chemotherapies are frequently used, regimens<br/>           with bevacizumab and at least 2 cytotoxic agents should be investigated.<br/><br/>        -  Docetaxel and capecitabine showed a benefit in PFS and survival. This combi- nation is<br/>           therefore a reasonable choice.<br/><br/>        -  Dose of capecitabine and docetaxel should be reduced to 1800 mg/m2 and 75 mg/m2 to<br/>           improve tolerability without compromising efficacy.<br/><br/>        -  Paclitaxel and capecitabine is well tolerated and showed a PFS of 10.3 months.<br/><br/>        -  Docetaxel 100 mg/m2 as monotherapy in MBC not very often used b/o toxicity. 75 mg/m2<br/>           much more accepted in daily practice. Better comparability with DBX, if both arms have<br/>           75mg/m2 docetaxel as assumed.<br/>";"Primary Objective:<br/><br/>      - To determine the Progression Free Survival (PFS) in patients with metastatic  breast<br/>      cancer after treatment with taxane plus bevacizumab with (TXB) or without capecitabine (TB).<br/><br/>      Secondary Objective(s):<br/><br/>        -  To determine the objective response rate in both arms.<br/><br/>        -  To determine the duration of response in both arms.<br/><br/>        -  To determine the Time to Progression (TTP) in both arms.<br/><br/>        -  To determine the clinical benefit defined as CR, PR, or stable disease ≥ 24 weeks in<br/>           both arms.<br/><br/>        -  To determine the overall survival rate 3 years after ""Last Patient In"".<br/><br/>        -  To determine PFS and TTP response rates in patient's ≥ age 65.<br/><br/>        -  To determine the toxicity and compliance in both arms.<br/><br/>        -  To determine the predictive value of serum markers such as VEGF.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003639";"2014-05-14T15:16:06.273+02:00";
"DRKS00003880";2012/04/30;2005/12/14;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00273338";"ClinicalTrials.gov";"Sponsor-ID";"011-007";"Novacea";;;;;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: calcitriol";"Arm 2";"Drug: docetaxel";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Open (masking not used)";"[---]*";"Treatment";"Parallel";"III";"[---]*";"[---]*";"[---]*";"US";"United States";"CA";"Canada";"CZ";"Czech Republic";"DE";"Germany";"HU";"Hungary";"PR";"Puerto Rico";"RO";"Romania";"SK";"Slovakia";;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Universitätsklinikum Köln";"Köln";"[---]*";"Gemeinschaftspraxis für Hämatologie & Onkologie";"Augsburg";"[---]*";"Facharzt f. Urologie";"Bad Schwartau";"[---]*";"Urologische Praxis";"Bautzen";"[---]*";"Klinik am Urban";"Berlin";"[---]*";"Urologische Praxis";"Berlin";"[---]*";"Universitatsmedizin Charité";"Berlin";"[---]*";"Universitätsmedizin Charité Campus Benjamin Franklin";"Berlin";"[---]*";"Städtisches Klinikum Braunschweig";"Braunschweig";"[---]*";"Facharzt f. Urologie";"Cottbus";"[---]*";"Urologische Klinik";"Dresden";"[---]*";"Urologische Klinik der Universitätsklink Düsseldorf";"Düsseldorf";"[---]*";"Universitäsklinikum Düsseldorf";"Düsseldorf";"[---]*";"Universitätsklinikum Essen";"Essen";"[---]*";"Klinikum Fulda, Urologische Klinik";"Fulda";"[---]*";"Urologische Praxis";"Hagenow";"[---]*";"Urologische Gemeinschaftspraxis";"Hamburg";"[---]*";"Medizinische Hochschule Hannover";"Hannover";"[---]*";"Nationales Centrum für Tumorerkrankungen";"Heidelberg";"[---]*";"Universitätsklinikum Homburg/Saar";"Homburg";2006/01/31;"[---]*";"1200";2007/11/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"-  Histopathologically or cytologically proven adenocarcinoma of the prostate<br/><br/>          -  Documented metastatic prostate adenocarcinoma<br/><br/>          -  Documented progression while on androgen ablation therapy detected by rising prostate<br/>             specific antigen (PSA) and/or imaging<br/><br/>          -  Age >= 18 years<br/><br/>          -  Eastern Cooperative Oncology Group (ECOG) performance status <= 2<br/><br/>          -  Adequate hematologic, renal and hepatic function<br/><br/>          -  Life expectancy >= 3 months<br/>";"-  Prior chemotherapy, except estramustine<br/><br/>          -  Prior chemotherapy with docetaxel<br/><br/>          -  Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)<br/><br/>          -  One or more contraindications to the use of corticosteroids<br/><br/>          -  History of cancer-related hypercalcemia<br/>";"Primary Sponsor";"Novacea";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center";"[---]*";"[---]*";"[---]*";"Howard I. Scher, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center";"[---]*";"[---]*";"[---]*";"Howard I. Scher, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)";"[---]*";"[---]*";"The primary objective of this study is:<br/><br/>        -  To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on<br/>           survival in metastatic androgen-independent prostate cancer<br/><br/>      The secondary objectives of this study are:<br/><br/>        -  To determine the effect of the ASCENT regimen on the rate of thromboembolic events<br/>           (blood clots)<br/><br/>        -  To determine the effect of the ASCENT regimen on prevention of skeletal-related events<br/>           (fractures)<br/><br/>        -  A Separate sub-study will be conducted at selected study sites in North America to<br/>           determine the population PK of DN-101.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003880";"2016-01-19T15:09:00.419+01:00";
"DRKS00003883";2012/04/30;2008/01/24;no;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00626548";"ClinicalTrials.gov";"Sponsor-ID";"D4320C00015";"AstraZeneca";;;;;;;;;;"Free text";"[---]*";"Prostate Cancer";"ICD10";"C61";"Malignant neoplasm of prostate";;;;;;;;;;"Arm 1";"Drug: ZD4054";"Arm 2";"Drug: Palcebo";;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Randomized controlled trial";"Blinded";"Placebo";"Treatment";"Parallel";"III";"[---]*";"- Overall Survival; time frame: From date of randomization until date of death, assessed up to 33 months; Number of participants who have died at early analysis data cut off (DCO)<br/>- Progression Free Survival; time frame: Participants were followed up for progression every 4 weeks for the first 16 weeks then every 16 weeks; Number of participants who have a progression event at the early analysis DCO, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline<br/>";"- Health Related Quality of Life; time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks<br/>- Time to Prostate-specific Antigen (PSA) Progression; time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks<br/>- Time to Symptomatic Progression; time frame: Participants were followed up every 4 weeks for the first 16 weeks then every 16 weeks<br/>";"US";"United States";"AR";"Argentina";"AU";"Australia";"AT";"Austria";"BE";"Belgium";"BR";"Brazil";"CA";"Canada";"CL";"Chile";"CN";"China";"CO";"Colombia";"CZ";"Czech Republic";"DK";"Denmark";"FI";"Finland";"FR";"France";"DE";"Germany";"HU";"Hungary";"IN";"India";"IE";"Ireland";"IL";"Israel";"IT";"Italy";"[---]*";"Research Site";"Augsburg";"[---]*";"Research Site";"Bad Ems";"[---]*";"Research Site";"Berlin";"[---]*";"Research Site";"Bonn";"[---]*";"Research Site";"Borken";"[---]*";"Research Site";"Chemnitz";"[---]*";"Research Site";"Emmendingen";"[---]*";"Research Site";"Fuerth";"[---]*";"Research Site";"Gelsenkirchen-Buer";"[---]*";"Research Site";"Germering";"[---]*";"Research Site";"Goettingen";"[---]*";"Research Site";"Holzminden";"[---]*";"Research Site";"Kirchheim/Teck";"[---]*";"Research Site";"Leipzig";"[---]*";"Research Site";"Lubeck";"[---]*";"Research Site";"Mannheim";"[---]*";"Research Site";"Muehlacker";"[---]*";"Research Site";"Muehlheim an der Ruhr";"[---]*";"Research Site";"Muenchen";"[---]*";"Research Site";"Muenchen-Planegg";2008/01/31;"[---]*";"2496";2011/05/01;"Multicenter trial";"International";"Male";"18";"Years";"[---]*";"no maximum age";"Patients who answer TRUE to the following criteria may be eligible to participate in this<br/>        study.<br/><br/>          -  Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT<br/>             spread to the other parts of the body (metastases). Patients with lymph node<br/>             involvement may be eligible if specified criteria is met.<br/><br/>          -  Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment<br/><br/>          -  Currently receiving treatment with surgical or medical castration<br/>";"Patients who answer TRUE to the following may NOT be eligible to participate in this<br/>        study.<br/><br/>          -  Currently using opiate based pain killers for cancer related pain<br/><br/>          -  Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior<br/>             targeted cancer therapies are permitted if received during a previous clinical trial<br/><br/>          -  Suffering from heart failure or had a myocardial infarction within last 6 months<br/><br/>          -  A history of epilepsy or seizures<br/>";"Primary Sponsor";"AstraZeneca";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Charité Campus Benjamin Franklin";"[---]*";"[---]*";"[---]*";"Kurt Miller, Prof., M.D.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Charité Campus Benjamin Franklin";"[---]*";"[---]*";"[---]*";"Kurt Miller, Prof., M.D.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients";"ENTHUSE M0";"[---]*";"Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan)<br/>      in hormone resistant prostate cancer (HRPC).<br/><br/>      This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan)<br/>      can improve progression-free survival and overall survival against a background of existing<br/>      prostate cancer treatments.<br/><br/>      ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and<br/>      spread by blocking Endothelin receptor activity. This trial will look at the effects of<br/>      ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC) patients who have had rising<br/>      PSA after surgical or medical castration but have no evidence of metastases.<br/><br/>      All patients participating in this clinical trial will receive existing prostate cancer<br/>      treatments in addition to trial therapy.<br/><br/>      Half the patients will receive ZD4054 (Zibotentan) , and half the patients will receive<br/>      placebo in addition to standard prostate cancer therapy. By participating in this trial<br/>      there is a 50% chance that patients will receive an agent that may slow the progression of<br/>      the tumour.<br/><br/>      No patients will be deprived of standard prostate cancer therapy.<br/>";"[---]*";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003883";"2016-01-19T15:18:41.769+01:00";
"DRKS00003747";2012/05/04;2008/07/17;yes;"[---]*";"[---]*";"[---]*";"Primary Registry-ID";"NCT00720850";"ClinicalTrials.gov";"Sponsor-ID";"TUD-LENAMA-022";"Dresden University of Technology";;;;;;;;;;"Free text";"[---]*";"Myelodysplastic Syndromes";"Free text";"[---]*";"Acute Myelogenous Leukemia";"ICD10";"D46";"Myelodysplastic syndromes";"ICD10";"C92.0";"Acute myeloid leukaemia";;;;"Arm 1";"Drug: lenalidomide";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Treatment";"Single (group)";"II";"[---]*";"- Cumulative incidence of relapse rate; time frame: 1 year post transplantation<br/>";"- Overall survival, Incidence and severity of acute and chronic GVHD, Safety; time frame: 1 year post transplantation<br/>";"DE";"Germany";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Dresden University of Technology, Medizinische Klinik und Poliklinik 1";"Dresden";"[---]*";"Universitätsklinikum Düsseldorf, Medizinische Klinik und Poliklinik, Klinik für Hämatologie, Onkologie und klinische Immunologie";"Düsseldorf";"[---]*";"Universitätsklinikum Essen, Klinik für Knochenmarktransplantation";"Essen";"[---]*";"Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum";"Hamburg";"[---]*";"Medizinische Hochschule Hannover, Zentrum Innere Medizin, Hämatologie";"Hannover";"[---]*";"Universitätsklinikum Ulm, Klinik für Innere Medizin III";"Ulm";"[---]*";"Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II";"Würzburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2008/04/30;"[---]*";"50";2011/01/01;"Multicenter trial";"National";"Both, male and female";"18";"Years";"[---]*";"no maximum age";"-  Understand and voluntarily sign an informed consent form.<br/><br/>          -  Age >=18 years at the time of signing the informed consent form.<br/><br/>          -  Able to adhere to the study visit schedule and other protocol requirements.<br/><br/>          -  AML (>/= 20% blasts) including secondary (s)AML (after radio-chemotherapy) with<br/>             karyotype abnormalities involving monosomy 5 or del5q or MDS and sMDS RAEB-1 and<br/>             RAEB-2 with karyotype abnormalities involving monosomy 5 or del5q or MDS and sMDS<br/>             type RA(+/-RS) or RCMD(+/-RS) only with complex karyotype abnormalities involving<br/>             monosomy 5 or del5q<br/><br/>          -  in complete hematological remission documented by bone marrow aspiration within 8-12<br/>             weeks after allogeneic HSCT<br/><br/>          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must<br/>             have been discontinued at least 4 weeks prior to treatment in this study.<br/><br/>          -  ECOG performance status of </= 2 at study entry.<br/><br/>          -  Laboratory test results within these ranges:<br/><br/>               -  Absolute neutrophil count >= 1.0 x 10 9/L<br/><br/>               -  Platelet count >= 100 x 10 9/L<br/><br/>               -  Serum creatinine <= 2.0 mg/dL<br/><br/>               -  Total bilirubin <= 1.5 mg/dL<br/><br/>               -  AST (SGOT) and ALT (SGPT) <= 5 x ULN<br/><br/>          -  Females of childbearing potential (FCBP)† must agree to use two reliable forms of<br/>             contraception simultaneously or to practice complete abstinence from heterosexual<br/>             intercourse during the following time periods related to this study: 1) for at least<br/>             28 days before starting study drug; 2) while participating in the study; and 3) for<br/>             at least 28 days after discontinuation from the study. The two methods of reliable<br/>             contraception must include one highly effective method (i.e. intrauterine device<br/>             (IUD), hormonal [birth control pills, injections, or implants], tubal ligation,<br/>             partner's vasectomy) and one additional effective (barrier) method (i.e. latex<br/>             condom, diaphragm, cervical cap).  FCBP must be referred to a qualified provider of<br/>             contraceptive methods if needed.<br/><br/>          -  Disease free of prior malignancies for >= 5 years with exception of currently treated<br/>             basal cell, squamous cell carcinoma of the skin, or carcinoma ""in situ"" of the cervix<br/>             or breast<br/><br/>          -  Able to take aspirin (ASA) 100mg daily as prophylactic anticoagulation in case of<br/>             concomitant steroid treatment (patients intolerant to ASA may use low molecular<br/>             weight heparin).<br/>";"-  Any serious medical condition, laboratory abnormality, or psychiatric illness that<br/>             would prevent the subject from signing the informed consent form.<br/><br/>          -  active uncontrolled acute GVHD overall grade 3-4<br/><br/>          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed<br/>             while taking lenalidomide).<br/><br/>          -  History of arterial or venous embolism or stroke<br/><br/>          -  Any condition, including the presence of laboratory abnormalities, which places the<br/>             subject at unacceptable risk if he/she were to participate in the study or confounds<br/>             the ability to interpret data from the study.<br/><br/>          -  Use of any other experimental drug or therapy to treat MDS or AML within 28 days of<br/>             baseline (patients within a clinical trial evaluating new conditioning regimens are<br/>             allowed to participate in the LENAMAINT study)<br/><br/>          -  Known hypersensitivity to thalidomide or lenalidomide.<br/><br/>          -  history of erythema nodosum if characterized by a desquamating rash while taking<br/>             thalidomide or similar drugs.<br/><br/>          -  Known positive for HIV or infectious hepatitis, type A, B or C.<br/>";"Primary Sponsor";"Technische Universität Dresden";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Dresden University of Technology, Medizinische Klinik und Poliklinik 1";"[---]*";"[---]*";"[---]*";"Uwe Platzbecker, PD Dr. med.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Dresden University of Technology, Medizinische Klinik und Poliklinik 1";"[---]*";"[---]*";"[---]*";"Uwe Platzbecker, PD Dr. med.";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"Lenalidomide Maintenance Therapy in Patients With MDS or AML With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)";"LENAMAINT";"[---]*";"The hypothesis of this study is that lenalidomide can be an effective drug in preventing<br/>      relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q<br/>      after allogeneic HSCT. Due to its immunomodulatory action it might also be able to enhance a<br/>      T - or NK cell mediated graft versus leukemia (GVL) effects. Nevertheless, one has to keep<br/>      in mind a possible, yet unknown influence on modulation of clinical GVHD.<br/>";"Cytogenetics are main predictors of outcome in patients with MDS and AML. In fact, a<br/>      monosomy 5 (-5) or del5q (excluding typical 5q-syndrome) are mostly poor prognostic markers<br/>      also because being frequently part of a complex karyotype. Together, these patients often do<br/>      not respond to conventional chemotherapy and can only be cured by allogeneic HSCT.<br/>      Nevertheless, even after transplantation the relapse rate is considerably high and in the<br/>      majority of patient's relapses occur within the first year after HSCT.<br/><br/>      Lenalidomide has been successfully used in MDS patients with del5q, irrespective of<br/>      additional cytogenetic abnormalities. Furthermore, in vitro studies have demonstrated also<br/>      impressive anti-proliferative effects of the compound in cell lines harbouring a monosomy 5.<br/>      Therefore, it seems to be a promising compound in preventing relapse of high-risk MDS or AML<br/>      patients with chromosomal abnormalities involving del5q or -5 after allogeneic HSCT. Due to<br/>      its immunomodulatory action it might also be able to enhance T - or NK cell mediated graft<br/>      versus leukemia effects. Nevertheless, it is unknown whether lenalidomide could modulate or<br/>      enhance clinical graft versus host disease.<br/>";"Recruiting stopped after recruiting started ";"Further trial documents";"[---]*";"http://www.mk1dd.de";"Dresden University Hospital C. G. Carus, Medizinische Klinik und Poliklinik 1";;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003747";"2015-10-12T10:54:45.614+02:00";
"DRKS00003773";2012/05/04;2009/08/26;no;"[---]*";"[---]*";"[---]*";"EudraCT-No.<br/>(for studies acc. to Drug Law)";"2008-008198-73";"[---]*";"Primary Registry-ID";"NCT00967343";"ClinicalTrials.gov";"Sponsor-ID";"CR-AIR-004";"Kiadis Pharma";"Other Secondary-ID";"EudraCT no. 2008-008198-73";"[---]*";;;;"Free text";"[---]*";"Myeloid Leukemia";"Free text";"[---]*";"Lymphoblastic Leukemia";"Free text";"[---]*";"Lymphoma";"Free text";"[---]*";"Multiple Myeloma";"Free text";"[---]*";"Myelodysplastic Syndrome";"Arm 1";"Biological: Donor lymphocyte preparation depleted of host functional alloreactive T-cells";;;;;;;;;;;;;;;;;;;"Interventional";"[---]*";"Single arm study";"Open (masking not used)";"Uncontrolled/Single arm";"Prevention";"Single (group)";"II-III";"[---]*";"- Transplant related mortality; time frame: 6 and 12 months after the transplantation<br/>";"- Incidence and severity of acute and chronic graft-versus-host disease; time frame: Up to 24 months after the transplantation<br/>- Progression free survival; time frame: Up to 24 months after the transplantation<br/>- Incidence and severity of bacterial, viral or fungal infection; time frame: Up to 24 months after the transplantation<br/>- Immune reconstitution; time frame: Up to 24 months after the transplantation<br/>- Health status (including Quality of Life); time frame: Up to 24 months after the transplantation<br/>- Overall survival; time frame: Up to 24 months after the transplantation<br/>";"US";"United States";"BE";"Belgium";"CA";"Canada";"DE";"Germany";"IT";"Italy";"NL";"Netherlands";"UK";"United Kingdom";;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Universitätsklinikum Freiburg, Medizinische UNI-Klinik";"Freiburg";"[---]*";"Universitätsklinikums Schleswig-Holstein Campus Kiel";"Kiel";"[---]*";"Universitätsklinikum Mainz";"Mainz";"[---]*";"Universitätsklinikum Würzburg";"Würzburg";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;2009/08/31;"[---]*";"70";2012/02/01;"Multicenter trial";"International";"Both, male and female";"18";"Years";"65";"Years";"One of the following hematological malignancies:<br/><br/>          -  Acute Myeloid Leukemia (AML)<br/><br/>          -  Acute Lymphoblastic Leukemia (ALL)<br/><br/>          -  Myelodysplastic Syndrome (MDS)<br/><br/>          -  Ph-positive chronic myeloid leukemia (CML)<br/><br/>          -  Non-Hodgkin Lymphoma (NHL)<br/><br/>          -  Myelodysplastic Syndrome (MDS)<br/><br/>          -  Chronic Myeloid Leukemia (CML)<br/><br/>          -  Multiple Myeloma (MM)<br/><br/>          -  Chronic Lymphocytic Leukemia (CLL)<br/><br/>          -  Myeloproliferative Syndrome (MPS)<br/>";"-  AML in 1st complete remission with good risk karyotypes<br/><br/>          -  MM featuring concurrent extramedullar disease or being non-responsive to prior<br/>             therapy<br/><br/>          -  CML in blast crisis<br/><br/>          -  CLL concurrently transformed into high-grade lymphoma and failing to demonstrate at<br/>             least partial remission<br/><br/>          -  NHL with concurrent bulky disease (≥ 5 cm)<br/><br/>          -  Diffusing Capacity for Carbon Monoxide (DLCO) < 40% predicted<br/><br/>          -  Left ventricular ejection fraction < 40%<br/><br/>          -  AST/SGOT > 2.5 x ULN<br/><br/>          -  Bilirubin > 1.5 x ULN<br/><br/>          -  Creatinine > 1.5 x ULN<br/><br/>          -  HIV positive<br/><br/>          -  Positive pregnancy test for women of childbearing age<br/><br/>          -  Prior haploidentical peripheral blood stem cell or cord blood transplantation<br/><br/>          -  Less than 2 years from a prior allogeneic stem cell transplantation<br/><br/>          -  Estimated probability of surviving less than three months<br/><br/>          -  Major anticipated illness or organ failure incompatible with survival from transplant<br/><br/>          -  Severe psychiatric illness or mental deficiency sufficiently severe as to make<br/>             compliance with the transplant treatment unlikely and informed consent impossible<br/><br/>          -  Known allergy to any of the components of ATIR<br/><br/>          -  Any other condition which, in the opinion of the investigator, makes the patient<br/>             ineligible for the study<br/><br/>        Donor Inclusion Criteria:<br/><br/>          -  Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or DR loci of<br/>             the unshared haplotype.<br/><br/>          -  Male or female, age ≥ 16, ≤ 75 years.<br/><br/>          -  Donors must be fit to receive G-CSF and undergo apheresis (normal blood count,<br/>             normotensive and no history of stroke).<br/><br/>          -  Donor must have Eastern Cooperative Oncology Group (ECOG) performance status of 2 or<br/>             less.<br/><br/>          -  Donor must provide written informed consent.<br/><br/>        Donor Exclusion Criteria:<br/><br/>          -  Medically uncontrolled coronary heart disease.<br/><br/>          -  Myocardial infarction within the last 3 months.<br/><br/>          -  History of uncontrolled seizures.<br/><br/>          -  History of malignancy (except basal cell or squamous carcinoma of the skin, positive<br/>             PAP smear and subsequent negative follow up).<br/><br/>          -  Positive test result for any of the mandatory viral tests in the applicable region,<br/>             except for a positive cytomegalovirus (CMV) result, which does not lead to exclusion.<br/><br/>          -  Presence of a transmissible disease (such as HIV positive), a major illness, a<br/>             suspected systemic dysfunction and/or an active inflammatory or autoimmune disorder.<br/><br/>          -  Female donors who are pregnant or nursing.<br/>";"Primary Sponsor";"Kiadis Pharma";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Scientific Queries";"Julius Maximilian University of Würzburg, Germany";"[---]*";"[---]*";"[---]*";"Stephan Mielke, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"Contact for Public Queries";"Julius Maximilian University of Würzburg, Germany";"[---]*";"[---]*";"[---]*";"Stephan Mielke, MD";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"[---]*";"Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";"[---]*";;;;;;;;;;;;;;;;;;;;;;;;;;;;;"An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor";"[---]*";"[---]*";"The purpose of this study is to determine whether the administration of a donor lymphocyte<br/>      preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted<br/>      stem cell transplant from a related, haploidentical donor enhances survival by improving the<br/>      immune effect against infections while preventing graft-versus-host disease .<br/>";"Allogeneic stem cell transplantation is the treatment of choice for many patients with<br/>      leukemia and other hematologic malignancies. However, a major limitation of this therapy is<br/>      that for a significant number of patients no fully HLA-matched donor can be found. The<br/>      application of partially HLA-matched (haploidentical) family donors, who are virtually<br/>      always available, has some complications. If there is no T-cell add-back it increases the<br/>      risk for life-threatening infections and disease relapse, while in case of T-cell add-back<br/>      the risk for graft-versus-host disease is raised.<br/><br/>      Kiadis Pharma has developed a method to selectively deplete host alloreactive T-cells<br/>      through photodynamic therapy, using TH9402 ex vivo. The donor lymphocyte preparation<br/>      depleted of functional host alloreactive T-cells (ATIR) is administered to the patient 28-42<br/>      days after the stem cell transplant.<br/>";"Recruiting stopped after recruiting started ";;;;;;;;;;;;;;;;;;;;;"http://www.drks.de//drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00003773";"2015-10-12T10:48:15.745+02:00";
